<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD006633.pub2" GROUP_ID="SCHIZ" ID="523106051014375738" MERGED_FROM="" MODIFIED="2010-11-10 15:26:30 +0100" MODIFIED_BY="Claire Irving" NOTES="&lt;p&gt;Exported from Review Manager 4.2.10&lt;br&gt;Exported from Review Manager 4.2.8&lt;br&gt;Exported from Review Manager 4.2.7&lt;br&gt;Exported from Review Manager 4.2.8&lt;br&gt;Exported from Review Manager 4.3.1&lt;br&gt;Exported from Review Manager 4.2.8&lt;/p&gt;" NOTES_MODIFIED="2010-10-06 14:43:30 +0100" NOTES_MODIFIED_BY="[Empty name]" REVIEW_NO="" REVMAN_SUB_VERSION="5.0.25" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="5.0">
<COVER_SHEET MODIFIED="2010-11-10 15:26:30 +0100" MODIFIED_BY="Claire Irving">
<TITLE MODIFIED="2009-10-06 16:31:50 +0100" MODIFIED_BY="[Empty name]">Clozapine versus other atypical antipsychotics for schizophrenia</TITLE>
<CONTACT MODIFIED="2010-11-10 15:26:30 +0100" MODIFIED_BY="Claire Irving"><PERSON ID="640B1C9B82E26AA201E0E19D50AC57BC" ROLE="AUTHOR"><FIRST_NAME>Claudia</FIRST_NAME><LAST_NAME>Asenjo Lobos</LAST_NAME><SUFFIX>MS. MSc (c)</SUFFIX><POSITION>Clinical Epidemiologist</POSITION><EMAIL_1>casenjolob@googlemail.com</EMAIL_1><EMAIL_2>casenjo@udec.cl</EMAIL_2><ADDRESS><ORGANISATION>University of Concepcion</ORGANISATION><ADDRESS_1>Victoria 232</ADDRESS_1><CITY>Concepcion</CITY><REGION>Región del Bio Bio</REGION><COUNTRY CODE="CL">Chile</COUNTRY><PHONE_1>056 41 2203770</PHONE_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2010-11-10 15:26:30 +0100" MODIFIED_BY="Claire Irving"><PERSON ID="640B1C9B82E26AA201E0E19D50AC57BC" ROLE="AUTHOR"><FIRST_NAME>Claudia</FIRST_NAME><LAST_NAME>Asenjo Lobos</LAST_NAME><SUFFIX>MS. MSc (c)</SUFFIX><POSITION>Clinical Epidemiologist</POSITION><EMAIL_1>casenjolob@googlemail.com</EMAIL_1><EMAIL_2>casenjo@udec.cl</EMAIL_2><ADDRESS><ORGANISATION>University of Concepcion</ORGANISATION><ADDRESS_1>Victoria 232</ADDRESS_1><CITY>Concepcion</CITY><REGION>Región del Bio Bio</REGION><COUNTRY CODE="CL">Chile</COUNTRY><PHONE_1>056 41 2203770</PHONE_1></ADDRESS></PERSON><PERSON ID="87F1AFC682E26AA20078D4E6A8FF088C" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Katja</FIRST_NAME><LAST_NAME>Komossa</LAST_NAME><POSITION>4th Year Resident (Dr. Med)</POSITION><EMAIL_1>k.komossa@lrz.tu-muenchen.de</EMAIL_1><ADDRESS><DEPARTMENT>Klinik und Poliklinik für Psychiatrie und Psychotherapie</DEPARTMENT><ORGANISATION>Technische Universität München Klinikum rechts der Isar</ORGANISATION><ADDRESS_1>Moehlstrasse 26</ADDRESS_1><CITY>München</CITY><ZIP>81675</ZIP><COUNTRY CODE="DE">Germany</COUNTRY><PHONE_1>0049 (0) 89 4141/4247</PHONE_1></ADDRESS></PERSON><PERSON ID="11852B3682E26AA201DC7B3E1C938991" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Christine</FIRST_NAME><LAST_NAME>Rummel-Kluge</LAST_NAME><POSITION>Assistenzärztin</POSITION><EMAIL_1>christine.rummel@lrz.tum.de</EMAIL_1><ADDRESS><DEPARTMENT>Klinik und Poliklinik für Psychiatrie und Psychotherapie</DEPARTMENT><ORGANISATION>Technische Universität München Klinikum rechts der Isar</ORGANISATION><ADDRESS_1>Möhlstr. 26</ADDRESS_1><CITY>München</CITY><ZIP>81675</ZIP><COUNTRY CODE="DE">Germany</COUNTRY><PHONE_1>+49-89-4140-6676</PHONE_1><FAX_1>+49-89-4140-6688</FAX_1></ADDRESS></PERSON><PERSON ID="2E84257C82E26AA201BA4B54250245B7" ROLE="AUTHOR"><FIRST_NAME>Heike</FIRST_NAME><LAST_NAME>Hunger</LAST_NAME><EMAIL_1>mailtoHeike@gmx.de</EMAIL_1><ADDRESS><DEPARTMENT>Klinik und Poliklinik für Psychiatrie und Psychotherapie</DEPARTMENT><ORGANISATION>Technische Universität München Klinikum rechts der Isar</ORGANISATION><ADDRESS_1>Möhlstr. 26</ADDRESS_1><CITY>München</CITY><ZIP>81675</ZIP><COUNTRY CODE="DE">Germany</COUNTRY><PHONE_1>+498 941 404247</PHONE_1></ADDRESS></PERSON><PERSON ID="D99E43AC82E26AA201BA4B549DE5F4E8" ROLE="AUTHOR"><FIRST_NAME>Franziska</FIRST_NAME><LAST_NAME>Schmid</LAST_NAME><EMAIL_1>supra.renin@web.de</EMAIL_1><ADDRESS><DEPARTMENT>Klinik und Poliklinik für Psychiatrie und Psychotherapie</DEPARTMENT><ORGANISATION>Technische Universität München Klinikum rechts der Isar</ORGANISATION><ADDRESS_1>Möhlstr. 26</ADDRESS_1><CITY>München</CITY><ZIP>81675</ZIP><COUNTRY CODE="DE">Germany</COUNTRY><PHONE_1>0049/89/4140/4247</PHONE_1></ADDRESS></PERSON><PERSON ID="90591E5482E26AA201AA8B42BEBB7D04" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Sandra</FIRST_NAME><LAST_NAME>Schwarz</LAST_NAME><EMAIL_1>sandra.schwarz@khsweb.de</EMAIL_1><ADDRESS><DEPARTMENT>Klinik und Poliklinik für Psychiatrie und Psychotherapie</DEPARTMENT><ORGANISATION>Technische Universität München Klinikum rechts der Isar</ORGANISATION><ADDRESS_1>Möhlstr. 26</ADDRESS_1><CITY>München</CITY><ZIP>81675</ZIP><COUNTRY CODE="DE">Germany</COUNTRY><PHONE_1>0049/89/4140/4247</PHONE_1></ADDRESS></PERSON><PERSON ID="D3501EE082E26AA20080535F42019853" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Stefan</FIRST_NAME><LAST_NAME>Leucht</LAST_NAME><POSITION>Oberarzt</POSITION><EMAIL_1>Stefan.Leucht@lrz.tu-muenchen.de</EMAIL_1><ADDRESS><DEPARTMENT>Klinik und Poliklinik für Psychiatrie und Psychotherapie</DEPARTMENT><ORGANISATION>Technische Universität München Klinikum rechts der Isar</ORGANISATION><ADDRESS_1>Möhlstr. 26</ADDRESS_1><CITY>München</CITY><ZIP>81675</ZIP><COUNTRY CODE="DE">Germany</COUNTRY><PHONE_1>+49-89-4140 ext: 4249</PHONE_1><FAX_1>+49-89-4140-4888</FAX_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2010-11-10 15:26:30 +0100" MODIFIED_BY="Claire Irving">
<UP_TO_DATE>
<DATE DAY="15" MONTH="10" YEAR="2008"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="15" MONTH="5" YEAR="2007"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="12" MONTH="11" YEAR="2011"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="3" YEAR="2007"/>
<REVIEW_PUBLISHED ISSUE="11" YEAR="2010"/>
<LAST_CITATION_ISSUE ISSUE="11" YEAR="2010"/>
</DATES>
<WHATS_NEW MODIFIED="2010-11-10 15:26:30 +0100" MODIFIED_BY="Claire Irving"><WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2010-11-10 15:26:30 +0100" MODIFIED_BY="Claire Irving"><DATE DAY="10" MONTH="11" YEAR="2010"/><DESCRIPTION><P>Contact details updated.</P></DESCRIPTION></WHATS_NEW_ENTRY>

</WHATS_NEW>
<HISTORY MODIFIED="2010-11-10 15:26:30 +0100" MODIFIED_BY="Claire Irving"><WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS" MODIFIED="2010-11-10 15:26:30 +0100" MODIFIED_BY="Claire Irving">
<DATE DAY="6" MONTH="10" YEAR="2010"/>
<DESCRIPTION>
<P>This review is an update of the review "Newer atypical antipsychotic medication vs. clozapine" which compared clozapine with all other atypical antipsychotics pooled into one group. Since the atypical antipsychotics are a heterogenous group with quite different pharmacological profile and the amount of data published on this topic has grown enormously during the last few years, it is now possible to explore atypical comparisons with clozapine separately. For this reason, the title and the review protocol have been modified.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2010-10-06 10:01:28 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="15" MONTH="10" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new format</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT MODIFIED="2009-02-02 01:06:10 +0000" MODIFIED_BY="[Empty name]">
<INTERNAL_SOURCES MODIFIED="2009-02-02 01:06:10 +0000" MODIFIED_BY="[Empty name]">
<SOURCE MODIFIED="2009-02-02 01:06:10 +0000" MODIFIED_BY="[Empty name]">
<NAME>Klinikum Rechts der Isar der TU-München</NAME>
<COUNTRY CODE="DE">Germany</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE>
<NAME>CIGES Capacitacion, Investigación y Gestion para la Salud Basada en la Evidencia, Universidad de la Frontera, Temuco</NAME>
<COUNTRY CODE="CL">Chile</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES>
<SOURCE>
<NAME>Bundesministerium für Bildung und Forschung Nr FKZ:01KG 0606, GZ:GF-GFKG01100506</NAME>
<COUNTRY CODE="DE">Germany</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2010-10-06 14:38:30 +0100" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2010-04-04 02:07:57 +0100" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2009-04-22 16:16:21 +0100" MODIFIED_BY="[Empty name]">Clozapine versus other atypical antipsychotics for schizophrenia</TITLE>
<SUMMARY_BODY MODIFIED="2010-04-04 02:07:57 +0100" MODIFIED_BY="[Empty name]">
<P>This review compared the clinical effects of clozapine with the other atypical antipsychotics. Twenty-seven studies fulfilled the review's criteria and provided data to compare clozapine with antipsychotics such as olanzapine, quetiapine, risperidone, ziprasidone and zotepine. Clozapine was somewhat more efficacious than zotepine. Also, inefficacy of treatment led more frequently to leaving the studies early in the risperidone group suggesting a certain higher efficacy of clozapine. The principal drawback of clozapine were its adverse effects which lead to significantly higher numbers of participants leaving the studies early compared to olanzapine and risperidone. Clozapine was associated with more sedation and hypersalivation than olanzapine, quetiapine and risperidone and with more seizures than olanzapine and risperidone. There was a higher incidence of white blood cell decrease in clozapine groups than olanzapine and more weight gain than in risperidone groups. On the other hand clozapine produced fewer movement disorder than risperidone and less prolactin increase than olanzapine, quetiapine and zotepine.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2010-04-04 02:06:12 +0100" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND MODIFIED="2009-10-06 14:40:48 +0100" MODIFIED_BY="[Empty name]">
<P>Clozapine is an atypical antipsychotic demonstrated to be superior in the treatment of refractory schizophrenia which causes fewer movement disorders. Clozapine, however, entails a significant risk of serious blood disorders such as agranulocytosis which could be potentially fatal. Currently there are a number of newer antipsychotics which have been developed with the purpose to find both a better tolerability profile and a superior effectiveness.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES>
<P>To compare the clinical effects of clozapine with other atypical antipsychotics (such as amisulpride, aripiprazole, olanzapine, quetiapine, risperidone, sertindole, ziprasidone and zotepine) in the treatment of schizophrenia and schizophrenia-like psychoses.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2009-04-17 18:39:20 +0100" MODIFIED_BY="[Empty name]">
<P>We searched the Cochrane Schizophrenia Groups Register (June 2007) and reference lists of all included randomised controlled trials. We also manually searched appropriate journals and conference proceedings relating to clozapine combination strategies and contacted relevant pharmaceutical companies.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2009-05-14 16:05:29 +0100" MODIFIED_BY="[Empty name]">
<P>All relevant randomised, at least single-blind trials, comparing clozapine with other atypical antipsychotics, any dose and oral formulations, for people with schizophrenia or related disorders.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2009-10-05 23:19:27 +0100" MODIFIED_BY="[Empty name]">
<P>We selected trials and extracted data independently. For dichotomous data we calculated relative risks (RR) and their 95% confidence intervals (CI) based on a random-effects model. We calculated numbers needed to treat/harm (NNT/NNH) where appropriate. For continuous data, we calculated mean differences (MD) again based on a random-effects model.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2010-04-04 02:06:12 +0100" MODIFIED_BY="[Empty name]">
<P>The review currently includes 27 blinded randomised controlled trials, which involved 3099 participants. Twelve randomised control trials compared clozapine with olanzapine, five with quetiapine, nine with risperidone, one with ziprasidone and two with zotepine. Attrition from these studies was high (overall 30.1%), leaving the interpretation of results problematic. Clozapine had a higher attrition rate due to adverse effects than olanzapine (9 RCTs, n=1674, RR 1.60 CI 1.07 to 2.40, NNT 25 CI 15 to 73) and risperidone (6 RCTs, n=627, RR 1.88 CI 1.11 to 3.21, NNT 16 CI 9 to 59). Fewer participants in the clozapine groups left the trials early due to inefficacy than risperidone (6 RCTs, n=627, RR 0.40 CI 0.23 to 0.70, NNT 11 CI 7 to 21), suggesting a certain higher efficacy of clozapine.</P>
<P>Clozapine was more efficacious than zotepine in improving the participants general mental state (BPRS total score: 1 RCT, n=59, MD -6.00 CI -9.83 to -2.17), but not consistently more than olanzapine, quetiapine, risperidone and ziprasidone. There was no significant difference between clozapine and olanzapine or risperidone in terms of positive or negative symptoms of schizophrenia. According to two studies from China quetiapine was more efficacious for negative symptoms than clozapine (2 RCTs, n=142, MD 2.23 CI 0.99 to 3.48).</P>
<P>Clozapine produced somewhat fewer extrapyramidal side-effects than risperidone (use of antiparkinson medication: 6 RCTs, n=304, RR 0.39 CI 0.22 to 0.68, NNT 7 CI 5 to 18) and zotepine (n=59, RR 0.05 CI 0.00 to 0.86, NNT 3 CI 2 to 5). More participants in the clozapine group showed decreased white blood cells than those taking olanzapine, more hypersalivation and sedation than those on olanzapine, risperidone and quetiapine and more seizures than people on olanzapine and risperidone. Also clozapine produced an important weight gain not seen with risperidone.</P>
<P>Other differences in adverse effects were less documented and should be replicated, for example, clozapine did not alter prolactin levels whereas olanzapine, risperidone and zotepine did; compared with quetiapine, clozapine produced a higher incidence of electrocardiogram (ECG) alterations; and compared with quetiapine and risperidone clozapine produced a higher increase of triglyceride levels. Other findings that should be replicated were: clozapine improved social functioning less than risperidone and fewer participants in the clozapine group had to be hospitalised to avoid suicide attempts compared to olanzapine.</P>
<P>Other important outcomes such as service use, cognitive functioning, satisfaction with care or quality of life were rarely reported.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2010-03-26 20:29:43 +0000" MODIFIED_BY="[Empty name]">
<P>Clozapine may be a little more efficacious than zotepine and risperidone but further trials are required to confirm this finding. Clozapine differs more clearly in adverse effects from other second generation antipsychotics and the side-effect profile could be key in the selection of treatment depending on the clinical situation and a patient&#8217;s preferences. Data on other important outcomes such as cognitive functioning, quality of life, death or service use are currently largely missing, making further large and well-designed trials necessary. It is also important to take into account that the large number of people leaving the studies early limits the validity and interpretation of our findings.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2010-10-05 11:38:34 +0100" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2010-09-30 13:16:33 +0100" MODIFIED_BY="[Empty name]">
<CONDITION MODIFIED="2010-09-30 13:16:33 +0100" MODIFIED_BY="[Empty name]">
<P>Schizophrenia is a chronic and disabling severe mental disorders, which involves a complex set of disturbances, associated with abnormalities of brain structure and function, disorganised speech and behavior, delusions, and hallucinations (<LINK REF="REF-WHO-1998" TYPE="REFERENCE">WHO 1998</LINK>). It is sometimes called a psychotic disorder or a psychosis. Also, people with schizophrenia present dysfunction in one or more major areas of functioning e.g. social and occupational areas (<LINK REF="REF-Mueser-2004" TYPE="REFERENCE">Mueser 2004</LINK>). The prevalence is between 0.7 - 1% of the adult population (<LINK REF="REF-Lehman-2004" TYPE="REFERENCE">Lehman 2004</LINK>), however, due to frequent chronicity, this disease leads to high levels of social burden and cost, as well as an incalculable amount of individual pain and suffering (<LINK REF="REF-WHO-1998" TYPE="REFERENCE">WHO 1998</LINK>, <LINK REF="REF-van-Os-2009" TYPE="REFERENCE">van Os 2009</LINK>).<BR/>
</P>
</CONDITION>
<INTERVENTION MODIFIED="2010-04-04 02:17:38 +0100" MODIFIED_BY="[Empty name]">
<P>The therapeutic arsenal for schizophrenia is wide and varied. Conventional, typical or first generation antipsychotics, such as chlorpromazine and haloperidol have been used as a first choice for treatment for over 50 years (<LINK REF="REF-Kane-1990" TYPE="REFERENCE">Kane 1990</LINK>). They are effective in reducing the positive and some of the negative symptoms of schizophrenia, however they could produce unpleasant adverse effects such as sedation, demotivation and movement disorders that often lead to treatment discontinuation which then may result in relapse of symptoms (<LINK REF="REF-Gaebel-1997" TYPE="REFERENCE">Gaebel 1997</LINK>). In 1959 the development of a new generation of neuroleptics, classified as atypical antipsychotics, began with clozapine (<LINK REF="REF-ACP-2002" TYPE="REFERENCE">ACP 2002</LINK>). Although clozapine has demonstrated to be superior to the older typical antipsychotics in the treatment of the refractory schizophrenia (<LINK REF="REF-Wahlbeck-1999" TYPE="REFERENCE">Wahlbeck 1999</LINK>), it can also produce severe adverse effects, particularly hypersalivation and blood disorders which restrict its use.</P>
<P>After clozapine, a considerable number of newer atypical antipsychotics drugs have been developed in the hope of finding new compounds with a better tolerability profile and higher efficacy (<LINK REF="REF-Stroup-2003" TYPE="REFERENCE">Stroup 2003</LINK>). These include amisulpride, aripiprazole, olanzapine, quetiapine, risperidone, sertindole, ziprasidone, and zotepine. The effectiveness of these newer atypical antipsychotics compared to clozapine is not yet established. Some studies suggest that the newer atypical antipsychotics have a similar effectiveness to clozapine, and suggest that they may also be effective in resistant schizophrenia with a better security profile (<LINK REF="REF-Kane-2006" TYPE="REFERENCE">Kane 2006</LINK>, <LINK REF="REF-Citrome-2002" TYPE="REFERENCE">Citrome 2002</LINK>).<BR/>
</P>
</INTERVENTION>
<THEORY MODIFIED="2009-04-22 16:27:29 +0100" MODIFIED_BY="[Empty name]">
<P>Clozapine was the first atypical antipsychotic manufactured by Sandoz in 1959 and introduced to the market in the 1960s. Most atypical antipsychotics are antagonists at serotonin and dopamine receptors, but they have different pharmacological profiles according to their level of affinity with the different receptor subtypes (<LINK REF="REF-Miyamoto-2005" TYPE="REFERENCE">Miyamoto 2005</LINK>). Clozapine has multiple sites of action such as dopaminergic, serotonergic, cholinergic and histaminergic receptors, with high affinity to D4 and 5HT2A receptors and low affinity to D1, D2 and D3 receptors. The low affinity of striatal D2 receptors and high one of 5HT2A receptors could explain its low extra-pyramidal symptoms liability, its atypical profile (<LINK REF="REF-Beaumont-2000" TYPE="REFERENCE">Beaumont 2000</LINK>, <LINK REF="REF-Miyamoto-2005" TYPE="REFERENCE">Miyamoto 2005</LINK>). Clozapine differs from conventional antipsychotics for its greater efficacy in controlling positive symptoms in people with treatment-resistant illness and by inducing few extra-pyramidal effects (<LINK REF="REF-Kane-1988" TYPE="REFERENCE">Kane 1988</LINK>, <LINK REF="REF-Wahlbeck-1999" TYPE="REFERENCE">Wahlbeck 1999</LINK>). In 1975, however, sixteen people in Finland developed severe blood reactions - a substantial decline in the white blood cells (neutropenia) which made the individuals dangerously susceptible to infection (<LINK REF="REF-Id_x00e4_np_x00e4__x00e4_n_x002d_-He.1977" TYPE="REFERENCE">Idänpään- He.1977</LINK>). From these sixteen, eight died. The drug was then largely withdrawn from the market (in the UK, Australia and USA), although the withdrawal was not worldwide (<LINK REF="REF-O_x0027_Brien-2004" TYPE="REFERENCE">O'Brien 2004</LINK>) e.g. Scandinavia, Germany and China kept the drug in the market. The cumulative experience with these patients and the subsequent studies demonstrated its superiority in patients with treatment-resistant schizophrenia and also that clozapine could be administered safely, when patients are carefully monitored (<LINK REF="REF-Naheed-2001" TYPE="REFERENCE">Naheed 2001</LINK>,<LINK REF="REF-O_x0027_Brien-2004" TYPE="REFERENCE">O'Brien 2004</LINK>). Clozapine was reintroduced, over a decade later, for people with schizophrenia who were either resistant to typical neuroleptics or who were intolerant of the adverse effects of them (<LINK REF="REF-Wahlbeck-1999" TYPE="REFERENCE">Wahlbeck 1999</LINK>).</P>
</THEORY>
<IMPORTANCE MODIFIED="2009-09-19 21:43:48 +0100" MODIFIED_BY="[Empty name]">
<P>So far, reviews have not found any robust evidence that other atypical drugs have a clinical effect and tolerability similar to clozapine (<LINK REF="REF-Gilbody-2000" TYPE="REFERENCE">Gilbody 2000</LINK>, <LINK REF="REF-McEvoy-2006" TYPE="REFERENCE">McEvoy 2006</LINK>). This could in part be due to a lack of primary studies with good methodological quality, which measure important clinical outcomes during a prolonged time with enough statistical power (<LINK REF="REF-Tuunainen-2000" TYPE="REFERENCE">Tuunainen 2000</LINK>). By systematically searching for all known randomised controlled trials of clozapine versus other atypical antipsychotics, this review should amass more data and provide robust, useful evidence.</P>
<P>This new review is an update of the previous review "Newer atypical antipsychotic medication vs. clozapine" which compared clozapine with all other atypical antipsychotics pooled into one group (<LINK REF="REF-Tuunainen-2000" TYPE="REFERENCE">Tuunainen 2000</LINK>) . Since the atypical antipsychotics are a heterogenous group with quite different pharmacological profile and the amount of data published on this topic has grown enormously during the last few years, it is now possible to explore atypical comparisons with clozapine separately. For this reason, the title and the review protocol have been modified.</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES>
<P>To compare the clinical effects of clozapine with other atypical antipsychotic drugs in the treatment of schizophrenia and schizophrenia-like psychoses.</P>
</OBJECTIVES>
<METHODS MODIFIED="2010-09-30 13:29:11 +0100" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2010-09-30 13:24:23 +0100" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES MODIFIED="2009-10-05 22:30:09 +0100" MODIFIED_BY="[Empty name]">
<P>All relevant randomised controlled trials that compared clozapine with other atypical antipsychotics for treatment of schizophrenia and similar psychotic mental illness. We included only the first treatment phase of randomised cross-over studies. Quasi-randomised trials were excluded. All Included trials needed to be at least single-blind (blind raters).</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS>
<P>People with schizophrenia, and other types of schizophrenia-like psychoses (schizophreniform and schizoaffective disorders) diagnosed by any criteria. We included people with schizophreniform and schizoaffective disorders as there is no evidence that the schizophrenia-like psychoses are caused by fundamentally different disease processes or require different treatment approaches (<LINK REF="REF-Carpenter-1994" TYPE="REFERENCE">Carpenter 1994</LINK>).</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2009-08-14 14:08:30 +0100" MODIFIED_BY="[Empty name]">
<P>1. Clozapine: oral formulation, any dose.<BR/>2. New atypical antipsychotics such as amisulpride, aripiprazole, olanzapine, quetiapine, risperidone, sertindole, ziprasidone and zotepine: oral formulation, any dose.</P>
<P>We excluded studies where participants were prescribed more than one, or combinations of atypical antipsychotics.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2010-09-30 13:24:23 +0100" MODIFIED_BY="[Empty name]">
<P>We grouped outcomes by time - short term (up to 12 weeks), medium term (up to 26 weeks) and long term (more than 26 weeks). As schizophrenia is a long term disorder, short treatment studies are not clinically relevant. We decided to exclude studies lasting less than two weeks.</P>
<CRIT_OUTCOMES_PRIMARY MODIFIED="2009-09-25 14:05:21 +0100" MODIFIED_BY="[Empty name]">
<P>No clinically important response as defined by the individual studies (e.g. global impression less than much improved or less than 50% reduction on a rating scale) at long term.</P>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2010-09-30 13:24:23 +0100" MODIFIED_BY="[Empty name]">
<P>1. Death<BR/>1.1 Suicide<BR/>1.2 Natural causes</P>
<P>2. Leaving the studies early<BR/>2.1 Any reason<BR/>2.2 Specific reason (as described by individual studies)</P>
<P>3. Global state<BR/>3.1 No clinically important change in global state (as defined by individual studies) at short and medium term<BR/>3.2 Relapse (as defined by the individual studies)</P>
<P>4. Mental state<BR/>4.1 No clinically important change in general mental state at short and medium term<BR/>4.2 Average endpoint general mental state score<BR/>4.3 Average change in general mental state scores<BR/>4.4 No clinically important change in specific symptoms (positive symptoms of schizophrenia, negative symptoms of schizophrenia) at short and medium term<BR/>4.5 Average endpoint specific symptom score<BR/>4.6 Average change in specific symptom scores</P>
<P>5. General functioning<BR/>5.1 No clinically important change in general functioning at short and medium term<BR/>5.2 Average endpoint general functioning score<BR/>5.3 Average change in general functioning scores</P>
<P>6. Quality of life/satisfaction with treatment<BR/>6.1 No clinically important change in quality of life at short and medium term<BR/>6.2 Average endpoint quality of life score<BR/>6.3 Average change in quality of life scores</P>
<P>7. Cognitive functioning<BR/>7.1 No clinically important change in cognitive functioning at short and medium term<BR/>7.2 Average endpoint cognitive functioning score<BR/>7.3 Average change in cognitive functioning scores</P>
<P>8. Service use<BR/>8.1 Number of patients hospitalised<BR/>8.2 Number of patients discharged or readmitted (as defined in individual trial)</P>
<P>9. Adverse effects - general and specific<BR/>9.1 Number of participants with at least one adverse effect<BR/>9.2 Clinically important specific adverse effects (cardiac effects, movement disorders, prolactin increase and associated adverse events, metabolic side effects (as such weight gain, hyperlipidaemia and hyperglycaemia), effects on white blood cell count)<BR/>9.3 Average endpoint specific adverse effects<BR/>9.4 Average change in specific adverse effects</P>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2010-09-27 11:27:50 +0100" MODIFIED_BY="[Empty name]">
<ELECTRONIC_SEARCHES MODIFIED="2010-09-27 11:27:50 +0100" MODIFIED_BY="[Empty name]">
<P>We searched the Cochrane Schizophrenia Group's Trials Register (June 2007) using the phrase:</P>
<P>[(*clozapin* OR *clozaril* OR *denzapin* OR *zaponex*) in title, abstract and index terms in REFERENCE and interventions of STUDY]</P>
<P>This register is compiled by systematic searches of major databases, hand searches and conference proceedings (see <A HREF="http://www.mrw.interscience.wiley.com/cochrane/clabout/articles/SCHIZ/frame.html">Group module</A>).<BR/>
</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2009-08-14 14:11:55 +0100" MODIFIED_BY="[Empty name]">
<P>1. Reference lists<BR/>We searched references of articles selected for further relevant trials.</P>
<P>2. Conferences<BR/>We sought studies from recent conference proceedings if available.</P>
<P>3. Pharmaceutical companies:<BR/>We contacted companies performing trials with amisulpride, clozapine, olanzapine, quetiapine, risperidone, sertindole, ziprasidone or zotepine directly to obtain data on unpublished trials.</P>
<P>4. Personal contact<BR/>We contacted the first author of each included study for information regarding unpublished trials or for missing information.</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2010-09-30 13:29:11 +0100" MODIFIED_BY="[Empty name]">
<P>
<BR/>
</P>
<STUDY_SELECTION MODIFIED="2010-09-30 13:24:52 +0100" MODIFIED_BY="[Empty name]">
<P>CA and KK independently inspected all reports. We resolved any disagreement by discussion, and where there was still doubt, we acquired the full article for further inspection. Once the full articles were obtained, we independently decided whether the studies met the review criteria. If disagreement could not be resolved by discussion, we sought additional information and these trials were added to the list of those awaiting assessment.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2010-09-30 13:25:23 +0100" MODIFIED_BY="[Empty name]">
<P>1. Data extraction<BR/>CA, KK, CR, HH, FS, SS, SL independently extracted the data from selected trials. When disputes arose we attempted to resolve these by discussion. When this was not possible and further information was necessary to resolve the dilemma, the data were not entered and we added the trial to the list of those awaiting assessment.</P>
<P>2. Management<BR/>We extracted the data onto standard simple forms. Where possible, we entered data into RevMan in such a way that the area to the left of the line of no effect indicated a favourable outcome for clozapine.</P>
<P>3. Scale-derived data<BR/>3.1 Valid scales<BR/>A wide range of instruments are available to measure mental health outcomes. These instruments vary in quality and many are not valid, or are even ad hoc. It is accepted generally that measuring instruments should have the properties of reliability (the extent to which a test effectively measures anything at all) and validity (the extent to which a test measures that which it is supposed to measure) (<LINK REF="REF-Rust-1989" TYPE="REFERENCE">Rust 1989</LINK>). Unpublished scales are known to be subject to bias in trials of treatments for schizophrenia (<LINK REF="REF-Marshall-2000" TYPE="REFERENCE">Marshall 2000</LINK>). Therefore continuous data from rating scales were included only if the measuring instrument had been described in a peer-reviewed journal. In addition, the following minimum standards for instruments were set: the instrument should either be (a) a self-report or (b) completed by an independent rater or relative (not the therapist) and (c) the instrument should be a global assessment of an area of functioning.</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2010-09-27 13:17:54 +0100" MODIFIED_BY="[Empty name]">
<P>We assessed risk of bias using the tool described in the Cochrane Handbook for Systematic Reviews of Interventions (<LINK REF="REF-Higgins-2009" TYPE="REFERENCE">Higgins 2009</LINK>). This tool encourages consideration of how the sequence was generated, how allocation was concealed, the integrity of blinding at outcome, the completeness of outcome data, selective reporting and other biases. We would not have included studies where sequence generation was at high risk of bias or where allocation was clearly not concealed.<BR/>
</P>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2010-09-30 13:28:22 +0100" MODIFIED_BY="[Empty name]">
<P>1. Binary data<BR/>We calculated the relative risk (RR) and its 95% confidence interval (CI) based on the random-effects model, as this takes into account any differences between studies even if there is no statistically significant heterogeneity. It has been shown that RR is more intuitive (<LINK REF="REF-Boissel-1999" TYPE="REFERENCE">Boissel 1999</LINK>) than odds ratios and that odds ratios tend to be interpreted as RR by clinicians (<LINK REF="REF-Deeks-2000" TYPE="REFERENCE">Deeks 2000</LINK>). This misinterpretation then leads to an overestimate of the impression of the effect. When the overall results were significant we calculated the number needed to treat (NNT) and the number needed to harm (NNH) as the inverse of the risk difference, and its 95% confidence interval (CI).</P>
<P>Where possible, efforts were made to convert outcome measures to dichotomous data. This can be done by identifying cut-off points on rating scales and dividing participants accordingly into 'clinically improved' or 'not clinically improved'. It was generally assumed that if there had been a 50% reduction in a scale-derived score such as the Brief Psychiatric Rating Scale (BPRS, <LINK REF="REF-Overall-1962" TYPE="REFERENCE">Overall 1962</LINK>) or the Positive and Negative Syndrome Scale (PANSS, <LINK REF="REF-Kay-1986" TYPE="REFERENCE">Kay 1986</LINK>), this could be considered as a clinically significant response (<LINK REF="REF-Leucht-2005a" TYPE="REFERENCE">Leucht 2005a</LINK>, <LINK REF="REF-Leucht-2005b" TYPE="REFERENCE">Leucht 2005b</LINK>). If data based on these thresholds were not available, we used the primary cut-off presented by the original authors.</P>
<P>We carried out an intention-to-treat analysis. Everyone allocated to the interventions were counted, whether they completed the follow up or not. It was assumed that those who dropped out had no change of their outcome. This rule is conservative concerning response to treatment, because it assumes that those discontinuing the studies would not have responded. It is not conservative concerning side-effects, because it assumes that those discontinuing the studies would not have developed the side-effect if they had remained in the study, but we felt that assuming that all drop-outs would have developed side-effects would overestimate the risk.</P>
<P>2. Continuous data<BR/>
<BR/>2.1 Rating scales<BR/>A wide range of instruments are available to measure mental health outcomes. These instruments vary in quality and many are not valid, or are even ad hoc. For outcome instruments some minimum standards have to be set. They were that: (i) the psychometric properties of the instrument should have been described in a peer-reviewed journal (<LINK REF="REF-Marshall-2000" TYPE="REFERENCE">Marshall 2000</LINK>);and (ii) the instrument should either be: (a) a self report, or (b) completed by an independent rater or relative (not the therapist).</P>
<P>2.2 Summary statistic<BR/>For continuous outcomes we estimated a mean difference (MD) between groups. MDs were again based on the random-effects model, as this takes into account any differences between studies even if there is no statistically significant heterogeneity. When standard errors instead of standard deviations (SD) were presented, we converted the former to standard deviations. If both were missing we estimated SDs from P-values or used the average SD of the other studies (<LINK REF="REF-Furukawa-2006" TYPE="REFERENCE">Furukawa 2006</LINK>).</P>
<P>2.3 Endpoint versus change data<BR/>We combined both endpoint data and change data in the analysis, because there is no principal statistical reason why endpoint and change data should measure different effects (<LINK REF="REF-Higgins-2009" TYPE="REFERENCE">Higgins 2009</LINK>).</P>
<P>2.4 Skewed data<BR/>The meta-analytic formulas applied by RevMan Analyses (the statistical programme included in RevMan) require a normal distribution of data. The software is robust towards some skew, but to which degree of skewness meta-analytic calculations can still be reliably carried out is unclear. On the other hand, excluding all studies on the basis of estimates of the normal distribution of the data also leads to a bias, because a considerable amount of data may be lost leading to a selection bias. Therefore, we included all studies in the primary analysis. In a sensitivity analysis we excluded potentially skewed data applying the following rules:</P>
<P>a) When a scale started from the finite number zero the standard deviation, when multiplied by two, was less than the mean (as otherwise the mean is unlikely to be an appropriate measure of the centre of the distribution, <LINK REF="REF-Altman-1996" TYPE="REFERENCE">Altman 1996</LINK>).<BR/>b) If a scale started from a positive value (such as PANSS which can have values from 30 to 210) the calculation described above was modified to take the scale starting point into account. In these cases skew is present if 2SD&gt;(S-Smin), where S is the mean score and Smin is the minimum score.<BR/>c) In large studies (as a cut-off we used 200 participants) skewed data pose less of a problem. In these cases we entered the data in a synthesis.<BR/>d) The rules explained in a) and b) do not apply to change data. The reason is that when continuous data are presented on a scale which includes a possibility of negative values, it is difficult to tell whether data are non-normally distributed (skewed) or not. This is also the case for change data (endpoint minus baseline). In the absence of individual patient data it is impossible to know if data are skewed, though this is likely. After consulting the ALLSTAT electronic statistics mailing list, we presented change data in RevMan Analyses in order to summarise available information. In doing this, it was assumed either that data were not skewed or that the analysis could cope with the unknown degree of skew. Without individual patient data it is impossible to test this assumption. Change data were therefore included and a sensitivity analysis was not applied.</P>
<P>
<BR/>
</P>
</EFFECT_MEASURES>
<UNIT_OF_ANALYSIS MODIFIED="2010-09-30 13:28:37 +0100" MODIFIED_BY="[Empty name]">
<P>1. Cluster trials<BR/>Studies increasingly employ 'cluster randomisation' (such as randomisation by clinician or practice) but analysis and pooling of clustered data poses problems. Firstly, authors often fail to account for intraclass correlation in clustered studies, leading to a 'unit of analysis' error (<LINK REF="REF-Divine-1992" TYPE="REFERENCE">Divine 1992</LINK>) whereby P values are spuriously low, confidence intervals unduly narrow and statistical significance overestimated. This can cause type 1 errors (<LINK REF="REF-Bland-1997" TYPE="REFERENCE">Bland 1997</LINK>, <LINK REF="REF-Gulliford-1999" TYPE="REFERENCE">Gulliford 1999</LINK>).</P>
<P>Where clustering was not accounted for in primary studies, we presented the data in a table, with a (*) symbol to indicate the presence of a probable unit of analysis error. In subsequent versions of this review we will seek to contact first authors of studies to obtain intraclass correlation coefficients of their clustered data and to adjust for this using accepted methods (<LINK REF="REF-Gulliford-1999" TYPE="REFERENCE">Gulliford 1999</LINK>). Where clustering has been incorporated into the analysis of primary studies, we will also present these data as if from a non-cluster randomised study, but adjusted for the clustering effect.</P>
<P>We have sought statistical advice and have been advised that the binary data as presented in a report should be divided by a 'design effect'. This is calculated using the mean number of participants per cluster (m) and the intraclass correlation coefficient (ICC) [Design effect=1+(m-1)*ICC] (<LINK REF="REF-Donner-2002" TYPE="REFERENCE">Donner 2002</LINK>). If the ICC was not reported it was assumed to be 0.1 (<LINK REF="REF-Ukoumunne-1999" TYPE="REFERENCE">Ukoumunne 1999</LINK>).</P>
<P>If cluster studies had been appropriately analysed taking into account intraclass correlation coefficients and relevant data documented in the report, synthesis with other studies would have been possible using the generic inverse variance technique.</P>
<P>2. Cross-over trials<BR/>A major concern of cross-over trials is the carry-over effect. It occurs if an effect (e.g. pharmacological, physiological or psychological) of the treatment in the first phase is carried over to the second phase. As a consequence on entry to the second phase the participants can differ systematically from their initial state despite a wash-out phase. For the same reason cross-over trials are not appropriate if the condition of interest is unstable (<LINK REF="REF-Elbourne-2002" TYPE="REFERENCE">Elbourne 2002</LINK>). As both effects are very likely in schizophrenia, we will only use data of the first phase of cross-over studies.</P>
<P>3. Studies with multiple treatment groups<BR/>Where a study involved more than two treatment arms, if relevant, the additional treatment arms were presented in comparisons. Where the additional treatment arms were not relevant, these data were not reproduced.</P>
</UNIT_OF_ANALYSIS>
<MISSING_DATA MODIFIED="2009-10-05 22:31:53 +0100" MODIFIED_BY="[Empty name]">
<P>Although high rates of premature discontinuation are a major problem in this field, we felt that it is unclear which degree of attrition leads to a high degree of bias. We, therefore, did not exclude trials on the basis of the percentage of participants completing them. However we addressed the drop-out problem in all parts of the review, including the abstract. For this purpose we calculated, presented and commented on frequency statistics (overall rates of leaving the studies early in all studies and comparators pooled and their ranges).</P>
</MISSING_DATA>
<HETEROGENEITY_ASSESSMENT MODIFIED="2009-08-14 14:20:56 +0100" MODIFIED_BY="[Empty name]">
<P>1. Clinical heterogeneity<BR/>We considered all the included studies within any comparison to judge for clinical heterogeneity. </P>
<P>2. Statistical<BR/>2.1 Visual inspection<BR/>We visually inspected graphs to investigate the possibility of statistical heterogeneity. </P>
<P>2.2 Employing the I-squared statistic<BR/>Visual inspection was supplemented using, primarily, the I-squared statistic. This provides an estimate of the percentage of variability due to heterogeneity rather than chance alone. Where the I-squared estimate was greater than or equal to 50% we interpreted this as indicating the presence of considerable levels of heterogeneity (<LINK REF="REF-Higgins-2003" TYPE="REFERENCE">Higgins 2003</LINK>). If inconsistency was high and clear reasons explaining the heterogeneity were found, we presented the data separately. If not, we commented on the heterogeneity of the data.</P>
</HETEROGENEITY_ASSESSMENT>
<BIAS_ASSESSMENT MODIFIED="2009-10-05 22:40:56 +0100" MODIFIED_BY="[Empty name]">
<P>Reporting biases arise when the dissemination of research findings is influenced by the nature and direction of results (<LINK REF="REF-Egger-1997" TYPE="REFERENCE">Egger 1997</LINK>). We entered data from all identified and selected trials into a funnel graph (trial effect versus trial size) in an attempt to investigate the likelihood of overt publication bias. A formal test for funnel-plot asymmetry was not undertaken. We are aware that funnel plots may be useful in investigating reporting biases but are of limited power to detect small-study effects. We did not use funnel plots for outcomes where there were ten or fewer studies, or where all studies were of similar sizes.</P>
</BIAS_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2009-10-05 22:54:16 +0100" MODIFIED_BY="[Empty name]">
<P>We understand that there is a debate around the use of fixed or random-effects models. The random-effects method incorporates an assumption that the different studies are estimating different, yet related, intervention effects. This does seem true to us as we are a priori expecting some clinical heterogeneity between the patients in the different trials. Therefore, we chose the random effects model for all analyses (<LINK REF="REF-DerSimonian-1986" TYPE="REFERENCE">DerSimonian 1986</LINK>). This said, we acknowledge that as a disadvantage the random effects model puts added weight onto small studies which often are the most biased ones. Depending on the direction of effect these studies can either inflate or deflate the effect size.</P>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2010-09-30 13:29:11 +0100" MODIFIED_BY="[Empty name]">
<P>1. Subgroup analysis<BR/>We assessed each outcome by trial length. No other subgroup analysis was pre-specified.</P>
<P>2. Investigation of heterogeneity<BR/>If data were clearly heterogeneous we checked that data are correctly extracted and entered and that we had not made unit of analysis errors. If high levels of heterogeneity remained we did not undertake a meta-analyse at this point, because if there is considerable variation in results, and particularly if there is inconsistency in the direction of effects, it may be misleading to quote an average value for the intervention effect.</P>
</SUBGROUP_ANALYSIS>
<SENSITIVITY_ANALYSIS MODIFIED="2010-03-26 20:31:33 +0000" MODIFIED_BY="[Empty name]">
<P>We excluded studies with potentially skewed data. A recent report showed that some of the comparisons of atypical antipsychotics may have been biased by using inappropriate comparator doses (<LINK REF="REF-Heres-2006" TYPE="REFERENCE">Heres 2006</LINK>). We, therefore, also analysed whether the exclusion of studies with inappropriate comparator doses changed the results of the primary outcome and the general mental state.</P>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2010-09-30 14:49:52 +0100" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2010-09-30 13:34:53 +0100" MODIFIED_BY="[Empty name]">
<P>For substantive descriptions of studies, please see <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK> and <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK> tables.</P>
<SEARCH_RESULTS MODIFIED="2010-09-30 13:30:27 +0100" MODIFIED_BY="[Empty name]">
<P>Through the search strategy we found 1341 references, which includes a first search (857) in July 2006 and an update search (484) in June 2007. Two-hundred-and-twenty-six studies compared clozapine versus other atypical antipsychotics, from them only 27 studies fulfilled the review criteria.</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2010-09-30 13:34:33 +0100" MODIFIED_BY="[Empty name]">
<P>We selected 27 studies of which all were described as randomised. Only three studies gave details about randomisation methods and their implementation (<LINK REF="STD-Kumra-2008" TYPE="STUDY">Kumra 2008</LINK>, <LINK REF="STD-Shaw-2006" TYPE="STUDY">Shaw 2006 </LINK>and <LINK REF="STD-Wahlbeck-2000" TYPE="STUDY">Wahlbeck 2000</LINK>), the rest did not state methods used to generate the random allocation sequence, the allocation concealment and randomisation implementation. Twenty studies were double-blind and 7 single-blind/rater-blinded. In the studies the blindness was not assessed and no further details about it were given. Twenty-five studies were parallel clinical trials, two were cross-over studies (we included only the first phase) (<LINK REF="STD-Conley-2003" TYPE="STUDY">Conley 2003</LINK>, <LINK REF="STD-Lin-2003" TYPE="STUDY">Lin 2003</LINK>).</P>
<P>1. Length of trial<BR/>Twenty studies were short term studies (two up to 12 weeks), five studies belong to the medium term category (up to 26 weeks), and only two studies reported long term data (more than 26 weeks).</P>
<P>2. Participants<BR/>The 27 studies involved a total of 3099 participants. The comparison of clozapine versus olanzapine included 1753 participants, clozapine versus quetiapine, 306 participants, clozapine versus risperidone, 843 participants, clozapine versus ziprasidone, 146 participants, and the clozapine versus zotepine comparison, 109 participants.</P>
<P>Almost all studies used operationalised diagnostic criteria. Most studies included participants with diagnoses of schizophrenia or schizoaffective disorder according to the <I>Diagnostic and Statistical Manual of Mental Disorders</I> (DSM) III - R or IV criteria and only one used <I>The International Classification of Diseases</I>, <I>9th Revision </I>( ICD-9) criteria. Chinese studies used the <I>Chinese Classification of Mental Disorders</I> (CCMD) version 2 or 3 criteria. Two studies did not state if any operationalised diagnostic criteria were used. One of them, which compared clozapine versus ziprasidone, enrolled participants with schizophrenia who met criteria for treatment resistance (non-response in three adequate trials in past five years) and/or inability to tolerate antipsychotic treatment. The other one compared clozapine versus zotepine and reported that the participants were people with schizophrenia who have been treated with clozapine for more than five months.</P>
<P>Many participants were diagnosed as treatment resistant to prior antipsychotics. The criteria and definitions used varied.</P>
<P>
<LINK REF="STD-Moresco-2004" TYPE="STUDY">Moresco 2004</LINK> defined treatment resistance as lack of satisfactory clinical response to two previous antipsychotics, with duration of at least six weeks each, given an appropriate dosage (at least 500 mg chlorpromazine equivalent).</P>
<P>
<LINK REF="STD-Tollefson-2001" TYPE="STUDY">Tollefson 2001</LINK> included participants who had a history of 'resistance to previous antipsychotic', defined as lack of satisfactory clinical response to at least two previous oral neuroleptic treatments, each from a different chemical class, given for a duration of at least six weeks at an appropriate daily dosage equivalent to at least 500 mg/day of chlorpromazine, or to the maximum daily dosage when intolerable side-effects had been documented.</P>
<P>
<LINK REF="STD-Conley-2003" TYPE="STUDY">Conley 2003</LINK> defined 'treatment resistant' when there was evidence of: a persistent positive psychotic symptoms: item score &gt; or = 4 (moderate) on at least two of four positive symptoms items on the Brief Psychiatric Rating Scale (1 - 7) (BPRS); the concurrent presence of at least moderately severe illness as rated by the total BPRS score (score &gt; or = 45 on the 18 item scale) and score of at least moderate on the Clinical Global Impression scale (CGI) ; two failed historical trials of antipsychotics of at least six weeks duration at doses of at least 600 mg/day chlorpromazine equivalents; and no stable period of good social and/or occupational functioning within the last five years.</P>
<P>
<LINK REF="STD-McGurk-2005" TYPE="STUDY">McGurk 2005</LINK> included subjects who had evidence of 'treatment resistance' defined as at least one trial of a conventional antipsychotic at a dose equivalent to 600 mg/day of chlorpromazine, a second trial of a different conventional antipsychotic at a dose equivalent to 250 &#8211; 500 mg/day of chlorpromazine and at least a moderate severity score on one of the BPRS psychotics symptoms items or on one of the Scale for the Assessment of Negative Symptoms (SANS) global subscale.</P>
<P>
<LINK REF="STD-Wahlbeck-2000" TYPE="STUDY">Wahlbeck 2000</LINK> included participants with 'resistance to previous antipsychotics', defined as persistent psychotic symptoms for at least six months during which the participants received antipsychotic treatment from at least two different chemical classes at dosages equivalent to or greater than 1000 mg/day of chlorpromazine for a period of at least six weeks each.</P>
<P>
<LINK REF="STD-Kumra-2008" TYPE="STUDY">Kumra 2008</LINK> included participants who had a documented treatment failure of at least two prior adequate antipsychotic trials and a baseline BPRS total score of at least 35 and a score of at least moderate on one or more psychotic items on the BPRS scale.</P>
<P>
<LINK REF="STD-Breier-1999" TYPE="STUDY">Breier 1999</LINK> included participants who meet the criteria for 'partial response' to neuroleptics, i.e. a history of residual positive and/or negative symptoms after at least a six weeks trial of a therapeutic dose of a neuroleptic agent; at least a minimum level of positive and/or negative symptoms at the time of evaluation for the study; and at least a minimum level of positive and/or negative symptoms after a prospective trial of at least two weeks with fluphenazine, 20 mg/day (with dose adjustments between 10 mg/day and 30 mg/day allowed in order to optimise outcome). The minimum positive symptoms level was a total score of at least eight for the four BPRS positive symptoms items (conceptual disorganization, hallucinations, unusual thought content, and suspiciousness). The minimum negative symptoms level was a total score on SANS of at least 20.</P>
<P>
<LINK REF="STD-Volavka-2002" TYPE="STUDY">Volavka 2002</LINK> included participants with a history of 'sub-optimal treatment response' defined as</P>
<P>1) persistent positive symptoms (hallucinations, delusions, or marked thought disorder) after at least six contiguous weeks of treatment, presented or documented in the past, with one or more typical antipsychotics at doses 600 mg/day as chlorpromazine equivalents.<BR/>2) Poor level of functioning over the past two years, defined by the lack of competitive employment or enrolment in an academic or vocational program and not having age&#8211;expected interpersonal relationships with someone outside the biological family of origin with whom ongoing regular contacts were maintained.</P>
<P>
<LINK REF="STD-Azorin-2001" TYPE="STUDY">Azorin 2001</LINK> included participants with 'poor response to previous treatment', i.e. the patient's current episode had been treated continually with neuroleptic for at least the preceding 6 month without significant clinical improvement; the patients had undergone one unsuccessful trial of antipsychotic medication equivalent to 20 mg/day of haloperidol for at least six weeks (less if the patient was experiencing dose-limiting adverse events) since the onset of the concurrent episode. If several drugs have been prescribed simultaneously, the final equivalence dosage could be calculated by adding the individual equivalence and when the participants had not experienced a period of good functioning for at least 24 months despite a sufficient period of use of two antipsychotics from at least two chemical classes, or no period of good functioning for five years despite the use of three antipsychotics.</P>
<P>
<LINK REF="STD-Lin-2003" TYPE="STUDY">Lin 2003</LINK> included participants with partial response to clozapine, not stating the criteria.</P>
<P>Another six studies included participants who were treatment resistant and/or intolerant to treatment, again using various definitions:</P>
<P>
<LINK REF="STD-Naber-2005" TYPE="STUDY">Naber 2005</LINK> included participants who had failed to respond to at least one antipsychotic other than clozapine and olanzapine or had experienced intolerable side-effects during these prior antipsychotics treatment.</P>
<P>
<LINK REF="STD-Bondolfi-1998" TYPE="STUDY">Bondolfi 1998</LINK> used a similar definition and considered participants who had previously failed to respond to or be intolerant of at least two different antipsychotic drugs given in appropriate dose for at least four weeks each.</P>
<P>
<LINK REF="STD-Sacchetti-2006" TYPE="STUDY">Sacchetti 2006</LINK> defined treatment resistance as non response to three adequate trials in the past five years and/or inability to tolerate antipsychotic treatment.</P>
<P>
<LINK REF="STD-Bitter-2004" TYPE="STUDY">Bitter 2004</LINK> included participants who had failed to adequately respond to a standard acceptable treatment with a conventional antipsychotic medication (at least one treatment trial of four to six weeks duration 400 -600 mg chlorpromazine equivalents with either insufficient effectiveness or intolerable side-effects caused by the medication).</P>
<P>
<LINK REF="STD-Lindenberg-1997" TYPE="STUDY">Lindenberg 1997</LINK> included only participants who had been treated before for at least three weeks, each with two conventional neuroleptic using effective doses, without a satisfactory result or with intolerable side-effects.</P>
<P>
<LINK REF="STD-Shaw-2006" TYPE="STUDY">Shaw 2006</LINK> included participants with 'failure to respond to two antipsychotic medications' (typical or atypical) used at adequate doses (&gt;100 mg of chlorpromazine equivalents) and for adequate duration (four weeks unless terminated owing to intolerable adverse effects). 'Failed' was defined as insufficient response with persistent symptoms significantly impairing the child&#8217;s functioning according to child, parental, medical, and school reports or intolerable adverse effects.</P>
<P>
<LINK REF="STD-Meltzer-2003" TYPE="STUDY">Meltzer 2003</LINK> included participants who met the DMS-IV criteria for schizophrenia or schizoaffective disorder and had a high risk for suicide.</P>
<P>The following studies did not require treatment resistance as an inclusion criterion (<LINK REF="STD-Atmaca-2003" TYPE="STUDY">Atmaca 2003</LINK>, <LINK REF="STD-Heinrich-1994" TYPE="STUDY">Heinrich 1994</LINK>, <LINK REF="STD-Krakowski-2006" TYPE="STUDY">Krakowski 2006</LINK>, Li 2002, <LINK REF="STD-Li-2003" TYPE="STUDY">Li 2003</LINK>, <LINK REF="STD-Liu-2004" TYPE="STUDY">Liu 2004</LINK>, Li 2005, <LINK REF="STD-Ren-2002" TYPE="STUDY">Ren 2002</LINK>, <LINK REF="STD-Wang-2002" TYPE="STUDY">Wang 2002</LINK> and <LINK REF="STD-Zhou-2000" TYPE="STUDY">Zhou 2000</LINK>).</P>
<P>Some of the studies additionally considered criteria of inclusion based on minimum scores in BPRS, PANSS, CGI or Intelligence Quotient (IQ) (<LINK REF="STD-Azorin-2001" TYPE="STUDY">Azorin 2001</LINK>, <LINK REF="STD-Bitter-2004" TYPE="STUDY">Bitter 2004</LINK>, <LINK REF="STD-Bondolfi-1998" TYPE="STUDY">Bondolfi 1998</LINK>, <LINK REF="STD-Kumra-2008" TYPE="STUDY">Kumra 2008</LINK>, <LINK REF="STD-Naber-2005" TYPE="STUDY">Naber 2005</LINK>, <LINK REF="STD-Sacchetti-2006" TYPE="STUDY">Sacchetti 2006</LINK> and <LINK REF="STD-Tollefson-2001" TYPE="STUDY">Tollefson 2001</LINK>).</P>
<P>The age of the participants ranged from 7 to 70 years old. Most participants were from 18 to 65 years old; except for two studies (<LINK REF="STD-Kumra-2008" TYPE="STUDY">Kumra 2008</LINK>, <LINK REF="STD-Shaw-2006" TYPE="STUDY">Shaw 2006</LINK>) which included younger people (age from 7 to 18 years old). Overall there were more men than women in the included trials.</P>
<P>3. Setting<BR/>Trials took place in a mixture of inpatient and outpatient settings. Most of the studies were carried out with inpatients (13 studies: <LINK REF="STD-Atmaca-2003" TYPE="STUDY">Atmaca 2003</LINK>, <LINK REF="STD-Bitter-2004" TYPE="STUDY">Bitter 2004</LINK>, <LINK REF="STD-Conley-2003" TYPE="STUDY">Conley 2003</LINK>, <LINK REF="STD-Heinrich-1994" TYPE="STUDY">Heinrich 1994</LINK>, <LINK REF="STD-Krakowski-2006" TYPE="STUDY">Krakowski 2006</LINK>, <LINK REF="STD-Li-2003" TYPE="STUDY">Li 2003</LINK>, <LINK REF="STD-Li--2005" TYPE="STUDY">Li 2005</LINK>, <LINK REF="STD-Lin-2003" TYPE="STUDY">Lin 2003</LINK>, <LINK REF="STD-Liu-2004" TYPE="STUDY">Liu 2004</LINK>, <LINK REF="STD-Moresco-2004" TYPE="STUDY">Moresco 2004</LINK>, <LINK REF="STD-Shaw-2006" TYPE="STUDY">Shaw 2006</LINK>, <LINK REF="STD-Volavka-2002" TYPE="STUDY">Volavka 2002</LINK> and <LINK REF="STD-Zhou-2000" TYPE="STUDY">Zhou 2000</LINK>), followed by studies performed with in and outpatients (six studies: <LINK REF="STD-Azorin-2001" TYPE="STUDY">Azorin 2001</LINK>, <LINK REF="STD-Kumra-2008" TYPE="STUDY">Kumra 2008</LINK>, <LINK REF="STD-Li--2002" TYPE="STUDY">Li 2002</LINK>, <LINK REF="STD-McGurk-2005" TYPE="STUDY">McGurk 2005</LINK>, <LINK REF="STD-Meltzer-2003" TYPE="STUDY">Meltzer 2003</LINK> and <LINK REF="STD-Wang-2002" TYPE="STUDY">Wang 2002</LINK>). Other studies were carried out initially with inpatients, who were later discharged (four studies: <LINK REF="STD-Bondolfi-1998" TYPE="STUDY">Bondolfi 1998</LINK>, <LINK REF="STD-Naber-2005" TYPE="STUDY">Naber 2005</LINK>, <LINK REF="STD-Tollefson-2001" TYPE="STUDY">Tollefson 2001</LINK>and <LINK REF="STD-Wahlbeck-2000" TYPE="STUDY">Wahlbeck 2000</LINK>) and finally one study was performed only with outpatients (<LINK REF="STD-Ren-2002" TYPE="STUDY">Ren 2002</LINK>). Three studies did not report the setting of the participants. Twelve of the twenty-seven studies were multicenter and the participants were recruited in diverse countries including Turkey, Canada, France, Hungary, Switzerland, USA, China, Croatia, South Africa, Italy, United Kingdom, Czech Republic, Argentina, Chile, Germany, Belgium, Denmark, Finland, Norway, Portugal, Spain, and Ireland, leading to a wide ethnic diversity.</P>
<P>4. Study size<BR/>In the studies that compared clozapine and olanzapine, the largest and smallest studies were <LINK REF="STD-Meltzer-2003" TYPE="STUDY">Meltzer 2003</LINK> (n=980) and <LINK REF="STD-Conley-2003" TYPE="STUDY">Conley 2003</LINK>, respectively. The latter was a cross-over study, of which only the first phase was considered (n=13). The largest study that compared clozapine and risperidone was <LINK REF="STD-Azorin-2001" TYPE="STUDY">Azorin 2001</LINK> (n=273) and the smallest was <LINK REF="STD-Wahlbeck-2000" TYPE="STUDY">Wahlbeck 2000</LINK>, which is a pilot study (n=20). <LINK REF="STD-Li-2003" TYPE="STUDY">Li 2003</LINK> was the largest study that compared clozapine with quetiapine (n=76) and the smallest was <LINK REF="STD-Atmaca-2003" TYPE="STUDY">Atmaca 2003</LINK> (n=28). The study that compared clozapine versus ziprasidone randomised 146 participants (<LINK REF="STD-Sacchetti-2006" TYPE="STUDY">Sacchetti 2006</LINK>), and 109 participants were randomised to the comparison of clozapine versus zotepine studies (<LINK REF="STD-Lindenberg-1997" TYPE="STUDY">Lindenberg 1997</LINK>, <LINK REF="STD-Lin-2003" TYPE="STUDY">Lin 2003</LINK>), n=50 and n= 59 respectively).</P>
<P>5. Intervention and comparators<BR/>The 27 trials administered clozapine in a wide range of doses, from 207 mg/day to 642 mg/day (mean doses range). The ranges of comparator doses were wide, as well.The range of mean olanzapine doses was 16 mg/day to 30 mg/day. <LINK REF="STD-Conley-2003" TYPE="STUDY">Conley 2003</LINK> did not state the mean dose used but mentioned an allowed dose range between 30 - 50 mg/day. For quetiapine the mean dose ranged from 362 mg/day to 536 mg/day, and one study reported a dose range from 400 -700 mg daily after the first 10 days (<LINK REF="STD-Liu-2004" TYPE="STUDY">Liu 2004</LINK>). Risperidone was used in a range from 3.2 mg/day to 12 mg/day. The mean dose of the single ziprasidone arm was 130 mg/day. Regarding clozapine versus zotepine trials, one study used a mean dose of 377 mg/day (<LINK REF="STD-Lin-2003" TYPE="STUDY">Lin 2003</LINK>) and the other one used doses from 150 to 450 mg/day (<LINK REF="STD-Lindenberg-1997" TYPE="STUDY">Lindenberg 1997</LINK>).</P>
<P>6. Outcomes<BR/>6.1 Death<BR/>Death was reported in some studies that compared clozapine with olanzapine (<LINK REF="STD-Conley-2003" TYPE="STUDY">Conley 2003</LINK>; <LINK REF="STD-Meltzer-2003" TYPE="STUDY">Meltzer 2003</LINK>) and clozapine with risperidone (<LINK REF="STD-Azorin-2001" TYPE="STUDY">Azorin 2001</LINK>; <LINK REF="STD-Wahlbeck-2000" TYPE="STUDY">Wahlbeck 2000</LINK>).</P>
<P>6.2 Leaving the study early<BR/>Leaving the study early was frequently reported, but in some studies it was not indicated how many participants of each group left early.</P>
<P>6.3 Global state<BR/>Improvement on global state was presented as dichotomous data, the criterion used was of 'at least much improved' using Clinical Global Impression (CGI) scales. Olanzapine (<LINK REF="STD-Naber-2005" TYPE="STUDY">Naber 2005</LINK>, <LINK REF="STD-Tollefson-2001" TYPE="STUDY">Tollefson 2001</LINK>) and risperidone (<LINK REF="STD-Heinrich-1994" TYPE="STUDY">Heinrich 1994</LINK>) trials reported this outcome. Other studies used the criterion as 'less than common criteria' (<LINK REF="STD-Li-2003" TYPE="STUDY">Li 2003</LINK>) and 'less than successfully treated and no increase on the Clinical Global Impression - Severity scale (CGI-S)' (<LINK REF="STD-Lin-2003" TYPE="STUDY">Lin 2003</LINK>).</P>
<P>6.4 Mental state<BR/>6.4.1 Mental state - dichotomous<BR/>Our predefined criterion was an at least a 50% reduction of the baseline value of the BPRS or Positive and Negative Syndrome Scale (PANSS). When such a criterion was not available, the primary cut-off presented by the original author was used. Some studies also used combined criteria: at least 20% BPRS total score reduction plus CGI-S &lt; 3 or BPRS &lt; 35 (this was described as at least 20% BPRS reduction and 'mildly ill or better' in the comparison and data tables). <LINK REF="STD-Kumra-2008" TYPE="STUDY">Kumra 2008</LINK> used the criterion of at least 30% BPRS total plus 'very much' or 'much improved' on CGI. One study (<LINK REF="STD-McGurk-2005" TYPE="STUDY">McGurk 2005</LINK>) that compared clozapine with risperidone used the criterion of at least 40% improvement on the BPRS psychotics cluster (cluster: hallucinations, delusions, suspiciousness and conceptual disorganization).</P>
<P>6.4.2 Mental state - continuous<BR/>The PANSS total was used in most studies to examine the participants overall mental state. Specific symptoms were mainly measured by the PANSS positive and negative symptoms subscores. Other studies used the Scale for the Assessment of Positive Symptoms (SAPS) or Scale for the Assessment of Negative Symptoms (SANS) scores, respectively. Only a few studies used the BPRS total score and its subscores. The data were presented as average change or average at endpoint on the score.</P>
<P>6.5 General functioning and social functioning<BR/>General functioning and social functioning were reported in only one study that compared clozapine with risperidone (<LINK REF="STD-Wahlbeck-2000" TYPE="STUDY">Wahlbeck 2000</LINK>). These outcomes were measured by Global Assessment of Functioning (GAF) and Social Functioning Scale (SFS) respectively. The average scores at endpoint were presented.</P>
<P>6.6 Quality of Life / satisfaction with treatment<BR/>Quality of life / satisfaction with treatment was measured in only one study that compared clozapine with olanzapine (<LINK REF="STD-Naber-2005" TYPE="STUDY">Naber 2005</LINK>) using the Subjective Well Being Under Neuroleptic Treatment (SWN) and Munich Life Dimension List (MLDL) respectively. Average score at endpoint was reported. <LINK REF="STD-Wahlbeck-2000" TYPE="STUDY">Wahlbeck 2000</LINK> assessed satisfaction with the treatment by the Drug Attitude Inventory (DAI) and reported the average score at endpoint.</P>
<P>6.7 Cognitive functioning<BR/>Cognitive functioning was reported in only one study (<LINK REF="STD-Volavka-2002" TYPE="STUDY">Volavka 2002</LINK>) that compared clozapine with risperidone and with olanzapine. The outcome was evaluated through the number of participants who presented a clinically important improvement in the neurocognitive score defined as a reduction of 0.5 SD on neurocognitive score.</P>
<P>In <LINK REF="STD-Volavka-2002" TYPE="STUDY">Volavka 2002</LINK> continuous data based on the PANSS cognitive subscore (average at endpoint and average change) were reported as a factor score and the neurocognitive global score at endpoint was reported as a Z score. The Z score was based on the mean and SD of each test (16 cognitive tests) at baseline. Only the variables from participants who completed each test at both baseline and follow-up, were used. This Z score result was the contribution of each test to each of the four domains chosen by the author. These variables were not useful for the analysis of this review.</P>
<P>6.8 Service use<BR/>Service use was missing in all studies, except one that reported the number of participants hospitalised due to risk of suicide (<LINK REF="STD-Meltzer-2003" TYPE="STUDY">Meltzer 2003</LINK>).</P>
<P>6.9 Adverse effects<BR/>Adverse effects were obtained through routine measures, e.g. blood sample, weight measure, ECG, or recorded from the clinical evaluation and spontaneously reports. Few studies used a checklist to report the adverse effects, i.e. validated questionnaires such as the Association for Methodology and Documentation in Psychiatry (AMDP) somatic scale (<LINK REF="STD-Heinrich-1994" TYPE="STUDY">Heinrich 1994</LINK>; <LINK REF="STD-Tollefson-2001" TYPE="STUDY">Tollefson 2001</LINK>), and the Udvalg for Kliniske Undersgelser (UKU) (<LINK REF="STD-Bondolfi-1998" TYPE="STUDY">Bondolfi 1998</LINK>; <LINK REF="STD-Lindenberg-1997" TYPE="STUDY">Lindenberg 1997</LINK>; <LINK REF="STD-Lin-2003" TYPE="STUDY">Lin 2003</LINK>), Subjective Treatment Emergent Symptoms Scale (STESS) (<LINK REF="STD-Shaw-2006" TYPE="STUDY">Shaw 2006</LINK>; <LINK REF="STD-Kumra-2008" TYPE="STUDY">Kumra 2008</LINK>) and Coding Symbols for a Thesaurus of Adverse Reaction Terms (COSTART) (<LINK REF="STD-Bitter-2004" TYPE="STUDY">Bitter 2004</LINK>; <LINK REF="STD-Tollefson-2001" TYPE="STUDY">Tollefson 2001</LINK>). Additionally some researchers developed their own checklist specially for the study. Data were dichotomous as well as continuous.</P>
<P>There were some adverse effect data that could not be examined because comparator data were not reported (continuous data) or the number of patients assessed were not stated (dichotomous data) (<LINK REF="STD-Azorin-2001" TYPE="STUDY">Azorin 2001</LINK>, Li 2002, <LINK REF="STD-Sacchetti-2006" TYPE="STUDY">Sacchetti 2006</LINK>, <LINK REF="STD-Shaw-2006" TYPE="STUDY">Shaw 2006</LINK>, <LINK REF="STD-Tollefson-2001" TYPE="STUDY">Tollefson 2001</LINK> and <LINK REF="STD-Wang-2002" TYPE="STUDY">Wang 2002</LINK>).</P>
<P>Extrapyramidal effects were assessed by specific scales such as Abnormal Involuntary Movement Scale (AIMS), Barnes Akathisia Scale (BAS), Simpson Angus Scale (SAS), Hillside akathisia scale (HAS), Extrapyramidal Symptom Rating Scale (ESRS) and by means of a checklist or clinical evaluation of adverse effects.</P>
<P>7. Outcome scales<BR/>Details of scales that provided usable data are shown below. Reasons for data exclusion from other instruments are given under &#8220;Notes&#8221; in the &#8220;<LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>&#8221; tables.</P>
<P>7.1 Global state<BR/>Clinical Global Impression Scale - CGI Scale (<LINK REF="REF-Guy-1972" TYPE="REFERENCE">Guy 1972</LINK>).<BR/>This scale is used to assess both severity of illness and clinical improvement, by comparing the conditions of the person standardized against other people with the same diagnosis. A seven-point scoring system is usually used with low scores showing a decrease on severity and/or an overall improvement.</P>
<P>7.2 Mental state<BR/>7.2.1 Brief Psychiatric Rating Scale - BPRS (<LINK REF="REF-Overall-1962" TYPE="REFERENCE">Overall 1962</LINK>).<BR/>This scale is used to assess the severity of abnormal mental state. The original scale has 16 items, but a revised 18-item scale is commonly used. Each item is defined on a seven-point scale (0-6 or 1-7) varying from 'not present' to 'extremely severe'. Scores can range from 0 to126, where high scores indicate more severe symptoms.</P>
<P>7.2.2 Positive and Negative Syndrome Scale - PANSS (<LINK REF="REF-Kay-1986" TYPE="REFERENCE">Kay 1986</LINK>).<BR/>This schizophrenia scale has 30 items, each of which can be defined on a seven-point scoring system varying from one - absent to seven - extreme. This scale can be divided into three subscales for measuring the severity of general psychopathology, positive symptoms (PANSS-P), and negative symptoms (PANSS-N). A low score indicates less severity.</P>
<P>7.2.3 Scale for the Assessment of Positive Symptoms &#8211; SAPS (<LINK REF="REF-Andreasen-1984" TYPE="REFERENCE">Andreasen 1984</LINK>).<BR/>This instrument covers a specific positive symptoms scale (hallucinations, delusions, thought disorder, bizarre/disorganized behavior and inappropriate affect). It is scored from 0 (not present) to 5 (very frequent) points.</P>
<P>7.2.4 Scale for the Assessment of Negative Symptoms - SANS (<LINK REF="REF-Andreasen-1984b" TYPE="REFERENCE">Andreasen 1984b</LINK>).<BR/>This six-point scale gives a global rating of the following negative symptoms; alogia, affective blunting, avolition-apathy, anhedonia-asociality and attention impairment. Higher scores indicate more symptoms.</P>
<P>7.3 General Functioning<BR/>7.3.1 Global Assessment of Functioning - GAF (<LINK REF="REF-APA-1994" TYPE="REFERENCE">APA 1994</LINK>).<BR/>The GAF is a clinician-rated assessment of overall functioning, which considers psychological, social, and occupational functioning on a scale 0-100. Lower scores indicate poorer functioning.</P>
<P>7.3.2 Social Functioning Scale - SFS (<LINK REF="REF-Birchwood-1990" TYPE="REFERENCE">Birchwood 1990</LINK>).<BR/>The SFS assesses function areas that are crucial for the community maintenance of individuals with schizophrenia. The seven areas are social engagement/withdrawal, interpersonal behavior, pro-social activities, recreation, independence-competence, independence-performance and employment/occupation. The range of total scores is from 418 (poor) to 944.5 (optimum).</P>
<P>7.4 Quality of Life / treatment satisfaction<BR/>7.4.1 Subjective well being under neuroleptic treatment - SWN (<LINK REF="REF-Naber-1995" TYPE="REFERENCE">Naber 1995</LINK>).<BR/>This scale assesses the subjective effects of antipsychotics, both benefits and burden, from the perspective of the patients. This scale is a self-rating scale, which has 38 items related to the antipsychotic treatment, each of which can be defined on six point scoring. A high score indicates better subjective well-being.</P>
<P>7.4.2 Munich Life Dimension List - MLDL (<LINK REF="REF-Heinisch-1991" TYPE="REFERENCE">Heinisch 1991</LINK>).<BR/>The MLDL focuses on the subjective evaluation of the quality of life and comprises 19 areas of life. The scale ranges from zero (very dissatisfied, completely unimportant) to ten (very satisfied, very important).</P>
<P>7.4.3 Drug Attitude Inventory - DAI-10 (<LINK REF="REF-Hogan-1983" TYPE="REFERENCE">Hogan 1983</LINK>).<BR/>This scale is a self-report ten-item scale for assessing patient satisfaction with antipsychotic treatment. Each item is rated one (does not favour drug) or two (favour drug). The range of a total score is 10-20. Higher scores indicate a more favourable attitude towards antipsychotic drug treatment.</P>
<P>7.5 Side-effects<BR/>7.5.1 Abnormal Involuntary Movement Scale - AIMS (<LINK REF="REF-NIMH-1975" TYPE="REFERENCE">NIMH 1975</LINK>).<BR/>This scale has been used to assess tardive dyskinesia, a long term, drug-induced movement disorder. The AIMS can also be used to assess some short term movement disorders such as tremor.</P>
<P>7.5.2 Barnes Akathisia Scale - BAS (<LINK REF="REF-Barnes-1989" TYPE="REFERENCE">Barnes 1989</LINK>).<BR/>The scale comprises items rating the observable, restless movements that characterize akathisia, a subjective awareness of restlessness, and any distress associated with the condition. These items are rated from zero - normal to three - severe. In addition, there is an item for rating global severity (from zero - absent to five - severe). A low score indicates low levels of akathisia.</P>
<P>7.5.3 Extrapyramidal Symptom Rating Scale - ESRS (<LINK REF="REF-Chouinard-1980" TYPE="REFERENCE">Chouinard 1980</LINK>).<BR/>This scale consists of a questionnaire relating to parkinsonian symptoms (nine items), a physician's examination for parkinsonism and dyskinetic movements (eight items), and a clinical global impression of tardive dyskinesia. High scores indicate severe levels of movement disorder.</P>
<P>7.5.4 Simpson Angus Scale - SAS (<LINK REF="REF-Simpson-1970" TYPE="REFERENCE">Simpson 1970</LINK>).<BR/>This ten-item scale, with a scoring system from zero to four for each item, measures drug-induced Parkinsonism, a short term drug-induced movement disorder. A low score indicates low levels of Parkinsonism.</P>
<P>7.5.5 Hillside akathisia scale - HAS (<LINK REF="REF-Fleischhaker-1989" TYPE="REFERENCE">Fleischhaker 1989</LINK>).<BR/>Scale comprises two subjective items: inner restlessness and urge to move combined with a division of objective signs in three regional items: axial, upper limbs and lower limbs. Each item is rated from zero to four for each item, with separate evaluations for patient sitting, standing and lying. The global evaluation for each item can also be recorded. The full scale allows the assessment of the effect of activation; global impression items for severity and improvements under treatment are also provided with a scoring system of zero &#8211; seven points.</P>
<P>8. Missing outcomes<BR/>In general there were the following missing outcomes: global functioning, quality of life, cognitive functioning, service use and mortality. The studies' principal focus was the response to the treatment, leaving the study early and adverse effects, which were not always adequately documented.</P>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2010-09-30 13:34:53 +0100" MODIFIED_BY="[Empty name]">
<P>We excluded 189 studies. Thirty-four were not randomised trials, including seven naturalistic, nine open label studies and one naturalistic/open label trial. One-hundred-and-thirty-one were randomised trials but the blindness was unclear. Ten were not clinical trials but rather reviews or observational studies. In another four studies the allocation was unclear. Other studies were excluded because participants or interventions did not fulfil the review criteria (three and five studies respectively). Finally, the CATIE (<LINK REF="STD-CATIE" TYPE="STUDY">CATIE</LINK>) and the CUtLASS (<LINK REF="STD-CUTLASS" TYPE="STUDY">CUTLASS</LINK>) studies were excluded, the first one because the clozapine trial was an open one concerning the clozapine arm. The second study was excluded because the analysis compared clozapine versus the other newer antipsychotics pooled.</P>
<SUBSECTION>
<HEADING LEVEL="4">Awaiting assessment</HEADING>
<P>The ten studies in this category were mostly conference abstracts for which the data reported were not sufficient to decide if they fulfil the criteria to be selected. When it was possible, we contacted the relevant sources and we are waiting for some answers.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Ongoing studies</HEADING>
<P>To the best of our knowledge, there are no ongoing studies during the period of the search.</P>
</SUBSECTION>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2009-09-19 23:46:12 +0100" MODIFIED_BY="[Empty name]">
<P>Judgement of risks are illustrated in <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>
</P>
<ALLOCATION MODIFIED="2009-08-14 14:33:14 +0100" MODIFIED_BY="[Empty name]">
<P>Details regarding randomisation methods as well as sequence generation and allocation concealment, were largely missing. This made it difficult to judge the risk of bias. All studies included were stated to be randomised. From 27 only eight presented some details about the sequence generation, allocation concealment and restriction. <LINK REF="STD-Shaw-2006" TYPE="STUDY">Shaw 2006</LINK> used a random numbers chart and was conducted in blocks of four, numbered containers were used to implement the allocation sequence. The pharmaceutical development service generated the allocation sequence. Also <LINK REF="STD-Kumra-2008" TYPE="STUDY">Kumra 2008</LINK> and <LINK REF="STD-Wahlbeck-2000" TYPE="STUDY">Wahlbeck 2000</LINK> stated that participants were assigned to treatment by computer generated randomisation. The following studies made some statements on restriction: <LINK REF="STD-Naber-2005" TYPE="STUDY">Naber 2005</LINK> and <LINK REF="STD-Tollefson-2001" TYPE="STUDY">Tollefson 2001</LINK> stated that they used a 1:1 allocation scheme. <LINK REF="STD-Krakowski-2006" TYPE="STUDY">Krakowski 2006</LINK> used a block randomisation scheme with a block size of three and no baseline stratification. <LINK REF="STD-Meltzer-2003" TYPE="STUDY">Meltzer 2003</LINK> randomised in a 1:1 ratio within blocks of four participants from each medical centre (67 medical centres). <LINK REF="STD-Azorin-2001" TYPE="STUDY">Azorin 2001</LINK>stated that the allocation was balanced by country, with block size of six. The rest of the studies did not present further details.</P>
</ALLOCATION>
<BLINDING MODIFIED="2009-04-23 13:48:36 +0100" MODIFIED_BY="[Empty name]">
<P>Twenty studies were double-blind and seven were stated to be single-blind (rater-blinded). Some of the 27 studies gave details about people who were blinded (e.g. psychiatrics, raters, patients, nurses, investigator) (<LINK REF="STD-Atmaca-2003" TYPE="STUDY">Atmaca 2003</LINK>, <LINK REF="STD-Breier-1999" TYPE="STUDY">Breier 1999</LINK>, <LINK REF="STD-Krakowski-2006" TYPE="STUDY">Krakowski 2006</LINK>, <LINK REF="STD-Meltzer-2003" TYPE="STUDY">Meltzer 2003</LINK>, <LINK REF="STD-Moresco-2004" TYPE="STUDY">Moresco 2004</LINK>, <LINK REF="STD-Shaw-2006" TYPE="STUDY">Shaw 2006</LINK> and <LINK REF="STD-Volavka-2002" TYPE="STUDY">Volavka 2002</LINK>). Only <LINK REF="STD-Meltzer-2003" TYPE="STUDY">Meltzer 2003</LINK> reported that an external entity regularly monitored the masking of the raters, however the monitoring methods were not explained. No study formally assessed the effectiveness of blinding.</P>
</BLINDING>
<EXCLUSIONS MODIFIED="2009-08-14 14:33:56 +0100" MODIFIED_BY="[Empty name]">
<P>Most findings were presented in graphs and tables. Some results were described in the text, but often these reports were incomplete (lack of case numbers or standard deviations). Descriptive statistics and statistical test were used to show similarity and equilibrium between the treatment groups and their characteristics at baseline.</P>
<P>Often incomplete outcome data were not correctly addressed, because intention-to-treat analysis were not always applied.</P>
<P>Most studies reported the loss of follow up indicating the specific reason of the dropout. However, not all studies considered these data in their analysis. Intention-to-treat analysis (ITT) was applied by <LINK REF="STD-Azorin-2001" TYPE="STUDY">Azorin 2001</LINK>, <LINK REF="STD-Bitter-2004" TYPE="STUDY">Bitter 2004</LINK>, <LINK REF="STD-Bondolfi-1998" TYPE="STUDY">Bondolfi 1998</LINK>, <LINK REF="STD-Heinrich-1994" TYPE="STUDY">Heinrich 1994</LINK>, <LINK REF="STD-Krakowski-2006" TYPE="STUDY">Krakowski 2006</LINK>, <LINK REF="STD-Kumra-2008" TYPE="STUDY">Kumra 2008</LINK>, <LINK REF="STD-Meltzer-2003" TYPE="STUDY">Meltzer 2003</LINK>, <LINK REF="STD-Naber-2005" TYPE="STUDY">Naber 2005</LINK>, <LINK REF="STD-Sacchetti-2006" TYPE="STUDY">Sacchetti 2006</LINK>, <LINK REF="STD-Shaw-2006" TYPE="STUDY">Shaw 2006</LINK> and <LINK REF="STD-Wahlbeck-2000" TYPE="STUDY">Wahlbeck 2000</LINK>. The use of this analysis was unclear in <LINK REF="STD-Azorin-2001" TYPE="STUDY">Azorin 2001</LINK> and <LINK REF="STD-Naber-2005" TYPE="STUDY">Naber 2005</LINK> because not all randomised participants were included. <LINK REF="STD-Azorin-2001" TYPE="STUDY">Azorin 2001</LINK> established as ITT criteria all participants with at least one BPRS evaluation after treatment initiation and <LINK REF="STD-Naber-2005" TYPE="STUDY">Naber 2005</LINK> considered as ITT population all participants with a baseline and at least one post baseline value.</P>
<P>Missing values were replaced by the last observed value (LOCF last observation carried forward) in <LINK REF="STD-Azorin-2001" TYPE="STUDY">Azorin 2001</LINK>, <LINK REF="STD-Bitter-2004" TYPE="STUDY">Bitter 2004</LINK>, <LINK REF="STD-Bondolfi-1998" TYPE="STUDY">Bondolfi 1998</LINK>, <LINK REF="STD-Conley-2003" TYPE="STUDY">Conley 2003</LINK>, <LINK REF="STD-Heinrich-1994" TYPE="STUDY">Heinrich 1994</LINK>, <LINK REF="STD-Naber-2005" TYPE="STUDY">Naber 2005</LINK>, <LINK REF="STD-Sacchetti-2006" TYPE="STUDY">Sacchetti 2006</LINK>, <LINK REF="STD-Shaw-2006" TYPE="STUDY">Shaw 2006</LINK>, <LINK REF="STD-Tollefson-2001" TYPE="STUDY">Tollefson 2001</LINK> and <LINK REF="STD-Wahlbeck-2000" TYPE="STUDY">Wahlbeck 2000</LINK>.</P>
</EXCLUSIONS>
<SELECTIVE_REPORTING MODIFIED="2009-04-27 14:10:09 +0100" MODIFIED_BY="[Empty name]">
<P>Many authors reported only adverse events that occurred in at least 5% of the participants. This procedure could miss rare but important adverse events.</P>
<P>There is some evidence that pharmaceutical companies sometimes highlight the benefits of their compounds and tend to suppress their disadvantages (<LINK REF="REF-Heres-2006" TYPE="REFERENCE">Heres 2006</LINK>). Data on sponsoring of six studies were not available.</P>
</SELECTIVE_REPORTING>
<OTHER_BIAS_SOURCES MODIFIED="2009-05-26 08:22:38 +0100" MODIFIED_BY="[Empty name]">
<P>Eight studies were sponsored by pharmaceutical companies (<LINK REF="STD-Azorin-2001" TYPE="STUDY">Azorin 2001</LINK>, <LINK REF="STD-Bitter-2004" TYPE="STUDY">Bitter 2004</LINK>, <LINK REF="STD-Bondolfi-1998" TYPE="STUDY">Bondolfi 1998</LINK>, <LINK REF="STD-Krakowski-2006" TYPE="STUDY">Krakowski 2006</LINK>, <LINK REF="STD-Lindenberg-1997" TYPE="STUDY">Lindenberg 1997</LINK>, <LINK REF="STD-Meltzer-2003" TYPE="STUDY">Meltzer 2003</LINK>, <LINK REF="STD-Moresco-2004" TYPE="STUDY">Moresco 2004</LINK> and <LINK REF="STD-Naber-2005" TYPE="STUDY">Naber 2005</LINK>) and in <LINK REF="STD-Breier-1999" TYPE="STUDY">Breier 1999</LINK> and <LINK REF="STD-Tollefson-2001" TYPE="STUDY">Tollefson 2001</LINK> authors work for a pharmaceutical company. From eight studies, six studies did not declare if the study methods and data analysis were performed independently of the sponsor. Two of the eight studies were supported by pharmaceutical companies marketing clozapine (<LINK REF="STD-Azorin-2001" TYPE="STUDY">Azorin 2001</LINK> and <LINK REF="STD-Meltzer-2003" TYPE="STUDY">Meltzer 2003</LINK>), five trials were supported by pharmaceutical companies marketing the comparator substances and only one was supported by pharmaceutical companies of both clozapine and its comparator (<LINK REF="STD-Bondolfi-1998" TYPE="STUDY">Bondolfi 1998</LINK>). Pharmaceutical companies have an inevitable conflict of interest which may well lead to bias (<LINK REF="REF-Heres-2006" TYPE="REFERENCE">Heres 2006</LINK> and <LINK REF="REF-Leucht-2008" TYPE="REFERENCE">Leucht 2008</LINK>).</P>
</OTHER_BIAS_SOURCES>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2010-09-30 14:49:52 +0100" MODIFIED_BY="[Empty name]">
<P>1. Comparison 1. CLOZAPINE versus OLANZAPINE<BR/>Twelve studies fulfilled the review criteria. Seven were short term studies ( <LINK REF="STD-Atmaca-2003" TYPE="STUDY">Atmaca 2003</LINK>; <LINK REF="STD-Krakowski-2006" TYPE="STUDY">Krakowski 2006</LINK>; <LINK REF="STD-Kumra-2008" TYPE="STUDY">Kumra 2008</LINK>; <LINK REF="STD-Moresco-2004" TYPE="STUDY">Moresco 2004</LINK>; <LINK REF="STD-Shaw-2006" TYPE="STUDY">Shaw 2006</LINK>; <LINK REF="STD-Wang-2002" TYPE="STUDY">Wang 2002</LINK>) four medium term studies (<LINK REF="STD-Bitter-2004" TYPE="STUDY">Bitter 2004</LINK>;<LINK REF="STD-Naber-2005" TYPE="STUDY">Naber 2005</LINK>; <LINK REF="STD-Tollefson-2001" TYPE="STUDY">Tollefson 2001</LINK>; <LINK REF="STD-Volavka-2002" TYPE="STUDY">Volavka 2002</LINK>) and one was a long term study (<LINK REF="STD-Volavka-2002" TYPE="STUDY">Volavka 2002</LINK>). Most of these studies were performed in America and Europe. Two studies were multinational including participants from Latin American and Africa and another one was performed in China.</P>
<P>1.1 Death<BR/>Only two studies reported the mortality during the trials (<LINK REF="STD-Conley-2003" TYPE="STUDY">Conley 2003</LINK>; <LINK REF="STD-Meltzer-2003" TYPE="STUDY">Meltzer 2003</LINK>). Deaths from any reason (1 RCT, n=980, RR 1.50 CI 0.62 to 3.64), natural causes (2 RCTs, n=993, RR 1.40 CI 0.45 to 4.38) and suicide (2 RCTs, n=993, RR 1.67 CI 0.40 to 6.94) were all similarly likely whether allocated to clozapine or olanzapine.</P>
<P>1.2.Leaving the study early: 1. Any reason<BR/>Overall a high percentage of attrition for any reason were observed in both groups. The percentage of participants that discontinued the trials was 40% and 38% for clozapine and olanzapine groups, respectively. There was no significant difference between groups (11 RCTs, n=1702, RR 1.04 CI 0.93 to 1.17).</P>
<P>1.3. Leaving the study early: 2. Adverse effects<BR/>Leaving the study early due to adverse effects was more common in the clozapine group (10%) than in the olanzapine group (6%). This difference was statistically significant (9 RCTs, n=1674, RR 1.60 CI 1.07 to 2.40, NNT 25 CI 15 to 73).</P>
<P>1.4. Leaving the study early: 3. Inefficacy<BR/>Both groups showed similar attrition rates due to inefficacy (5% clozapine and 6% olanzapine) there was no significant difference between groups (10 RCTs, n=1674, RR 0.72 CI 0.40 to 1.30). <LINK REF="STD-Meltzer-2003" TYPE="STUDY">Meltzer 2003</LINK> found that in the long term clozapine was associated with less attrition due to lack of efficacy than olanzapine (1 RCT, n=980, RR 0.33 CI 0.12 to 0.91, NNT 49 CI 26 to 364).</P>
<P>1.5 Global state<BR/>1.5.1 No clinically important change: less than much improved<BR/>No clinically important change in global state was defined as the number of people who were not 'at least much improved' according to the CGI improvement rating. The frequencies in both groups were similar (clozapine: 61%; olanzapine: 54%) and not statistically significantly different (2 RCTs, n=294, RR 1.13 CI 0.93 to 1.38).</P>
<P>1.5.2 Relapse<BR/>
<LINK REF="STD-Naber-2005" TYPE="STUDY">Naber 2005</LINK> reported that one participant of each group suffered a relapse (2%) during the trial. Hence no significant difference between groups was found (1 RCT, n=114, RR 1.00 CI 0.06 to 15.60).</P>
<P>1.6 Mental state: 1. No clinically important change - various criteria<BR/>1.6.1. Less than 20% reduction on BPRS-24 (1-7) total score<BR/>The short term study <LINK REF="STD-Shaw-2006" TYPE="STUDY">Shaw 2006</LINK> found that fewer people taking clozapine (67%) than those taking olanzapine (85%) did not have an improvement on their mental state, however this difference was not statistically significant (1 RCT, n=25, RR 0.79 CI 0.50 to 1.25).</P>
<P>1.6.2 Less than 50% reduction on BPRS-18 (1-7) total score<BR/>The short term study <LINK REF="STD-Wang-2002" TYPE="STUDY">Wang 2002</LINK> found that 45% of the participants of the clozapine group and 40% of the olanzapine group did not improve as this criterion. There was no significant difference between groups (1 RCT, n=61, RR 1.13 CI 0.63 to 2.03).</P>
<P>1.6.3 Less than 20% reduction on BPRS-24 (1-7) total score and mildly ill or better (short term)<BR/>
<LINK REF="STD-Shaw-2006" TYPE="STUDY">Shaw 2006</LINK> reported that 100% of the participants from clozapine group and 92% from olanzapine group did not improve. This difference was not significant (1 RCT, n=25, RR 1.08 CI 0.87 to 1.33).</P>
<P>1.6.4 Less than 20% reduction on BPRS-18 (1-7) total score and mildly ill or better (medium term)<BR/>Fifty-four per cent of those participants allocated to clozapine and fifty-three per cent of those allocated to olanzapine did not improve as this criterion. There was no significant difference between groups (2 RCTs, n=327, MD 1.03 CI 0.85 to 1.25).</P>
<P>1.6.5 Less than 30% reduction on BPRS total score and much improved or very much improved<BR/>Even though more participants in the olanzapine group (67%) than in the clozapine group (33%) were not improved. There is some suggestion that this difference reached a borderline level of significance (1 RCT, n=39, RR 0.50 CI 0.24 to 1.03).</P>
<P>1.6.6 Less than 50% reduction on PANSS total<BR/>Through this criterion, <LINK REF="STD-Bitter-2004" TYPE="STUDY">Bitter 2004</LINK> and <LINK REF="STD-Tollefson-2001" TYPE="STUDY">Tollefson 2001</LINK> medium term studies indicated that 82% of the people taking clozapine and 81% on olanzapine did not improve. No statistically significant difference between the groups was demonstrated (2 RCTs, n=327, RR 1.00 CI 0.92 to 1.10).</P>
<P>1.7 Mental state: 2a. PANSS total score<BR/>A trend in favour of olanzapine was observed at the short to medium terms, however this difference was not statistically significant (7 RCTs, n=618, MD 1.97 CI -0.71 to 4.66).</P>
<P>1.8 Mental state: 2b. BPRS-18 (1-7) total score<BR/>The pooled analysis showed a trend in favour of olanzapine at the short to medium terms, but this difference did not reach the conventional levels of significance (5 RCTs, n=304, MD 1.31 CI -0.30 to 2.92).</P>
<P>1.9 Mental state: 2c. BPRS total score (various version)<BR/>Since different versions of the BPRS score were used we present the results of the single studies separately.</P>
<P>1.9.1 BPRS-24 l<BR/>One short term study (<LINK REF="STD-Shaw-2006" TYPE="STUDY">Shaw 2006</LINK>) assessed the mental state using the BPRS-24 (1-7) total score. The clozapine group presented a greater reduction from baseline to endpoint than the olanzapine group, but this difference was not significant (1 RCT, n=25, MD -7.00 CI -28.47 to 14.47).</P>
<P>1.9.2 BPRS-18 (0-6)<BR/>In one medium term study (<LINK REF="STD-Naber-2005" TYPE="STUDY">Naber 2005</LINK>) olanzapine produced a greater reduction on average change on BPRS-18 (0-6) total score compared to clozapine, however this difference was not significant (1 RCT, n=108, MD 2.80 CI -4.05 to 9.65).</P>
<P>1.10 Mental state: 3a. Positive symptoms: PANSS positive subscore<BR/>Two short term study and four medium term studies assessed the positive symptoms by the PANSS positive subscore. The results did not indicate that one drug was clearly more efficacious than the other one (6 RCTs, n=592, MD 0.08 CI -0.96 to 1.11).</P>
<P>1.11 Mental state: 3b. Positive symptoms: SAPS<BR/>One short term study <LINK REF="STD-Shaw-2006" TYPE="STUDY">Shaw 2006</LINK> found a greater SAPS decrease in the clozapine group. However this difference was not statistically significant (1 RCT, n=25, MD -9.00 CI -22.06 to 4.06).</P>
<P>1.12 Mental state: 3c. Positive symptoms: BPRS-18 positive subscore<BR/>1.12.1 BPRS-18 (1-7)<BR/>Positive symptoms, measured by the BPRS18 (1-7) positive subscore, were not significantly different between groups (2 RCTs, n=189, MD -0.01 CI -1.39 to 1.37).</P>
<P>1.12.2 BPRS-18 (0-6)<BR/>There was no significant difference (1 RCT, n=108, MD 0.40 CI -1.57 to 2.37).</P>
<P>1.13 Mental state: 4a. Negative symptoms: PANSS negative subscore<BR/>There was no indication of any significant superiority of clozapine or olanzapine in this outcome (6 RCTs, n=592, MD 0.78 CI -0.21 to 1.77).</P>
<P>1.14 Mental state: 4b. Negative symptoms: SANS<BR/>Two short term studies assessed the negative symptoms using the SANS and the results were heterogeneous. <LINK REF="STD-Kumra-2008" TYPE="STUDY">Kumra 2008</LINK> found a trend in favour of clozapine, but this difference was not statistically significant (2 RCTs, n=39, MD -1.00 CI -3.6 to 1.6). Furthermore, in <LINK REF="STD-Shaw-2006" TYPE="STUDY">Shaw 2006</LINK> clozapine reduced the mean SANS score more than the olanzapine group (1 RCT, n=25, MD -11.00 CI -20.90 to -1.10).</P>
<P>1.15 Mental state: 4c. Negative symptoms: BPRS-18 negative subscore<BR/>1.15.1 BPRS-18 (1-7) negative sub-score<BR/>There was no significant difference between groups (2 RCTs, n=189, MD -0.29 CI -1.17 to 0.60).</P>
<P>1.15.2 BPRS-18 (0-6) negative sub-score<BR/>One medium term study (<LINK REF="STD-Naber-2005" TYPE="STUDY">Naber 2005</LINK>) analysed this outcome but did not find a significant difference between groups (1 RCT, n=108, MD 0.20 CI -1.29 to 1.69).</P>
<P>1.16 Cognitive functioning: 1. No clinically important change - less than 0.5 SD reduction<BR/>Most studies did not report data about cognitive function of participants. One medium term study (<LINK REF="STD-Volavka-2002" TYPE="STUDY">Volavka 2002</LINK>) defined no clinically important response as 'less than 0.5 SD reduction on global neurocognitive score'. More people taking clozapine (80%) than people taking olanzapine (49%) met this criterion, a statistically significant difference was found (1 RCT, n=79, RR 1.64 CI 1.15 to 2.35, NNT 3 CI 2 to 9).</P>
<P>1.17 Quality of life: 1. SWN-38 score<BR/>In one medium term study there was no significant difference between clozapine and olanzapine in the SWN-38 score (1 RCT, n=99, MD -8.20 CI -21.67 to 5.27).</P>
<P>1.18 Quality of life: 2. MLDL score<BR/>There was no significant difference in the average change of the MLDL satisfaction scale (1 RCT, n=97, MD 0.00 CI -0.72 to 0.72).</P>
<P>1.19 Service use: Hospital re-admission<BR/>Most of studies did not provide data on service use. Only one long term study (<LINK REF="STD-Meltzer-2003" TYPE="STUDY">Meltzer 2003</LINK>) reported the hospitalisation for imminent risk of suicide as a rescue intervention. Significantly fewer people taking clozapine (20%) were hospitalised compared to those taking olanzapine (26%)(1 RCT, n=980, RR 0.78 CI 0.62 to 0.98, NNT 18 CI 9 to 230).</P>
<P>1.20 Adverse effects: 1. At least one adverse effect<BR/>Due to the high heterogeneity (I-square=81%) we did not perform the meta-analytic combination of data. Five short term studies presented the number of participants that suffered at least one adverse effect. Only one of them, <LINK REF="STD-Wang-2002" TYPE="STUDY">Wang 2002</LINK> study, showed a statistically significant difference between treatment groups in favour of olanzapine (1 RCT, n=61, RR 3.39 CI 1.85 to 6.20, NNH 2 CI 1 to 2). All the rest reported the same trend in favour olanzapine, but the differences were not significant.</P>
<P>Two homogeneous medium term studies (<LINK REF="STD-Bitter-2004" TYPE="STUDY">Bitter 2004</LINK> and <LINK REF="STD-Naber-2005" TYPE="STUDY">Naber 2005</LINK>) reported that people allocated to clozapine (49%) were significantly more susceptible to experience at least one adverse effect than those in the olanzapine group (39%), (2 RCTs, n=261, RR 1.19 CI 1.02 to 1.40, NNH 10 CI 4 to infinity).</P>
<P>1.21 Adverse effects: 2. Cardiac problems<BR/>A lack of data about the appearance of cardiac problems was a common factor for almost all studies. Overall, a low incidence of ECG anomalies was observed in both groups.</P>
<P>Four per cent of the clozapine group (3 of 74 participants) showed ECG alterations, in two participants the anomalies were not specified and in the other one the alteration was a QT time prolongation. One per cent in the olanzapine group (1 of 78 participants) presented any ECG alterations. This difference was not significant (3 RCTs, n=152, RR 2.42 CI 0.38 to 15.33).</P>
<P>1.22 Adverse effects: 3a. Extrapyramidal: antiparkinson medication use<BR/>A similar proportion of participants from each group (7% clozapine versus 8% olanzapine) required antiparkinson medication during the trials. The combined analysis of the studies did not show any difference between the treatment groups (6 RCTs, n=561, RR 0.87 CI 0.46 to 1.67).</P>
<P>1.23 Adverse effects: 3b. Extrapyramidal: various symptoms<BR/>1.23.1 At least one EPS<BR/>In a short term study (<LINK REF="STD-Wang-2002" TYPE="STUDY">Wang 2002</LINK>, n=61) none of the participants experienced 'at least one EPS'.</P>
<P>1.23.2 Akathisia<BR/>Four studies reported the akathisia incidence during the trials.Overall there was no significant difference (4 RCTs, n=1320, RR 0.73 CI 0.38 to 1.41). Only the long term study by <LINK REF="STD-Meltzer-2003" TYPE="STUDY">Meltzer 2003</LINK> found that more people in the olanzapine group (8%) experienced akathisia than those in the clozapine group (4%), (1 RCT, n=980, RR 0.54 CI 0.32 to 0.90, NNH 27 CI 15 to 147).</P>
<P>1.23.3 Dyskinesia  <BR/>A trend in favour of clozapine was observed which did not reach the conventional level of significance (2 RCTs, n=327, RR 0.53 CI 0.20 to 1.43).</P>
<P>1.23.4 Extrapyramidal symptoms<BR/>No extrapyramidal events were reported in <LINK REF="STD-Moresco-2004" TYPE="STUDY">Moresco 2004</LINK> and <LINK REF="STD-Wang-2002" TYPE="STUDY">Wang 2002</LINK> studies.</P>
<P>1.23.5 Parkinsonism<BR/>No parkinsonism events were reported in <LINK REF="STD-Bitter-2004" TYPE="STUDY">Bitter 2004</LINK> study.</P>
<P>1.23.6 Pseudoparkinsonism<BR/>There was no significant difference in pseudoparkinsonism symptoms between clozapine and olanzapine (1 RCT, n=180, RR 1.29 CI 0.50 to 3.30).</P>
<P>1.23.7 Rigor<BR/>There was no significant difference between groups (1 RCT, n=980, RR 0.17 CI 0.02 to 1.38).</P>
<P>1.24 Adverse effects: 3c. Extrapyramidal: ESRS total score at endpoint<BR/>A medium term study (<LINK REF="STD-Volavka-2002" TYPE="STUDY">Volavka 2002</LINK>) found no significant difference in the ESRS score at endpoint (1 RCT, n=79, MD 1.30, CI -0.23 to 2.83).</P>
<P>1.25 Adverse effects: 3d. Extrapyramidal: SAS change or endpoint<BR/>Three short term studies and three medium term studies reported on this outcome. Overall, there was not significant difference between groups (6 RCTs, n=481, MD 0.43 CI -0.45 to 1.30).</P>
<P>1.26 Adverse effects: 3e. Extrapyramidal: akathisia - BARS change<BR/>A medium term study (<LINK REF="STD-Tollefson-2001" TYPE="STUDY">Tollefson 2001</LINK>) assessed akathisia by the BARS change from baseline to endpoint . There was no significant difference between groups (1 RCT, n=175, MD -0.10 CI -0.38 to 0.18).</P>
<P>1.27 Adverse effects: 3f. Extrapyramidal: Hillside Akathisia Scale<BR/>There was no significant difference between groups (1 RCT, n=137, MD -0.40 CI -3.10 to 2.3).</P>
<P>1.28 Adverse effects: 3g. Extrapyramidal: tardive dyskinesia - AIMS change or endpoint<BR/>There was no significant difference between groups in one short term and two medium term studies (3 RCTs, n=352, MD 0.13, CI -0.25 to 0.51).</P>
<P>1.29 Adverse effects: 4a. Glucose: number of participants with significant increase<BR/>One long term study (<LINK REF="STD-Meltzer-2003" TYPE="STUDY">Meltzer 2003</LINK>) indicated the number of participants with significant increase of glucose levels during the study. Three per cent and four per cent of participants had an elevation of glucose levels taking clozapine and olanzapine, respectively. Hence no significant difference between clozapine and olanzapine groups was found (1 RCT, n=980, RR 0.76 CI 0.40 to 1.44).</P>
<P>1.30 Adverse effects: 4b. Glucose: average change or endpoint<BR/>Two short term studies showed an advantage of olanzapine (2 RCTs, n= 50, MD 9.70 CI 1.73 to 17.68). The medium term study reported an opposite result but the difference was not statistically significant (1 RCT, n=39, MD -9.9 CI -23.30 to 3.50).</P>
<P>1.31 Adverse effects: 5. Hypersalivation<BR/>Five studies reported that hypersalivation was more frequent in participants taking clozapine than those taking olanzapine in the short term (2 RCTs, n=64, RR 1.64 CI 1.14 to 2.38, NNH 3 CI 2 to 9), in the medium term (2 RCTs, n=289, RR 5.33 CI 1.76 to 16.68, NNH 3 CI 2 to 4), as well as in the long term (1 RCT, n=980, RR 8.18 CI 5.64 to 11.86, NNH 2, CI 2 to 3).</P>
<P>1.32 Adverse effects: 6a. Lipids: number of participants with significant increase<BR/>1.32.1 Increase on cholesterol total<BR/>A short term study (<LINK REF="STD-Shaw-2006" TYPE="STUDY">Shaw 2006</LINK>) reported that one of twelve in clozapine group and none in the olanzapine group presented moderate hypercholesterolaemia during the trial. No significant difference between the groups was found (1 RCT, n=25, RR 3.23 CI 0.14 to 72.46).</P>
<P>1.32.2 Increase on triglycerides<BR/>Two short term studies provided the number of participants that presented an increase on triglycerides during the study. 17% in clozapine group and 15% in olanzapine group showed an increase on triglyceride levels, but this difference was not significant (2 RCTs, n=64, RR 1.08 CI 0.37 to 3.20).</P>
<P>1.33 Adverse effects:6b. Lipids: average cholesterol change or endpoint<BR/>Two short term and one medium term study assessed cholesterol total levels. The two short term studies were heterogeneous showing an opposite tendency. The combined analysis of all three studies did not demonstrate any clear difference between groups (3 RCTs, n=89, MD -1.16 CI -19.85 to 17.52).</P>
<P>1.34 Adverse effects: 6c. Lipids: average triglycerides change<BR/>Two short term studies provided data regarding triglyceride levels. No significant difference between clozapine and olanzapine was found (2 RCTs, n=38, MD 36.07 CI -83.57 to 155.71).</P>
<P>1.35 Adverse effects: 7. Prolactin: average change or endpoint<BR/>1.35.1 Average change from baseline<BR/>A medium term study (<LINK REF="STD-Tollefson-2001" TYPE="STUDY">Tollefson 2001</LINK>) assessed prolactin levels (ng /mL). A statistically significant difference was observed between clozapine and olanzapine groups, where clozapine group showed a slightly decrease while olanzapine group had a mild increase on prolactin levels (1 RCT, n=120, MD -0.57 CI -1.05 to -0.09).</P>
<P>1.35.2 Average endpoint ng/ml - men only<BR/>Two heterogeneous studies (<LINK REF="STD-Kumra-2008" TYPE="STUDY">Kumra 2008</LINK> and <LINK REF="STD-Volavka-2002" TYPE="STUDY">Volavka 2002</LINK>) assessed on prolactin levels in men, only one of them (<LINK REF="STD-Kumra-2008" TYPE="STUDY">Kumra 2008</LINK>) showed a significant superiority of clozapine (1 RCT, n=21, MD -14.20 CI -23.8 to -5.32).</P>
<P>1.35.3 Average endpoint ng/ml - women only<BR/>The same study reported on prolactin levels in women. Again, the results were in favour of clozapine ( 1 RCT, n=18, MD -54.4, CI -86.74 to -22.06).</P>
<P>1.36 Adverse effects: 8. Sedation<BR/>Seven studies reported the number of participants that experienced sedation. All studies observed a tendency in favour of olanzapine. Due to high degrees of heterogeneity we did not perform a meta-analysis (I-square= 88%). Four heterogeneous short term studies reported a trend in favour of olanzapine. In <LINK REF="STD-Wang-2002" TYPE="STUDY">Wang 2002</LINK> this difference was significant (1 RCT, n=61, RR 3.06 CI 1.42 to 6.61, NNH 3 CI 2 to 7). The studies by <LINK REF="STD-Shaw-2006" TYPE="STUDY">Shaw 2006</LINK> and <LINK REF="STD-Kumra-2008" TYPE="STUDY">Kumra 2008</LINK> did not find any significant difference (1 RCT, n=25, RR 1.08 CI 0.18 to 6.53 and 1 RCT, n=39, RR 1.10 CI 0.93 to 1.30, respectively), while in <LINK REF="STD-Conley-2003" TYPE="STUDY">Conley 2003</LINK> study all participants experienced sedation. Two medium term studies showed the same trend in favour of olanzapine, but only <LINK REF="STD-Bitter-2004" TYPE="STUDY">Bitter 2004</LINK> reported a significant difference between groups (1 RCT, n=147, RR 5.73 CI 1.32 to 24.96, NNH 8 CI 5 to 28). The single long term study (<LINK REF="STD-Meltzer-2003" TYPE="STUDY">Meltzer 2003</LINK>) found a significant superiority of olanzapine in this regard (1 RCT, n=490, RR 1.86 CI 1.55 to 2.24, NNH 5 CI 4 to 7).</P>
<P>1.37 Adverse effects: 9. Seizures<BR/>Four studies (two short, one medium and one long term) assessed this outcome. Clozapine group participants were more likely to experience seizures than olanzapine participants (3% versus 0.4%; 4 RCTs, n=1097, RR 6.50 CI 1.73 to 24.47, NNH 39 CI 25 to 94).</P>
<P>1.38 Adverse effects: 10a. Weight: number of participant with weight gain<BR/>More than 50% of the studies reported the number of participants that presented a weight increase. These studies were highly heterogeneous and a meta-analysis was not undertaken.</P>
<P>1.38.1 Short term<BR/>20% of the participants in each group reported a weight increase according to various criteria (<LINK REF="STD-Wang-2002" TYPE="STUDY">Wang 2002</LINK> study did not specify the criterion, <LINK REF="STD-Kumra-2008" TYPE="STUDY">Kumra 2008</LINK> used the criterion more than 7% increase of the baseline body weight), therefore there was no difference between groups (2 RCTs, n=100, RR 0.99 CI 0.45 to 2.16).</P>
<P>1.38.2 Medium term<BR/>Four medium term studies reported this outcome. There was no clear difference between groups (4 RCTs, n=520, RR1.03 CI 0.60 to 1.78).</P>
<P>1.38.3 Long term<BR/>The only long term study (<LINK REF="STD-Meltzer-2003" TYPE="STUDY">Meltzer 2003</LINK>) showed a significant superiority in favour of olanzapine (30% clozapine versus 52% olanzapine; 1 RCT, n=980, RR 0.57 CI 0.48 to 0.66, NNH 4 CI 3 to 6).</P>
<P>1.39 Adverse effects: 10b. Weight: average weight change<BR/>Three short term and four medium term studies reported on average weight change in kg. There was no significant difference between groups (7 RCTs, n=581, MD -0.04 CI -1.06 to 0.97).</P>
<P>1.40 Adverse effects: 11. White blood cell count: number of participants with a decrease<BR/>Four studies (one short term, two medium term and one long term) reported a higher number of participants with a decrease of the WBC in the clozapine group (6%) than in the olanzapine group (1%). This difference was statistically significant (4 RCTs, n=1264, RR 5.68 CI 2.48 to 13.00, NNH 20, CI 14 to 33).</P>
<P>1.41. Publication bias<BR/>Due to the small number of included studies a funnel plot analysis was not performed.</P>
<P>1.42. Missing outcomes<BR/>No data were reported for general and social functioning.</P>
<P>2. CLOZAPINE versus OLANZAPINE Sensitivity analysis<BR/>When studies with possibly skewed data were excluded the following changes were noted: Excluding <LINK REF="STD-Kumra-2008" TYPE="STUDY">Kumra 2008</LINK> from the analysis of the SANS total score clozapine was significantly more efficacious than olanzapine (1 RCT, n=25, MD -11.00 CI -20.90 to -1.10). The results of other sensitivity analyses on the PANSS total score (excluded study: <LINK REF="STD-Moresco-2004" TYPE="STUDY">Moresco 2004</LINK> ), the BPRS-18 (1-7) total score (excluded studies: <LINK REF="STD-Kumra-2008" TYPE="STUDY">Kumra 2008</LINK>,<LINK REF="STD-Wang-2002" TYPE="STUDY">Wang 2002</LINK>), the PANSS positive subscore (excluded study: <LINK REF="STD-Moresco-2004" TYPE="STUDY">Moresco 2004</LINK>) and the BPRS positive subscore (Excluded studies:<LINK REF="STD-Tollefson-2001" TYPE="STUDY">Tollefson 2001</LINK>) did not change to an important degree.</P>
<P>3. Comparison 2. CLOZAPINE versus QUETIAPINE<BR/>From five studies selected, four were carried out in China (<LINK REF="STD-Li--2002" TYPE="STUDY">Li 2002</LINK>; <LINK REF="STD-Li--2003" TYPE="STUDY">Li 2003</LINK>; <LINK REF="STD-Li--2005" TYPE="STUDY">Li 2005</LINK>; <LINK REF="STD-Liu--2004" TYPE="STUDY">Liu 2004</LINK>) and one in Turkey (<LINK REF="STD-Atmaca-2003" TYPE="STUDY">Atmaca 2003</LINK>). All of them were short term studies.</P>
<P>3.1 Leaving the studies early<BR/>Only three studies reported this outcome.</P>
<P>3.1.1 any reason<BR/>More people allocated to clozapine (11%) left the study early for any reason in comparison with those allocated of quetiapine (6%), however this difference was not statistically significant (2 RCTs, n=94, RR 1.51 CI 0.42 to 5.50).</P>
<P>3.1.2 adverse effects<BR/>Eight per cent of the participants taking clozapine and none of those taking quetiapine left the study early due to adverse effects, but this difference was not significant (1 RCT, n=72, RR 7.0 CI 0.37 to 130.82).</P>
<P>3.1.3 inefficacy<BR/>No participant left a study early for this reason.</P>
<P>3.2 Global state: no clinically important change - less than "common criteria"<BR/>One study reported the number of participants showing no clinically important change in global state according to 'common criteria'. The author did not give further details about this criterion. There was no significant difference between groups (1 RCT, n=76, RR 1.07 CI 0.85 to 1.35).</P>
<P>3.3 Mental state: 1. No clinically important change - less than 50% reduction PANSS total<BR/>Only one study (<LINK REF="STD-Li--2002" TYPE="STUDY">Li 2002</LINK>) reported this outcome. 32% of the participants in the clozapine group and 34% in the quetiapine group did not improve. There was no significant difference between both antipsychotics (1 RCT, n=63, RR 0.94 CI 0.47 to 1.89).</P>
<P>3.4 Mental state: 2a. PANSS total score<BR/>Four studies reported the average PANSS total score at endpoint. There was no significant difference between clozapine and quetiapine in this regard (4 RCTs, n=232, MD 0.50 CI -1.86 to 2.85).</P>
<P>3.5 Mental state: 2b. BPRS-18 (1-7) total score<BR/>There was no statistical significant difference in this outcome (1 RCT, n=72, MD 0.89 CI -1.33 to 3.11).</P>
<P>3.6 Mental state: 3. Positive symptoms: PANSS positive subscore<BR/>There was no evidence of a significant difference between clozapine and quetiapine in this aspect (2 RCTs, n=142, MD 0.70 CI -0.68 to 2.07).</P>
<P>3.7 Mental state: 4. No clinically important change - less than 50% reduction SANS<BR/>One study defined no important clinical response on negative symptoms as the number of people of each treatment group who did not present 'at least a 50% reduction on SANS'. 89% of those taking clozapine and 83% of those allocated to quetiapine did not improve as this criterion. This difference was not significant (1 RCT, n=72, RR 1.07 CI 0.89 to 1.29).</P>
<P>3.8 Mental state: 5a. Negative symptoms: PANSS negative subscore<BR/>People taking clozapine had a higher score on the PANSS negative subscore than those allocated to quetiapine. A statistically significant superiority of quetiapine over clozapine was found (2 RCTs, n=142, MD 2.23 CI 0.99 to 3.48).</P>
<P>3.9 Mental state: 5b. Negative symptoms:SANS<BR/>The study that used SANS score to assess the negative symptoms, showed a trend in favour quetiapine, however this difference did not reach the conventional levels of significance (1 RCT, n=72, MD 1.64 CI -4.66 to 7.94).</P>
<P>3.10 Adverse effects: 1. At least one adverse effect<BR/>In <LINK REF="STD-Li--2002" TYPE="STUDY">Li 2002</LINK> significantly more participants allocated to clozapine (90%) than to quetiapine (38%) experienced at least one adverse effect (1 RCT, n= 63, RR 2.41 CI 1.52 to 3.82, NNH 2 CI 2 to 5).</P>
<P>3.11 Adverse effects: 2. Cardiac problems<BR/>The incidence of cardiac effects was missing in almost all studies. Overall, in the two studies that reported this outcome the incidence was low.</P>
<P>3.11.1 ECG abnormalities<BR/>
<LINK REF="STD-Liu--2004" TYPE="STUDY">Liu 2004</LINK> showed that those taking clozapine were significantly more likely to experience ECG abnormalities than those allocated to quetiapine (1 RCT, n=72, RR 8.00 CI 1.05 to 60.72, NNH 5 CI 3 to 21), but this outcome must be interpreted with caution due to the large confidence interval.</P>
<P>3.11.2 Palpitation<BR/>
<LINK REF="STD-Li--2002" TYPE="STUDY">Li 2002</LINK>, reported the incidence of palpitation (45% clozapine versus 38% quetiapine). There was no significant difference in this regard (1 RCT, n=63, RR 1.20 CI 0.67 to 2.18).</P>
<P>3.12 Adverse effects: 3a. Extrapyramidal: antiparkinson medication use<BR/>In <LINK REF="STD-Atmaca-2003" TYPE="STUDY">Atmaca 2003</LINK> no participants (of 27) used antiparkinson medication.</P>
<P>3.13 Adverse effects: 3b. Extrapyramidal: various symptoms<BR/>3.13.1 akathisia<BR/>There was no significant difference (2 RCTs, n=135, RR 2.52 CI 0.50 to 12.61).</P>
<P>3.13.2 tremor<BR/>There was no significant difference (2 RCTs, n=135, RR 1.01 CI 0.30 to 3.43).</P>
<P>3.13.3 rigor<BR/>There was no significant difference (1 RCT, n=63, RR 0.52 CI 0.05 to 5.41).</P>
<P>3.14 Adverse effects: 4. Hypersalivation<BR/>In two studies significantly more people taking clozapine (76%) experienced hypersalivation than those taking quetiapine (1%), (2 RCTs, n=135, RR 33.91 CI 6.96 to 165.24, NNH 1 CI 1 to 2). However, this outcome must be interpreted with caution due to the large confidence interval.</P>
<P>3.15 Adverse effects: 5. Lipids: average triglyceride change<BR/>Clozapine group presented a significantly more pronounced increase in triglycerides levels than quetiapine (n=27, MD 24.64 CI 20.76 to 28.52).</P>
<P>3.16 Adverse effects: 6. Sedation<BR/>People allocated to clozapine (48%) were significantly more likely to suffer sedation than those allocated to quetiapine group (10%), (2 RCTs, n= 135, RR 4.47 CI 2.11 to 9.49, NNH 3 CI 2 to 4).</P>
<P>3.17 Adverse effects: 7a. Weight: number of participant with weight gain<BR/>The combined analysis of two studies suggested that weight increase was more common with clozapine than quetiapine (25% clozapine versus 13% quetiapine), however this difference was not significant (2 RCTs, n=135, RR 1.89 CI 0.90 to 3.96).</P>
<P>3.18 Adverse effects: 7b. Weight: average weight change<BR/>One study showed a trend in favour quetiapine regarding weight increase, but this difference did not reach conventional levels of statistical significance (1 RCT, n=27, MD 2.11 CI -0.08 to 4.30).</P>
<P>3.19 Adverse effects: 8. White blood cell count: number of participants with a decrease<BR/>Decrease of white blood cells (WBC) was evaluated in the <LINK REF="STD-Li--2002" TYPE="STUDY">Li 2002</LINK> study, where those taking clozapine (6%) were more likely to experience decrease in WBC (criterion not stated) than those allocated to quetiapine (0%). However, no statistically significant difference was found between groups (1 RCT, n=63, RR 5.16 CI 0.26 to 103.27).</P>
<P>3.20 Publication bias<BR/>Due to the small number of included studies a funnel plot analysis was not performed.</P>
<P>3.21 Missing outcomes<BR/>No data were reported for death, service use, general and social functioning, cognitive functioning, quality of life/satisfaction with treatment and some adverse effects such as increase glucose levels, increase triglycerides, increase prolactin levels and seizures.</P>
<P>4. CLOZAPINE versus QUETIAPINE sensitivity analysis<BR/>The results of the comparison of clozapine with quetiapine regarding the average on PANSS total score at endpoint did not change when studies with possible skewed data were excluded (<LINK REF="STD-Li--2002" TYPE="STUDY">Li 2002</LINK>, <LINK REF="STD-Li--2003" TYPE="STUDY">Li 2003</LINK> and <LINK REF="STD-Li--2005" TYPE="STUDY">Li 2005</LINK>).</P>
<P>5. Comparison 3. CLOZAPINE versus RISPERIDONE<BR/>Ten studies were selected according to the criterion of this review. Eight were short term studies (<LINK REF="STD-Atmaca-2003" TYPE="STUDY">Atmaca 2003</LINK>; <LINK REF="STD-Azorin-2001" TYPE="STUDY">Azorin 2001</LINK>; <LINK REF="STD-Bondolfi-1998" TYPE="STUDY">Bondolfi 1998</LINK>;<LINK REF="STD-Breier-1999" TYPE="STUDY">Breier 1999</LINK>; <LINK REF="STD-Heinrich-1994" TYPE="STUDY">Heinrich 1994</LINK>; <LINK REF="STD-Ren-2002" TYPE="STUDY">Ren 2002</LINK>; <LINK REF="STD-Wahlbeck-2000" TYPE="STUDY">Wahlbeck 2000</LINK>; <LINK REF="STD-Zhou-2000" TYPE="STUDY">Zhou 2000</LINK>), one medium term (<LINK REF="STD-Volavka-2002" TYPE="STUDY">Volavka 2002</LINK>) and one long term (<LINK REF="STD-McGurk-2005" TYPE="STUDY">McGurk 2005</LINK>). Most studies were carried out in Europe and America and two were performed in China.</P>
<P>5.1 Death<BR/>Only two short term studies reported on death. There were no reports of suicides (<LINK REF="STD-Wahlbeck-2000" TYPE="STUDY">Wahlbeck 2000</LINK>). Regarding death due to natural causes, no difference was found between clozapine and risperidone (2 RCTs, n=293, RR 0.98 CI 0.06 to 15.48).</P>
<P>5.2. Leaving the study early: 1. Any reason<BR/>There was a similar number of participants leaving the studies early due to any reason (32% clozapine versus 35% risperidone, 7 RCTs, n=655, RR 0.92 CI 0.73 to 1.16).</P>
<P>5.3 Leaving the study early: 2. Adverse effects<BR/>Twelve per cent of the participants in treatment with clozapine and six per cent of those in treatment with risperidone left the study early due to adverse effects. A statistically significant difference between groups was observed (6 RCTs, n=627, RR 1.88 CI 1.11 to 3.21, NNT 16 CI 9 to 59).</P>
<P>5.4 Leaving the study early: 3. Inefficacy<BR/>In contrast, fewer people allocated to clozapine left the studies early due to inefficacy (5% versus 13% respectively). This difference was again statistically significant (6 RCTs, n=627, RR 0.40 CI 0.23 to 0.70, NNT 11 CI 7 to 21).</P>
<P>5.5 Global state: No clinically important change - less than much improved on CGI<BR/>The number of participants with no clinical improvement were all those categorized as 'less than much improved' on the CGI. A single, small, short term study (<LINK REF="STD-Heinrich-1994" TYPE="STUDY">Heinrich 1994</LINK>) found no significant difference in this regard (1 RCT, n=60, RR 0.80 CI 0.43 to 1.49).</P>
<P>5.6 Mental state: 1. No clinically important change - various criteria<BR/>Various criteria were used to assess an improvement of the mental state.</P>
<P>5.6.1 less than 20% reduction on BPRS-18 (1-7) total score<BR/>One short term study, <LINK REF="STD-Breier-1999" TYPE="STUDY">Breier 1999</LINK>, reported that 64% of the participants taking clozapine and 80% of those taking risperidone did not improve at this criterion. No statistically significant difference was observed between groups (1 RCT, n=29, RR 0.80 CI 0.50 to 1.28).</P>
<P>5.6.2 less than 20% reduction on BPRS-18 (1-7) total score and mildly ill or better<BR/>No significant difference was found between clozapine and risperidone in <LINK REF="STD-Azorin-2001" TYPE="STUDY">Azorin 2001</LINK> study (1 RCT, n=273, RR 0.95 CI 0.78 to 1.17).</P>
<P>5.6.3 less than 20% reduction on the 4-item on BPRS psychosis and no psychotic symptoms rated less than mild<BR/>This criterion was used to define 'remission' during the <LINK REF="STD-McGurk-2005" TYPE="STUDY">McGurk 2005</LINK> study. No significant difference between groups was observed (1 RCT, n=107, RR 0.97 CI 0.78 to 1.21).</P>
<P>5.6.4 less than 40% improvement on the 4-item on BPRS psychosis cluster<BR/>There was no significant difference between groups (1 RCT, n=107, RR 0.96 CI 0.69 to 1.32).</P>
<P>5.6.5 less than 20% reduction on PANSS total score<BR/>There was no significant difference between clozapine (39% not improved) and risperidone (33% not improved) (2 RCTs, n=106, RR 1.18 CI 0.70 to 1.99).</P>
<P>5.7 Mental state: 2a. PANSS total score<BR/>Four short term studies and one medium term study provided data, but we did not combine the data due to significant heterogeneity (I-square=52%).</P>
<P>The short term <LINK REF="STD-Azorin-2001" TYPE="STUDY">Azorin 2001</LINK> study was the only study that showed a statistically significant difference in favour of clozapine (n=273, MD -7.60, CI -13.28 to -1.92).</P>
<P>
<LINK REF="STD-Atmaca-2003" TYPE="STUDY">Atmaca 2003</LINK> and <LINK REF="STD-Volavka-2002" TYPE="STUDY">Volavka 2002</LINK> suggested a better improvement on mental state using clozapine than risperidone, but these differences did not reach the conventional significance level (n=26, MD -1.20 CI -5.01 to 2.61 and n=81, MD -3.60 CI -13.32 to 6.12 respectively).</P>
<P>Contrarily, the short term <LINK REF="STD-Bondolfi-1998" TYPE="STUDY">Bondolfi 1998</LINK> study and <LINK REF="STD-Wahlbeck-2000" TYPE="STUDY">Wahlbeck 2000</LINK>  showed a trend in favour of risperidone, but both differences were not significant (n=86, MD 4.20 CI -5.34 to 13.74 and n=19, MD13.00 CI -4.59 to 30.59 respectively).</P>
<P>5.8 Mental state: 2b. BPRS-18 (1-7) total score<BR/>Three heterogeneous studies (I-square=80%) provided data on the BPRS-18 (1-7) total score. Two homogeneous short term studies (<LINK REF="STD-Azorin-2001" TYPE="STUDY">Azorin 2001</LINK> and <LINK REF="STD-Breier-1999" TYPE="STUDY">Breier 1999</LINK>) showed a statistically significant difference in favour of clozapine (2 RCTs, n=285, MD -5.11 CI -7.99 to -2.23). The long term study, <LINK REF="STD-McGurk-2005" TYPE="STUDY">McGurk 2005</LINK>, did not show any clear difference between drugs (1 RCT, n=52, MD 0.40 CI -3.52 to 4.32).</P>
<P>5.9 Mental state: 3a. Positive symptoms: PANSS positive subscore<BR/>There was no clear difference between clozapine and risperidone (5 RCTs, n=562, MD -0.99 CI -2.29 to 0.32).</P>
<P>5.10 Mental state: 3b. Positive symptoms: BPRS-18 (1-7) positive subscore.<BR/>The short term <LINK REF="STD-Breier-1999" TYPE="STUDY">Breier 1999</LINK> study showed a trend in favour of clozapine on BPRS positive subscore at endpoint, but this difference was not significant (1 RCT, n=29, MD -2.10 CI -4.76 to 0.56).</P>
<P>5.11 Mental state: 4a. Negative symptoms: PANSS negative subscore<BR/>Five studies reported heterogeneous results (I-square= 61%), only one of them (<LINK REF="STD-Wahlbeck-2000" TYPE="STUDY">Wahlbeck 2000</LINK>) showed a significant difference between groups in favour of risperidone (1 RCT, n=19, MD 4.00 CI 0.40 to 7.60).</P>
<P>5.12 Mental scale: 4b. Negative symptoms: SANS<BR/>The meta-analysis of two short term studies found no significant difference between clozapine or risperidone (2 RCTs, n=69, MD 0.62 CI -2.51 to 3.74).</P>
<P>5.13 General functioning: 1. GAF score<BR/>Only the short term study by <LINK REF="STD-Wahlbeck-2000" TYPE="STUDY">Wahlbeck 2000</LINK> reported on this outcome and found no significant difference between groups (1 RCT, n=19, MD -9.00 CI -18.44 to 0.44).</P>
<P>5.14 Social functioning: SFS score<BR/>Again, only <LINK REF="STD-Wahlbeck-2000" TYPE="STUDY">Wahlbeck 2000</LINK> examined social functioning and found a higher (= better) average SFS score at endpoint in the risperidone group. This result should be considered with caution due to the great variability of the scores.</P>
<P>5.15 Treatment satisfaction: DAI score<BR/>In the short term <LINK REF="STD-Wahlbeck-2000" TYPE="STUDY">Wahlbeck 2000</LINK> study there was no significant difference between clozapine and risperidone regarding treatment satisfaction (1 RCT, n=19, MD 0.10 CI -2.57 to 2.77).</P>
<P>5.16 Cognitive Functioning: no clinically important change - less than 0.5 SD improved<BR/>The medium term study by <LINK REF="STD-Volavka-2002" TYPE="STUDY">Volavka 2002</LINK> defined 'important clinical response in cognition' as those who presented an 'at least 0.5 SD reduction in neurocognitive score'. A trend in favour of risperidone was observed but this difference did not reach the conventional levels of significance (1 RCT, n=81, RR 1.26 CI 0.95 to 1.67).</P>
<P>5.17 Adverse effects: 1. At least one adverse effect<BR/>The proportion of participants experiencing 'at least one adverse effect' was reported by two short term studies. The combined analysis was impossible to perform due to the heterogeneity amongst them (I-square= 83%).</P>
<P>
<LINK REF="STD-Azorin-2001" TYPE="STUDY">Azorin 2001</LINK> showed similar proportion of participants that experience at least one adverse effect (78% clozapine and 82% risperidone). No significant difference was observed between groups (1 RCT, n=273, RR 0.94 CI 0.84 to 1.06).</P>
<P>
<LINK REF="STD-Heinrich-1994" TYPE="STUDY">Heinrich 1994</LINK> compared one clozapine group with two risperidone groups (two different doses). To analyse this study the data of the two groups of risperidone were pooled. Significantly more people allocated to clozapine reported at least one adverse effect (75%) than those taking risperidone (48%) (1 RCT, n=60, RR 1.58 CI 1.05 to 2.39, NNH 4 CI 2 to 33).</P>
<P>5.18 Adverse effects: 2. Cardiac problems<BR/>Data cardiac effects were missing in most studies. The short term <LINK REF="STD-Heinrich-1994" TYPE="STUDY">Heinrich 1994</LINK> study mentioned that only one participant of the risperidone group presented ECG abnormalities. There was no significant difference between groups (1 RCT,n=60, RR 0.65 CI 0.03 to 15.30). The long term <LINK REF="STD-McGurk-2005" TYPE="STUDY">McGurk 2005</LINK> study assessed the presence of myocarditis, but found that no participants experienced this cardiac alteration during the study. The combined analysis showed no significant difference between groups (2 RCTs, n=167, RR 0.65 CI 0.03 to 15.30).</P>
<P>5.19 Adverse effects: 3a. Extrapyramidal: antiparkinson medication use<BR/>Most studies reported on the use of antiparkinson medication. The meta-analysis of four short term studies and one medium term study revealed that the participants taking clozapine (13 from 142 participant) were less likely to use antiparkinson medication than those taking risperidone (37 of 162 participants). There was a statistically significant difference between groups (6 RCTs, n=304, RR 0.39 CI 0.22 to 0.68, NNH 7 CI 5 to 18).</P>
<P>This tendency persisted over time and it was statistically significant in the combined analysis of the short term subcategory (5 RCTs, n=223, RR 0.39 CI 0.19 to 0.77, NNH 8 CI 5 to 32).</P>
<P>5.20 Adverse effects: 3b. Extrapyramidal: various symptoms<BR/>5.20.1 at least one EPS<BR/>Two short term studies reported the participants who experienced at least one EPS, but due to heterogeneity (I-square=81%) we analysed them separately. The smaller study <LINK REF="STD-Heinrich-1994" TYPE="STUDY">Heinrich 1994</LINK> did not reveal any significant difference between groups, while <LINK REF="STD-Azorin-2001" TYPE="STUDY">Azorin 2001</LINK>reported a significant difference in favour of clozapine (1 RCT, n=273, RR 0.46 CI 0.28 to 0.77, NNT 7 CI 4 to 18).</P>
<P>5.20.2 akathisia<BR/>The short term <LINK REF="STD-Zhou-2000" TYPE="STUDY">Zhou 2000</LINK> study reported the incidence of akathisia. Only four out of twenty people in the clozapine group and none of the twenty participants in the risperidone group experienced akathisia. However, this difference was not significant (1 RCT, n=40, RR 9.00 CI 0.52 to 156.91).</P>
<P>5.20.3 dyskinesia<BR/>The short term <LINK REF="STD-Bondolfi-1998" TYPE="STUDY">Bondolfi 1998</LINK> study reported on the incidence of dyskinesia defined as a score of one or more on ESRS. There was no significant difference between the groups (1 RCT, n=86, RR 1.00 CI 0.38 to 2.61).</P>
<P>5.20.4 dystonia<BR/>According to the same criterion, there was no significant difference in the frequency of dystonia (1 RCT, n=86, RR 0.50 CI 0.05 to 5.31).</P>
<P>5.20.5 parkinsonism<BR/>Again in <LINK REF="STD-Bondolfi-1998" TYPE="STUDY">Bondolfi 1998</LINK> there was a higher risk to have a score of at least one in the parkinsonism item of the ESRS in people taking clozapine than those taking risperidone (63% clozapine versus 40% risperidone, 1 RCT, n=86, RR 1.59 CI 1.03 to 2.45, NNH 4 CI 2 to 37).</P>
<P>5.20.6 tremor<BR/>More participants in the clozapine group (40%) experienced tremor during the study than in the risperidone group (20%). There was no indication of superiority of either drug (1 RCT, n=40, RR 2.00 CI 0.72 to 5.59).</P>
<P>5.21 Adverse effects: 3c. Extrapyramidal: symptom scales<BR/>5.21.1 ESRS score<BR/>Skewed data of the ESRS score did not show any difference between clozapine and risperidone (1 RCT, n=81, MD 0.30 CI -1.31 to 1.91).</P>
<P>5.21.2 SAS score<BR/>Pooled data from two studies (<LINK REF="STD-Breier-1999" TYPE="STUDY">Breier 1999</LINK> and <LINK REF="STD-Heinrich-1994" TYPE="STUDY">Heinrich 1994</LINK>) did not reveal any significant difference between groups (2 RCTs, n=69, MD -0.81 CI -1.73 to 0.10).</P>
<P>5.21.3 BARS score<BR/>The long term <LINK REF="STD-McGurk-2005" TYPE="STUDY">McGurk 2005</LINK> study assessed akathisia by the BARS scale. No statistically significant difference was found (1 RCT, n=107, MD - 0.20 CI -0.50 to 0.10).</P>
<P>5.22 Adverse effects: 4. Glucose: average change<BR/>Both treatments produced an average increase of glucose level at medium term (14 weeks) (clozapine +4 mg/dl versus risperidone +3 mg/dl), but there was no significant difference between groups (1 RCT, n=31, MD 1.70 CI -8.64 to 12.04).</P>
<P>5.23 Adverse effects: 5. Hypersalivation<BR/>In the short term those receiving clozapine were significantly more likely to experience hypersalivation than those receiving risperidone (37% clozapine, 10% risperidone; 3 RCTs, n=373, RR 4.38 CI 1.86 to 10.30, NNH 4 CI 3 to 5).</P>
<P>5.24 Adverse effects: 6. Lipids: average change<BR/>5.24.1 average cholesterol change<BR/>The <LINK REF="STD-Volavka-2002" TYPE="STUDY">Volavka 2002</LINK> study reported a higher increase of cholesterol levels in the clozapine group than in the risperidone group, but this difference was not significant (1 RCT, n=31, MD 7.10 CI -19.81 to 34.01).</P>
<P>5.24.2 average triglyceride change<BR/>The short term <LINK REF="STD-Atmaca-2003" TYPE="STUDY">Atmaca 2003</LINK> study measured the average change of triglyceride levels which was more pronounced in the clozapine group (1 RCT, n=26, MD 32.41 CI 29.26 to 35.46).</P>
<P>5.25. Adverse effects: 7a. Prolactin: associated side effects<BR/>Only one short term study (<LINK REF="STD-Bondolfi-1998" TYPE="STUDY">Bondolfi 1998</LINK>) reported on diminished sexual drive and found no significant difference between clozapine (5%) and risperidone (10%) (1 RCT, n=86, RR 0.50 CI 0.10 to 2.59).</P>
<P>5.26 Adverse effects: 7b. Prolactin: average at endpoint<BR/>Two studies found a statistically significant difference in favour of clozapine, but we did not combine the results due to significant heterogeneity (I-square=72%): <LINK REF="STD-Breier-1999" TYPE="STUDY">Breier 1999</LINK> (short term, women and men combined: 1 RCT, n= 27, MD -38.50 CI -53.70 to -23.30) and <LINK REF="STD-Volavka-2002" TYPE="STUDY">Volavka 2002</LINK> (medium term, only men: 1 RCT, n=28, MD -20, CI -31.81 to -8.19).</P>
<P>5.27 Adverse effects: 8. Sedation<BR/>The combined analysis of five short term studies showed that sedation is more common in participants taking clozapine (30%) than those taking risperidone (17%). A significant difference between groups was demonstrated. (5 RCTs, n=479, RR 1.73 CI 1.24 to 2.42, NNH 8 CI 5 to 18).</P>
<P>5.28 Adverse effects: 9. Seizures<BR/>In two studies (one short term and one medium term) people taking clozapine were more likely to experience seizures than those in the risperidone group (9% versus 2% respectively: 2 RCTs, n=354, RR 4.47 CI 1.43 to 14.01, NNH 14, CI 8 to 38).</P>
<P>5.29 Adverse effects: 10a. Weight: number of participants with weight gain<BR/>Two short term studies and one medium term study assessed the frequency of participants who reported weight gain. The pooled results were slightly heterogeneous (I-square= 53%) but the trend was the same in all studies.</P>
<P>The short term <LINK REF="STD-Bondolfi-1998" TYPE="STUDY">Bondolfi 1998</LINK> study showed that more people in the clozapine group (37%) reported weight gain than those in the risperidone group (23%), but this difference was not significant (1 RCT, n=86, RR 1.60 CI 0.82 to 3.12).</P>
<P>The short term <LINK REF="STD-Zhou-2000" TYPE="STUDY">Zhou 2000</LINK> study showed that 55% of the participants of the clozapine group and none of the risperidone group participants reported weight gain. This difference was significant (1 RCT, n=40, RR 23 CI 1.45 to 365.61, NNH 2 CI 1 to 3) but should be considered with caution due to the great data variability.</P>
<P>In the medium term <LINK REF="STD-Volavka-2002" TYPE="STUDY">Volavka 2002</LINK> study 18% of participants taking clozapine and 10% of those taking risperidone reported weight increase. This difference was not significant (1 RCT, n= 81, RR 1.79 CI 0.57 to 5.66).</P>
<P>5.30 Adverse effects: 10b. Weight: average weight change<BR/>Three short term studies and one medium term study assessed the weight change. Again there was a consistent superiority of risperidone, although the degree of difference varied, leading to significant heterogeneity (I-square=80%).</P>
<P>In the short term studies by <LINK REF="STD-Atmaca-2003" TYPE="STUDY">Atmaca 2003</LINK> (1 RCT, n=26, MD 5.98 CI 4.09 to 7.87) and <LINK REF="STD-Azorin-2001" TYPE="STUDY">Azorin 2001</LINK> (1 RCT, n=270, MD 2.20, CI 1.28 to 3.12) the superiority of risperidone was statistically significant, while <LINK REF="STD-Bondolfi-1998" TYPE="STUDY">Bondolfi 1998</LINK> found no significant difference between groups (1 RCT, n=86, MD 1.60 CI -0.03 to 3.23).</P>
<P>In the medium term study of <LINK REF="STD-Volavka-2002" TYPE="STUDY">Volavka 2002</LINK> clozapine again produced more weight gain than risperidone (1 RCT, n=77, MD 1.90 CI 0.17 to 3.63).</P>
<P>5.31 Adverse effects: 11. White blood cell count: number of participants with a decrease<BR/>Overall it was observed a low incidence on WBC decrease in the treatment groups.</P>
<P>Three percent (4/147) of those treated with clozapine (one person suffered from leucopenia/neutropenia, two reported only neutropenia and one agranulocytosis), and two per cent (3/147) of those treated with risperidone (three people suffered from neutropenia) experienced a decrease in WBC. This difference was not statistically significant (4 RCTs, n=294, RR 1.27 CI 0.33 to 4.99).</P>
<P>5.32 Publication bias<BR/>Due to the small number of included studies a funnel plot analysis was not performed.</P>
<P>5.33 Missing outcomes<BR/>Data on service use were not reported.</P>
<P>6. CLOZAPINE versus RISPERIDONE &#8211; Sensitivity analysis<BR/>When the study with potentially skewed data on the BPRS-18 (1-7) total score was excluded, there was still no significant difference between groups according to the remaining two studies (<LINK REF="STD-Breier-1999" TYPE="STUDY">Breier 1999</LINK> and <LINK REF="STD-McGurk-2005" TYPE="STUDY">McGurk 2005</LINK>). The remaining sensitivity analysis excluding possibly skewed data (PANSS positive subscore - excluded studies: <LINK REF="STD-Ren-2002" TYPE="STUDY">Ren 2002</LINK> and <LINK REF="STD-Wahlbeck-2000" TYPE="STUDY">Wahlbeck 2000</LINK>) and PANSS negative subscore (Excluded study: <LINK REF="STD-Ren-2002" TYPE="STUDY">Ren 2002</LINK>) did not lead to an important change either.</P>
<P>7. Comparison 4. CLOZAPINE versus ZIPRASIDONE<BR/>Only one study (<LINK REF="STD-Sacchetti-2006" TYPE="STUDY">Sacchetti 2006</LINK>, n=146) fulfilled the criteria of our review, it was a medium term study (18 weeks), published as a poster, which provided data on only a few outcomes.</P>
<P>7.1 Leaving the study early: any reason<BR/>
<LINK REF="STD-Sacchetti-2006" TYPE="STUDY">Sacchetti 2006</LINK> reported on 'leaving the study early' due to any reason. 38% of the participants in each group left the study before its end (1 RCT, n=146, RR 1.00 CI 0.66 to 1.51).</P>
<P>7.2 Mental state: PANSS total score<BR/>There was no significant difference between clozapine and ziprasidone in the mean change from baseline (1 RCT, n=146, MD 0.50 CI -6.72 to 7.72).</P>
<P>7.3 Adverse effects: Cardiac problems<BR/>No participants experienced QT interval prolongation on the ECG during the trial.</P>
<P>7.4 Publication bias<BR/>Due to small number of included studies a funnel plot analysis was not performed.</P>
<P>7.5 Investigation of heterogeneity and sensitivity analysis<BR/>The reasons for the preplanned sensitivity analysis did not apply.</P>
<P>7.6 Missing outcomes<BR/>Data on death, leaving the study early (adverse effects and inefficacy), cognitive functioning, quality of life, service use and relevant adverse effects, other than cardiac effects, were missing.</P>
<P>8. Comparison 5. CLOZAPINE versus ZOTEPINE<BR/>Two studies fulfilled the criteria for this review (<LINK REF="STD-Lin-2003" TYPE="STUDY">Lin 2003</LINK> and <LINK REF="STD-Lindenberg-1997" TYPE="STUDY">Lindenberg 1997</LINK>). <LINK REF="STD-Lin-2003" TYPE="STUDY">Lin 2003</LINK> was a short term study from Taiwan which has to date only been published as a poster. The <LINK REF="STD-Lindenberg-1997" TYPE="STUDY">Lindenberg 1997</LINK> study was from Germany. Only results on leaving the study early could be analysed, because all other outcomes were not analysed on the basis of the randomised participants.</P>
<P>8.1 Leaving the study early: any reason<BR/>The <LINK REF="STD-Lindenberg-1997" TYPE="STUDY">Lindenberg 1997</LINK> study showed a trend in favour of clozapine in this aspect, but this was not statistically significant (1 RCT, n=50, RR 0.70 CI 0.32 to 1.54).</P>
<P>8.2 Global state: no clinically important change - less than successfully and no increase on CGI-S<BR/>Significantly fewer people allocated to clozapine (1/24) were considered to be not improved than those allocated to zotepine (12/35), (1 RCT, n=59, RR 0.12 CI 0.02 to 0.87, NNT 3 CI 2 to 8).</P>
<P>8.3 Mental state: BPRS-18 total score<BR/>The people taking clozapine had a small reduction of the mean BPRS score total, while the mean BPRS in the zotepine group increased. This difference was significant in favour of clozapine (1 RCT, n=59, MD -6.00 CI -9.83 to -2.17).</P>
<P>8.4. Adverse effects: 1. Extrapyramidal: antiparkinson medication use<BR/>No people allocated to clozapine used antiparkinson medication, but 13 of 35 participants on the zotepine group used it. A statistical significant difference was found (1 RCT, n=59, RR 0.05 CI 0.00 to 0.86, NNH 3 CI 2 to 5).</P>
<P>8.5 Adverse effects: 2. Prolactin: average change<BR/>Risperidone increased the mean prolactin level significantly more than clozapine (1 RCT, n=59, MD -33.40, CI -48.67 to -18.13).</P>
<P>8.6 Publication bias<BR/>Due to the small number of included studies a funnel plot analysis was not performed.</P>
<P>8.7 Investigation of heterogeneity and sensitivity analysis<BR/>The reasons for the preplanned sensitivity analysis did not apply.</P>
<P>8.8 Missing outcomes<BR/>There were no data on death, leaving the study early (adverse effects and inefficacy), cognitive functioning, quality of life, service use, and adverse effects, other than EPS and prolactin levels.</P>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2010-10-05 11:38:34 +0100" MODIFIED_BY="[Empty name]">
<P>Clozapine is an atypical antipsychotic which is thought to be superior to conventional antipsychotic drugs in the treatment of refractory schizophrenia, and it causes fewer movement disorders. Clozapine, however, entails a significant risk of serious blood disorders such as agranulocytosis, which could be potentially fatal. Currently there are a number of newer antipsychotics which have been developed with the purpose to find both a better tolerability profile, and a superior effectiveness.</P>
<P>In the last years the number of randomised clozapine trials has dramatically increased. A previous Cochrane review comparing clozapine with newer atypical antipsychotics medication included 8 studies (<LINK REF="REF-Tuunainen-2000" TYPE="REFERENCE">Tuunainen 2000</LINK>). The current review includes 27 randomised controlled trials. Nevertheless, many problems that were identified by the previous review have not been solved.</P>
<P>The number of participants leaving schizophrenia trials prematurely remains high. The overall attrition rate of 30% in the included studies is a threat to the validity of the findings.</P>
<P>Often adverse events were only reported if they had occurred in 5% of the participants or greater. This procedure results in under-reporting of rare but important adverse effects. We suggest it would be better to abandon the rules for reporting of adverse effects and that all adverse events should be reported instead, for example as online supplements that are nowadays made available by most journals.</P>
<P>Most trials provide data on leaving the studies early and overall efficacy. Outcomes that are possibly more important to improve the quality of life such as general functioning or satisfaction with treatment are rarely presented. Authors keep using different criteria for 'response to treatment' making comparison difficult, although validated suggestions for the presentation of response to treatment are available (<LINK REF="REF-Van-Os-2006" TYPE="REFERENCE">Van Os 2006</LINK>, <LINK REF="REF-Leucht-2005a" TYPE="REFERENCE">Leucht 2005a</LINK>, and <LINK REF="REF-Leucht-2005b" TYPE="REFERENCE">Leucht 2005b</LINK>).</P>
<P>Twenty of the included trials were categorised as 'short term' studies and only two were 'long term' studies with a length of more than 26 weeks. Schizophrenia is a chronic, often life-long disorder making more long term studies necessary.</P>
<P>Eight studies were sponsored by pharmaceutical companies producing either clozapine or its comparator drugs. Seven studies did not declare if data and/or implementation of the study were carried out without input from the industry. Due to the inevitable conflict of interest, industry sponsorship is a concern (<LINK REF="REF-Heres-2006" TYPE="REFERENCE">Heres 2006</LINK>).</P>
<P>Finally, most studies compared clozapine with olanzapine, risperidone and quetiapine. Fewer randomised controlled trials comparing clozapine with zotepine and ziprasidone are available, and comparisons with amisulpride, aripiprazole and sertindole are missing.</P>
<SUMMARY_OF_RESULTS MODIFIED="2010-10-05 11:38:34 +0100" MODIFIED_BY="[Empty name]">
<P>The review currently includes 27 blinded randomised controlled trials, which involve 3099 participants that compare clozapine versus olanzapine, quetiapine, risperidone, ziprasidone and olanzapine. There were no studies that met the criteria for this review comparing clozapine with amisulpride, aripiprazole or sertindole. Attrition from these studies was high (30.1%), making the interpretation of the results problematic. Clozapine had a higher attrition rate due to adverse effects than olanzapine and risperidone. Contrarily, fewer participants in the clozapine groups left the trials early due to inefficacy than risperidone.</P>
<P>Clozapine was more efficacious than zotepine (and risperidone in one of two rating scales) in improving the participants&#8217; general mental state. However it is necessary to replicate these findings in order to confirm these assertions with more robust evidence. Regarding olanzapine, quetiapine and ziprasidone, no differences were observed on this issue.</P>
<P>There was no significant difference between clozapine, olanzapine and risperidone in terms of positive or negative symptoms of schizophrenia. According to two studies from China, quetiapine was more efficacious for improving negative symptoms than clozapine. One of the most important adverse effects of clozapine is the white blood cell decrease, where it was found that only olanzapine is safer than clozapine in this regard. No differences were observed when it was compared with quetiapine and risperidone. This important side effect was not documented in the comparisons with zotepine and ziprasidone.</P>
<P>More participants of the clozapine group showed hypersalivation and sedation than those on olanzapine, risperidone and quetiapine, and there were more seizures than in people on olanzapine and risperidone. Also clozapine produced an important weight gain not observed with risperidone. Clozapine produced somewhat fewer extrapyramidal side-effects (use of antiparkinson medication) than risperidone and zotepine.</P>
<P>Other differences in adverse effects were less documented and should be replicated, clozapine did not alter prolactin levels in contrast to olanzapine, risperidone and zotepine; compared with quetiapine, clozapine produced a higher incidence of ECG alterations and compared with quetiapine and risperidone, clozapine produce a higher increase of triglyceride levels.</P>
<P>Other findings that should be replicated were that clozapine improved social functioning less than risperidone and fewer participants in the clozapine group had to be hospitalised to avoid suicide attempts in comparison with those from olanzapine group.</P>
<P>It was observed that pharmaceutical companies generally compare newer atypical antipsychotic against a very low dose of clozapine. These doses are lower than those used in the pivotal study of <LINK REF="REF-Kane-1988" TYPE="REFERENCE">Kane 1988</LINK>. For this reason, it is not fully clear if this can be included in a sensitivity analysis/meta-regression, because there are only a limited number of studies that use adequate doses. Future research comparing adequate doses are needed.</P>
<P>1. Comparison 1: CLOZAPINE versus OLANZAPINE<BR/>1.1 Death<BR/>Only two studies assessed this outcome. Data on deaths for any reason as well as for natural causes and suicide were available. A tendency in favour of olanzapine was observed, but these differences were not statistically significant. Hence, it can be concluded that the incidence of death was generally low and similar between treatment groups.</P>
<P>1.2 Leaving the study early: 1. Any reason<BR/>Both groups presented a high rate of leaving the studies early for any reason. An overall attrition rate of 39% limits the interpretation of most other findings. The meta-analysis did not show any significant difference between clozapine and olanzapine which may be equally acceptable for individuals with schizophrenia.</P>
<P>1.3 Leaving the study early : 2. Adverse effects<BR/>In regard to leaving the study early due to adverse effects, significantly more people taking clozapine left the studies early in comparison with those taking olanzapine, suggesting that olanzapine is tolerated better than clozapine, although the lower limit of the confidence interval is located near the line 'no difference'. The results of the <LINK REF="STD-Bitter-2004" TYPE="STUDY">Bitter 2004</LINK>, <LINK REF="STD-Naber-2005" TYPE="STUDY">Naber 2005</LINK> and <LINK REF="STD-Meltzer-2003" TYPE="STUDY">Meltzer 2003</LINK> studies may have affected our result in this regard due to the low clozapine dose (less 300 mg/day) used in their studies.</P>
<P>1.4 Leaving the study early: 3. Inefficacy<BR/>Despite the certain heterogeneity observed on leaving the study due to inefficacy there was a trend in favour of clozapine which did not reach a conventional level of statistical significance. The heterogeneity could be due to <LINK REF="STD-Naber-2005" TYPE="STUDY">Naber 2005</LINK>, which, unlike other studies, reported a higher attrition rate in the clozapine group than in the olanzapine group.</P>
<P>1.5 Global state<BR/>This analysis was based on two medium term studies not finding a significant difference between clozapine and olanzapine on the CGI improvement scale. During these studies more than 50% of the participants in each group did not improve. Only <LINK REF="STD-Naber-2005" TYPE="STUDY">Naber 2005</LINK> reported relapses and no significant difference between groups was found. The numbers of relapses was very low in both groups.</P>
<P>1.6 to 1.15 Mental state<BR/>Various criteria were used to evaluate a clinically significant improvement of the participants mental state, using the PANSS or the BPRS. Neither in the short term nor in the medium term was there a statistically significant superiority displayed by either group. Nevertheless it is interesting to note a slight trend in favour of clozapine in the two small studies with children (<LINK REF="STD-Kumra-2008" TYPE="STUDY">Kumra 2008</LINK>; <LINK REF="STD-Shaw-2006" TYPE="STUDY">Shaw 2006</LINK>).</P>
<P>The mean values on PANSS and BPRS total scores showed a trend in favour of olanzapine, but this difference did not reach conventional levels of statistical significance even when we excluded studies with skewed data. These results were probably affected due to the low doses of clozapine used (&lt; 400 mg/day) and it may be the sample power was not enough to find a statistical difference between groups. New studies are necessary to assess the effect and impact of this difference, if any exists.</P>
<P>Observing the primary studies, both drugs produced a score decrease from baseline. However, the degree of reduction in short term studies by <LINK REF="STD-Krakowski-2006" TYPE="STUDY">Krakowski 2006</LINK> and <LINK REF="STD-Volavka-2002" TYPE="STUDY">Volavka 2002</LINK> (less than 10 PANSS points) may not be clinically important. Studies with duration of more than 18 weeks showed a more pronounced reduction of symptoms (more than 10 points, <LINK REF="STD-Naber-2005" TYPE="STUDY">Naber 2005</LINK>, <LINK REF="STD-Bitter-2004" TYPE="STUDY">Bitter 2004</LINK> and <LINK REF="STD-Tollefson-2001" TYPE="STUDY">Tollefson 2001</LINK>).</P>
<P>The studies in children again showed a trend in favour of clozapine which was not statistically significant (<LINK REF="STD-Kumra-2008" TYPE="STUDY">Kumra 2008</LINK> and <LINK REF="STD-Shaw-2006" TYPE="STUDY">Shaw 2006</LINK>). It could be interesting to clarify by further studies whether children respond differently to therapy than adults.</P>
<P>There was no significant difference between clozapine and olanzapine in the reduction of positive and negative symptoms of schizophrenia. Again, the small studies with children showed a non-significant trend in favour of clozapine in terms of the average SAPS and SANS change, which could stimulate further studies. On SANS, which excluded the study with possibly skewed data, clozapine showed a superiority over olanzapine, but this finding has a limited utility due to the low power of the sample (one study), and because the participants were children.</P>
<P>1.16 Cognitive functioning<BR/>This outcome was evaluated by only one study, which reported that significantly more participants in the olanzapine group than those assigned to the clozapine group presented a clinically relevant improvement, defined as a decrease of at least 0.5 standard deviation units on the neurocognitive score. More evidence on this important outcome is needed.</P>
<P>1.17 to 1.18 Quality of life<BR/>Subjective well being and quality of life were assessed in one study at medium term using SWN-38 score and MLDL satisfaction with treatment score, respectively. The SWN-38 showed a marked tendency in favour of olanzapine, but due to a great variability of the data the difference was not statistically significant. Furthermore, when the MLDL instead of the SWN-38 was considered, the satisfaction with clozapine and olanzapine was similar.</P>
<P>1.19 Service use<BR/>A long term study, <LINK REF="STD-Meltzer-2003" TYPE="STUDY">Meltzer 2003</LINK>, showed a significant difference, where more participants in the olanzapine group had to be hospitalised to avoid suicide attempts. The relevance of this finding is limited due to the small effect size and the CI observed, which showed that it is possible that the true RR value is likely to be very close to 1.</P>
<P>1.20 Adverse effects: 1. At least one adverse effects<BR/>The results on the number of participants with at least one adverse effect were statistically significantly heterogeneous and were therefore not combined. In general, all studies showed a trend indicating more people in the clozapine group had at least one adverse effect, but only one showed a significant difference between groups. Although this study presented an important effect size its generality is limited because only Chinese participants were included who might have a different idiosyncratic response to the treatment. It is possible that the biological and cultural variability between studies was the cause of the heterogeneity among them.</P>
<P>1.21 Adverse effects: 2. Cardiac effects<BR/>Regarding cardiac effects, a low incidence of ECG alteration was observed in both groups, even when the alteration incidence was lower in the olanzapine group, there was no statistical significant difference.</P>
<P>1.22 to 1.28 Adverse effects: Extrapyramidal effects<BR/>Concerning extrapyramidal side-effects there was no significant difference between clozapine and olanzapine in terms of the use of antiparkinson medication. There was also no significant difference in terms of specific extrapyramidal symptoms such as akathisia, dyskinesia, pseudoparkinsonism and rigor. All of them, except pseudoparkinsonism, showed a trend in favour of clozapine. Both antipsychotic drugs may cause some extrapyramidal effects because a number of participants needed antiparkinson medication during the trials and movement disorders occurred in both groups. Rating scales for general and specific extrapyramidal side-effects (ESRS, BARS, AIMS, SAS and HAS) did not reveal statistically significant differences.</P>
<P>1.29 to 1.30 Adverse effects: Glucose<BR/>There was no conclusive difference between clozapine and olanzapine in terms of glucose levels. Dichotomous data from <LINK REF="STD-Meltzer-2003" TYPE="STUDY">Meltzer 2003</LINK> showed no difference regarding the incidence of diabetes mellitus (criterion not specified). Continuous glucose data were heterogeneous. Only short term studies significantly favoured olanzapine, but there was a high variability of the results and the sample sizes were small. In contrast, a medium term study showed a non-significant trend in favour of clozapine.</P>
<P>1.31 Adverse effects: Hypersalivation<BR/>Five studies reported on hypersalivation but as the results were heterogeneous we did not combine them in a meta-analysis. Nevertheless four studies reported a significant difference in favour of olanzapine. The results of the single studies suggest that longer study durations were associated with larger effect sizes and indeed when only studies of each duration category were pooled the results were homogeneous. It can be clearly concluded that people using clozapine are more prone to present hypersalivation than those using olanzapine.</P>
<P>1.32 to 1.34 Adverse effects: Lipids<BR/>Data on lipid levels were equivocal and heterogeneous. Currently there is no evidence for any superiority of one drug over the other. In order to obtain a valid conclusion further studies would be necessary.</P>
<P>1.35 Adverse effects: Prolactin<BR/>According to a small study, the average change in prolactin levels at medium term showed a statistically significant difference in favour of clozapine, which slightly decreased the level, while the prolactin level in the olanzapine group increased. Whether this difference is clinically important or not is questionable, but at least in specific situations (e.g. women with a history of breast cancer) it may be relevant. Others studies indicated prolactin levels by gender. The results in men were heterogeneous, possibly due to different participant ages. The study in children and adolescents found a significant difference in favour of clozapine (<LINK REF="STD-Kumra-2008" TYPE="STUDY">Kumra 2008</LINK>: male only). The same study also found a significant superiority of clozapine in female participants. The effect sizes were relatively large and probably clinically meaningful, at least in female participants in whom the mean prolactin level in the olanzapine group was above normal. These results should be replicated in larger samples to corroborate the evidence base. The clinical importance of prolactin increase should also be addressed by recording associated side-effects (galactorrhoea, impotence etc).</P>
<P>1.36 Adverse effects: Sedation<BR/>In seven studies sedation was more frequent in participants using clozapine than in participants using olanzapine. Although all studies showed at least a trend in favour of olanzapine (irrespective of their duration), the results were heterogeneous. The heterogeneity could be caused by differences in participants age because the two studies in children and adolescents found only minimal differences between groups (<LINK REF="STD-Shaw-2006" TYPE="STUDY">Shaw 2006</LINK> and <LINK REF="STD-Kumra-2008" TYPE="STUDY">Kumra 2008</LINK>). This observation suggests that children may differ in their sensitivity to sedative effects from adults but this needs to be confirmed in further trials.</P>
<P>1.37 Adverse effects: Seizures<BR/>Participants using clozapine presented a 6.5 times higher risk for seizures than those using olanzapine. Therefore olanzapine is more secure on this regard.</P>
<P>1.38 to 1.39 Adverse effects: Weight gain<BR/>Results on weight gain were inconclusive. The results in terms of &#8216;number of patients with weight gain&#8217; were heterogeneous and only one study (<LINK REF="STD-Meltzer-2003" TYPE="STUDY">Meltzer 2003</LINK>) showed a significant difference between groups in favour of clozapine. The heterogeneity could be due to different criteria applied to define &#8216;weight gain&#8217;. There was also no significant difference in the mean weight gain between clozapine and olanzapine. We highlight that both drugs produced a considerable increase of weight, clozapine from 1.5 to 6.5 kg and olanzapine from 1.6 to 8.9 kg.</P>
<P>1.40 Adverse effects: White blood cell count<BR/>Significantly more participants in the clozapine group experienced an important reduction of the white blood cell count during the studies. The risk in the clozapine group was six times higher than in the olanzapine group. Therefore, olanzapine is a safe drug regarding this important outcome.</P>
<P>2. CLOZAPINE versus OLANZAPINE - Sensitivity analysis<BR/>The sensitivity analysis carried -out did not show any significant change in the results, except for the comparison average change on SANS excluding the studies with potentially skewed data. This result was difficult to interpret due to the small size sample from one study.</P>
<P>3. Comparison 2: CLOZAPINE versus QUETIAPINE<BR/>These studies have a limited external validity mainly for two reasons: time (only short term results) and participants&#8217; ethnicity (80% of the studies were of oriental origin).</P>
<P>3.1 Leaving the study early<BR/>A trend was observed indicating that more people receiving clozapine than quetiapine left the study early due to any reason and/or adverse effects. However these differences did not reach the conventional statistical significance level. Probably due to the small size of the trial, the possibility to detect any difference between the groups, if any existed, was low. The outcome 'leaving the study early due inefficacy' could not be estimated since the trial that reported this result did not have any attrition due to this cause.</P>
<P>3.2 Global state<BR/>In practice several criteria have been used to measure the participants&#8217; global state during the treatment. The only study that reported the number of participants with no clinical important change on the global state did not give any details regarding the criterion and only stated that a 'common criterion' was used. There was no evidence of any difference amongst the groups on this regard. Since the study was done in China, where criteria and medical praxis could differ from the ones used in other countries, its applicability could be limited.</P>
<P>3.3 to 3.9 Mental state<BR/>A similar percentage of participants in both groups (32% in clozapine versus 34% in quetiapine) did not improve their mental state using the criterion of at least 50% of reduction on PANSS at short term. The participants also had similar scores on PANSS or BPRS total at endpoint. No statistically significant evidence of superiority of either drug regarding the efficacy of them on mental state was found.</P>
<P>Regarding positive symptoms, both treatment groups at short term presented similar PANSS positive subscore at endpoint. Concerning the clinical improvement of negative symptoms (at least 50% diminution on SANS score), no evidence of any difference was found amongst groups. Skewed data pooled of average PANSS negative subscore at endpoint showed a quetiapine superiority over clozapine, but due to the asymmetry this result had a limited confidence level (&lt;95%). One study that used SANS total score showed the same trend, but without reaching the conventional significance levels. Summarising both treatments were not different in efficacy on general mental state or positive and negative symptoms.</P>
<P>3.10 Adverse effects: At lease one adverse effects<BR/>Participants receiving clozapine presented two times more risk of at least one adverse effect than those with quetiapine treatment (NNH 2, CI 2 to 5). This NNH suggests that adverse effects were common in participants receiving clozapine.</P>
<P>3.11 Adverse effects: Cardiac effects<BR/>Participants on clozapine had a higher risk of presenting ECG abnormalities, but this result should be taken with precaution due to its low statistical power, which limits its interpretation (NNH 5, CI 3 to 21). The incidence of specific cardiac effects was similar in both groups.</P>
<P>3.12 to 3.13 Adverse effects: Extrapyramidal effects<BR/>Regarding extrapyramidal symptoms, the effect of both treatments on the use during the study of antiparkinson medication could not be estimated since only one study reported this outcome without any event amongst groups.</P>
<P>Evaluating the specific extrapyramidal symptoms, a trend in favour of quetiapine and clozapine was found with respect to the incidences of akathisia and rigor respectively. Regarding tremor, the trend was the same for both groups. By general rule there were no statistically significant differences between treatment groups, therefore is not possible to establish which drug was safest with regard to specific extrapyramidal adverse effects.</P>
<P>3.14 Adverse effects: Hypersalivation<BR/>Hypersalivation was significantly more frequent in people allocated to clozapine (NNH 1, CI 1 to 2), the NNH value indicates that this adverse effect was very common with clozapine. Although a great variability in the relative risk values, the minimum value, which is likely to include RR, was clinically important and the maximum one was overrated.</P>
<P>3.15 Adverse effects: Lipids<BR/>There was statistically significant evidence that participants receiving clozapine had a greater increase in triglyceride levels. This result was based only on a small study (n=25). It would be necessary to replicate this finding.<BR/>
</P>
<P>3.16 Adverse effects: Sedation<BR/>People on treatment with clozapine had 4.47 times more risk of suffering sedation (NNH 3, CI 2 to 4) than people allocated to quetiapine. This adverse effect was common in this group of participants.</P>
<P>3.17 to 3.18 Adverse effects: Weight<BR/>People taking clozapine were more prone to weight gain than those receiving quetiapine, the magnitude of this increase was higher in the clozapine group (+ 6.5 kg) than quetiapine group (+ 4.4 kg), however both differences were not statistically significant.</P>
<P>3.19 Adverse effects: White blood cell count<BR/>Concerning white blood cell decrease, there was no statistically significant difference between the treatment groups. Due to the small power of the trial it was not possible to detect any difference between the groups, if any existed. Furthermore it is necessary to have more details e.g. if the decrease was transient or conserved, the decrease severity, etc. in order to evaluate the clinical importance, as well as data from longer trials.<BR/>
<BR/>Overall, evaluating the results of the adverse effect analysis, it is possible to mention the existence of a trend in favour of quetiapine, but it is not statistically significant.<BR/>
</P>
<P>4. Comparison CLOZAPINE versus QUETIAPINE Sensitivity analysis<BR/>The sensitivity analysis for the comparison average PANSS total score at endpoint excluding the studies with potentially skewed data, showed no change in the results, supporting that there was no evidence to indicate a difference between clozapine and quetiapine in these aspects.</P>
<P>5. Comparison 3: CLOZAPINE versus RISPERIDONE<BR/>5.1 Death<BR/>Death is an outcome not usually evaluated in studies. There was no evidence of any difference between short term treatment groups with respect of the incidence of death due to natural causes. In the case of death by suicide, a small study reported that it did not occur, therefore the treatment effect was not estimable.</P>
<P>5.2 to 5.4 Leaving the study early<BR/>Overall, a high percentage of participants withdrew from the study in both treatments. No statistically significant difference between comparison groups was found on leaving the study early due to any reason.</P>
<P>More people treated with clozapine left the treatment because of adverse effects than those allocated to risperidone. Clozapine is more prone to produce important adverse effects such as sedation, seizures, hypersalivation, agranulocytosis, etc. which could explain this result. More participants allocated to risperidone left early due to the ineffectiveness compared to the people who received clozapine, suggesting a certain superior efficacy of clozapine.</P>
<P>5.5 Global state<BR/>This outcome is based on a single study and showed that there was no clear difference between clozapine and risperidone for CGI clinical response.</P>
<P>5.6 to 5.12 Mental state<BR/>A wide variety of criteria to measure the clinical improvement on mental state were used in different studies. Regardless of the criterion used either using PANSS or BPRS, studies at short and long term did not find robust evidence to demonstrate the superiority of one drug over the other.</P>
<P>Heterogeneous data could not be combined to estimate the treatment effects on mental state using PANSS or BPRS scale. Therefore it was difficult to obtain any conclusions on this regard. Only the short term <LINK REF="STD-Azorin-2001" TYPE="STUDY">Azorin 2001</LINK> study showed a statistically significant difference in favour of clozapine on PANSS, which was replicated in the same study by using BPRS scale.</P>
<P>Overall, the studies reported that mental state scale data showed a wide variability in their measurements, which could be caused by differences in sample sizes, length of the studies, clozapine doses used and methodology used in the analysis (LOCF and/or ITT). The results of combined analysis of the short term studies were strongly influenced by Azorin&#8217;s study (<LINK REF="STD-Azorin-2001" TYPE="STUDY">Azorin 2001</LINK>) showing a statistically significant difference in favour of clozapine on BPRS, but the PANSS analysis did not support these results, which makes it difficult to define if there is any superiority in efficacy of either drug over the other. It would be desirable to have further studies using appropriate doses with a high quality methodological procedure, in order to include them in future versions of this review to obtain the best evidence in this regard.</P>
<P>There was a slight trend in favour of clozapine on the PANSS positive subscore, which was not significant. It was observed that the results of individual studies are contradictory and equivocal; this could be the cause of certain level of heterogeneity among them. Skewed data in subscores suggests the same trend on the BPRS positive, but neither was significant.</P>
<P>For negative symptoms, again data from PANSS were heterogeneous and equivocal, hampering the analysis. Two studies used SANS score (only short term) and did not find any statistically significant differences between groups.</P>
<P>5.13 General functioning<BR/>A trend in favour of risperidone is noted on GAF measures, where risperidone presented a score greater than clozapine at endpoint. The small sample size of the single available study makes any conclusions impossible.</P>
<P>5.14 Social functioning<BR/>Risperidone was superior to clozapine on measures of social functioning (short term). It is important to take into account the low power of the sample, which implies a high degree of variability in the measurements, therefore the clinical significance of this finding is difficult to interpret.</P>
<P>5.15 Treatment satisfaction<BR/>Skewed data showed no difference between clozapine and risperidone in treatment satisfaction.</P>
<P>5.16 Cognitive Functioning<BR/>There were no statistically significant differences between groups in terms of participants who showed a neurocognitive improvement. This study used a score composed by four neurocognitive domains performed especially for this study, therefore its application to clinical practice would require a validation procedure.</P>
<P>5.17 Adverse effects: At least one adverse effect<BR/>Two heterogeneous studies compared clozapine and risperidone regarding the number of people who experienced 'at least one side effect' during the study. One of them showed a significant difference, where more people taking clozapine suffered at least one adverse effect than those receiving risperidone. This result should be interpreted with caution due to the low sample power. The other, larger, study did not show a difference between treatment groups.</P>
<P>5.18 Adverse effects: Cardiac effects<BR/>There was no evidence that the treatment groups were different in terms of the incidence of cardiac alterations (ECG abnormalities - myocarditis).</P>
<P>5.19 to 5.21 Adverse effects: Extrapyramidal<BR/>With regard to extrapyramidal symptoms, fewer people in the clozapine group received an antiparkinson medication compared with those assigned to risperidone (NNH 6, CI 4 to 12). Two heterogeneous studies assessed the number of people who experienced at least one extrapyramidal symptom, only one of them showed a significant statistical difference in favour of clozapine. It was difficult to contrast these results with the other outcomes appraised regarding extrapyramidal symptoms since no comparison showed any statistically significant difference between clozapine and risperidone. The evaluation of the relative risk of presenting some specific extrapyramidal symptoms did not show any difference between groups with respect to akathisia, dyskinesia, tremor and dystonia. Surprisingly parkinsonism was significantly more frequent in participants with clozapine than risperidone, but the clinical significance is unclear because the criterion used was an ESRS score considering only 'participants with score of 1 or more in ESRS', because the mean score was not reported and because the confidence interval was very large and the lower limit very close to one (equal effects).</P>
<P>When extrapyramidal symptoms were evaluated by means of ESRS and BARS scores, skewed data were equivocal. Using SAS, a small study showed no difference between the treatment groups.</P>
<P>In general studies did not report or at least not clearly, the occurrence of extrapyramidal symptoms. In further studies a clear description of the criteria for reporting adverse effects and along with it, the way of reporting the use of antiparkinson medication during the trial, is necessary. Thus the process could systematically eliminate confusion factors. As a result it might be possible to demonstrate whether there is any difference between clozapine and risperidone in this aspect.</P>
<P>5.22 Adverse effects: Glycaemia<BR/>There was no evidence that the drugs were different with respect to glycaemia. Clearly, both drugs produced an average increase of glucose of 3 - 4 mg/dL on glucose level at 14 weeks (medium term). It would be interesting to know their long term effects, as well as with a bigger sample size to evaluate their clinical importance in particular situations.</P>
<P>5.23 Adverse effects: Hypersalivation<BR/>Hypersalivation was 4.34 times more common in participants taking clozapine than those with risperidone (NNH 4, CI 3 to 5).</P>
<P>5.24 Adverse effects: Lipids<BR/>With regard to lipid levels, both drugs increased the cholesterol and triglycerides levels. Although no significant differences between groups in the average change of total cholesterol at medium term was observed, a marked trend in favour of risperidone was noted, which might reflect a type II error. By contrast, there was a statistical significant difference between clozapine and risperidone in the average change on the triglycerides level, where the clozapine group showed a pronounced increase. Despite the small sample size, the precision of the measurements contributed to increase the magnitude of treatment effect, clinically and statistically significant but limited because these results were based on only one small study, and should be replicated.</P>
<P>5.25 to 5.26 Adverse effects: Prolactin<BR/>A single short term study reported the outcome of the diminution of sexual drive, which is a side-effect associated with an increase of prolactin levels. This side-effect presented a higher incidence in the risperidone group but without reaching the conventional levels of statistical significance. People treated with risperidone showed a high level of prolactin at endpoint (short and medium term) over the adults&#8217; reference levels unlike those treated with clozapine who presented values inside the reference levels. Two studies reported these findings showing significant differences between groups in favour of clozapine, but these results could not be combined due to the heterogeneity amongst them. The difference between these two studies could be due to the variability of the measurements caused by the small power of the samples. Also the results in the <LINK REF="STD-Volavka-2002" TYPE="STUDY">Volavka 2002</LINK> study were biased, since the measures reported were obtained from a subgroup of male patients and not from the entire group. It would be desirable to replicate these results, in order to support with more confidence these findings. Nevertheless, it is very likely that risperidone is associated with much more prolactin increase than clozapine.</P>
<P>5.27 Adverse effects: Sedation<BR/>Sedation was statistically more frequent in participants using clozapine than those using risperidone (NNH 7 CI 4 to 17 ).<BR/>
<BR/>5.28 Adverse effects: Seizures<BR/>People taking clozapine were more prone to suffer seizures than those on risperidone (NNH 14 CI 8 to 38).</P>
<P>5.29 to 5.30 Adverse effects: Weight<BR/>The studies that reported the outcome of 'number of participants with weight gain' were heterogeneous. These studies showed that more participants using clozapine suffered weight gain than those using risperidone. Only a small short term study conducted in China reached levels of statistical significance in favour of risperidone, however the ample confidence interval made it difficult to conclude its clinical significance. The heterogeneity could be due to the different criteria used to define weight gain and the idiosyncratic sample variability. This trend was supported by the results of individual heterogeneous studies at short and medium term that measured average weight change, where three of four studies showed statistical significant differences between the treatment groups. Clozapine treatment produced an increase between 2 - 6 kg more than risperidone.</P>
<P>5.31 Adverse effects: White blood cell count<BR/>There was no evidence of difference in the incidence of white blood cell decrease between clozapine and risperidone. In general, the incidence was very low and non-fatal in both groups, neutropenia being the most frequent alteration.</P>
<P>6. Comparison 4: CLOZAPINE versus ZIPRASIDONE<BR/>These results are based on only one unpublished short term study including people with refractory schizophrenia.</P>
<P>6.1 Leaving the study early<BR/>Overall, in both groups a high number of participants left the study early due to any reason. Clozapine and ziprasidone were similar in this aspect showing a 38% rate of attrition to medium term (18 weeks). This high attrition value could affect the validity of the results.</P>
<P>6.2 Mental state<BR/>Both drugs produced a similar diminution, near to 24.5 points on PANSS total score after 18 weeks of treatment. Both antipsychotics drugs showed to be efficacious in decreasing schizophrenia symptoms. There was no evidence of superiority by either drug.</P>
<P>6.3 Adverse effects: Cardiac problems<BR/>None of participants suffered any cardiac alteration during the length of the trial, therefore both treatments were shown to be safe in this aspect at 18 weeks. Again, this result was based on a single study which has only been published as a poster.</P>
<P>7. Comparison 5: CLOZAPINE versus ZOTEPINE<BR/>Only two studies provided data to compare clozapine with zotepine. The <LINK REF="STD-Lindenberg-1997" TYPE="STUDY">Lindenberg 1997</LINK> study was based on six weeks of the following of only Caucasian participants which limited its external validity. This study provided only data for leaving the study early for any reason. The other data are based only in one short term study from Taiwan (<LINK REF="STD-Lin-2003" TYPE="STUDY">Lin 2003</LINK>). The objective of this study was to evaluate switching from clozapine to zotepine in patients with partial response to clozapine. Therefore the results presented two limitations: they are only applicable to the drug-switching situation and the external validity is limited since the study only included oriental participants.</P>
<P>7.1 Leaving the study early<BR/>No statistically significant difference was found between clozapine and zotepine in the rate of participants who left the study early for any reason. The specific reasons for leaving the study early were not reported.</P>
<P>7.2 Global state<BR/>The limited data showed a clear difference between groups, where more people on zotepine did not improve ('less than successfully and no increase on CGI-S') during the twelve weeks of the study in comparison with those from the clozapine group (NNT 3, CI 2 to 8). It is difficult to support this finding as results are based on one small single study.</P>
<P>7.3 Mental state<BR/>A statistically significant difference in favour of clozapine in the average change on BPRS total was found. The effect size was influenced by an unexpected increase of 4.7 points in the score of participants taking zotepine, while in the clozapine group only a slight decrease of 1.3 points was noted. This finding suggests that those on clozapine treatment conserved their score almost without changes and those using zotepine worsened in the twelve weeks, therefore despite clozapine being superior in comparative terms, its effect on the participants' improvement was not clinically important.</P>
<P>7.4 Adverse effects: Extrapyramidal effects<BR/>The relative risk of use of antiparkinson medication was higher in the zotepine group than in the clozapine group (NNH 3, CI 2 to 5). This study reported that only participants who switched to zotepine needed medication at some point within the 12 weeks, whereas participants treated with clozapine did not require it. Due to the study features it is important to consider that participants treated with clozapine probably experienced some transient extrapyramidal symptoms before the study, therefore the conclusion obtained from this study could, in some way, be biased.</P>
<P>7.5 Adverse effects: Prolactin<BR/>Another adverse effect assessed in this study was increase of the prolactin level. Participants treated with zotepine presented a significant increase of the prolactin levels. Although the wide confidence interval indicates low precision of estimated effect, the increase in values over the normal levels suggest that zotepine could have some negative implications for patient health. Again, the limited data make any conclusive statement difficult and a replication is needed.</P>
<P>Limited data made it impossible to compare these antipsychotics regarding other important adverse effects.</P>
</SUMMARY_OF_RESULTS>
<APPLICABILITY_OF_FINDINGS MODIFIED="2009-04-27 16:26:55 +0100" MODIFIED_BY="[Empty name]">
<P>Data on five out of eight possible comparisons were found, hence the evidence is incomplete. Limited information on general functioning, satisfaction with the treatment or care, cognition and service use was available. Most studies were short term, which limits the applicability considering that schizophrenia is a chronic, often life-long disorder. The high attrition in the studies also limits the applicability of the evidence to practice.</P>
</APPLICABILITY_OF_FINDINGS>
<QUALITY_OF_EVIDENCE MODIFIED="2010-10-05 11:24:38 +0100" MODIFIED_BY="[Empty name]">
<P>Twenty of twenty-seven studies were double-blind and seven were single-blind, and the reporting of details were limited. Without an adequate description of the methodology of the studies, it was difficult to assess their quality. Moreover, many outcomes were assessed in sample sizes that were not large enough to detect significant differences if they exist.</P>
</QUALITY_OF_EVIDENCE>
<POTENTIAL_BIASES MODIFIED="2009-04-27 16:27:24 +0100" MODIFIED_BY="[Empty name]">
<P>We are not aware of any obvious flaws in our review process.</P>
</POTENTIAL_BIASES>
<AGREEMENT MODIFIED="2009-04-27 16:27:42 +0100" MODIFIED_BY="[Empty name]">
<P>The former Cochrane review that compared clozapine with other second generation antipsychotic drugs  (<LINK REF="REF-Tuunainen-2000" TYPE="REFERENCE">Tuunainen 2000</LINK>) included only eight studies, while the current report comprises 27 studies. This large increase in the evidence base makes the two reviews hardly comparable. Nevertheless, some differences in adverse events found in <LINK REF="REF-Tuunainen-2000" TYPE="REFERENCE">Tuunainen 2000</LINK> persisted in the current review making these results more robust.</P>
</AGREEMENT>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2010-10-05 11:29:15 +0100" MODIFIED_BY="[Empty name]">
<IMPLICATIONS_PRACTICE MODIFIED="2010-10-05 11:29:15 +0100" MODIFIED_BY="[Empty name]">
<P>1. For people with schizophrenia<BR/>People with schizophrenia need to know that clozapine differs most clearly in adverse effects from other second generation antipsychotic drugs. It seems to produce somewhat fewer movement disorders than risperidone and zotepine, and is likely to increase prolactin levels less than olanzapine, risperidone and zotepine. On the other hand, clozapine is associated with more frequent decrease of white blood cells than olanzapine, more hypersalivation and sedation than olanzapine, quetiapine and risperidone, and more seizures than olanzapine and risperidone. Compared to risperidone, clozapine may also lead to more weight gain. Differences in efficacy are less clear, but clozapine may be slightly more efficacious than risperidone and zotepine.</P>
<P>2. For clinicians<BR/>The overall attrition in the included studies of this review was considerable (30%) making the interpretation of the results difficult. Furthermore, a reasonable amount of evidence is only available compared to olanzapine (12 trials) and risperidone (9 trials). Five small trials on quetiapine were conducted outside the US and Europe, limiting generalisability. Only two small studies compared clozapine with zotepine and one with ziprasidone. Randomised clinical trials comparing clozapine with other second generation antipsychotic drugs (e.g. amisulpride, aripiprazole and sertindole) are not available.</P>
<P>Although clozapine is usually considered to be the most efficacious antipsychotic drug available, this review could not document convincing differences in efficacy.  </P>
<P>Adverse effects profiles are very similar, some specific differences could be crucial to selecting the more adequate treatment according to the characteristics of each patient and their expectations. Here, clozapine seems to produce more hypersalivation and sedation than olanzapine, quetiapine and risperidone; more seizures than olanzapine and risperidone; more weight gain than risperidone and more frequent leukopenia than olanzapine. On the other hand, clozapine was associated with fewer movement disorders than risperidone and zotepine, and less prolactin increase than olanzapine, risperidone and zotepine.</P>
<P>3. For managers/policy makers<BR/>There is insufficient information to guide the decisions of managers and policy makers. The abandonment of treatment often leads to worsening of patients' health and therefore a greater demand for medical care. Clozapine, risperidone, olanzapine and ziprasidone show similar rates of abandonment of treatment, nearly 31%, which makes it necessary to apply efforts to improve the patient compliance. Service use was reported by only one large study which showed fewer hospitalisations to avoid suicide attempts. This evidence base is too limited for making recommendations. This review did not attempt to measure the economic impact of clozapine compared to other second generation antipsychotic drugs.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2010-09-30 13:31:40 +0100" MODIFIED_BY="[Empty name]">
<P>1. General<BR/>There is room for improvement in the conduct and reporting of randomised controlled schizophrenia trials. Rating scale derived efficacy outcomes dominate the trials and even in this regard authors keep using different definitions for response to treatment making a comparison of the results difficult. Potentially important outcomes such as satisfaction with care, functioning in the community or service use are rarely examined. Simple descriptions of the randomisation or blinding methods are usually not presented. Strict adherence to the CONSORT statement (<LINK REF="REF-Moher-2001" TYPE="REFERENCE">Moher 2001</LINK>) would improve the reporting and conduct of future trials.</P>
<P>2. Specific<BR/>Studies comparing clozapine with the second generation antipsychotic drugs amisulpride, aripiprazole and sertindole are currently completely missing and are therefore mandatory. But even the available evidence on the other comparisons was incomplete, most importantly concerning global outcomes such as satisfaction with care, death, quality of life or service use. Furthermore, only 8% of the included studies fell in the long term category. As schizophrenia is usually a chronic disorder, there is a need for further long term trials. <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK> makes a suggestion as to how such a study could look. Limited available evidence addressed the effects of clozapine in children and adolescents with schizophrenia. As children may have a different response treatment, this evidence should be extended.</P>
<P>Pharmaceutical companies generally compare new drugs against a very low dose of clozapine. These doses are lower than used in the pivotal study of <LINK REF="REF-Kane-1988" TYPE="REFERENCE">Kane 1988</LINK> and his collaborators. It is not fully clear if this can be included in sensitivity analysis/meta-regression, because there are only a limited number of studies that use adequate doses. This certainly indicates the need for future research using adequate doses</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2010-10-06 14:38:30 +0100" MODIFIED_BY="[Empty name]">
<P>We would like to thank all members of the Cochrane Schizophrenia Group for their editorial assistance, and acknowledge use of the Cochrane Schizophrenia Group's template for the <LINK TAG="METHODS" TYPE="SECTION">Methods</LINK> section which we have adapted for use in this review.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2009-10-06 00:22:34 +0100" MODIFIED_BY="[Empty name]">
<P>Claudia Asenjo L: none known.<BR/>Katja Komossa: participated in investigator meetings for clinical trials sponsored by Astra Zeneca, Pfizer, Sanofi Aventis, Servier.<BR/>Christine Rummel: received lecture honoraria and travel grants to attend scientific meetings from AstraZeneca, Janssen-Cilag, EliLilly and Pfizer.<BR/>Heike Hunger: none<BR/>Franziske Schmidt: none.<BR/>Sandra Schwarz: none.<BR/>Stefan Leucht: received speaker/consultancy honoraria from SanofiAventis, BMS, EliLilly, Janssen, Lundbeck and Pfizer. He received research support from SanofiAventis and EliLilly.<BR/>
</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2009-10-06 16:36:33 +0100" MODIFIED_BY="[Empty name]">
<P>Claudia Asenjo L: protocol development, searching, study selection, data extraction, report writing.<BR/>Katja Komossa: protocol development, searching, study selection, data extraction, helped with report writing.<BR/>Christine Rummel: protocol development, helped with data extraction.<BR/>Heike Hunger: protocol development, helped with data extraction.<BR/>Franziska Schmidt: protocol development, helped with data extraction.<BR/>Sandra Schwarz: protocol development, helped with data extraction.<BR/>Stefan Leucht: protocol development, searching, helped with data extraction, report writing.<BR/>
</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2009-08-14 14:47:25 +0100" MODIFIED_BY="[Empty name]">
<P>The review was adapted to new functions and formatting available in Review Manager 5, notably the risk of bias tables.</P>
</PRO_REV_DIFF>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2010-09-27 13:37:29 +0100" MODIFIED_BY="[Empty name]">
<STUDIES MODIFIED="2010-09-27 13:00:40 +0100" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2010-09-27 12:27:26 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Atmaca-2003" MODIFIED="2009-04-18 22:47:58 +0100" MODIFIED_BY="[Empty name]" NAME="Atmaca 2003" YEAR="2003">
<REFERENCE MODIFIED="2009-04-18 22:47:58 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Atmaca M, Kuloglu M, Tezcan E, Ustundag B</AU>
<TI>Serum leptin and triglyceride levels in patients on treatment with atypical antipsychotics</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>2003</YR>
<VL>64</VL>
<NO>5</NO>
<PG>598-604</PG>
<IDENTIFIERS MODIFIED="2009-04-18 22:47:58 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Azorin-2001" MODIFIED="2009-04-18 22:48:06 +0100" MODIFIED_BY="[Empty name]" NAME="Azorin 2001" YEAR="2001">
<REFERENCE MODIFIED="2009-04-18 22:48:06 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Azorin JM, Spiegel R, Remington G, Vanelle JM, Pere JJ, Giguere M, Bourdeix I</AU>
<TI>A double-blind comparative study of clozapine and risperidone in the management of severe chronic schizophrenia</TI>
<SO>American Journal of Psychiatry</SO>
<YR>2001</YR>
<VL>158</VL>
<NO>8</NO>
<PG>1305-13</PG>
<IDENTIFIERS MODIFIED="2009-04-18 22:48:06 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bitter-2004" MODIFIED="2010-09-27 12:06:18 +0100" MODIFIED_BY="[Empty name]" NAME="Bitter 2004" YEAR="2004">
<REFERENCE MODIFIED="2009-04-18 22:48:13 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bitter I, Brook S, Dossenbach M, Janka Z, Banki CsM, Selemani S, Grundy S, Martenyi F</AU>
<TI>Olanzapine versus clozapine in patients non-responsive or intolerant to standard acceptable treatment of schizophrenia</TI>
<SO>Journal of the European College of Neuropsychopharmacology</SO>
<YR>1999</YR>
<VL>9</VL>
<PG>S288</PG>
<IDENTIFIERS MODIFIED="2009-04-18 22:48:13 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2009-05-14 16:12:21 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bitter I, Dossenbach MRK, Brook S, Feldman PD, Metcalfe S, Gagiano CA, Furedi J, Bartko G, Janka Z, Banki CM, Kovacs G, Breier A</AU>
<TI>Olanzapine versus clozapine in treatment-resistant or treatment-intolerant schizophrenia</TI>
<SO>Progress in Neuro-Psychopharmacology and Biological Psychiatry</SO>
<YR>2004</YR>
<VL>28</VL>
<PG>173-80</PG>
<IDENTIFIERS MODIFIED="2009-04-18 22:48:18 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2009-04-18 22:48:23 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Bitter I, Slabber M, Pretorius J, Bartko GY, Danics Z, Dossenbach M, Martenyi F</AU>
<TI>Olanzapine versus clozapine in patients non responsive or intolerant to standard acceptable treatment of schizophrenia</TI>
<SO>International Journal of Neuropsychopharmacology</SO>
<YR>2000</YR>
<VL>3</VL>
<NO>Suppl 1</NO>
<PG>S141</PG>
<IDENTIFIERS MODIFIED="2009-04-18 22:48:23 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2009-05-15 11:08:05 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Dossenbach M, Bitter I, Slabber M, Pretorius J, Bartko GY, Banics Z, Martenyi F</AU>
<TI>Olanzapine versus clozapine in patients nonresponsive or intolerant to standard acceptable treatment for schizophrenia</TI>
<SO>Proceedings of the 153rd Annual Meeting of the American Psychiatric Association; 2000 May 13-18; Chicago, Illinois, USA</SO>
<YR>2000</YR>
<IDENTIFIERS MODIFIED="2009-04-18 22:48:26 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2010-09-27 12:06:18 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Dossenbach M, Bitter I, Slabber M, Pretorius J, Bartko GY, Banics Z, Martenyi F</AU>
<TI>Olanzapine versus clozapine in patients nonresponsive or intolerant to standard acceptable treatment for schizophrenia</TI>
<SO>Proceedings of the 155th Annual Meeting of the American Psychiatric Association; 2002 May 18-23; Philadelphia, Pennsylvania, USA</SO>
<YR>2002</YR>
<IDENTIFIERS MODIFIED="2009-04-18 22:48:29 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2009-05-15 11:09:01 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Dossenbach M, Slabber M, Martenyi F, Bartko G, Bitter I</AU>
<TI>Olanzapine vs. clozapine in patients non responsive or intolerant to standard acceptable treatment of schizophrenia</TI>
<SO>Proceedings of the 11th World Congress of Psychiatry; 1999 Aug 6-11; Hamburg, Germany</SO>
<YR>1999</YR>
<VL>2</VL>
<PG>148</PG>
<IDENTIFIERS MODIFIED="2009-04-18 22:48:33 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2009-01-15 13:19:33 +0000" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bondolfi-1998" MODIFIED="2010-09-27 12:07:34 +0100" MODIFIED_BY="[Empty name]" NAME="Bondolfi 1998" YEAR="1998">
<REFERENCE MODIFIED="2009-04-18 22:48:37 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bondolfi G, Baumann P, Dufour H</AU>
<TI>Treatment-resistant schizophrenia - clinical experience with new antipsychotics</TI>
<SO>European Neuropsychopharmacology</SO>
<YR>1996</YR>
<VL>6</VL>
<NO>Suppl 2</NO>
<PG>S21-5</PG>
<IDENTIFIERS MODIFIED="2009-04-18 22:48:37 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2010-09-27 12:06:51 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Bondolfi G, Baumann P, Patris M, May J, Billeter U, Dufour H, De Smedt G, Lemmens P</AU>
<TI>A randomized double-bind trial of risperidone versus clozapine for treatment-resistant chronic schizophrenia</TI>
<SO>Proceedings of the 8th European College of Neuropsychopharmacology Congress; 1995 Sep 30 - Oct 4; Venice, Italy</SO>
<YR>1995</YR>
<IDENTIFIERS MODIFIED="2009-04-18 22:48:42 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2009-05-15 11:10:39 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Bondolfi G, Baumann P, Patris M, May JP, Billeter U, Dufour H</AU>
<TI>A randomised double-blind trial of risperidone versus clozapine for treatment-resistant chronic schizophrenia</TI>
<SO>Proceedings of the 148th Annual Meeting of the American Psychiatric Association; 1995 May 20-25; Miami, Florida, USA</SO>
<YR>1995</YR>
<IDENTIFIERS MODIFIED="2009-04-18 22:48:46 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2010-09-27 12:07:34 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Bondolfi G, Baumann P, Patris M, May JP, Billeter U, Dufour H</AU>
<TI>A randomized double-blind trial of risperidone versus clozapine for treatment-resistant chronic schizophrenia</TI>
<SO>Proceedings of the Workshop on Critical Issues in the Treatment of Schizophrenia; 1995 Mar 10-12; Florence, Italy</SO>
<YR>1995</YR>
<PG>174-5</PG>
<IDENTIFIERS MODIFIED="2009-04-18 22:48:49 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2009-04-18 22:48:52 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Bondolfi G, Dufour H, Patris M, May JP, Billeter U, Eap CB, Baumann P</AU>
<TI>Risperidone versus clozapine in treatment-resistant chronic schizophrenia: a randomized double-blind study. The Risperidone Study Group</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1998</YR>
<VL>155</VL>
<NO>4</NO>
<PG>499-504</PG>
<IDENTIFIERS MODIFIED="2009-04-18 22:48:52 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2009-01-15 13:19:46 +0000" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Breier-1999" MODIFIED="2009-04-18 22:49:15 +0100" MODIFIED_BY="[Empty name]" NAME="Breier 1999" YEAR="1999">
<REFERENCE MODIFIED="2009-04-18 22:49:15 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Breier AF, Malhotra AK, Su TP, Pinals DA, Elman I, Adler CM, Lafargue RT, Clifton A, Pickar D</AU>
<TI>Clozapine and risperidone in chronic schizophrenia: effects on symptoms, parkinsonian side effects, and neuroendocrine response</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1999</YR>
<VL>156</VL>
<NO>2</NO>
<PG>294-8</PG>
<IDENTIFIERS MODIFIED="2009-04-18 22:49:15 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2009-01-15 13:19:51 +0000" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Conley-2003" MODIFIED="2009-04-18 22:49:24 +0100" MODIFIED_BY="[Empty name]" NAME="Conley 2003" YEAR="2003">
<REFERENCE MODIFIED="2009-04-18 22:49:20 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Conley RR, Kelly DL, Richardson CM, Tamminga CA, Carpenter Jr WT</AU>
<TI>The efficacy of high-dose olanzapine versus clozapine in treatment-resistant schizophrenia: a double-blind, crossover study</TI>
<SO>Journal of Clinical Psychopharmacology</SO>
<YR>2003</YR>
<VL>23</VL>
<NO>6</NO>
<PG>668-71</PG>
<CY>United States of America</CY>
<IDENTIFIERS MODIFIED="2009-04-18 22:49:20 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2009-04-18 22:49:24 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kelly DL, Conley RR, Richardson CM, Tamminga CA, Carpenter Jr WT</AU>
<TI>Adverse effects and laboratory parameters of high-dose olanzapine vs. clozapine in treatment-resistant schizophrenia</TI>
<SO>Annals of Clinical Psychiatry</SO>
<YR>2003</YR>
<VL>15</VL>
<NO>3-4</NO>
<PG>181-6</PG>
<CY>United States of America</CY>
<IDENTIFIERS MODIFIED="2009-04-18 22:49:24 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2009-01-15 13:19:58 +0000" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Heinrich-1994" MODIFIED="2009-05-26 08:06:14 +0100" MODIFIED_BY="[Empty name]" NAME="Heinrich 1994" YEAR="1994">
<REFERENCE MODIFIED="2009-04-18 22:49:28 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Heinrich K, Klieser E, Lehmann E, Kinzler E, Hruschka H</AU>
<TI>Risperidone versus clozapine in the treatment of schizophrenic patients with acute symptoms: a double blind, randomized trial</TI>
<SO>Progress in Neuropsychopharmacology and Biological Psychiatry</SO>
<YR>1994</YR>
<VL>18</VL>
<NO>1</NO>
<PG>129-37</PG>
<IDENTIFIERS MODIFIED="2009-04-18 22:49:28 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2009-05-26 08:03:42 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Heinrich K, Klieser E, Lehmann E, Kinzler E</AU>
<TI>Experimental comparison of the efficacy and compatibility of clozapine and risperidone in acute schizophrenia</TI>
<SO>Clinical Neuropharmacology</SO>
<YR>1992</YR>
<VL>15</VL>
<NO>Suppl 1 (Pt B)</NO>
<PG>375B</PG>
<IDENTIFIERS MODIFIED="2009-04-18 22:49:31 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2009-05-26 08:04:00 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Heinrich K, Klieser E, Lehmann E, Kinzler E</AU>
<TI>Experimental comparison of the efficacy and compatibility of risperidone and clozapine in acute schizophrenia</TI>
<SO>Proceedings of the 17th Collegium Internationale Neuro-Psychopharmacologicum Congress; 1990 Sep 10-14; Kyoto, Japan</SO>
<YR>1991</YR>
<PG>37-9</PG>
<IDENTIFIERS MODIFIED="2009-04-18 22:49:36 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2009-05-26 08:05:11 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Heinrich K</AU>
<TI>Risperidone versus clozapine in acute schizophrenia</TI>
<SO>Proceedings of the 1st International Risperidone Investigators' Meeting; 1992 Mar 9-10; Paris, France</SO>
<YR>1992</YR>
<PG>27-28</PG>
<IDENTIFIERS MODIFIED="2009-04-18 22:49:42 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2009-04-18 22:49:45 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>Klieser E, Kinzler E</AU>
<TI>Risperidone versus clozapine in the treatment of schizophrenic patients with acute symptoms: a double-blind, randomised trial</TI>
<SO>Clinical report</SO>
<YR>1991</YR>
<IDENTIFIERS MODIFIED="2009-04-18 22:49:45 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2009-04-18 22:49:50 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Klieser E, Lehmann E, Kinzler E, Wurthmann C, Heinrich K</AU>
<TI>Randomized, double-blind, controlled trial of risperidone versus clozapine in patients with chronic schizophrenia</TI>
<SO>Journal of Clinical Psychopharmacology</SO>
<YR>1995</YR>
<VL>15</VL>
<NO>1 Suppl 1</NO>
<PG>S45-51</PG>
<IDENTIFIERS MODIFIED="2009-04-18 22:49:50 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2009-05-26 08:06:02 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Klieser E, Rappard F</AU>
<TI>Randomized, double-blind, controlled trial of risperidone versus clozapine in patients with acute exacerbations of schizophrenia</TI>
<SO>European Psychiatry</SO>
<YR>1994</YR>
<VL>9</VL>
<NO>Suppl 1</NO>
<PG>154S</PG>
<IDENTIFIERS MODIFIED="2009-04-18 22:49:53 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Krakowski-2006" MODIFIED="2009-05-26 08:08:21 +0100" MODIFIED_BY="[Empty name]" NAME="Krakowski 2006" YEAR="2006">
<REFERENCE MODIFIED="2009-04-18 22:50:09 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Krakowski MI, Czobor P, Citrome L, Bark N, Cooper TB</AU>
<TI>Atypical antipsychotic agents in the treatment of violent patients with schizophrenia and schizoaffective disorder</TI>
<SO>Archives of General Psychiatry</SO>
<YR>2006</YR>
<VL>63</VL>
<NO>6</NO>
<PG>622-9</PG>
<CY>United States</CY>
<IDENTIFIERS MODIFIED="2009-04-18 22:50:09 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2009-05-26 08:08:21 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Krakowski MI</AU>
<TI>Clozapine and olanzapine in violent schizophrenics</TI>
<SO>CRISP database (https://www-commons.cit.nih.gov/crisp/index.html)</SO>
<YR>(accessed 19th February 2001)</YR>
<IDENTIFIERS MODIFIED="2009-04-18 22:50:12 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Kumra-2008" MODIFIED="2010-09-27 12:09:07 +0100" MODIFIED_BY="[Empty name]" NAME="Kumra 2008" YEAR="2008">
<REFERENCE MODIFIED="2010-09-27 12:09:07 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Kumra S, Kranzler H, Gerbino-Rosen G, Kester HM, DeThomas C, Kafantaris V, Correl CU, Kane JM</AU>
<TI>Clozapine and "high-dose" olanzapine in refractory early-onset schizophrenia: a 12 weeks randomized and double-blind comparison</TI>
<SO>Biological Psychiatry</SO>
<YR>2008</YR>
<VL>63</VL>
<NO>5</NO>
<PG>524 -29</PG>
<IDENTIFIERS MODIFIED="2009-04-18 22:50:16 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Li--2002" MODIFIED="2009-05-26 08:19:40 +0100" MODIFIED_BY="[Empty name]" NAME="Li  2002" YEAR="2002">
<REFERENCE MODIFIED="2009-05-26 08:19:40 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Li Yan, Wang CH, Zhang DH</AU>
<TI>A study of quetiapine and clozapine in treatment of the first episode schizophrenia</TI>
<SO>Chinese Journal of Nervous and Mental Diseases</SO>
<YR>2002</YR>
<VL>28</VL>
<NO>3</NO>
<PG>219-20</PG>
<IDENTIFIERS MODIFIED="2009-04-18 22:50:20 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Li--2003" MODIFIED="2009-05-26 08:21:16 +0100" MODIFIED_BY="[Empty name]" NAME="Li  2003" YEAR="2003">
<REFERENCE MODIFIED="2009-05-26 08:21:16 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Li CH</AU>
<TI>A study of quetiapine and clozapine in treatment of schizophrenia</TI>
<SO>Chinese Journal of Nervous and Mental Diseases</SO>
<YR>2003</YR>
<VL>29</VL>
<NO>4</NO>
<PG>306-07</PG>
<IDENTIFIERS MODIFIED="2009-04-18 22:50:26 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Li--2005" MODIFIED="2009-04-18 22:50:29 +0100" MODIFIED_BY="[Empty name]" NAME="Li  2005" YEAR="2005">
<REFERENCE MODIFIED="2009-04-18 22:50:29 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Li Y-F, Feng Y-G</AU>
<TI>A double blind comparing study between the effects of quetiapine and clozapine on the life quality of the patients with schizophrenia</TI>
<SO>Medical Journal of Chinese People Health</SO>
<YR>2005</YR>
<VL>17</VL>
<NO>6</NO>
<PG>262-4</PG>
<IDENTIFIERS MODIFIED="2009-04-18 22:50:29 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lin-2003" MODIFIED="2009-05-26 08:21:59 +0100" MODIFIED_BY="[Empty name]" NAME="Lin 2003" YEAR="2003">
<REFERENCE MODIFIED="2009-04-18 22:50:33 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lin C-C, Bai Y-M, Chen J-Y, Wang Y-C, Liou Y-J, Chao C-H, Lai I-C, Tsai K-Y, Chiu H-J</AU>
<TI>Switching from clozapine to zotepine in schizophrenic patients: a randomized, single-blind controlled study</TI>
<SO>Journal of the European College of Neuropsychopharmacology</SO>
<YR>2003</YR>
<VL>13</VL>
<NO>4</NO>
<PG>S318</PG>
<IDENTIFIERS MODIFIED="2009-04-18 22:50:33 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2009-04-18 22:50:36 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lin CC, Chen JY, Bai YM, Chen TT, Wang YC, Liou YJ, Lin WK</AU>
<TI>Remission of tardive dyskinesia following the switch from clozapine to zotepine: 2-year follow-up</TI>
<SO>Journal of the European College of Neuropsychopharmacology</SO>
<YR>2006</YR>
<VL>16</VL>
<NO>Suppl 4</NO>
<PG>S410</PG>
<IDENTIFIERS MODIFIED="2009-04-18 22:50:36 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2009-05-26 08:21:59 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lin CC, Chen JY, Bai YM, Wang YC, Liou YJ, Lin WK, Chen TT</AU>
<TI>Long-term outcome of switching from clozapine to zotepine in refractory schizophrenia: a 2-year follow-up study</TI>
<SO>Journal of the European College of Neuropsychopharmacology</SO>
<YR>2005</YR>
<VL>15</VL>
<NO>Suppl 3</NO>
<PG>S500</PG>
<IDENTIFIERS MODIFIED="2009-04-18 22:50:40 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lindenberg-1997" MODIFIED="2009-05-26 08:25:45 +0100" MODIFIED_BY="[Empty name]" NAME="Lindenberg 1997" YEAR="1977">
<REFERENCE MODIFIED="2009-05-26 08:24:21 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gallhofer B, Gruppe H, Bauer U</AU>
<TI>Zotepine versus clozapine: A comparison of the impact on the cognitive dysfunction syndrome in schizophrenia (a double blind trial)</TI>
<SO>Pharmacopsychiatry</SO>
<YR>1995</YR>
<VL>28</VL>
<PG>179</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2009-05-26 08:23:10 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gallhofer B, Ulferts J, Bauer U, Gruppe H</AU>
<TI>Cognitive dysfunction in schizophrenia: a comparison of the impact of zotepine versus clozapine on the syndrome (a double blind trial)</TI>
<SO>Schizophrenia Research</SO>
<YR>1996</YR>
<VL>18</VL>
<NO>2-3</NO>
<PG>220</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2009-05-26 08:25:45 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Meyer-Lindenberg A, Bauer U, Lis S, Krieger S, Gallhofer B</AU>
<TI>Improvement of cognitive function in schizophrenic patients receiving clozapine or zotepine: Results from a double blind trial</TI>
<SO>Pharmacopsychiatry</SO>
<YR>1997</YR>
<VL>30</VL>
<NO>2</NO>
<PG>35-42</PG>
<IDENTIFIERS MODIFIED="2009-04-18 22:50:53 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Liu--2004" MODIFIED="2009-05-01 14:27:22 +0100" MODIFIED_BY="[Empty name]" NAME="Liu  2004" YEAR="2004">
<REFERENCE MODIFIED="2009-05-01 14:27:22 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Liu Y, Xu M, Chen X</AU>
<TI>A controlled study of quetiapine and clozapine in the treatment of schizophrenia with predominantly negative symptoms</TI>
<SO>Shandong Archives of Psychiatry</SO>
<YR>2004</YR>
<VL>17</VL>
<NO>1</NO>
<PG>6-8</PG>
<IDENTIFIERS MODIFIED="2009-04-18 22:50:44 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-McGurk-2005" MODIFIED="2010-09-27 12:11:08 +0100" MODIFIED_BY="[Empty name]" NAME="McGurk 2005" YEAR="2005">
<REFERENCE MODIFIED="2009-05-26 08:27:50 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bellack AS, Schooler NR, Marder SR, Kane JM, Brown CH, Yang Y</AU>
<TI>Do clozapine and risperidone affect social competence and problem solving?</TI>
<SO>American Journal of Psychiatry</SO>
<YR>2004</YR>
<VL>161</VL>
<NO>2</NO>
<PG>364-7</PG>
<IDENTIFIERS MODIFIED="2009-04-18 22:50:56 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2010-09-27 12:10:15 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Marder SR, Schooler NR, Kane JM, Petrides G, Chengappa KN, Wirshing WC, Wirshing DA, Umbricht D, Parapelli H</AU>
<TI>Tolerability of clozapine and risperidone during a twenty nine week trial</TI>
<SO>Schizophrenia Research</SO>
<YR>2003</YR>
<VL>60</VL>
<NO>1</NO>
<PG>293-4</PG>
<IDENTIFIERS MODIFIED="2009-04-18 22:51:01 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2009-05-26 08:28:18 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>McGurk SR, Carter C, Goldman R, Green MF, Marder SR, Xie H, Schooler NR, Kane JM</AU>
<TI>The effects of clozapine and risperidone on spatial working memory in schizophrenia</TI>
<SO>American Journal of Psychiatry</SO>
<YR>2005</YR>
<VL>162</VL>
<NO>5</NO>
<PG>1013-6</PG>
<CY>United States</CY>
<IDENTIFIERS MODIFIED="2009-04-18 22:51:07 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2009-05-26 08:28:54 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>McGurk SR, Goldman RS, Carter C, Green MF, Schooler N, Marder SR, Kane J</AU>
<TI>A double-blind comparison of clozapine and risperidone on spatial working memory in treatment-resistant schizophrenia.</TI>
<SO>Proceedings of the 39th Annual Meeting of the American College of Neuropsychopharmacology; 2000 Dec 10-14; San Juan, Puerto Rico</SO>
<YR>2000</YR>
<IDENTIFIERS MODIFIED="2009-04-18 22:51:10 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2009-05-26 08:29:24 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>McGurk SR, Goldman RS, Carter C, Green MF, Schooler R, Marder SR, Kane JM</AU>
<TI>A double-blind comparison of clozapine and risperidone on spatial working memory in treatment resistant schizophrenia</TI>
<SO>Schizophrenia Research</SO>
<YR>2001</YR>
<VL>49</VL>
<NO>1-2 Suppl</NO>
<PG>238</PG>
<IDENTIFIERS MODIFIED="2009-04-18 22:51:15 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2010-09-27 12:11:08 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schooler N, Marder S, Kane J, Chengappa KNR, Wirshing W, Umbricht D, Parepally H, Wirshing D, Petrides G</AU>
<TI>Clozapine and risperidone: a 29-week randomized clinical trial</TI>
<SO>Schizophrenia Research</SO>
<YR>1999</YR>
<VL>1, 2 &amp; 3</VL>
<PG>296</PG>
<IDENTIFIERS MODIFIED="2009-04-18 22:51:18 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Meltzer-2003" MODIFIED="2010-09-27 12:14:29 +0100" MODIFIED_BY="[Empty name]" NAME="Meltzer 2003" YEAR="2003">
<REFERENCE MODIFIED="2009-05-26 08:30:12 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Alphs L, Anand R, Islam MZ, Meltzer HY, Kane JM, Krishnan R, Green AI, Potkin S, Chouinard G, Lindenmayer JP, Kerwin R</AU>
<TI>The International Suicide Prevention Trial (InterSePT): Rationale and design of a trial comparing the relative ability of clozapine and olanzapine to reduce suicidal behavior in schizophrenia and schizoaffective patients</TI>
<SO>Schizophrenia Bulletin</SO>
<YR>2004</YR>
<VL>30</VL>
<NO>3</NO>
<PG>577-86</PG>
<CY>United States</CY>
<IDENTIFIERS MODIFIED="2009-04-18 22:51:41 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2009-05-26 08:30:39 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bourgeois M, Swendsen J, Young F, Amador X, Pini S, Cassano GB, Lindenmayer JP, Hsu C, Alphs L, Meltzer HY, InterSePT Study Group</AU>
<TI>Awareness of disorder and suicide risk in the treatment of schizophrenia: results of the international suicide prevention trial</TI>
<SO>American Journal of Psychiatry</SO>
<YR>2004</YR>
<VL>161</VL>
<NO>8</NO>
<PG>1494-6</PG>
<IDENTIFIERS MODIFIED="2009-04-18 22:51:44 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2009-05-26 08:30:47 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Glick ID, Zaninelli R, Hsu C, Young FK, Weiss L, Gunay I, Kumar V</AU>
<TI>Patterns of concomitant psychotropic medication use during a 2-year study comparing clozapine and olanzapine for the prevention of suicidal behavior</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>2004</YR>
<VL>65</VL>
<NO>5</NO>
<PG>679-85</PG>
<CY>United States of America</CY>
<IDENTIFIERS MODIFIED="2009-04-18 22:51:47 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2009-05-26 08:31:10 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kane J, Alphs LD, Meltzer HY, Green AI, Hsu C, Anand R, Young F, Fahy T</AU>
<TI>The relationship between clinical response and changes in weight for clozapine and olanzapine-treated patients</TI>
<SO>International Journal of Neuropsychopharmacology</SO>
<YR>2002</YR>
<VL>5</VL>
<NO>Suppl 1</NO>
<PG>S171</PG>
<IDENTIFIERS MODIFIED="2009-04-18 22:51:49 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2010-09-27 12:14:29 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Meltzer H</AU>
<TI>Decreasing suicide in schizophrenia: the intersept study</TI>
<SO>European Psychiatry</SO>
<YR>2002</YR>
<VL>17</VL>
<NO>Suppl 1</NO>
<PG>26</PG>
<IDENTIFIERS MODIFIED="2009-04-18 22:51:52 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2009-05-26 08:31:53 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Meltzer HY, Alphs L, Anand AR, Islam MZ, Potkin SG</AU>
<TI>The intersept trial: reduced suicidality with clozapine treatment</TI>
<SO>Proceedings of the 155th Annual Meeting of the American Psychiatric Association; 2002 May 18-23; Philadelphia, Pennsylvania, USA</SO>
<YR>2002</YR>
<IDENTIFIERS MODIFIED="2009-04-18 22:51:55 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2009-05-26 08:32:08 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Meltzer HY, Alphs L, Greem AI, Altamura AC, Anand R, Bertoldi A, Bourgeois M, Chouinard G, Islam MZ, Kane J, Krishnan R, Lindenmayer J-P, Potkin S, InterSePT Study Group</AU>
<TI>Clozapine treatment for suicidality in schizophrenia</TI>
<SO>Archives of General Psychiatry</SO>
<YR>2003</YR>
<VL>60</VL>
<PG>82-91</PG>
<IDENTIFIERS MODIFIED="2009-04-18 22:51:59 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2009-04-18 22:52:02 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Meltzer HY, Baldessarini RJ</AU>
<TI>Reducing the risk for suicide in schizophrenia and affective disorders</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>2003</YR>
<VL>64</VL>
<NO>9</NO>
<PG>1122-9</PG>
<CY>United States of America</CY>
<IDENTIFIERS MODIFIED="2009-04-18 22:52:02 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2009-05-26 08:32:31 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Meltzer HY</AU>
<TI>An evidence-based approach to reducing the risk of suicide in schizophrenia</TI>
<SO>Journal of the European College of Neuropsychopharmacology</SO>
<YR>2004</YR>
<VL>14</VL>
<NO>Suppl 3</NO>
<PG>S145</PG>
<IDENTIFIERS MODIFIED="2009-04-18 22:52:04 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2009-05-26 08:32:42 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Meltzer HY</AU>
<TI>Reducing risk of suicide in schizophrenia</TI>
<SO>Journal of the European College of Neuropsychopharmacology</SO>
<YR>2003</YR>
<VL>13</VL>
<NO>4</NO>
<PG>S163</PG>
<IDENTIFIERS MODIFIED="2009-04-18 22:52:08 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2009-05-26 08:33:12 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Meltzer HY</AU>
<TI>Reducing suicidality in schizophrenia and schizoaffective disorder</TI>
<SO>Proceedings of the 156th Annual Meeting of the American Psychiatric Association; 2003 May 17-22; San Francisco, California, USA</SO>
<YR>2003</YR>
<IDENTIFIERS MODIFIED="2009-04-18 22:52:11 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2009-04-18 22:52:14 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Meltzer HY</AU>
<TI>Suicide and schizophrenia: clozapine and the InterSePT study</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>1999</YR>
<VL>60</VL>
<NO>Suppl 12</NO>
<PG>47-50</PG>
<IDENTIFIERS MODIFIED="2009-04-18 22:52:14 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2009-05-26 08:33:35 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Meltzer HY</AU>
<TI>Treatment of suicidality in schizophrenia</TI>
<SO>Annals of the New York Academy of Sciences</SO>
<YR>2001</YR>
<VL>932</VL>
<PG>44-58</PG>
<IDENTIFIERS MODIFIED="2009-04-18 22:52:17 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2009-10-05 23:45:07 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Mortimer A</AU>
<TI>A prospective, randomised, international, parallel group comparison of Clozaril/Leponex vs Zyprexa in the reduction of suicidality in patients with schizophrenia or schizoaffective disorder who are at risk of suicide.</TI>
<SO>National Research Register</SO>
<YR>2001</YR>
<VL>3</VL>
<IDENTIFIERS MODIFIED="2009-04-18 22:52:21 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2009-05-26 08:33:46 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Mortimer A</AU>
<TI>Randomised prospective parallel group comparison of clozapine vs. olanzapine in the reduction of suicidality in patients with schizophrenia/schizoaffective disorder</TI>
<SO>National Research Register</SO>
<YR>2002</YR>
<VL>1</VL>
<IDENTIFIERS MODIFIED="2009-04-18 22:52:23 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2009-04-18 22:52:26 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Novartis Pharmaceuticals Group</AU>
<TI>New treatment for suicidal behavior in schizophrenia or schizoaffective disorder. International suicide prevention trial (InterSePT): reduced suicidality in schizophrenia with clozapine treatment [CLO-8176]</TI>
<SO>Archives of General Psychiatry</SO>
<YR>2003</YR>
<PB>Novartis Pharmaceuticals Corporation</PB>
<CY>New Jersey</CY>
<IDENTIFIERS MODIFIED="2009-04-18 22:52:26 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2009-05-26 08:35:35 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Potkin SG, Alphs L, Hsu C, Krishn n K, Ranga Rama, Anand R, Young FK, Meltzer H, Green A</AU>
<TI>Predicting suicidal risk in schizophrenic and schizoaffective patients in a prospective two-year trial</TI>
<SO>Biological Psychiatry</SO>
<YR>2003</YR>
<VL>54</VL>
<NO>4</NO>
<PG>444-52</PG>
<CY>United States of America</CY>
<IDENTIFIERS MODIFIED="2009-04-18 22:52:29 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2009-05-26 08:36:05 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Young F, Meltzer H, Alphs L, Anand R, Green A, Potkin S, Kane J, Krishnan R, Islam Z, Hsu C, Martin S</AU>
<TI>The Intersept study: reduced suicidal behavior in schizophrenic clozapine-treated patients</TI>
<SO>International Journal of Neuropsychopharmacology</SO>
<YR>2002</YR>
<VL>5</VL>
<NO>Suppl 1</NO>
<PG>S77</PG>
<IDENTIFIERS MODIFIED="2009-04-18 22:52:32 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Moresco-2004" MODIFIED="2009-05-26 08:36:55 +0100" MODIFIED_BY="[Empty name]" NAME="Moresco 2004" YEAR="2004">
<REFERENCE MODIFIED="2009-05-26 08:36:55 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Moresco RM, Cavallaro R, Messa C, Bravi D, Gobbo C, Galli LLG, Colombo C, Rizzo G, Velona I, Smeraldi E, Fazio F</AU>
<TI>Cerebral D2 and 5-HT2 receptor occupancy in schizophrenic patients treated with olanzapine or clozapine</TI>
<SO>Journal of Psychopharmacology</SO>
<YR>2004</YR>
<VL>18</VL>
<NO>3</NO>
<PG>355-65</PG>
<CY>United States</CY>
<IDENTIFIERS MODIFIED="2009-04-18 22:52:51 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Naber-2005" MODIFIED="2010-09-27 12:15:47 +0100" MODIFIED_BY="[Empty name]" NAME="Naber 2005" YEAR="2005">
<REFERENCE MODIFIED="2009-05-26 08:39:30 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bender S, Dittmann-Balcar A, Schall U, Klimke A, Riedel M, Vorbach U, Kuehn KU, Lambert M, Dittmann RW, Naber D</AU>
<TI>Effects of olanzapine versus clozapine on executive functions in schizophrenia</TI>
<SO>Schizophrenia Research</SO>
<YR>2002</YR>
<VL>53</VL>
<NO>3 Suppl 1</NO>
<PG>194</PG>
<PB>Elsevier Science B.V</PB>
<IDENTIFIERS MODIFIED="2009-04-18 22:52:55 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2009-04-18 22:52:59 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bender S, Dittmann-Balcar A, Schall U, Wolstein J, Klimke A, Riedel M, Vorbach E-U, Kuhn K-U, Lambert M, Dittmann RW, Naber D</AU>
<TI>Influence of atypical neuroleptics on executive functioning in patients with schizophrenia: a randomized, double-blind comparison of olanzapine vs clozapine</TI>
<SO>International Journal of Neuropsychopharmacology</SO>
<YR>2006</YR>
<VL>9</VL>
<NO>2</NO>
<PG>135-45</PG>
<CY>England</CY>
<IDENTIFIERS MODIFIED="2009-04-18 22:52:59 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2010-09-27 12:15:47 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dittmann-Balcar A, Bender S, Schall U, Klimke A, Mueller N, Vorbach U, Kuehn KU, Dittmann RW, Naber D</AU>
<TI>Effects of olanzapine versus clozapine on executive functions in schizophrenia</TI>
<SO>Schizophrenia Research</SO>
<YR>2003</YR>
<VL>60</VL>
<NO>1</NO>
<PG>131</PG>
<IDENTIFIERS MODIFIED="2009-04-18 22:53:05 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2009-10-06 00:27:56 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Naber D, Bandelow B, Bender S, Klimke A, Kuehn K, Lambert M, Lemmer W, Dittmann M, Riedel ER</AU>
<TI>Subjective well-being under neuroleptic treatment with olanzapine versus clozapine: first results from a double-blind clinical trial using the SWN self-rating scale</TI>
<SO>Schizophrenia Research</SO>
<YR>2001</YR>
<VL>49</VL>
<NO>1, 2</NO>
<PG>240</PG>
<IDENTIFIERS MODIFIED="2009-04-18 22:53:09 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2009-05-26 08:40:27 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Naber D, Degner D, Bender S, Klimke A, Kuhn KU, Lambert M, Lemmer W, Riedel M, Vorbach EU, Dittmann RW</AU>
<TI>Olanzapine vs. clozapine: findings on subjective well-being from a double-blind clinical trial</TI>
<SO>Schizophrenia Research</SO>
<YR>2002</YR>
<VL>53</VL>
<NO>3 Suppl 1</NO>
<PG>176</PG>
<PB>Elsevier Science B.V</PB>
<IDENTIFIERS MODIFIED="2009-04-18 22:53:13 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2009-04-18 22:53:17 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Naber D, Riedel M, Klimke A, Vorbach E-U, Lambert M, Kühn K-U, Bender S, Bandelow B, Lemmer W, Moritz S, Dittmann RW</AU>
<TI>Randomized double blind comparison of olanzapine vs. clozapine on subjective well-being and clinical outcome in patients with schizophrenia</TI>
<SO>Acta Psychiatrica Scandinavica</SO>
<YR>2005</YR>
<VL>111</VL>
<NO>2</NO>
<PG>106-15</PG>
<IDENTIFIERS MODIFIED="2009-04-18 22:53:17 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ren-2002" MODIFIED="2010-09-27 12:16:08 +0100" MODIFIED_BY="[Empty name]" NAME="Ren 2002" YEAR="2002">
<REFERENCE MODIFIED="2010-09-27 12:16:08 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Ren Q, Lu Y</AU>
<TI>Comparison of quality of life of schizophrenic outpatients treated with risperdal or clozapine</TI>
<SO>Chinese Mental Health Journal</SO>
<YR>2002</YR>
<VL>16</VL>
<NO>3</NO>
<PG>198-9</PG>
<IDENTIFIERS MODIFIED="2009-04-18 22:53:22 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sacchetti-2006" MODIFIED="2010-09-27 12:16:20 +0100" MODIFIED_BY="[Empty name]" NAME="Sacchetti 2006" YEAR="2006">
<REFERENCE MODIFIED="2010-09-27 12:16:20 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Sacchetti E, Galluzzo A, Valsecchi P, Romeo F, Gorini B, Warrington L</AU>
<TI>Efficacy and safety of ziprasidone and clozapine in treatment refractory schizophrenic patients: results of a randomized, double-blind, 18-week trial</TI>
<SO>Journal of the European College of Neuropsychopharmacology</SO>
<YR>2006</YR>
<VL>16</VL>
<NO>Suppl 4</NO>
<PG>S374</PG>
<IDENTIFIERS MODIFIED="2009-04-18 22:53:28 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Shaw-2006" MODIFIED="2009-05-26 08:42:00 +0100" MODIFIED_BY="[Empty name]" NAME="Shaw 2006" YEAR="2006">
<REFERENCE MODIFIED="2009-05-26 08:42:00 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Shaw P, Sporn A, Gogtay N, Overman GP, Greenstein D, Gochman P, Tossell JW, Lenane M, Rapoport JL</AU>
<TI>Childhood-onset schizophrenia: a double blind, randomized clozapine-olanzapine comparison</TI>
<SO>Archives of General Psychiatry</SO>
<YR>2006</YR>
<VL>63</VL>
<NO>7</NO>
<PG>721-30</PG>
<CY>United States</CY>
<IDENTIFIERS MODIFIED="2009-04-18 22:53:33 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tollefson-2001" MODIFIED="2010-09-27 12:23:02 +0100" MODIFIED_BY="[Empty name]" NAME="Tollefson 2001" YEAR="2001">
<REFERENCE MODIFIED="2010-09-27 12:16:48 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Beasley CM, Beuzen JN, Birkett MA, Kiesler GM, Tollefson GD, Wood AJ</AU>
<TI>Olanzapine versus clozapine: an international double-blind study of the treatment of resistant schizophrenia</TI>
<SO>Proceedings of the 152nd Annual Meeting of the American Psychiatric Association; 1999 May 15-20; Washington DC, USA</SO>
<YR>1999</YR>
<IDENTIFIERS MODIFIED="2009-04-18 22:53:40 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2010-09-27 12:17:56 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Beasley CM, Beuzen JN, Birkett MA</AU>
<TI>Olanzapine versus clozapine: an international double-blind study in the treatment of patients with treatment-resistant schizophrenia</TI>
<SO>Proceedings of the 39th Annual Meeting of the New Clinical Drug Evaluation Unit; 1999 Jun 1-4; Boca Raton, Florida, USA</SO>
<YR>1999</YR>
<IDENTIFIERS MODIFIED="2009-04-18 22:53:37 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2009-05-26 08:52:01 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Beuzen JN, Birkett M, Kiesler G, Wood A</AU>
<TI>Olanzapine vs. clozapine in resistant schizophrenic patients - results of an international double- blind randomised clinical trial</TI>
<SO>Proceedings of the 21st Collegium Internationale Neuro-Psychopharmacologicum Congress; 1998 Jul 12-16; Glasgow, UK</SO>
<YR>1998</YR>
<IDENTIFIERS MODIFIED="2009-04-18 22:53:43 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2010-09-27 12:18:19 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Beuzen JN, Birkett MA, Kiesler GM</AU>
<TI>An investigation of subgroup effects in a study of olanzapine versus clozapine in the treatment of resistant schizophrenic patients</TI>
<SO>Proceedings of the 11th European College of Neuropsychopharmacology Congress; 1998 Oct 31 - Nov 4; Paris, France</SO>
<YR>1998</YR>
<IDENTIFIERS MODIFIED="2009-04-18 22:53:46 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2009-05-26 08:53:13 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Beuzen JN, Wood AJ, Kiesler GM, Birkett M, Tollefson GD</AU>
<TI>Olanzapine vs. Clozapine: an international double-blind study in the treatment of patients with treatment-resistant schizophrenia</TI>
<SO>Proceedings of the 11th World Congress of Psychiatry; 1999 Aug 6-11; Hamburg, Germany</SO>
<YR>1999</YR>
<IDENTIFIERS MODIFIED="2009-04-18 22:53:51 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2009-05-26 08:53:43 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>David SR, Meehan KM, Sutton VK, Taylor CC</AU>
<TI>Treatment of negative symptoms with olanzapine in comparison with other novel antipsychotic agents</TI>
<SO>International Journal of Neuropsychopharmacology</SO>
<YR>2000</YR>
<VL>3</VL>
<NO>Suppl 1</NO>
<PG>s140</PG>
<IDENTIFIERS MODIFIED="2009-04-18 22:53:53 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2010-09-27 12:18:43 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Dossenbach M, Bitter I, Slabber M, Pretorius J, Bartko GY, Banics Z, Martenyi F</AU>
<TI>Olanzapine versus clozapine in patients nonresponsive or intolerant to standard acceptable treatment for schizophrenia</TI>
<SO>Proceedings of the 153rd Annual Meeting of the American Psychiatric Association; 2000 May 13-18; Chicago, Illinois</SO>
<YR>2000</YR>
<IDENTIFIERS MODIFIED="2009-04-18 22:53:57 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2009-05-26 08:55:06 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Dossenbach M, Bitter I, Slabber M, Pretorius J, Bartko GY, Banics Z, Martenyi F</AU>
<TI>Olanzapine versus clozapine in patients nonresponsive or intolerant to standard acceptable treatment for schizophrenia</TI>
<SO>Proceedings of the 155th Annual Meeting of the American Psychiatric Association; 2002 May 18-23; Philadelphia, Pennsylvania, USA</SO>
<YR>2002</YR>
<IDENTIFIERS MODIFIED="2009-04-18 22:54:01 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2010-09-27 12:22:09 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Dossenbach M, Slabber M, Martenyi F, Bartko G, Bitter I</AU>
<TI>Olanzapine vs. clozapine in patients non responsive or intolerant to standard acceptable treatment of schizophrenia</TI>
<SO>World Psychiatry</SO>
<YR>1999</YR>
<VL>2</VL>
<PG>148</PG>
<IDENTIFIERS MODIFIED="2009-04-18 22:54:04 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2010-09-27 12:22:54 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jean-Noel B, Wood AJ, Kiesler GM, Birkett M, Tollefson GD</AU>
<TI>Olanzapine vs. clozapine: an international double blind study in the treatment of resistant schizophrenia</TI>
<SO>World Psychiatry</SO>
<YR>1999</YR>
<VL>2</VL>
<PG>143</PG>
<IDENTIFIERS MODIFIED="2009-04-18 22:54:07 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2010-09-27 12:23:02 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Tollefson GD, Birkett MA, Kiesler GM, Wood AJ, Lilly Resistant Schizophrenia Study Group</AU>
<TI>Double-blind comparison of olanzapine versus clozapine in schizophrenic patients clinically eligible for treatment with clozapine</TI>
<SO>Biological Psychiatry</SO>
<YR>2001</YR>
<VL>49</VL>
<NO>1</NO>
<PG>52-63</PG>
<IDENTIFIERS MODIFIED="2009-04-18 22:54:09 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Volavka-2002" MODIFIED="2010-09-27 12:24:48 +0100" MODIFIED_BY="[Empty name]" NAME="Volavka 2002" YEAR="2002">
<REFERENCE MODIFIED="2009-04-18 22:54:50 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bilder RM, Goldman RS, Volavka J, Czobor P, Hoptman M, Sheitman B, Lindenmayer J-P, Citrome L, McEvoy J, Kunz M, Chakos M, Lieberman JA</AU>
<TI>Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol on treatment-resistant patients with schizophrenia and schizoaffective disorder</TI>
<SO>Schizophrenia Research</SO>
<YR>2002</YR>
<VL>53</VL>
<NO>3 Suppl 1</NO>
<PG>194</PG>
<PB>Elsevier Science B.V</PB>
<IDENTIFIERS MODIFIED="2009-04-18 22:54:50 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2010-09-27 12:23:49 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bilder RM, Goldman RS, Volavka J, Czobor P, Hoptman M, Sheitman B, Lindenmayer JP, Citrome L, McEvoy J, Kunz M, Chakos M, Cooper TB, Horowitz TL, Lieberman JA</AU>
<TI>Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder</TI>
<SO>American Journal of Psychiatry</SO>
<YR>2002</YR>
<VL>159</VL>
<NO>6</NO>
<PG>1018-28</PG>
<IDENTIFIERS MODIFIED="2009-04-18 22:54:54 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2009-04-18 22:54:56 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bilder RM, Goldman RS, Volavka J, Czobor P, Hoptman M, Sheitman B, Lindenmayer JP, Citrome L, McEvoy J, Kunz M, Chakos M, Lieberman JA</AU>
<TI>Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol on treatment-resistant patients with schizophrenia and schizoaffective disorder</TI>
<SO>European Neuropsychopharmacology</SO>
<YR>2001</YR>
<VL>11</VL>
<NO>3</NO>
<PG>256</PG>
<IDENTIFIERS MODIFIED="2009-04-18 22:54:56 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2009-04-18 22:54:59 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Citrome L, Volavka J, Czobor P, Sheitman B, Lindenmayer J-P, McEvoy J, Cooper TB, Chakos M, Lieberman JA</AU>
<TI>Effects of clozapine, olanzapine, risperidone, and haloperidol on hostility among patients with schizophrenia</TI>
<SO>Psychiatric Services</SO>
<YR>2001</YR>
<VL>52</VL>
<NO>11</NO>
<PG>1510-4</PG>
<PB>American Psychiatric Association, US</PB>
<CY>USA</CY>
<IDENTIFIERS MODIFIED="2009-04-18 22:54:59 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2009-05-26 09:02:21 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Citrome LL, Volavka J, Czobor P, Nolan K, Lieberman JA, Lindenmayer J-P, Sheitman BB</AU>
<TI>Overt aggression and psychotic symptoms in patients with schizophrenia treated with clozapine, olanzapine, risperidone, or haloperidol</TI>
<SO>Proceedings of the 156th Annual Meeting of the American Psychiatric Association; 2003 May 17-22; San Francisco, California, USA</SO>
<YR>2003</YR>
<IDENTIFIERS MODIFIED="2009-04-18 22:55:02 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2009-05-26 09:02:38 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Citrome LL, Volavka J, Czobor P, Sheitman BB, Lindenmayer J-P, McEvoy JP, Lieberman JA</AU>
<TI>Atypical antipsychotics and hostility in schizophrenia: a double-blind study</TI>
<SO>Proceedings of the 154th Annual Meeting of the American Psychiatric Association; 2001 May 5-10; New Orleans, Louisiana, USA</SO>
<YR>2001</YR>
<PB>Marathon Multimedia</PB>
<IDENTIFIERS MODIFIED="2009-04-18 22:55:05 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2010-09-27 12:24:18 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Citrome LL, Volavka J, Czobor P, Sheitman BB, Lindenmayer J-P, McEvoy JP, Lieberman JA</AU>
<TI>Atypical antipsychotics and hostility in schizophrenia: a double-blind study</TI>
<SO>Proceedings of the 155th Annual Meeting of the American Psychiatric Association; 2002 May 18-23; Philadelphia, Pennsylvania, USA</SO>
<YR>2002</YR>
<IDENTIFIERS MODIFIED="2009-04-18 22:55:08 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2010-09-27 12:24:37 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Czobor P, Volavka J, Sheitman B, Lindenmayer JP, Citrome L, McEvoy J, Cooper TB, Chakos M, Lieberman JA</AU>
<TI>Antipsychotic-induced weight gain and therapeutic response: a differential association</TI>
<SO>Journal of Clinical Psychopharmacology</SO>
<YR>2002</YR>
<VL>22</VL>
<NO>3</NO>
<PG>244-51</PG>
<IDENTIFIERS MODIFIED="2009-04-18 22:55:11 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2010-09-27 12:24:48 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>De Luca V, Vincent JB, Muller DJ, Hwang R, Shinkai T, Volavka J, Czobor P, Sheitman BB, Lindenmayer J-P, Citrome L, McEvoy JP, Lieberman JA, Kennedy JL</AU>
<TI>Identification of a naturally occurring 21 bp deletion in alpha 2c noradrenergic receptor gene and cognitive correlates to antipsychotic treatment</TI>
<SO>Pharmacological Research</SO>
<YR>2005</YR>
<VL>51</VL>
<NO>4</NO>
<PG>381-4</PG>
<IDENTIFIERS MODIFIED="2009-04-18 22:55:14 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2009-05-26 09:03:46 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Lindenmayer J-P, Czobor P, Volavka J, Citrome LL, Sheitman BB, McEvoy JP, Cooper TB</AU>
<TI>Changes in glucose and cholesterol in schizophrenia treated with atypicals</TI>
<SO>Proceedings of the 155th Annual Meeting of the American Psychiatric Association; 2002 May 18-23; Philadelphia, Pennsylvania, USA</SO>
<YR>2002</YR>
<IDENTIFIERS MODIFIED="2009-04-18 22:55:17 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2009-05-26 09:04:00 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Lindenmayer J-P, Czobor P, Volavka J, Lieberman JA, Citrome LL, Sheitman BB, McEvoy JP</AU>
<TI>Effects of atypicals on the syndromal profile in treatment-resistant schizophrenia</TI>
<SO>Proceedings of the 156th Annual Meeting of the American Psychiatric Association; 2003 May 17-22; San Francisco, California, USA</SO>
<YR>2003</YR>
<IDENTIFIERS MODIFIED="2009-04-18 22:55:20 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2009-05-26 09:04:17 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Lindenmayer J-P, Czobor P, Yolayka J, Lieberman JA, McEvoy JP, Citrome LL, Sheitman BB</AU>
<TI>Do atypicals change the syndrome profile in treatment-resistant schizophrenia?</TI>
<SO>Proceedings of the 154th Annual Meeting of the American Psychiatric Association; 2001 May 5-10; New Orleans, Louisiana, USA</SO>
<YR>2001</YR>
<PB>Marathon Multimedia</PB>
<IDENTIFIERS MODIFIED="2009-04-18 22:55:23 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2009-05-26 09:04:42 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Lindenmayer J-P, Volavka J, Lieberman JA, Citrome LL, Sheitman B, McEvoy JP, Cooper T</AU>
<TI>Do atypicals change the syndromal profile in treatment-resistant schizophrenia?</TI>
<SO>Proceedings of the155th Annual Meeting of the American Psychiatric Association; 2002 May 18-23; Philadelphia, Pennsylvania, USA</SO>
<YR>2002</YR>
<IDENTIFIERS MODIFIED="2009-04-18 22:55:26 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2009-05-26 08:57:03 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lindenmayer JP, Czobor P, Volavka J, Citrome L, Sheitman B, McEvoy J, Cooper TB, Chakos M, Lieberman JA</AU>
<TI>Changes in glucose and cholesterol levels in schizophrenia patients treated with typical and atypical antipsychotics</TI>
<SO>International Journal of Neuropsychopharmacology</SO>
<YR>2002</YR>
<VL>5</VL>
<NO>Suppl 1</NO>
<PG>S169</PG>
<IDENTIFIERS MODIFIED="2009-04-18 22:55:29 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2009-05-26 09:04:57 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lindenmayer JP, Czobor P, Volavka J, Citrome L, Sheitman B, McEvoy JP, Cooper TB, Chakos M, Lieberman JA</AU>
<TI>Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics</TI>
<SO>American Journal of Psychiatry</SO>
<YR>2003</YR>
<VL>160</VL>
<NO>2</NO>
<PG>290-6</PG>
<CY>United States of America</CY>
<IDENTIFIERS MODIFIED="2009-04-18 22:55:32 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2009-04-18 22:55:35 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lindenmayer JP, Czobor P, Volavka J, Lieberman JA, Citrome L, Sheitman B, McEvoy JP, Cooper TB, Chakos M</AU>
<TI>Effects of atypical antipsychotics on the syndromal profile in treatment-resistant schizophrenia</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>2004</YR>
<VL>65</VL>
<NO>4</NO>
<PG>551-6</PG>
<CY>United States of America</CY>
<IDENTIFIERS MODIFIED="2009-04-18 22:55:35 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2009-05-26 09:05:51 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mohr P, Volavka J, Lieberman JA, Czobor P, McEnvoy J, Lindenmayer J-P, Citrome L, Sheitman B</AU>
<TI>Clozapine, olanzapine, risperidone, and haloperidol in refractory schizophrenia</TI>
<SO>European Psychiatry</SO>
<YR>2000</YR>
<VL>15</VL>
<NO>Suppl 2</NO>
<PG>284S</PG>
<CY>USA</CY>
<IDENTIFIERS MODIFIED="2009-04-18 22:55:37 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2009-04-18 22:55:42 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nolan KA, Volavka J, Czobor P, Sheitman B, Lindenmayer J-P, Citrome LL, McEvoy J, Lieberman JA</AU>
<TI>Aggression and psychopathology in treatment-resistant inpatients with schizophrenia and schizoaffective disorder</TI>
<SO>Journal of Psychiatric Research</SO>
<YR>2005</YR>
<VL>39</VL>
<NO>1</NO>
<PG>109-15</PG>
<CY>England</CY>
<IDENTIFIERS MODIFIED="2009-04-18 22:55:42 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2009-04-18 22:55:45 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Volavka J, Czobor P, Cooper TB, Sheitman B, Lindenmayer JP, Citrome L, McEvoy JP, Lieberman JA</AU>
<TI>Prolactin levels in schizophrenia and schizoaffective disorder patients treated with clozapine, olanzapine, risperidone, or haloperidol</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>2004</YR>
<VL>65</VL>
<NO>1</NO>
<PG>57-61</PG>
<CY>United States of America</CY>
<IDENTIFIERS MODIFIED="2009-04-18 22:55:45 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2009-04-18 22:55:48 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Volavka J, Czobor P, Nolan K, Sheitman B, Lindenmayer JP, Citrome LMJP, Cooper TB, Lieberman JA</AU>
<TI>Overt aggression and psychotic symptoms in patients with schizophrenia treated with clozapine, olanzapine, risperidone, or haloperidol</TI>
<SO>Journal of Clinical Psychopharmacology</SO>
<YR>2004</YR>
<VL>24</VL>
<NO>2</NO>
<PG>225-8</PG>
<CY>United States of America</CY>
<IDENTIFIERS MODIFIED="2009-04-18 22:55:48 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2009-05-26 09:06:28 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Volavka J, Czobor P, Sheitman B, Lindenmayer J-P, Citrome L, McEvoy J, Cooper TB, Chakos M, Kline JALN</AU>
<TI>Clozapine, olanzapine, risperidone, and haloperidol in refractory schizophrenia</TI>
<SO>Proceedings of the 39th Annual Meeting of the American College of Neuropsychopharmacology; 2000 Dec 10-14; San Juan, Puerto Rico</SO>
<YR>2000</YR>
<IDENTIFIERS MODIFIED="2009-04-18 22:55:51 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2009-05-26 09:06:44 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Volavka J, Czobor P, Sheitman B, Lindenmayer JP, Citrome L, McEvoy JP, Cooper TB, Chakos M, Lieberman JA</AU>
<TI>Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder</TI>
<SO>American Journal of Psychiatry</SO>
<YR>2002</YR>
<VL>159</VL>
<NO>2</NO>
<PG>255-62</PG>
<CY>USA</CY>
<IDENTIFIERS MODIFIED="2009-04-18 22:55:54 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wahlbeck-2000" MODIFIED="2010-09-27 12:27:03 +0100" MODIFIED_BY="[Empty name]" NAME="Wahlbeck 2000" YEAR="2000">
<REFERENCE MODIFIED="2010-09-27 12:27:03 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Cheine MV, Wahlbeck K, Tuisku K, Joffe G</AU>
<TI>Risperidone versus clozapine in the treatment of neuroleptic-refractory/intolerant schizophrenia patients: a single-blind randomized trial: Preliminary report of an on-going study</TI>
<SO>Nordic Journal of Psychiatry</SO>
<YR>1997</YR>
<VL>51</VL>
<PG>99</PG>
<IDENTIFIERS MODIFIED="2009-04-18 22:56:00 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2009-05-26 09:07:09 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wahlbeck K, Cheine M, Tuisku K, Ahokas A, Joffe G, Rimón R</AU>
<TI>Risperidone versus clozapine in treatment-resistant schizophrenia: a randomized pilot study</TI>
<SO>International Journal of Neuropsychopharmacology</SO>
<YR>2000</YR>
<VL>3</VL>
<NO>Suppl 1</NO>
<PG>S122</PG>
<IDENTIFIERS MODIFIED="2009-04-18 22:56:03 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2009-04-18 22:56:05 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Wahlbeck K, Cheine M, Tuisku K, Ahokas A, Joffe G, Rimon R</AU>
<TI>Risperidone versus clozapine in treatment-resistant schizophrenia: a randomized pilot study</TI>
<SO>Progress in Neuropsychopharmacology and Biological Psychiatry</SO>
<YR>2000</YR>
<VL>24</VL>
<NO>6</NO>
<PG>911-22</PG>
<IDENTIFIERS MODIFIED="2009-04-18 22:56:05 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2009-04-18 22:56:10 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wahlbeck K, Cheine M, Tuisku K, Joffe G</AU>
<TI>Risperidone versus clozapine in treatment resistant schizophrenia: a randomised pilot trial</TI>
<SO>Schizophrenia Research</SO>
<YR>2000</YR>
<VL>41</VL>
<NO>1</NO>
<PG>197</PG>
<IDENTIFIERS MODIFIED="2009-04-18 22:56:10 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wang-2002" MODIFIED="2010-09-27 12:27:26 +0100" MODIFIED_BY="[Empty name]" NAME="Wang 2002" YEAR="2002">
<REFERENCE MODIFIED="2010-09-27 12:27:26 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Wang C, Feng Y, Wang L</AU>
<TI>A double-blind randomized controlled study of olanzapine and clozapine on treatment of schizophrenia</TI>
<SO>Shanghai Archives of Psychiatry</SO>
<YR>2002</YR>
<VL>14</VL>
<NO>3</NO>
<PG>143-5</PG>
<IDENTIFIERS MODIFIED="2009-04-18 22:56:14 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zhou-2000" MODIFIED="2009-04-18 22:56:18 +0100" MODIFIED_BY="[Empty name]" NAME="Zhou 2000" YEAR="2000">
<REFERENCE MODIFIED="2009-04-18 22:56:18 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Zhou Z, Shu Z, Yu Y</AU>
<TI>A control study of risperidone and clozapine in the treatment of the negative symptoms of schizophrenia</TI>
<SO>Aerospace Medicine</SO>
<YR>2000</YR>
<VL>11</VL>
<NO>2</NO>
<PG>69-71</PG>
<IDENTIFIERS MODIFIED="2009-04-18 22:56:18 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2010-09-27 13:00:40 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Agelink-2001" MODIFIED="2010-09-27 12:27:43 +0100" MODIFIED_BY="[Empty name]" NAME="Agelink 2001" YEAR="2001">
<REFERENCE MODIFIED="2010-09-27 12:27:43 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Agelink MW, Majewski T, Wurthmann C, Lukas K, Ullrich H, Linka T, Klieser E</AU>
<TI>Effects of newer atypical antipsychotics on autonomic neurocardiac function: a comparison between amisulpride, olanzapine, sertindole, and clozapine</TI>
<SO>Journal of Clinical Psychopharmacology</SO>
<YR>2001</YR>
<VL>21</VL>
<NO>1</NO>
<PG>8-13</PG>
<IDENTIFIERS MODIFIED="2009-04-18 22:57:30 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Allison-2001" MODIFIED="2009-05-26 09:10:03 +0100" MODIFIED_BY="[Empty name]" NAME="Allison 2001" YEAR="2001">
<REFERENCE MODIFIED="2009-05-26 09:09:44 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Allison D, Cavazzoni P, Beasley C, Holcombe J, Buse J</AU>
<TI>Analysis of random glucose concentration data from patients with schizophrenia treated with typical and atypical agents during double-blind, randomized, controlled clinical trials</TI>
<SO>Proceedings of the 7th World Congress of Biological Psychiatry; 2001 Jul 1-6; Berlin, Germany</SO>
<YR>2001</YR>
<NO>Suppl 1</NO>
<IDENTIFIERS MODIFIED="2009-04-18 22:57:34 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2009-05-26 09:10:03 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Allison DB, Cavazzoni P, Beasley Jr CM, Berg PH, Mukhopadhyay N, Mallinckrodt C, Baker RW, Holcombe J, Taylor CC, Breier A, Buse JB</AU>
<TI>Random blood glucose levels in patients with schizophrenia treated with typical and atypical antipsychotic agents: an analysis of data from double-blind, randomized, controlled clinical trial</TI>
<SO>European Neuropsychopharmacology</SO>
<YR>2001</YR>
<VL>11</VL>
<NO>3</NO>
<PG>280</PG>
<IDENTIFIERS MODIFIED="2009-04-18 22:57:37 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Altamura-1999" MODIFIED="2009-04-18 22:57:43 +0100" MODIFIED_BY="[Empty name]" NAME="Altamura 1999" YEAR="1999">
<REFERENCE MODIFIED="2009-04-18 22:57:43 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Altamura AC, Cao A, La Croce ML, Serri L, Soddu A, Laddomada A, Percudani M</AU>
<TI>Are atypical antipsychotics less depressogenic than typical compounds?</TI>
<SO>Journal of the European College of Neuropsychopharmacology</SO>
<YR>1999</YR>
<VL>9</VL>
<PG>S168</PG>
<IDENTIFIERS MODIFIED="2009-04-18 22:57:43 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Anonymous-1994" MODIFIED="2009-05-26 09:11:04 +0100" MODIFIED_BY="[Empty name]" NAME="Anonymous 1994" YEAR="1994">
<REFERENCE MODIFIED="2009-05-26 09:11:04 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Anonymous</AU>
<TI>Risperidone vs clozapine</TI>
<SO>Biological Therapies in Psychiatry</SO>
<YR>1994</YR>
<VL>17</VL>
<NO>12</NO>
<PG>47-8</PG>
<CY>USA</CY>
<IDENTIFIERS MODIFIED="2009-04-18 22:57:50 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ascher_x002d_Svanum-2006" MODIFIED="2009-04-19 01:04:33 +0100" MODIFIED_BY="[Empty name]" NAME="Ascher-Svanum 2006" YEAR="2006">
<REFERENCE MODIFIED="2009-04-19 01:04:33 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ascher-Svanum H, Zhu B, Faries D, Landbloom R, Swartz M, Swanson J</AU>
<TI>Time to discontinuation of atypical versus typical antipsychotics in the naturalistic treatment of schizophrenia</TI>
<SO>BMC Psychiatry</SO>
<YR>2006</YR>
<VL>6</VL>
<PG>8</PG>
<CY>United Kingdom</CY>
<IDENTIFIERS MODIFIED="2009-04-18 22:57:54 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Baumann-1993" MODIFIED="2010-09-27 12:28:45 +0100" MODIFIED_BY="[Empty name]" NAME="Baumann 1993" YEAR="1993">
<REFERENCE MODIFIED="2010-09-27 12:28:45 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Baumann P, Billeter U, Kasas A, Blajev B, Juvet P, Souche A, Bondolfi G, Meylan C, Dufour H</AU>
<TI>Pharmacogenetic investigations about risperidone and clozapine in schizophrenic patients</TI>
<SO>Proceedings of the 9th World Congress of Psychiatry; 1993 Jun 6-12; Rio de Janeiro, Brazil</SO>
<YR>1993</YR>
<PG>76</PG>
<CY>Switzerland</CY>
<IDENTIFIERS MODIFIED="2009-04-18 22:57:58 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Beasley-2001" MODIFIED="2010-09-27 12:28:53 +0100" MODIFIED_BY="[Empty name]" NAME="Beasley 2001" YEAR="2001">
<REFERENCE MODIFIED="2010-09-27 12:28:53 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Beasley CM, Berg PH, Dananberg J, Kwong KC, Taylor CCM, Breier A</AU>
<TI>Treatment emergent potential impaired glucose tolerance and potential diabetes with olanzapine compared to other antipsychotic agents and placebo. emergent potential impaired glucose tolerance and potential diabetes with olanzapine compared to other antipsychotic agents and placebo emergent potential impaired glucose tolerance and potential diabetes with olanzapine compared to other antipsychotic agents and placebo</TI>
<SO>Biological Psychiatry</SO>
<YR>2001</YR>
<VL>49</VL>
<NO>8</NO>
<PG>121S</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bondolfi-1996" MODIFIED="2009-04-18 22:58:13 +0100" MODIFIED_BY="[Empty name]" NAME="Bondolfi 1996" YEAR="1996">
<REFERENCE MODIFIED="2009-04-18 22:58:13 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bondolfi G, Baumann P, Dufour H</AU>
<TI>Treatment-resistant schizophrenia - clinical experience with new antipsychotics</TI>
<SO>European Neuropsychopharmacology</SO>
<YR>1996</YR>
<VL>6</VL>
<NO>Suppl 2</NO>
<PG>S21-5</PG>
<IDENTIFIERS MODIFIED="2009-04-18 22:58:13 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cai-2000" MODIFIED="2009-04-18 22:58:18 +0100" MODIFIED_BY="[Empty name]" NAME="Cai 2000" YEAR="2000">
<REFERENCE MODIFIED="2009-04-18 22:58:18 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cai C, Wan C, Cheng F</AU>
<TI>The controlled investigation of risperidone and clozapine in the treatment of schizophrenia</TI>
<SO>Health Psychology Journal</SO>
<YR>2000</YR>
<VL>8</VL>
<NO>2</NO>
<PG>152-4</PG>
<IDENTIFIERS MODIFIED="2009-04-18 22:58:18 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-CATIE" MODIFIED="2010-09-27 12:29:15 +0100" MODIFIED_BY="[Empty name]" NAME="CATIE" YEAR="2001">
<REFERENCE MODIFIED="2009-05-26 09:15:44 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Lieberman JA, Schneider LS, McEvoy J, Pariot P, Stroup S, Adiao J, Lebowitz BD</AU>
<TI>Effectiveness trials of antipsychotic drugs</TI>
<SO>Proceedings of the 154th Annual Meeting of the American Psychiatric Association; 2001 May 5-10; New Orleans, Louisiana, USA</SO>
<YR>2001</YR>
<PB>Marathon Multimedia</PB>
<IDENTIFIERS MODIFIED="2009-04-18 22:58:28 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2010-09-27 12:29:15 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Lieberman JA, Schneider LS, McEvoy J, Pariot P, Stroup S, Adiao J, Lebowitz BD</AU>
<TI>Effectiveness trials of antipsychotic drugs</TI>
<SO>Proceedings of the 155th Annual Meeting of the American Psychiatric Association; 2002 May 18-23; Philadelphia, Pennsylvania, USA</SO>
<YR>2002</YR>
<IDENTIFIERS MODIFIED="2009-04-18 22:58:33 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2009-05-26 09:16:54 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lieberman JA, Stroup S.</AU>
<TI>Schizophrenia, VI. The CATIE Project Protocol</TI>
<SO>American Journal of Psychiatry</SO>
<YR>2003</YR>
<VL>160</VL>
<NO>10</NO>
<PG>1748</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2009-04-18 22:58:42 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>McEvoy JP, Lieberman JA, Stroup TS, Davis SM, Meltzer HY, Rosenheck RA, Swartz MS, Perkins DO, Keefe RS, Davis CE, Severe J, Hsiao JK</AU>
<TI>Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment</TI>
<SO>American Journal of Psychiatry</SO>
<YR>2006</YR>
<VL>163</VL>
<NO>4</NO>
<PG>600-10</PG>
<CY>United States</CY>
<IDENTIFIERS MODIFIED="2009-04-18 22:58:42 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2009-05-26 09:17:14 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>McEvoy JP</AU>
<TI>Comparison of clozapine versus other atypical drugs in prospectively defined, unresponsive patients</TI>
<SO>Proceedings of the 159th Annual Meeting of the American Psychiatric Association; 2006 May 20-25, Toronto, Canada</SO>
<YR>2006</YR>
<IDENTIFIERS MODIFIED="2009-04-18 22:58:45 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2009-04-18 22:58:48 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Stroup TS, McEvoy JP, Swartz MS, Byerly MJ, Glick ID, Canive JM, McGee MF, Simpson GM, Stevens MC, Lieberman JA</AU>
<TI>The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: Schizophrenia trial design and protocol development</TI>
<SO>Schizophrenia Bulletin</SO>
<YR>2003</YR>
<VL>29</VL>
<NO>1</NO>
<PG>15-31</PG>
<CY>United States of America</CY>
<IDENTIFIERS MODIFIED="2009-04-18 22:58:48 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cavazzoni-2002" MODIFIED="2010-09-27 12:29:47 +0100" MODIFIED_BY="[Empty name]" NAME="Cavazzoni 2002" YEAR="2002">
<REFERENCE MODIFIED="2010-09-27 12:29:47 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cavazzoni P, Berg PH, Millikan M, Carlson C, Beasley CM</AU>
<TI>An integrated analysis of treatment-emergent extrapyramidal syndrome in schizophrenic patients during olanzapine clinical trials versus placebo, haloperidol, risperidone or clozapine</TI>
<SO>International Journal of Neuropsychopharmacology</SO>
<YR>2002</YR>
<VL>5</VL>
<NO>Suppl 1</NO>
<PG>S164</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2009-04-18 22:58:54 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cavazzoni P, Berg PH, Millikan M, Carlson C, Beasley CM</AU>
<TI>An integrated analysis of treatment-emergent extrapyramidal syndrome in schizophrenic patients during olanzapine clinical trials versus placebo, haloperidol, risperidone or clozapine</TI>
<SO>Schizophrenia Research</SO>
<YR>2002</YR>
<VL>53</VL>
<NO>3 Suppl 1</NO>
<PG>171</PG>
<PB>Elsevier Science B.V</PB>
<IDENTIFIERS MODIFIED="2009-04-18 22:58:54 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cha-2002" MODIFIED="2009-04-18 22:59:04 +0100" MODIFIED_BY="[Empty name]" NAME="Cha 2002" YEAR="2002">
<REFERENCE MODIFIED="2009-04-18 22:59:04 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cha A, Xu Y, Zhu XH</AU>
<TI>The curative effect comparison of risperidone and clozapine to treat recurrent schizophrenia</TI>
<SO>Chinese Medical Journal of Metallurgical Industry</SO>
<YR>2002</YR>
<VL>19</VL>
<NO>3</NO>
<PG>143-4</PG>
<IDENTIFIERS MODIFIED="2009-04-18 22:59:04 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chen-2002" MODIFIED="2009-05-26 09:23:37 +0100" MODIFIED_BY="[Empty name]" NAME="Chen 2002" YEAR="2002">
<REFERENCE MODIFIED="2009-05-26 09:23:37 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chen SZ, Chi XZ, Li QH, Jiang YQ</AU>
<TI>A study of risperidone and clozapine in treatment of resistant schizophrenia</TI>
<SO>Heath Psychology Journal</SO>
<YR>2002</YR>
<VL>10</VL>
<NO>1</NO>
<PG>44-46</PG>
<IDENTIFIERS MODIFIED="2009-04-18 22:59:53 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chen-2003" MODIFIED="2010-09-27 12:30:32 +0100" MODIFIED_BY="[Empty name]" NAME="Chen 2003" YEAR="2003">
<REFERENCE MODIFIED="2010-09-27 12:30:32 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chen F, Liang L, Zhu XH</AU>
<TI>A control study of elderly patients with schizophrenia treated with olanzapine or clozapine</TI>
<SO>Journal of Clinical Psychological Medicine</SO>
<YR>2003</YR>
<VL>13</VL>
<NO>5</NO>
<PG>298-99</PG>
<IDENTIFIERS MODIFIED="2009-04-18 22:59:09 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chen-2003b" MODIFIED="2009-05-26 09:25:10 +0100" MODIFIED_BY="[Empty name]" NAME="Chen 2003b" YEAR="2003">
<REFERENCE MODIFIED="2009-05-26 09:25:10 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chen CQ</AU>
<TI>A study of risperidone and clozapine in treatment of first episode schizophrenia</TI>
<SO>HuaXia Medicine</SO>
<YR>2003</YR>
<VL>27</VL>
<PG>578-79</PG>
<IDENTIFIERS MODIFIED="2009-04-18 22:59:49 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chen-2004" MODIFIED="2009-05-26 09:25:20 +0100" MODIFIED_BY="[Empty name]" NAME="Chen 2004" YEAR="2004">
<REFERENCE MODIFIED="2009-05-26 09:25:20 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chen YH, Li YM</AU>
<TI>A study of risperidone with haloperidol and clozapine in treatment of positive symptoms in schizophrenia</TI>
<SO>Suzhou University Journal of Medical Science</SO>
<YR>2004</YR>
<VL>24</VL>
<NO>6</NO>
<PG>912-17</PG>
<IDENTIFIERS MODIFIED="2009-04-18 22:59:59 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chen-2005" MODIFIED="2009-04-18 22:59:13 +0100" MODIFIED_BY="[Empty name]" NAME="Chen 2005" YEAR="2005">
<REFERENCE MODIFIED="2009-04-18 22:59:13 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chen J, Li Z</AU>
<TI>A controlled study of olanzapine versus clozapine in schizophrenia</TI>
<SO>Journal of Clinical Psychosomatic Diseases</SO>
<YR>2005</YR>
<VL>11</VL>
<NO>3</NO>
<PG>217-8</PG>
<IDENTIFIERS MODIFIED="2009-04-18 22:59:13 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chen-2005b" MODIFIED="2009-05-26 09:22:53 +0100" MODIFIED_BY="[Empty name]" NAME="Chen 2005b" YEAR="2005">
<REFERENCE MODIFIED="2009-05-26 09:22:53 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chen B, Liu X, Zhang X</AU>
<TI>A study of risperidone combination with clozapine in the treatment of the schizophrenia</TI>
<SO>Health Psychology Journal</SO>
<YR>2005</YR>
<VL>13</VL>
<NO>2</NO>
<PG>116-7</PG>
<IDENTIFIERS MODIFIED="2009-04-18 22:59:17 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cheng-2004" MODIFIED="2009-05-26 09:24:52 +0100" MODIFIED_BY="[Empty name]" NAME="Cheng 2004" YEAR="2004">
<REFERENCE MODIFIED="2009-05-26 09:24:52 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cheng Q, Huang CF</AU>
<TI>The influence of risperidone and clozapine in the quality of life of schizophrenia</TI>
<SO>Chinese Journal of Clinical Rehabilitation</SO>
<YR>2004</YR>
<VL>8</VL>
<NO>18</NO>
<PG>3640-41</PG>
<IDENTIFIERS MODIFIED="2009-04-18 23:00:03 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chou-1999" MODIFIED="2009-04-18 23:00:07 +0100" MODIFIED_BY="[Empty name]" NAME="Chou 1999" YEAR="1999">
<REFERENCE MODIFIED="2009-04-18 23:00:07 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chou X, Chen Q, Li J</AU>
<TI>A clinical controlled study between risperidone and clozapine in the treatment of chronic schizophrenia</TI>
<SO>Sichuan Mental Health</SO>
<YR>1999</YR>
<VL>12</VL>
<NO>4</NO>
<PG>244-6</PG>
<IDENTIFIERS MODIFIED="2009-04-18 23:00:07 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chouinard-1994" MODIFIED="2009-04-18 23:00:13 +0100" MODIFIED_BY="[Empty name]" NAME="Chouinard 1994" YEAR="1994">
<REFERENCE MODIFIED="2009-04-18 23:00:13 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chouinard G, Vainer JL, Belanger MC, Turnier L, Beaudry P, Roy JY, Miller R</AU>
<TI>Risperidone and clozapine in the treatment of drug-resistant schizophrenia and neuroleptic-induced supersensitivity psychosis</TI>
<SO>Progress in Neuropsychopharmacology and Biological Psychiatry</SO>
<YR>1994</YR>
<VL>18</VL>
<NO>7</NO>
<PG>1129-41</PG>
<IDENTIFIERS MODIFIED="2009-04-18 23:00:13 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Conley-1999a" MODIFIED="2009-09-22 23:14:02 +0100" MODIFIED_BY="[Empty name]" NAME="Conley 1999a" YEAR="1999">
<REFERENCE MODIFIED="2009-09-22 23:14:02 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Conley J, Goldman RS, Bilder RM, Bates J, Reiter G, Pappadopulos E, Robinson D, Alvir JMA, Lieberman J, Schooler N</AU>
<TI>A comparison of the neurocognitive effects of treatment with typical and atypical neuroleptics in first-episode schizophrenia</TI>
<SO>Schizophrenia Research</SO>
<YR>1999</YR>
<VL>36</VL>
<NO>1-3</NO>
<PG>128</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cui-2002" MODIFIED="2009-04-18 23:00:17 +0100" MODIFIED_BY="[Empty name]" NAME="Cui 2002" YEAR="2002">
<REFERENCE MODIFIED="2009-04-18 23:00:17 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cui B, Shen J, Tian H, Wang Y, Guo X</AU>
<TI>A comparative study of the effects of risperidone, chlorpromazine and clozapine to patients with schizophrenia by the electrocardiograms</TI>
<SO>Tianjin Pharmacy</SO>
<YR>2002</YR>
<VL>3</VL>
<PG>54-5</PG>
<IDENTIFIERS MODIFIED="2009-04-18 23:00:17 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-CUTLASS" MODIFIED="2010-09-27 12:31:59 +0100" MODIFIED_BY="[Empty name]" NAME="CUTLASS" YEAR="2000">
<REFERENCE MODIFIED="2009-04-18 23:00:22 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Brownlee MM</AU>
<TI>The CUTLASS study: a multi-centre randomised controlled trial of atypical anti-psychotic drugs in severe schizophrenia</TI>
<SO>National Research Register</SO>
<YR>2000</YR>
<IDENTIFIERS MODIFIED="2009-04-18 23:00:22 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2009-04-18 23:00:25 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Jones PB</AU>
<TI>Cost utility of the latest antipsychotics in severe schizophrenia (CUtlASS)</TI>
<SO>National Research Register</SO>
<YR>2001</YR>
<VL>3</VL>
<IDENTIFIERS MODIFIED="2009-04-18 23:00:25 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2009-04-18 23:00:29 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Kerwin R</AU>
<TI>Cost utility of the latest antipsychotics in severe schizophrenia (CUTLASS) - a multi-centre, randomised controlled trial</TI>
<SO>National Research Register</SO>
<YR>2000</YR>
<IDENTIFIERS MODIFIED="2009-04-18 23:00:29 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2009-04-18 23:00:34 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Lewis S, Davies L, Jones P, Barnes T, Murray R, Kerwin R, Taylor D, Hayhurst K, Markwick A, Lloyd H, Dunn G</AU>
<TI>Randomised controlled trials of conventional antipsychotic versus new atypical drugs, and new atypical drugs versus clozapine, in people with schizophrenia responding poorly to, or intolerant of, current drug treatment</TI>
<SO>Draft final report for NCCHTA</SO>
<YR>2003</YR>
<IDENTIFIERS MODIFIED="2009-04-18 23:00:34 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2009-05-26 09:26:56 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Lewis S</AU>
<TI>Cost utility of the latest antipsychotics in severe schizophrenia (CUTLASS): a multi-centre, randomised, controlled trial</TI>
<SO>National Research Register</SO>
<YR>2000</YR>
<IDENTIFIERS MODIFIED="2009-04-18 23:00:53 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2009-04-18 23:00:37 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Lewis S</AU>
<TI>The CUTLASS study: a multi-centre randomised controlled trial of atypical anti-psychotic drugs in severe schizophrenia</TI>
<SO>National Research Register</SO>
<YR>2000</YR>
<IDENTIFIERS MODIFIED="2009-04-18 23:00:37 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2009-04-18 23:00:42 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lewis SW, Barnes TRE, Davies L, Murray RM, Dunn G, Hayhurst KP, Markwick A, Lloyd H, Jones PB</AU>
<TI>Randomized controlled trial of effect of prescription of clozapine versus other second-generation antipsychotic drugs in resistant schizophrenia</TI>
<SO>Schizophrenia Bulletin</SO>
<YR>2006</YR>
<VL>32</VL>
<NO>4</NO>
<PG>715-23</PG>
<CY>United Kingdom</CY>
<IDENTIFIERS MODIFIED="2009-04-18 23:00:42 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2009-05-26 09:26:48 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lewis SW, Davies L, Jones PB, Barnes TRE, Murray RM, Kerwin R, Taylor D, Hayhurst KP, Markwick A, Lloyd H, Dunn G</AU>
<TI>Randomised controlled trials of conventional antipsychotic versus new atypical drugs, and new atypical drugs versus clozapine, in people with schizophrenia responding poorly to, or intolerant of, current drug treatment</TI>
<SO>Health Technology Assessment</SO>
<YR>2006</YR>
<VL>10</VL>
<NO>17</NO>
<PG>III-182</PG>
<IDENTIFIERS MODIFIED="2009-04-18 23:00:50 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2009-04-18 23:01:00 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Marshall M</AU>
<TI>Cost utility of the latest anti psychotics in severe schizophrenia (CUTLASS)</TI>
<SO>National Research Register</SO>
<YR>2000</YR>
<IDENTIFIERS MODIFIED="2009-04-18 23:01:00 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2010-09-27 12:31:59 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Spurrell M</AU>
<TI>Cost utility of the latest antipsychotics in severe schizophrenia (CUTLASS)</TI>
<SO>National Research Register</SO>
<YR>2002</YR>
<VL>1</VL>
<IDENTIFIERS MODIFIED="2009-04-18 23:01:03 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dai-2004" MODIFIED="2009-05-26 09:28:20 +0100" MODIFIED_BY="[Empty name]" NAME="Dai 2004" YEAR="2004">
<REFERENCE MODIFIED="2009-05-26 09:28:20 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dai J-P, Zhao Z-H, Mai G-Y</AU>
<TI>Comparative study on the influence of olanzapine and clozapine on efficacy and quality of life in schizophrenia</TI>
<SO>Chinese Journal of Behavioral Medical Science</SO>
<YR>2004</YR>
<VL>13</VL>
<NO>4</NO>
<PG>396-98</PG>
<IDENTIFIERS MODIFIED="2009-04-18 23:01:08 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-David-1999" MODIFIED="2009-04-18 23:01:16 +0100" MODIFIED_BY="[Empty name]" NAME="David 1999" YEAR="1999">
<REFERENCE MODIFIED="2009-04-18 23:01:11 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>David SR, Meehan KM, Sutton VK, Taylor CC</AU>
<TI>Treatment of negative symptoms with olanzapine in comparison with other novel antipsychotic agents</TI>
<SO>International Journal of Neuropsychopharmacology</SO>
<YR>2000</YR>
<VL>3</VL>
<NO>Suppl 1</NO>
<PG>s140</PG>
<IDENTIFIERS MODIFIED="2009-04-18 23:01:11 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2009-04-18 23:01:16 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>David SR, Meehan KM, Sutton VK, Taylor CC</AU>
<TI>Treatment of negative symptoms with olanzapine in comparison with other novel antipsychotic agents</TI>
<SO>Journal of the European College of Neuropsychopharmacology</SO>
<YR>1999</YR>
<VL>9</VL>
<PG>S292</PG>
<IDENTIFIERS MODIFIED="2009-04-18 23:01:16 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Deng-2000" MODIFIED="2009-05-26 09:28:30 +0100" MODIFIED_BY="[Empty name]" NAME="Deng 2000" YEAR="2000">
<REFERENCE MODIFIED="2009-05-26 09:28:30 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Deng H, Zheng H, He Z</AU>
<TI>A comparative trial of olanzapine versus clozapine in the treatment of schizophrenia</TI>
<SO>Shanghai Archives of Psychiatry</SO>
<YR>2000</YR>
<VL>12</VL>
<NO>3</NO>
<PG>143-45</PG>
<IDENTIFIERS MODIFIED="2009-04-18 23:01:20 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ding-2005" MODIFIED="2010-09-27 12:32:28 +0100" MODIFIED_BY="[Empty name]" NAME="Ding 2005" YEAR="2005">
<REFERENCE MODIFIED="2010-09-27 12:32:28 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ding Z, Yu Z, Xu G</AU>
<TI>Control studies of increase of blood sugar induced by neo-antipsychotics</TI>
<SO>Journal of Clinical Psychosomatic Diseases</SO>
<YR>2005</YR>
<VL>11</VL>
<NO>4</NO>
<PG>309-10</PG>
<IDENTIFIERS MODIFIED="2010-09-27 12:32:28 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Du-2003" MODIFIED="2009-05-26 09:29:08 +0100" MODIFIED_BY="[Empty name]" NAME="Du 2003" YEAR="2003">
<REFERENCE MODIFIED="2009-05-26 09:29:08 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Du JF, Zhou T, Xiong LH, Tian DF</AU>
<TI>A study of quetiapine and clozapine in treatment of chronic schizophrenia</TI>
<SO>Journal of Luzhou Medical College</SO>
<YR>2003</YR>
<VL>26</VL>
<NO>6</NO>
<PG>511-12</PG>
<IDENTIFIERS MODIFIED="2009-04-18 23:01:44 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Du-2003b" MODIFIED="2009-05-26 09:31:22 +0100" MODIFIED_BY="[Empty name]" NAME="Du 2003b" YEAR="2003">
<REFERENCE MODIFIED="2009-05-26 09:31:22 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Du WJ, Yu JL, Zhen HB, Zhong XQ, Ma C</AU>
<TI>The influence of chlorpromazine, clozapine and risperidone on the cognitive function of schizophrenia</TI>
<SO>International Medicine &amp; Health Guidance News</SO>
<YR>2003</YR>
<VL>9</VL>
<NO>16</NO>
<PG>86-8</PG>
<IDENTIFIERS MODIFIED="2009-04-18 23:02:18 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Du-2004" MODIFIED="2009-05-26 09:30:08 +0100" MODIFIED_BY="[Empty name]" NAME="Du 2004" YEAR="2004">
<REFERENCE MODIFIED="2009-05-26 09:30:08 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Du Z-H</AU>
<TI>A study on the change of serum thyroxin treated with Risperdal or clozapine</TI>
<SO>Journal of Practical Medical Techniques</SO>
<YR>2004</YR>
<VL>11</VL>
<NO>68</NO>
<PG>1020-21</PG>
<IDENTIFIERS MODIFIED="2009-04-18 23:01:49 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Du-2005" MODIFIED="2009-05-01 14:30:17 +0100" MODIFIED_BY="[Empty name]" NAME="Du 2005" YEAR="2005">
<REFERENCE MODIFIED="2009-05-01 14:30:17 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Du Z, Wu H</AU>
<TI>Effects of clozapine and risperidone on the glucose metabolism in schizophrenic patients</TI>
<SO>Qilu Journal of Medical laboratory Sciences</SO>
<YR>2005</YR>
<VL>16</VL>
<NO>1</NO>
<PG>8-9</PG>
<IDENTIFIERS MODIFIED="2009-04-18 23:02:13 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Earnst-1999" MODIFIED="2009-04-18 23:02:23 +0100" MODIFIED_BY="[Empty name]" NAME="Earnst 1999" YEAR="1999">
<REFERENCE MODIFIED="2009-04-18 23:02:23 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Earnst KS, Taylor SF, Smet IC, Goldman RS, Tandon R, Berent S</AU>
<TI>The effects of typical antipsychotics, clozapine, and risperidone on neuropsychological test performance in schizophrenia</TI>
<SO>Schizophrenia Research</SO>
<YR>1999</YR>
<VL>40</VL>
<NO>3</NO>
<PG>255-6</PG>
<IDENTIFIERS MODIFIED="2009-04-18 23:02:23 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ellis-2000" MODIFIED="2009-05-26 09:31:44 +0100" MODIFIED_BY="[Empty name]" NAME="Ellis 2000" YEAR="2000">
<REFERENCE MODIFIED="2009-05-26 09:31:44 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ellis T, Cudkowicz ME, Sexton PM, Growdon JH</AU>
<TI>Clozapine and risperidone treatment of psychosis in parkinson's disease</TI>
<SO>Journal of Neuropsychiatry and Clinical Neurosciences</SO>
<YR>2000</YR>
<VL>12</VL>
<NO>3</NO>
<PG>364-9</PG>
<IDENTIFIERS MODIFIED="2009-04-18 23:02:28 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fan-2003" MODIFIED="2009-04-18 23:02:34 +0100" MODIFIED_BY="[Empty name]" NAME="Fan 2003" YEAR="2003">
<REFERENCE MODIFIED="2009-04-18 23:02:34 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fan C, Leiying, Wang K</AU>
<TI>The effect of clozapine and risperidone on blood sugar of patients with schizophrenia</TI>
<SO>Shandong Archives of Psychiatry</SO>
<YR>2003</YR>
<VL>16</VL>
<NO>3</NO>
<PG>131-2</PG>
<IDENTIFIERS MODIFIED="2009-04-18 23:02:34 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fang-2005" MODIFIED="2009-05-26 09:32:18 +0100" MODIFIED_BY="[Empty name]" NAME="Fang 2005" YEAR="2005">
<REFERENCE MODIFIED="2009-05-26 09:32:18 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fang JH, Li WJ</AU>
<TI>A study of quetiapine in treatment of the dominant negative symptoms in schizophrenia</TI>
<SO>Sichuan Mental Health</SO>
<YR>2005</YR>
<VL>18</VL>
<NO>3</NO>
<PG>178</PG>
<IDENTIFIERS MODIFIED="2009-04-18 23:02:38 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Feng-2004" MODIFIED="2009-05-26 09:32:31 +0100" MODIFIED_BY="[Empty name]" NAME="Feng 2004" YEAR="2004">
<REFERENCE MODIFIED="2009-05-26 09:32:31 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Feng Y</AU>
<TI>The influence of clozapine and risperidone on the weight</TI>
<SO>Journal of Clinical Psychological Medicine</SO>
<YR>2004</YR>
<VL>14</VL>
<NO>2</NO>
<PG>101</PG>
<IDENTIFIERS MODIFIED="2009-04-18 23:02:44 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fleming-1999" MODIFIED="2010-09-27 12:33:25 +0100" MODIFIED_BY="[Empty name]" NAME="Fleming 1999" YEAR="1999">
<REFERENCE MODIFIED="2010-09-27 12:33:25 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fleming K, Potkin SG, Alva G, Carreon D</AU>
<TI>Dissociation of improvement in neurocognition and negative symptomatology with olanzapine and clozapine conference abstract</TI>
<SO>Schizophrenia Research</SO>
<YR>1999</YR>
<VL>1, 2 &amp; 3</VL>
<PG>279</PG>
<IDENTIFIERS MODIFIED="2009-04-18 23:02:48 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Flynn-1997" MODIFIED="2009-05-26 09:32:51 +0100" MODIFIED_BY="[Empty name]" NAME="Flynn 1997" YEAR="1997">
<REFERENCE MODIFIED="2009-05-26 09:32:51 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Flynn SW, MacEwan GW, Altman S, Kopala LC, Smith GN, Honer WG</AU>
<TI>A comparison of two atypical antipsychotics in treatment resistant schizophrenia</TI>
<SO>Schizophrenia Research</SO>
<YR>1997</YR>
<VL>24</VL>
<NO>1, 2</NO>
<PG>185</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fu-2005" MODIFIED="2009-04-18 23:02:57 +0100" MODIFIED_BY="[Empty name]" NAME="Fu 2005" YEAR="2005">
<REFERENCE MODIFIED="2009-04-18 23:02:57 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fu H, Yu H , Huo J</AU>
<TI>A comparative study of quetiapine vs clozapine in the treatment of schizophrenia</TI>
<SO>Journal of Clinical Psychosomatic Diseases</SO>
<YR>2005</YR>
<VL>11</VL>
<NO>4</NO>
<PG>313-4</PG>
<IDENTIFIERS MODIFIED="2009-04-18 23:02:57 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gaertner-1999" MODIFIED="2009-04-18 23:03:05 +0100" MODIFIED_BY="[Empty name]" NAME="Gaertner 1999" YEAR="1999">
<REFERENCE MODIFIED="2009-04-18 23:03:05 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gaertner I, Gaertner HJ, Lampe D</AU>
<TI>Therapeutic drug monitoring of clozapine and olanzapine. Similarities and differences</TI>
<SO>Psychopharmakotherapie</SO>
<YR>1999</YR>
<VL>6</VL>
<NO>3</NO>
<PG>105-9</PG>
<IDENTIFIERS MODIFIED="2009-04-18 23:03:05 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gallhofer-1995" MODIFIED="2009-04-18 23:03:11 +0100" MODIFIED_BY="[Empty name]" NAME="Gallhofer 1995" YEAR="1995">
<REFERENCE MODIFIED="2009-04-18 23:03:11 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gallhofer B, Gruppe H, Bauer U</AU>
<TI>Zotepine versus clozapine: A comparison of the impact on the cognitive dysfunction syndrome in schizophrenia (a double blind trial)</TI>
<SO>Pharmacopsychiatry</SO>
<YR>1995</YR>
<VL>28</VL>
<PG>179</PG>
<IDENTIFIERS MODIFIED="2009-04-18 23:03:11 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gallhofer-1996" MODIFIED="2009-05-26 09:33:39 +0100" MODIFIED_BY="[Empty name]" NAME="Gallhofer 1996" YEAR="1996">
<REFERENCE MODIFIED="2009-05-26 09:33:39 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gallhofer B, Bauer U, Lis S, Krieger S, Gruppe H</AU>
<TI>Cognitive dysfunction in schizophrenia: comparison of treatment with atypical antipsychotic agents and conventional neuroleptic drugs</TI>
<SO>European Neuropsychopharmacology</SO>
<YR>1996</YR>
<VL>6</VL>
<NO>Suppl 2</NO>
<PG>S13-20</PG>
<IDENTIFIERS MODIFIED="2009-04-18 23:03:15 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ganguli-2005" MODIFIED="2009-05-26 09:33:46 +0100" MODIFIED_BY="[Empty name]" NAME="Ganguli 2005" YEAR="2005">
<REFERENCE MODIFIED="2009-05-26 09:33:46 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ganguli R, Brar JS</AU>
<TI>Prevention of weight gain, by behavioral interventions, in patients starting novel antipsychotics</TI>
<SO>Schizophrenia Bulletin</SO>
<YR>2005</YR>
<VL>31</VL>
<PG>561-62</PG>
<IDENTIFIERS MODIFIED="2009-04-18 23:03:18 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gao-2003" MODIFIED="2009-04-18 23:03:32 +0100" MODIFIED_BY="[Empty name]" NAME="Gao 2003" YEAR="2003">
<REFERENCE MODIFIED="2009-04-18 23:03:32 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gao CZ, Gao Z</AU>
<TI>A study of quetiapine in the treatment of first-onset schizophrenia</TI>
<SO>Journal of Clinical Psychological Medicine</SO>
<YR>2003</YR>
<VL>13</VL>
<NO>4</NO>
<PG>221-2</PG>
<IDENTIFIERS MODIFIED="2009-04-18 23:03:32 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Goldberg-2000" MODIFIED="2009-04-18 23:03:38 +0100" MODIFIED_BY="[Empty name]" NAME="Goldberg 2000" YEAR="2000">
<REFERENCE MODIFIED="2009-04-18 23:03:38 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Goldberg TE, Dodge M, Aloia M, Egan MF, Weinberger DR</AU>
<TI>Effects of neuroleptic medications on speech disorganization in schizophrenia: biasing associative networks towards meaning</TI>
<SO>Psychological Medicine</SO>
<YR>2000</YR>
<VL>30</VL>
<NO>5</NO>
<PG>1123-30</PG>
<IDENTIFIERS MODIFIED="2009-04-18 23:03:38 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Green-2001" MODIFIED="2010-09-27 13:00:40 +0100" MODIFIED_BY="[Empty name]" NAME="Green 2001" YEAR="2001">
<REFERENCE MODIFIED="2010-09-27 13:00:40 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Green AI</AU>
<TI>Cannabis and schizophrenia-clozapine vs risperidone</TI>
<SO>CRISP database (https://www-commons.cit.nih.gov/crisp/index.html)</SO>
<YR>(accessed 19th February 2001).</YR>
<IDENTIFIERS MODIFIED="2009-04-18 23:03:43 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Guan-2005" MODIFIED="2010-09-27 12:35:35 +0100" MODIFIED_BY="[Empty name]" NAME="Guan 2005" YEAR="2005">
<REFERENCE MODIFIED="2010-09-27 12:35:35 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Guan D-H, Song H-F</AU>
<TI>A control study of social function improvement in schizophrenia patients with risperdal and clozapine</TI>
<SO>Medical Journal of Chinese People Health</SO>
<YR>2005</YR>
<VL>17</VL>
<NO>9</NO>
<PG>506-7</PG>
<IDENTIFIERS MODIFIED="2009-04-18 23:03:47 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Guo-2001" MODIFIED="2009-04-18 23:03:50 +0100" MODIFIED_BY="[Empty name]" NAME="Guo 2001" YEAR="2001">
<REFERENCE MODIFIED="2009-04-18 23:03:50 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Guo HR, Zhang SR, Sun FG</AU>
<TI>Clinical controlled study of risperidone and clozapine in treatment of schizophrenia</TI>
<SO>Journal of Xinxiang Medical College</SO>
<YR>2001</YR>
<VL>18</VL>
<NO>3</NO>
<PG>174-6</PG>
<IDENTIFIERS MODIFIED="2009-04-18 23:03:50 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Guo-2003" MODIFIED="2009-05-26 09:34:41 +0100" MODIFIED_BY="[Empty name]" NAME="Guo 2003" YEAR="2003">
<REFERENCE MODIFIED="2009-05-26 09:34:41 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Guo S, Lu L, Cheng W</AU>
<TI>Effect of clozapine and risperidone on interleukin-2 on schizophrenia</TI>
<SO>Shanghai Archives of Psychiatry</SO>
<YR>2003</YR>
<VL>15</VL>
<NO>1</NO>
<PG>35-8</PG>
<IDENTIFIERS MODIFIED="2009-04-18 23:03:54 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Han-2005" MODIFIED="2009-05-26 09:35:14 +0100" MODIFIED_BY="[Empty name]" NAME="Han 2005" YEAR="2005">
<REFERENCE MODIFIED="2009-05-26 09:35:14 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Han Z-Y, Wang L-J, Wang J</AU>
<TI>Analysis of risperidone, clonazepam in treatment of positive symptoms in schizophrenia</TI>
<SO>Ningxia Medical Journal</SO>
<YR>2005</YR>
<VL>27</VL>
<NO>9</NO>
<PG>631-2</PG>
<IDENTIFIERS MODIFIED="2009-04-18 23:04:00 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hang-2000" MODIFIED="2009-05-26 09:35:26 +0100" MODIFIED_BY="[Empty name]" NAME="Hang 2000" YEAR="2000">
<REFERENCE MODIFIED="2009-05-26 09:35:26 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hang P</AU>
<TI>A study of risperidone and clozapine in treatment of resistant schizophrenia</TI>
<SO>Journal of Jining Medical College</SO>
<YR>2000</YR>
<VL>23</VL>
<NO>3</NO>
<PG>75</PG>
<IDENTIFIERS MODIFIED="2009-04-18 23:04:04 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-He-2005" MODIFIED="2009-04-18 23:04:07 +0100" MODIFIED_BY="[Empty name]" NAME="He 2005" YEAR="2005">
<REFERENCE MODIFIED="2009-04-18 23:04:07 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>He Y-Q, Ma S-H, Du J</AU>
<TI>A controlled study on hostility and side effects in clozapine and risperidone for treatment of patients with schizophrenia</TI>
<SO>Journal of Xinxiang Medical College</SO>
<YR>2005</YR>
<VL>22</VL>
<NO>2</NO>
<PG>118-20</PG>
<IDENTIFIERS MODIFIED="2009-04-18 23:04:07 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hu-2000" MODIFIED="2009-05-26 09:37:16 +0100" MODIFIED_BY="[Empty name]" NAME="Hu 2000" YEAR="2000">
<REFERENCE MODIFIED="2009-05-26 09:36:13 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hu X-C, Tao R-F</AU>
<TI>A study of risperidone and clozapine in treatment of schizophrenia</TI>
<SO>Journal of Handan Medical College</SO>
<YR>2000</YR>
<VL>13</VL>
<NO>2</NO>
<PG>91</PG>
<IDENTIFIERS MODIFIED="2009-04-18 23:04:15 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hu-2005" MODIFIED="2009-05-26 09:37:10 +0100" MODIFIED_BY="[Empty name]" NAME="Hu 2005" YEAR="2005">
<REFERENCE MODIFIED="2009-05-26 09:35:49 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hu T-S</AU>
<TI>A study of risperidone in treatment of dominant positive symptoms in schizophrenia</TI>
<SO>Chinese Journal of Behavioral Medical Science</SO>
<YR>2005</YR>
<VL>14</VL>
<NO>5</NO>
<PG>428</PG>
<IDENTIFIERS MODIFIED="2009-04-18 23:04:11 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Huang-2001" MODIFIED="2010-09-27 12:38:37 +0100" MODIFIED_BY="[Empty name]" NAME="Huang 2001" YEAR="2001">
<REFERENCE MODIFIED="2010-09-27 12:38:37 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Huang QM, Li J, Zhu XW, Mel QY</AU>
<TI>A study of risperidone and clozapine in treatment of the behaviours in schizophrenia</TI>
<SO>Shanghai Archives of Psychiatry</SO>
<YR>2001</YR>
<VL>13</VL>
<NO>3</NO>
<PG>152-4</PG>
<IDENTIFIERS MODIFIED="2009-04-18 23:05:10 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Huang-2003" MODIFIED="2010-09-27 12:40:06 +0100" MODIFIED_BY="[Empty name]" NAME="Huang 2003" YEAR="2003">
<REFERENCE MODIFIED="2010-09-27 12:40:06 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Huang S-P, Ma Z-W, Guo B-Y</AU>
<TI>Effectiveness of quetiapine vs clozapine in the treatment of schizophrenia</TI>
<SO>Journal of Clinical Psychosomatic Diseases</SO>
<YR>2003</YR>
<VL>9</VL>
<NO>4</NO>
<PG>206-7</PG>
<IDENTIFIERS MODIFIED="2009-04-18 23:05:14 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kelemen-2006" MODIFIED="2009-04-18 23:05:04 +0100" MODIFIED_BY="[Empty name]" NAME="Kelemen 2006" YEAR="2006">
<REFERENCE MODIFIED="2009-04-18 23:05:04 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kelemen O, Nagy O, Máttyássy A, Kiss I, Janka Z, Kéri S</AU>
<TI>Do second-generation antipsychotics disrupt decision-making abilities in schizophrenia?</TI>
<SO>Journal of the European College of Neuropsychopharmacology</SO>
<YR>2006</YR>
<VL>16</VL>
<NO>Suppl 4</NO>
<PG>S430</PG>
<IDENTIFIERS MODIFIED="2009-04-18 23:05:04 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kong-2001" MODIFIED="2009-05-26 09:38:32 +0100" MODIFIED_BY="[Empty name]" NAME="Kong 2001" YEAR="2001">
<REFERENCE MODIFIED="2009-05-26 09:38:32 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kong Q-R, Yang R-X, Li S-C, Lu Z-S, Li J-Y, Chen X</AU>
<TI>A study of clozapine with risperidone and clozapine with sulpiride in treatment of resistant schizophrenia</TI>
<SO>Shandong Archives of Psychiatry</SO>
<YR>2001</YR>
<VL>14</VL>
<NO>2</NO>
<PG>119-20</PG>
<IDENTIFIERS MODIFIED="2009-04-18 23:05:00 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Konrad-1996" MODIFIED="2009-05-26 09:39:11 +0100" MODIFIED_BY="[Empty name]" NAME="Konrad 1996" YEAR="1996">
<REFERENCE MODIFIED="2009-05-26 09:38:52 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Konrad C, Schormair C, Eikelmann B, Berger K, Rottmann P</AU>
<TI>Clozapine and risperidone in the treatment of therapy-resistant schizophrenia: a preliminary report on two ongoing clinical trials</TI>
<SO>Proceedings of the 8th Congress of the Association of European Psychiatrists; 1996 Jul 7-12; London, UK</SO>
<YR>1996</YR>
<IDENTIFIERS MODIFIED="2009-04-18 23:04:49 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2009-04-18 23:04:52 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Konrad C, Schormair C, Knickelbein U, Ophaus P, Eikelmann B</AU>
<TI>Risperidone and clozapine in pharmaco-resistant schizophrenia</TI>
<SO>Pharmacopsychiatry</SO>
<YR>1997</YR>
<VL>30</VL>
<PG>190</PG>
<IDENTIFIERS MODIFIED="2009-04-18 23:04:52 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2009-05-26 09:39:11 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Konrad C, Schormair C, Ophaus P, Knickelbein U, Eikelmann B</AU>
<TI>Clozapine versus risperidone in pharmaco- refractory schizophrenia: a preliminary report</TI>
<SO>Proceedings of the 150th Annual Meeting of the American Psychiatric Association; 1997 May 17-22; San Diego, California, USA</SO>
<YR>1997</YR>
<IDENTIFIERS MODIFIED="2009-04-18 23:04:56 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kufferle-1997" MODIFIED="2009-04-18 23:05:25 +0100" MODIFIED_BY="[Empty name]" NAME="Kufferle 1997" YEAR="1997">
<REFERENCE MODIFIED="2009-04-18 23:05:25 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kufferle B, Tauscher J, Asenbaum S, Vesely C, Podreka I, Brucke T, Kasper S</AU>
<TI>IBZM SPECT imaging of striatal dopamine-2 receptors in psychotic patients treated with the novel antipsychotic substance quetiapine in comparison to clozapine and haloperidol</TI>
<SO>Psychopharmacology</SO>
<YR>1997</YR>
<VL>133</VL>
<PG>323-28</PG>
<IDENTIFIERS MODIFIED="2009-04-18 23:05:25 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lee-1995" MODIFIED="2009-09-24 23:06:13 +0100" MODIFIED_BY="[Empty name]" NAME="Lee 1995" YEAR="1995">
<REFERENCE MODIFIED="2009-09-24 23:01:12 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Lee MS, Jung IK, Kwak DI</AU>
<TI>Clinical efficacy of clozapine in treatment-refractory schizophrenic patients</TI>
<SO>Proceedings of the 8th European College of Neuropsychopharmacology Congress; 1995 Sep 30 - Oct 4; Venice, Italy</SO>
<YR>1995</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lei-2002" MODIFIED="2009-04-18 23:05:30 +0100" MODIFIED_BY="[Empty name]" NAME="Lei 2002" YEAR="2002">
<REFERENCE MODIFIED="2009-04-18 23:05:30 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lei X, Liang T, Zhang X</AU>
<TI>A controlled study on risperidone and clozapine in treatment of schizophrenia</TI>
<SO>China Pharmacist</SO>
<YR>2002</YR>
<VL>5</VL>
<NO>3</NO>
<PG>169-71</PG>
<IDENTIFIERS MODIFIED="2009-04-18 23:05:30 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lei-G-2004" MODIFIED="2009-05-26 09:40:45 +0100" MODIFIED_BY="[Empty name]" NAME="Lei G 2004" YEAR="2004">
<REFERENCE MODIFIED="2009-05-26 09:40:45 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lei G-W, Hen A-P, Qi L, Liu G-X</AU>
<TI>The influence of atypical antipsychotics on glucose, triglycerides and total cholesterol</TI>
<SO>Chinese Journal of Misdiagnostics</SO>
<YR>2004</YR>
<VL>4</VL>
<NO>10</NO>
<PG>1665</PG>
<IDENTIFIERS MODIFIED="2009-04-18 23:05:34 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Li--2003b" MODIFIED="2009-05-26 09:42:50 +0100" MODIFIED_BY="[Empty name]" NAME="Li  2003b" YEAR="2003">
<REFERENCE MODIFIED="2009-05-26 09:42:50 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Li T, Xue XM, Gong CF</AU>
<TI>A comparison study on the efficacy of risperidone vs clozapin in cognition of schizophrenia</TI>
<SO>Medical Journal of Chinese People Health</SO>
<YR>2003</YR>
<VL>15</VL>
<NO>11</NO>
<PG>653-6</PG>
<IDENTIFIERS MODIFIED="2009-04-18 23:06:01 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Li-2001" MODIFIED="2009-04-18 23:05:38 +0100" MODIFIED_BY="[Empty name]" NAME="Li 2001" YEAR="2001">
<REFERENCE MODIFIED="2009-04-18 23:05:38 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Li J, Dai X</AU>
<TI>A comparative study of risperidone and sulpiride in treating schizophrenia</TI>
<SO>Medical Journal of Chinese Civil Administration</SO>
<YR>2001</YR>
<VL>13</VL>
<NO>3</NO>
<PG>136-8</PG>
<IDENTIFIERS MODIFIED="2009-04-18 23:05:38 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Li-2003" MODIFIED="2009-05-26 09:42:11 +0100" MODIFIED_BY="[Empty name]" NAME="Li 2003" YEAR="2003">
<REFERENCE MODIFIED="2009-05-26 09:42:11 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Li C-M, Guo L</AU>
<TI>A comparison of cognitive function in the first-onset schizophrenia treated with quetiapine and clozapine</TI>
<SO>Medical Journal of Chinese People Health</SO>
<YR>2003</YR>
<VL>15</VL>
<NO>12</NO>
<PG>718-21</PG>
<IDENTIFIERS MODIFIED="2009-04-18 23:05:44 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Li-2004" MODIFIED="2009-05-26 09:42:30 +0100" MODIFIED_BY="[Empty name]" NAME="Li 2004" YEAR="2004">
<REFERENCE MODIFIED="2009-05-26 09:42:30 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Li Z</AU>
<TI>A comparative study of clozapine and risperidone lead to putting on weight</TI>
<SO>Heath Psychology Journal</SO>
<YR>2004</YR>
<VL>12</VL>
<NO>5</NO>
<PG>396-97</PG>
<IDENTIFIERS MODIFIED="2009-04-18 23:05:57 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Liang-2002" MODIFIED="2009-05-26 09:43:17 +0100" MODIFIED_BY="[Empty name]" NAME="Liang 2002" YEAR="2002">
<REFERENCE MODIFIED="2009-05-26 09:43:17 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Liang S, Yu G, Ding G</AU>
<TI>Controlled study of olanzapine and clozapine in the treatment of schizophrenia</TI>
<SO>Shandong Archives of Psychiatry</SO>
<YR>2002</YR>
<VL>15</VL>
<NO>4</NO>
<PG>193-94</PG>
<IDENTIFIERS MODIFIED="2009-04-18 23:06:05 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Liang-2005" MODIFIED="2009-05-26 09:43:40 +0100" MODIFIED_BY="[Empty name]" NAME="Liang 2005" YEAR="2005">
<REFERENCE MODIFIED="2009-05-26 09:43:40 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Liang Z-Y, Huang X-S</AU>
<TI>A study of risperidone and clozapine in treatment of first episode schizophrenia</TI>
<SO>Medical Journal of Chinese People Health</SO>
<YR>2005</YR>
<VL>17</VL>
<NO>9</NO>
<PG>509-10</PG>
<IDENTIFIERS MODIFIED="2009-04-18 23:06:10 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lindenmayer-1996" MODIFIED="2010-09-27 12:42:40 +0100" MODIFIED_BY="[Empty name]" NAME="Lindenmayer 1996" YEAR="1996">
<REFERENCE MODIFIED="2009-05-26 09:43:52 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Lindenmayer JP, Iskander A, Apergi FS, Park M</AU>
<TI>Cognitive profile and soft signs in clozapine versus risperidone treatment</TI>
<SO>Proceedings of the 150th Annual Meeting of the American Psychiatric Association; 1997 May 17-22; San Diego, California, USA</SO>
<YR>1997</YR>
<IDENTIFIERS MODIFIED="2009-04-18 23:06:13 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2010-09-27 12:42:40 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Lindenmayer JP, Park M, Iskander A, Bark NM, Smith RM, Cooper TB</AU>
<TI>Clozapine versus risperidone in treatment refractory state psychiatric inpatients</TI>
<SO>Proceedings of the 149th Annual Meeting of the American Psychiatric Association; 1996 Oct 2 - May 9; New York, USA</SO>
<YR>1996</YR>
<IDENTIFIERS MODIFIED="2009-04-18 23:06:16 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Liu-1999" MODIFIED="2009-05-26 09:44:33 +0100" MODIFIED_BY="[Empty name]" NAME="Liu 1999" YEAR="1999">
<REFERENCE MODIFIED="2009-05-26 09:44:33 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Liu Q, Man C, Li X</AU>
<TI>A control study of risperidone and clozapine to treating the positive symptoms of schizophrenia</TI>
<SO>Sichuan Mental Health</SO>
<YR>1999</YR>
<VL>12</VL>
<NO>2</NO>
<PG>98-100</PG>
<IDENTIFIERS MODIFIED="2009-04-18 23:06:22 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Liu-2001" MODIFIED="2009-04-18 23:06:28 +0100" MODIFIED_BY="[Empty name]" NAME="Liu 2001" YEAR="2001">
<REFERENCE MODIFIED="2009-04-18 23:06:28 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Liu Q, Li X</AU>
<TI>A comparative study on the efficacy of combining risperidone and clozapine in the treatment of schizophrenia</TI>
<SO>Shandong Archives of Psychiatry</SO>
<YR>2001</YR>
<VL>14</VL>
<NO>1</NO>
<PG>28-30</PG>
<IDENTIFIERS MODIFIED="2009-04-18 23:06:28 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Liu-2003" MODIFIED="2009-04-18 23:06:32 +0100" MODIFIED_BY="[Empty name]" NAME="Liu 2003" YEAR="2003">
<REFERENCE MODIFIED="2009-04-18 23:06:32 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Liu X, Cheng J</AU>
<TI>A comparative study between quetiapine and clozapine in the treatment of schizophrenia and the relation with the plasma levels of il-2, sil-2r. an Baofu</TI>
<SO>Sichuan Mental Health</SO>
<YR>2003</YR>
<VL>16</VL>
<NO>3</NO>
<PG>152-4</PG>
<IDENTIFIERS MODIFIED="2009-04-18 23:06:32 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Liu-2003b" MODIFIED="2009-05-26 09:47:36 +0100" MODIFIED_BY="[Empty name]" NAME="Liu 2003b" YEAR="2003">
<REFERENCE MODIFIED="2009-05-26 09:45:58 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Liu F, Dai M</AU>
<TI>The effects of risperidone and clozapine to patients with schizophrenia's life quality</TI>
<SO>Sichuan Mental Health</SO>
<YR>2003</YR>
<VL>16</VL>
<NO>4</NO>
<PG>203-4</PG>
<IDENTIFIERS MODIFIED="2009-04-18 23:06:51 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Liu-2004" MODIFIED="2009-05-26 09:45:05 +0100" MODIFIED_BY="[Empty name]" NAME="Liu 2004" YEAR="2004">
<REFERENCE MODIFIED="2009-05-26 09:45:05 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Liu W, Li H, Zheng L</AU>
<TI>A controlled study on olanzapine and clozapine in the treatment of the acute phase of schizophrenia</TI>
<SO>Shanghai Archives of Psychiatry</SO>
<YR>2004</YR>
<VL>16</VL>
<NO>5</NO>
<PG>282-84</PG>
<IDENTIFIERS MODIFIED="2009-04-18 23:06:37 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Liu-2004b" MODIFIED="2009-05-26 09:47:57 +0100" MODIFIED_BY="[Empty name]" NAME="Liu 2004b" YEAR="2004">
<REFERENCE MODIFIED="2009-05-26 09:46:51 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Liu J-B,Wu J-H</AU>
<TI>The influence of clozapine, risperidone and chlorpromazine on the glucose, triglycerides, total cholesterol and the weight in first episode schizophrenia</TI>
<SO>Chinese Journal of Nervous and Mental Diseases</SO>
<YR>2004</YR>
<VL>30</VL>
<NO>4</NO>
<PG>293-95</PG>
<IDENTIFIERS MODIFIED="2009-04-18 23:07:06 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Liu-2004c" MODIFIED="2009-05-26 09:48:10 +0100" MODIFIED_BY="[Empty name]" NAME="Liu 2004c" YEAR="2004">
<REFERENCE MODIFIED="2009-05-26 09:47:16 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Liu N-H, Zhang J-Y</AU>
<TI>A study of risperidone with clonazepam in treatment of schizophrenia</TI>
<SO>Journal of Hainan Medical College</SO>
<YR>2004</YR>
<VL>10</VL>
<NO>6</NO>
<PG>394-95</PG>
<IDENTIFIERS MODIFIED="2009-04-18 23:07:12 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Liu-2005" MODIFIED="2009-04-18 23:06:43 +0100" MODIFIED_BY="[Empty name]" NAME="Liu 2005" YEAR="2005">
<REFERENCE MODIFIED="2009-04-18 23:06:43 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Liu Y</AU>
<TI>A comparative study of risperidone and clozapine in the treatment of refractory schizophrenia</TI>
<SO>Journal of Heze Medical College</SO>
<YR>2005</YR>
<VL>17</VL>
<NO>1</NO>
<PG>13-4</PG>
<IDENTIFIERS MODIFIED="2009-04-18 23:06:43 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Liu-2005b" MODIFIED="2009-05-26 09:47:28 +0100" MODIFIED_BY="[Empty name]" NAME="Liu 2005b" YEAR="2005">
<REFERENCE MODIFIED="2009-05-26 09:45:48 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Liu C-X, Liu S-H, Tu Z-M, Liu B</AU>
<TI>A study of quetiapine with small dose of clozapine in treatment of resistant schizophrenia</TI>
<SO>Medical Journal of Chinese People Health</SO>
<YR>2005</YR>
<VL>17</VL>
<NO>12</NO>
<PG>748-9</PG>
<IDENTIFIERS MODIFIED="2009-04-18 23:06:46 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Liu-2005c" MODIFIED="2009-05-26 09:47:49 +0100" MODIFIED_BY="[Empty name]" NAME="Liu 2005c" YEAR="2005">
<REFERENCE MODIFIED="2009-05-26 09:46:21 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Liu GF, Zhou JS</AU>
<TI>The influence of risperidone and clozapine in the quality of life of schizophrenia</TI>
<SO>Medical Journal of Chinese People Health</SO>
<YR>2005</YR>
<VL>17</VL>
<NO>6</NO>
<PG>289-90</PG>
<IDENTIFIERS MODIFIED="2009-04-18 23:06:54 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Louwerens-1996" MODIFIED="2009-05-26 09:49:20 +0100" MODIFIED_BY="[Empty name]" NAME="Louwerens 1996" YEAR="1996">
<REFERENCE MODIFIED="2009-05-26 09:49:20 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Louwerens JW, Slooff CJ, Korf J, Coppens HJ, Paans AMJ</AU>
<TI>Dopamine2- and serotonine2-receptor-antagonism by antipsychotics in man</TI>
<SO>Schizophrenia Research</SO>
<YR>1996</YR>
<VL>18</VL>
<NO>2</NO>
<PG>141</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lu-2002" MODIFIED="2009-05-26 09:49:38 +0100" MODIFIED_BY="[Empty name]" NAME="Lu 2002" YEAR="2002">
<REFERENCE MODIFIED="2009-05-26 09:49:38 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lu Y, Ren Q, Tian M</AU>
<TI>A comparison of cognitive function in the first-onset schizophrenia treated with risperidone and clozapine</TI>
<SO>Shandong Archives of Psychiatry</SO>
<YR>2002</YR>
<VL>15</VL>
<NO>4</NO>
<PG>206-7</PG>
<IDENTIFIERS MODIFIED="2009-04-18 23:07:18 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lu-2005" MODIFIED="2010-09-27 12:44:16 +0100" MODIFIED_BY="[Empty name]" NAME="Lu 2005" YEAR="2005">
<REFERENCE MODIFIED="2010-09-27 12:44:16 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lu S, Zhang S-A, Ren Y</AU>
<TI>Comparative study on the psychopathology and the quality of life of schizophrenia treated with risperidone, clozapine and quetiapine</TI>
<SO>Journal of Nursing Science</SO>
<YR>2005</YR>
<VL>20</VL>
<NO>3</NO>
<PG>57-59</PG>
<IDENTIFIERS MODIFIED="2009-04-18 23:07:22 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Luo-2005" MODIFIED="2010-09-27 12:44:16 +0100" MODIFIED_BY="[Empty name]" NAME="Luo 2005" YEAR="2005">
<REFERENCE MODIFIED="2010-09-27 12:44:16 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Luo Y, Zhang S-W, Wang A-Q</AU>
<TI>The comparative study of quetiapine and clozapine in the treatment of female schizophrene</TI>
<SO>Medical Journal of Chinese People Health</SO>
<YR>2005</YR>
<VL>17</VL>
<NO>6</NO>
<PG>269-70</PG>
<IDENTIFIERS MODIFIED="2009-04-18 23:07:26 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ma-1999" MODIFIED="2009-05-26 09:51:30 +0100" MODIFIED_BY="[Empty name]" NAME="Ma 1999" YEAR="1999">
<REFERENCE MODIFIED="2009-05-26 09:51:30 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ma QM, Guan HY, Jiang L, Zhang YY, Yi XR, Guo JM, Sun SG, Liu KH, Gao SQ, Wu HR, Xu SW</AU>
<TI>A study of risperidone in treatment of chronic schizophrenia</TI>
<SO>Heath Psychology Journal</SO>
<YR>1999</YR>
<VL>7</VL>
<NO>3</NO>
<PG>290-93</PG>
<IDENTIFIERS MODIFIED="2009-04-18 23:07:30 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-McKenna-2004" MODIFIED="2009-05-26 09:51:38 +0100" MODIFIED_BY="[Empty name]" NAME="McKenna 2004" YEAR="2004">
<REFERENCE MODIFIED="2009-05-26 09:51:38 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>McKenna PJ</AU>
<TI>An international study of improving treatment for the most severely ill with schizophrenia</TI>
<SO>National Research Register</SO>
<YR>2004</YR>
<VL>2</VL>
<IDENTIFIERS MODIFIED="2009-04-18 23:07:34 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Meehan-2000" MODIFIED="2009-04-18 23:07:38 +0100" MODIFIED_BY="[Empty name]" NAME="Meehan 2000" YEAR="2000">
<REFERENCE MODIFIED="2009-04-18 23:07:38 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Meehan KM, David SR, Taylor CC, Sutton VK</AU>
<TI>Change in extrapyramidal symptoms with olanzapine in comparison with other antipsychotic agents</TI>
<SO>Schizophrenia Research</SO>
<YR>2000</YR>
<VL>41</VL>
<NO>1</NO>
<PG>192</PG>
<IDENTIFIERS MODIFIED="2009-04-18 23:07:38 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mei-2001" MODIFIED="2010-09-27 12:44:46 +0100" MODIFIED_BY="[Empty name]" NAME="Mei 2001" YEAR="2001">
<REFERENCE MODIFIED="2010-09-27 12:44:46 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mei Q, Zhu X, Shen J</AU>
<TI>A comparative study of social function in schizophrenic patients treated with risperidone or clozapine</TI>
<SO>Journal of Clinical Psychological Medicine</SO>
<YR>2001</YR>
<VL>11</VL>
<NO>2</NO>
<PG>83-5</PG>
<IDENTIFIERS MODIFIED="2009-04-18 23:07:43 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mulqueen-2000" MODIFIED="2009-05-26 09:52:04 +0100" MODIFIED_BY="[Empty name]" NAME="Mulqueen 2000" YEAR="2000">
<REFERENCE MODIFIED="2009-04-18 23:07:52 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Mulqueen AW, Wudarsky M, Nicolson RJ, Gochman P, Hamburger S, Lenane M, Rapoport JHL</AU>
<TI>Weight gain in pediatric patients on typical and atypical antipsychotics</TI>
<SO>155th Annual Meeting of the American Psychiatric Association; 2002 May 18-23; Philadelphia, Pennsylvania, USA</SO>
<YR>2002</YR>
<IDENTIFIERS MODIFIED="2009-04-18 23:07:52 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2009-05-26 09:52:04 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Mulqueen AW, Wudarsky M, Nicolson RJ, Gochman P, Hamburger S, Lenane M, Rapoport JHL</AU>
<TI>Weight gain in pediatric patients on typical and atypical antipsychotics</TI>
<SO>Proceedings of the 153rd Annual Meeting of the American Psychiatric Association; 2000 May 13-18; Chicago, Illinois, USA</SO>
<YR>2000</YR>
<IDENTIFIERS MODIFIED="2009-04-18 23:07:48 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nan-2001" MODIFIED="2009-05-26 09:52:18 +0100" MODIFIED_BY="[Empty name]" NAME="Nan 2001" YEAR="2001">
<REFERENCE MODIFIED="2009-05-26 09:52:18 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nan Z, Wang J, Ji H</AU>
<TI>A controlled study of risperidone and clozapine both influences cognitive function of patients with schizophrenia</TI>
<SO>Sichuan Mental Health</SO>
<YR>2001</YR>
<VL>14</VL>
<NO>4</NO>
<PG>198-200</PG>
<IDENTIFIERS MODIFIED="2009-04-18 23:08:06 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ni-2001" MODIFIED="2009-05-26 09:53:07 +0100" MODIFIED_BY="[Empty name]" NAME="Ni 2001" YEAR="2001">
<REFERENCE MODIFIED="2009-05-26 09:53:07 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ni JL, Jiiang LC, Hong X, Yang H, Zheng XP</AU>
<TI>A study of clozapine and risperidone in treatment of schizophrenia</TI>
<SO>Heath Psychology Journal</SO>
<YR>2001</YR>
<VL>9</VL>
<NO>3</NO>
<PG>181-82</PG>
<IDENTIFIERS MODIFIED="2009-04-18 23:08:09 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Opjordsmoen-2000" MODIFIED="2009-05-26 09:53:31 +0100" MODIFIED_BY="[Empty name]" NAME="Opjordsmoen 2000" YEAR="2000">
<REFERENCE MODIFIED="2009-05-26 09:53:31 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Opjordsmoen S, Brunsvik S, Melle I, Dahl A, Friis S, Haahr U, Hustoft K, Johannessen JO, Larsen TK, McGlashan TH, Simonsen E, Vaglum P</AU>
<TI>A comparison between novel and traditional antipsychotics as first-line medication in early psychosis</TI>
<SO>Proceedings of the 2nd International Conference on Early Psychosis; 2000 Mar 31 - Apr 2; New York, USA</SO>
<YR>2000</YR>
<IDENTIFIERS MODIFIED="2009-04-18 23:08:14 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pajonk-1998" MODIFIED="2010-09-27 12:45:31 +0100" MODIFIED_BY="[Empty name]" NAME="Pajonk 1998" YEAR="1999">
<REFERENCE MODIFIED="2010-09-27 12:45:31 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Pajonk FG, Tiessen F, Holtzbach R, Naber D</AU>
<TI>Clozapine versus risperidone: an open comparative and prospective study on efficacy, tolerability and quality of life</TI>
<SO>Proceedings of the 21st congress of the collegium Internationale Neuro-psychopharmacologicum; 1998 Jul 12-16, Glasgow</SO>
<YR>1998</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pan-2006" MODIFIED="2009-05-26 10:05:53 +0100" MODIFIED_BY="[Empty name]" NAME="Pan 2006" YEAR="2006">
<REFERENCE MODIFIED="2009-05-26 10:05:53 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pan SM, Zhao LJ</AU>
<TI>A study of olanzapine and clozapine in treatment of schizophrenia</TI>
<SO>Zhejiang Journal of Integrated Traditional Chinese and Western Medicine</SO>
<YR>2006</YR>
<VL>16</VL>
<NO>1</NO>
<PG>32-3</PG>
<IDENTIFIERS MODIFIED="2009-04-18 23:08:29 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pao-2004" MODIFIED="2009-05-26 10:06:15 +0100" MODIFIED_BY="[Empty name]" NAME="Pao 2004" YEAR="2004">
<REFERENCE MODIFIED="2009-05-26 10:06:15 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pao M, Zhang SQ, Zhao Z</AU>
<TI>Influence of three antipsychotic drugs on electrocardiogram in patients with schizophrenia</TI>
<SO>Journal of Xinxiang Medical College</SO>
<YR>2004</YR>
<VL>21</VL>
<NO>5</NO>
<PG>403-4</PG>
<IDENTIFIERS MODIFIED="2009-04-18 23:08:35 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Peng-2001" MODIFIED="2009-04-18 23:08:39 +0100" MODIFIED_BY="[Empty name]" NAME="Peng 2001" YEAR="2001">
<REFERENCE MODIFIED="2009-04-18 23:08:39 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Peng H, Kuang Y, Huang X</AU>
<TI>A control study of risperidone in combination with clozapine in treating refractory schizophrenia</TI>
<SO>Journal of Modern Clinical Medical Bioengineering</SO>
<YR>2001</YR>
<VL>7</VL>
<NO>2</NO>
<PG>100-2</PG>
<IDENTIFIERS MODIFIED="2009-04-18 23:08:39 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Qian-2004" MODIFIED="2009-05-26 10:06:32 +0100" MODIFIED_BY="[Empty name]" NAME="Qian 2004" YEAR="2004">
<REFERENCE MODIFIED="2009-05-26 10:06:32 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Qian D, Pan B, Yang G</AU>
<TI>Cost-effectiveness analysis of 3 kinds of therapeutic schemes for schizophrenia</TI>
<SO>Evaluation and Analysis of Drug-use in Hospital of China</SO>
<YR>2004</YR>
<VL>4</VL>
<NO>2</NO>
<PG>110-11</PG>
<IDENTIFIERS MODIFIED="2009-04-18 23:08:46 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Qin-2005" MODIFIED="2009-05-26 10:06:40 +0100" MODIFIED_BY="[Empty name]" NAME="Qin 2005" YEAR="2005">
<REFERENCE MODIFIED="2009-05-26 10:06:40 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Qin Y, Kang W, Song L</AU>
<TI>A comparative study of risperidone combining alprazolam and clozapine in the treatment of patients with schizophrenia</TI>
<SO>Heath Psychology Journal</SO>
<YR>2005</YR>
<VL>13</VL>
<NO>6</NO>
<PG>444-5</PG>
<IDENTIFIERS MODIFIED="2009-04-18 23:08:51 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rapoport-1997" MODIFIED="2009-05-26 10:06:56 +0100" MODIFIED_BY="[Empty name]" NAME="Rapoport 1997" YEAR="1997">
<REFERENCE MODIFIED="2009-05-26 10:06:56 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Rapoport J, Kumra S, Jacobsen LK</AU>
<TI>The spectrum of extrapyramidal symptoms in children and young adults</TI>
<SO>Proceedings of the 150th Annual Meeting of the American Psychiatric Association; 1997 May 17-22; San Diego, California, USA</SO>
<YR>1997</YR>
<IDENTIFIERS MODIFIED="2009-04-18 23:08:54 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ren-2000" MODIFIED="2009-05-26 10:07:35 +0100" MODIFIED_BY="[Empty name]" NAME="Ren 2000" YEAR="2000">
<REFERENCE MODIFIED="2009-05-26 10:07:35 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ren JJ, Su JL, Li BQ</AU>
<TI>A study of risperidone and clozapine in treatment of resistant schizophrenia</TI>
<SO>Baotou Medical Journal</SO>
<YR>2000</YR>
<VL>35</VL>
<NO>2</NO>
<PG>6-7</PG>
<IDENTIFIERS MODIFIED="2009-04-18 23:08:59 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ren-2004" MODIFIED="2009-04-18 23:09:03 +0100" MODIFIED_BY="[Empty name]" NAME="Ren 2004" YEAR="2004">
<REFERENCE MODIFIED="2009-04-18 23:09:03 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ren k, Zhao X, Jiang X</AU>
<TI>Effects of risperidone and clozapine on life quality of schizophrenics</TI>
<SO>Journal of Clinical Psychosomatic Diseases</SO>
<YR>2004</YR>
<VL>10</VL>
<NO>1</NO>
<PG>3-4</PG>
<IDENTIFIERS MODIFIED="2009-04-18 23:09:03 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rettenbacher-2004" MODIFIED="2010-09-27 12:46:20 +0100" MODIFIED_BY="[Empty name]" NAME="Rettenbacher 2004" YEAR="2004">
<REFERENCE MODIFIED="2010-09-27 12:46:20 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rettenbacher MA, Baumgartner S, Ebenbichler C, Edlinger M, Hofer a, Hummer M, Kemmler G, Lechleitner M, Fleischhacker W</AU>
<TI>Alterations of glucose metabolism under treatment with clozapine vs. amisulpride</TI>
<SO>Schizophrenia Research</SO>
<YR>2004</YR>
<VL>67</VL>
<NO>1</NO>
<PG>191</PG>
<IDENTIFIERS MODIFIED="2009-04-18 23:09:07 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2009-05-26 10:08:03 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rettenbacher MA, Hummer M, Hofer A, Baumgartner S, Ebenbichler C, Edlinger M, Kemmler G, Lechleitner M, Fleischhacker WW</AU>
<TI>Alterations of glucose metabolism during treatment with clozapine or amisulpride: results from a prospective 16-week study</TI>
<SO>Journal of Psychopharmacology</SO>
<YR>2006</YR>
<VL>21</VL>
<NO>4</NO>
<PG>400-4</PG>
<IDENTIFIERS MODIFIED="2009-04-18 23:09:11 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Saletu-1987" MODIFIED="2009-04-18 23:09:16 +0100" MODIFIED_BY="[Empty name]" NAME="Saletu 1987" YEAR="1987">
<REFERENCE MODIFIED="2009-04-18 23:09:16 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Saletu B, Grunberger J, Linzmayer L, Anderer P</AU>
<TI>Comparative placebo-controlled pharmacodynamic studies with zotepine and clozapine utilizing pharmaco-EEG and psychometry</TI>
<SO>Pharmacopsychiatry</SO>
<YR>1987</YR>
<VL>20</VL>
<NO>Suppl 1</NO>
<PG>12-27</PG>
<IDENTIFIERS MODIFIED="2009-04-18 23:09:16 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Scherer-2004" MODIFIED="2010-09-27 12:46:40 +0100" MODIFIED_BY="[Empty name]" NAME="Scherer 2004" YEAR="2004">
<REFERENCE MODIFIED="2010-09-27 12:46:40 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Scherer H, Bedard M-A, Stip E, Paquet F, Richer F, Beriault M, Rodriguez J-P, Motard J-P</AU>
<TI>Procedural learning in schizophrenia can reflect the pharmacologic properties of the antipsychotic treatments</TI>
<SO>Cognitive and Behavioral Neurology</SO>
<YR>2004</YR>
<VL>17</VL>
<NO>1</NO>
<PG>32-40</PG>
<IDENTIFIERS MODIFIED="2009-04-18 23:09:19 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schlogelhofer-2006" MODIFIED="2009-05-26 10:09:36 +0100" MODIFIED_BY="[Empty name]" NAME="Schlogelhofer 2006" YEAR="2006">
<REFERENCE MODIFIED="2009-05-26 10:09:36 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Schlogelhofer M, Amminger GP, Werneck-Rohrer S, Aschauer HN, Edwards J</AU>
<TI>Emotion recognition deficit in first-episode schizophrenic patients and atypical antipsychotics</TI>
<SO>Proceedings of the 19th European College of Neuropsychopharmacology Congress; 2006 Sep 16-20; Paris, France</SO>
<YR>2006</YR>
<IDENTIFIERS MODIFIED="2009-04-18 23:09:24 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schuld-2000" MODIFIED="2009-04-18 23:09:35 +0100" MODIFIED_BY="[Empty name]" NAME="Schuld 2000" YEAR="2000">
<REFERENCE MODIFIED="2009-04-18 23:09:35 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schuld A, Kuhn M, Haack M, Kraus T, Hinze Selch D, Lechner C, Pollmacher T</AU>
<TI>A comparison of the effects of clozapine and olanzapine on the EEG in patients with schizophrenia</TI>
<SO>Pharmacopsychiatry</SO>
<YR>2000</YR>
<VL>33</VL>
<NO>3</NO>
<PG>109-11</PG>
<IDENTIFIERS MODIFIED="2009-04-18 23:09:35 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Shao-1999" MODIFIED="2010-09-27 12:47:02 +0100" MODIFIED_BY="[Empty name]" NAME="Shao 1999" YEAR="1999">
<REFERENCE MODIFIED="2010-09-27 12:47:02 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Shao YQ</AU>
<TI>The extrapyramidal side effects of risperidone</TI>
<SO>Journal of Southeast China National Defense Medicinal Science</SO>
<YR>1999</YR>
<VL>1</VL>
<NO>1</NO>
<PG>28-9</PG>
<IDENTIFIERS MODIFIED="2009-04-18 23:09:40 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sharma-2002" MODIFIED="2009-04-18 23:09:48 +0100" MODIFIED_BY="[Empty name]" NAME="Sharma 2002" YEAR="2002">
<REFERENCE MODIFIED="2009-04-18 23:09:48 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sharma T, Kumari V, Hughes C, Soni W, Mehrotra R, Binneman B</AU>
<TI>Cognitive effects of clozapine and olanzapine in patients with chronic schizophrenia</TI>
<SO>Schizophrenia Research</SO>
<YR>2002</YR>
<VL>53</VL>
<NO>3 Suppl 1</NO>
<PG>195</PG>
<PB>Elsevier Science B.V</PB>
<IDENTIFIERS MODIFIED="2009-04-18 23:09:48 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sheng-2003" MODIFIED="2010-09-27 12:47:19 +0100" MODIFIED_BY="[Empty name]" NAME="Sheng 2003" YEAR="2003">
<REFERENCE MODIFIED="2010-09-27 12:47:19 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sheng Y, Liu T, Li Y</AU>
<TI>A comparison study of the blood sugar in the treatment of schizophrenic patients with risperidone, clozapine and chlorpromazine</TI>
<SO>Qilu Journal of Medical Laboratory Sciences</SO>
<YR>2003</YR>
<VL>14</VL>
<NO>1</NO>
<PG>11-2</PG>
<IDENTIFIERS MODIFIED="2009-04-18 23:09:52 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sheng-2005" MODIFIED="2009-05-01 14:33:37 +0100" MODIFIED_BY="[Empty name]" NAME="Sheng 2005" YEAR="2005">
<REFERENCE MODIFIED="2009-05-01 14:33:37 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sheng Y</AU>
<TI>Effects of clozapine and risperidone on serum interleukin-2 and interleukin-6 of patients with first episode schizophrenia</TI>
<SO>Qilu Journal of Medical Laboratory Sciences</SO>
<YR>2005</YR>
<VL>16</VL>
<NO>5</NO>
<PG>14-5</PG>
<IDENTIFIERS MODIFIED="2009-04-18 23:09:56 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Shi-2000" MODIFIED="2010-09-27 12:47:30 +0100" MODIFIED_BY="[Empty name]" NAME="Shi 2000" YEAR="2000">
<REFERENCE MODIFIED="2010-09-27 12:47:30 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Shi F, Cheng X, Zhang Y</AU>
<TI>Controlled study of risperidone and clozapine in the treatment of schizophrenia</TI>
<SO>Shanghai Archives of Psychiatry</SO>
<YR>2000</YR>
<VL>12</VL>
<NO>1</NO>
<PG>27-9</PG>
<IDENTIFIERS MODIFIED="2009-04-18 23:09:59 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Shi-2001" MODIFIED="2009-05-26 10:10:59 +0100" MODIFIED_BY="[Empty name]" NAME="Shi 2001" YEAR="2001">
<REFERENCE MODIFIED="2009-05-26 10:10:59 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Shi XH</AU>
<TI>A study of risperidone and clozapine in treatment of schizophrenia</TI>
<SO>Medical Journal of Communications</SO>
<YR>2001</YR>
<VL>15</VL>
<NO>6</NO>
<PG>652-3</PG>
<IDENTIFIERS MODIFIED="2009-04-18 23:10:02 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Smith-2004" MODIFIED="2009-04-18 23:10:06 +0100" MODIFIED_BY="[Empty name]" NAME="Smith 2004" YEAR="2004">
<REFERENCE MODIFIED="2009-04-18 23:10:06 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Smith R</AU>
<TI>An addition of pioglitazone or placebo to 40 patients with schizophrenia under treatment with olanzapine or clozapine</TI>
<SO>Stanley Foundation Research Programs</SO>
<YR>2004</YR>
<IDENTIFIERS MODIFIED="2009-04-18 23:10:06 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Speer-1997" MODIFIED="2010-09-27 12:47:49 +0100" MODIFIED_BY="[Empty name]" NAME="Speer 1997" YEAR="1997">
<REFERENCE MODIFIED="2010-09-27 12:47:49 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Speer AM, Risch SC, Hamner MB, Molloy M, Ulmer HG, De Vane CL, Vincent DJ, George MS</AU>
<TI>The effect of an atypical antipsychotic (risperidone) on temporal lobe and prefrontal cortex activity in schizophrenia</TI>
<SO>Schizophrenia Research</SO>
<YR>1997</YR>
<VL>24</VL>
<NO>1, 2</NO>
<PG>173</PG>
<IDENTIFIERS MODIFIED="2009-04-18 23:10:13 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Su-1996" MODIFIED="2009-04-18 23:10:28 +0100" MODIFIED_BY="[Empty name]" NAME="Su 1996" YEAR="1996">
<REFERENCE MODIFIED="2009-04-18 23:10:25 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Su TP, Breier A, Coppola R, Hadd K, Elman I, Adler C, Malhotra AK, Watsky E, Gorey J, Weinberger D, Pickar D</AU>
<TI>D2 receptor occupancy in risperidone and clozapine-treated schizophrenics</TI>
<SO>Biological Psychiatry</SO>
<YR>1996</YR>
<VL>39</VL>
<PG>513-4</PG>
<IDENTIFIERS MODIFIED="2009-04-18 23:10:25 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2009-04-18 23:10:28 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Su TP, Malhotra AK, Hadd K, Breier A, Pickar D</AU>
<TI>D-2 dopamine receptor occupancy: a crossover comparison of risperidone with clozapine therapy in schizophrenic patients</TI>
<SO>Archives of General Psychiatry</SO>
<YR>1997</YR>
<VL>54</VL>
<NO>10</NO>
<PG>972-3</PG>
<IDENTIFIERS MODIFIED="2009-04-18 23:10:28 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sun-2001" MODIFIED="2009-05-26 10:12:03 +0100" MODIFIED_BY="[Empty name]" NAME="Sun 2001" YEAR="2001">
<REFERENCE MODIFIED="2009-05-26 10:12:03 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sun QZ, Liang JS, Yu GH, Huang X</AU>
<TI>A study of risperidone and clozapine in treatment of negative symptoms of resistant schizophrenia</TI>
<SO>Journal of Qiqihar Medical</SO>
<YR>2001</YR>
<VL>22</VL>
<NO>11</NO>
<PG>1247-8</PG>
<IDENTIFIERS MODIFIED="2009-04-18 23:10:32 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Swanson-2006" MODIFIED="2009-09-24 23:05:47 +0100" MODIFIED_BY="[Empty name]" NAME="Swanson 2006" YEAR="2006">
<REFERENCE MODIFIED="2009-09-24 23:01:20 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Swanson JW, Swartz MS, Van Dorn RA</AU>
<TI>Effectiveness of atypical antipsychotics for substance abuse in schizophrenia patients</TI>
<SO>Proceedings of the 159th Annual Meeting of the American Psychiatric Association; 2006 May 20-25, Toronto, Canada</SO>
<YR>2006</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tandon-2004" MODIFIED="2009-05-26 10:12:56 +0100" MODIFIED_BY="[Empty name]" NAME="Tandon 2004" YEAR="2004">
<REFERENCE MODIFIED="2009-05-26 10:12:26 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Octavio I, Tandon R, Stock E, Riera L, Kujawa M, Lam S, Pans M, Iwamoto T, Carson W</AU>
<TI>A naturalistic study of aripiprazole treatment in a general psychiatric setting</TI>
<SO>Proceedings of the Thematic Conference of the World Psychiatric Association on "Treatments in Psychiatry: An Update"; 2004 Nov 10-13; Florence, Italy</SO>
<YR>2004</YR>
<IDENTIFIERS MODIFIED="2009-04-18 23:10:39 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2009-04-18 23:10:43 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tandon R, Marcus RN, Stock EG, Riera LC, Kostic D, Pans M, McQuade RD, Nyilas M, Iwamoto T, Crandall DT</AU>
<TI>A prospective, multicenter, randomized, parallel-group, open-label study of aripiprazole in the management of patients with schizophrenia or schizoaffective disorder in general psychiatric practice: Broad Effectiveness Trial With Aripiprazole (BETA)</TI>
<SO>Schizophrenia Research</SO>
<YR>2006</YR>
<VL>84</VL>
<NO>1</NO>
<PG>77-89</PG>
<CY>Netherlands</CY>
<IDENTIFIERS MODIFIED="2009-04-18 23:10:43 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2009-05-26 10:12:56 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Tandon R, Stock E, Riera L, Kujawa M, Lam S, Pans M, Iwamoto T</AU>
<TI>A naturalistic trial with aripiprazole in a general psychiatric setting</TI>
<SO>Proceedings of the 157th Annual Meeting of the American Psychiatric Association; 2004 May 1-6; New York, New York, USA</SO>
<YR>2004</YR>
<IDENTIFIERS MODIFIED="2009-04-18 23:10:47 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tang-2003" MODIFIED="2009-04-18 23:10:51 +0100" MODIFIED_BY="[Empty name]" NAME="Tang 2003" YEAR="2003">
<REFERENCE MODIFIED="2009-04-18 23:10:51 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tang Y</AU>
<TI>A controlled study of schizophrenia treated with quetiapine and clozapine</TI>
<SO>Shanghai Archives of Psychiatry</SO>
<YR>2003</YR>
<VL>15</VL>
<NO>1</NO>
<PG>27-9</PG>
<IDENTIFIERS MODIFIED="2009-04-18 23:10:51 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tang-2005" MODIFIED="2009-05-26 10:13:10 +0100" MODIFIED_BY="[Empty name]" NAME="Tang 2005" YEAR="2005">
<REFERENCE MODIFIED="2009-05-26 10:13:10 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tang Z-K, Xu C-M, Chen D-C</AU>
<TI>A comparative study of quetiapine and clozapine in the treatment of recurrent schizophrenia</TI>
<SO>Shandong Archives of Psychiatry</SO>
<YR>2005</YR>
<VL>18</VL>
<NO>3</NO>
<PG>167-8</PG>
<IDENTIFIERS MODIFIED="2009-04-18 23:10:57 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tang-2005b" MODIFIED="2009-05-26 10:13:29 +0100" MODIFIED_BY="[Empty name]" NAME="Tang 2005b" YEAR="2005">
<REFERENCE MODIFIED="2009-04-18 23:11:01 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tang B, Lu Z, Zhou Z</AU>
<TI>A control study of ziprasidone vs clozapine in the treatment of refractory schizophrenia</TI>
<SO>Journal of Clinical Psychosomatic Diseases</SO>
<YR>2005</YR>
<VL>11</VL>
<NO>4</NO>
<PG>303-4</PG>
<IDENTIFIERS MODIFIED="2009-04-18 23:11:01 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tian-2005" MODIFIED="2009-05-26 10:13:53 +0100" MODIFIED_BY="[Empty name]" NAME="Tian 2005" YEAR="2005">
<REFERENCE MODIFIED="2009-05-26 10:13:53 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tian RF</AU>
<TI>A study of risperidone and clozapine in treatment of schizophrenia in children</TI>
<SO>Journal of Clinical Psychosomatic Diseases</SO>
<YR>2005</YR>
<VL>11</VL>
<NO>3</NO>
<PG>261</PG>
<IDENTIFIERS MODIFIED="2009-04-18 23:11:04 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tong-2005" MODIFIED="2009-05-26 10:14:18 +0100" MODIFIED_BY="[Empty name]" NAME="Tong 2005" YEAR="2005">
<REFERENCE MODIFIED="2009-05-26 10:14:18 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tong SN, Gan HQ, Liu YY</AU>
<TI>A study of clozapine and risperidone influencing on IQ and memory in schizophrenia</TI>
<SO>Chinese Journal of Behavioral Medical Science</SO>
<YR>2005</YR>
<VL>14</VL>
<NO>7</NO>
<PG>634</PG>
<IDENTIFIERS MODIFIED="2009-04-18 23:11:09 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Trichard-1998" MODIFIED="2009-04-18 23:11:13 +0100" MODIFIED_BY="[Empty name]" NAME="Trichard 1998" YEAR="1998">
<REFERENCE MODIFIED="2009-04-18 23:11:13 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Trichard C, Paillere Martinot ML, Attar Levy D, Recassens C, Monnet F, Martinot J L</AU>
<TI>Binding of antipsychotic drugs to cortical 5-HT(2A) receptors: A PET study of chlorpromazine, clozapine, and amisulpride in schizophrenic patients</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1998</YR>
<VL>155</VL>
<NO>4</NO>
<PG>505-8</PG>
<IDENTIFIERS MODIFIED="2009-04-18 23:11:13 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Turrone-2002" MODIFIED="2009-04-18 23:11:16 +0100" MODIFIED_BY="[Empty name]" NAME="Turrone 2002" YEAR="2002">
<REFERENCE MODIFIED="2009-04-18 23:11:16 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Turrone P, Kapur S, Seeman MV, Flint AJ</AU>
<TI>Elevation of prolactin levels by atypical antipsychotics</TI>
<SO>American Journal of Psychiatry</SO>
<YR>2002</YR>
<VL>159</VL>
<NO>1</NO>
<PG>133-5</PG>
<IDENTIFIERS MODIFIED="2009-04-18 23:11:16 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Vaughan-2000" MODIFIED="2009-04-18 23:11:21 +0100" MODIFIED_BY="[Empty name]" NAME="Vaughan 2000" YEAR="2000">
<REFERENCE MODIFIED="2009-04-18 23:11:21 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Vaughan K, McConaghy N, Wolf C, Myhr C, Black T</AU>
<TI>Community Treatment Orders: Relationship to clinical care, medication compliance, behavioural disturbance and readmission</TI>
<SO>Australian and New Zealand Journal of Psychiatry</SO>
<YR>2000</YR>
<VL>34</VL>
<NO>5</NO>
<PG>801-8</PG>
<IDENTIFIERS MODIFIED="2009-04-18 23:11:21 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wang-2002b" MODIFIED="2009-05-26 10:22:02 +0100" MODIFIED_BY="[Empty name]" NAME="Wang 2002b" YEAR="2002">
<REFERENCE MODIFIED="2009-05-26 10:19:50 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wang G, Chen Z, Wang H</AU>
<TI>Comparative study on quality of life of schizophrenics treated with risperidone or clozapine</TI>
<SO>Chinese Mental Health Journal</SO>
<YR>2002</YR>
<VL>16</VL>
<NO>3</NO>
<PG>200-2</PG>
<IDENTIFIERS MODIFIED="2009-04-18 23:11:41 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wang-2003" MODIFIED="2009-05-26 10:15:32 +0100" MODIFIED_BY="[Empty name]" NAME="Wang 2003" YEAR="2003">
<REFERENCE MODIFIED="2009-05-26 10:15:32 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wang J, Zhao J, Wang J</AU>
<TI>A comparative study of risperidone and clozapine on life quality of schizophrenia</TI>
<SO>Shandong Archires of Psychiatry</SO>
<YR>2003</YR>
<VL>16</VL>
<NO>3</NO>
<PG>149-50</PG>
<IDENTIFIERS MODIFIED="2009-04-18 23:11:25 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wang-2003b" MODIFIED="2009-05-26 10:22:25 +0100" MODIFIED_BY="[Empty name]" NAME="Wang 2003b" YEAR="2003">
<REFERENCE MODIFIED="2009-05-26 10:20:17 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wang JJ</AU>
<TI>A study of risperidone and clozapine with sulpiride in treatment of schizophrenia</TI>
<SO>Shandong Archives of Psychiatry</SO>
<YR>2003</YR>
<VL>16</VL>
<NO>4</NO>
<PG>234-35</PG>
<IDENTIFIERS MODIFIED="2009-04-18 23:11:49 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wang-2003c" MODIFIED="2009-05-26 10:22:50 +0100" MODIFIED_BY="[Empty name]" NAME="Wang 2003c" YEAR="2003">
<REFERENCE MODIFIED="2009-05-26 10:20:31 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wang K, Zhang K</AU>
<TI>A study of olanzapine and clozapine in the treatment of schizophrenia</TI>
<SO>Shandong Archires of Psychiatry</SO>
<YR>2003</YR>
<VL>16</VL>
<NO>03</NO>
<PG>141-3</PG>
<IDENTIFIERS MODIFIED="2009-04-18 23:12:11 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wang-2004" MODIFIED="2009-05-26 10:15:44 +0100" MODIFIED_BY="[Empty name]" NAME="Wang 2004" YEAR="2004">
<REFERENCE MODIFIED="2009-05-26 10:15:44 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wang X</AU>
<TI>Comparative study of effects of quetiapine and clozapine on quality of life of schizophrenics</TI>
<SO>Journal of Clinical Psychosomatic Diseases</SO>
<YR>2004</YR>
<VL>10</VL>
<NO>3</NO>
<PG>167-8</PG>
<IDENTIFIERS MODIFIED="2009-04-18 23:11:29 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wang-2004b" MODIFIED="2009-05-26 10:22:11 +0100" MODIFIED_BY="[Empty name]" NAME="Wang 2004b" YEAR="2004">
<REFERENCE MODIFIED="2009-05-26 10:20:00 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wang H</AU>
<TI>Controlled study of the effect of olanzapine and clozapine on electroencephalogram of schizophrenic patients</TI>
<SO>Journal of North China Coal Medical College</SO>
<YR>2004</YR>
<VL>6</VL>
<NO>3</NO>
<PG>289-90</PG>
<IDENTIFIERS MODIFIED="2009-04-18 23:11:45 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wang-2005" MODIFIED="2009-05-26 10:19:34 +0100" MODIFIED_BY="[Empty name]" NAME="Wang 2005" YEAR="2005">
<REFERENCE MODIFIED="2009-05-26 10:19:34 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wang Y, Sun M, Shao X</AU>
<TI>A comparative study between quetiapine and clozapine in the treatment of schizophrenia</TI>
<SO>Heath Psychology Journal</SO>
<YR>2005</YR>
<VL>13</VL>
<NO>4</NO>
<PG>271-2</PG>
<IDENTIFIERS MODIFIED="2009-04-18 23:11:33 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wang-2005b" MODIFIED="2009-05-26 10:21:50 +0100" MODIFIED_BY="[Empty name]" NAME="Wang 2005b" YEAR="2005">
<REFERENCE MODIFIED="2009-05-26 10:19:43 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wang C-H, Li Y, Ma J-D, Wang L-H, Pan M, Mu J-L</AU>
<TI>Comparison of cognitive function and p300 potentials in first-episode schizophrenia treated with risperidone and clozapine</TI>
<SO>Chinese Journal of Nervous and Mental Diseases</SO>
<YR>2005</YR>
<VL>31</VL>
<NO>4</NO>
<PG>267-71</PG>
<IDENTIFIERS MODIFIED="2009-04-18 23:11:37 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wang-2005c" MODIFIED="2009-05-26 10:22:40 +0100" MODIFIED_BY="[Empty name]" NAME="Wang 2005c" YEAR="2005">
<REFERENCE MODIFIED="2009-04-18 23:11:53 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wang J, Guo H, Yu X</AU>
<TI>Controlled studies of risperidone combined with clozapine in negative symptoms of schizophrenia</TI>
<SO>Journal of Clinical Psychosomatic Diseases</SO>
<YR>2005</YR>
<VL>11</VL>
<NO>3</NO>
<PG>225-7</PG>
<IDENTIFIERS MODIFIED="2009-04-18 23:11:53 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wang-2005d" MODIFIED="2009-05-26 10:23:05 +0100" MODIFIED_BY="[Empty name]" NAME="Wang 2005d" YEAR="2005">
<REFERENCE MODIFIED="2009-05-26 10:21:00 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wang SY, Liu Z, Bian J, Xu JG</AU>
<TI>The influence of risperidone in the quality of life in schizophrenia</TI>
<SO>Nervous Diseases and Mental Hygiene</SO>
<YR>2005</YR>
<VL>5</VL>
<NO>2</NO>
<PG>153-4</PG>
<IDENTIFIERS MODIFIED="2009-04-18 23:12:15 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wang-2005e" MODIFIED="2009-05-26 10:23:16 +0100" MODIFIED_BY="[Empty name]" NAME="Wang 2005e" YEAR="2005">
<REFERENCE MODIFIED="2009-05-26 10:21:27 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wang XF, Wang WH, Wang JQ</AU>
<TI>Analysis of quetiapine in treatment of first episode schizophrenia</TI>
<SO>Sichuan Mental Health</SO>
<YR>2005</YR>
<VL>18</VL>
<NO>4</NO>
<PG>235-6</PG>
<IDENTIFIERS MODIFIED="2009-04-18 23:12:19 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wang-2005f" MODIFIED="2009-05-26 10:23:27 +0100" MODIFIED_BY="[Empty name]" NAME="Wang 2005f" YEAR="2005">
<REFERENCE MODIFIED="2009-05-26 10:21:36 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wang Y-B, Xu H-C, Sun Y, Yang M-S, Wang X-H, Li Y-C</AU>
<TI>Effectiveness of olanzapine in treatment of schizophrenia</TI>
<SO>Journal of Clinical Psychological Medicine</SO>
<YR>2005</YR>
<VL>15</VL>
<NO>4</NO>
<PG>224-5</PG>
<IDENTIFIERS MODIFIED="2009-04-18 23:12:24 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Weickert-2003" MODIFIED="2009-04-18 23:12:29 +0100" MODIFIED_BY="[Empty name]" NAME="Weickert 2003" YEAR="2003">
<REFERENCE MODIFIED="2009-04-18 23:12:29 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Weickert TW, Goldberg TE, Marenco S, Bigelow LB, Egan MF, Weinberger DR</AU>
<TI>Comparison of cognitive performances during a placebo period and an atypical antipsychotic treatment period in schizophrenia: critical examination of confounds</TI>
<SO>Neuropyschopharmacology</SO>
<YR>2003</YR>
<VL>28</VL>
<NO>8</NO>
<PG>1491-500</PG>
<CY>United States of America</CY>
<IDENTIFIERS MODIFIED="2009-04-18 23:12:29 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Weng-1998" MODIFIED="2009-04-18 23:12:33 +0100" MODIFIED_BY="[Empty name]" NAME="Weng 1998" YEAR="1998">
<REFERENCE MODIFIED="2009-04-18 23:12:33 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Weng Y</AU>
<TI>A controlled trial of risperidone versus clozapine in the treatment of schizophrenia</TI>
<SO>Journal of Clinical Psychological Medicine</SO>
<YR>1998</YR>
<VL>8</VL>
<NO>2</NO>
<PG>83-5</PG>
<IDENTIFIERS MODIFIED="2009-04-18 23:12:33 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wirshing-1999" MODIFIED="2009-05-26 10:23:56 +0100" MODIFIED_BY="[Empty name]" NAME="Wirshing 1999" YEAR="1999">
<REFERENCE MODIFIED="2009-05-26 10:23:56 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Wirshing DA, Perkins V, Marder SR, Wirshing WC</AU>
<TI>Sexual side effects of atypical antipsychotic medications</TI>
<SO>Proceedings of the 152nd Annual Meeting of the American Psychiatric Association; 1999 May 15-20; Washington DC, USA</SO>
<YR>1999</YR>
<IDENTIFIERS MODIFIED="2009-04-18 23:12:38 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wu-2002" MODIFIED="2009-05-26 10:24:05 +0100" MODIFIED_BY="[Empty name]" NAME="Wu 2002" YEAR="2002">
<REFERENCE MODIFIED="2009-05-26 10:24:05 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wu L</AU>
<TI>A control study of risperidone and clozapine combination for the treatment of refractory schizophrenia</TI>
<SO>Health Psychology Journal</SO>
<YR>2002</YR>
<VL>10</VL>
<NO>2</NO>
<PG>135-7</PG>
<IDENTIFIERS MODIFIED="2009-04-18 23:12:41 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wu-2004" MODIFIED="2010-09-27 12:51:13 +0100" MODIFIED_BY="[Empty name]" NAME="Wu 2004" YEAR="2004">
<REFERENCE MODIFIED="2010-09-27 12:51:13 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wu JF, Li Z</AU>
<TI>A study of risperidone and clozapine in treatment of schizophrenia</TI>
<SO>Medical Journal of Chinese People Health</SO>
<YR>2004</YR>
<VL>16</VL>
<NO>4</NO>
<PG>213-14</PG>
<IDENTIFIERS MODIFIED="2009-04-18 23:12:48 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wudarsky-1999" MODIFIED="2009-04-18 23:12:54 +0100" MODIFIED_BY="[Empty name]" NAME="Wudarsky 1999" YEAR="1999">
<REFERENCE MODIFIED="2009-04-18 23:12:54 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wudarsky M, Nicolson R, Hamburger SD, Spechler L, Gochman P, Bedwell J, Lenane MC, Rapoport JL</AU>
<TI>Elevated prolactin in pediatric patients on typical and atypical antipsychotics</TI>
<SO>Journal of Child and Adolescent Psychopharmacology</SO>
<YR>1999</YR>
<VL>9</VL>
<NO>4</NO>
<PG>239-45</PG>
<IDENTIFIERS MODIFIED="2009-04-18 23:12:54 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Xiang-2005" MODIFIED="2009-04-18 23:12:57 +0100" MODIFIED_BY="[Empty name]" NAME="Xiang 2005" YEAR="2005">
<REFERENCE MODIFIED="2009-04-18 23:12:57 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Xiang D-F, Liu X-L</AU>
<TI>Treatment of 31 cases of schizophrenia with quetiapine</TI>
<SO>Herald of Medicine</SO>
<YR>2005</YR>
<VL>24</VL>
<NO>1</NO>
<PG>40-42</PG>
<IDENTIFIERS MODIFIED="2009-04-18 23:12:57 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Xiao-2000" MODIFIED="2009-06-17 09:16:21 +0100" MODIFIED_BY="[Empty name]" NAME="Xiao 2000" YEAR="2000">
<REFERENCE MODIFIED="2009-06-17 09:15:56 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Xiao XM, Song XC, Jiang HY</AU>
<TI>A study of risperidone and clozapine in treatment of schizophrenia</TI>
<SO>Journal of Clinicial Psychological Medicine</SO>
<YR>2000</YR>
<VL>10</VL>
<NO>4</NO>
<PG>229</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Xie-2005" MODIFIED="2009-05-26 10:28:05 +0100" MODIFIED_BY="[Empty name]" NAME="Xie 2005" YEAR="2005">
<REFERENCE MODIFIED="2009-05-26 10:28:05 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Xie B-Q, Wang Z-M, Han Q-L</AU>
<TI>A control study of risperidone and clozapine in the treatment the chronic schizophrenia</TI>
<SO>Shandong Archives of Psychiatry</SO>
<YR>2005</YR>
<VL>18</VL>
<NO>2</NO>
<PG>76-7</PG>
<IDENTIFIERS MODIFIED="2009-04-18 23:13:04 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Xin-2001" MODIFIED="2009-04-18 23:13:12 +0100" MODIFIED_BY="[Empty name]" NAME="Xin 2001" YEAR="2001">
<REFERENCE MODIFIED="2009-04-18 23:13:12 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Xin X, Du B, Zeng Z</AU>
<TI>A controlled clinical study of risperidone and low dose of clozapine in treating schizophrenia</TI>
<SO>Herald of Medicine</SO>
<YR>2001</YR>
<VL>8</VL>
<PG>501-2</PG>
<IDENTIFIERS MODIFIED="2009-04-18 23:13:12 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Xu-2001" MODIFIED="2009-05-26 10:28:19 +0100" MODIFIED_BY="[Empty name]" NAME="Xu 2001" YEAR="2001">
<REFERENCE MODIFIED="2009-05-26 10:28:19 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Xu C, Tang J, Zhang X</AU>
<TI>The effect of risperidone and clozapine treatment on serum interleukin 8, interleukin 15 in schizophrenia</TI>
<SO>Medical Journal of Chinese Civil Administration</SO>
<YR>2001</YR>
<VL>13</VL>
<NO>3</NO>
<PG>132-5</PG>
<IDENTIFIERS MODIFIED="2009-04-18 23:13:24 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Xu-2002" MODIFIED="2009-05-26 10:28:47 +0100" MODIFIED_BY="[Empty name]" NAME="Xu 2002" YEAR="2002">
<REFERENCE MODIFIED="2009-05-26 10:28:47 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Xu MQ, Peng HY</AU>
<TI>A study of quetiapine in treatment of schizophrenia</TI>
<SO>Journal of Clinical Psychological Medicine</SO>
<YR>2002</YR>
<VL>12</VL>
<NO>4</NO>
<PG>227-28</PG>
<IDENTIFIERS MODIFIED="2009-04-18 23:13:28 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yagdiran-2000" MODIFIED="2009-09-24 23:05:37 +0100" MODIFIED_BY="[Empty name]" NAME="Yagdiran 2000" YEAR="2000">
<REFERENCE MODIFIED="2009-09-24 23:01:28 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yagdiran O, Krausz M</AU>
<TI>Depressive symptoms under atypical neuroleptic treatment in schizophrenia</TI>
<SO>Nervenarzt</SO>
<YR>2000</YR>
<VL>71</VL>
<NO>Suppl 1</NO>
<PG>S135-36</PG>
<CY>Germany</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2009-09-24 23:01:28 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yagdiran O, Moritz S, Haasen C, Krausz M</AU>
<TI>Depressive symptoms among patients with schizophrenia treated with atypical antipsychotics</TI>
<SO>European Neuropsychopharmacology</SO>
<YR>2001</YR>
<VL>11</VL>
<NO>3</NO>
<PG>244</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yang-1998" MODIFIED="2009-04-18 23:13:32 +0100" MODIFIED_BY="[Empty name]" NAME="Yang 1998" YEAR="1998">
<REFERENCE MODIFIED="2009-04-18 23:13:32 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yang Z, Xu H, Song Y</AU>
<TI>A controlled study of efficacy of risperidone and clozapine on treating schizophrenia whose predominant clinical features were negative symptoms</TI>
<SO>Sichuan Mental Health</SO>
<YR>1998</YR>
<VL>11</VL>
<NO>3</NO>
<PG>151-2, 159</PG>
<IDENTIFIERS MODIFIED="2009-04-18 23:13:32 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yang-2002" MODIFIED="2009-05-26 10:29:38 +0100" MODIFIED_BY="[Empty name]" NAME="Yang 2002" YEAR="2002">
<REFERENCE MODIFIED="2009-05-26 10:29:38 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yang M, Wu BQ</AU>
<TI>A study of risperidone and clozapine in treatment of chronic schizophrenia</TI>
<SO>Medical Journal of Chinese Civil Administration</SO>
<YR>2002</YR>
<VL>14</VL>
<NO>6</NO>
<PG>350-51</PG>
<IDENTIFIERS MODIFIED="2009-04-18 23:13:36 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yang-2004" MODIFIED="2009-05-26 10:29:47 +0100" MODIFIED_BY="[Empty name]" NAME="Yang 2004" YEAR="2004">
<REFERENCE MODIFIED="2009-05-26 10:29:47 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yang B, Wang YD, Zhang L</AU>
<TI>Effects of clozapine, risperidone and haloperidol on plasma leptin in first-episode schizophrenic patients</TI>
<SO>Journal of The Fourth Military Medical University</SO>
<YR>2004</YR>
<VL>25</VL>
<NO>14</NO>
<PG>1323-25</PG>
<IDENTIFIERS MODIFIED="2009-04-18 23:13:40 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yang-L-2004" MODIFIED="2009-05-26 10:30:18 +0100" MODIFIED_BY="[Empty name]" NAME="Yang L 2004" YEAR="2004">
<REFERENCE MODIFIED="2009-05-26 10:30:18 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yang L, Yang QN, Hou YH, Liu T, Yan HL</AU>
<TI>The influence of antipsychotics on the ECG in schizophrenia</TI>
<SO>Journal of Applied Clinical Pediatrics</SO>
<YR>2004</YR>
<VL>19</VL>
<NO>12</NO>
<PG>1076-77</PG>
<IDENTIFIERS MODIFIED="2009-04-18 23:13:47 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yang-X-2004" MODIFIED="2009-05-26 10:30:39 +0100" MODIFIED_BY="[Empty name]" NAME="Yang X 2004" YEAR="2004">
<REFERENCE MODIFIED="2009-05-26 10:30:39 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yang XN, Mei QY</AU>
<TI>A study of risperidone with clonazepam in treatment of schizophrenia</TI>
<SO>Journal of Clinical Psychological Medicine</SO>
<YR>2004</YR>
<VL>14</VL>
<NO>3</NO>
<PG>163</PG>
<IDENTIFIERS MODIFIED="2009-04-18 23:13:50 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ye-2005" MODIFIED="2009-05-26 10:30:52 +0100" MODIFIED_BY="[Empty name]" NAME="Ye 2005" YEAR="2005">
<REFERENCE MODIFIED="2009-05-26 10:30:52 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ye S-C, Zhang W-Y, Zhang Y-M</AU>
<TI>Observation of developments of the level of serum prolactin of first-episode schizophrenia patients during the treatment</TI>
<SO>Medical Journal of Chinese People Health</SO>
<YR>2005</YR>
<VL>17</VL>
<NO>6</NO>
<PG>267-8</PG>
<IDENTIFIERS MODIFIED="2009-04-18 23:13:54 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yin-2004" MODIFIED="2010-09-27 12:53:31 +0100" MODIFIED_BY="[Empty name]" NAME="Yin 2004" YEAR="2004">
<REFERENCE MODIFIED="2010-09-27 12:53:31 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yin HR, Fang YM, Huang RH, Yang XQ</AU>
<TI>A study of risperidone and clozapine in treatment of schizophrenia</TI>
<SO>China Medical Engineering</SO>
<YR>2004</YR>
<VL>12</VL>
<NO>3</NO>
<PG>87-8</PG>
<IDENTIFIERS MODIFIED="2009-04-18 23:13:57 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yu-2002" MODIFIED="2009-04-18 23:14:04 +0100" MODIFIED_BY="[Empty name]" NAME="Yu 2002" YEAR="2002">
<REFERENCE MODIFIED="2009-04-18 23:14:04 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yu G, Ding G, Li X</AU>
<TI>An economic burden comparison of typical and atypical antipsychotic therapies for schizophrenia</TI>
<SO>Chinese Journal of Psychiatry</SO>
<YR>2002</YR>
<VL>35</VL>
<NO>3</NO>
<PG>177-9</PG>
<IDENTIFIERS MODIFIED="2009-04-18 23:14:04 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yuan-2002" MODIFIED="2009-05-26 10:32:00 +0100" MODIFIED_BY="[Empty name]" NAME="Yuan 2002" YEAR="2002">
<REFERENCE MODIFIED="2009-05-26 10:32:00 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yuan GZ, Huang YP, Li X</AU>
<TI>The influence of antipsychotics on the weight and glucose</TI>
<SO>Journal of Clinical Psychological Medicine</SO>
<YR>2002</YR>
<VL>12</VL>
<NO>6</NO>
<PG>369-70</PG>
<IDENTIFIERS MODIFIED="2009-04-18 23:14:08 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yuan-2005" MODIFIED="2009-05-26 10:32:07 +0100" MODIFIED_BY="[Empty name]" NAME="Yuan 2005" YEAR="2005">
<REFERENCE MODIFIED="2009-05-26 10:32:07 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yuan F-J, Gao M-Z, Liu X</AU>
<TI>A contrast observation of quetiapine and clozapine in affecting electroencephalogram</TI>
<SO>Journal of Practical Medical Techniques</SO>
<YR>2005</YR>
<VL>12</VL>
<NO>2B</NO>
<PG>482-4</PG>
<IDENTIFIERS MODIFIED="2009-04-18 23:14:11 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yuo-1999" MODIFIED="2009-05-26 10:32:31 +0100" MODIFIED_BY="[Empty name]" NAME="Yuo 1999" YEAR="1999">
<REFERENCE MODIFIED="2009-05-26 10:32:31 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yu GH, Huang X</AU>
<TI>A study of risperidone and clozapine in treatment of resistant patients in schizophrenia</TI>
<SO>Chinese Journal of Nervous and Mental Diseases</SO>
<YR>1999</YR>
<VL>25</VL>
<NO>6</NO>
<PG>366-67</PG>
<IDENTIFIERS MODIFIED="2009-04-18 23:14:14 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zelaschi-2000" MODIFIED="2009-05-26 10:32:43 +0100" MODIFIED_BY="[Empty name]" NAME="Zelaschi 2000" YEAR="2000">
<REFERENCE MODIFIED="2009-05-26 10:32:43 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Zelaschi NM, Rodriguez JL, Gaitan S, Panizzo S, Sobrera A, Lopez A, Archuby F</AU>
<TI>A follow-up study comparing clinical and endocrine effects of clozapine and risperidone</TI>
<SO>Proceedings of the 153rd Annual Meeting of the American Psychiatric Association; 2000 May 13-18; Chicago, Illinois, USA</SO>
<YR>2000</YR>
<IDENTIFIERS MODIFIED="2009-04-18 23:14:45 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zelaschi-2006" MODIFIED="2009-05-26 10:33:21 +0100" MODIFIED_BY="[Empty name]" NAME="Zelaschi 2006" YEAR="2006">
<REFERENCE MODIFIED="2009-05-26 10:33:21 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Zelaschi Sr NM, Rodriguez Sr JL, Gaitan S, Palacios Vallejos ME, Zieher LM</AU>
<TI>The effects of the switch of conventional neuroleptics to atypical antipsychotics: a follow-up study of patients with chronic schizophrenia</TI>
<SO>Proceedings of the 159th Annual Meeting of the American Psychiatric Association; 2006 May 20-25, Toronto, Canada</SO>
<YR>2006</YR>
<IDENTIFIERS MODIFIED="2009-04-18 23:14:51 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zhan-2002" MODIFIED="2009-05-26 10:33:38 +0100" MODIFIED_BY="[Empty name]" NAME="Zhan 2002" YEAR="2002">
<REFERENCE MODIFIED="2009-05-26 10:33:38 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zhan LY</AU>
<TI>Analysis of risperidone and clozapine in behavioral change in schizophrenia</TI>
<SO>Modern Rehabilitation</SO>
<YR>2002</YR>
<VL>6</VL>
<NO>19</NO>
<PG>2943</PG>
<IDENTIFIERS MODIFIED="2009-04-18 23:14:56 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zhang-2002" MODIFIED="2009-05-26 10:33:50 +0100" MODIFIED_BY="[Empty name]" NAME="Zhang 2002" YEAR="2002">
<REFERENCE MODIFIED="2009-05-26 10:33:50 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zhang Q</AU>
<TI>A comparison of cognitive function in the first-onset schizophrenia treated with risperidone and clozapine</TI>
<SO>Journal of Qiqihar Medical</SO>
<YR>2002</YR>
<VL>23</VL>
<NO>8</NO>
<PG>852-3</PG>
<IDENTIFIERS MODIFIED="2009-04-18 23:15:00 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zhang-2002b" MODIFIED="2009-05-26 10:37:28 +0100" MODIFIED_BY="[Empty name]" NAME="Zhang 2002b" YEAR="2002">
<REFERENCE MODIFIED="2009-05-26 10:35:59 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zhang X-Z, Yu J-L</AU>
<TI>Control studies of relapses between risperidone and clozapine in schizophrenia</TI>
<SO>Journal of Clinical Psychosomatic Diseases</SO>
<YR>2002</YR>
<VL>8</VL>
<NO>3</NO>
<PG>145-47</PG>
<IDENTIFIERS MODIFIED="2009-04-18 23:15:43 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zhang-2004" MODIFIED="2009-05-26 10:34:26 +0100" MODIFIED_BY="[Empty name]" NAME="Zhang 2004" YEAR="2004">
<REFERENCE MODIFIED="2009-05-26 10:34:26 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zhang HY, Lin QC, Lin JC, Guo YB</AU>
<TI>A study of olanzapine and clozapine in EEG</TI>
<SO>International Medicine &amp; Health Guidance News</SO>
<YR>2004</YR>
<VL>10</VL>
<NO>14</NO>
<PG>113-14</PG>
<IDENTIFIERS MODIFIED="2009-04-18 23:15:05 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zhang-2005" MODIFIED="2009-04-18 23:15:08 +0100" MODIFIED_BY="[Empty name]" NAME="Zhang 2005" YEAR="2005">
<REFERENCE MODIFIED="2009-04-18 23:15:08 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zhang Y, Jiang Y, Zhao S</AU>
<TI>A comparative study of quetiapine combined with clomipramine in treatment of schizophrenia with obsessive-compulsive symptoms</TI>
<SO>Heath Psychology Journal</SO>
<YR>2005</YR>
<VL>13</VL>
<NO>4</NO>
<PG>260-2</PG>
<IDENTIFIERS MODIFIED="2009-04-18 23:15:08 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zhang-2005b" MODIFIED="2009-05-26 10:36:34 +0100" MODIFIED_BY="[Empty name]" NAME="Zhang 2005b" YEAR="2005">
<REFERENCE MODIFIED="2009-05-26 10:34:50 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zhang H, Zhang M, Gu W</AU>
<TI>A comparative study of social function in schizophrenia patients treated with Seroquel (quetiapine) or clozapine</TI>
<SO>Sichuan Mental Health</SO>
<YR>2005</YR>
<VL>18</VL>
<NO>2</NO>
<PG>91-3</PG>
<IDENTIFIERS MODIFIED="2009-04-18 23:15:14 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zhang-2005c" MODIFIED="2009-05-26 10:36:46 +0100" MODIFIED_BY="[Empty name]" NAME="Zhang 2005c" YEAR="2005">
<REFERENCE MODIFIED="2009-05-26 10:35:08 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zhang HY, Zhan C</AU>
<TI>Cost efficiency analysis of four atypical antipsychotics in treatment of schizophrenia</TI>
<SO>Medical Journal of Chinese People Health</SO>
<YR>2005</YR>
<VL>17</VL>
<NO>12</NO>
<PG>756-7</PG>
<IDENTIFIERS MODIFIED="2009-04-18 23:15:18 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zhang-2005d" MODIFIED="2009-05-26 10:36:55 +0100" MODIFIED_BY="[Empty name]" NAME="Zhang 2005d" YEAR="2005">
<REFERENCE MODIFIED="2009-05-26 10:35:17 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zhang J-X, Zhu F-Y, Shi X-M, Zhang X-M, Wei Li-H, Ji Z-F, Lin R-M</AU>
<TI>Controlled study of risperidone versus clozapine in treatment of refractory schizophrenia with depressive symptoms</TI>
<SO>Journal of Clinical Psychological Medicine</SO>
<YR>2005</YR>
<VL>15</VL>
<NO>4</NO>
<PG>201-2</PG>
<IDENTIFIERS MODIFIED="2009-04-18 23:15:23 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zhang-2005e" MODIFIED="2009-05-26 10:37:03 +0100" MODIFIED_BY="[Empty name]" NAME="Zhang 2005e" YEAR="2005">
<REFERENCE MODIFIED="2009-05-26 10:35:42 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zhang M, Zhang H-F, Gu W</AU>
<TI>A comparative study of quetiapine and clozapine in the treatment of schizophrenia</TI>
<SO>Shandong Archives of Psychiatry</SO>
<YR>2005</YR>
<VL>18</VL>
<NO>2</NO>
<PG>86-8</PG>
<IDENTIFIERS MODIFIED="2009-04-18 23:15:28 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zhang-2005f" MODIFIED="2009-05-26 10:37:12 +0100" MODIFIED_BY="[Empty name]" NAME="Zhang 2005f" YEAR="2005">
<REFERENCE MODIFIED="2009-05-26 10:35:50 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zhang R-X, Cao Y-F</AU>
<TI>A comparative study of EKG changed by quetiapine and clozapine in the treatment of schizophrenia</TI>
<SO>Medical Journal of Chinese People Health</SO>
<YR>2005</YR>
<VL>17</VL>
<NO>6</NO>
<PG>290-1</PG>
<IDENTIFIERS MODIFIED="2009-04-18 23:15:32 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zhang-2005g" MODIFIED="2009-05-26 10:37:37 +0100" MODIFIED_BY="[Empty name]" NAME="Zhang 2005g" YEAR="2005">
<REFERENCE MODIFIED="2009-05-26 10:36:22 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zhang ZP, Xie YY</AU>
<TI>40 cases of olanzapine in treatment of schizophrenia</TI>
<SO>Shandong Medical Journal</SO>
<YR>2005</YR>
<VL>56</VL>
<PG>61</PG>
<IDENTIFIERS MODIFIED="2009-04-18 23:15:47 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zhao-2005" MODIFIED="2009-05-26 10:38:17 +0100" MODIFIED_BY="[Empty name]" NAME="Zhao 2005" YEAR="2005">
<REFERENCE MODIFIED="2009-05-26 10:38:17 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zhao YH, Fang JH, Wang SH, An CG, Ma X, Li HX</AU>
<TI>A study of quetiapine and clozapine in treatment of schizophrenia</TI>
<SO>Journal of Clinical Psychological Medicine</SO>
<YR>2005</YR>
<VL>15</VL>
<NO>4</NO>
<PG>231-2</PG>
<IDENTIFIERS MODIFIED="2009-04-18 23:15:52 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zheng-2001" MODIFIED="2009-05-26 10:38:39 +0100" MODIFIED_BY="[Empty name]" NAME="Zheng 2001" YEAR="2001">
<REFERENCE MODIFIED="2009-05-26 10:38:39 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zheng H, Xu CT</AU>
<TI>A clinical study of clozapine and olanzapine in treatment of resistant schizophrenia</TI>
<SO>Journal of Qiqihar Medical</SO>
<YR>2001</YR>
<VL>22</VL>
<NO>8</NO>
<PG>865</PG>
<IDENTIFIERS MODIFIED="2009-04-18 23:15:56 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zheng-2003" MODIFIED="2009-05-26 10:38:45 +0100" MODIFIED_BY="[Empty name]" NAME="Zheng 2003" YEAR="2003">
<REFERENCE MODIFIED="2009-05-26 10:38:45 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zheng YJ, Wang GH, Cheng ZL</AU>
<TI>Effects of clozapine and risperidone on the glucose metabolism in first-episode schizophrenic patients</TI>
<SO>Chinese Journal of Psychiatry</SO>
<YR>2003</YR>
<VL>36</VL>
<NO>4</NO>
<PG>207-10</PG>
<IDENTIFIERS MODIFIED="2009-04-18 23:15:59 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zheng-X-2001" MODIFIED="2009-05-26 10:39:12 +0100" MODIFIED_BY="[Empty name]" NAME="Zheng X 2001" YEAR="2001">
<REFERENCE MODIFIED="2009-05-26 10:39:12 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zheng XX, Huang JH, Huang ZZ</AU>
<TI>A study of risperidone and clozapine in treatment of side effects on schizophrenia</TI>
<SO>Strait Pharmaceutical Journal</SO>
<YR>2001</YR>
<VL>13</VL>
<NO>3</NO>
<PG>79-80</PG>
<IDENTIFIERS MODIFIED="2009-04-18 23:16:03 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zhong-2003" MODIFIED="2009-05-26 10:39:32 +0100" MODIFIED_BY="[Empty name]" NAME="Zhong 2003" YEAR="2003">
<REFERENCE MODIFIED="2009-05-26 10:39:32 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zhong H, Wang H</AU>
<TI>The influence of risperidone , chlorpromazine and clozapine on ECG</TI>
<SO>Journal of Gannan Medical College</SO>
<YR>2003</YR>
<VL>23</VL>
<NO>6</NO>
<PG>644-45</PG>
<IDENTIFIERS MODIFIED="2009-04-18 23:16:07 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zhou-2003" MODIFIED="2010-09-27 12:56:13 +0100" MODIFIED_BY="[Empty name]" NAME="Zhou 2003" YEAR="2003">
<REFERENCE MODIFIED="2010-09-27 12:56:13 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zhou P, Gong F, Fan C</AU>
<TI>A control of treating chronic schizophrenia with seroquel or clozapine</TI>
<SO>Jiangxi Medical Journal</SO>
<YR>2003</YR>
<VL>6</VL>
<PG>395-6</PG>
<IDENTIFIERS MODIFIED="2009-04-18 23:16:11 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zhou-2003b" MODIFIED="2009-05-26 10:40:26 +0100" MODIFIED_BY="[Empty name]" NAME="Zhou 2003b" YEAR="2003">
<REFERENCE MODIFIED="2009-05-26 10:40:15 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zhou HJ, Zhu YP, Lu SL</AU>
<TI>The influence of clozapine on glucose in schizophrenia</TI>
<SO>Liaoning Journal of Practical Diabetology</SO>
<YR>2003</YR>
<VL>11</VL>
<NO>1</NO>
<PG>21-22</PG>
<IDENTIFIERS MODIFIED="2009-04-18 23:16:19 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zhou-2005" MODIFIED="2009-04-18 23:16:15 +0100" MODIFIED_BY="[Empty name]" NAME="Zhou 2005" YEAR="2005">
<REFERENCE MODIFIED="2009-04-18 23:16:15 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zhou B, Tang Y, Zhu L</AU>
<TI>Effects of risperidone vs clozapine on blood-lipid of first-episode schizophrenia</TI>
<SO>Journal of Clinical Psychosomatic Diseases</SO>
<YR>2005</YR>
<VL>11</VL>
<NO>4</NO>
<PG>315-6</PG>
<IDENTIFIERS MODIFIED="2009-04-18 23:16:15 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zhu-1999" MODIFIED="2010-09-27 12:56:32 +0100" MODIFIED_BY="[Empty name]" NAME="Zhu 1999" YEAR="1999">
<REFERENCE MODIFIED="2010-09-27 12:56:32 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zhu X, Mei Q</AU>
<TI>A controlled study comparing drug compliance with risperidone and clozapine in treatment of schizophrenia</TI>
<SO>Journal of Clinical Psychological Medicine</SO>
<YR>1999</YR>
<VL>9</VL>
<NO>3</NO>
<PG>151-2</PG>
<IDENTIFIERS MODIFIED="2010-09-27 12:56:32 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zhu-2002" MODIFIED="2009-05-26 10:40:42 +0100" MODIFIED_BY="[Empty name]" NAME="Zhu 2002" YEAR="2002">
<REFERENCE MODIFIED="2009-05-26 10:40:42 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zhu H, Ma C, Hou J, Yin Q, Hu H, Guo Y</AU>
<TI>Study of serum IL-6 and a-IFN in the pre-and post-treatment of 68 patients with first episode schizophrenia</TI>
<SO>Chinese Journal of Nervous and Mental Diseases</SO>
<YR>2002</YR>
<VL>28</VL>
<NO>5</NO>
<PG>324-6</PG>
<IDENTIFIERS MODIFIED="2009-04-18 23:16:26 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zhu-2003" MODIFIED="2009-04-18 23:16:30 +0100" MODIFIED_BY="[Empty name]" NAME="Zhu 2003" YEAR="2003">
<REFERENCE MODIFIED="2009-04-18 23:16:30 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zhu F, Lin R, Zhang J</AU>
<TI>Risperidone versus clozapine in treatment-resistant schizophrenia:a randomized controlled study</TI>
<SO>Shanghai Archives of Psychiatry</SO>
<YR>2003</YR>
<VL>15</VL>
<NO>3</NO>
<PG>168-71</PG>
<IDENTIFIERS MODIFIED="2009-04-18 23:16:30 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zhu-Q-2003" MODIFIED="2009-05-26 10:41:12 +0100" MODIFIED_BY="[Empty name]" NAME="Zhu Q 2003" YEAR="2003">
<REFERENCE MODIFIED="2009-05-26 10:41:12 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zhu QY, Zhang SW</AU>
<TI>15 cases of risperidone in treatment of resistant schizophrenia</TI>
<SO>Herald of Medicine</SO>
<YR>2003</YR>
<VL>6</VL>
<NO>S1</NO>
<PG>13-14</PG>
<IDENTIFIERS MODIFIED="2009-04-18 23:16:34 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zoccali-2003" MODIFIED="2009-04-18 23:16:39 +0100" MODIFIED_BY="[Empty name]" NAME="Zoccali 2003" YEAR="2003">
<REFERENCE MODIFIED="2009-04-18 23:16:39 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zoccali R, Muscatello MR, Torre DL, Malara G, Canale A, Crucitti DDC, Spina E</AU>
<TI>Lack of a pharmacokinetic interaction between mirtazepine and the newer antipsychotics clozapine, risperidone and olanzapine in patients with chronic schizophrenia</TI>
<SO>Pharmacological Research</SO>
<YR>2003</YR>
<VL>48</VL>
<NO>4</NO>
<PG>411-4</PG>
<CY>England</CY>
<IDENTIFIERS MODIFIED="2009-04-18 23:16:39 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES MODIFIED="2010-09-27 12:58:09 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Anand-1999" MODIFIED="2009-04-18 23:16:52 +0100" MODIFIED_BY="[Empty name]" NAME="Anand 1999" YEAR="1999">
<REFERENCE MODIFIED="2009-04-18 23:16:52 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Anand R, Alphs L, Azorin JM, Remington G, Péré J-J, Bourdeix I</AU>
<TI>Superior efficacy of clozapine in chronic, severe schizophrenia: comparison with risperidone</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>1999</YR>
<VL>60</VL>
<NO>Suppl 12</NO>
<PG>3-50</PG>
<PB>Physicians Postgraduate Press Inc</PB>
<CY>USA</CY>
<IDENTIFIERS MODIFIED="2009-04-18 23:16:52 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Byerly-1999" NAME="Byerly 1999" YEAR="1999">
<REFERENCE PRIMARY="NO" TYPE="OTHER">
<AU>Byerly M, Weber M</AU>
<TI>Clozapine versus quetiapine for schizophrenia</TI>
<SO>Stanley Foundation Research Programs</SO>
<YR>1999</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chengappa-2001" MODIFIED="2010-09-27 12:57:52 +0100" MODIFIED_BY="[Empty name]" NAME="Chengappa 2001" YEAR="2001">
<REFERENCE MODIFIED="2010-09-27 12:57:52 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Chengappa KN</AU>
<TI>New antipsychotics-clinical trials and follow up</TI>
<SO>CRISP database (https://www-commons.cit.nih.gov/crisp/index.html)</SO>
<YR>(accessed 19th February 2001)</YR>
<IDENTIFIERS MODIFIED="2009-04-18 23:16:58 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chowdhury-1999" MODIFIED="2009-04-18 23:17:10 +0100" MODIFIED_BY="[Empty name]" NAME="Chowdhury 1999" YEAR="1999">
<REFERENCE MODIFIED="2009-04-18 23:17:10 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Chowdhury AN, Mukherjee A, Ghosh K, Chowdhury S, Das Sen K</AU>
<TI>Horizon of a new hope: Recovery of schizophrenia in India</TI>
<SO>International Medical Journal</SO>
<YR>1999</YR>
<VL>6</VL>
<NO>3</NO>
<PG>181-5</PG>
<IDENTIFIERS MODIFIED="2009-04-18 23:17:10 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Daniel-1996" MODIFIED="2010-09-27 12:58:09 +0100" MODIFIED_BY="[Empty name]" NAME="Daniel 1996" YEAR="1996">
<REFERENCE MODIFIED="2009-04-18 23:17:20 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Daniel D</AU>
<TI>Crossover comparison of risperidone and clozapine on clinical, cognitive, and side effect measures in treatment-resistant psychosis</TI>
<SO>Psychopharmacology Bulletin</SO>
<YR>1994</YR>
<VL>30</VL>
<NO>4</NO>
<PG>629</PG>
<IDENTIFIERS MODIFIED="2009-04-18 23:17:20 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2010-09-27 12:58:09 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Daniel DG, Goldberg TE, Lubick LJ, Weinberger DR, Kleinman JE, Pickar D, Williams TS</AU>
<TI>Self-reported cognitive impairment predicts patient preference between risperidone and clozapine</TI>
<SO>Schizophrenia Research</SO>
<YR>1995</YR>
<VL>15</VL>
<NO>1, 2</NO>
<PG>147-8</PG>
<CY>USA</CY>
<IDENTIFIERS MODIFIED="2009-04-18 23:17:23 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2009-04-18 23:17:26 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Daniel DG, Goldberg TE, Weinberger DR, Kleinman JE, Pickar D, Lubick LJ, Williams TS</AU>
<TI>Different side effect profiles of risperidone and clozapine in 20 outpatients with schizophrenia or schizoaffective disorder: a pilot study</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1996</YR>
<VL>153</VL>
<NO>3</NO>
<PG>417-9</PG>
<IDENTIFIERS MODIFIED="2009-04-18 23:17:26 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Estrella-1996" MODIFIED="2009-05-26 10:43:33 +0100" MODIFIED_BY="[Empty name]" NAME="Estrella 1996" YEAR="1996">
<REFERENCE MODIFIED="2009-05-26 10:43:33 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Estrella MH, Soria FL, Gonzalez CJC, Butron MAL, Torres JA, Escareño RR</AU>
<TI>Cost-effectiveness of clozapine vs risperidone for treatment-resistant schizophrenic patients</TI>
<SO>Proceedings of the 10th World Congress of Psychiatry; 1996 Aug 23-28; Madrid, Spain</SO>
<YR>1996</YR>
<IDENTIFIERS MODIFIED="2009-04-18 23:17:31 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lieberman-2001" MODIFIED="2009-05-26 10:44:29 +0100" MODIFIED_BY="[Empty name]" NAME="Lieberman 2001" YEAR="2001">
<REFERENCE MODIFIED="2009-05-26 10:44:29 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Lieberman JA</AU>
<TI>Risperidone and clozapine in chronic schizophrenia</TI>
<SO>CRISP database (https://www-commons.cit.nih.gov/crisp/index.html)</SO>
<YR>(accessed 19th February 2001)</YR>
<IDENTIFIERS MODIFIED="2009-04-18 23:17:40 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Loza-2002" MODIFIED="2009-04-18 23:17:46 +0100" MODIFIED_BY="[Empty name]" NAME="Loza 2002" YEAR="2002">
<REFERENCE MODIFIED="2009-04-18 23:17:46 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Loza B</AU>
<TI>Atypical antipsychotic treatment prognosis in first-episode paranoid schizophrenia based on syllabic and language-related dichotic listening scores</TI>
<SO>Journal of the European College of Neuropsychopharmacology</SO>
<YR>2002</YR>
<VL>12</VL>
<NO>Suppl 3</NO>
<PG>S298</PG>
<IDENTIFIERS MODIFIED="2009-04-18 23:17:46 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Magnuson-2001" MODIFIED="2009-05-26 10:44:47 +0100" MODIFIED_BY="[Empty name]" NAME="Magnuson 2001" YEAR="2001">
<REFERENCE MODIFIED="2009-05-26 10:44:47 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Magnuson WG</AU>
<TI>Childhood onset psychotic disorders:characterization and treatment with atypical neuroleptics / treatment of childhood onset psychotic disorders with olanzapine or clozapine</TI>
<SO>National Institutes of Health</SO>
<YR>2001</YR>
<IDENTIFIERS MODIFIED="2009-04-18 23:17:50 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Oliemeulen-2000" MODIFIED="2009-05-26 10:44:57 +0100" MODIFIED_BY="[Empty name]" NAME="Oliemeulen 2000" YEAR="2000">
<REFERENCE MODIFIED="2009-05-26 10:44:57 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Oliemeulen EAP, Van Hoof JJM, Jogem-Kosterman BJM, Hulsttijn W, Tuynman-Qua HG</AU>
<TI>Is olanzapine a substitute for clozapine? The effects on psychomotor performance</TI>
<SO>Schizophrenia Research</SO>
<YR>2000</YR>
<VL>41</VL>
<NO>1</NO>
<PG>187</PG>
<IDENTIFIERS MODIFIED="2009-04-18 23:17:53 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</AWAITING_STUDIES>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2010-09-27 13:37:29 +0100" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2010-09-27 13:37:29 +0100" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-ACP-2002" MODIFIED="2010-09-27 13:05:53 +0100" MODIFIED_BY="[Empty name]" NAME="ACP 2002" TYPE="OTHER">
<AU>Carpenter WT, Thaker K</AU>
<TI>Section 13 Psychiatry (VII. Schizophrenia) In schizophrenia: management</TI>
<SO>ACP Medicine Online ( www.acpmedicine.com/)</SO>
<YR>2002</YR>
<PB>The American College of Physicians and WebMD Professional Publishing</PB>
<MD>online version</MD>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Altman-1996" MODIFIED="2009-05-01 14:35:16 +0100" MODIFIED_BY="[Empty name]" NAME="Altman 1996" TYPE="JOURNAL_ARTICLE">
<AU>Altman DG, Bland JM</AU>
<TI>Detecting skewness from summary information</TI>
<SO>BMJ</SO>
<YR>1996</YR>
<VL>313</VL>
<PG>1200</PG>
<IDENTIFIERS MODIFIED="2009-04-18 23:18:25 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Andreasen-1984" MODIFIED="2010-09-27 13:36:49 +0100" MODIFIED_BY="[Empty name]" NAME="Andreasen 1984" TYPE="BOOK">
<AU>Andreasen NC</AU>
<SO>Scale for the Assessment of Positive Symptoms (SAPS)</SO>
<YR>1984</YR>
<PB>Univ. of Iowa</PB>
<CY>Iowa City</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Andreasen-1984b" MODIFIED="2010-09-27 13:37:29 +0100" MODIFIED_BY="[Empty name]" NAME="Andreasen 1984b" TYPE="BOOK">
<AU>Andreasen NC</AU>
<SO>Scale for the Assessment of Negative Symptoms (SANS)</SO>
<YR>1984</YR>
<PB>Univ. of Iowa</PB>
<CY>Iowa City</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-APA-1994" MODIFIED="2010-09-27 13:10:07 +0100" MODIFIED_BY="[Empty name]" NAME="APA 1994" TYPE="BOOK">
<AU>American Psychiatric Association</AU>
<SO>Diagnostic and Statistical Manual of Mental Disorders</SO>
<YR>1994</YR>
<EN>4th</EN>
<PB>American Psychiatric Association</PB>
<CY>Washington, DC</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Barnes-1989" MODIFIED="2009-05-26 10:58:00 +0100" MODIFIED_BY="[Empty name]" NAME="Barnes 1989" TYPE="JOURNAL_ARTICLE">
<AU>Barnes TR</AU>
<TI>A rating scale for drug-induced akathisia</TI>
<SO>British Journal of Psychiatry</SO>
<YR>1989</YR>
<VL>154</VL>
<PG>672-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Beaumont-2000" MODIFIED="2010-09-27 13:10:49 +0100" MODIFIED_BY="[Empty name]" NAME="Beaumont 2000" TYPE="JOURNAL_ARTICLE">
<AU>Beaumont G</AU>
<TI>Antipsychotics - The future of schizophrenia treatment</TI>
<SO>Current Medical Research and Opinion</SO>
<YR>2000</YR>
<VL>16</VL>
<NO>1</NO>
<PG>37-42</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Birchwood-1990" MODIFIED="2010-09-27 13:11:06 +0100" MODIFIED_BY="[Empty name]" NAME="Birchwood 1990" TYPE="JOURNAL_ARTICLE">
<AU>Birchwood M, Smith J, Cochrane R, Wetton S, Copestake S</AU>
<TI>The social functioning scale. The development and validation of a new scale of social adjustment for use in family intervention programmes with schizophrenic patients</TI>
<SO>British Journal of Psychiatry</SO>
<YR>1990</YR>
<VL>157</VL>
<PG>853-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bland-1997" NAME="Bland 1997" TYPE="JOURNAL_ARTICLE">
<AU>Bland JM, Kerry SM</AU>
<TI>Statistics notes. Trials randomised in clusters</TI>
<SO>BMJ</SO>
<YR>1997</YR>
<VL>315</VL>
<PG>600</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Boissel-1999" NAME="Boissel 1999" TYPE="JOURNAL_ARTICLE">
<AU>Boissel JP, Cucherat M, Li W, Chatellier G, Gueyffier F, Buyse M, Boutitie F, Nony P, Haugh M, Mignot G</AU>
<TI>The problem of therapeutic efficacy indices. 3. Comparison of the indices and their use</TI>
<SO>Therapie</SO>
<YR>1999</YR>
<VL>54</VL>
<NO>4</NO>
<PG>405-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Carpenter-1994" MODIFIED="2009-05-26 10:58:58 +0100" MODIFIED_BY="[Empty name]" NAME="Carpenter 1994" TYPE="JOURNAL_ARTICLE">
<AU>Carpenter WT Jr, Buchanan RW</AU>
<TI>Schizophrenia</TI>
<SO>New England Journal of Medicine</SO>
<YR>1994</YR>
<VL>330</VL>
<PG>681-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Chouinard-1980" MODIFIED="2010-09-27 13:13:07 +0100" MODIFIED_BY="[Empty name]" NAME="Chouinard 1980" TYPE="JOURNAL_ARTICLE">
<AU>Chouinard G, Ross-Chouinard A, Annable L, Jones BD</AU>
<TI>The extrapyramidal symptom rating scale</TI>
<SO>Canadian Journal of Neurological Sciences</SO>
<YR>1980</YR>
<VL>7</VL>
<PG>233</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Citrome-2002" MODIFIED="2009-05-26 10:59:11 +0100" MODIFIED_BY="[Empty name]" NAME="Citrome 2002" TYPE="JOURNAL_ARTICLE">
<AU>Citrome L, Bilder RM, Volavka J</AU>
<TI>Managing treatment-resistant schizophrenia: evidence from randomized clinical trials</TI>
<SO>Journal of psychiatric practice</SO>
<YR>2002</YR>
<VL>8</VL>
<NO>4</NO>
<PG>205-15</PG>
<IDENTIFIERS MODIFIED="2009-04-18 23:18:41 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Deeks-2000" MODIFIED="2009-05-26 10:59:30 +0100" MODIFIED_BY="[Empty name]" NAME="Deeks 2000" TYPE="CONFERENCE_PROC">
<AU>Deeks J</AU>
<TI>Issues in the selection for meta-analyses of binary data</TI>
<SO>Proceedings of the 8th International Cochrane Colloquium; 2000 Oct 25-28th; Cape Town, South Africa</SO>
<YR>2000</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-DerSimonian-1986" MODIFIED="2010-09-27 13:13:27 +0100" MODIFIED_BY="[Empty name]" NAME="DerSimonian 1986" TYPE="JOURNAL_ARTICLE">
<AU>DerSimonian R, Laird N</AU>
<TI>Meta-analysis in clinical trials</TI>
<SO>Controlled Clinical Trial</SO>
<YR>1986</YR>
<VL>7</VL>
<PG>177-88</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Divine-1992" NAME="Divine 1992" TYPE="JOURNAL_ARTICLE">
<AU>Divine GW, Brown JT, Frazer LM</AU>
<TI>The unit of analysis error in studies about physicians' patient care behavior</TI>
<SO>Journal of General Internal Medicine</SO>
<YR>1992</YR>
<VL>7</VL>
<PG>623-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Donner-2002" NAME="Donner 2002" TYPE="JOURNAL_ARTICLE">
<AU>Donner A, Klar N</AU>
<TI>Issues in the meta-analysis of cluster randomized trials</TI>
<SO>Statistics in Medicine</SO>
<YR>2002</YR>
<VL>21</VL>
<PG>2971-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Egger-1997" MODIFIED="2010-09-27 13:14:44 +0100" MODIFIED_BY="[Empty name]" NAME="Egger 1997" TYPE="JOURNAL_ARTICLE">
<AU>Egger M, Davey Smith G, Schneider M, Minder C</AU>
<TI>Bias in meta-analysis detected by a simple, graphical test</TI>
<SO>BMJ</SO>
<YR>1997</YR>
<VL>315</VL>
<NO>7109</NO>
<PG>629-34</PG>
<IDENTIFIERS MODIFIED="2010-09-27 13:14:44 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2010-09-27 13:14:44 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="9310563"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Elbourne-2002" MODIFIED="2010-09-27 13:15:20 +0100" MODIFIED_BY="[Empty name]" NAME="Elbourne 2002" TYPE="JOURNAL_ARTICLE">
<AU>Elbourne DR, Altman DG, Higgins JP, Curtin F, Worthington HV, Vail A</AU>
<TI>Meta-analyses involving cross-over trials: methodological issues</TI>
<SO>International Journal of Epidemiology</SO>
<YR>2002</YR>
<VL>31</VL>
<NO>1</NO>
<PG>140-9</PG>
<IDENTIFIERS MODIFIED="2010-09-27 13:15:20 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2010-09-27 13:15:20 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="11914310"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Fleischhaker-1989" MODIFIED="2010-09-27 13:15:43 +0100" MODIFIED_BY="[Empty name]" NAME="Fleischhaker 1989" TYPE="JOURNAL_ARTICLE">
<AU>Fleischhaker, W, Bergmann K, Perovich R</AU>
<TI>The hillside akathisia scale: a new rating instrument for neuroleptic-induced akathisia</TI>
<SO>Psychopharmacology Bulletin</SO>
<YR>1989</YR>
<VL>25</VL>
<PG>222-26</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Furukawa-2006" NAME="Furukawa 2006" TYPE="JOURNAL_ARTICLE">
<AU>Furukawa TA, Barbui C, Cipriani A, Brambilla P, Watanabe N</AU>
<TI>Imputing missing standard deviations in meta-analyses can provide accurate results</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>2006</YR>
<VL>59</VL>
<PG>7-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gaebel-1997" MODIFIED="2009-05-26 11:00:04 +0100" MODIFIED_BY="[Empty name]" NAME="Gaebel 1997" TYPE="JOURNAL_ARTICLE">
<AU>Gaebel W</AU>
<TI>Towards the improvement of compliance: the significance of psycho-education and new antipsychotic drugs</TI>
<SO>International Clinical Psychopharmacology</SO>
<YR>1997</YR>
<VL>12 Suppl 1</VL>
<PG>S37-42</PG>
<IDENTIFIERS MODIFIED="2009-04-18 23:18:50 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Gilbody-2000" MODIFIED="2010-09-27 13:16:07 +0100" MODIFIED_BY="[Empty name]" NAME="Gilbody 2000" TYPE="COCHRANE_REVIEW">
<AU>Gilbody SM, Bagnall AM, Duggan L, Tuunainen A</AU>
<TI>Risperidone versus other atypical antipsychotic medication for schizophrenia</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2000</YR>
<NO>3</NO>
<PB>John Wiley &amp; Sons</PB>
<CY>UK</CY>
<IDENTIFIERS MODIFIED="2010-09-27 13:16:07 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2010-09-27 13:16:07 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE=" 10.1002/14651858.CD002306"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Gulliford-1999" NAME="Gulliford 1999" TYPE="JOURNAL_ARTICLE">
<AU>Gulliford MC, Ukoumunne OC, Chinn S</AU>
<TI>Components of variance and intraclass correlations for the design of community-based surveys and intervention studies: data from the Health Survey for England 1994</TI>
<SO>American Journal of Epidemiology</SO>
<YR>1999</YR>
<VL>149</VL>
<PG>876-83</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Guy-1972" MODIFIED="2009-01-15 19:47:41 +0000" MODIFIED_BY="[Empty name]" NAME="Guy 1972" TYPE="BOOK">
<AU>Guy W</AU>
<SO>Early Clinical Drug Evaluation Unit (ECDEU) assessment manual for psychopharmacology. Publication no 76-338</SO>
<YR>1976</YR>
<PB>National Institute of Mental Health</PB>
<CY>Rockville, MD</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Heinisch-1991" MODIFIED="2009-05-26 11:00:35 +0100" MODIFIED_BY="[Empty name]" NAME="Heinisch 1991" TYPE="BOOK">
<AU>Heinisch M, Ludwig M, Bullinger M</AU>
<SO>Psychometric testing of the Münchner Lebensqualitäts Dimensionen Liste (MLDL)</SO>
<YR>1991</YR>
<PB>Hogrefe Verlag für Psychologie</PB>
<CY>Göttingen,Toronto, Zurich</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Heres-2006" NAME="Heres 2006" TYPE="JOURNAL_ARTICLE">
<AU>Heres S, Davis J, Maino K, Jetzinger E, Kissling W, Leucht S</AU>
<TI>Why olanzapine beats risperidone, risperidone beats quetiapine, and quetiapine beats olanzapine</TI>
<SO>American Journal of Psychiatry</SO>
<YR>2006</YR>
<VL>163</VL>
<PG>185-94</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2003" NAME="Higgins 2003" TYPE="JOURNAL_ARTICLE">
<AU>Higgins JPT, Thompson SG, Deeks JJ, Altman DG</AU>
<TI>Measuring inconsistency in meta-analyses</TI>
<SO>BMJ</SO>
<YR>2003</YR>
<VL>327</VL>
<PG>557-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2009" MODIFIED="2010-09-27 13:18:01 +0100" MODIFIED_BY="[Empty name]" NAME="Higgins 2009" TYPE="OTHER">
<AU>Higgins JPT, Green S</AU>
<TI>Cochrane Handbook for Systematic Reviews of Interventions 5.0.2 [updated September 2009] The Cochrane Collaboration, 2009</TI>
<SO>Available from www.cochrane-handbook.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hogan-1983" MODIFIED="2009-05-26 11:01:43 +0100" MODIFIED_BY="[Empty name]" NAME="Hogan 1983" TYPE="JOURNAL_ARTICLE">
<AU>Hogan TP, Awad AG, Eastwood MR</AU>
<TI>A self-report scale predictive of drug compliance in schizophrenics: reliability and discriminative validity</TI>
<SO>Psychological Medicine</SO>
<YR>1983</YR>
<VL>13</VL>
<PG>177-83</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Id_x00e4_np_x00e4__x00e4_n_x002d_-He.1977" MODIFIED="2009-05-26 11:01:55 +0100" MODIFIED_BY="[Empty name]" NAME="Idänpään- He.1977" TYPE="JOURNAL_ARTICLE">
<AU>Idänpään- Heikkilä J, Alhava E, Olkinuora M, Palva IP</AU>
<TI>Agranulocytosis during treatment with clozapine</TI>
<SO>European Journal of Clinical Pharmacology</SO>
<YR>1977</YR>
<VL>11</VL>
<NO>3</NO>
<PG>193-98</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kane-1988" MODIFIED="2009-05-26 11:02:04 +0100" MODIFIED_BY="[Empty name]" NAME="Kane 1988" TYPE="JOURNAL_ARTICLE">
<AU>Kane J, Honigfeld G, Singer J, Meltzer H</AU>
<TI>Clozapine for the treatment resistant schizophrenic: a double-blind comparison with chlorpromazine</TI>
<SO>Archives of General Psychiatry</SO>
<YR>1988</YR>
<VL>45</VL>
<NO>9</NO>
<PG>789-96</PG>
<IDENTIFIERS MODIFIED="2009-04-18 23:19:36 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Kane-1990" MODIFIED="2009-05-26 11:08:01 +0100" MODIFIED_BY="[Empty name]" NAME="Kane 1990" TYPE="JOURNAL_ARTICLE">
<AU>Kane JM</AU>
<TI>Treatment programme and long term outcome in chronic schizophrenia</TI>
<SO>Acta Psychiatrica Scandinavica Supplementum</SO>
<YR>1990</YR>
<VL>358</VL>
<PG>151-7</PG>
<IDENTIFIERS MODIFIED="2009-04-18 23:19:40 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Kane-2006" MODIFIED="2009-05-26 11:02:56 +0100" MODIFIED_BY="[Empty name]" NAME="Kane 2006" TYPE="JOURNAL_ARTICLE">
<AU>Kane JM, Khanna S, Rajadhyaksha S, Giller E</AU>
<TI>Efficacy and tolerability of ziprasidone in patients with treatment-resistant schizophrenia</TI>
<SO>International Clinical Psychopharmacology</SO>
<YR>2006</YR>
<VL>21</VL>
<NO>1</NO>
<PG>21-28</PG>
<IDENTIFIERS MODIFIED="2009-04-18 23:19:42 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Kay-1986" NAME="Kay 1986" TYPE="BOOK">
<AU>Kay SR, Opler LA, Fiszbein A</AU>
<SO>Positive and negative syndrome scale (PANSS) manual</SO>
<YR>1986</YR>
<PB>Multi-Health Systems</PB>
<CY>North Tonawanda (NY)</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lehman-2004" MODIFIED="2010-09-27 13:21:02 +0100" MODIFIED_BY="[Empty name]" NAME="Lehman 2004" TYPE="JOURNAL_ARTICLE">
<AU>Lehman AF, Lieberman JA, Dixon LB, McGlashan TH, Miller AL, Perkins DO, Kreyenbuhl J; American Psychiatric Association; Steering Committee on Practice Guidelines</AU>
<TI>Practice guideline for the treatment of patients with schizophrenia, second edition</TI>
<SO>American Journal of Psychiatry</SO>
<YR>2004</YR>
<VL>161</VL>
<NO>2 Suppl</NO>
<PG>1-56</PG>
<IDENTIFIERS MODIFIED="2010-09-27 13:20:58 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2010-09-27 13:20:58 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="15000267"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Leucht-2005a" NAME="Leucht 2005a" TYPE="JOURNAL_ARTICLE">
<AU>Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel R</AU>
<TI>What does the PANSS mean?</TI>
<SO>Schizophrenia Research</SO>
<YR>2005</YR>
<VL>79</VL>
<PG>231-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Leucht-2005b" NAME="Leucht 2005b" TYPE="JOURNAL_ARTICLE">
<AU>Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel R</AU>
<TI>Clinical implications of Brief Psychiatric Rating Scale Scores</TI>
<SO>British Journal of Psychiatry</SO>
<YR>2005</YR>
<VL>187</VL>
<PG>366-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Leucht-2008" MODIFIED="2009-04-19 01:18:46 +0100" MODIFIED_BY="[Empty name]" NAME="Leucht 2008" TYPE="JOURNAL_ARTICLE">
<AU>Leucht S, Komossa K, Rummel-Kluge C, Corves C, Hunger H, Schmid F, Asenjo Lobos C, Schwarz S, Davis JM</AU>
<TI>A meta-analysis of head-to-head comparisons of second generation antipsychotics in the treatment of schizophrenia</TI>
<SO>American Journal of Psychiatry</SO>
<YR>2008</YR>
<VL>166</VL>
<NO>2</NO>
<PG>152-63</PG>
<IDENTIFIERS MODIFIED="2009-04-18 23:19:50 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Marshall-2000" NAME="Marshall 2000" TYPE="JOURNAL_ARTICLE">
<AU>Marshall M, Lockwood A, Adams C, Bradley C, Joy C, Fenton M</AU>
<TI>Unpublished rating scales - a major source of bias in randomised controlled trials of treatments for schizophrenia?</TI>
<SO>British Journal of Psychiatry</SO>
<YR>2000</YR>
<VL>176</VL>
<PG>249-52</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-McEvoy-2006" MODIFIED="2009-05-26 11:03:47 +0100" MODIFIED_BY="[Empty name]" NAME="McEvoy 2006" TYPE="JOURNAL_ARTICLE">
<AU>McEvoy JP, Lieberman JA, Stroup TS, Davis SM, Meltzer HY, Rosenheck RA, Swartz MS, Perkins DO, Keefe RS, Davis CE, Severe J, Hsiao JK</AU>
<TI>Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment</TI>
<SO>American Journal of Psychiatry</SO>
<YR>2006</YR>
<VL>163</VL>
<NO>4</NO>
<PG>600-10</PG>
<IDENTIFIERS MODIFIED="2009-04-18 23:19:55 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Miyamoto-2005" MODIFIED="2009-04-18 23:21:12 +0100" MODIFIED_BY="[Empty name]" NAME="Miyamoto 2005" TYPE="JOURNAL_ARTICLE">
<AU>Miyamoto S, Duncan GE, Marx CE, Lieberman JA</AU>
<TI>Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs</TI>
<SO>Molecular Psychiatry</SO>
<YR>2005</YR>
<VL>10</VL>
<NO>1</NO>
<PG>79-104</PG>
<IDENTIFIERS MODIFIED="2009-04-18 23:19:58 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Moher-2001" MODIFIED="2009-04-18 23:20:01 +0100" MODIFIED_BY="[Empty name]" NAME="Moher 2001" TYPE="JOURNAL_ARTICLE">
<AU>Moher D, Schulz KF, Altman DG</AU>
<TI>The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials</TI>
<SO>Lancet</SO>
<YR>2001</YR>
<VL>357</VL>
<NO>9263</NO>
<PG>1191-4</PG>
<IDENTIFIERS MODIFIED="2009-04-18 23:20:01 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Mueser-2004" MODIFIED="2010-09-27 13:22:53 +0100" MODIFIED_BY="[Empty name]" NAME="Mueser 2004" TYPE="JOURNAL_ARTICLE">
<AU>Mueser KT, McGurk SR</AU>
<TI>Schizophrenia</TI>
<SO>Lancet</SO>
<YR>2004</YR>
<VL>363</VL>
<NO>9426</NO>
<PG>2063-72</PG>
<IDENTIFIERS MODIFIED="2010-09-27 13:22:53 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2010-09-27 13:22:53 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="15207959"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Naber-1995" MODIFIED="2009-05-26 11:04:16 +0100" MODIFIED_BY="[Empty name]" NAME="Naber 1995" TYPE="JOURNAL_ARTICLE">
<AU>Naber D</AU>
<TI>A self-rating to measure subjective effects of neuroleptic drugs, relationships to objective psychopathology, quality of life, compliance and other clinical variables</TI>
<SO>International Clinical Psychopharmacology</SO>
<YR>1995</YR>
<VL>10</VL>
<NO>Suppl 3</NO>
<PG>133-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Naheed-2001" MODIFIED="2009-05-26 11:04:39 +0100" MODIFIED_BY="[Empty name]" NAME="Naheed 2001" TYPE="JOURNAL_ARTICLE">
<AU>Naheed M, Green B</AU>
<TI>Focus on clozapine</TI>
<SO>Current Medical Research and Opinion</SO>
<YR>2001</YR>
<VL>17</VL>
<NO>3</NO>
<PG>223-9</PG>
<IDENTIFIERS MODIFIED="2009-04-18 23:20:10 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-NIMH-1975" MODIFIED="2010-09-27 13:24:13 +0100" MODIFIED_BY="[Empty name]" NAME="NIMH 1975" TYPE="JOURNAL_ARTICLE">
<AU>National Institute of Mental Health; Psychopharmacology Research Branch</AU>
<TI>Development of a dyskinetic movement scale. Early clinical drug evaluation unit</TI>
<SO>Intercom</SO>
<YR>1975</YR>
<VL>3</VL>
<PG>3-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-O_x0027_Brien-2004" MODIFIED="2009-05-26 11:04:56 +0100" MODIFIED_BY="[Empty name]" NAME="O'Brien 2004" TYPE="JOURNAL_ARTICLE">
<AU>O'Brien A</AU>
<TI>Starting clozapine in the community: a UK perspective</TI>
<SO>CNS Drugs</SO>
<YR>2004</YR>
<VL>18</VL>
<NO>13</NO>
<PG>845-52</PG>
<IDENTIFIERS MODIFIED="2009-04-18 23:20:15 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Overall-1962" MODIFIED="2010-09-27 13:24:57 +0100" MODIFIED_BY="[Empty name]" NAME="Overall 1962" TYPE="JOURNAL_ARTICLE">
<AU>Overall JE, Gorham DR</AU>
<TI>The brief psychiatric rating scale</TI>
<SO>Psychological Reports</SO>
<YR>1962</YR>
<VL>10</VL>
<PG>799-812</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rust-1989" MODIFIED="2009-09-19 22:07:56 +0100" MODIFIED_BY="[Empty name]" NAME="Rust 1989" TYPE="BOOK">
<AU>Rust J, Golombok S</AU>
<SO>Modern Psychometrics</SO>
<YR>1989</YR>
<PB>Routledge</PB>
<CY>London</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Simpson-1970" MODIFIED="2009-05-26 11:05:25 +0100" MODIFIED_BY="[Empty name]" NAME="Simpson 1970" TYPE="JOURNAL_ARTICLE">
<AU>Simpson EN, Angus JWF</AU>
<TI>A rating scale for extrapyramidal side-effects</TI>
<SO>Acta Physiologica Scandinavica Supplementum</SO>
<YR>1970</YR>
<VL>212</VL>
<PG>11-19</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Stroup-2003" MODIFIED="2010-09-27 13:26:55 +0100" MODIFIED_BY="[Empty name]" NAME="Stroup 2003" TYPE="JOURNAL_ARTICLE">
<AU>Stroup S, McEvoy J, Swartz MS, Byerly M, Glick I, Canive J, McGee MF, Simpson GM, Stevens MC,Lieberman JA</AU>
<TI>The national institute of mental health clinical antipsychotic trial of intervention effectiveness (CATIE) project: Schizophrenia trial design and protocol development</TI>
<SO>Schizophrenia Bulletin</SO>
<YR>2003</YR>
<VL>29</VL>
<NO>1</NO>
<PG>15-31</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ukoumunne-1999" MODIFIED="2009-04-18 23:20:23 +0100" MODIFIED_BY="[Empty name]" NAME="Ukoumunne 1999" TYPE="JOURNAL_ARTICLE">
<AU>Ukoumunne OC, Gulliford MC, Chinn S, Sterne JAC, Burney PGJ</AU>
<TI>Methods for evaluating area-wide and organisation-based interventions in health and health care: a systematic review</TI>
<SO>Health Technology Assessment</SO>
<YR>1999</YR>
<VL>3</VL>
<NO>5</NO>
<PG>iii-92</PG>
<IDENTIFIERS MODIFIED="2009-04-18 23:20:23 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Van-Os-2006" MODIFIED="2010-09-27 13:27:09 +0100" MODIFIED_BY="[Empty name]" NAME="Van Os 2006" TYPE="JOURNAL_ARTICLE">
<AU>Van Os J, Drukker M, à Campo J, Meijer J, Bak M, Delespaul P</AU>
<TI>Validation of remission criteria for schizophrenia</TI>
<SO>American Journal of Psychiatry</SO>
<YR>2006</YR>
<VL>163</VL>
<NO>11</NO>
<PG>2000-2</PG>
<IDENTIFIERS MODIFIED="2009-04-18 23:20:26 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-van-Os-2009" MODIFIED="2010-09-27 13:27:48 +0100" MODIFIED_BY="[Empty name]" NAME="van Os 2009" TYPE="JOURNAL_ARTICLE">
<AU>Van Os J, Kapur S</AU>
<TI>Schizophrenia</TI>
<SO>Lancet</SO>
<YR>2009</YR>
<VL>374</VL>
<NO>9690</NO>
<PG>635-45</PG>
<IDENTIFIERS MODIFIED="2010-09-27 13:27:48 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2010-09-27 13:27:48 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="19700006"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Wahlbeck-1999" MODIFIED="2010-09-27 13:27:55 +0100" MODIFIED_BY="[Empty name]" NAME="Wahlbeck 1999" TYPE="COCHRANE_REVIEW">
<AU>Wahlbeck K, Cheine MV, Essali A</AU>
<TI>Clozapine versus typical neuroleptic medication for schizophrenia</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>1999</YR>
<NO>4</NO>
<PB>John Wiley &amp; Sons, Ltd</PB>
<CY>UK</CY>
<IDENTIFIERS MODIFIED="2010-09-27 13:27:55 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2010-09-27 13:27:55 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD000059"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-WHO-1998" MODIFIED="2010-09-27 13:28:06 +0100" MODIFIED_BY="[Empty name]" NAME="WHO 1998" TYPE="OTHER">
<AU>Barbato A</AU>
<TI>Schizophrenia and public health</TI>
<SO>Division of Mental Health and Prevention of Substance Abuse. World Health Organization</SO>
<YR>1998</YR>
<PG>1-32</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2010-09-27 13:28:22 +0100" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Tuunainen-2000" MODIFIED="2010-09-27 13:28:22 +0100" MODIFIED_BY="[Empty name]" NAME="Tuunainen 2000" TYPE="COCHRANE_REVIEW">
<AU>Tuunainen A, Wahlbeck K, Gilbody SM</AU>
<TI>Newer atypical antipsychotic medication versus clozapine for schizophrenia</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2000</YR>
<NO>2</NO>
<PB>John Wiley &amp; Sons</PB>
<CY>Chichester,UK</CY>
<IDENTIFIERS MODIFIED="2010-09-27 13:28:22 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2010-09-27 13:28:22 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD000966"/>
</IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2010-10-06 09:51:29 +0100" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2010-10-06 09:51:29 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2010-10-05 11:56:42 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Atmaca-2003">
<CHAR_METHODS MODIFIED="2009-09-24 23:07:16 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Blindness: single, rater-blinded.<BR/>Duration: 6 weeks.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-10-05 11:36:42 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis: (DSM-IV) schizophrenia.<BR/>N=56.<BR/>Age: 19-46 years (mean clozapine=31.3 years, mean olanzapine=29.6 years, mean quetiapine=30.1 years, mean risperidone=27.9 years, mean control group=32.1 years).<BR/>Gender: 24 M, 29 F.<BR/>Setting: inpatient.<BR/>History: duration ill mean clozapine=6.6 years, mean olanzapine=6.3 years, mean quetiapine=5.9 years, mean risperidone=5.6, age at onset not reported.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-10-05 11:53:33 +0100" MODIFIED_BY="[Empty name]">
<P>1. Clozapine: flexible dose. Allowed dose range: not reported. Mean dose: 207.1 mg/day. N=14.<BR/>2. Olanzapine: flexible dose. Allowed dose range: not reported. Mean dose: 15.7 mg/day. N=14.<BR/>3. Quetiapine: flexible dose. Allowed dose range: not reported. Mean dose: 535.7 mg/day. N=14.<BR/>4. Risperidone: flexible dose. Allowed dose range: not reported. Mean dose: 6.7 mg/day. N=14.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-10-05 11:56:42 +0100" MODIFIED_BY="[Empty name]">
<P>Leaving the study early: any reason.<BR/>Mental state: PANSS total score.<BR/>Adverse effects: use of antiparkinson medication, extrapyramidal side effects, lipid change, weight change.<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-10-05 11:40:39 +0100" MODIFIED_BY="[Empty name]">
<P>There was a control group (N=11) (not randomised) receiving no pharmacologic treatment.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-10-05 11:56:27 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Azorin-2001">
<CHAR_METHODS MODIFIED="2009-09-24 23:07:57 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Blindness: double.<BR/>Duration: 12 weeks.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-10-05 11:41:31 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis: (DSM-IV) schizophrenia disorganised, catatonic, paranoid, residual or undifferentiated.<BR/>N=273.<BR/>Age: 18-65 years (mean clozapine=37.8, mean risperidone=39.5) (of intent-to-treat population).<BR/>Gender: 182 M, 74 F (of intent-to-treat population, N=256).<BR/>Setting: in- and outpatient.<BR/>History: duration ill mean clozapine=13.0 years, mean risperidone=15.5 years (of intent-to-treat population), age at onset not reported.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-08-14 14:50:41 +0100" MODIFIED_BY="[Empty name]">
<P>1. Clozapine: flexible dose. Allowed dose range: 200-900 mg/day. Mean dose: 642 mg/day. N=138.<BR/>2. Risperidone: flexible dose. Allowed dose range: 2-15 mg/day. Mean dose: 9 mg/day. N=135.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-10-05 11:56:27 +0100" MODIFIED_BY="[Empty name]">
<P>Death.<BR/>Leaving the study early: any reason, adverse events, inefficacy.<BR/>Global state: CGI.<BR/>Mental state: PANSS total score, BPRS total score, PANSS positive and negative subscore.<BR/>Adverse effects: at least one adverse effect, extrapyramidal side-effects, sedation, seizures, weight gain, white blood cell count.<BR/>
<BR/>Unable to use:<BR/>Change of weight (no SD).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-09-24 23:07:58 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-10-05 11:56:18 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bitter-2004">
<CHAR_METHODS MODIFIED="2009-09-24 23:08:46 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Blindness: double.<BR/>Duration: 18 weeks.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-09-24 23:08:46 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis: (DSM-IV) schizophrenia, non-response to, or intolerance of, standard antipsychotic therapy.<BR/>N=147.<BR/>Age: 18-65 years (mean=37.6).<BR/>Gender: 88 M, 59 F.<BR/>Setting: inpatient.<BR/>History: duration ill not reported, age at onset not reported.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-10-05 11:53:46 +0100" MODIFIED_BY="[Empty name]">
<P>1. Clozapine: flexible dose. Allowed dose range: 100-500 mg/day. Mean dose: 216.2 mg/day. N=72.<BR/>2. Olanzapine: flexible dose. Allowed dose range: 5-25 mg/day. Mean dose: 17.2 mg/day. N=75.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-10-05 11:56:18 +0100" MODIFIED_BY="[Empty name]">
<P>Leaving the study early: any reason, adverse events, inefficacy.<BR/>Global state: CGI.<BR/>Mental state: PANSS total score, PANSS positive and negative subscore.<BR/>Adverse effects: at least one adverse effect, extrapyramidal side effects (akathisia, dyskinesia, parkinsonism, use of antiparkinson medication, AIMS, Hillside Akathisia Scale, SAS), sedation, weight change.</P>
<P>Unable to use:<BR/>Leukopenia (no data).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-09-24 23:08:46 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-10-05 11:56:09 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bondolfi-1998">
<CHAR_METHODS MODIFIED="2010-10-05 11:46:54 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Blindness: double.<BR/>Duration: 8 weeks.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-09-24 23:10:33 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis: (DSM-III-R) chronic schizophrenia, non-responders or intolerance.<BR/>N=86.<BR/>Age: 18-65 years (mean=37.3).<BR/>Gender: 61 M, 25 F.<BR/>Setting: inpatient.<BR/>History: age at first hospitalisation mean clozapine=25.0, mean risperidone=26.0, age at onset mean clozapine=23.5, mean risperidone=22.4.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-10-05 11:53:57 +0100" MODIFIED_BY="[Empty name]">
<P>1. Clozapine: flexible dose. Allowed dose range: 150-400 mg/day. Mean dose: 291.2 mg/day. N=43.<BR/>2. Risperidone: flexible dose. Allowed dose range: 3-10 mg/day. Mean dose: 6.4 mg/day. N=43.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-10-05 11:56:09 +0100" MODIFIED_BY="[Empty name]">
<P>Leaving the study early: any reason, adverse events, inefficacy.<BR/>Mental state: PANSS total score, PANSS positive and negative subscore.<BR/>Adverse effects: cardiac effects (any significant cardiac effect), extrapyramidal side-effects (akinesia, dystonia, parkinsonism, use of antiparkinson medication), prolactin associated side-effects (sexual dysfunction), sedation, weight (as "weight gain" reported adverse event), white blood cell count.</P>
<P>Unable to use:<BR/>Change of weight in kg (no usable data).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-09-24 23:10:33 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-10-05 11:56:00 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Breier-1999">
<CHAR_METHODS MODIFIED="2009-09-24 23:11:02 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Blindness: double.<BR/>Duration: 6 weeks.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-09-24 23:11:02 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis: (DSM-IV) chronic schizophrenia.<BR/>N=29.<BR/>Age: 18-55 years (mean clozapine=37.7, mean risperidone=32.4).<BR/>Gender: 19 M, 10 F.<BR/>Setting: not reported.<BR/>History: duration ill mean clozapine=13.9 years, mean risperidone=11.1 years, age at onset mean clozapine=23.7, mean risperidone=21.3.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-09-24 23:11:02 +0100" MODIFIED_BY="[Empty name]">
<P>1. Clozapine: flexible dose. Allowed dose range: 200-600 mg/day. Mean dose: 403.6 mg/day. N=14.<BR/>2. Risperidone: flexible dose. Allowed dose range: 2-9 mg/day. Mean dose: 5.9 mg/day. N=15.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-10-05 11:56:00 +0100" MODIFIED_BY="[Empty name]">
<P>Mental state: BPRS total score, PANSS positive and negative subscore.<BR/>Adverse effects: extrapyramidal side-effects (use of antiparkinson medication, SAS), prolactin (change of prolactin in ng/ml).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-09-24 23:11:02 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-10-05 11:55:50 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Conley-2003">
<CHAR_METHODS MODIFIED="2009-09-24 23:11:34 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Blindness: double.<BR/>Duration: 16 weeks (first 8 weeks observed).<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-09-24 23:11:34 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis: (DSM-IV) schizophrenia, resistance to previous treatment.<BR/>N=13.<BR/>Age: mean=37.58 years.<BR/>Gender: 8 M, 5 F.<BR/>Setting: not reported.<BR/>History: duration ill not reported, age at onset not reported.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-08-14 14:52:11 +0100" MODIFIED_BY="[Empty name]">
<P>1. Clozapine: fixed dose: 450 mg/day. N=5.<BR/>2. Olanzapine: fixed dose: 50 mg/day. N=8.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-10-05 11:55:50 +0100" MODIFIED_BY="[Empty name]">
<P>Death: natural causes, suicide.<BR/>Leaving the study early: any reason, adverse events, inefficacy.<BR/>Global state: CGI.<BR/>Mental state: BPRS total score, PANSS positive and negative subscore.<BR/>Adverse effects: at least one adverse effect; cardiac effects (QTc prolongation), lipids (change on cholesterol from baseline in mg/dl), extrapyramidal side effects (akathisia, use of antiparkinson medication, SAS), glucose (change from baseline in mg/dl), sedation, seizures, weight change.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-09-24 23:11:34 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-10-05 11:55:06 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Heinrich-1994">
<CHAR_METHODS MODIFIED="2009-09-24 23:12:12 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Blindness: double.<BR/>Duration: four weeks.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-10-05 11:50:34 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis:(ICD-9) acute schizophrenia, disorganised, catatonic, paranoid, unspecified type. Schizoaffective psychosis, schizodominant type.<BR/>N=59.<BR/>Age: 19-65 years.<BR/>Gender: 31 M, 28 F.<BR/>Setting: not reported.<BR/>History: duration ill not reported, age at onset not reported.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-10-05 11:50:59 +0100" MODIFIED_BY="[Empty name]">
<P>1. Clozapine: fixed dose: 400 mg/day. N=20.<BR/>2. Risperidone: fixed dose: 4 mg/day. N=20.<BR/>3. Risperidone: fixed dose: 8 mg/day. N=19.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-10-05 11:55:06 +0100" MODIFIED_BY="[Empty name]">
<P>Leaving the study early: any reason, adverse events, inefficacy.<BR/>Global state: CGI.<BR/>Mental state: BPRS total score, BPRS subscore.<BR/>Adverse effects: at least one adverse effect, cardiac effects (pre terminal negative T-wave), extrapyramidal side-effects (extrapyramidal symptoms, use of antiparkinson medication, Simpson-Angus Scale), sedation.<BR/>
<BR/>Unable to use:<BR/>White blood cell count: agranulocytosis (no data).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-09-24 23:12:12 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-10-05 11:57:19 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Krakowski-2006">
<CHAR_METHODS MODIFIED="2009-09-24 23:12:38 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised - block randomisation (block size of three).<BR/>Blindness: double.<BR/>Duration: 12 weeks.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-10-05 11:52:36 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis: (DSM-IV) schizophrenia (N=71) or schizoaffective disorder (N=39), persistent aggression. N=110.<BR/>Age: 18-60 years (mean clozapine=35.1 years, mean haloperidol=32.7 years, mean olanzapine=35.6 years).<BR/>Gender: 90 M, 20 F.<BR/>Setting: inpatient.<BR/>History: duration ill mean clozapine=15.7 years, mean haloperidol=13.9 years, mean olanzapine=16.8 years, age at onset not reported.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-10-05 11:54:23 +0100" MODIFIED_BY="[Empty name]">
<P>1. Clozapine: flexible dose. Allowed dose range: 200-800 mg/day. Mean dose: 565.5 mg/day (at the end of the last six weeks). N=37.<BR/>2. Haloperidol: flexible dose. Allowed dose range: 10-30 mg/day. Mean dose: 23.3 mg/day (at the end of the last six weeks). N=36.<BR/>3. Olanzapine: flexible dose. Allowed dose range: 10-35 mg/day. Mean dose: 24.7 mg/day (at the end of the last six weeks). N=37.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-10-05 11:57:19 +0100" MODIFIED_BY="[Empty name]">
<P>Leaving the study early: any reason, adverse events, inefficacy.<BR/>Mental state: PANSS total score, PANSS positive and negative subscore.<BR/>
<BR/>Unable to use:<BR/>Extrapyramidal Symptom Rating Scale (ESRS / EPS) (no data)<BR/>ECG (no data)<BR/>White cell count (no data)<BR/>Adverse events (no data)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-09-24 23:12:39 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-10-05 12:00:30 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kumra-2008">
<CHAR_METHODS MODIFIED="2009-09-24 23:13:06 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised - computer-generated randomisation.<BR/>Blindness: double.<BR/>Duration: 12 weeks.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-10-05 11:59:51 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis: children and adolescents with (DSM-IV) schizophrenia (N=25) or schizoaffective disorder (N=14) (of intent-to-treat population), resistant to, or intolerant of, at least two antipsychotic treatments.<BR/>N=40.<BR/>Age: 10-18 years (mean=15.6 years).<BR/>Gender: 21 M, 18 F (of intent-to-treat population).<BR/>Setting: in- and outpatient.<BR/>History: duration ill not reported, age at onset mean clozapine=12.7 years, mean olanzapine=11.7 years (of intent-to-treat population).</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-10-05 11:58:24 +0100" MODIFIED_BY="[Empty name]">
<P>1. Clozapine: flexible dose. Allowed dose range: 50-700 mg/day. Mean dose: 403.1 mg/day. N=18 (of intent-to-treat population).<BR/>2. Olanzapine: flexible dose. Allowed dose range: 10-30 mg/day. Mean dose: 26.2 mg/day. N=21 (of intent-to-treat population).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-10-05 12:00:30 +0100" MODIFIED_BY="[Empty name]">
<P>Leaving the study early: any reason, adverse events, inefficacy.<BR/>Global state: CGI.<BR/>Mental state: BPRS total score, SANS total score.<BR/>Adverse effects:at least one adverse effect, extrapyramidal side effects (AIMS, SAS), glucose (change from baseline in mg/dl), lipids (change on cholesterol from baseline in mg/dl), prolactin associated side effects (change from baseline in ng/ml - of men only, change from baseline in ng/ml - of women only), sedation, weight change.</P>
<P>Unable to use:<BR/>Extrapyramidal symptoms (no data)<BR/>Diabetes mellitus (no data).<BR/>Hyperglycemia (no data).<BR/>Neutropenia (no data).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-10-05 11:59:32 +0100" MODIFIED_BY="[Empty name]">
<P>One person was excluded owing to withdrawal of parental consent after randomisation.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-10-05 12:01:34 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Li--2002">
<CHAR_METHODS MODIFIED="2009-09-24 23:13:30 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Blindness: double.<BR/>Duration: 8 weeks.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-10-05 12:00:53 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis: (CCMD-3) schizophrenia. <BR/>N=63.<BR/>Age: mean clozapine=30 years, mean quetiapine=28 years.<BR/>Gender: not reported.<BR/>Setting: in- and outpatient.<BR/>History: duration ill mean clozapine=0.63 years, mean quetiapine=0.65 years, age at onset not reported.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-10-05 12:01:04 +0100" MODIFIED_BY="[Empty name]">
<P>1. Clozapine: flexible dose. Allowed dose range: 25-750 mg/day. Mean dose: 270.5 mg/day. N=31.<BR/>2. Quetiapine: flexible dose. Allowed dose range: 25-750 mg/day. Mean dose: 478.5 mg/day. N=32.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-10-05 12:01:34 +0100" MODIFIED_BY="[Empty name]">
<P>Global state: CGI.<BR/>Mental State: PANSS total score.<BR/>Adverse effects: at least one adverse effect, cardiac effects (palpitation), extrapyramidal side effects (akathisia, rigor, tremor), sedation, weight gain, white blood cell count.</P>
<P>Unable to use:<BR/>Leaving the study early due to adverse events (no data).<BR/>Cardiac effects (no data).<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-09-24 23:13:31 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-10-05 12:03:34 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Li--2003">
<CHAR_METHODS MODIFIED="2009-09-24 23:13:54 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Blindness: single, rater-blinded.<BR/>Duration: 8 weeks.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-09-24 23:13:54 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis: (CCMD-2) schizophrenia.<BR/>N=76.<BR/>Age: mean clozapine=36.2 years, mean quetiapine=34.7 years.<BR/>Gender: not reported.<BR/>Setting: inpatient.<BR/>History: duration ill mean clozapine= 6.12 years, mean quetiapine=5.71 years, age at onset not reported.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-10-05 12:03:06 +0100" MODIFIED_BY="[Empty name]">
<P>1. Clozapine: fixed/flexible dose: not reported. Allowed dose range: start with 25 mg, in two weeks supposed dose, no further details. Mean dose: 325 mg/day. N=38.<BR/>2. Quetiapine: fixed/flexible dose: not reported. Allowed dose range: start with 25 mg, in two weeks supposed dose, no further details. Mean dose: 375 mg/day. N=38.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-10-05 12:03:34 +0100" MODIFIED_BY="[Empty name]">
<P>Global state: CGI.<BR/>Mental state: PANSS total score, PANSS positive and negative subscore.<BR/>
</P>
<P>Unable to use:<BR/>Leaving the study early due to inefficacy (no data).<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-09-24 23:13:55 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-10-05 12:04:58 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Li--2005">
<CHAR_METHODS MODIFIED="2009-09-24 23:14:24 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Blindness: double.<BR/>Duration: 12 weeks.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-09-24 23:14:24 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis: (CCMD-3) schizophrenia.<BR/>N=67.<BR/>Age: mean=26.18 years.<BR/>Gender: not reported.<BR/>Setting: inpatient.<BR/>History: duration ill mean clozapine=0.49 years, mean quetiapine=0.5 years, age at onset not reported.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-10-05 12:04:38 +0100" MODIFIED_BY="[Empty name]">
<P>1. Clozapine: flexible dose. Allowed dose range: 100-550 mg/day. Mean dose: 255.96 mg/day. N=34.<BR/>2. Quetiapine: flexible dose. Allowed dose range: 150-650 mg/day. Mean dose: 362.09 mg/day. N=33.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-10-05 12:04:58 +0100" MODIFIED_BY="[Empty name]">
<P>Leaving the study early: any reason.<BR/>Mental state: PANSS total score, PANSS positive and negative subscore.<BR/>
<BR/>Unable to use:<BR/>Extrapyramidal symptoms (no data).<BR/>Sedation (no data).<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-09-24 23:14:25 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-10-05 14:17:53 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lin-2003">
<CHAR_METHODS MODIFIED="2009-09-24 23:14:48 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Blindness: single, rater-blind.<BR/>Duration: 12 weeks.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-09-24 23:14:48 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis: schizophrenia.<BR/>N=59.<BR/>Age: 20-65 years.<BR/>Gender: not reported.<BR/>Setting: inpatient.<BR/>History: BPRS &gt;30, clozapine treatment for more than 5 months.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-01-20 19:22:42 +0000" MODIFIED_BY="[Empty name]">
<P>1. Clozapine: flexible dose, mean ~ 387 mg/day. N=24.<BR/>2. Zotepine: flexible dose, mean ~ 377 mg/day. N=35.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-10-05 14:17:53 +0100" MODIFIED_BY="[Empty name]">
<P>Global state: CGI.<BR/>Mental state: BPRS total score.<BR/>Adverse effects:use of antiparkinson medication.</P>
<P>Unable to use:<BR/>BAS, SAS, UKU (no data).<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-09-24 23:14:48 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-10-05 14:19:18 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lindenberg-1997">
<CHAR_METHODS MODIFIED="2009-09-24 23:15:10 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Blindness: double.<BR/>Duration: 6 weeks.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-09-24 23:15:10 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis:(DSM-III-R) schizophrenia catatonic, hebephrenic, paranoid or residual.<BR/>N=50.<BR/>Age: 18-60 years.<BR/>Gender: not reported.<BR/>History: BPRS &gt;40 after washout phase, no previous treatment with either medication.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-01-20 19:23:28 +0000" MODIFIED_BY="[Empty name]">
<P>1. Clozapine: flexible dose, allowed range 150-450 mg/day. N=25.<BR/>2. Zotepine: flexible dose, allowed range 150-450 mg/day. N=25.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-10-05 14:19:18 +0100" MODIFIED_BY="[Empty name]">
<P>Leaving the study early: any reason.<BR/>
</P>
<P>Unable to use:<BR/>CGI, BPRS, SANS, adverse events: ECG, weight gain (matched samples).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-09-24 23:15:10 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-10-05 14:20:17 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Liu--2004">
<CHAR_METHODS MODIFIED="2009-09-24 23:15:35 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised<BR/>Blindness: single, rater-blinded.<BR/>Duration: 12 weeks.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-09-24 23:15:35 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis: (CCMD-3) schizophrenia.<BR/>N=72.<BR/>Age: mean clozapine=37.44 years, mean quetiapine=36.86 years.<BR/>Gender: not reported.<BR/>Setting: inpatient.<BR/>History: duration ill mean clozapine=9.36 years, mean quetiapine=8.64 years, age at onset not reported.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-10-05 14:19:37 +0100" MODIFIED_BY="[Empty name]">
<P>1. Clozapine: flexible dose. Allowed dose range: initial dose: 50 mg/day, after 10 days: 400-600 mg/day.<BR/>Mean dose: not reported. N=36.<BR/>2. Quetiapine: flexible dose. Allowed dose range: initial dose: 100 mg/day, after 10 days: 400-700 mg/day. Mean dose: not reported. N=36.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-10-05 14:20:17 +0100" MODIFIED_BY="[Empty name]">
<P>Leaving the study early: adverse events, inefficacy.<BR/>Global state: CGI.<BR/>Mental state: BPRS total score, SANS total score.<BR/>Adverse effects: cardiac effects (ECG abnormalities), extrapyramidal side effects (akathisia, tremor), sedation, weight gain.</P>
<P>Unable to use:<BR/>Leaving the study early due to any reason (no data).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-09-24 23:15:35 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-10-05 14:21:15 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-McGurk-2005">
<CHAR_METHODS MODIFIED="2009-09-24 23:16:05 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Blindness: double, double-dummy protocol.<BR/>Duration: 29 weeks.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-09-24 23:16:05 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis: (DSM-IV) schizophrenia (n=93) or schizoaffective disorder (n=14), treatment resistance.<BR/>N=107.<BR/>Age: 18-60 years (mean=42 years).<BR/>Gender: 84 M, 23 F.<BR/>Setting: in- and outpatient.<BR/>History: duration ill not reported, age at onset mean clozapine=23 years, mean risperidone=22 years.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-10-05 14:20:42 +0100" MODIFIED_BY="[Empty name]">
<P>1. Clozapine: flexible dose. Allowed dose range: 500-800 mg/day. Mean dose: 456.7 mg/day. N=53.<BR/>2. Risperidone: flexible dose. Allowed dose range: 6-16 mg/day. Mean dose: 6.8 mg/day. N=54.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-10-05 14:21:15 +0100" MODIFIED_BY="[Empty name]">
<P>Leaving the study early: any reason, adverse events, inefficacy.<BR/>Mental state: BPRS total score.<BR/>Adverse effects: white blood cell count.</P>
<P>Unable to use:<BR/>SANS (modified version).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-09-24 23:16:05 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-10-05 14:22:21 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Meltzer-2003">
<CHAR_METHODS MODIFIED="2009-09-24 23:16:28 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Blindness: single, rater-blinded.<BR/>Duration: 104 weeks.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-10-05 14:21:40 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis: (DSM-IV) schizophrenia (N=609) or schizoaffective disorder (N=371), high suicidal risk.<BR/>N=980.<BR/>Age: 18-65 years (mean=37.1 years).<BR/>Gender: 602 M, 378 F.<BR/>Setting: in- and outpatient.<BR/>History: duration ill not reported, age at onset mean=24.7 years.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-10-05 14:21:55 +0100" MODIFIED_BY="[Empty name]">
<P>1. Clozapine: flexible dose. Allowed dose range: 200-900 mg/day. Mean dose: 274.2 mg/day. N=490.<BR/>2. Olanzapine: Flexible dose. Allowed dose range: 5-20 mg/day. Mean dose: 16.6 mg/day. N=490.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-10-05 14:22:21 +0100" MODIFIED_BY="[Empty name]">
<P>Death: any reason, suicide attempt, suicide.<BR/>Leaving the study early: any reason, adverse events, inefficacy.<BR/>Service use: number of participants re-hospitalised.<BR/>Adverse effects: extrapyramidal side effects (akathisia, rigor), glucose (diabetes mellitus), sedation, seizures, weight gain, white blood cell count.</P>
<P>Unable to use:<BR/>ESRS (no data)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-09-24 23:16:29 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-10-05 14:23:53 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Moresco-2004">
<CHAR_METHODS MODIFIED="2009-09-24 23:16:54 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Blindness: double.<BR/>Duration: 8 weeks.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-09-24 23:16:55 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis: (DSM-IV) schizophrenia, treatment resistance to two previous antipsychotic medications, BPRS score of 27 or more.<BR/>N=23.<BR/>Age: 18 years or more (mean clozapine=38.3 years, mean olanzapine=34.1 years) (of completer population).<BR/>Gender: 16 M, 7 F.<BR/>Setting: inpatient.<BR/>History: duration ill not reported, age at onset not reported.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-10-05 14:23:26 +0100" MODIFIED_BY="[Empty name]">
<P>1. Clozapine: flexible dose. Allowed dose range: 300-400 mg/day. Mean dose: 325.4 mg/day. N=12.<BR/>2. Olanzapine: flexible dose. Allowed dose range: 15-20 mg/day. Mean dose: 18.3 mg/day. N=11.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-10-05 14:23:53 +0100" MODIFIED_BY="[Empty name]">
<P>Leaving the study early: any reason, adverse events, inefficacy.<BR/>Mental state: PANSS total score, BPRS total score, PANSS positive and negative subscore.<BR/>Adverse effects: at least one adverse effect, extrapyramidal side effects (SAS).<BR/>
</P>
<P>Unable to use:<BR/>AIMS (no useable data)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-09-24 23:16:55 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-10-05 14:25:25 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Naber-2005">
<CHAR_METHODS MODIFIED="2009-09-24 23:17:13 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised - computer-generated randomisation.<BR/>Blindness: double.<BR/>Duration: 26 weeks.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-10-05 14:25:25 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis: (DSM-IV) schizophrenia, non-response to, or intolerance of, standard antipsychotic therapy. <BR/>N=114.<BR/>Age: 18-65 years (mean=34.0 years).<BR/>Gender: 69 M, 45 F.<BR/>Setting: in- and outpatient, initially inpatient.<BR/>History: duration ill not reported, age at onset 26.9 years.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-09-24 23:17:13 +0100" MODIFIED_BY="[Empty name]">
<P>1. Clozapine: flexible dose. Allowed dose range: 100-400 mg/day. Mean dose: 209 mg/day. N=57.</P>
<P>2. Olanzapine: flexible dose. Allowed dose range: 5-25 mg/day. Mean dose: 16.2 mg/day. N=57.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-10-05 14:25:01 +0100" MODIFIED_BY="[Empty name]">
<P>Leaving the study early: any reason, adverse events, inefficacy.<BR/>Global state: CGI.<BR/>Mental state: PANSS total score, BPRS total score, PANSS positive and negative subscore, BPRS positive and negative subscore.<BR/>Quality of life: SWN.<BR/>Adverse effects: at least one adverse effect, cardiac effects (QTc prolongation), extrapyramidal side effects (use of antiparkinson medication, SAS), weight change.<BR/>
<BR/>Unable to use:<BR/>Glucose elevation (non fasting)<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-09-24 23:17:14 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-10-05 14:25:59 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ren-2002">
<CHAR_METHODS MODIFIED="2009-09-24 23:17:36 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised - ball drawing out of box.<BR/>Blindness: double.<BR/>Duration: 12 weeks.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-10-05 14:25:39 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis:(CCMD-3) schizophrenia.<BR/>N=120<BR/>Age: mean clozapine=33.5 years, mean risperidone=35.4 years.<BR/>Gender: not reported.<BR/>Setting: outpatient.<BR/>History duration ill: clozapine: 6.2 years risperidone 6.4 years</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-10-05 14:25:46 +0100" MODIFIED_BY="[Empty name]">
<P>1.Clozapine: mean dose: 350 mg/day.N=60<BR/>2.Risperidone: mean dose: 3.2 mg/day.N=60</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-10-05 14:25:59 +0100" MODIFIED_BY="[Empty name]">
<P>Mental state: PANSS positive and negative subscore.<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-09-24 23:17:36 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-10-05 14:26:55 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sacchetti-2006">
<CHAR_METHODS MODIFIED="2010-10-05 14:26:23 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Blindness: double.<BR/>Duration: 18 weeks.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-09-24 23:18:06 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis: schizophrenia - treatment resistance (non-response in 3 adequate trials in past 5 years) and/or inability to tolerate antipsychotic treatment.<BR/>N=146.<BR/>Age: mean clozapine= 38.3 years, mean ziprasidone= 41.6 years.<BR/>Gender: 101 M, 45 F.<BR/>Setting: not reported.<BR/>History: duration ill not reported, age at onset not reported.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-10-05 14:26:30 +0100" MODIFIED_BY="[Empty name]">
<P>1. Clozapine: flexible dose. Allowed dose range: 250-600 mg/day. Mean dose: 345.7 mg/day. N=73.<BR/>2. Ziprasidone: flexible dose. Allowed dose range: 80-160 mg/day. Mean dose: 130.4 mg/day. N=73.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-10-05 14:26:55 +0100" MODIFIED_BY="[Empty name]">
<P>Leaving the study early: any reason.<BR/>Mental state: PANSS total score.<BR/>Adverse effects: cardiac effects (QTc prolongation).</P>
<P>Unable to use:<BR/>Global state:CGI (no data).<BR/>Mental state: PANSS positive and negative subscore (no data).<BR/>Laboratory parameters (no usable data).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-09-24 23:18:06 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-10-05 14:29:38 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Shaw-2006">
<CHAR_METHODS MODIFIED="2009-09-24 23:18:28 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Blindness: double.<BR/>Duration: 18 weeks.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-10-05 14:28:58 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis: (DSM-IV) schizophrenia catatonic (N=3), disorganised (N=34), paranoid (N=101), residual (N=8) or undifferentiated (N=34), previous treatment resistance.<BR/>N=180.<BR/>Age: 18-70 years (mean=38.6 years).<BR/>Gender: 115 M, 65 F.<BR/>Setting: in- and outpatient.<BR/>History: duration ill not reported, age at onset mean=22.8 years.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-10-05 14:29:05 +0100" MODIFIED_BY="[Empty name]">
<P>1. Clozapine: flexible dose. Allowed dose range: 200-600 mg/day. Mean dose: 303.6 mg/day. N=90.<BR/>2. Olanzapine: flexible dose. Allowed dose range: 15-25 mg/day. Mean dose: 20.5 mg/day. N=90.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-10-05 14:29:38 +0100" MODIFIED_BY="[Empty name]">
<P>Death: natural causes.<BR/>Leaving the study early: any reason, adverse events, inefficacy.<BR/>Mental state: PANSS total score, BPRS total score, PANSS positive and negative subscore, BPRS positive and negative subscore.<BR/>Adverse effects: extrapyramidal side effects (akathisia, akinesia, parkinsonism, use of antiparkinson medication, AIMS, BAS, SAS), prolactin (change from baseline in ng/ml), sedation, weight gain, white blood cell count (leukopenia).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-09-24 23:18:29 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-10-06 09:51:29 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Tollefson-2001">
<CHAR_METHODS MODIFIED="2009-09-24 23:18:50 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Blindness: double.<BR/>Duration: 18 weeks.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-10-05 14:30:42 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis: (DSM-IV) schizophrenia catatonic (N=3), disorganised (N=34), paranoid (N=101), residual (N=8) or undifferentiated (N=34), previous treatment resistance.<BR/>N=180<BR/>Age: 18-70 years (mean=38.6 years).<BR/>Gender: 115 M, 65 F.<BR/>Setting: in- and outpatient.<BR/>History: duration ill not reported, age at onset mean=22.8 years.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-10-05 14:30:49 +0100" MODIFIED_BY="[Empty name]">
<P>1. Clozapine: flexible dose. Allowed dose range: 200-600 mg/day.Mean dose: 303.6 mg/day. N=90.<BR/>2. Olanzapine: flexible dose. Allowed dose range: 15-25 mg/day. Mean dose: 20.5 mg/day. N=90.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-10-06 09:51:29 +0100" MODIFIED_BY="[Empty name]">
<P>Leaving the study early: any reason, adverse events, inefficacy.<BR/>Mental state: clinical improvement (at least 20%BPRS reduction+CGI-S&lt;3 or BPRS&lt;35) ( &gt; or = 50% reduction on PANSS total), PANSS total , positive and negative subscore, BPRS total score.<BR/>Adverse effects:extrapyramidal effects (SAS, AIMS, BAS), prolactin levels, weight change.<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-09-24 23:18:50 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-10-05 14:39:10 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Volavka-2002">
<CHAR_METHODS MODIFIED="2009-09-24 23:19:14 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised<BR/>Blindness: double, identical capsules.<BR/>Duration: 14 weeks.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-10-05 14:36:40 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis: (DSM-IV) chronic schizophrenia (N=135) or schizoaffective disorder (N=22), sub optimal response to previous treatment, PANSS of 60 or more.<BR/>N=167.<BR/>Age: 18-60 years (mean=40.8 years) (of intent-to-treat population).<BR/>Gender: 133 M, 24 F (of intent-to-treat population).<BR/>Setting: inpatient.<BR/>History: duration ill mean=19.5 years (of intent-to-treat population), age at onset not reported</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-10-05 14:37:01 +0100" MODIFIED_BY="[Empty name]">
<P>1. Clozapine: flexible dose. Allowed dose range: 200-800 mg/day. Mean dose: 526.6 mg/day (at the end of the last six weeks). N=40.<BR/>2. Haloperidol: flexible dose. Allowed dose range: 10-30 mg/day. Mean dose: 25.7 mg/day (at the end of the last six weeks). N=37.<BR/>3. Olanzapine: flexible dose. Allowed dose range: 10-40 mg/day. Mean dose: 30.4 mg/day (at the end of the last six weeks). N=39.<BR/>4. Risperidone: flexible dose. Allowed dose range: 4-16 mg/day. Mean dose: 11.6 mg/day (at the end of the last six weeks). N=41.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-10-05 14:39:10 +0100" MODIFIED_BY="[Empty name]">
<P>Leaving the study early: any reason, adverse events, inefficacy.<BR/>Mental state: PANSS total score, PANSS positive and negative subscore.<BR/>Cognitive functioning: Global Neurocognitive Score.<BR/>Adverse effects: extrapyramidal effects (use of antiparkinson medication, ESRS), glucose (change from baseline in mg/dl), lipids levels (change on cholesterol from baseline in mg/dl), prolactin associated side effects (change from baseline in ng/ml), seizures, weight gain, white blood cell count (agranulocytosis, neutropenia).</P>
<P>Unable to use:<BR/>Quality of life scale (no data).<BR/>Cognitive functioning (PANSS cognitive subscore, at endpoint and change, was reported as factor score and the neurocognitive global score at endpoint was reported as Z score, which didn't allow its use as comparator).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-04-30 16:33:33 +0100" MODIFIED_BY="[Empty name]">
<P>The two participants with neutropenia (clozapine) are additional participants to the one with agranulocytosis.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-10-05 14:43:28 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wahlbeck-2000">
<CHAR_METHODS MODIFIED="2009-09-24 23:19:33 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised - computer-generated randomisation.<BR/>Blindness: single, rater-blinded.<BR/>Duration: 10 weeks.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-09-24 23:19:33 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis: (DSM-IV) schizophrenia, resistance to previous treatment.<BR/>N=20.<BR/>Age: 24-55 years (mean clozapine=35.7 years, mean risperidone=36.8 years) (of intent-to-treat population).<BR/>Gender: 10 M, 9 F (of intent-to-treat population).<BR/>Setting: in- and outpatient (initially inpatient).<BR/>History: duration ill mean clozapine=12.6 years, mean risperidone=13.1 years (of intent-to-treat population), age at onset not reported.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-10-05 14:40:41 +0100" MODIFIED_BY="[Empty name]">
<P>1. Clozapine: flexible dose. Allowed dose range: 25-600 mg/day. Mean dose: 385 mg/day. N=11.<BR/>2. Risperidone: flexible dose. Allowed dose range: 2-10 mg/day. Mean dose: 7.8 mg/day. N=9.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-10-05 14:43:28 +0100" MODIFIED_BY="[Empty name]">
<P>Death: natural causes, suicide.<BR/>Leaving the study early: any reason, adverse events, inefficacy.<BR/>Mental state: PANSS total score, PANSS positive and negative subscore.<BR/>General functioning: GAF, SFS.<BR/>Treatment satisfaction: DAI.<BR/>Adverse effects: extrapyramidal side effects (use of antiparkinson medication), sedation, white blood cell count.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-09-24 23:19:33 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-10-05 14:44:50 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wang-2002">
<CHAR_METHODS MODIFIED="2009-09-24 23:20:01 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Blindness: double.<BR/>Duration: 8 weeks.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-09-24 23:20:01 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis: (CCMD-3) schizophrenia.<BR/>N=61.<BR/>Age: mean clozapine=30 years, mean olanzapine=25.8 years.<BR/>Gender: 29 M, 32 F.<BR/>Setting: in- and outpatient.<BR/>History: duration ill mean= 4.2 years, age at onset not reported.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-10-05 14:44:39 +0100" MODIFIED_BY="[Empty name]">
<P>1. Clozapine: flexible dose. Allowed dose range: 25-400 mg/day. Mean dose: not reported. N=31.<BR/>2. Olanzapine: flexible dose. Allowed dose range: 5-20 mg/day. Mean dose: not reported. N=30.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-10-05 14:44:50 +0100" MODIFIED_BY="[Empty name]">
<P>Mental state: BPRS total score.<BR/>Adverse effects: at least one adverse effect, extrapyramidal side effects (extrapyramidal symptoms), sedation, weight gain.</P>
<P>Unable to use:<BR/>White blood cell count- leukopenia (no usable data).<BR/>Leaving the study early -adverse events (no usable data).<BR/>Hypersalivation (no usable data).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-09-24 23:20:02 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-10-05 14:45:34 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zhou-2000">
<CHAR_METHODS MODIFIED="2009-09-24 23:20:28 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised<BR/>Blindness: single, rater-blinded.<BR/>Duration: 8 weeks.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-09-24 23:20:28 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis: (CCMD-2) schizophrenia.<BR/>N=40.<BR/>Age: mean clozapine=27.6 years, mean risperidone=29 years.<BR/>Gender: 23 M, 17 F.<BR/>Setting: inpatient<BR/>History: duration ill mean clozapine=2.7 years, mean risperidone=3.2 years, age at onset not reported.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-10-05 14:45:26 +0100" MODIFIED_BY="[Empty name]">
<P>1. Clozapine: fixed and flexible dose (first two weeks). Allowed dose range: 25-300 mg/day (first two weeks), then 300 mg/day fixed. Mean dose: not reported. N=20.<BR/>2. Risperidone: Fixed and flexible dose (first two weeks). Allowed dose range: 1-6 mg/day (first two weeks), then 6 mg/day fixed. Mean dose: not reported. N=20.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-10-05 14:45:34 +0100" MODIFIED_BY="[Empty name]">
<P>Mental state: SANS.<BR/>Adverse effects: extrapyramidal side-effects (akathisia, tremor), sedation, weight gain.<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-09-24 23:20:28 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>
<B>Scales:</B>
<BR/>AIMS: Abnormal Involuntary Movement Score<BR/>BAS: Barnes Akathisia Scale<BR/>BPRS: Brief Psychiatric Rating Scale.<BR/>CGI: Clinical Global impression.<BR/>ESRS: Extrapyramidal Symptoms Rating Scale<BR/>GAF: Global Assessment of Functioning<BR/>HAS: Hillside Akathisia Scale<BR/>MLDL: Munich Life Dimension List<BR/>PANSS: Positive and Negative Syndrome Scale for Schizophrenia<BR/>SANS: Scale for the Assessment of Negative Symptoms<BR/>SAPS: Scale for the Assessment of Positive Symptoms<BR/>SAS: Simpson Angus scale<BR/>SFS: Social Functioning scale.<BR/>SWN: Subjective Well Being under Neuroleptic Treatment - 38 Items<BR/>
<BR/>
<B>Diagnostic Tools:</B>
<BR/>DSM -III-R: Diagnostic and Statistical Manual of Mental Disorders, third edition, revised.<BR/>DSM-IV: Diagnostic and Statistical Manual of Mental Disorders, fourth edition.<BR/>ICD-9: International Classification of Disease.<BR/>CCMD-2: Chinese Classification of Mental Disorders, Second Edition.<BR/>CCMD-3: Chinese Classification of Mental Disorders, Third Edition.</P>
<P>
<B>Others:</B>
<BR/>ECG: electrocardiogram<BR/>ITT: intent- to- treat .<BR/>mg: milligram.<BR/>SD: standard deviation.<BR/>N: number<BR/>
</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2010-10-05 15:06:29 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY">
<EXCLUDED_CHAR STUDY_ID="STD-Agelink-2001">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-09-22 21:13:40 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Allison-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-09-22 21:13:40 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: unclear<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-05-11 23:26:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Altamura-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-05-11 23:26:24 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: not randomised (naturalistic).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-05-11 23:26:44 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Anonymous-1994">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-05-11 23:26:44 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: unclear.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-05-11 23:26:52 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ascher_x002d_Svanum-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-05-11 23:26:52 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: not randomised (naturalistic).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-05-11 23:25:16 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Baumann-1993">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-05-11 23:25:16 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: unclear.<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-09-22 21:13:55 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Beasley-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-09-22 21:13:55 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: unclear.<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-10-06 15:01:20 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bondolfi-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-10-06 15:01:20 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: not applicable (review) .</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-09-25 15:23:22 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Cai-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-09-25 15:23:22 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised, no blinding.<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-09-22 21:20:39 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-CATIE">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-09-22 21:20:39 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised, open label trial for clozapine, double-blind for other atypicals. Raters were blinded only to the newer, not for clozapine.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-05-14 14:53:49 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Cavazzoni-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-05-14 14:53:49 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: unclear (analysis of extracted data from olanzapine clinical trial database).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-09-25 15:23:47 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Cha-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-09-25 15:23:47 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised, no blinding.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-09-25 15:24:06 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Chen-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-09-25 15:24:06 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised, no blinding.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-09-25 15:24:13 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Chen-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-09-25 15:24:13 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised, no blinding.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-09-25 15:24:18 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Chen-2003b">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-09-25 15:24:18 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised, no blinding.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-09-25 15:24:26 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Chen-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-09-25 15:24:26 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised, no blinding.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-09-25 15:24:32 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Chen-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-09-25 15:24:32 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised, no blinding.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-09-25 15:25:14 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Chen-2005b">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-09-25 15:25:14 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised, no blinding.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-09-25 15:25:05 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Cheng-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-09-25 15:25:05 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised, no blinding.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-09-25 15:25:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Chou-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-09-25 15:25:24 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised, no blinding.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-05-14 14:55:28 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Chouinard-1994">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-05-14 14:55:28 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: not randomised (case reports).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-09-22 23:15:05 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Conley-1999a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-09-22 23:15:05 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation:unclear, open label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-09-25 15:25:44 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Cui-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-09-25 15:25:44 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised, no blinding.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-05-14 14:55:50 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-CUTLASS">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-05-14 14:55:50 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Participants: people with schizophrenia, treatment-resistant.<BR/>Intervention: clozapine vs. other pooled newer antipsychotics.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-09-25 15:25:53 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Dai-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-09-25 15:25:53 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised, no blinding.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-09-22 21:23:25 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-David-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-09-22 21:23:25 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: not randomised (review).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-09-25 15:26:03 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Deng-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-09-25 15:26:03 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised, no blinding.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-09-25 15:26:10 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ding-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-09-25 15:26:10 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised, no blinding.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-09-25 15:26:15 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Du-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-09-25 15:26:15 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised, no blinding.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-09-25 15:26:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Du-2003b">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-09-25 15:26:24 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised, no blinding.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-09-25 15:26:33 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Du-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-09-25 15:26:33 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised, no blinding.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-09-25 15:26:40 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Du-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-09-25 15:26:40 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised, no blinding.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-05-12 00:05:02 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Earnst-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-05-12 00:05:02 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: not randomised (naturalistic).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-10-05 15:00:53 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ellis-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-10-05 15:00:53 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Participants: people with Parkinson's disease and psychosis, not schizophrenia.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-09-25 15:26:47 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Fan-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-09-25 15:26:47 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised, no blinding.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-09-25 15:26:55 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Fang-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-09-25 15:26:55 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised, no blinding.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-09-25 15:27:03 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Feng-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-09-25 15:27:03 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised, no blinding.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Fleming-1999">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-09-22 21:25:06 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Flynn-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-09-22 21:25:06 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: not randomised.<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-09-25 15:27:15 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Fu-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-09-25 15:27:15 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised, no blinding.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-05-14 14:58:10 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gaertner-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-05-14 14:58:10 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: not randomised (retrospective study).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Gallhofer-1995">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Gallhofer-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-05-14 04:28:08 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ganguli-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-05-14 04:28:08 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Participants: people with schizophrenia, schizoaffective disorder.<BR/>Intervention: behaviour therapy vs. standard care.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-09-25 15:27:37 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gao-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-09-25 15:27:37 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised, no blinding.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-05-12 00:10:30 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Goldberg-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-05-12 00:10:30 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-09-22 21:26:09 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Green-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-09-22 21:26:09 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Participants: people with schizophrenia and cannabis use disorder.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-09-25 15:27:58 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Guan-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-09-25 15:27:58 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised, no blinding.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-09-25 15:28:05 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Guo-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-09-25 15:28:05 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised, no blinding.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-09-25 15:28:11 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Guo-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-09-25 15:28:11 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised, no blinding.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-09-25 15:28:15 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Han-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-09-25 15:28:15 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised, no blinding.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-09-25 15:28:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hang-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-09-25 15:28:24 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised, no blinding.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-09-25 15:28:30 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-He-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-09-25 15:28:30 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised, no blinding.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-09-25 15:28:35 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hu-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-09-25 15:28:35 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised, no blinding.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-09-25 15:28:40 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hu-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-09-25 15:28:40 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised, no blinding.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-09-25 15:28:47 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Huang-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-09-25 15:28:47 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised, no blinding.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-09-25 15:28:53 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Huang-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-09-25 15:28:53 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised, no blinding.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-09-25 15:29:14 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kelemen-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-09-25 15:29:14 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised, no blinding.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-09-25 15:29:23 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kong-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-09-25 15:29:23 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised, no blinding.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-05-14 15:02:58 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Konrad-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-05-14 15:02:58 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: not randomised (naturalistic).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-09-22 21:27:50 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kufferle-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-09-22 21:27:50 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: not randomised.<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-10-05 15:02:14 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lee-1995">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-10-05 15:02:14 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: unclear, open trial.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-09-25 15:29:44 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lei-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-09-25 15:29:44 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised, no blinding.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-09-25 15:29:51 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lei-G-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-09-25 15:29:51 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised, no blinding.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-09-25 15:29:58 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Li--2003b">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-09-25 15:29:58 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised, no blinding.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-09-25 15:30:06 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Li-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-09-25 15:30:06 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised, no blinding.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-09-25 15:30:13 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Li-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-09-25 15:30:13 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised, no blinding.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-09-25 15:30:20 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Li-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-09-25 15:30:20 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised, no blinding.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-09-25 15:30:29 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Liang-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-09-25 15:30:29 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised, no blinding.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-09-25 15:30:35 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Liang-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-09-25 15:30:35 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised, no blinding.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-09-22 21:28:51 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lindenmayer-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-09-22 21:28:51 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: unclear.<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-09-25 15:30:47 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Liu-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-09-25 15:30:47 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised, no blinding.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-09-25 15:30:54 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Liu-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-09-25 15:30:54 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised, no blinding.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-09-25 15:31:04 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Liu-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-09-25 15:31:04 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised, no blinding.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-09-25 15:31:11 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Liu-2003b">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-09-25 15:31:11 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised, no blinding.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-09-25 15:31:17 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Liu-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-09-25 15:31:17 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised, no blinding.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-09-25 15:31:25 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Liu-2004b">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-09-25 15:31:25 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised, no blinding.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-09-25 15:31:31 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Liu-2004c">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-09-25 15:31:31 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised, no blinding.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-09-25 15:31:41 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Liu-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-09-25 15:31:41 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised, no blinding.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-09-25 15:31:47 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Liu-2005b">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-09-25 15:31:47 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised, no blinding.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-09-25 15:31:53 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Liu-2005c">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-09-25 15:31:53 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised, no blinding.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Louwerens-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-09-25 15:32:05 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lu-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-09-25 15:32:05 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised, no blinding.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-09-25 15:32:12 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lu-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-09-25 15:32:12 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised, no blinding.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-09-25 15:32:21 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Luo-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-09-25 15:32:21 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised, no blinding.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-09-25 15:32:31 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ma-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-09-25 15:32:31 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised, no blinding.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-09-22 21:30:32 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-McKenna-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-09-22 21:30:32 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Participants: people with schizophrenia or psychotic disorders.<BR/>Intervention: risperidone augmentation therapy of clozapine.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-05-13 23:24:26 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Meehan-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-05-13 23:24:26 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: not randomised (data report from 8 different trials).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-09-25 15:32:44 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Mei-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-09-25 15:32:44 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised, no blinding.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-05-13 23:26:57 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Mulqueen-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-05-13 23:26:57 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation:not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-09-25 15:32:50 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Nan-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-09-25 15:32:50 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised, no blinding.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-09-25 15:32:58 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ni-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-09-25 15:32:57 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised, no blinding.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-05-13 23:27:13 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Opjordsmoen-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-05-13 23:27:13 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: not randomised (naturalistic).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-09-22 21:31:17 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Pajonk-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-09-22 21:31:17 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: not randomised.<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-09-25 15:33:12 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Pan-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-09-25 15:33:12 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised, no blinding.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-09-25 15:33:17 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Pao-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-09-25 15:33:17 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised, no blinding.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-09-25 15:33:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Peng-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-09-25 15:33:24 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised, no blinding.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-09-25 15:33:32 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Qian-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-09-25 15:33:32 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised, no blinding.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-09-25 15:33:41 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Qin-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-09-25 15:33:41 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised, no blinding.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-09-22 21:32:04 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Rapoport-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-09-22 21:32:04 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: not randomised.<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-09-25 15:33:50 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ren-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-09-25 15:33:50 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised, no blinding.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-09-25 15:33:57 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ren-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-09-25 15:33:57 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised, no blinding.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-09-22 21:32:23 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Rettenbacher-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-09-22 21:32:23 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: not randomised.<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-09-25 15:39:01 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Saletu-1987">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-09-25 15:39:01 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Participants: healthy people.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Scherer-2004">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-09-22 21:32:47 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Schlogelhofer-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-09-22 21:32:47 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: not randomised.<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Schuld-2000">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-09-25 15:39:09 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Shao-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-09-25 15:39:09 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised, no blinding.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-05-13 23:47:43 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sharma-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-05-13 23:47:43 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: not randomised (naturalistic).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-09-25 15:39:34 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sheng-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-09-25 15:39:34 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised, no blinding.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-09-25 15:39:45 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sheng-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-09-25 15:39:45 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised, no blinding.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-09-25 15:43:40 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Shi-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-09-25 15:43:40 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised, no blinding.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-09-25 15:43:47 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Shi-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-09-25 15:43:47 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised, no blinding.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-09-22 21:33:34 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Smith-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-09-22 21:33:34 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Participants: people with schizophrenia.<BR/>Intervention: addition of pioglitazone or placebo to clozapine and olanzapine.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-05-13 23:58:58 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Speer-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-05-13 23:58:58 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-05-13 23:59:08 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Su-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-05-13 23:59:08 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-09-25 15:44:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sun-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-09-25 15:44:24 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised, no blinding.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-10-05 15:05:02 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Swanson-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-10-05 15:05:02 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: non applicable (observational study)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-09-22 21:34:25 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Tandon-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-09-22 21:34:25 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised, open label study.<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-09-25 15:44:37 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Tang-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-09-25 15:44:37 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised, no blinding.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-09-25 15:44:43 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Tang-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-09-25 15:44:43 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised, no blinding.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-09-25 15:44:48 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Tang-2005b">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-09-25 15:44:48 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised, no blinding.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-09-25 15:44:54 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Tian-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-09-25 15:44:54 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised, no blinding.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-09-25 15:45:00 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Tong-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-09-25 15:45:00 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised, no blinding.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-09-22 21:35:04 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Trichard-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-09-22 21:35:04 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: not randomised.<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Turrone-2002">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Vaughan-2000">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-09-25 15:45:11 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wang-2002b">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-09-25 15:45:11 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised, no blinding.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-09-25 15:45:16 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wang-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-09-25 15:45:16 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised, no blinding.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-09-25 15:45:21 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wang-2003b">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-09-25 15:45:21 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised, no blinding.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-09-25 15:45:27 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wang-2003c">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-09-25 15:45:27 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised, no blinding.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-09-25 15:45:34 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wang-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-09-25 15:45:34 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised, no blinding.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-09-25 15:45:40 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wang-2004b">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-09-25 15:45:40 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised, no blinding.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-09-25 15:45:45 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wang-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-09-25 15:45:45 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised, no blinding.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-09-25 15:45:58 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wang-2005b">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-09-25 15:45:58 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised, no blinding.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-09-25 15:46:02 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wang-2005c">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-09-25 15:46:02 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised, no blinding.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-09-25 15:46:08 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wang-2005d">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-09-25 15:46:08 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised, no blinding.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-09-25 15:46:13 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wang-2005e">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-09-25 15:46:13 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised, no blinding.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-09-25 15:46:19 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wang-2005f">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-09-25 15:46:19 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised, no blinding.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Weickert-2003">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-09-25 15:46:27 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Weng-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-09-25 15:46:27 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised, no blinding.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-05-14 15:48:11 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wirshing-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-05-14 15:48:11 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: not randomised (cross-sectional study).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-09-25 15:46:35 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wu-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-09-25 15:46:35 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised, no blinding.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-09-25 15:46:41 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wu-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-09-25 15:46:41 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised, no blinding.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-05-14 00:05:32 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wudarsky-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-05-14 00:05:32 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: not randomised (data report from different studies).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-09-25 15:46:48 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Xiang-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-09-25 15:46:48 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised, no blinding.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-09-25 15:46:58 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Xiao-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-09-25 15:46:58 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised, no blinding.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-09-25 15:47:04 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Xie-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-09-25 15:47:04 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised, no blinding.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-09-25 15:47:10 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Xin-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-09-25 15:47:10 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised, no blinding.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-09-25 15:47:15 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Xu-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-09-25 15:47:15 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised, no blinding.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-09-25 15:47:21 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Xu-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-09-25 15:47:21 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised, no blinding.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-10-05 15:06:29 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Yagdiran-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-10-05 15:06:29 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: non applicable (observational study).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-09-25 15:47:35 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Yang-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-09-25 15:47:35 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised, no blinding.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-09-25 15:47:44 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Yang-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-09-25 15:47:44 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised, no blinding.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-09-25 15:47:49 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Yang-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-09-25 15:47:49 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised, no blinding.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-09-25 15:47:54 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Yang-L-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-09-25 15:47:54 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised, no blinding.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-09-25 15:48:00 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Yang-X-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-09-25 15:48:00 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised, no blinding.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-09-25 15:48:06 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ye-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-09-25 15:48:06 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised, no blinding.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-09-25 15:48:10 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Yin-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-09-25 15:48:10 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised, no blinding.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-09-25 15:48:18 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Yu-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-09-25 15:48:18 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised, no blinding.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-09-25 15:48:25 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Yuan-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-09-25 15:48:25 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised, no blinding.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-09-25 15:48:29 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Yuan-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-09-25 15:48:29 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised, no blinding.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-09-25 15:48:34 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Yuo-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-09-25 15:48:34 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised, no blinding.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-09-22 21:39:03 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zelaschi-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-09-22 21:39:03 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: not randomised.<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-09-22 21:39:08 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zelaschi-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-09-22 21:39:08 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: not randomised (naturalistic).<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-09-25 15:48:48 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zhan-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-09-25 15:48:48 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised, no blinding.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-09-25 15:48:53 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zhang-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-09-25 15:48:53 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised, no blinding.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-09-25 15:48:58 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zhang-2002b">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-09-25 15:48:58 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised, no blinding.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-09-25 15:49:05 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zhang-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-09-25 15:49:05 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised, no blinding.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-09-22 21:39:42 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zhang-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-09-22 21:39:42 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Participants: people with schizophrenia + obsessive compulsive symptoms.<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-09-25 15:49:13 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zhang-2005b">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-09-25 15:49:13 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised, no blinding.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-09-25 15:49:21 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zhang-2005c">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-09-25 15:49:21 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised, no blinding.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-09-25 15:49:29 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zhang-2005d">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-09-25 15:49:29 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised, no blinding.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-09-25 15:49:38 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zhang-2005e">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-09-25 15:49:38 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised, no blinding.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-09-25 15:49:48 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zhang-2005f">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-09-25 15:49:48 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised, no blinding.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-09-25 15:50:23 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zhang-2005g">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-09-25 15:50:23 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised, no blinding.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-09-25 15:50:29 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zhao-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-09-25 15:50:29 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised, no blinding.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-09-25 15:50:34 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zheng-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-09-25 15:50:34 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised, no blinding.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-09-25 15:50:39 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zheng-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-09-25 15:50:39 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised, no blinding.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-09-25 15:50:48 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zheng-X-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-09-25 15:50:48 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised, no blinding.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-09-25 15:50:54 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zhong-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-09-25 15:50:54 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised, no blinding.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-09-25 15:50:59 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zhou-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-09-25 15:50:59 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised, no blinding.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-09-25 15:51:05 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zhou-2003b">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-09-25 15:51:05 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised, no blinding.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-09-25 15:51:12 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zhou-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-09-25 15:51:12 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised, no blinding.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-09-25 15:51:18 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zhu-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-09-25 15:51:18 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised, no blinding.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-09-25 15:51:25 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zhu-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-09-25 15:51:25 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised, no blinding.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-09-25 15:51:32 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zhu-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-09-25 15:51:32 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised, no blinding.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-09-25 15:51:42 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zhu-Q-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-09-25 15:51:42 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised, no blinding.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Zoccali-2003">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2010-10-05 14:57:49 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<AWAITING_CHAR MODIFIED="2009-09-24 22:56:13 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Anand-1999">
<CHAR_METHODS MODIFIED="2009-09-24 22:56:13 +0100" MODIFIED_BY="[Empty name]"/>
<CHAR_PARTICIPANTS MODIFIED="2009-09-22 21:44:40 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis:chronic, severe schizophrenia.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-09-22 22:24:41 +0100" MODIFIED_BY="[Empty name]">
<P>1. Clozapine.<BR/>2. Risperidone.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-09-24 22:56:13 +0100" MODIFIED_BY="[Empty name]"/>
<CHAR_NOTES MODIFIED="2009-01-16 15:41:51 +0000" MODIFIED_BY="[Empty name]">
<P>No abstract.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2009-09-24 22:56:39 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Byerly-1999">
<CHAR_METHODS MODIFIED="2009-09-24 22:56:38 +0100" MODIFIED_BY="[Empty name]"/>
<CHAR_PARTICIPANTS MODIFIED="2009-09-24 22:56:39 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis:schizophrenia who have not responded to olanzapine or risperidone.<BR/>N= 60</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-09-22 22:26:28 +0100" MODIFIED_BY="[Empty name]">
<P>1. Clozapine.<BR/>2. Quetiapine.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-09-24 22:56:39 +0100" MODIFIED_BY="[Empty name]"/>
<CHAR_NOTES MODIFIED="2009-01-16 15:44:00 +0000" MODIFIED_BY="[Empty name]">
<P>Abstract incomplete.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2010-10-05 14:53:54 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Chengappa-2001">
<CHAR_METHODS MODIFIED="2009-09-24 22:57:16 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation:randomised.<BR/>Binding: double.<BR/>Duration:29 week.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-10-05 14:53:54 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis:Moderately treatment refractory .<BR/>N=180.<BR/>Setting: inpatients.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-09-24 22:57:16 +0100" MODIFIED_BY="[Empty name]">
<P>1. Clozapine.<BR/>2. Risperidone.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-09-22 22:42:02 +0100" MODIFIED_BY="[Empty name]">
<P>Cognition.<BR/>Psychosocial functioning.<BR/>Adverse effects.<BR/>Psychopathology<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-02-02 00:42:24 +0000" MODIFIED_BY="[Empty name]">
<P>Protocol abstract available.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2010-10-05 14:54:11 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Chowdhury-1999">
<CHAR_METHODS MODIFIED="2009-09-22 23:07:23 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Blinding: not stated.<BR/>Duration:17 weeks.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-10-05 14:54:01 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis: (ICD-10) resistant schizophrenia .<BR/>N=60.<BR/>Age:15 - 60 years.<BR/>Gender: 45 M - 15 F.<BR/>History:duration of illness clozapine:6.92±5.07 and risperidone:18±4.38 years.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-10-05 14:54:11 +0100" MODIFIED_BY="[Empty name]">
<P>1. Clozapine:dose 342.86±84.21 mg/day. N=30.<BR/>2. Risperidone: dose 5.8±1.33 mg/day. N=30.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-10-05 14:53:32 +0100" MODIFIED_BY="[Empty name]">
<P>Leaving the study early: any reason, adverse effects, inefficacy.<BR/>Clinically important change: at least 20% improvement on PANSS.<BR/>Mental state: PANSS total, BPRS modified score, PANSS positive and negative subscore.<BR/>Adverse effects: cardiac (tachycardia), extrapyramidal (akatisia), hypersalivation, sedation, weight change.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-05-01 14:24:25 +0100" MODIFIED_BY="[Empty name]">
<P>Full text available.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2010-10-05 14:55:32 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Daniel-1996">
<CHAR_METHODS MODIFIED="2009-09-24 22:58:26 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation:randomised-dose (cross-over trial).<BR/>Blinding: single-blind.<BR/>Duration:12 weeks.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-10-05 14:54:33 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis:(DSM-III-R) chronic schizophrenia or schizoaffective disorder.<BR/>N=20.<BR/>Age: mean: 33.8 years (range=22-51).<BR/>Gender: 7M -13F.<BR/>Setting:19 outpatients and 1 inpatient.<BR/>History:mean age at onset of psychosis was 22.7 years (range=15-32)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-10-05 14:54:48 +0100" MODIFIED_BY="[Empty name]">
<P>1. Clozapine:dose 375 mg/day (range=75-800).N=10.<BR/>2. Risperidone:dose 6.1 mg/day (range=1-10). N=10.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-10-05 14:55:32 +0100" MODIFIED_BY="[Empty name]">
<P>Leaving the study early: adverse effects.<BR/>Global state: severity of illness sub scale of the CGI.<BR/>Mental state: PANSS total score and positive and negative subscore.<BR/>Adverse effects: extrapyramidal (antiparkinson medication use), sedation, weight gain.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-01-18 00:25:38 +0000" MODIFIED_BY="[Empty name]">
<P>No report of first arm outcomes (6 weeks).</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2010-10-05 14:56:03 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Estrella-1996">
<CHAR_METHODS MODIFIED="2009-09-22 21:57:55 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation:randomised.<BR/>Blinding: open label.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-10-05 23:44:15 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis: resistant schizophrenia.<BR/>N=22</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-09-24 22:58:49 +0100" MODIFIED_BY="[Empty name]">
<P>1. Clozapine<BR/>2. Risperidone.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-10-05 14:56:03 +0100" MODIFIED_BY="[Empty name]">
<P>Mental state: PANSS.<BR/>Adverse effects: Dimascio and UKU Side Effect Scale.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-02-02 00:42:55 +0000" MODIFIED_BY="[Empty name]">
<P>Abstract available. No outcome information.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2010-10-05 14:57:16 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lieberman-2001">
<CHAR_METHODS MODIFIED="2009-09-24 22:59:28 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Blinding: double.<BR/>Duration:12 weeks.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-10-05 14:56:13 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis: treatment resistant schizophrenia.<BR/>N=224.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-09-24 22:59:28 +0100" MODIFIED_BY="[Empty name]">
<P>1.Clozapine.<BR/>2.Risperidone doses: 6 mg/day and 16 mg/day.<BR/>3.Haloperidol.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-10-05 14:57:16 +0100" MODIFIED_BY="[Empty name]">
<P>Global functioning: CGI.<BR/>Mental state: PANSS total score.<BR/>Social functioning: NOSIE.<BR/>Quality of life: Quality of Life Interview.<BR/>Adverse effects: extrapyramidal: ESRS.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-02-02 00:43:01 +0000" MODIFIED_BY="[Empty name]">
<P>Only abstract available.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2010-10-05 14:57:30 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Loza-2002">
<CHAR_METHODS MODIFIED="2009-09-22 22:08:10 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Blinding: not stated.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-09-24 22:59:47 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis:paranoid schizophrenia (first-episode).<BR/>N:39.<BR/>Age:18 - 29 years.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-09-24 22:59:47 +0100" MODIFIED_BY="[Empty name]">
<P>1.Clozapine<BR/>2.Olanzapine<BR/>3.Risperidone.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-10-05 14:57:30 +0100" MODIFIED_BY="[Empty name]">
<P>Mental state: PANSS total score.<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-02-02 00:43:26 +0000" MODIFIED_BY="[Empty name]">
<P>Abstract available.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2009-09-24 23:00:06 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Magnuson-2001">
<CHAR_METHODS MODIFIED="2009-09-24 23:00:06 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: unclear<BR/>Blinding: double</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-09-24 23:00:06 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis: (DSM-III-R) several psychotic conditions (schizophrenia, schizoaffective disorder, and psychotic disorders not otherwise specified).who have not responded to at least two prior typical neuroleptics.<BR/>Age:6 to 18 years<BR/>History: onset of psychosis by age 12.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-09-24 23:00:06 +0100" MODIFIED_BY="[Empty name]">
<P>1. Clozapine.<BR/>2. Olanzapine.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-09-24 23:00:06 +0100" MODIFIED_BY="[Empty name]"/>
<CHAR_NOTES MODIFIED="2009-02-02 00:43:37 +0000" MODIFIED_BY="[Empty name]">
<P>Abstract available.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2010-10-05 14:57:49 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Oliemeulen-2000">
<CHAR_METHODS MODIFIED="2009-09-24 23:00:29 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Blinding: not stated.<BR/>Duration:8 weeks.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-09-24 23:00:29 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis:(DSM-IV) resistant schizophrenia or other psychotic disorder.<BR/>N:40</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-09-24 23:00:29 +0100" MODIFIED_BY="[Empty name]">
<P>1.Olanzapine.<BR/>2.Clozapine.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-10-05 14:57:49 +0100" MODIFIED_BY="[Empty name]">
<P>Mental state: PANSS total score, positive and negative subscore.<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-02-02 00:44:01 +0000" MODIFIED_BY="[Empty name]">
<P>Abstract available.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2010-10-05 14:46:46 +0100" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2009-08-14 14:50:03 +0100" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Adequate sequence generation?</NAME>
<DESCRIPTION>
<P>Was the allocation sequence adequately generated?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-14 14:50:03 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Atmaca-2003">
<DESCRIPTION>
<P>Quote: "The patients were randomly divided into 4 treatment group.."<BR/>Comment: Incomplete information.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-01-15 15:30:55 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Azorin-2001">
<DESCRIPTION>
<P>Quote: &#8220; patients who satisfied the eligibility criteria were then randomly assigned..(balanced by country, with a block size of six)&#8221;</P>
<P>Comment: Incomplete information.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-02 00:35:05 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bitter-2004">
<DESCRIPTION>
<P>Quote:&#8220;This was a Phase III, 18-week, randomised.. (1:1 ratio)&#8221;</P>
<P>Comment: Incomplete information.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-01-15 15:36:48 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bondolfi-1998">
<DESCRIPTION>
<P>Quote: &#8220; Patients randomly assigned to receive risperidone  or clozapine..&#8221;</P>
<P>Comment: Incomplete information.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-01-15 15:38:56 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Breier-1999">
<DESCRIPTION>
<P>Quote: &#8220;All patients were then randomly assigned to treatment with clozapine or risperidone..&#8221;</P>
<P>Comment: Incomplete information.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-02 00:36:22 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Conley-2003">
<DESCRIPTION>
<P>Quote: &#8220;In a randomised crossover design..&#8221;</P>
<P>Comment: Probably not done.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-02 00:36:59 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Heinrich-1994">
<DESCRIPTION>
<P>Quote: &#8220;This is a randomised, double blind study..&#8221;</P>
<P>Comment: Incomplete information.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-02 00:37:27 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Krakowski-2006">
<DESCRIPTION>
<P>Quote: &#8220; patients were randomly assigned to 1 of 3 treatment arm..&#8221; &#8220;The study used block randomisation scheme with a block size of 3..&#8221;</P>
<P>Comment: Incomplete information.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-04-30 15:44:55 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kumra-2008">
<DESCRIPTION>
<P>Quote: &#8220;...medication were assigned to their groups by research pharmacist with a computer-generated randomisation schedule.&#8221;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-18 20:05:48 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Li--2002">
<DESCRIPTION>
<P>Random, no further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-18 20:09:22 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Li--2003">
<DESCRIPTION>
<P>Random, no further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-18 19:57:22 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Li--2005">
<DESCRIPTION>
<P>Random, no further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-01-15 18:52:24 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lin-2003">
<DESCRIPTION>
<P>Quote: &#8220;59 patients were allocated on a random..&#8221;</P>
<P>Comment: Incomplete information.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-01-15 18:55:19 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lindenberg-1997">
<DESCRIPTION>
<P>Quote: &#8220;They were randomly assigned..&#8221;</P>
<P>Comment: Incomplete information.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-18 20:11:26 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Liu--2004">
<DESCRIPTION>
<P>Random, no further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-01-15 18:57:10 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-McGurk-2005">
<DESCRIPTION>
<P>Quote: &#8220; random assignment trial..&#8221;</P>
<P>Comment: Incomplete information.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-02 00:39:30 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Meltzer-2003">
<DESCRIPTION>
<P>Quote: &#8220;For randomisation, patients were blocked by country and medical centre&#8221; &#8220;..The 2 treatment groups were allocated randomly in a 1:1 ratio within blocks of 4 patients in each medical centre&#8221;.</P>
<P>Comment: Probably not done.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-02 00:39:57 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Moresco-2004">
<DESCRIPTION>
<P>Quote: &#8220;Before randomisation..&#8221;</P>
<P>Comment: Information incomplete.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-02 00:40:19 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Naber-2005">
<DESCRIPTION>
<P>Quote: "This randomised double blind controlled trial.." Patients were allocated 1:1 ratio.</P>
<P>Comment: Incomplete information.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-04-30 16:22:28 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ren-2002">
<DESCRIPTION>
<P>Allocation: random, ball drawing out of a covered box. Probably yes.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-04-12 21:44:48 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sacchetti-2006">
<DESCRIPTION>
<P>Quote: &#8220;Patients completed a 3-7 day screening period before being randomised&#8221;</P>
<P>Comment: Incomplete information.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-01-15 19:07:36 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Shaw-2006">
<DESCRIPTION>
<P>Quote: "Random allocation used a random-numbers chart and was conducted  in blocks of 4".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-01-29 14:52:23 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Tollefson-2001">
<DESCRIPTION>
<P>Quote: &#8220;patients were randomly allocated in a 1:1 ratio to treatment with olanzapine 15-25 mg/day or clozapine 200-600 mg/day&#8221;</P>
<P>Comment: Incomplete information.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-01-15 19:12:53 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Volavka-2002">
<DESCRIPTION>
<P>Quote: &#8220;.. patients were randomly assigned to one of the four treatment arm..&#8221;</P>
<P>Comment: Incomplete information.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-02 00:42:02 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Wahlbeck-2000">
<DESCRIPTION>
<P>Quote: &#8220;Patients were individually assigned to open label treatment by computer-generated randomisation&#8221;.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-18 20:13:33 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wang-2002">
<DESCRIPTION>
<P>Random, no further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-18 20:19:33 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Zhou-2000">
<DESCRIPTION>
<P>Random, no further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2009-02-18 20:19:35 +0000" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment?</NAME>
<DESCRIPTION>
<P>Was allocation adequately concealed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-01-15 15:13:41 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Atmaca-2003">
<DESCRIPTION>
<P>No information. Probably not done.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-01-15 15:31:13 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Azorin-2001">
<DESCRIPTION>
<P>No information. Probably not done.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-01-15 15:33:59 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Bitter-2004">
<DESCRIPTION>
<P>Probably not done.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-01-15 15:37:03 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Bondolfi-1998">
<DESCRIPTION>
<P>No information. Probably not done.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-01-15 15:39:14 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Breier-1999">
<DESCRIPTION>
<P>No information. Probably not done.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-01-15 15:41:18 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Conley-2003">
<DESCRIPTION>
<P>No information. Probably not done.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-01-15 15:44:06 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Heinrich-1994">
<DESCRIPTION>
<P>No information. Probably not done.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-01-15 15:47:19 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Krakowski-2006">
<DESCRIPTION>
<P>Probably not done.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-01-15 15:49:43 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Kumra-2008">
<DESCRIPTION>
<P>Probably not done.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-18 20:08:38 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Li--2002">
<DESCRIPTION>
<P>No further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-18 20:09:25 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Li--2003">
<DESCRIPTION>
<P>No further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-18 19:57:51 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Li--2005">
<DESCRIPTION>
<P>No further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-01-15 18:52:26 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Lin-2003">
<DESCRIPTION>
<P>No information. Probably not done.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-01-15 18:55:31 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Lindenberg-1997">
<DESCRIPTION>
<P>Probably not done.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-18 20:11:30 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Liu--2004">
<DESCRIPTION>
<P>No further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-01-15 18:57:31 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-McGurk-2005">
<DESCRIPTION>
<P>Probably not done.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-01-15 18:59:15 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Meltzer-2003">
<DESCRIPTION>
<P>No Information. Probably not done.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-01-15 19:01:12 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Moresco-2004">
<DESCRIPTION>
<P>Probably not done.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-01-15 19:03:13 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Naber-2005">
<DESCRIPTION>
<P>No information. Probably not done.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-18 20:16:28 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ren-2002">
<DESCRIPTION>
<P>No further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-01-15 19:06:02 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Sacchetti-2006">
<DESCRIPTION>
<P>No information. Probably not done.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-01-15 19:07:52 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Shaw-2006">
<DESCRIPTION>
<P>Quote: &#8220;Numbered containers were used to implement the random allocation sequence..&#8221;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-01-15 19:09:40 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Tollefson-2001">
<DESCRIPTION>
<P>No information. Probably not done.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-01-15 19:13:09 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Volavka-2002">
<DESCRIPTION>
<P>No information. Probably not done.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-01-15 19:15:50 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Wahlbeck-2000">
<DESCRIPTION>
<P>Quote: &#8220;..the treating physician contacted the senior investigator, who provided the allocation information..&#8221;</P>
<P>Comment: Probably done.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-18 20:13:35 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wang-2002">
<DESCRIPTION>
<P>No further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-18 20:19:35 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Zhou-2000">
<DESCRIPTION>
<P>No further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2010-10-05 14:46:46 +0100" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Blinding?</NAME>
<DESCRIPTION>
<P>Was knowledge of the allocated interventions adequately prevented during the study?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-08-14 14:50:08 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Atmaca-2003">
<DESCRIPTION>
<P>Quote: "raters were blind to drug assignment." "The prescribing physician was not blind to assignment"<BR/>Comment: Single/rater blind study. Subjective measures may lead a source of bias. Also review authors believe that the fact the prescribing physician was not blind will introduce bias. The success of blinding was not evaluated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-01-15 15:31:34 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Azorin-2001">
<DESCRIPTION>
<P>Quote: &#8220;..assigned to double-blind treatment&#8221;.</P>
<P>Comment: Probably done. The success of blinding was not evaluated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-02-02 00:35:06 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bitter-2004">
<DESCRIPTION>
<P>Quote: &#8220;This was a Phase III, 18-week, randomised, double blind, parallel study&#8221;</P>
<P>Comment: The success of blinding was not evaluated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-01-15 15:37:25 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bondolfi-1998">
<DESCRIPTION>
<P>Quote: &#8220;Double blind, double dummy protocol&#8221;</P>
<P>Comment: Probably done. The success of blinding was not evaluated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-04-30 13:00:50 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Breier-1999">
<DESCRIPTION>
<P>Quote: "..double blind comparison trial.&#8221;</P>
<P>Comment: Probably done. The success of blinding was not evaluated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-04-30 13:02:14 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Conley-2003">
<DESCRIPTION>
<P>Quote: &#8221;randomised double-blind 16 week..&#8221;</P>
<P>Comment: Probably done. The success of blinding was not evaluated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-02-02 00:37:01 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Heinrich-1994">
<DESCRIPTION>
<P>Quote: &#8220;This is a randomised, double blind study..&#8221;</P>
<P>Tablets were identical appearance.</P>
<P>Comment: Probably done. The success of blinding was not evaluated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-01-15 15:47:49 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Krakowski-2006">
<DESCRIPTION>
<P>Quote: &#8220;The medication was administered in a double-blind fashion..&#8221; The success of blinding was not evaluated.</P>
<P>Comment: Probably done.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-01-15 15:50:02 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kumra-2008">
<DESCRIPTION>
<P>Quote: &#8220;medication was administered under double-blind condition&#8221;. The success of blinding was not evaluated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-10-05 14:46:46 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Li--2002">
<DESCRIPTION>
<P>Double, probably identical capsules. Whether blinding was successful has not been examined, but both compounds differ quite substantially in side-effects. This can be a problem for blinding.</P>
<P>Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding. This latter, probably leads a low risk of bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-04-30 15:49:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Li--2003">
<DESCRIPTION>
<P>Single, rater-blind. Whether blinding was successful has not been examined, but both compounds differ quite substantially in side-effects. This can be a problem for blinding.</P>
<P>Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding. This latter, probably leads a low risk of bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-10-05 12:05:11 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Li--2005">
<DESCRIPTION>
<P>Double, no further details. Whether blinding was successful has not been examined, but both compounds differ quite substantially in side-effects. This can be a problem for blinding.</P>
<P>Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding. This latter, probably leads a low risk of bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-01-15 18:52:54 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lin-2003">
<DESCRIPTION>
<P>Quote: ".. patients were allocated on a random, rater blind basis.."</P>
<P>Probably done. The success of blinding was not evaluated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-01-15 18:55:47 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lindenberg-1997">
<DESCRIPTION>
<P>Quote: &#8220;They were randomly assigned in a double design to clozapine or zotepine&#8221;</P>
<P>Comment: Probably done. The success of blinding was not evaluated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-04-30 16:14:20 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Liu--2004">
<DESCRIPTION>
<P>Single, rater-blind. Whether blinding was successful has not been examined, but both compounds differ quite substantially in side-effects. This can be a problem for blinding.</P>
<P>Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding. This latter, probably leads a low risk of bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-04-30 16:16:54 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-McGurk-2005">
<DESCRIPTION>
<P>Quote: &#8220; double-blind, 29 week trial..&#8221;</P>
<P>Comment: Probably done.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-04-30 16:18:28 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Meltzer-2003">
<DESCRIPTION>
<P>Single-open label/blind raters.</P>
<P>Comment: Probably done. The rater&#8217;s masking was monitored by external service.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-01-15 19:01:28 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Moresco-2004">
<DESCRIPTION>
<P>Quote:&#8220; A double blind, parallel study.&#8221;</P>
<P>Comment: Probably done. The success of blinding was not evaluated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-02-02 00:40:20 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Naber-2005">
<DESCRIPTION>
<P>Quote: &#8220;This randomised double blind controlled trial..&#8221;</P>
<P>Comment: Probably done. Identical capsules were used.The success of blinding was not evaluated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-10-05 14:26:07 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ren-2002">
<DESCRIPTION>
<P>Double, no further details. Whether blinding was successful has not been examined, but the compounds differ quite substantially in side-effects. This can be a problem for blinding.</P>
<P>Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding. This latter, probably leads a low risk of bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-10-05 14:27:06 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sacchetti-2006">
<DESCRIPTION>
<P>Quote: &#8220;Patients completed a 3-7 day screening period before being randomised, double-blind..&#8221;</P>
<P>Comment: Probably done. The success of blinding was not evaluated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-01-16 12:06:49 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Shaw-2006">
<DESCRIPTION>
<P>Double blind. Identic tablet form.</P>
<P>Quote: &#8220;Participants and those administering and assessing the intervention and assessing outcomes were blind..&#8221; &#8220;The success of the blinding was not formally assessed&#8221;. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-10-05 14:35:05 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Tollefson-2001">
<DESCRIPTION>
<P>Quote: &#8220;An 18-week double-blind therapy&#8221;</P>
<P>Comment: Probably done. The success of blinding was not evaluated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-01-15 19:13:24 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Volavka-2002">
<DESCRIPTION>
<P>Quote: &#8220;In a double blind trial..&#8221; &#8220;.. all tablets looked alike&#8221;.</P>
<P>Comment: Probably done.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-01-15 19:16:05 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Wahlbeck-2000">
<DESCRIPTION>
<P>Open label/assessor blinded<B> </B>study.</P>
<P>Comment: probably done. The success of blinding was not evaluated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-10-05 14:45:12 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wang-2002">
<DESCRIPTION>
<P>Double, no further details. Whether blinding was successful has not been examined, but both compounds differ quite substantially in side-effects. This can be a problem for blinding.</P>
<P>Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding. This latter, probably leads a low risk of bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-10-05 14:45:43 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Zhou-2000">
<DESCRIPTION>
<P>Single, rater-blind. Whether blinding was successful has not been examined, but the compounds differ quite substantially in side-effects. This can be a problem for blinding.</P>
<P>Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding. This latter, probably leads a low risk of bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2010-10-05 12:09:12 +0100" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Incomplete outcome data addressed?</NAME>
<DESCRIPTION>
<P>Were incomplete outcome data adequately addressed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-08-14 14:50:29 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Atmaca-2003">
<DESCRIPTION>
<P>6/62 patients were excluded (four due to requirement of additional drug and two due to intolerance). The author did not state from which group they were excluded. Another three patients did not complete the study (one clozapine / one olanzapine / one risperidone).</P>
<P>Intention-to-treat analysis was not undertaken.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-01-15 15:31:57 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Azorin-2001">
<DESCRIPTION>
<P>38/138 missing from clozapine group. 34/135 missing from risperidone group. Analysis by intention to treat and LOCF.</P>
<P>Comment: ITT &#8220;considered patients randomly assigned with at least one post-dose BPRS evaluation&#8221;.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-04-30 12:58:42 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Bitter-2004">
<DESCRIPTION>
<P>33/74 missing from clozapine and 30/76 missing from olanzapine. Analysis by intention to treat and LOCF.</P>
<P>Comment: patients analysed were all those had at least one post-baseline measurement.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-01-15 15:37:46 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bondolfi-1998">
<DESCRIPTION>
<P>9/43 missing from clozapine group. 9/43 missing from risperidone group.</P>
<P>Analysis by intention to treat and LOCF.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-02-02 00:35:37 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Breier-1999">
<DESCRIPTION>
<P>Exclusion of 5 patients after randomisation who were not considered in the total sample. Incomplete information. ITT was not performed.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-04-30 13:02:27 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Conley-2003">
<DESCRIPTION>
<P>0/5 missing from clozapine and 3/8 missing from olanzapine. LOCF for patients completing at least two weeks. ITT was not performed.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-04-30 13:15:34 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Heinrich-1994">
<DESCRIPTION>
<P>6/20 missing from clozapine, 13/19 from risperidone 8 mg and 9/20 from risperidone 4 mg. Intention to treat analyses and LOCF.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-04-30 15:42:45 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Krakowski-2006">
<DESCRIPTION>
<P>13/37 missing from clozapine and 11/37 missing from olanzapine. Analysis by intention-to-treat was used.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-04-30 15:45:26 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Kumra-2008">
<DESCRIPTION>
<P>4/19 missing from clozapine and 7/21 missing from olanzapine</P>
<P>Quote:"...analyses were performed on the intent-to-treat population"</P>
<P>Comment: ITT considered all patients who received at least one dose of study medication.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-02-18 20:07:32 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Li--2002">
<DESCRIPTION>
<P>The authors only mention two participants leaving the study early due to adverse events in the clozapine group. There is some doubt whether all data on leaving the study early have been presented.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-02-18 20:10:18 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Li--2003">
<DESCRIPTION>
<P>The authors describe only one participant in the quetiapine group who left the<BR/>study early due to inefficacy. This participant was not included in the analysis. There is some doubt whether all data on leaving the study early have been presented.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-10-05 12:09:12 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Li--2005">
<DESCRIPTION>
<P>The overall attrition was 9.1%. Those leaving early were only reported due to any reason. Only completer data were assessed.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-01-15 18:53:08 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lin-2003">
<DESCRIPTION>
<P>No information on abstract.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-04-30 16:15:24 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Lindenberg-1997">
<DESCRIPTION>
<P>7/25 missing from clozapine and 10/25 missing from zotepine. ITT was not performed.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-02-18 20:12:29 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Liu--2004">
<DESCRIPTION>
<P>The authors mention five participants leaving the study early, three due to adverse events in the clozapine group and two due to unclear reasons in the quetiapine group. These five subjects were not included in the analysis. There is some doubt whether all data on leaving the study early have been presented.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-01-15 18:58:02 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-McGurk-2005">
<DESCRIPTION>
<P>30/47 missing from clozapine and 32/50 risperidone. ITT was not performed.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-01-15 18:59:53 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Meltzer-2003">
<DESCRIPTION>
<P>192/490 missing from clozapine and 187/490 missing from olanzapine.</P>
<P>Quote: &#8220;All data obtained was used in intent-to-treat analysis&#8221;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-01-20 19:04:38 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Moresco-2004">
<DESCRIPTION>
<P>6/12 missing from clozapine and 2/11 missing from olanzapine.</P>
<P>ITT not performed.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-01-15 19:03:50 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Naber-2005">
<DESCRIPTION>
<P>35/57 missing from clozapine and 36/57 from olanzapine.Intention to treat analyses and LOCF was used.</P>
<P>Comment: ITT considered the patients with at least one post-baseline value.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-02-18 20:17:11 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Ren-2002">
<DESCRIPTION>
<P>Data on leaving the study early were not provided.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-01-15 19:06:34 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sacchetti-2006">
<DESCRIPTION>
<P>Analysis by intention to treat and LOCF.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-01-20 19:06:31 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Shaw-2006">
<DESCRIPTION>
<P>No participant was loss during trial on clozapine group. 1/13 was missing from olanzapine group. Analysis by intention to treat and LOCF</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-01-15 19:10:38 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Tollefson-2001">
<DESCRIPTION>
<P>37/90 missing from clozapine and 36/90 missing from olanzapine.</P>
<P>Quote: &#8220;All end point analyses used a last observation carried forward (LOCF) algorithm&#8221; Comment: OC technique for weekly measures of patients with at least  one post-baseline measurement. ITT analysis was not performed.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-01-15 19:13:43 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Volavka-2002">
<DESCRIPTION>
<P>18/40 missing from clozapine, 13/39 from olanzapine and 19/41 from risperidone. ITT was not performed.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-01-15 19:16:25 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Wahlbeck-2000">
<DESCRIPTION>
<P>6/11 missing from clozapine and 1/9 missing from risperidone. Analysis by intention to treat and LOCF.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-02-18 20:14:43 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Wang-2002">
<DESCRIPTION>
<P>Data on leaving the study early were not provided.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-02-18 20:20:21 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Zhou-2000">
<DESCRIPTION>
<P>No participant left the study early.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2010-10-05 14:40:17 +0100" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Free of selective reporting?</NAME>
<DESCRIPTION>
<P>Are reports of the study free of suggestion of selective outcome reporting?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-01-15 15:14:25 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Atmaca-2003">
<DESCRIPTION>
<P>Review authors do not believe this will introduce bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-01-15 15:32:31 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Azorin-2001">
<DESCRIPTION>
<P>Review authors do not believe this will introduce bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-01-20 18:55:19 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Bitter-2004">
<DESCRIPTION>
<P>Quote: &#8220;Spontaneously reported adverse events with an incidence of 5% in either treatment group or with a statistically significant difference ( P &lt; .05) between groups&#8221;.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-01-15 15:38:03 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Bondolfi-1998">
<DESCRIPTION>
<P>Quote: &#8220;Adverse events reported by 5% or more of either treatment group during the trial&#8221;.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-01-15 15:40:06 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Breier-1999">
<DESCRIPTION>
<P>Review authors do not believe this will introduce bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-01-15 15:42:57 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Conley-2003">
<DESCRIPTION>
<P>Adverse events that occurred only in one person were not reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-10-06 00:24:14 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Heinrich-1994">
<DESCRIPTION>
<P>There was incomplete information about some adverse events as body weight, blood pressure, ECG.</P>
<P>Adverse events considered only the most frequent spontaneously reported adverse experience.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-01-15 15:48:24 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Krakowski-2006">
<DESCRIPTION>
<P>Adverse events assessed but it was not reported in the article.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-04-30 15:45:31 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Kumra-2008">
<DESCRIPTION>
<P>Side-effects: Study reported only the participants who gained &gt;7% of their baseline body weight.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-18 20:08:19 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Li--2002">
<DESCRIPTION>
<P>We did not find evidence for selective reporting.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-18 20:10:34 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Li--2003">
<DESCRIPTION>
<P>The study duration was eight weeks, but outcomes only at four weeks were available.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-18 20:00:42 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Li--2005">
<DESCRIPTION>
<P>There was no reporting on adverse effects</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-01-15 18:53:14 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lin-2003">
<DESCRIPTION>
<P>No information on abstract.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-01-15 18:56:23 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Lindenberg-1997">
<DESCRIPTION>
<P>Quote: &#8220;Analysis refers to a sub-sample of 26 patients, (matched for age).&#8221;</P>
<P>Comment: Data from sub sample was not used in our review.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-18 20:12:31 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Liu--2004">
<DESCRIPTION>
<P>The mean doses of the medications used were not indicated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-01-15 18:58:18 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-McGurk-2005">
<DESCRIPTION>
<P>Review authors do not believe this will introduce bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-01-15 19:00:09 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Meltzer-2003">
<DESCRIPTION>
<P>Review authors do not believe this will introduce bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-01-15 19:02:02 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Moresco-2004">
<DESCRIPTION>
<P>No information about form to assess the adverse events.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-01-15 19:04:13 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Naber-2005">
<DESCRIPTION>
<P>Adverse event were recorded from spontaneously report. Probably reporting bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-18 20:17:13 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Ren-2002">
<DESCRIPTION>
<P>Secondary outcomes were poorly reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-01-15 19:06:58 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sacchetti-2006">
<DESCRIPTION>
<P>No information on abstract.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-01-15 19:08:36 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Shaw-2006">
<DESCRIPTION>
<P>Review authors do not believe this will introduce bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-02 00:41:21 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Tollefson-2001">
<DESCRIPTION>
<P>Spontaneously Reported Treatment-Emergent Adverse Events with an Incidence of &#8805;5% in either Treatment Group, or with a statistically significant difference (P<I>&lt; </I>.05) between treatment Groups. Solicited treatment-emergent adverse events with statistically significant difference.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-05 14:40:17 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Volavka-2002">
<DESCRIPTION>
<P>Some outcomes were reported on subgroup from the entire sample (Czobor 2002, Volavka 2004, Bilder 2001, Lindenmayer 2003).The author reported the use of the Quality of Life Scale, but the results are not on article, (Bilder 2001).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-01-15 19:16:38 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Wahlbeck-2000">
<DESCRIPTION>
<P>Review authors do not believe this will introduce bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-18 20:14:44 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Wang-2002">
<DESCRIPTION>
<P>Data were not available for all of the predefined adverse effect outcomes.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-18 20:20:23 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Zhou-2000">
<DESCRIPTION>
<P>No clear evidence for selective reporting.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2010-10-05 11:48:06 +0100" MODIFIED_BY="[Empty name]" NO="6">
<NAME>Free of other bias?</NAME>
<DESCRIPTION>
<P>Was the study apparently free of other problems that could put it at a high risk of bias?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-01-15 15:14:31 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Atmaca-2003">
<DESCRIPTION>
<P>Review authors have not found other sources of bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-01-15 15:32:54 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Azorin-2001">
<DESCRIPTION>
<P>Study supported by a grant from Novartis Pharma S.A.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-01-15 15:36:09 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bitter-2004">
<DESCRIPTION>
<P>The study was sponsored by Eli Lilly and company.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-05 11:48:06 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bondolfi-1998">
<DESCRIPTION>
<P>Study supported by a grant from industry of both study drugs. The study used low clozapine doses.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-01-15 15:40:30 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Breier-1999">
<DESCRIPTION>
<P>Quote: &#8220;Nineteen of the 29 patients underwent a drug-free period before random assignment&#8221;. Comment: Probably performance bias. Author from Industry.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-01-15 15:43:13 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Conley-2003">
<DESCRIPTION>
<P>Review authors have not found other sources of bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-01-15 15:46:00 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Heinrich-1994">
<DESCRIPTION>
<P>Review authors have not found other sources of bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-02 00:37:30 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Krakowski-2006">
<DESCRIPTION>
<P>Quote: &#8220;The setting limits the generalisability of the findings&#8221;.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-01-15 15:51:15 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kumra-2008">
<DESCRIPTION>
<P>Review authors have not found other sources of bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-18 20:07:53 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Li--2002">
<DESCRIPTION>
<P>There were no data on pre study medication, therefore baseline imbalance can not be excluded.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-18 20:10:24 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Li--2003">
<DESCRIPTION>
<P>The allowed dose range was not indicated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-18 20:01:11 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Li--2005">
<DESCRIPTION>
<P>Baseline characteristics have not been presented for both groups separately. Therefore, baseline imbalance can not be excluded. Furthermore, there was no wash-out period.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-01-15 18:53:29 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Lin-2003">
<DESCRIPTION>
<P>Quote: &#8220;Patients taking clozapine for more 5 month were allocated on a random to two groups: one maintained on clozapine and another switched to zotepine&#8221;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-04-30 16:15:34 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lindenberg-1997">
<DESCRIPTION>
<P>Quote: &#8220;This study was sponsored and monitored by Klinge Pharma (manufacturer of zotepine)&#8221;.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-04-30 16:14:34 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Liu--2004">
<DESCRIPTION>
<P>Clozapine was titrated to 400 mg/day within 10 days. Such a fast dose increase can be accompanied by a higher rate of adverse effects.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-01-15 18:58:32 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-McGurk-2005">
<DESCRIPTION>
<P>Review authors have not found other sources of bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-01-15 19:00:24 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Meltzer-2003">
<DESCRIPTION>
<P>The study sponsor was Novartis Pharmaceuticals Corp.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-01-15 19:02:24 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Moresco-2004">
<DESCRIPTION>
<P>Quote: &#8220;Study was partially supported by Eli-Lilly&#8221;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-01-15 19:04:46 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Naber-2005">
<DESCRIPTION>
<P>Study funded by Lilly Deutschland GmbH.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-18 20:17:15 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ren-2002">
<DESCRIPTION>
<P>The allowed dose ranges were not indicated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-01-15 19:06:54 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sacchetti-2006">
<DESCRIPTION>
<P>No information on abstract.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-01-15 19:08:53 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Shaw-2006">
<DESCRIPTION>
<P>Review authors have not found other sources of bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-01-15 19:12:25 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Tollefson-2001">
<DESCRIPTION>
<P>Review authors have not found other sources of bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-02 00:41:47 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Volavka-2002">
<DESCRIPTION>
<P>&#8220;The olanzapine arm was added in November 1997 and required a modified randomisation procedure&#8221;..." it entails the potential for a bias that could be manifested as a cohort effect.&#8221;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-01-15 19:17:03 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Wahlbeck-2000">
<DESCRIPTION>
<P>Quote: "Readers have to bear in mind that the low statistical power of this study may hides some clinically relevant differences in drug efficacy".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-04-30 16:36:47 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Wang-2002">
<DESCRIPTION>
<P>The sponsor was unclear. The upper dose range limit of clozapine was 400 mg/day which was reached rather quickly (10 days), which could mean a disadvantage for clozapine in terms of side-effects.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-18 20:20:25 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Zhou-2000">
<DESCRIPTION>
<P>The description of blinding differed between the abstract (double-blind) and the method section (single-blind).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES MODIFIED="2009-02-01 18:47:28 +0000" MODIFIED_BY="[Empty name]"/>
<ADDITIONAL_TABLES MODIFIED="2010-10-05 14:58:22 +0100" MODIFIED_BY="[Empty name]">
<ADDITIONAL_TABLE ID="TBL-01" MODIFIED="2010-10-05 14:58:22 +0100" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2009-04-15 05:29:52 +0100" MODIFIED_BY="[Empty name]">Suggested design of future study</TITLE>
<TABLE COLS="2" ROWS="4">
<TR>
<TD>
<P>
<B>Methods</B>
</P>
</TD>
<TD>
<P>Allocation:randomised - clearly described generation of sequence and concealment of allocation.<BR/>Blinding: double - described and tested.<BR/>Duration: 6 months minimum.</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Participants</B>
</P>
</TD>
<TD>
<P>Diagnosis: schizophrenia (operational criteria).<BR/>N=2700.*<BR/>Age: any.<BR/>Sex: both.<BR/>History: any.</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Interventions</B>
</P>
</TD>
<TD>
<P>1. Clozapine: dose ~ 300-800 mg/day. N=300.<BR/>2. Amisulpride: dose ~ 400-800 mg/day. N=300.<BR/>3. Aripiprazole: dose ~ 10-30 mg/day. N=300.<BR/>4. Olanzapine: dose ~ 10-20 mg/day. N=300.<BR/>5. Quetiapine: dose ~300-800 mg/day. N=300.<BR/>6. Risperidone: dose ~ 4-8 mg/day. N=300.<BR/>7. Sertindole: dose ~ 12-24 mg/day. N=300.<BR/>8. Ziprasidone: dose ~ 120-160 mg/day. N=300.<BR/>9. Zotepine: dose ~ 100-300 mg/day. N=300.</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Outcomes</B>
</P>
</TD>
<TD>
<P>Leaving study early (any reason, adverse events, inefficacy).<BR/>Service outcomes: hospitalised, time in hospital, attending out patient clinics.<BR/>Global impression: CGI**, relapse.<BR/>Mental state: PANSS.<BR/>Adverse events: UKU.<BR/>Employment, family satisfaction, patient satisfaction.</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>* Power calculation suggested 300/group would allow good chance of showing a 10% difference between groups for primary outcome.<BR/>
<BR/>** Primary outcome.</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2010-10-05 15:11:48 +0100" MODIFIED_BY="[Empty name]">
<COMPARISON ID="CMP-001" MODIFIED="2010-10-05 15:09:32 +0100" MODIFIED_BY="[Empty name]" NO="1">
<NAME>CLOZAPINE versus OLANZAPINE</NAME>
<DICH_OUTCOME CHI2="0.035025242141721945" CI_END="2.809758383020477" CI_START="0.8000277777502789" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="1.499294752603066" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="16" I2="0.0" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="0.4486689756230472" LOG_CI_START="-0.0968949336152674" LOG_EFFECT_SIZE="0.17588702100388984" METHOD="MH" MODIFIED="2009-09-20 00:08:10 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.982639837484493" P_Q="0.0" P_Z="0.2063144914829773" Q="0.0" RANDOM="YES" SCALE="40.435013021863305" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="1480" TOTAL_2="1486" WEIGHT="300.0" Z="1.263764778711113">
<NAME>Death</NAME>
<GROUP_LABEL_1>clozapine</GROUP_LABEL_1>
<GROUP_LABEL_2>olanzapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours clozapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours olanzapine</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.6373501348802266" CI_START="0.6185821866373856" DF="0" EFFECT_SIZE="1.5" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="8" I2="0.0" ID="CMP-001.01.01" LOG_CI_END="0.5607851086784039" LOG_CI_START="-0.20860259056704147" LOG_EFFECT_SIZE="0.17609125905568124" NO="1" P_CHI2="1.0" P_Z="0.3696327354849108" STUDIES="1" TAU2="0.0" TOTAL_1="490" TOTAL_2="490" WEIGHT="100.0" Z="0.8971615378824657">
<NAME>Any reason</NAME>
<DICH_DATA CI_END="3.6373501348802266" CI_START="0.6185821866373856" EFFECT_SIZE="1.5" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="8" LOG_CI_END="0.5607851086784039" LOG_CI_START="-0.20860259056704147" LOG_EFFECT_SIZE="0.17609125905568124" ORDER="1" O_E="0.0" SE="0.4519421430673091" STUDY_ID="STD-Meltzer-2003" TOTAL_1="490" TOTAL_2="490" VAR="0.2042517006802721" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.380916749944716" CI_START="0.4473949430846257" DF="0" EFFECT_SIZE="1.4" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="5" I2="0.0" ID="CMP-001.01.02" LOG_CI_END="0.6415650004086819" LOG_CI_START="-0.349308929052206" LOG_EFFECT_SIZE="0.14612803567823798" NO="2" P_CHI2="1.0" P_Z="0.5632053611471604" STUDIES="2" TAU2="0.0" TOTAL_1="495" TOTAL_2="498" WEIGHT="100.00000000000001" Z="0.5780870372011047">
<NAME>Natural causes</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="3" O_E="0.0" SE="0.0" STUDY_ID="STD-Conley-2003" TOTAL_1="5" TOTAL_2="8" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="4.380916749944716" CI_START="0.4473949430846257" EFFECT_SIZE="1.4" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="5" LOG_CI_END="0.6415650004086819" LOG_CI_START="-0.349308929052206" LOG_EFFECT_SIZE="0.14612803567823798" ORDER="2" O_E="0.0" SE="0.5820442510703817" STUDY_ID="STD-Meltzer-2003" TOTAL_1="490" TOTAL_2="490" VAR="0.3387755102040816" WEIGHT="100.00000000000001"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="6.935778431956695" CI_START="0.4004997860051481" DF="0" EFFECT_SIZE="1.6666666666666667" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" I2="0.0" ID="CMP-001.01.03" LOG_CI_END="0.8410952108644119" LOG_CI_START="-0.397397711631699" LOG_EFFECT_SIZE="0.22184874961635637" NO="3" P_CHI2="1.0" P_Z="0.4825738906578896" STUDIES="2" TAU2="0.0" TOTAL_1="495" TOTAL_2="498" WEIGHT="100.0" Z="0.7021688236812158">
<NAME>Suicide</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="5" O_E="0.0" SE="0.0" STUDY_ID="STD-Conley-2003" TOTAL_1="5" TOTAL_2="8" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="6.935778431956695" CI_START="0.4004997860051481" EFFECT_SIZE="1.6666666666666667" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" LOG_CI_END="0.8410952108644119" LOG_CI_START="-0.397397711631699" LOG_EFFECT_SIZE="0.22184874961635637" ORDER="4" O_E="0.0" SE="0.7274968733130556" STUDY_ID="STD-Meltzer-2003" TOTAL_1="490" TOTAL_2="490" VAR="0.529251700680272" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="5.631693960695902" CI_END="1.166676962297103" CI_START="0.9256324305643768" CI_STUDY="95" CI_TOTAL="95" DF="10" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0391891224866296" ESTIMABLE="YES" EVENTS_1="338" EVENTS_2="327" I2="0.0" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="0.06695062218697628" LOG_CI_START="-0.0335614377982911" LOG_EFFECT_SIZE="0.016694592194342616" METHOD="MH" MODIFIED="2009-09-20 22:42:40 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.8451997765811264" P_Q="0.0" P_Z="0.5149935218052963" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="11" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="847" TOTAL_2="855" WEIGHT="100.00000000000001" Z="0.6510820580593223">
<NAME>Leaving the study early: 1. Any reason</NAME>
<GROUP_LABEL_1>clozapine</GROUP_LABEL_1>
<GROUP_LABEL_2>olanzapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours clozapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours olanzapine</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="4.464744316442489" CI_END="1.7419101300744095" CI_START="0.6478169945604068" DF="5" EFFECT_SIZE="1.0622800879519163" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="25" I2="0.0" ID="CMP-001.02.01" LOG_CI_END="0.24102574480506092" LOG_CI_START="-0.18854766307638862" LOG_EFFECT_SIZE="0.02623904086433611" MODIFIED="2009-09-20 00:39:23 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.4846146206758354" P_Z="0.8107678578279008" STUDIES="6" TAU2="0.0" TOTAL_1="98" TOTAL_2="104" WEIGHT="5.474715676774575" Z="0.23943556160332055">
<NAME>short term</NAME>
<DICH_DATA CI_END="14.45413717356195" CI_START="0.06918434410800384" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1599921719703592" LOG_CI_START="-1.1599921719703592" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-04-12 22:22:45 +0100" MODIFIED_BY="[Empty name]" ORDER="1633" O_E="0.0" SE="1.3627702877384937" STUDY_ID="STD-Atmaca-2003" TOTAL_1="14" TOTAL_2="14" VAR="1.8571428571428572" WEIGHT="0.1877008500974181"/>
<DICH_DATA CI_END="3.4447687671831364" CI_START="0.01332988378911924" EFFECT_SIZE="0.21428571428571427" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.5371600748628567" LOG_CI_START="-1.875173636780008" LOG_EFFECT_SIZE="-0.6690067809585756" ORDER="7" O_E="0.0" SE="1.4170167634634772" STUDY_ID="STD-Conley-2003" TOTAL_1="5" TOTAL_2="8" VAR="2.007936507936508" WEIGHT="0.17360473882528"/>
<DICH_DATA CI_END="2.289125259784771" CI_START="0.6101432016032856" EFFECT_SIZE="1.1818181818181819" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="11" LOG_CI_END="0.3596695577007303" LOG_CI_START="-0.21456822340350684" LOG_EFFECT_SIZE="0.07255066714861175" ORDER="8" O_E="0.0" SE="0.33731011514348896" STUDY_ID="STD-Krakowski-2006" TOTAL_1="37" TOTAL_2="37" VAR="0.11377811377811378" WEIGHT="3.063746457582038"/>
<DICH_DATA CI_END="1.9144491531490953" CI_START="0.2321526501309129" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="7" LOG_CI_END="0.28204383618382767" LOG_CI_START="-0.6342263542951901" LOG_EFFECT_SIZE="-0.17609125905568127" ORDER="11" O_E="0.0" SE="0.5382216454979674" STUDY_ID="STD-Kumra-2008" TOTAL_1="18" TOTAL_2="21" VAR="0.2896825396825397" WEIGHT="1.2033424362409817"/>
<DICH_DATA CI_END="10.880425950165126" CI_START="0.6950555092822654" EFFECT_SIZE="2.75" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="2" LOG_CI_END="1.0366458975850705" LOG_CI_START="-0.1579805099245452" LOG_EFFECT_SIZE="0.43933269383026263" ORDER="9" O_E="0.0" SE="0.701729465267237" STUDY_ID="STD-Moresco-2004" TOTAL_1="12" TOTAL_2="11" VAR="0.4924242424242423" WEIGHT="0.7079003489388341"/>
<DICH_DATA CI_END="8.051043318273" CI_START="0.01600570079017955" EFFECT_SIZE="0.358974358974359" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9058521633503449" LOG_CI_START="-1.7957253060468672" LOG_EFFECT_SIZE="-0.44493657134826115" ORDER="10" O_E="0.0" SE="1.5869199785480734" STUDY_ID="STD-Shaw-2006" TOTAL_1="12" TOTAL_2="13" VAR="2.518315018315018" WEIGHT="0.13842084509002325"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.1755960817193796" CI_END="1.2622044788399087" CI_START="0.8781059507989217" DF="3" EFFECT_SIZE="1.0527816791692262" ESTIMABLE="YES" EVENTS_1="122" EVENTS_2="115" I2="0.0" ID="CMP-001.02.02" LOG_CI_END="0.10112971690356953" LOG_CI_START="-0.05645307968474451" LOG_EFFECT_SIZE="0.022338318609412496" MODIFIED="2009-09-20 00:39:31 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.7588631852681309" P_Z="0.5784340096256253" STUDIES="4" TAU2="0.0" TOTAL_1="259" TOTAL_2="261" WEIGHT="40.683540517788245" Z="0.5556736001330252">
<NAME>medium term</NAME>
<DICH_DATA CI_END="1.622880075838585" CI_START="0.7607265130768422" EFFECT_SIZE="1.1111111111111112" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="30" LOG_CI_END="0.21028642843631223" LOG_CI_START="-0.1187714473149619" LOG_EFFECT_SIZE="0.04575749056067514" ORDER="15" O_E="0.0" SE="0.19329022507905333" STUDY_ID="STD-Bitter-2004" TOTAL_1="72" TOTAL_2="75" VAR="0.0373611111111111" WEIGHT="9.33021750882546"/>
<DICH_DATA CI_END="1.2938441242481262" CI_START="0.7305486276656366" EFFECT_SIZE="0.9722222222222222" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="36" LOG_CI_END="0.11188195789638253" LOG_CI_START="-0.13635087073040583" LOG_EFFECT_SIZE="-0.012234456417011635" ORDER="12" O_E="0.0" SE="0.1458131923076946" STUDY_ID="STD-Naber-2005" TOTAL_1="57" TOTAL_2="57" VAR="0.02126148705096073" WEIGHT="16.395245177468"/>
<DICH_DATA CI_END="1.4640186248869425" CI_START="0.7215257665013659" EFFECT_SIZE="1.0277777777777777" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="36" LOG_CI_END="0.16554660174571584" LOG_CI_START="-0.14174815514630051" LOG_EFFECT_SIZE="0.01189922329970769" ORDER="13" O_E="0.0" SE="0.1805064613319495" STUDY_ID="STD-Tollefson-2001" TOTAL_1="90" TOTAL_2="90" VAR="0.03258258258258258" WEIGHT="10.698577749463109"/>
<DICH_DATA CI_END="2.3650445055190543" CI_START="0.7705986063886006" EFFECT_SIZE="1.35" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="13" LOG_CI_END="0.37383931772477164" LOG_CI_START="-0.11317178073475934" LOG_EFFECT_SIZE="0.13033376849500614" ORDER="14" O_E="0.0" SE="0.28607272997894584" STUDY_ID="STD-Volavka-2002" TOTAL_1="40" TOTAL_2="39" VAR="0.08183760683760685" WEIGHT="4.259500082031673"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.2021256153940005" CI_START="0.8769390164035032" DF="0" EFFECT_SIZE="1.0267379679144386" ESTIMABLE="YES" EVENTS_1="192" EVENTS_2="187" I2="0.0" ID="CMP-001.02.03" LOG_CI_END="0.07994985137891683" LOG_CI_START="-0.05703060704481542" LOG_EFFECT_SIZE="0.011459622167050685" NO="3" P_CHI2="1.0" P_Z="0.7429596685116229" STUDIES="1" TAU2="0.0" TOTAL_1="490" TOTAL_2="490" WEIGHT="53.8417438054372" Z="0.3279365098104366">
<NAME>long term</NAME>
<DICH_DATA CI_END="1.2021256153940005" CI_START="0.8769390164035032" EFFECT_SIZE="1.0267379679144386" ESTIMABLE="YES" EVENTS_1="192" EVENTS_2="187" LOG_CI_END="0.07994985137891683" LOG_CI_START="-0.05703060704481542" LOG_EFFECT_SIZE="0.011459622167050685" ORDER="16" O_E="0.0" SE="0.0804629993423052" STUDY_ID="STD-Meltzer-2003" TOTAL_1="490" TOTAL_2="490" VAR="0.006474294263159808" WEIGHT="53.8417438054372"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="7.817785019690982" CI_END="2.3960298367990736" CI_START="1.073427986147651" CI_STUDY="95" CI_TOTAL="95" DF="7" EFFECT_MEASURE="RR" EFFECT_SIZE="1.6037348541653993" ESTIMABLE="YES" EVENTS_1="87" EVENTS_2="54" I2="10.460571858028745" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="0.3794922218460362" LOG_CI_START="0.03077291391640899" LOG_EFFECT_SIZE="0.2051325678812226" METHOD="MH" MODIFIED="2009-09-20 22:42:34 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.34893556880060583" P_Q="0.0" P_Z="0.021117336463201724" Q="0.0" RANDOM="YES" SCALE="14.842480658576743" SORT_BY="STUDY" STUDIES="10" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.03898868631803198" TOTALS="YES" TOTAL_1="833" TOTAL_2="841" WEIGHT="100.0" Z="2.3058800356678257">
<NAME>Leaving the study early: 2. Adverse effects</NAME>
<GROUP_LABEL_1>clozapine</GROUP_LABEL_1>
<GROUP_LABEL_2>olanzapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours clozapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours olanzapine</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.19894084157483385" CI_END="11.466381558255804" CI_START="0.9478911860753302" DF="2" EFFECT_SIZE="3.296798752615541" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="3" I2="0.0" ID="CMP-001.03.01" LOG_CI_END="1.059426389373761" LOG_CI_START="-0.02324151498197966" LOG_EFFECT_SIZE="0.5180924371958906" NO="1" P_CHI2="0.9053168027303556" P_Z="0.060680644386677425" STUDIES="5" TAU2="0.0" TOTAL_1="84" TOTAL_2="90" WEIGHT="10.046001639297623" Z="1.8758153141535703">
<NAME>short term</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="21" O_E="0.0" SE="0.0" STUDY_ID="STD-Conley-2003" TOTAL_1="5" TOTAL_2="8" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="27.534342362162683" CI_START="0.32686453453733744" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.4398747081318253" LOG_CI_START="-0.4856321986925004" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="17" O_E="0.0" SE="1.1310522884815182" STUDY_ID="STD-Krakowski-2006" TOTAL_1="37" TOTAL_2="37" VAR="1.2792792792792793" WEIGHT="3.182903659591968"/>
<DICH_DATA CI_END="23.658624211736104" CI_START="0.23012514995456376" EFFECT_SIZE="2.3333333333333335" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.3739894860812747" LOG_CI_START="-0.6380359154920859" LOG_EFFECT_SIZE="0.36797678529459443" ORDER="20" O_E="0.0" SE="1.1818736805705576" STUDY_ID="STD-Kumra-2008" TOTAL_1="18" TOTAL_2="21" VAR="1.3968253968253967" WEIGHT="2.9223281630142606"/>
<DICH_DATA CI_END="33.363817277128824" CI_START="0.6296325228601729" EFFECT_SIZE="4.583333333333333" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="1" LOG_CI_END="1.5232757340385592" LOG_CI_START="-0.2009128471453211" LOG_EFFECT_SIZE="0.661181443446619" ORDER="18" O_E="0.0" SE="1.0127969074585368" STUDY_ID="STD-Moresco-2004" TOTAL_1="12" TOTAL_2="11" VAR="1.0257575757575759" WEIGHT="3.940769816691395"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="19" O_E="0.0" SE="0.0" STUDY_ID="STD-Shaw-2006" TOTAL_1="12" TOTAL_2="13" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="5.588391809991328" CI_END="4.1705516246518" CI_START="0.8047234728893209" DF="3" EFFECT_SIZE="1.8319772889569335" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="18" I2="46.317293024508686" ID="CMP-001.03.02" LOG_CI_END="0.6201935014241817" LOG_CI_START="-0.09435333060093268" LOG_EFFECT_SIZE="0.2629200854116245" NO="2" P_CHI2="0.13344647973517354" P_Z="0.14920319854500388" STUDIES="4" TAU2="0.31859543893107045" TOTAL_1="259" TOTAL_2="261" WEIGHT="42.52419737969293" Z="1.4423516419729001">
<NAME>medium term</NAME>
<DICH_DATA CI_END="2.821614201637872" CI_START="0.3845562741407349" EFFECT_SIZE="1.0416666666666667" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="7" LOG_CI_END="0.45049763253887765" LOG_CI_START="-0.4150400986180145" LOG_EFFECT_SIZE="0.017728766960431616" ORDER="25" O_E="0.0" SE="0.5084211477624269" STUDY_ID="STD-Bitter-2004" TOTAL_1="72" TOTAL_2="75" VAR="0.2584920634920635" WEIGHT="14.104845220072608"/>
<DICH_DATA CI_END="2.9164669835623265" CI_START="0.3428806174169499" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="6" LOG_CI_END="0.464857064277827" LOG_CI_START="-0.464857064277827" LOG_EFFECT_SIZE="0.0" ORDER="22" O_E="0.0" SE="0.5461186812727502" STUDY_ID="STD-Naber-2005" TOTAL_1="57" TOTAL_2="57" VAR="0.2982456140350877" WEIGHT="12.442150539340075"/>
<DICH_DATA CI_END="9.588356826727352" CI_START="1.1015964665141835" EFFECT_SIZE="3.25" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="4" LOG_CI_END="0.981744187751595" LOG_CI_START="0.04202253420615382" LOG_EFFECT_SIZE="0.5118833609788743" ORDER="23" O_E="0.0" SE="0.5519971509897987" STUDY_ID="STD-Tollefson-2001" TOTAL_1="90" TOTAL_2="90" VAR="0.3047008547008547" WEIGHT="12.208459761631104"/>
<DICH_DATA CI_END="59.48068694218465" CI_START="1.0228530154525053" EFFECT_SIZE="7.8" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="1" LOG_CI_END="1.7743759755438884" LOG_CI_START="0.009813229837072668" LOG_EFFECT_SIZE="0.8920946026904804" ORDER="24" O_E="0.0" SE="1.0365128915546467" STUDY_ID="STD-Volavka-2002" TOTAL_1="40" TOTAL_2="39" VAR="1.0743589743589745" WEIGHT="3.7687418586491463"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.0150754219023645" CI_START="0.8425927645985204" DF="0" EFFECT_SIZE="1.303030303030303" ESTIMABLE="YES" EVENTS_1="43" EVENTS_2="33" I2="0.0" ID="CMP-001.03.03" LOG_CI_END="0.30429130591286396" LOG_CI_START="-0.07438227450946588" LOG_EFFECT_SIZE="0.11495451570169903" NO="3" P_CHI2="1.0" P_Z="0.23405486175835588" STUDIES="1" TAU2="0.0" TOTAL_1="490" TOTAL_2="490" WEIGHT="47.42980098100945" Z="1.1899785054150993">
<NAME>long term</NAME>
<DICH_DATA CI_END="2.0150754219023645" CI_START="0.8425927645985204" EFFECT_SIZE="1.303030303030303" ESTIMABLE="YES" EVENTS_1="43" EVENTS_2="33" LOG_CI_END="0.30429130591286396" LOG_CI_START="-0.07438227450946588" LOG_EFFECT_SIZE="0.11495451570169903" ORDER="26" O_E="0.0" SE="0.22243473560453064" STUDY_ID="STD-Meltzer-2003" TOTAL_1="490" TOTAL_2="490" VAR="0.04947721160345746" WEIGHT="47.42980098100945"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="12.388680018907076" CI_END="1.2982583848746276" CI_START="0.4047581419305838" CI_STUDY="95" CI_TOTAL="95" DF="8" EFFECT_MEASURE="RR" EFFECT_SIZE="0.724900442548944" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="53" I2="35.424920267609295" I2_Q="0.0" ID="CMP-001.04" LOG_CI_END="0.11336113619143266" LOG_CI_START="-0.39280440641656494" LOG_EFFECT_SIZE="-0.13972163511256616" METHOD="MH" MODIFIED="2009-09-20 22:42:28 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.1346862208487215" P_Q="0.0" P_Z="0.2792282913484406" Q="0.0" RANDOM="YES" SCALE="11.604849235724071" SORT_BY="STUDY" STUDIES="10" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.25316220121050714" TOTALS="YES" TOTAL_1="833" TOTAL_2="841" WEIGHT="99.99999999999999" Z="1.0820545834498287">
<NAME>Leaving the study early: 3. Inefficacy</NAME>
<GROUP_LABEL_1>clozapine</GROUP_LABEL_1>
<GROUP_LABEL_2>olanzapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours clozapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours olanzapine</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="2.8958676653321107" CI_END="1.6411309929023021" CI_START="0.16386959869735626" DF="3" EFFECT_SIZE="0.5185860364652081" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="11" I2="0.0" ID="CMP-001.04.01" LOG_CI_END="0.21514324724697245" LOG_CI_START="-0.7855016098378901" LOG_EFFECT_SIZE="-0.28517918129545883" MODIFIED="2009-04-11 02:29:22 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.40796068279486664" P_Z="0.2639253226964329" STUDIES="5" TAU2="0.0" TOTAL_1="84" TOTAL_2="90" WEIGHT="21.19952660136762" Z="1.1171614394902454">
<NAME>short term</NAME>
<DICH_DATA CI_END="3.4447687671831364" CI_START="0.01332988378911924" EFFECT_SIZE="0.21428571428571427" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.5371600748628567" LOG_CI_START="-1.875173636780008" LOG_EFFECT_SIZE="-0.6690067809585756" ORDER="31" O_E="0.0" SE="1.4170167634634772" STUDY_ID="STD-Conley-2003" TOTAL_1="5" TOTAL_2="8" VAR="2.007936507936508" WEIGHT="3.909676610467817"/>
<DICH_DATA CI_END="6.7278533183775675" CI_START="0.14863582077041354" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8278765143425244" LOG_CI_START="-0.8278765143425244" LOG_EFFECT_SIZE="0.0" ORDER="27" O_E="0.0" SE="0.9725975251592748" STUDY_ID="STD-Krakowski-2006" TOTAL_1="37" TOTAL_2="37" VAR="0.945945945945946" WEIGHT="7.372283107303116"/>
<DICH_DATA CI_END="1.4675858912548878" CI_START="0.025762473052244744" EFFECT_SIZE="0.19444444444444445" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="6" LOG_CI_END="0.1666035279819741" LOG_CI_START="-1.589012449488035" LOG_EFFECT_SIZE="-0.7112044607530305" ORDER="30" O_E="0.0" SE="1.0312575156051293" STUDY_ID="STD-Kumra-2008" TOTAL_1="18" TOTAL_2="21" VAR="1.0634920634920635" WEIGHT="6.714112409082602"/>
<DICH_DATA CI_END="61.65259024353402" CI_START="0.12438470180997305" EFFECT_SIZE="2.769230769230769" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.7899513275634158" LOG_CI_START="-0.905233030642515" LOG_EFFECT_SIZE="0.4423591484604505" MODIFIED="2009-04-11 02:29:22 +0100" MODIFIED_BY="[Empty name]" ORDER="28" O_E="0.0" SE="1.583164633387904" STUDY_ID="STD-Moresco-2004" TOTAL_1="12" TOTAL_2="11" VAR="2.506410256410256" WEIGHT="3.2034544745140834"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-04-11 02:29:14 +0100" MODIFIED_BY="[Empty name]" ORDER="29" O_E="0.0" SE="0.0" STUDY_ID="STD-Shaw-2006" TOTAL_1="12" TOTAL_2="13" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="4.557371822847731" CI_END="2.0045966787684493" CI_START="0.5273909572815759" DF="3" EFFECT_SIZE="1.0282053109078753" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="27" I2="34.172586380599235" ID="CMP-001.04.02" LOG_CI_END="0.3020270064798561" LOG_CI_START="-0.2778673209521047" LOG_EFFECT_SIZE="0.012079842763875748" MODIFIED="2009-04-12 20:40:34 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.20722964048910975" P_Z="0.9349199086582117" STUDIES="4" TAU2="0.15728957581609126" TOTAL_1="259" TOTAL_2="261" WEIGHT="61.65997484943577" Z="0.08165645234348695">
<NAME>medium term</NAME>
<DICH_DATA CI_END="3.3694215271395667" CI_START="0.18114431738024517" EFFECT_SIZE="0.78125" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.5275553462316497" LOG_CI_START="-0.7419752855273865" LOG_EFFECT_SIZE="-0.10720996964786836" MODIFIED="2009-04-11 02:29:01 +0100" MODIFIED_BY="[Empty name]" ORDER="35" O_E="0.0" SE="0.7457285773732365" STUDY_ID="STD-Bitter-2004" TOTAL_1="72" TOTAL_2="75" VAR="0.5561111111111111" WEIGHT="10.92358366761245"/>
<DICH_DATA CI_END="4.858499900991737" CI_START="0.9451140945287603" EFFECT_SIZE="2.142857142857143" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="7" LOG_CI_END="0.6865021982156487" LOG_CI_START="-0.024515760132799925" LOG_EFFECT_SIZE="0.3309932190414244" MODIFIED="2009-04-12 20:40:34 +0100" MODIFIED_BY="[Empty name]" ORDER="32" O_E="0.0" SE="0.4176554683295358" STUDY_ID="STD-Naber-2005" TOTAL_1="57" TOTAL_2="57" VAR="0.1744360902255639" WEIGHT="20.673994527484506"/>
<DICH_DATA CI_END="1.6916365305617505" CI_START="0.33251823889923193" EFFECT_SIZE="0.75" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="12" LOG_CI_END="0.22830705508096752" LOG_CI_START="-0.4781845282975674" LOG_EFFECT_SIZE="-0.12493873660829993" MODIFIED="2009-04-11 02:28:58 +0100" MODIFIED_BY="[Empty name]" ORDER="33" O_E="0.0" SE="0.4149966532662911" STUDY_ID="STD-Tollefson-2001" TOTAL_1="90" TOTAL_2="90" VAR="0.17222222222222222" WEIGHT="20.781590133868754"/>
<DICH_DATA CI_END="2.510815306856899" CI_START="0.09465301942001621" EFFECT_SIZE="0.4875" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" LOG_CI_END="0.39981476760621143" LOG_CI_START="-1.0238655275371" LOG_EFFECT_SIZE="-0.3120253799654444" MODIFIED="2009-04-11 02:29:08 +0100" MODIFIED_BY="[Empty name]" ORDER="34" O_E="0.0" SE="0.8362768526983001" STUDY_ID="STD-Volavka-2002" TOTAL_1="40" TOTAL_2="39" VAR="0.6993589743589743" WEIGHT="9.280806520470069"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.9100398109033878" CI_START="0.12209478066768546" DF="0" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="15" I2="0.0" ID="CMP-001.04.03" LOG_CI_END="-0.04093960847288894" LOG_CI_START="-0.9133029009664361" LOG_EFFECT_SIZE="-0.4771212547196625" NO="3" P_CHI2="1.0" P_Z="0.0320389445381182" STUDIES="1" TAU2="0.0" TOTAL_1="490" TOTAL_2="490" WEIGHT="17.140498549196597" Z="2.143924402953984">
<NAME>long term</NAME>
<DICH_DATA CI_END="0.9100398109033878" CI_START="0.12209478066768546" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="15" LOG_CI_END="-0.04093960847288894" LOG_CI_START="-0.9133029009664361" LOG_EFFECT_SIZE="-0.4771212547196625" ORDER="36" O_E="0.0" SE="0.5124305162786515" STUDY_ID="STD-Meltzer-2003" TOTAL_1="490" TOTAL_2="490" VAR="0.2625850340136054" WEIGHT="17.140498549196597"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.7277016978479373" CI_END="1.378283791468788" CI_START="0.929824382427857" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="1.132060897307557" ESTIMABLE="YES" EVENTS_1="91" EVENTS_2="80" I2="0.0" I2_Q="0.0" ID="CMP-001.05" LOG_CI_END="0.13933864890645203" LOG_CI_START="-0.0315990696661229" LOG_EFFECT_SIZE="0.05386978962016457" METHOD="MH" MODIFIED="2009-09-20 23:40:15 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.6949949681754687" P_Q="0.0" P_Z="0.21670511809906068" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="204" TOTAL_2="204" WEIGHT="200.0" Z="1.2353370384482456">
<NAME>Global state</NAME>
<GROUP_LABEL_1>clozapine</GROUP_LABEL_1>
<GROUP_LABEL_2>olanzapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours clozapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours olanzapine</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.7207384682457025" CI_END="1.3798650186215347" CI_START="0.929947957232945" DF="1" EFFECT_SIZE="1.1327853527144036" ESTIMABLE="YES" EVENTS_1="90" EVENTS_2="79" I2="0.0" ID="CMP-001.05.01" LOG_CI_END="0.13983660485414748" LOG_CI_START="-0.031541355229913214" LOG_EFFECT_SIZE="0.05414762481211715" MODIFIED="2009-09-20 23:40:04 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.3959018095650948" P_Z="0.2155238582191843" STUDIES="2" TAU2="0.0" TOTAL_1="147" TOTAL_2="147" WEIGHT="100.0" Z="1.2385185869651105">
<NAME>no clinically important change: less than much improved - medium term</NAME>
<DICH_DATA CI_END="1.3847984365220463" CI_START="0.7652294755446947" EFFECT_SIZE="1.0294117647058822" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="34" LOG_CI_END="0.14138656453643683" LOG_CI_START="-0.1162083099203959" LOG_EFFECT_SIZE="0.012589127308020467" ORDER="37" O_E="0.0" SE="0.15131250437113686" STUDY_ID="STD-Naber-2005" TOTAL_1="57" TOTAL_2="57" VAR="0.022895473979065314" WEIGHT="44.262455545042236"/>
<DICH_DATA CI_END="1.5919380689052962" CI_START="0.9383701474775742" EFFECT_SIZE="1.2222222222222223" ESTIMABLE="YES" EVENTS_1="55" EVENTS_2="45" LOG_CI_END="0.20192616839169125" LOG_CI_START="-0.02762581695389083" LOG_EFFECT_SIZE="0.0871501757189002" ORDER="38" O_E="0.0" SE="0.1348399724926484" STUDY_ID="STD-Tollefson-2001" TOTAL_1="90" TOTAL_2="90" VAR="0.018181818181818174" WEIGHT="55.737544454957764"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="15.601794815114387" CI_START="0.06409518980670356" DF="0" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" I2="0.0" ID="CMP-001.05.02" LOG_CI_END="1.1931745620380056" LOG_CI_START="-1.1931745620380056" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-09-20 23:40:15 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="1.0" STUDIES="1" TAU2="0.0" TOTAL_1="57" TOTAL_2="57" WEIGHT="100.0" Z="0.0">
<NAME>relapse - medium term</NAME>
<DICH_DATA CI_END="15.601794815114387" CI_START="0.06409518980670356" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1931745620380056" LOG_CI_START="-1.1931745620380056" LOG_EFFECT_SIZE="0.0" ORDER="39" O_E="0.0" SE="1.4017532881009247" STUDY_ID="STD-Naber-2005" TOTAL_1="57" TOTAL_2="57" VAR="1.9649122807017543" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="6.1347634225919805" CI_END="1.0808922023295693" CI_START="0.9343992161989344" CI_STUDY="95" CI_TOTAL="95" DF="7" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0049800130611004" ESTIMABLE="YES" EVENTS_1="260" EVENTS_2="270" I2="0.0" I2_Q="0.0" ID="CMP-001.06" LOG_CI_END="0.03378238380730173" LOG_CI_START="-0.02946753453028497" LOG_EFFECT_SIZE="0.0021574246385083814" METHOD="MH" MODIFIED="2009-09-21 00:12:57 +0100" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.5241050121808828" P_Q="0.0" P_Z="0.8936343653388716" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="397" TOTAL_2="407" WEIGHT="600.0" Z="0.13370687905925613">
<NAME>Mental state: 1. No clinically important change - various criteria</NAME>
<GROUP_LABEL_1>clozapine</GROUP_LABEL_1>
<GROUP_LABEL_2>olanzapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours clozapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours olanzapine</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.2510216779047931" CI_START="0.4961968248455798" DF="0" EFFECT_SIZE="0.7878787878787878" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="11" I2="0.0" ID="CMP-001.06.01" LOG_CI_END="0.09726483528323739" LOG_CI_START="-0.3043460190973764" LOG_EFFECT_SIZE="-0.10354059190706953" NO="1" P_CHI2="1.0" P_Z="0.31220347938693704" STUDIES="1" TAU2="0.0" TOTAL_1="12" TOTAL_2="13" WEIGHT="99.99999999999999" Z="1.010609294356819">
<NAME>less than 20% BPRS reduction (short term)</NAME>
<DICH_DATA CI_END="1.2510216779047931" CI_START="0.4961968248455798" EFFECT_SIZE="0.7878787878787878" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="11" LOG_CI_END="0.09726483528323739" LOG_CI_START="-0.3043460190973764" LOG_EFFECT_SIZE="-0.10354059190706953" ORDER="40" O_E="0.0" SE="0.2359082038689639" STUDY_ID="STD-Shaw-2006" TOTAL_1="12" TOTAL_2="13" VAR="0.05565268065268064" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.027156662643833" CI_START="0.62881861241438" DF="0" EFFECT_SIZE="1.1290322580645162" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="12" I2="0.0" ID="CMP-001.06.02" LOG_CI_END="0.3068873131195627" LOG_CI_START="-0.2014746120875567" LOG_EFFECT_SIZE="0.052706350516002996" NO="2" P_CHI2="1.0" P_Z="0.6844388778608546" STUDIES="1" TAU2="0.0" TOTAL_1="31" TOTAL_2="30" WEIGHT="100.0" Z="0.4064133981939027">
<NAME>less than 50% BPRS reduction (short term)</NAME>
<DICH_DATA CI_END="2.027156662643833" CI_START="0.62881861241438" EFFECT_SIZE="1.1290322580645162" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="12" LOG_CI_END="0.3068873131195627" LOG_CI_START="-0.2014746120875567" LOG_EFFECT_SIZE="0.052706350516002996" ORDER="41" O_E="0.0" SE="0.2986143112987762" STUDY_ID="STD-Wang-2002" TOTAL_1="31" TOTAL_2="30" VAR="0.08917050691244241" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.3306160668389362" CI_START="0.8715987597869961" DF="0" EFFECT_SIZE="1.0769230769230769" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="12" I2="0.0" ID="CMP-001.06.03" LOG_CI_END="0.12405276313330134" LOG_CI_START="-0.059683396390498814" LOG_EFFECT_SIZE="0.032184683371401235" NO="3" P_CHI2="1.0" P_Z="0.49230603870167133" STUDIES="1" TAU2="0.0" TOTAL_1="12" TOTAL_2="13" WEIGHT="100.0" Z="0.6866456817782836">
<NAME>less than 20% BPRS reduction and mildly ill or better (short term)</NAME>
<DICH_DATA CI_END="1.3306160668389362" CI_START="0.8715987597869961" EFFECT_SIZE="1.0769230769230769" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="12" LOG_CI_END="0.12405276313330134" LOG_CI_START="-0.059683396390498814" LOG_EFFECT_SIZE="0.032184683371401235" ORDER="42" O_E="0.0" SE="0.1079275296129382" STUDY_ID="STD-Shaw-2006" TOTAL_1="12" TOTAL_2="13" VAR="0.011648351648351651" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.5418548939447273" CI_END="1.2493009888474325" CI_START="0.8522674409604761" DF="1" EFFECT_SIZE="1.0318616945862433" ESTIMABLE="YES" EVENTS_1="87" EVENTS_2="87" I2="0.0" ID="CMP-001.06.04" LOG_CI_END="0.09666708372853461" LOG_CI_START="-0.06942410252454471" LOG_EFFECT_SIZE="0.013621490601994973" NO="4" P_CHI2="0.46166510034488917" P_Z="0.7478454467178719" STUDIES="2" TAU2="0.0" TOTAL_1="162" TOTAL_2="165" WEIGHT="100.0" Z="0.3214816101678115">
<NAME>less than 20% BPRS reduction and mildly ill or better (medium term)</NAME>
<DICH_DATA CI_END="1.3562087052041445" CI_START="0.6069251675431858" EFFECT_SIZE="0.907258064516129" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="31" LOG_CI_END="0.13232652769029787" LOG_CI_START="-0.21686485312000547" LOG_EFFECT_SIZE="-0.04226916271485379" ORDER="44" O_E="0.0" SE="0.2051167456131845" STUDY_ID="STD-Bitter-2004" TOTAL_1="72" TOTAL_2="75" VAR="0.04207287933094384" WEIGHT="22.62383074894846"/>
<DICH_DATA CI_END="1.3315949282754989" CI_START="0.8620933883851228" EFFECT_SIZE="1.0714285714285714" ESTIMABLE="YES" EVENTS_1="60" EVENTS_2="56" LOG_CI_END="0.12437213236465441" LOG_CI_START="-0.06444568560976795" LOG_EFFECT_SIZE="0.029963223377443202" ORDER="43" O_E="0.0" SE="0.11091252094144873" STUDY_ID="STD-Tollefson-2001" TOTAL_1="90" TOTAL_2="90" VAR="0.012301587301587301" WEIGHT="77.37616925105154"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.0271396079730057" CI_START="0.24339437215682783" DF="0" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="14" I2="0.0" ID="CMP-001.06.05" LOG_CI_END="0.011629476558975747" LOG_CI_START="-0.6136894678869381" LOG_EFFECT_SIZE="-0.3010299956639812" NO="5" P_CHI2="1.0" P_Z="0.05915192645182514" STUDIES="1" TAU2="0.0" TOTAL_1="18" TOTAL_2="21" WEIGHT="100.0" Z="1.887062450316292">
<NAME>less than 30% BPRS reduction and much improved or very much improved (short term)</NAME>
<DICH_DATA CI_END="1.0271396079730057" CI_START="0.24339437215682783" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="14" LOG_CI_END="0.011629476558975747" LOG_CI_START="-0.6136894678869381" LOG_EFFECT_SIZE="-0.3010299956639812" ORDER="45" O_E="0.0" SE="0.36731544334622646" STUDY_ID="STD-Kumra-2008" TOTAL_1="18" TOTAL_2="21" VAR="0.1349206349206349" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.045735682861919855" CI_END="1.0963100535720416" CI_START="0.9195295570631911" DF="1" EFFECT_SIZE="1.0040366019050415" ESTIMABLE="YES" EVENTS_1="133" EVENTS_2="134" I2="0.0" ID="CMP-001.06.06" LOG_CI_END="0.03993339676918351" LOG_CI_START="-0.0364343063789899" LOG_EFFECT_SIZE="0.0017495451950968355" NO="6" P_CHI2="0.8306571464751328" P_Z="0.9284433240305748" STUDIES="2" TAU2="0.0" TOTAL_1="162" TOTAL_2="165" WEIGHT="100.0" Z="0.0898035538678329">
<NAME>less than 50% PANSS reduction (medium term)</NAME>
<DICH_DATA CI_END="1.2538001721749175" CI_START="0.8330751056112683" EFFECT_SIZE="1.0220125786163523" ESTIMABLE="YES" EVENTS_1="52" EVENTS_2="53" LOG_CI_END="0.09822832514132852" LOG_CI_START="-0.07931584315244503" LOG_EFFECT_SIZE="0.009456240994441745" ORDER="47" O_E="0.0" SE="0.10429032331356966" STUDY_ID="STD-Bitter-2004" TOTAL_1="72" TOTAL_2="75" VAR="0.010876471536848892" WEIGHT="18.50148696638717"/>
<DICH_DATA CI_END="1.1022917189034416" CI_START="0.907200864209339" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="81" EVENTS_2="81" LOG_CI_END="0.04229654473735869" LOG_CI_START="-0.042296544737358714" LOG_EFFECT_SIZE="0.0" ORDER="46" O_E="0.0" SE="0.049690399499995305" STUDY_ID="STD-Tollefson-2001" TOTAL_1="90" TOTAL_2="90" VAR="0.0024691358024691336" WEIGHT="81.49851303361284"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="1.684204124799995" CI_END="4.660559863177481" CI_START="-0.711404700190021" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="MD" EFFECT_SIZE="1.9745775814937296" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.07" MODIFIED="2009-09-20 01:18:53 +0100" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="0.9463342345365607" P_Q="0.9940033152571863" P_Z="0.14962670933293853" Q="5.648725751683514E-5" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="309" TOTAL_2="309" UNITS="" WEIGHT="100.0" Z="1.4408512560931266">
<NAME>Mental state: 2a. PANSS total score (high = poor)</NAME>
<GROUP_LABEL_1>clozapine</GROUP_LABEL_1>
<GROUP_LABEL_2>olanzapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours clozapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours olanzapine</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="1.192129975281583" CI_END="5.4156328726503915" CI_START="-1.4830752751990188" DF="2" EFFECT_SIZE="1.9662787987256862" ESTIMABLE="YES" I2="0.0" ID="CMP-001.07.01" MODIFIED="2009-01-18 01:43:11 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.550975704313222" P_Z="0.26388191510374104" STUDIES="3" TAU2="0.0" TOTAL_1="56" TOTAL_2="59" WEIGHT="60.6360264270746" Z="1.11726298503247">
<NAME>short term</NAME>
<CONT_DATA CI_END="6.714352920301082" CI_START="-2.3143529203010766" EFFECT_SIZE="2.200000000000003" ESTIMABLE="YES" MEAN_1="77.06" MEAN_2="74.86" MODIFIED="2009-01-18 01:43:11 +0000" MODIFIED_BY="[Empty name]" ORDER="329" SD_1="5.28" SD_2="6.41" SE="2.3032836092447204" STUDY_ID="STD-Atmaca-2003" TOTAL_1="13" TOTAL_2="13" WEIGHT="35.40097886775607"/>
<CONT_DATA CI_END="7.981086382514089" CI_START="-3.101086382514089" EFFECT_SIZE="2.44" ESTIMABLE="YES" MEAN_1="-2.39" MEAN_2="-4.83" ORDER="48" SD_1="14.2" SD_2="9.7" SE="2.8271368383406386" STUDY_ID="STD-Krakowski-2006" TOTAL_1="37" TOTAL_2="37" WEIGHT="23.497217975875785"/>
<CONT_DATA CI_END="11.175090689580372" CI_START="-29.575090689580378" EFFECT_SIZE="-9.200000000000003" ESTIMABLE="YES" MEAN_1="55.8" MEAN_2="65.0" ORDER="50" SD_1="18.9" SD_2="20.9" SE="10.395645455884134" STUDY_ID="STD-Moresco-2004" TOTAL_1="6" TOTAL_2="9" WEIGHT="1.7378295834427375"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.49201766226089516" CI_END="6.268444270386883" CI_START="-2.293722317994718" DF="3" EFFECT_SIZE="1.9873609761960824" ESTIMABLE="YES" I2="0.0" ID="CMP-001.07.02" NO="2" P_CHI2="0.9206416115750281" P_Z="0.3629001162255946" STUDIES="4" TAU2="0.0" TOTAL_1="253" TOTAL_2="250" WEIGHT="39.363973572925396" Z="0.9098528736663926">
<NAME>medium term</NAME>
<CONT_DATA CI_END="7.502754640080644" CI_START="-7.902754640080635" EFFECT_SIZE="-0.19999999999999574" ESTIMABLE="YES" MEAN_1="-37.9" MEAN_2="-37.7" ORDER="54" SD_1="23.4" SD_2="23.1" SE="3.9300490727579613" STUDY_ID="STD-Bitter-2004" TOTAL_1="70" TOTAL_2="70" WEIGHT="12.159456360724386"/>
<CONT_DATA CI_END="13.572644866337145" CI_START="-8.77264486633714" EFFECT_SIZE="2.400000000000002" ESTIMABLE="YES" MEAN_1="-30.2" MEAN_2="-32.6" ORDER="51" SD_1="29.6" SD_2="29.6" SE="5.700433760245361" STUDY_ID="STD-Naber-2005" TOTAL_1="56" TOTAL_2="52" WEIGHT="5.7795536291635194"/>
<CONT_DATA CI_END="10.685247227751553" CI_START="-3.6852472277515522" EFFECT_SIZE="3.5" ESTIMABLE="YES" MEAN_1="-22.1" MEAN_2="-25.6" ORDER="52" SD_1="23.1" SD_2="25.5" SE="3.6660098269294052" STUDY_ID="STD-Tollefson-2001" TOTAL_1="87" TOTAL_2="89" WEIGHT="13.974068099734723"/>
<CONT_DATA CI_END="12.240086310274894" CI_START="-7.440086310274894" EFFECT_SIZE="2.3999999999999995" ESTIMABLE="YES" MEAN_1="-6.7" MEAN_2="-9.1" ORDER="53" SD_1="22.31" SD_2="22.31" SE="5.020544452802316" STUDY_ID="STD-Volavka-2002" TOTAL_1="40" TOTAL_2="39" WEIGHT="7.450895483302767"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="4.352177856028067" CI_END="2.917386411745247" CI_START="-0.29830940731524835" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="MD" EFFECT_SIZE="1.3095385022149992" ESTIMABLE="YES" I2="8.091991358769416" I2_Q="0.0" ID="CMP-001.08" MODIFIED="2010-09-30 13:43:26 +0100" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="0.3604369765553289" P_Q="0.9137293383923932" P_Z="0.11041618375577449" Q="0.011736642382291329" RANDOM="YES" SCALE="13.349536306678317" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.45145029254031416" TOTALS="YES" TOTAL_1="147" TOTAL_2="157" UNITS="" WEIGHT="100.0" Z="1.596325302596439">
<NAME>Mental state: 2b. BPRS-18 (1-7) total score (high = poor)</NAME>
<GROUP_LABEL_1>clozapine</GROUP_LABEL_1>
<GROUP_LABEL_2>olanzapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours clozapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours olanzapine</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="4.340441213645776" CI_END="3.790512500842484" CI_START="-2.019645905280536" DF="3" EFFECT_SIZE="0.8854332977809739" ESTIMABLE="YES" I2="30.882602658725226" ID="CMP-001.08.01" MODIFIED="2009-01-27 20:06:41 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.22697201633695763" P_Z="0.5502580355312428" STUDIES="4" TAU2="3.1621782357790735" TOTAL_1="60" TOTAL_2="68" WEIGHT="86.84299131318545" Z="0.5973735148199654">
<NAME>short term</NAME>
<CONT_DATA CI_END="3.923876252308963" CI_START="-13.763876252308963" EFFECT_SIZE="-4.92" ESTIMABLE="YES" MEAN_1="-5.8" MEAN_2="-0.88" MODIFIED="2009-01-27 20:06:41 +0000" MODIFIED_BY="[Empty name]" ORDER="55" SD_1="7.36" SD_2="8.73" SE="4.512264675304409" STUDY_ID="STD-Conley-2003" TOTAL_1="5" TOTAL_2="8" WEIGHT="3.233555283941241"/>
<CONT_DATA CI_END="4.331342580269938" CI_START="-10.131342580269935" EFFECT_SIZE="-2.8999999999999986" ESTIMABLE="YES" MEAN_1="31.4" MEAN_2="34.3" MODIFIED="2009-01-27 20:06:40 +0000" MODIFIED_BY="[Empty name]" ORDER="56" SD_1="9.3" SD_2="13.6" SE="3.689528296085971" STUDY_ID="STD-Kumra-2008" TOTAL_1="18" TOTAL_2="21" WEIGHT="4.785008897527973"/>
<CONT_DATA CI_END="10.458300495018648" CI_START="-1.6583004950186355" EFFECT_SIZE="4.400000000000006" ESTIMABLE="YES" MEAN_1="48.7" MEAN_2="44.3" ORDER="57" SD_1="5.4" SD_2="6.5" SE="3.0910264386518027" STUDY_ID="STD-Moresco-2004" TOTAL_1="6" TOTAL_2="9" WEIGHT="6.725705066570842"/>
<CONT_DATA CI_END="2.960653012906101" CI_START="0.23934698709390223" EFFECT_SIZE="1.6000000000000014" ESTIMABLE="YES" MEAN_1="23.3" MEAN_2="21.7" MODIFIED="2009-01-27 20:06:39 +0000" MODIFIED_BY="[Empty name]" ORDER="58" SD_1="2.5" SD_2="2.9" SE="0.6942234773897666" STUDY_ID="STD-Wang-2002" TOTAL_1="31" TOTAL_2="30" WEIGHT="72.0987220651454"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="5.4325435224404455" CI_START="-3.032543522440447" DF="0" EFFECT_SIZE="1.1999999999999993" ESTIMABLE="YES" I2="0.0" ID="CMP-001.08.02" NO="2" P_CHI2="1.0" P_Z="0.5784268880651382" STUDIES="1" TAU2="0.0" TOTAL_1="87" TOTAL_2="89" WEIGHT="13.15700868681455" Z="0.5556840157645789">
<NAME>medium term</NAME>
<CONT_DATA CI_END="5.4325435224404455" CI_START="-3.032543522440447" EFFECT_SIZE="1.1999999999999993" ESTIMABLE="YES" MEAN_1="-14.0" MEAN_2="-15.2" ORDER="59" SD_1="13.3" SD_2="15.3" SE="2.1595006621683916" STUDY_ID="STD-Tollefson-2001" TOTAL_1="87" TOTAL_2="89" WEIGHT="13.15700868681455"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.7264696286415033" CI_END="8.421300914859202" CI_START="-4.633053688067071" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="1.894123613396065" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.09" MODIFIED="2009-09-20 23:35:31 +0100" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="0.39402994428459803" P_Q="0.39402994428459803" P_Z="0.5695172893632052" Q="0.7264696286415033" RANDOM="YES" SCALE="21.55514588279871" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="68" TOTAL_2="65" UNITS="" WEIGHT="200.0" Z="0.5687625589228257">
<NAME>Mental state: 2c. BPRS total score, various versions (high = poor)</NAME>
<GROUP_LABEL_1>clozapine</GROUP_LABEL_1>
<GROUP_LABEL_2>olanzapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours clozapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours olanzapine</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="14.468612545672354" CI_START="-28.468612545672354" DF="0" EFFECT_SIZE="-7.0" ESTIMABLE="YES" I2="0.0" ID="CMP-001.09.01" MODIFIED="2009-09-20 23:35:31 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.5227834083387852" STUDIES="1" TAU2="0.0" TOTAL_1="12" TOTAL_2="13" WEIGHT="100.0" Z="0.6390607619655425">
<NAME>BPRS - 24 - only short term</NAME>
<CONT_DATA CI_END="14.468612545672354" CI_START="-28.468612545672354" EFFECT_SIZE="-7.0" ESTIMABLE="YES" MEAN_1="-20.0" MEAN_2="-13.0" ORDER="60" SD_1="17.67" SD_2="34.95" SE="10.953575022303486" STUDY_ID="STD-Shaw-2006" TOTAL_1="12" TOTAL_2="13" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="9.651519011407007" CI_START="-4.051519011407006" DF="0" EFFECT_SIZE="2.8000000000000007" ESTIMABLE="YES" I2="0.0" ID="CMP-001.09.02" MODIFIED="2009-09-20 23:35:23 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.4231458121843059" STUDIES="1" TAU2="0.0" TOTAL_1="56" TOTAL_2="52" WEIGHT="100.00000000000001" Z="0.8009755424418177">
<NAME>BPRS - 18 (0-6) - only medium term</NAME>
<CONT_DATA CI_END="9.651519011407007" CI_START="-4.051519011407006" EFFECT_SIZE="2.8000000000000007" ESTIMABLE="YES" MEAN_1="-17.5" MEAN_2="-20.3" ORDER="61" SD_1="18.1" SD_2="18.2" SE="3.495737199994956" STUDY_ID="STD-Naber-2005" TOTAL_1="56" TOTAL_2="52" WEIGHT="100.00000000000001"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="2.60324923026021" CI_END="1.1082770823949366" CI_START="-0.9553409615314157" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="MD" EFFECT_SIZE="0.07646806043176048" ESTIMABLE="YES" I2="0.0" I2_Q="16.611708658993045" ID="CMP-001.10" MODIFIED="2009-09-20 22:43:20 +0100" MODIFIED_BY="[Empty name]" NO="10" P_CHI2="0.7608715712060875" P_Q="0.27347986930212764" P_Z="0.8845101357298245" Q="1.1992091262676357" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="296" TOTAL_2="296" UNITS="" WEIGHT="100.0" Z="0.1452542488228328">
<NAME>Mental state: 3a. Positive symptoms: PANSS positive subscore (high = poor)</NAME>
<GROUP_LABEL_1>clozapine</GROUP_LABEL_1>
<GROUP_LABEL_2>olanzapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours clozapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours olanzapine</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.770053615907459" CI_END="1.0032366777644288" CI_START="-2.2696486336896196" DF="1" EFFECT_SIZE="-0.6332059779625954" ESTIMABLE="YES" I2="0.0" ID="CMP-001.10.01" NO="1" P_CHI2="0.3802005058455832" P_Z="0.4482178538598849" STUDIES="2" TAU2="0.0" TOTAL_1="43" TOTAL_2="46" WEIGHT="39.755485289988464" Z="0.7583894903123157">
<NAME>short term</NAME>
<CONT_DATA CI_END="1.8552277208444963" CI_START="-2.1152277208444965" EFFECT_SIZE="-0.13000000000000012" ESTIMABLE="YES" MEAN_1="-1.54" MEAN_2="-1.41" ORDER="62" SD_1="5.0" SD_2="3.6" SE="1.0128898982347223" STUDY_ID="STD-Krakowski-2006" TOTAL_1="37" TOTAL_2="37" WEIGHT="27.01332105130934"/>
<CONT_DATA CI_END="1.190531600763037" CI_START="-4.590531600763036" EFFECT_SIZE="-1.6999999999999993" ESTIMABLE="YES" MEAN_1="9.5" MEAN_2="11.2" ORDER="63" SD_1="3.3" SD_2="1.8" SE="1.4747881203752624" STUDY_ID="STD-Moresco-2004" TOTAL_1="6" TOTAL_2="9" WEIGHT="12.742164238679125"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.6339864880851154" CI_END="1.874137242491199" CI_START="-0.7845702622082074" DF="3" EFFECT_SIZE="0.5447834901414959" ESTIMABLE="YES" I2="0.0" ID="CMP-001.10.02" NO="2" P_CHI2="0.8886097540629018" P_Z="0.4218508556935364" STUDIES="4" TAU2="0.0" TOTAL_1="253" TOTAL_2="250" WEIGHT="60.24451471001153" Z="0.8032143574741096">
<NAME>medium term</NAME>
<CONT_DATA CI_END="2.4197981369101487" CI_START="-2.6197981369101515" EFFECT_SIZE="-0.10000000000000142" ESTIMABLE="YES" MEAN_1="-11.8" MEAN_2="-11.7" ORDER="67" SD_1="7.9" SD_2="7.3" SE="1.28563491818523" STUDY_ID="STD-Bitter-2004" TOTAL_1="70" TOTAL_2="70" WEIGHT="16.76745467017197"/>
<CONT_DATA CI_END="4.5189181115803585" CI_START="-1.7189181115803573" EFFECT_SIZE="1.4000000000000004" ESTIMABLE="YES" MEAN_1="-7.6" MEAN_2="-9.0" ORDER="64" SD_1="8.0" SD_2="8.5" SE="1.5913139915743277" STUDY_ID="STD-Naber-2005" TOTAL_1="56" TOTAL_2="52" WEIGHT="10.944368242758081"/>
<CONT_DATA CI_END="2.5867883329020356" CI_START="-1.7867883329020366" EFFECT_SIZE="0.39999999999999947" ESTIMABLE="YES" MEAN_1="-6.4" MEAN_2="-6.8" ORDER="65" SD_1="7.2" SD_2="7.6" SE="1.1157288348924488" STUDY_ID="STD-Tollefson-2001" TOTAL_1="87" TOTAL_2="89" WEIGHT="22.263074807208003"/>
<CONT_DATA CI_END="4.219750339085913" CI_START="-2.219750339085913" EFFECT_SIZE="1.0" ESTIMABLE="YES" MEAN_1="-2.3" MEAN_2="-3.3" ORDER="66" SD_1="7.3" SD_2="7.3" SE="1.6427599509393502" STUDY_ID="STD-Volavka-2002" TOTAL_1="40" TOTAL_2="39" WEIGHT="10.26961698987348"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="4.063815373103846" CI_START="-22.063815373103846" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-9.0" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.11" MODIFIED="2009-09-20 22:43:30 +0100" MODIFIED_BY="[Empty name]" NO="11" P_CHI2="1.0" P_Q="1.0" P_Z="0.1769294437764986" Q="0.0" RANDOM="YES" SCALE="28.49253999767108" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="12" TOTAL_2="13" UNITS="" WEIGHT="100.0" Z="1.3502698374915458">
<NAME>Mental state: 3b. Positive symptoms: SAPS - short term (high = poor)</NAME>
<GROUP_LABEL_1>clozapine</GROUP_LABEL_1>
<GROUP_LABEL_2>olanzapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours clozapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours olanzapine</GRAPH_LABEL_2>
<CONT_DATA CI_END="4.063815373103846" CI_START="-22.063815373103846" EFFECT_SIZE="-9.0" ESTIMABLE="YES" MEAN_1="-22.0" MEAN_2="-13.0" ORDER="68" SD_1="16.65" SD_2="16.65" SE="6.665334402136751" STUDY_ID="STD-Shaw-2006" TOTAL_1="12" TOTAL_2="13" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.666604810334966" CI_END="1.254591233638146" CI_START="-1.0039420552396947" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="0.1253245891992257" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.12" MODIFIED="2010-09-30 13:43:26 +0100" MODIFIED_BY="[Empty name]" NO="12" P_CHI2="0.7165535396922185" P_Q="0.7381777690902254" P_Z="0.8278075382305514" Q="0.11173474871196831" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="148" TOTAL_2="149" UNITS="" WEIGHT="200.0" Z="0.21751433323331953">
<NAME>Mental state: 3c. Positive symptoms: BPRS positive subscore (high = poor)</NAME>
<GROUP_LABEL_1>clozapine</GROUP_LABEL_1>
<GROUP_LABEL_2>olanzapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours clozapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours olanzapine</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.5548700616229977" CI_END="1.369486818184234" CI_START="-1.3889194204963786" DF="1" EFFECT_SIZE="-0.009716301156072282" ESTIMABLE="YES" I2="0.0" ID="CMP-001.12.01" MODIFIED="2010-09-30 13:43:26 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.45633469003915905" P_Z="0.9889834124697399" STUDIES="2" TAU2="0.0" TOTAL_1="92" TOTAL_2="97" WEIGHT="99.99999999999999" Z="0.013807683626727444">
<NAME>BPRS-18 (1-7)</NAME>
<CONT_DATA CI_END="2.0967984738765573" CI_START="-4.316798473876558" EFFECT_SIZE="-1.11" ESTIMABLE="YES" MEAN_1="-0.8" MEAN_2="0.31" ORDER="69" SD_1="2.87" SD_2="2.87" SE="1.636151735017263" STUDY_ID="STD-Conley-2003" TOTAL_1="5" TOTAL_2="8" WEIGHT="18.497503789338698"/>
<CONT_DATA CI_END="1.7677165224202356" CI_START="-1.2877165224202352" EFFECT_SIZE="0.2400000000000002" ESTIMABLE="YES" MEAN_1="8.4" MEAN_2="8.16" ORDER="70" SD_1="5.05" SD_2="5.29" SE="0.7794615281049388" STUDY_ID="STD-Tollefson-2001" TOTAL_1="87" TOTAL_2="89" WEIGHT="81.50249621066129"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="2.367005053739437" CI_START="-1.5670050537394364" DF="0" EFFECT_SIZE="0.40000000000000036" ESTIMABLE="YES" I2="0.0" ID="CMP-001.12.02" MODIFIED="2010-09-30 13:43:26 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.6902114239678874" STUDIES="1" TAU2="0.0" TOTAL_1="56" TOTAL_2="52" WEIGHT="100.0" Z="0.3985681644923087">
<NAME>BPRS-18 ( 0-6) - only medium term</NAME>
<CONT_DATA CI_END="2.367005053739437" CI_START="-1.5670050537394364" EFFECT_SIZE="0.40000000000000036" ESTIMABLE="YES" MEAN_1="-5.5" MEAN_2="-5.9" ORDER="71" SD_1="5.0" SD_2="5.4" SE="1.0035924482566627" STUDY_ID="STD-Naber-2005" TOTAL_1="56" TOTAL_2="52" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="1.8848673903709494" CI_END="1.7672440198602581" CI_START="-0.21016250788587154" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="MD" EFFECT_SIZE="0.7785407559871933" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.13" MODIFIED="2009-09-20 22:44:02 +0100" MODIFIED_BY="[Empty name]" NO="13" P_CHI2="0.8648354821124211" P_Q="0.4582981195992948" P_Z="0.12274669741245466" Q="0.5500481420354704" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="296" TOTAL_2="296" UNITS="" WEIGHT="100.0" Z="1.5433466217700182">
<NAME>Mental state: 4a. Negative symptoms: PANSS negative subscore (high = poor)</NAME>
<GROUP_LABEL_1>clozapine</GROUP_LABEL_1>
<GROUP_LABEL_2>olanzapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours clozapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours olanzapine</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.01383171959485478" CI_END="3.054706569431767" CI_START="-0.4175807140557266" DF="1" EFFECT_SIZE="1.3185629276880202" ESTIMABLE="YES" I2="0.0" ID="CMP-001.13.01" NO="1" P_CHI2="0.9063780056817814" P_Z="0.13660602300381136" STUDIES="2" TAU2="0.0" TOTAL_1="43" TOTAL_2="46" WEIGHT="32.43102144246948" Z="1.4885495574678131">
<NAME>short term</NAME>
<CONT_DATA CI_END="3.131270970800164" CI_START="-0.571270970800164" EFFECT_SIZE="1.28" ESTIMABLE="YES" MEAN_1="0.56" MEAN_2="-0.72" ORDER="72" SD_1="4.9" SD_2="3.0" SE="0.9445433617162117" STUDY_ID="STD-Krakowski-2006" TOTAL_1="37" TOTAL_2="37" WEIGHT="28.522786646423878"/>
<CONT_DATA CI_END="6.601216373073384" CI_START="-3.401216373073388" EFFECT_SIZE="1.5999999999999979" ESTIMABLE="YES" MEAN_1="18.9" MEAN_2="17.3" ORDER="73" SD_1="5.6" SD_2="3.4" SE="2.5516878945339516" STUDY_ID="STD-Moresco-2004" TOTAL_1="6" TOTAL_2="9" WEIGHT="3.9082347960456003"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="1.3209875287406243" CI_END="1.7221436780082966" CI_START="-0.6834500713631845" DF="3" EFFECT_SIZE="0.519346803322556" ESTIMABLE="YES" I2="0.0" ID="CMP-001.13.02" NO="2" P_CHI2="0.7241556528400533" P_Z="0.3973974559915958" STUDIES="4" TAU2="0.0" TOTAL_1="253" TOTAL_2="250" WEIGHT="67.56897855753051" Z="0.8462784127737012">
<NAME>medium term</NAME>
<CONT_DATA CI_END="1.9043994478682449" CI_START="-2.104399447868246" EFFECT_SIZE="-0.10000000000000053" ESTIMABLE="YES" MEAN_1="-7.7" MEAN_2="-7.6" ORDER="77" SD_1="6.1" SD_2="6.0" SE="1.0226715713547252" STUDY_ID="STD-Bitter-2004" TOTAL_1="70" TOTAL_2="70" WEIGHT="24.331192055394755"/>
<CONT_DATA CI_END="3.727987652368163" CI_START="-2.727987652368163" EFFECT_SIZE="0.5" ESTIMABLE="YES" MEAN_1="-8.0" MEAN_2="-8.5" ORDER="74" SD_1="8.5" SD_2="8.6" SE="1.6469627390248585" STUDY_ID="STD-Naber-2005" TOTAL_1="56" TOTAL_2="52" WEIGHT="9.381411933976818"/>
<CONT_DATA CI_END="3.613239565168587" CI_START="-0.6132395651685871" EFFECT_SIZE="1.5" ESTIMABLE="YES" MEAN_1="-5.6" MEAN_2="-7.1" ORDER="75" SD_1="6.9" SD_2="7.4" SE="1.0782032638546173" STUDY_ID="STD-Tollefson-2001" TOTAL_1="87" TOTAL_2="89" WEIGHT="21.889430837449925"/>
<CONT_DATA CI_END="2.858079753051605" CI_START="-2.858079753051605" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="-1.6" MEAN_2="-1.6" ORDER="76" SD_1="6.48" SD_2="6.48" SE="1.4582307509708206" STUDY_ID="STD-Volavka-2002" TOTAL_1="40" TOTAL_2="39" WEIGHT="11.966943730709023"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="3.6648406974518517" CI_END="4.707182423930136" CI_START="-14.331185781683494" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="-4.812001678876679" ESTIMABLE="YES" I2="72.71368437118439" I2_Q="0.0" ID="CMP-001.14" MODIFIED="2009-09-20 22:44:22 +0100" MODIFIED_BY="[Empty name]" NO="14" P_CHI2="0.055572165187241285" P_Q="1.0" P_Z="0.3217964803149891" Q="0.0" RANDOM="YES" SCALE="25.228589263692168" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="36.356842185592164" TOTALS="YES" TOTAL_1="30" TOTAL_2="34" UNITS="" WEIGHT="100.0" Z="0.9907729362397403">
<NAME>Mental state: 4b. Negative symptoms: SANS - short term (high = poor)</NAME>
<GROUP_LABEL_1>clozapine</GROUP_LABEL_1>
<GROUP_LABEL_2>olanzapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours clozapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours olanzapine</GRAPH_LABEL_2>
<CONT_DATA CI_END="1.6025300443585557" CI_START="-3.6025300443585557" EFFECT_SIZE="-1.0" ESTIMABLE="YES" MEAN_1="6.6" MEAN_2="7.6" ORDER="79" SD_1="4.4" SD_2="3.8" SE="1.3278458506824515" STUDY_ID="STD-Kumra-2008" TOTAL_1="18" TOTAL_2="21" WEIGHT="61.87998321123322"/>
<CONT_DATA CI_END="-1.0981771766624302" CI_START="-20.901822823337568" EFFECT_SIZE="-11.0" ESTIMABLE="YES" MEAN_1="-25.0" MEAN_2="-14.0" ORDER="78" SD_1="12.62" SD_2="12.62" SE="5.052043252550498" STUDY_ID="STD-Shaw-2006" TOTAL_1="12" TOTAL_2="13" WEIGHT="38.12001678876679"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="2.1168292609683212" CI_END="0.6045579337012384" CI_START="-0.9216852071385891" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.15856363671867535" ESTIMABLE="YES" I2="5.519068690257944" I2_Q="0.0" ID="CMP-001.15" MODIFIED="2010-09-30 13:43:26 +0100" MODIFIED_BY="[Empty name]" NO="15" P_CHI2="0.3470056929280302" P_Q="0.5841996360947971" P_Z="0.6838265407459778" Q="0.29949442129020687" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.01774533615175393" TOTALS="SUB" TOTAL_1="148" TOTAL_2="149" UNITS="" WEIGHT="200.0" Z="0.40724706163827595">
<NAME>Mental state: 4c. Negative symptoms: BPRS negative subscore -(high = poor)</NAME>
<GROUP_LABEL_1>clozapine</GROUP_LABEL_1>
<GROUP_LABEL_2>olanzapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours clozapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours olanzapine</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="1.8173348396781144" CI_END="0.6024343474769989" CI_START="-1.1745961795749025" DF="1" EFFECT_SIZE="-0.28608091604895175" ESTIMABLE="YES" I2="44.97436695941406" ID="CMP-001.15.01" NO="1" P_CHI2="0.1776310024827189" P_Z="0.527999936332598" STUDIES="2" TAU2="0.18621636639545386" TOTAL_1="92" TOTAL_2="97" WEIGHT="100.0" Z="0.63106208203456">
<NAME>BPRS - 18 (1-7)</NAME>
<CONT_DATA CI_END="0.22561624616338039" CI_START="-1.7856162461633804" EFFECT_SIZE="-0.78" ESTIMABLE="YES" MEAN_1="0.3" MEAN_2="1.08" ORDER="80" SD_1="0.9" SD_2="0.9" SE="0.5130789412946121" STUDY_ID="STD-Conley-2003" TOTAL_1="5" TOTAL_2="8" WEIGHT="45.72317758779689"/>
<CONT_DATA CI_END="0.9897458975617303" CI_START="-0.7297458975617305" EFFECT_SIZE="0.1299999999999999" ESTIMABLE="YES" MEAN_1="5.28" MEAN_2="5.15" ORDER="81" SD_1="2.57" SD_2="3.22" SE="0.4386539264717598" STUDY_ID="STD-Tollefson-2001" TOTAL_1="87" TOTAL_2="89" WEIGHT="54.27682241220311"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="1.6899218723883378" CI_START="-1.2899218723883374" DF="0" EFFECT_SIZE="0.20000000000000018" ESTIMABLE="YES" I2="0.0" ID="CMP-001.15.02" MODIFIED="2010-09-30 13:43:26 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.7924764258051689" STUDIES="1" TAU2="0.0" TOTAL_1="56" TOTAL_2="52" WEIGHT="100.0" Z="0.2630962093869047">
<NAME>BPRS-18 (0-6)</NAME>
<CONT_DATA CI_END="1.6899218723883378" CI_START="-1.2899218723883374" EFFECT_SIZE="0.20000000000000018" ESTIMABLE="YES" MEAN_1="-3.3" MEAN_2="-3.5" ORDER="82" SD_1="4.1" SD_2="3.8" SE="0.7601781890589068" STUDY_ID="STD-Naber-2005" TOTAL_1="56" TOTAL_2="52" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.3474264324505056" CI_START="1.1487089256620244" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.642105263157895" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="19" I2="0.0" I2_Q="0.0" ID="CMP-001.16" LOG_CI_END="0.37059199050942093" LOG_CI_START="0.06020999562180682" LOG_EFFECT_SIZE="0.2154009930656139" METHOD="MH" MODIFIED="2009-09-21 00:08:28 +0100" MODIFIED_BY="[Empty name]" NO="16" P_CHI2="1.0" P_Q="0.0" P_Z="0.006520731171794637" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="40" TOTAL_2="39" WEIGHT="100.0" Z="2.72037808633604">
<NAME>Cognitive functioning: 1. No clinically important change - less than 0.5 SD improved - medium term</NAME>
<GROUP_LABEL_1>clozapine</GROUP_LABEL_1>
<GROUP_LABEL_2>olanzapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours clozapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours olanzapine</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.3474264324505056" CI_START="1.1487089256620242" EFFECT_SIZE="1.6421052631578947" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="19" LOG_CI_END="0.37059199050942093" LOG_CI_START="0.06020999562180673" LOG_EFFECT_SIZE="0.21540099306561383" ORDER="83" O_E="0.0" SE="0.18231992021263824" STUDY_ID="STD-Volavka-2002" TOTAL_1="40" TOTAL_2="39" VAR="0.03324055330634278" WEIGHT="100.0"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="5.274358431556536" CI_START="-21.674358431556534" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-8.2" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.17" MODIFIED="2009-02-02 00:58:15 +0000" MODIFIED_BY="[Empty name]" NO="17" P_CHI2="1.0" P_Q="1.0" P_Z="0.23296256071310084" Q="0.0" RANDOM="YES" SCALE="23.73" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="50" TOTAL_2="49" UNITS="" WEIGHT="100.0" Z="1.1927621455867614">
<NAME>Quality of Life: 1. SWN-38 total score - medium term (high= good)</NAME>
<GROUP_LABEL_1>clozapine</GROUP_LABEL_1>
<GROUP_LABEL_2>olanzapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours olanzapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours clozapine</GRAPH_LABEL_2>
<CONT_DATA CI_END="5.274358431556536" CI_START="-21.674358431556534" EFFECT_SIZE="-8.2" ESTIMABLE="YES" MEAN_1="13.7" MEAN_2="21.9" ORDER="84" SD_1="29.3" SD_2="38.4" SE="6.8747989952063175" STUDY_ID="STD-Naber-2005" TOTAL_1="50" TOTAL_2="49" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.7216773465287294" CI_START="-0.7216773465287294" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.18" NO="18" P_CHI2="1.0" P_Q="1.0" P_Z="1.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="49" TOTAL_2="48" UNITS="" WEIGHT="100.0" Z="0.0">
<NAME>Quality of Life: 2. MLDL total score - medium term (high = good)</NAME>
<GROUP_LABEL_1>clozapine</GROUP_LABEL_1>
<GROUP_LABEL_2>olanzapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours olanzapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours clozapine</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.7216773465287294" CI_START="-0.7216773465287294" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="1.3" MEAN_2="1.3" ORDER="85" SD_1="1.6" SD_2="2.0" SE="0.3682094937566344" STUDY_ID="STD-Naber-2005" TOTAL_1="49" TOTAL_2="48" WEIGHT="100.0"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.9829530891026772" CI_START="0.6209366136253569" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.78125" ESTIMABLE="YES" EVENTS_1="100" EVENTS_2="128" I2="0.0" I2_Q="0.0" ID="CMP-001.19" LOG_CI_END="-0.0074672081393692075" LOG_CI_START="-0.20695273115636745" LOG_EFFECT_SIZE="-0.10720996964786836" METHOD="MH" MODIFIED="2009-09-20 00:52:10 +0100" MODIFIED_BY="[Empty name]" NO="19" P_CHI2="1.0" P_Q="0.0" P_Z="0.035143936905414806" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="490" TOTAL_2="490" WEIGHT="100.0" Z="2.106696026012366">
<NAME>Service use: Hospital readmission - long term</NAME>
<GROUP_LABEL_1>clozapine</GROUP_LABEL_1>
<GROUP_LABEL_2>olanzapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours clozapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours olanzapine</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.9829530891026772" CI_START="0.6209366136253569" EFFECT_SIZE="0.78125" ESTIMABLE="YES" EVENTS_1="100" EVENTS_2="128" LOG_CI_END="-0.0074672081393692075" LOG_CI_START="-0.20695273115636745" LOG_EFFECT_SIZE="-0.10720996964786836" ORDER="86" O_E="0.0" SE="0.11717878368944942" STUDY_ID="STD-Meltzer-2003" TOTAL_1="490" TOTAL_2="490" VAR="0.013730867346938777" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="29.59744430612771" CI_END="1.8911788050777483" CI_START="1.0259220174042787" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="RR" EFFECT_SIZE="1.3929113306228709" ESTIMABLE="YES" EVENTS_1="128" EVENTS_2="94" I2="79.7279794230146" I2_Q="0.0" ID="CMP-001.20" LOG_CI_END="0.2767325919796308" LOG_CI_START="0.011114350348758522" LOG_EFFECT_SIZE="0.14392347116419466" METHOD="MH" NO="20" P_CHI2="4.687583200269074E-5" P_Q="0.0" P_Z="0.03367124706374484" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.10103578625092353" TOTALS="YES" TOTAL_1="207" TOTAL_2="215" WEIGHT="100.0" Z="2.123986803615859">
<NAME>Adverse effects: 1. At least one adverse effect</NAME>
<GROUP_LABEL_1>clozapine</GROUP_LABEL_1>
<GROUP_LABEL_2>olanzapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours clozapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours olanzapine</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="41.52622108856789" CI_END="2.8521255682483666" CI_START="0.8482551652561905" DF="4" EFFECT_SIZE="1.555419636376603" ESTIMABLE="YES" EVENTS_1="65" EVENTS_2="43" I2="90.36753189877614" ID="CMP-001.20.01" LOG_CI_END="0.45516864193610307" LOG_CI_START="-0.07147348713768548" LOG_EFFECT_SIZE="0.19184757739920877" NO="1" P_CHI2="2.0913228260255323E-8" P_Z="0.15330075411890015" STUDIES="5" TAU2="0.3806657013029477" TOTAL_1="78" TOTAL_2="83" WEIGHT="69.52501808183726" Z="1.427969095009586">
<NAME>short term</NAME>
<DICH_DATA CI_END="1.3346075891202989" CI_START="0.7492839154759685" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="8" LOG_CI_END="0.12535359009642288" LOG_CI_START="-0.1253535900964228" LOG_EFFECT_SIZE="0.0" ORDER="89" O_E="0.0" SE="0.14726663866583445" STUDY_ID="STD-Conley-2003" TOTAL_1="5" TOTAL_2="8" VAR="0.021687462863933443" WEIGHT="19.836459231261067"/>
<DICH_DATA CI_END="1.2980257302109677" CI_START="0.9296705902247057" EFFECT_SIZE="1.098515519568151" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="19" LOG_CI_END="0.11328330138414024" LOG_CI_START="-0.031670907564394175" LOG_EFFECT_SIZE="0.04080619690987304" ORDER="90" O_E="0.0" SE="0.08514681987127566" STUDY_ID="STD-Kumra-2008" TOTAL_1="18" TOTAL_2="21" VAR="0.007249980934191463" WEIGHT="22.48120682040464"/>
<DICH_DATA CI_END="3.609153609343594" CI_START="0.5238416550366368" EFFECT_SIZE="1.375" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="4" LOG_CI_END="0.5574053664791835" LOG_CI_START="-0.28079997014662067" LOG_EFFECT_SIZE="0.13830269816628143" ORDER="87" O_E="0.0" SE="0.4923659639173309" STUDY_ID="STD-Moresco-2004" TOTAL_1="12" TOTAL_2="11" VAR="0.2424242424242424" WEIGHT="7.087854552347729"/>
<DICH_DATA CI_END="5.373318675860461" CI_START="0.8736582971589145" EFFECT_SIZE="2.1666666666666665" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="4" LOG_CI_END="0.7302425980716918" LOG_CI_START="-0.058658394225305575" LOG_EFFECT_SIZE="0.3357921019231931" ORDER="91" O_E="0.0" SE="0.46340434799814917" STUDY_ID="STD-Shaw-2006" TOTAL_1="12" TOTAL_2="13" VAR="0.21474358974358976" WEIGHT="7.7091631463514405"/>
<DICH_DATA CI_END="6.199478717317696" CI_START="1.8505466476891257" EFFECT_SIZE="3.3870967741935485" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="8" LOG_CI_END="0.7923551734159683" LOG_CI_START="0.26730003705536254" LOG_EFFECT_SIZE="0.5298276052356654" ORDER="88" O_E="0.0" SE="0.308419986163062" STUDY_ID="STD-Wang-2002" TOTAL_1="31" TOTAL_2="30" VAR="0.09512288786482334" WEIGHT="12.410334331472383"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.7394277284380457" CI_END="1.4012446493640105" CI_START="1.0178787914066072" DF="1" EFFECT_SIZE="1.1942768565787474" ESTIMABLE="YES" EVENTS_1="63" EVENTS_2="51" I2="0.0" ID="CMP-001.20.02" LOG_CI_END="0.14651396725789378" LOG_CI_START="0.007696065468978092" LOG_EFFECT_SIZE="0.07710501636343592" NO="2" P_CHI2="0.38984428832135964" P_Z="0.02945932313811272" STUDIES="2" TAU2="0.0" TOTAL_1="129" TOTAL_2="132" WEIGHT="30.47498191816274" Z="2.1772848192087113">
<NAME>medium term</NAME>
<DICH_DATA CI_END="3.9890542499222854" CI_START="0.6717023714577676" EFFECT_SIZE="1.6369047619047619" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="7" LOG_CI_END="0.6008699426226207" LOG_CI_START="-0.17282311841382114" LOG_EFFECT_SIZE="0.2140234121043998" ORDER="93" O_E="0.0" SE="0.454471133895225" STUDY_ID="STD-Bitter-2004" TOTAL_1="72" TOTAL_2="75" VAR="0.20654401154401153" WEIGHT="7.914676923670323"/>
<DICH_DATA CI_END="1.3902873079183689" CI_START="1.0046083330554583" EFFECT_SIZE="1.1818181818181819" ESTIMABLE="YES" EVENTS_1="52" EVENTS_2="44" LOG_CI_END="0.1431045580598035" LOG_CI_START="0.0019967762374199973" LOG_EFFECT_SIZE="0.07255066714861175" ORDER="92" O_E="0.0" SE="0.08288740953725329" STUDY_ID="STD-Naber-2005" TOTAL_1="57" TOTAL_2="57" VAR="0.006870322659796348" WEIGHT="22.560304994492416"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.026881881883944025" CI_END="15.328918121416509" CI_START="0.3814294585945618" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="2.41803658779024" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-001.21" LOG_CI_END="1.1855115044643494" LOG_CI_START="-0.418585768523868" LOG_EFFECT_SIZE="0.38346286797024076" METHOD="MH" MODIFIED="2009-01-18 02:23:31 +0000" MODIFIED_BY="[Empty name]" NO="21" P_CHI2="0.8697650569456339" P_Q="0.0" P_Z="0.34872404140772095" Q="0.0" RANDOM="YES" SCALE="93.6895113651253" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="74" TOTAL_2="78" WEIGHT="100.0" Z="0.9370671258982065">
<NAME>Adverse effects: 2. Cardiac problems</NAME>
<GROUP_LABEL_1>clozapine</GROUP_LABEL_1>
<GROUP_LABEL_2>olanzapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours clozapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours olanzapine</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="20.942804971075702" CI_START="0.22415547730726543" DF="0" EFFECT_SIZE="2.1666666666666665" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" I2="0.0" ID="CMP-001.21.01" LOG_CI_END="1.3210348483971615" LOG_CI_START="-0.6494506445507751" LOG_EFFECT_SIZE="0.3357921019231931" NO="1" P_CHI2="1.0" P_Z="0.504134716733027" STUDIES="2" TAU2="0.0" TOTAL_1="17" TOTAL_2="21" WEIGHT="66.26968668262006" Z="0.6679982455266427">
<NAME>short term</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="95" O_E="0.0" SE="0.0" STUDY_ID="STD-Conley-2003" TOTAL_1="5" TOTAL_2="8" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="20.942804971075702" CI_START="0.22415547730726543" EFFECT_SIZE="2.1666666666666665" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.3210348483971615" LOG_CI_START="-0.6494506445507751" LOG_EFFECT_SIZE="0.3357921019231931" ORDER="94" O_E="0.0" SE="1.1574729326181195" STUDY_ID="STD-Shaw-2006" TOTAL_1="12" TOTAL_2="13" VAR="1.3397435897435899" WEIGHT="66.26968668262006"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="72.12921437580046" CI_START="0.12477607135867434" DF="0" EFFECT_SIZE="2.9999999999999996" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-001.21.02" LOG_CI_END="1.8581112019237023" LOG_CI_START="-0.9038686924843776" LOG_EFFECT_SIZE="0.4771212547196624" NO="2" P_CHI2="1.0" P_Z="0.49830935313259805" STUDIES="1" TAU2="0.0" TOTAL_1="57" TOTAL_2="57" WEIGHT="33.73031331737993" Z="0.6771522684885508">
<NAME>medium term</NAME>
<DICH_DATA CI_END="72.12921437580046" CI_START="0.12477607135867434" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8581112019237023" LOG_CI_START="-0.9038686924843776" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="96" O_E="0.0" SE="1.622400661996283" STUDY_ID="STD-Naber-2005" TOTAL_1="57" TOTAL_2="57" VAR="2.632183908045977" WEIGHT="33.73031331737993"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="4.5191101427675395" CI_END="1.6723126371010442" CI_START="0.4576339371914854" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8748182761760448" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="23" I2="11.48699912964795" I2_Q="0.0" ID="CMP-001.22" LOG_CI_END="0.22331747159306153" LOG_CI_START="-0.33948177663530593" LOG_EFFECT_SIZE="-0.058082152521122164" METHOD="MH" MODIFIED="2009-09-20 22:45:11 +0100" MODIFIED_BY="[Empty name]" NO="22" P_CHI2="0.3402876490224821" P_Q="0.0" P_Z="0.6858116913659125" Q="0.0" RANDOM="YES" SCALE="60.80010979532068" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0640917207690411" TOTALS="YES" TOTAL_1="278" TOTAL_2="283" WEIGHT="100.0" Z="0.40454541275353406">
<NAME>Adverse effects: 3a. Extrapyramidal: antiparkinson medication use</NAME>
<GROUP_LABEL_1>clozapine</GROUP_LABEL_1>
<GROUP_LABEL_2>olanzapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours clozapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours olanzapine</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="10.341647568454528" CI_START="0.0241740978258226" DF="0" EFFECT_SIZE="0.5000000000000001" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" ID="CMP-001.22.01" LOG_CI_END="1.0145897334279812" LOG_CI_START="-1.6166497247559433" LOG_EFFECT_SIZE="-0.3010299956639811" MODIFIED="2009-01-18 02:34:25 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.6538184379997736" STUDIES="2" TAU2="0.0" TOTAL_1="19" TOTAL_2="22" WEIGHT="4.455414419978815" Z="0.4484638963075401">
<NAME>short term</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-01-18 02:34:25 +0000" MODIFIED_BY="[Empty name]" ORDER="330" O_E="0.0" SE="0.0" STUDY_ID="STD-Atmaca-2003" TOTAL_1="14" TOTAL_2="14" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="10.341647568454523" CI_START="0.02417409782582259" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="1.014589733427981" LOG_CI_START="-1.6166497247559435" LOG_EFFECT_SIZE="-0.3010299956639812" ORDER="98" O_E="0.0" SE="1.5456030825826172" STUDY_ID="STD-Conley-2003" TOTAL_1="5" TOTAL_2="8" VAR="2.388888888888889" WEIGHT="4.455414419978815"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="4.375801874782606" CI_END="1.8621143906704254" CI_START="0.42070585003673244" DF="3" EFFECT_SIZE="0.8851002302522768" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="22" I2="31.441137285288026" ID="CMP-001.22.02" LOG_CI_END="0.2700063564041878" LOG_CI_START="-0.37602144895042083" LOG_EFFECT_SIZE="-0.05300754627311648" NO="2" P_CHI2="0.22363985342991388" P_Z="0.7477285105224276" STUDIES="4" TAU2="0.18114981537399244" TOTAL_1="259" TOTAL_2="261" WEIGHT="95.54458558002119" Z="0.32163594428299025">
<NAME>medium term</NAME>
<DICH_DATA CI_END="2.0043569203640264" CI_START="0.1353388502591865" EFFECT_SIZE="0.5208333333333334" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="6" LOG_CI_END="0.3019750598810342" LOG_CI_START="-0.8685775172881334" LOG_EFFECT_SIZE="-0.28330122870354957" ORDER="102" O_E="0.0" SE="0.6875883781578757" STUDY_ID="STD-Bitter-2004" TOTAL_1="72" TOTAL_2="75" VAR="0.4727777777777778" WEIGHT="20.356986585717298"/>
<DICH_DATA CI_END="1.5752647245268334" CI_START="0.11659847803862022" EFFECT_SIZE="0.42857142857142855" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="7" LOG_CI_END="0.19735354780207648" LOG_CI_START="-0.9333071183912652" LOG_EFFECT_SIZE="-0.36797678529459443" ORDER="99" O_E="0.0" SE="0.6641556721825317" STUDY_ID="STD-Naber-2005" TOTAL_1="57" TOTAL_2="57" VAR="0.44110275689223055" WEIGHT="21.633342531361144"/>
<DICH_DATA CI_END="7.042103120709159" CI_START="0.7188903532401258" EFFECT_SIZE="2.25" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="4" LOG_CI_END="0.8477023803517534" LOG_CI_START="-0.1433373441290284" LOG_EFFECT_SIZE="0.3521825181113625" ORDER="100" O_E="0.0" SE="0.582141639885766" STUDY_ID="STD-Tollefson-2001" TOTAL_1="90" TOTAL_2="90" VAR="0.33888888888888885" WEIGHT="27.12052371322651"/>
<DICH_DATA CI_END="3.1054237977223975" CI_START="0.30611763866085334" EFFECT_SIZE="0.975" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="5" LOG_CI_END="0.49212087680014677" LOG_CI_START="-0.5141116454030732" LOG_EFFECT_SIZE="-0.010995384301463193" ORDER="101" O_E="0.0" SE="0.5910659644734878" STUDY_ID="STD-Volavka-2002" TOTAL_1="40" TOTAL_2="39" VAR="0.34935897435897434" WEIGHT="26.433732749716235"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="7.357801002529777" CI_END="1.3046422530258184" CI_START="-0.45110211586480503" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="MD" EFFECT_SIZE="0.42677006858050665" ESTIMABLE="YES" I2="32.0449139861096" I2_Q="73.07811198375788" ID="CMP-001.23" MODIFIED="2010-10-05 15:09:32 +0100" MODIFIED_BY="[Empty name]" NO="23" P_CHI2="0.19536102783734388" P_Q="0.053943644718340344" P_Z="0.34068141244077743" Q="3.7144497421454794" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.3722853202867586" TOTALS="YES" TOTAL_1="236" TOTAL_2="245" UNITS="" WEIGHT="100.0" Z="0.9528197600041287">
<NAME>Adverse effects: 3d. Extrapyramidal: SAS change or endpoint (high = poor)</NAME>
<GROUP_LABEL_1>clozapine</GROUP_LABEL_1>
<GROUP_LABEL_2>olanzapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours clozapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours olanzapine</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.3483177307148063" CI_END="0.7570335465753715" CI_START="-1.6897388086976552" DF="2" EFFECT_SIZE="-0.46635263106114194" ESTIMABLE="YES" I2="0.0" ID="CMP-001.23.01" NO="1" P_CHI2="0.8401634475843281" P_Z="0.4549822146270531" STUDIES="3" TAU2="0.0" TOTAL_1="28" TOTAL_2="38" WEIGHT="35.4025877234335" Z="0.7471347786037412">
<NAME>short term</NAME>
<CONT_DATA CI_END="2.590117956961002" CI_START="-5.4101179569610025" EFFECT_SIZE="-1.41" ESTIMABLE="YES" MEAN_1="-1.16" MEAN_2="0.25" ORDER="116" SD_1="3.58" SD_2="3.58" SE="2.040914010927457" STUDY_ID="STD-Conley-2003" TOTAL_1="5" TOTAL_2="8" WEIGHT="4.421185322324288"/>
<CONT_DATA CI_END="0.9957966620851664" CI_START="-1.9957966620851664" EFFECT_SIZE="-0.5" ESTIMABLE="YES" MEAN_1="1.2" MEAN_2="1.7" ORDER="117" SD_1="2.0" SD_2="2.7" SE="0.7631755858188312" STUDY_ID="STD-Kumra-2008" TOTAL_1="17" TOTAL_2="21" WEIGHT="21.013061448192605"/>
<CONT_DATA CI_END="2.510169880833475" CI_START="-2.510169880833475" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="0.0" MEAN_2="0.0" ORDER="118" SD_1="2.43" SD_2="2.43" SE="1.2807224523681937" STUDY_ID="STD-Moresco-2004" TOTAL_1="6" TOTAL_2="9" WEIGHT="9.968340952916607"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="3.295033529669491" CI_END="2.008601415750173" CI_START="-0.16756631254265042" DF="2" EFFECT_SIZE="0.9205175516037613" ESTIMABLE="YES" I2="39.30259033811379" ID="CMP-001.23.02" NO="2" P_CHI2="0.19252759012862308" P_Z="0.09729183245912935" STUDIES="3" TAU2="0.3654166600593616" TOTAL_1="208" TOTAL_2="207" WEIGHT="64.5974122765665" Z="1.658127013670698">
<NAME>medium term</NAME>
<CONT_DATA CI_END="1.5551313789373342" CI_START="-1.355131378937334" EFFECT_SIZE="0.10000000000000009" ESTIMABLE="YES" MEAN_1="-2.9" MEAN_2="-3.0" ORDER="121" SD_1="3.9" SD_2="4.8" SE="0.7424276111271557" STUDY_ID="STD-Bitter-2004" TOTAL_1="70" TOTAL_2="69" WEIGHT="21.723859381258883"/>
<CONT_DATA CI_END="2.391840194419176" CI_START="-1.1918401944191759" EFFECT_SIZE="0.6000000000000001" ESTIMABLE="YES" MEAN_1="-2.1" MEAN_2="-2.7" ORDER="119" SD_1="4.5" SD_2="4.8" SE="0.9142209798511517" STUDY_ID="STD-Naber-2005" TOTAL_1="54" TOTAL_2="50" WEIGHT="16.60614355254618"/>
<CONT_DATA CI_END="3.026287674681178" CI_START="0.5737123253188225" EFFECT_SIZE="1.8000000000000003" ESTIMABLE="YES" MEAN_1="-1.4" MEAN_2="-3.2" ORDER="120" SD_1="3.3" SD_2="4.8" SE="0.625668473683179" STUDY_ID="STD-Tollefson-2001" TOTAL_1="84" TOTAL_2="88" WEIGHT="26.26740934276145"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="2.8275279006510026" CI_START="-0.22752790065100315" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="1.2999999999999998" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.24" MODIFIED="2009-09-20 22:46:43 +0100" MODIFIED_BY="[Empty name]" NO="24" P_CHI2="1.0" P_Q="1.0" P_Z="0.09531096505265486" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="40" TOTAL_2="39" UNITS="" WEIGHT="100.0" Z="1.6680239875266316">
<NAME>Adverse effects: 3c. Extrapyramidal: ESRS score at endpoint - medium term (high = poor)</NAME>
<GROUP_LABEL_1>clozapine</GROUP_LABEL_1>
<GROUP_LABEL_2>olanzapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours clozapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours olanzapine</GRAPH_LABEL_2>
<CONT_DATA CI_END="2.8275279006510026" CI_START="-0.22752790065100315" EFFECT_SIZE="1.2999999999999998" ESTIMABLE="YES" MEAN_1="5.1" MEAN_2="3.8" ORDER="115" SD_1="3.8" SD_2="3.1" SE="0.7793652907400075" STUDY_ID="STD-Volavka-2002" TOTAL_1="40" TOTAL_2="39" WEIGHT="100.0"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="9.38304954170992" CI_END="1.1540820205154967" CI_START="0.45948146055512723" CI_STUDY="95" CI_TOTAL="95" DF="7" EFFECT_MEASURE="RR" EFFECT_SIZE="0.728202782463012" ESTIMABLE="YES" EVENTS_1="49" EVENTS_2="79" I2="25.39738846221252" I2_Q="0.0" ID="CMP-001.25" LOG_CI_END="0.062236675190128786" LOG_CI_START="-0.3377320071092925" LOG_EFFECT_SIZE="-0.13774766595958185" METHOD="MH" MODIFIED="2010-10-05 15:09:32 +0100" MODIFIED_BY="[Empty name]" NO="25" P_CHI2="0.22631173731495247" P_Q="0.0" P_Z="0.17701341065388182" Q="0.0" RANDOM="YES" SCALE="29.22" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.1075073844464955" TOTALS="SUB" TOTAL_1="1545" TOTAL_2="1554" WEIGHT="400.0" Z="1.3500080190434705">
<NAME>Adverse effects: 3b. Extrapyramidal: various symptoms</NAME>
<GROUP_LABEL_1>clozapine</GROUP_LABEL_1>
<GROUP_LABEL_2>olanzapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours clozapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours olanzapine</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-001.25.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="31" TOTAL_2="30" WEIGHT="0.0" Z="0.0">
<NAME>at least one EPS - only short term</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="103" O_E="0.0" SE="0.0" STUDY_ID="STD-Wang-2002" TOTAL_1="31" TOTAL_2="30" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="4.65744407783331" CI_END="1.408245898409795" CI_START="0.38067506474392077" DF="3" EFFECT_SIZE="0.7321776413907417" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="54" I2="35.58698827371364" ID="CMP-001.25.02" LOG_CI_END="0.14867849500372274" LOG_CI_START="-0.4194455697282775" LOG_EFFECT_SIZE="-0.13538353736227737" NO="2" P_CHI2="0.19866934404031167" P_Z="0.3502441288314536" STUDIES="4" TAU2="0.15565919249984111" TOTAL_1="657" TOTAL_2="663" WEIGHT="99.99999999999999" Z="0.9341158870109396">
<NAME>akathisia</NAME>
<DICH_DATA CI_END="2.110832024111869" CI_START="0.006339321403671328" EFFECT_SIZE="0.1156773211567732" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="4" LOG_CI_END="0.324453674376401" LOG_CI_START="-2.19795722893438" LOG_EFFECT_SIZE="-0.9367517772789895" ORDER="106" O_E="0.0" SE="1.4816766507400978" STUDY_ID="STD-Bitter-2004" TOTAL_1="72" TOTAL_2="75" VAR="2.195365697348394" WEIGHT="4.737010510215855"/>
<DICH_DATA CI_END="8.006697337122388" CI_START="0.3197323305991313" EFFECT_SIZE="1.6" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.9034534119589024" LOG_CI_START="-0.4952134466470529" LOG_EFFECT_SIZE="0.2041199826559248" ORDER="107" O_E="0.0" SE="0.8215838362577492" STUDY_ID="STD-Conley-2003" TOTAL_1="5" TOTAL_2="8" VAR="0.675" WEIGHT="13.407218885370115"/>
<DICH_DATA CI_END="0.9016458131414242" CI_START="0.3215684298385238" EFFECT_SIZE="0.5384615384615384" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="39" LOG_CI_END="-0.04496402964935336" LOG_CI_START="-0.4927265949358066" LOG_EFFECT_SIZE="-0.26884531229257996" ORDER="105" O_E="0.0" SE="0.2630179473097074" STUDY_ID="STD-Meltzer-2003" TOTAL_1="490" TOTAL_2="490" VAR="0.06917844060701203" WEIGHT="49.53276486279959"/>
<DICH_DATA CI_END="2.604360903263411" CI_START="0.47403871701790057" EFFECT_SIZE="1.1111111111111112" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="9" LOG_CI_END="0.4157011670832415" LOG_CI_START="-0.32418618596189125" LOG_EFFECT_SIZE="0.04575749056067514" ORDER="104" O_E="0.0" SE="0.4346134936801766" STUDY_ID="STD-Tollefson-2001" TOTAL_1="90" TOTAL_2="90" VAR="0.1888888888888889" WEIGHT="32.32300574161444"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.9453739180478961" CI_END="1.4278073499194062" CI_START="0.1992489320586549" DF="1" EFFECT_SIZE="0.5333751865778347" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="12" I2="0.0" ID="CMP-001.25.03" LOG_CI_END="0.1546696132446687" LOG_CI_START="-0.7006039976722571" LOG_EFFECT_SIZE="-0.2729671922137942" NO="3" P_CHI2="0.3308997991070438" P_Z="0.21090701255197275" STUDIES="2" TAU2="0.0" TOTAL_1="162" TOTAL_2="165" WEIGHT="100.0" Z="1.2510753491540265">
<NAME>dyskinesia</NAME>
<DICH_DATA CI_END="1.3852684276018772" CI_START="0.06394219036595686" EFFECT_SIZE="0.2976190476190476" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="7" LOG_CI_END="0.1415339360942259" LOG_CI_START="-1.1942124908739138" LOG_EFFECT_SIZE="-0.5263392773898441" ORDER="109" O_E="0.0" SE="0.7846240632525366" STUDY_ID="STD-Bitter-2004" TOTAL_1="72" TOTAL_2="75" VAR="0.6156349206349206" WEIGHT="40.99794629953601"/>
<DICH_DATA CI_END="2.882809852471981" CI_START="0.2220056239405476" EFFECT_SIZE="0.8" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" LOG_CI_END="0.45981599766203435" LOG_CI_START="-0.6536360236781471" LOG_EFFECT_SIZE="-0.09691001300805639" ORDER="108" O_E="0.0" SE="0.6540472290116194" STUDY_ID="STD-Tollefson-2001" TOTAL_1="90" TOTAL_2="90" VAR="0.42777777777777776" WEIGHT="59.00205370046398"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-001.25.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2009-09-20 22:46:16 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.0" P_Z="0.0" STUDIES="2" TAU2="0.0" TOTAL_1="43" TOTAL_2="41" WEIGHT="0.0" Z="0.0">
<NAME>extrapyramidal symptoms</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="110" O_E="0.0" SE="0.0" STUDY_ID="STD-Moresco-2004" TOTAL_1="12" TOTAL_2="11" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="111" O_E="0.0" SE="0.0" STUDY_ID="STD-Wang-2002" TOTAL_1="31" TOTAL_2="30" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-001.25.05" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2009-09-20 22:46:23 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="72" TOTAL_2="75" WEIGHT="0.0" Z="0.0">
<NAME>parkinsonism</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="112" O_E="0.0" SE="0.0" STUDY_ID="STD-Bitter-2004" TOTAL_1="72" TOTAL_2="75" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.3030333277110557" CI_START="0.5004676188463828" DF="0" EFFECT_SIZE="1.2857142857142858" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="7" I2="0.0" ID="CMP-001.25.06" LOG_CI_END="0.518912955758621" LOG_CI_START="-0.30062401690848484" LOG_EFFECT_SIZE="0.10914446942506809" NO="6" P_CHI2="1.0" P_Z="0.6016362153104361" STUDIES="1" TAU2="0.0" TOTAL_1="90" TOTAL_2="90" WEIGHT="100.0" Z="0.5220490016177954">
<NAME>pseudoparkinsonism - only medium term</NAME>
<DICH_DATA CI_END="3.3030333277110557" CI_START="0.5004676188463828" EFFECT_SIZE="1.2857142857142858" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="7" LOG_CI_END="0.518912955758621" LOG_CI_START="-0.30062401690848484" LOG_EFFECT_SIZE="0.10914446942506809" ORDER="113" O_E="0.0" SE="0.4814000745180995" STUDY_ID="STD-Tollefson-2001" TOTAL_1="90" TOTAL_2="90" VAR="0.23174603174603176" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.3792462221686388" CI_START="0.020139825167765746" DF="0" EFFECT_SIZE="0.16666666666666669" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="6" I2="0.0" ID="CMP-001.25.07" LOG_CI_END="0.13964180307490298" LOG_CI_START="-1.6959443038421902" LOG_EFFECT_SIZE="-0.7781512503836436" NO="7" P_CHI2="1.0" P_Z="0.09656163958053487" STUDIES="1" TAU2="0.0" TOTAL_1="490" TOTAL_2="490" WEIGHT="100.0" Z="1.6617563398736674">
<NAME>rigor - only long term</NAME>
<DICH_DATA CI_END="1.3792462221686388" CI_START="0.020139825167765746" EFFECT_SIZE="0.16666666666666666" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="6" LOG_CI_END="0.13964180307490298" LOG_CI_START="-1.6959443038421902" LOG_EFFECT_SIZE="-0.7781512503836436" ORDER="114" O_E="0.0" SE="1.0782323655008716" STUDY_ID="STD-Meltzer-2003" TOTAL_1="490" TOTAL_2="490" VAR="1.1625850340136055" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.1821873798315708" CI_START="-0.38218737983157086" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.10000000000000003" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.26" MODIFIED="2009-09-20 23:34:17 +0100" MODIFIED_BY="[Empty name]" NO="26" P_CHI2="1.0" P_Q="1.0" P_Z="0.48733035462310526" Q="0.0" RANDOM="YES" SCALE="4.214011284936027" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="86" TOTAL_2="89" UNITS="" WEIGHT="100.0" Z="0.6945611762332882">
<NAME>Adverse effects: 3e. Extrapyramidal: akathisia - BARS change - medium term (high = poor)</NAME>
<GROUP_LABEL_1>clozapine</GROUP_LABEL_1>
<GROUP_LABEL_2>olanzapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours clozapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours olanzapine</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.1821873798315708" CI_START="-0.38218737983157086" EFFECT_SIZE="-0.10000000000000003" ESTIMABLE="YES" MEAN_1="-0.4" MEAN_2="-0.3" ORDER="122" SD_1="1.0" SD_2="0.9" SE="0.14397579856437612" STUDY_ID="STD-Tollefson-2001" TOTAL_1="86" TOTAL_2="89" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="2.298374784467539" CI_START="-3.0983747844675396" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.40000000000000036" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.27" MODIFIED="2009-09-20 22:47:21 +0100" MODIFIED_BY="[Empty name]" NO="27" P_CHI2="1.0" P_Q="1.0" P_Z="0.7714032158524604" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="69" TOTAL_2="68" UNITS="" WEIGHT="100.0" Z="0.2905399199284037">
<NAME>Adverse effects: 3f. Extrapyramidal: Hillside Akathisia Scale - medium term (high=poor)</NAME>
<GROUP_LABEL_1>clozapine</GROUP_LABEL_1>
<GROUP_LABEL_2>olanzapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours clozapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours olanzapine</GRAPH_LABEL_2>
<CONT_DATA CI_END="2.298374784467539" CI_START="-3.0983747844675396" EFFECT_SIZE="-0.40000000000000036" ESTIMABLE="YES" MEAN_1="-2.7" MEAN_2="-2.3" ORDER="123" SD_1="7.1" SD_2="8.9" SE="1.376747126861501" STUDY_ID="STD-Bitter-2004" TOTAL_1="69" TOTAL_2="68" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="1.315220956864533" CI_END="0.5095780588143263" CI_START="-0.25203618494507596" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="0.12877093693462519" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.28" MODIFIED="2009-09-20 23:34:23 +0100" MODIFIED_BY="[Empty name]" NO="28" P_CHI2="0.5180878737736643" P_Q="0.36231964661358007" P_Z="0.5074797876747562" Q="0.8298373015612254" RANDOM="YES" SCALE="3.605423362101026" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="173" TOTAL_2="179" UNITS="" WEIGHT="100.0" Z="0.6627670128687198">
<NAME>Adverse effects: 3g. Extrapyramidal: tardive dyskinesia - AIMS change or endpoint - (high = poor)</NAME>
<GROUP_LABEL_1>clozapine</GROUP_LABEL_1>
<GROUP_LABEL_2>olanzapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours clozapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours olanzapine</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.8298476622458784" CI_START="-0.22984766224587827" DF="0" EFFECT_SIZE="0.30000000000000004" ESTIMABLE="YES" I2="0.0" ID="CMP-001.28.01" NO="1" P_CHI2="1.0" P_Z="0.2671143115147532" STUDIES="1" TAU2="0.0" TOTAL_1="17" TOTAL_2="21" WEIGHT="51.65449011552351" Z="1.1097325462750787">
<NAME>short term</NAME>
<CONT_DATA CI_END="0.8298476622458784" CI_START="-0.22984766224587827" EFFECT_SIZE="0.30000000000000004" ESTIMABLE="YES" MEAN_1="0.4" MEAN_2="0.1" ORDER="124" SD_1="1.1" SD_2="0.2" SE="0.270335407397916" STUDY_ID="STD-Kumra-2008" TOTAL_1="17" TOTAL_2="21" WEIGHT="51.65449011552351"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.4853836553033076" CI_END="0.4935023363452373" CI_START="-0.6018579353430902" DF="1" EFFECT_SIZE="-0.05417779949892644" ESTIMABLE="YES" I2="0.0" ID="CMP-001.28.02" NO="2" P_CHI2="0.4859938524294065" P_Z="0.846266540206045" STUDIES="2" TAU2="0.0" TOTAL_1="156" TOTAL_2="158" WEIGHT="48.3455098844765" Z="0.19388421969304764">
<NAME>medium term</NAME>
<CONT_DATA CI_END="0.5821573637565416" CI_START="-1.1821573637565417" EFFECT_SIZE="-0.30000000000000004" ESTIMABLE="YES" MEAN_1="-0.9" MEAN_2="-0.6" ORDER="125" SD_1="2.8" SD_2="2.5" SE="0.45008855811376447" STUDY_ID="STD-Bitter-2004" TOTAL_1="70" TOTAL_2="69" WEIGHT="18.634510824105465"/>
<CONT_DATA CI_END="0.7986287184904153" CI_START="-0.5986287184904151" EFFECT_SIZE="0.10000000000000009" ESTIMABLE="YES" MEAN_1="-0.7" MEAN_2="-0.8" ORDER="126" SD_1="2.5" SD_2="2.2" SE="0.3564497735678356" STUDY_ID="STD-Tollefson-2001" TOTAL_1="86" TOTAL_2="89" WEIGHT="29.710999060371034"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.4423834730152183" CI_START="0.4024580682414871" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7619047619047619" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="21" I2="0.0" I2_Q="0.0" ID="CMP-001.29" LOG_CI_END="0.1590807375500265" LOG_CI_START="-0.3952793617060155" LOG_EFFECT_SIZE="-0.11809931207799451" METHOD="MH" MODIFIED="2009-09-20 23:33:58 +0100" MODIFIED_BY="[Empty name]" NO="29" P_CHI2="1.0" P_Q="0.0" P_Z="0.4036668200858091" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="490" TOTAL_2="490" WEIGHT="100.0" Z="0.8350903991194949">
<NAME>Adverse effects: 4a. Glucose: number of participants with significant increase - long term</NAME>
<GROUP_LABEL_1>clozapine</GROUP_LABEL_1>
<GROUP_LABEL_2>olanzapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours clozapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours olanzapine</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.4423834730152183" CI_START="0.4024580682414871" EFFECT_SIZE="0.7619047619047619" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="21" LOG_CI_END="0.1590807375500265" LOG_CI_START="-0.3952793617060155" LOG_EFFECT_SIZE="-0.11809931207799451" ORDER="127" O_E="0.0" SE="0.3256338664297471" STUDY_ID="STD-Meltzer-2003" TOTAL_1="490" TOTAL_2="490" VAR="0.1060374149659864" WEIGHT="100.0"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="6.123726649563487" CI_END="16.33536564875796" CI_START="-11.089879831685561" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="2.6227429085361997" ESTIMABLE="YES" I2="67.34014899011594" I2_Q="83.5209067115279" ID="CMP-001.30" MODIFIED="2009-09-20 23:33:50 +0100" MODIFIED_BY="[Empty name]" NO="30" P_CHI2="0.04680057194403897" P_Q="0.013763035946566249" P_Z="0.7077554840555873" Q="6.068295035986879" RANDOM="YES" SCALE="33.29" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="96.30474234647289" TOTALS="YES" TOTAL_1="39" TOTAL_2="50" UNITS="" WEIGHT="100.0" Z="0.3748722428103239">
<NAME>Adverse effects: 4b. Glucose: average change or endpoint (high = poor)</NAME>
<GROUP_LABEL_1>clozapine</GROUP_LABEL_1>
<GROUP_LABEL_2>olanzapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours clozapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours olanzapine</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.05543161357660771" CI_END="17.676178668580096" CI_START="1.7261938239909709" DF="1" EFFECT_SIZE="9.701186246285534" ESTIMABLE="YES" I2="0.0" ID="CMP-001.30.01" NO="1" P_CHI2="0.8138678711317374" P_Z="0.017116304782482068" STUDIES="2" TAU2="0.0" TOTAL_1="22" TOTAL_2="28" WEIGHT="65.78471750641961" Z="2.3841998390970596">
<NAME>short term</NAME>
<CONT_DATA CI_END="28.15042984456708" CI_START="-13.35042984456708" EFFECT_SIZE="7.4" ESTIMABLE="YES" MEAN_1="10.8" MEAN_2="3.4" ORDER="128" SD_1="2.9" SD_2="27.8" SE="10.587148543669079" STUDY_ID="STD-Conley-2003" TOTAL_1="5" TOTAL_2="7" WEIGHT="23.488910842508144"/>
<CONT_DATA CI_END="18.738458999570028" CI_START="1.4615410004299605" EFFECT_SIZE="10.099999999999994" ESTIMABLE="YES" MEAN_1="94.1" MEAN_2="84.0" ORDER="129" SD_1="16.8" SD_2="7.7" SE="4.407458028672514" STUDY_ID="STD-Kumra-2008" TOTAL_1="17" TOTAL_2="21" WEIGHT="42.29580666391146"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="3.5021136882879844" CI_START="-23.302113688287985" DF="0" EFFECT_SIZE="-9.9" ESTIMABLE="YES" I2="0.0" ID="CMP-001.30.02" NO="2" P_CHI2="1.0" P_Z="0.1476716725441633" STUDIES="1" TAU2="0.0" TOTAL_1="17" TOTAL_2="22" WEIGHT="34.21528249358039" Z="1.4478047193334322">
<NAME>medium term</NAME>
<CONT_DATA CI_END="3.5021136882879844" CI_START="-23.302113688287985" EFFECT_SIZE="-9.9" ESTIMABLE="YES" MEAN_1="4.4" MEAN_2="14.3" ORDER="130" SD_1="17.1" SD_2="25.5" SE="6.837938754998636" STUDY_ID="STD-Volavka-2002" TOTAL_1="17" TOTAL_2="22" WEIGHT="34.21528249358039"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="49.375618081357466" CI_END="10.046118242721247" CI_START="1.4937242774871742" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RR" EFFECT_SIZE="3.873774737082619" ESTIMABLE="YES" EVENTS_1="317" EVENTS_2="57" I2="91.89883558842931" I2_Q="0.0" ID="CMP-001.31" LOG_CI_END="1.0019982854957536" LOG_CI_START="0.17427043963677114" LOG_EFFECT_SIZE="0.5881343625662625" METHOD="MH" MODIFIED="2009-09-20 01:24:09 +0100" MODIFIED_BY="[Empty name]" NO="31" P_CHI2="4.874783909869507E-10" P_Q="0.0" P_Z="0.005348340705081202" Q="0.0" RANDOM="YES" SCALE="51.222073040584554" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.9397370461612797" TOTALS="YES" TOTAL_1="663" TOTAL_2="670" WEIGHT="100.0" Z="2.785268550447395">
<NAME>Adverse effects: 5. Hypersalivation</NAME>
<GROUP_LABEL_1>clozapine</GROUP_LABEL_1>
<GROUP_LABEL_2>olanzapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours clozapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours olanzapine</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.4747739524673079" CI_END="2.3785616001474263" CI_START="1.1354167603114935" DF="1" EFFECT_SIZE="1.6433680982180203" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="16" I2="0.0" ID="CMP-001.31.01" LOG_CI_END="0.3763144032891088" LOG_CI_START="0.055155300720002645" LOG_EFFECT_SIZE="0.21573485200455572" NO="1" P_CHI2="0.49079912447876195" P_Z="0.008459310702017988" STUDIES="2" TAU2="0.0" TOTAL_1="30" TOTAL_2="34" WEIGHT="44.54065517628945" Z="2.6331655354406407">
<NAME>short term</NAME>
<DICH_DATA CI_END="2.331807031553756" CI_START="1.0377158374067499" EFFECT_SIZE="1.5555555555555556" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="12" LOG_CI_END="0.3676926075797158" LOG_CI_START="0.01607844489811063" LOG_EFFECT_SIZE="0.19188552623891314" ORDER="132" O_E="0.0" SE="0.20653989967735084" STUDY_ID="STD-Kumra-2008" TOTAL_1="18" TOTAL_2="21" VAR="0.042658730158730146" WEIGHT="24.063780018987227"/>
<DICH_DATA CI_END="5.373318675860461" CI_START="0.8736582971589145" EFFECT_SIZE="2.1666666666666665" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="4" LOG_CI_END="0.7302425980716918" LOG_CI_START="-0.058658394225305575" LOG_EFFECT_SIZE="0.3357921019231931" ORDER="131" O_E="0.0" SE="0.46340434799814917" STUDY_ID="STD-Shaw-2006" TOTAL_1="12" TOTAL_2="13" VAR="0.21474358974358976" WEIGHT="20.476875157302224"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.2766664510669286" CI_END="16.083669475300642" CI_START="1.7631938385832742" DF="1" EFFECT_SIZE="5.325281863024714" ESTIMABLE="YES" EVENTS_1="64" EVENTS_2="13" I2="21.671005048790498" ID="CMP-001.31.02" LOG_CI_END="1.206385139628088" LOG_CI_START="0.24630005954807482" LOG_EFFECT_SIZE="0.7263425995880813" NO="2" P_CHI2="0.2585198780908392" P_Z="0.0030211116410125455" STUDIES="2" TAU2="0.2951108447139149" TOTAL_1="143" TOTAL_2="146" WEIGHT="31.231332880377096" Z="2.9655816243102007">
<NAME>medium term</NAME>
<DICH_DATA CI_END="350.06387931995613" CI_START="1.2597700764120507" EFFECT_SIZE="21.0" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="0" LOG_CI_END="2.5441473012211446" LOG_CI_START="0.10029128824669388" LOG_EFFECT_SIZE="1.3222192947339193" ORDER="133" O_E="0.0" SE="1.435533119303559" STUDY_ID="STD-Naber-2005" TOTAL_1="57" TOTAL_2="57" VAR="2.060755336617406" WEIGHT="7.8787588292606525"/>
<DICH_DATA CI_END="7.288830121397698" CI_START="2.5352809750740284" EFFECT_SIZE="4.298747763864043" ESTIMABLE="YES" EVENTS_1="54" EVENTS_2="13" LOG_CI_END="0.8626578283738315" LOG_CI_START="0.404026097461122" LOG_EFFECT_SIZE="0.6333419629174768" ORDER="134" O_E="0.0" SE="0.2694025490018079" STUDY_ID="STD-Tollefson-2001" TOTAL_1="86" TOTAL_2="89" VAR="0.07257773340867149" WEIGHT="23.35257405111644"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="11.862613726945582" CI_START="5.638641883812535" DF="0" EFFECT_SIZE="8.178571428571429" ESTIMABLE="YES" EVENTS_1="229" EVENTS_2="28" I2="0.0" ID="CMP-001.31.03" LOG_CI_END="1.074180389038987" LOG_CI_START="0.7511745129563505" LOG_EFFECT_SIZE="0.9126774509976688" NO="3" P_CHI2="1.0" P_Z="1.6394337014732914E-28" STUDIES="1" TAU2="0.0" TOTAL_1="490" TOTAL_2="490" WEIGHT="24.228011943333453" Z="11.076051960117333">
<NAME>long term</NAME>
<DICH_DATA CI_END="11.862613726945582" CI_START="5.638641883812535" EFFECT_SIZE="8.178571428571429" ESTIMABLE="YES" EVENTS_1="229" EVENTS_2="28" LOG_CI_END="1.074180389038987" LOG_CI_START="0.7511745129563505" LOG_EFFECT_SIZE="0.9126774509976688" ORDER="135" O_E="0.0" SE="0.18973525051581408" STUDY_ID="STD-Meltzer-2003" TOTAL_1="490" TOTAL_2="490" VAR="0.035999465288298726" WEIGHT="24.228011943333453"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.9872403607936733" CI_END="3.3913148319163295" CI_START="0.43916203215334243" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="1.220383838493507" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="5" I2="0.0" I2_Q="0.0" ID="CMP-001.32" LOG_CI_END="0.5303681092759202" LOG_CI_START="-0.35737521395655825" LOG_EFFECT_SIZE="0.08649644765968101" METHOD="MH" MODIFIED="2009-09-20 23:33:45 +0100" MODIFIED_BY="[Empty name]" NO="32" P_CHI2="0.6104126421741701" P_Q="0.0" P_Z="0.7025099150185945" Q="0.0" RANDOM="YES" SCALE="80.9018667470418" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="42" TOTAL_2="47" WEIGHT="200.0" Z="0.3819345474462843">
<NAME>Adverse effects: 6a. Lipids: number of participants with significant increase</NAME>
<GROUP_LABEL_1>clozapine</GROUP_LABEL_1>
<GROUP_LABEL_2>olanzapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours clozapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours olanzapine</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="72.45938986445702" CI_START="0.14405130711161593" DF="0" EFFECT_SIZE="3.230769230769231" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-001.32.01" LOG_CI_END="1.86009467278967" LOG_CI_START="-0.8414827966075424" LOG_EFFECT_SIZE="0.5093059380910637" NO="1" P_CHI2="1.0" P_Z="0.4599122083836973" STUDIES="1" TAU2="0.0" TOTAL_1="12" TOTAL_2="13" WEIGHT="100.0" Z="0.7389914278442653">
<NAME>increase cholesterol</NAME>
<DICH_DATA CI_END="72.45938986445702" CI_START="0.14405130711161593" EFFECT_SIZE="3.230769230769231" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.86009467278967" LOG_CI_START="-0.8414827966075424" LOG_EFFECT_SIZE="0.5093059380910637" ORDER="136" O_E="0.0" SE="1.5869199785480734" STUDY_ID="STD-Shaw-2006" TOTAL_1="12" TOTAL_2="13" VAR="2.518315018315018" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.5494684893262143" CI_END="3.2009957942193275" CI_START="0.3675746649301791" DF="1" EFFECT_SIZE="1.0847142280356987" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="5" I2="0.0" ID="CMP-001.32.02" LOG_CI_END="0.5052851035260323" LOG_CI_START="-0.4346544299850551" LOG_EFFECT_SIZE="0.03531533677048863" NO="2" P_CHI2="0.45853504542318857" P_Z="0.8829116210907788" STUDIES="2" TAU2="0.0" TOTAL_1="30" TOTAL_2="34" WEIGHT="100.00000000000001" Z="0.14727923596001044">
<NAME>increase triglycerides</NAME>
<DICH_DATA CI_END="2.9602296188691324" CI_START="0.2942714664965393" EFFECT_SIZE="0.9333333333333333" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" LOG_CI_END="0.4713253996873449" LOG_CI_START="-0.5312518464422313" LOG_EFFECT_SIZE="-0.02996322337744321" ORDER="137" O_E="0.0" SE="0.588918837213921" STUDY_ID="STD-Kumra-2008" TOTAL_1="18" TOTAL_2="21" VAR="0.34682539682539687" WEIGHT="87.89499477957001"/>
<DICH_DATA CI_END="72.45938986445702" CI_START="0.14405130711161593" EFFECT_SIZE="3.230769230769231" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.86009467278967" LOG_CI_START="-0.8414827966075424" LOG_EFFECT_SIZE="0.5093059380910637" ORDER="138" O_E="0.0" SE="1.5869199785480734" STUDY_ID="STD-Shaw-2006" TOTAL_1="12" TOTAL_2="13" VAR="2.518315018315018" WEIGHT="12.105005220429996"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="3.0048832629345696" CI_END="17.521688204433662" CI_START="-19.84903185503153" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.1636718252989326" ESTIMABLE="YES" I2="33.44167393555251" I2_Q="0.0" ID="CMP-001.33" MODIFIED="2009-09-20 23:33:40 +0100" MODIFIED_BY="[Empty name]" NO="33" P_CHI2="0.22258609252142503" P_Q="0.9240548935955697" P_Z="0.9028506601946598" Q="0.00908728598106201" RANDOM="YES" SCALE="93.42466718097748" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="92.5817913071367" TOTALS="YES" TOTAL_1="39" TOTAL_2="50" UNITS="" WEIGHT="100.00000000000001" Z="0.12206106084018194">
<NAME>Adverse effects: 6b. Lipids:average cholesterol change or endpoint (high = poor)</NAME>
<GROUP_LABEL_1>clozapine</GROUP_LABEL_1>
<GROUP_LABEL_2>olanzapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours clozapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours olanzapine</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="2.9957959769535076" CI_END="48.68966238491909" CI_START="-35.0258690140238" DF="1" EFFECT_SIZE="6.831896685447646" ESTIMABLE="YES" I2="66.61988974907021" ID="CMP-001.33.01" NO="1" P_CHI2="0.083481072240008" P_Z="0.7490446418146128" STUDIES="2" TAU2="636.1166862745088" TOTAL_1="22" TOTAL_2="28" WEIGHT="58.20735331590583" Z="0.3198993359013676">
<NAME>short term</NAME>
<CONT_DATA CI_END="78.01723134771197" CI_START="-11.417231347711969" EFFECT_SIZE="33.300000000000004" ESTIMABLE="YES" MEAN_1="37.6" MEAN_2="4.3" ORDER="139" SD_1="41.2" SD_2="35.6" SE="22.815333190015625" STUDY_ID="STD-Conley-2003" TOTAL_1="5" TOTAL_2="7" WEIGHT="14.823829504693002"/>
<CONT_DATA CI_END="10.792748876129892" CI_START="-31.592748876129846" EFFECT_SIZE="-10.399999999999977" ESTIMABLE="YES" MEAN_1="167.8" MEAN_2="178.2" ORDER="140" SD_1="32.6" SD_2="33.8" SE="10.812825665826294" STUDY_ID="STD-Kumra-2008" TOTAL_1="17" TOTAL_2="21" WEIGHT="43.383523811212825"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="18.10359314961563" CI_START="-25.70359314961563" DF="0" EFFECT_SIZE="-3.8000000000000007" ESTIMABLE="YES" I2="0.0" ID="CMP-001.33.02" NO="2" P_CHI2="1.0" P_Z="0.7338344740427701" STUDIES="1" TAU2="0.0" TOTAL_1="17" TOTAL_2="22" WEIGHT="41.79264668409419" Z="0.34002928608007427">
<NAME>medium term</NAME>
<CONT_DATA CI_END="18.10359314961563" CI_START="-25.70359314961563" EFFECT_SIZE="-3.8000000000000007" ESTIMABLE="YES" MEAN_1="16.3" MEAN_2="20.1" ORDER="141" SD_1="39.6" SD_2="26.8" SE="11.175507979936558" STUDY_ID="STD-Volavka-2002" TOTAL_1="17" TOTAL_2="22" WEIGHT="41.79264668409419"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="1.6936308983381685" CI_END="155.70904393180865" CI_START="-83.5739838975697" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="36.067530017119466" ESTIMABLE="YES" I2="40.955257666754655" I2_Q="0.0" ID="CMP-001.34" MODIFIED="2009-09-20 23:33:36 +0100" MODIFIED_BY="[Empty name]" NO="34" P_CHI2="0.19312311235772406" P_Q="1.0" P_Z="0.5546160527812717" Q="0.0" RANDOM="YES" SCALE="324.34" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="4678.385123625858" TOTALS="YES" TOTAL_1="18" TOTAL_2="20" UNITS="" WEIGHT="100.0" Z="0.5908572829935771">
<NAME>Adverse effects: 6c. Lipids: average triglyceride change -short term (high = poor)</NAME>
<GROUP_LABEL_1>clozapine</GROUP_LABEL_1>
<GROUP_LABEL_2>olanzapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours clozapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours olanzapine</GRAPH_LABEL_2>
<CONT_DATA CI_END="11.22140917669442" CI_START="-1.121409176694419" EFFECT_SIZE="5.050000000000001" ESTIMABLE="YES" MEAN_1="36.28" MEAN_2="31.23" MODIFIED="2009-01-18 03:21:39 +0000" MODIFIED_BY="[Empty name]" ORDER="331" SD_1="5.61" SD_2="9.87" SE="3.148736010137792" STUDY_ID="STD-Atmaca-2003" TOTAL_1="13" TOTAL_2="13" WEIGHT="79.47897451728782"/>
<CONT_DATA CI_END="383.7554288460376" CI_START="-71.3554288460376" EFFECT_SIZE="156.20000000000002" ESTIMABLE="YES" MEAN_1="162.8" MEAN_2="6.6" ORDER="143" SD_1="258.1" SD_2="33.1" SE="116.10184199350896" STUDY_ID="STD-Conley-2003" TOTAL_1="5" TOTAL_2="7" WEIGHT="20.521025482712183"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="19.70307548069967" CI_END="-0.11902061544569709" CI_START="-1.0700097445486074" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.5945151799971522" ESTIMABLE="YES" I2="84.773950630506" I2_Q="88.21226961020481" ID="CMP-001.35" MODIFIED="2009-09-20 23:47:24 +0100" MODIFIED_BY="[Empty name]" NO="35" P_CHI2="1.9557201808628744E-4" P_Q="2.06876777043008E-4" P_Z="0.014263387126396833" Q="16.966794572527963" RANDOM="YES" SCALE="88.13" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="102.3327914036372" TOTALS="SUB" TOTAL_1="90" TOTAL_2="95" UNITS="" WEIGHT="300.0" Z="2.4505608011648934">
<NAME>Adverse effects: 7. Prolactin: average change or endpoint (high=poor)</NAME>
<GROUP_LABEL_1>clozapine</GROUP_LABEL_1>
<GROUP_LABEL_2>olanzapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours clozapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours olanzapine</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.09407435777123624" CI_START="-1.045925642228764" DF="0" EFFECT_SIZE="-0.5700000000000001" ESTIMABLE="YES" I2="0.0" ID="CMP-001.35.01" NO="1" P_CHI2="1.0" P_Z="0.018905840777939786" STUDIES="1" TAU2="0.0" TOTAL_1="60" TOTAL_2="60" WEIGHT="100.0" Z="2.347382389307855">
<NAME>average change from baseline ng/ml</NAME>
<CONT_DATA CI_END="-0.09407435777123624" CI_START="-1.045925642228764" EFFECT_SIZE="-0.5700000000000001" ESTIMABLE="YES" MEAN_1="-0.25" MEAN_2="0.32" ORDER="144" SD_1="1.33" SD_2="1.33" SE="0.24282366716062365" STUDY_ID="STD-Tollefson-2001" TOTAL_1="60" TOTAL_2="60" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="2.7362809081717065" CI_END="3.2616654988034526" CI_START="-20.55387861355755" DF="1" EFFECT_SIZE="-8.646106557377049" ESTIMABLE="YES" I2="63.45404461166353" ID="CMP-001.35.02" MODIFIED="2009-09-20 23:47:15 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.09809289854431591" P_Z="0.15470456278007916" STUDIES="2" TAU2="47.22249999999997" TOTAL_1="20" TOTAL_2="27" WEIGHT="100.0" Z="1.4231089895745095">
<NAME>average endpoint ng/ml - men only</NAME>
<CONT_DATA CI_END="-5.318313398742674" CI_START="-23.081686601257324" EFFECT_SIZE="-14.2" ESTIMABLE="YES" MEAN_1="9.8" MEAN_2="24.0" ORDER="145" SD_1="6.2" SD_2="14.3" SE="4.5315560241488795" STUDY_ID="STD-Kumra-2008" TOTAL_1="8" TOTAL_2="13" WEIGHT="54.47628325718893"/>
<CONT_DATA CI_END="9.404902264758919" CI_START="-13.404902264758919" EFFECT_SIZE="-2.0" ESTIMABLE="YES" MEAN_1="12.0" MEAN_2="14.0" ORDER="146" SD_1="18.0" SD_2="9.8" SE="5.818934610390462" STUDY_ID="STD-Volavka-2002" TOTAL_1="12" TOTAL_2="14" WEIGHT="45.523716742811075"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-22.06112879513897" CI_START="-86.73887120486103" DF="0" EFFECT_SIZE="-54.4" ESTIMABLE="YES" I2="0.0" ID="CMP-001.35.03" MODIFIED="2009-09-20 23:47:24 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="9.771508362332669E-4" STUDIES="1" TAU2="0.0" TOTAL_1="10" TOTAL_2="8" WEIGHT="100.0" Z="3.2970241936877507">
<NAME>average endpoint ng/ml - women only</NAME>
<CONT_DATA CI_END="-22.06112879513897" CI_START="-86.73887120486103" EFFECT_SIZE="-54.4" ESTIMABLE="YES" MEAN_1="19.6" MEAN_2="74.0" ORDER="147" SD_1="11.1" SD_2="45.6" SE="16.499727270473294" STUDY_ID="STD-Kumra-2008" TOTAL_1="10" TOTAL_2="8" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="56.54974388630588" CI_END="2.5778792396737735" CI_START="1.0547707281481427" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="RR" EFFECT_SIZE="1.6489607523251382" ESTIMABLE="YES" EVENTS_1="297" EVENTS_2="167" I2="89.3898723713708" I2_Q="0.0" ID="CMP-001.36" LOG_CI_END="0.4112625690407763" LOG_CI_START="0.023158068808034647" LOG_EFFECT_SIZE="0.21721031892440543" METHOD="MH" MODIFIED="2009-09-20 01:25:00 +0100" MODIFIED_BY="[Empty name]" NO="36" P_CHI2="2.2534596411105667E-10" P_Q="0.0" P_Z="0.02824513013632724" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.24374798769621914" TOTALS="YES" TOTAL_1="718" TOTAL_2="727" WEIGHT="100.0" Z="2.1938648065507707">
<NAME>Adverse effects: 8. Sedation</NAME>
<GROUP_LABEL_1>clozapine</GROUP_LABEL_1>
<GROUP_LABEL_2>olanzapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours clozapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours olanzapine</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="20.166925552384335" CI_END="2.311328370951179" CI_START="0.7644768085249513" DF="3" EFFECT_SIZE="1.3292693242823037" ESTIMABLE="YES" EVENTS_1="44" EVENTS_2="35" I2="85.12415790792012" ID="CMP-001.36.01" LOG_CI_END="0.36386165017895306" LOG_CI_START="-0.11663568498339734" LOG_EFFECT_SIZE="0.12361298259777788" NO="1" P_CHI2="1.5674422307876412E-4" P_Z="0.31324203850178256" STUDIES="4" TAU2="0.21142429876922383" TOTAL_1="66" TOTAL_2="72" WEIGHT="58.15938205239044" Z="1.0084426122003802">
<NAME>short term</NAME>
<DICH_DATA CI_END="1.3346075891202989" CI_START="0.7492839154759685" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="8" LOG_CI_END="0.12535359009642288" LOG_CI_START="-0.1253535900964228" LOG_EFFECT_SIZE="0.0" ORDER="151" O_E="0.0" SE="0.14726663866583445" STUDY_ID="STD-Conley-2003" TOTAL_1="5" TOTAL_2="8" VAR="0.021687462863933443" WEIGHT="19.58004276786899"/>
<DICH_DATA CI_END="1.2980257302109677" CI_START="0.9296705902247057" EFFECT_SIZE="1.098515519568151" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="19" LOG_CI_END="0.11328330138414024" LOG_CI_START="-0.031670907564394175" LOG_EFFECT_SIZE="0.04080619690987304" ORDER="150" O_E="0.0" SE="0.08514681987127566" STUDY_ID="STD-Kumra-2008" TOTAL_1="18" TOTAL_2="21" VAR="0.007249980934191463" WEIGHT="20.706292972949075"/>
<DICH_DATA CI_END="6.528029811075431" CI_START="0.17978029284118263" EFFECT_SIZE="1.0833333333333333" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.814782129011123" LOG_CI_START="-0.7452579164926991" LOG_EFFECT_SIZE="0.03476210625921191" ORDER="148" O_E="0.0" SE="0.9163752450517144" STUDY_ID="STD-Shaw-2006" TOTAL_1="12" TOTAL_2="13" VAR="0.8397435897435896" WEIGHT="4.796749307785998"/>
<DICH_DATA CI_END="6.608143017258416" CI_START="1.4211646268205458" EFFECT_SIZE="3.064516129032258" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="6" LOG_CI_END="0.8200794336667468" LOG_CI_START="0.15264438924240314" LOG_EFFECT_SIZE="0.4863619114545751" ORDER="149" O_E="0.0" SE="0.3920546489516133" STUDY_ID="STD-Wang-2002" TOTAL_1="31" TOTAL_2="30" VAR="0.15370684776457272" WEIGHT="13.076297003786383"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.008192442078246" CI_END="7.7814240794115515" CI_START="0.9166742597527093" DF="1" EFFECT_SIZE="2.670773513013878" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="14" I2="50.20397552312686" ID="CMP-001.36.02" LOG_CI_END="0.8910590845518553" LOG_CI_START="-0.037784963483896594" LOG_EFFECT_SIZE="0.42663706053397943" NO="2" P_CHI2="0.15645199768765417" P_Z="0.07178124161732266" STUDIES="2" TAU2="0.3378717651217274" TOTAL_1="162" TOTAL_2="165" WEIGHT="21.272681703667992" Z="1.800503055136009">
<NAME>medium term</NAME>
<DICH_DATA CI_END="24.955470863072577" CI_START="1.315276753323626" EFFECT_SIZE="5.729166666666667" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="2" LOG_CI_END="1.3971657686042624" LOG_CI_START="0.11901714430508838" LOG_EFFECT_SIZE="0.7580914564546755" ORDER="153" O_E="0.0" SE="0.7507908288510647" STUDY_ID="STD-Bitter-2004" TOTAL_1="72" TOTAL_2="75" VAR="0.5636868686868688" WEIGHT="6.4367266696380145"/>
<DICH_DATA CI_END="3.4762502579570467" CI_START="0.9668783492838626" EFFECT_SIZE="1.8333333333333333" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="12" LOG_CI_END="0.5411110340992761" LOG_CI_START="-0.014628164550113268" LOG_EFFECT_SIZE="0.2632414347745814" ORDER="152" O_E="0.0" SE="0.32644395624005135" STUDY_ID="STD-Tollefson-2001" TOTAL_1="90" TOTAL_2="90" VAR="0.10656565656565656" WEIGHT="14.835955034029979"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.2439641174277867" CI_START="1.5490500106706033" DF="0" EFFECT_SIZE="1.864406779661017" ESTIMABLE="YES" EVENTS_1="220" EVENTS_2="118" I2="0.0" ID="CMP-001.36.03" LOG_CI_END="0.3510159079639346" LOG_CI_START="0.1900654390682271" LOG_EFFECT_SIZE="0.2705406735160809" NO="3" P_CHI2="1.0" P_Z="4.428485673876208E-11" STUDIES="1" TAU2="0.0" TOTAL_1="490" TOTAL_2="490" WEIGHT="20.56793624394157" Z="6.588983307508332">
<NAME>long term</NAME>
<DICH_DATA CI_END="2.2439641174277867" CI_START="1.5490500106706033" EFFECT_SIZE="1.8644067796610169" ESTIMABLE="YES" EVENTS_1="220" EVENTS_2="118" LOG_CI_END="0.3510159079639346" LOG_CI_START="0.1900654390682271" LOG_EFFECT_SIZE="0.27054067351608085" ORDER="154" O_E="0.0" SE="0.09454310214700891" STUDY_ID="STD-Meltzer-2003" TOTAL_1="490" TOTAL_2="490" VAR="0.008938398163579761" WEIGHT="20.56793624394157"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.05287311254483192" CI_END="24.467739935793773" CI_START="1.7271134932182064" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="6.500658719827044" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-001.37" LOG_CI_END="1.3885938557946247" LOG_CI_START="0.23732087714991024" LOG_EFFECT_SIZE="0.8129573664722674" METHOD="MH" MODIFIED="2009-09-20 01:25:07 +0100" MODIFIED_BY="[Empty name]" NO="37" P_CHI2="0.8181371970395255" P_Q="0.0" P_Z="0.005639984521415206" Q="0.0" RANDOM="YES" SCALE="141.8467367486994" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="547" TOTAL_2="550" WEIGHT="99.99999999999999" Z="2.7680093058865953">
<NAME>Adverse effects: 9. Seizures</NAME>
<GROUP_LABEL_1>clozapine</GROUP_LABEL_1>
<GROUP_LABEL_2>olanzapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours clozapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours olanzapine</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-001.37.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="2" TAU2="0.0" TOTAL_1="17" TOTAL_2="21" WEIGHT="0.0" Z="0.0">
<NAME>short term</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="156" O_E="0.0" SE="0.0" STUDY_ID="STD-Conley-2003" TOTAL_1="5" TOTAL_2="8" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="155" O_E="0.0" SE="0.0" STUDY_ID="STD-Shaw-2006" TOTAL_1="12" TOTAL_2="13" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="157.84642671859692" CI_START="0.4884302273694032" DF="0" EFFECT_SIZE="8.78048780487805" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" I2="0.0" ID="CMP-001.37.02" LOG_CI_END="2.1982347549076104" LOG_CI_START="-0.31119746681250704" LOG_EFFECT_SIZE="0.9435186440475518" NO="2" P_CHI2="1.0" P_Z="0.14052214973008406" STUDIES="1" TAU2="0.0" TOTAL_1="40" TOTAL_2="39" WEIGHT="21.047750295541082" Z="1.4738493792095104">
<NAME>medium term</NAME>
<DICH_DATA CI_END="157.84642671859692" CI_START="0.4884302273694032" EFFECT_SIZE="8.78048780487805" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="2.1982347549076104" LOG_CI_START="-0.31119746681250704" LOG_EFFECT_SIZE="0.9435186440475518" ORDER="157" O_E="0.0" SE="1.4740529089282322" STUDY_ID="STD-Volavka-2002" TOTAL_1="40" TOTAL_2="39" VAR="2.1728319783197834" WEIGHT="21.047750295541082"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="26.667893801341783" CI_START="1.3499378791657204" DF="0" EFFECT_SIZE="6.0" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="2" I2="0.0" ID="CMP-001.37.03" LOG_CI_END="1.4259887169806345" LOG_CI_START="0.1303137837866528" LOG_EFFECT_SIZE="0.7781512503836436" NO="3" P_CHI2="1.0" P_Z="0.01856189125430424" STUDIES="1" TAU2="0.0" TOTAL_1="490" TOTAL_2="490" WEIGHT="78.95224970445891" Z="2.3542146046108843">
<NAME>long term</NAME>
<DICH_DATA CI_END="26.667893801341783" CI_START="1.3499378791657204" EFFECT_SIZE="6.0" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="2" LOG_CI_END="1.4259887169806345" LOG_CI_START="0.1303137837866528" LOG_EFFECT_SIZE="0.7781512503836436" ORDER="158" O_E="0.0" SE="0.7610858694525028" STUDY_ID="STD-Meltzer-2003" TOTAL_1="490" TOTAL_2="490" VAR="0.5792517006802721" WEIGHT="78.95224970445891"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="21.922112899657183" CI_END="1.4210285170323402" CI_START="0.55375177761236" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8870721883502571" ESTIMABLE="YES" EVENTS_1="210" EVENTS_2="320" I2="72.63037542291907" I2_Q="0.0" ID="CMP-001.38" LOG_CI_END="0.1526027933852576" LOG_CI_START="-0.2566848666271136" LOG_EFFECT_SIZE="-0.05204103662092807" METHOD="MH" MODIFIED="2009-09-20 23:33:09 +0100" MODIFIED_BY="[Empty name]" NO="38" P_CHI2="0.0012508591828239712" P_Q="0.0" P_Z="0.6181881145855997" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.23490472605996746" TOTALS="YES" TOTAL_1="798" TOTAL_2="802" WEIGHT="100.00000000000001" Z="0.4984199010156621">
<NAME>Adverse effects: 10a. Weight: number of participants with weight gain</NAME>
<GROUP_LABEL_1>clozapine</GROUP_LABEL_1>
<GROUP_LABEL_2>olanzapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours clozapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours olanzapine</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.5684170223702258" CI_END="2.1623204018247466" CI_START="0.454354638696983" DF="1" EFFECT_SIZE="0.9911913563576903" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="10" I2="0.0" ID="CMP-001.38.01" LOG_CI_END="0.33492004597010716" LOG_CI_START="-0.34260503369439654" LOG_EFFECT_SIZE="-0.003842493862144699" NO="1" P_CHI2="0.45088875346692636" P_Z="0.9822634077477784" STUDIES="2" TAU2="0.0" TOTAL_1="49" TOTAL_2="51" WEIGHT="19.210836965554368" Z="0.022231352924526618">
<NAME>short term</NAME>
<DICH_DATA CI_END="9.340799061092136" CI_START="0.32786274278786687" EFFECT_SIZE="1.75" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.9703840296540015" LOG_CI_START="-0.4843079322814127" LOG_EFFECT_SIZE="0.24303804868629442" ORDER="160" O_E="0.0" SE="0.8544932592822075" STUDY_ID="STD-Kumra-2008" TOTAL_1="18" TOTAL_2="21" VAR="0.73015873015873" WEIGHT="5.989307834027451"/>
<DICH_DATA CI_END="2.0444980029519373" CI_START="0.35071031315474344" EFFECT_SIZE="0.8467741935483871" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="8" LOG_CI_END="0.3105866906754478" LOG_CI_START="-0.4550514628600417" LOG_EFFECT_SIZE="-0.07223238609229699" ORDER="159" O_E="0.0" SE="0.4497396413567304" STUDY_ID="STD-Wang-2002" TOTAL_1="31" TOTAL_2="30" VAR="0.2022657450076805" WEIGHT="13.221529131526918"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="5.799723562518148" CI_END="1.7782266171042238" CI_START="0.5955058057711723" DF="3" EFFECT_SIZE="1.029050180730948" ESTIMABLE="YES" EVENTS_1="50" EVENTS_2="45" I2="48.27339669448922" ID="CMP-001.38.02" LOG_CI_END="0.2499871066265318" LOG_CI_START="-0.22511400008868943" LOG_EFFECT_SIZE="0.012436553268921211" NO="2" P_CHI2="0.12177142290768106" P_Z="0.918272057447181" STUDIES="4" TAU2="0.1475656748387519" TOTAL_1="259" TOTAL_2="261" WEIGHT="56.83168155642929" Z="0.1026105650118391">
<NAME>medium term</NAME>
<DICH_DATA CI_END="2.821614201637872" CI_START="0.3845562741407349" EFFECT_SIZE="1.0416666666666667" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="7" LOG_CI_END="0.45049763253887765" LOG_CI_START="-0.4150400986180145" LOG_EFFECT_SIZE="0.017728766960431616" ORDER="164" O_E="0.0" SE="0.5084211477624269" STUDY_ID="STD-Bitter-2004" TOTAL_1="72" TOTAL_2="75" VAR="0.2584920634920635" WEIGHT="11.714835282799745"/>
<DICH_DATA CI_END="2.4567696947268125" CI_START="1.0147775746317937" EFFECT_SIZE="1.5789473684210527" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="19" LOG_CI_END="0.3903644462654857" LOG_CI_START="0.006370861268181175" LOG_EFFECT_SIZE="0.19836765376683346" ORDER="161" O_E="0.0" SE="0.22555973262631815" STUDY_ID="STD-Naber-2005" TOTAL_1="57" TOTAL_2="57" VAR="0.05087719298245613" WEIGHT="20.22542971938759"/>
<DICH_DATA CI_END="2.9838537792251403" CI_START="0.3351370656841249" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="6" LOG_CI_END="0.47477753715465826" LOG_CI_START="-0.4747775371546582" LOG_EFFECT_SIZE="0.0" ORDER="162" O_E="0.0" SE="0.557773351022717" STUDY_ID="STD-Tollefson-2001" TOTAL_1="90" TOTAL_2="90" VAR="0.31111111111111106" WEIGHT="10.585887304315012"/>
<DICH_DATA CI_END="1.175517260070701" CI_START="0.23447124883850937" EFFECT_SIZE="0.525" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="13" LOG_CI_END="0.07022901023546349" LOG_CI_START="-0.6299104034235496" LOG_EFFECT_SIZE="-0.2798406965940431" ORDER="163" O_E="0.0" SE="0.41126535732929675" STUDY_ID="STD-Volavka-2002" TOTAL_1="40" TOTAL_2="39" VAR="0.16913919413919415" WEIGHT="14.30552924992694"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.6617912241876094" CI_START="0.4841386629120627" DF="0" EFFECT_SIZE="0.5660377358490566" ESTIMABLE="YES" EVENTS_1="150" EVENTS_2="265" I2="0.0" ID="CMP-001.38.03" LOG_CI_END="-0.1792789961851798" LOG_CI_START="-0.31503023357707344" LOG_EFFECT_SIZE="-0.2471546148811266" NO="3" P_CHI2="1.0" P_Z="9.553453258190499E-13" STUDIES="1" TAU2="0.0" TOTAL_1="490" TOTAL_2="490" WEIGHT="23.95748147801636" Z="7.136791576808157">
<NAME>long term</NAME>
<DICH_DATA CI_END="0.6617912241876094" CI_START="0.4841386629120627" EFFECT_SIZE="0.5660377358490566" ESTIMABLE="YES" EVENTS_1="150" EVENTS_2="265" LOG_CI_END="-0.1792789961851798" LOG_CI_START="-0.31503023357707344" LOG_EFFECT_SIZE="-0.2471546148811266" ORDER="165" O_E="0.0" SE="0.07974094882346096" STUDY_ID="STD-Meltzer-2003" TOTAL_1="490" TOTAL_2="490" VAR="0.00635861891926582" WEIGHT="23.95748147801636"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="8.070741473220338" CI_END="0.9700686824774696" CI_START="-1.0567077704291687" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.04331954397584959" ESTIMABLE="YES" I2="25.657388234913725" I2_Q="72.21603651293667" ID="CMP-001.39" MODIFIED="2009-09-20 23:33:14 +0100" MODIFIED_BY="[Empty name]" NO="39" P_CHI2="0.23296635615755268" P_Q="0.05780760712717947" P_Z="0.9332289329549097" Q="3.5991985105566977" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.464756907542043" TOTALS="YES" TOTAL_1="287" TOTAL_2="294" UNITS="" WEIGHT="100.0" Z="0.08378303971076904">
<NAME>Adverse effects: 10b. Weight: average weight change (high = poor)</NAME>
<GROUP_LABEL_1>clozapine</GROUP_LABEL_1>
<GROUP_LABEL_2>olanzapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours clozapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours olanzapine</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="1.1559050189008906" CI_END="0.2814417603704622" CI_START="-3.6860575992230418" DF="2" EFFECT_SIZE="-1.7023079194262898" ESTIMABLE="YES" I2="0.0" ID="CMP-001.39.01" MODIFIED="2009-01-18 03:51:59 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.5610461126182433" P_Z="0.09258885583744109" STUDIES="3" TAU2="0.0" TOTAL_1="30" TOTAL_2="34" WEIGHT="21.695620481615634" Z="1.681896787005245">
<NAME>short term</NAME>
<CONT_DATA CI_END="0.11615175085611185" CI_START="-4.916151750856113" EFFECT_SIZE="-2.4000000000000004" ESTIMABLE="YES" MEAN_1="6.52" MEAN_2="8.92" MODIFIED="2009-01-18 03:51:59 +0000" MODIFIED_BY="[Empty name]" ORDER="332" SD_1="3.41" SD_2="3.13" SE="1.2837744829513176" STUDY_ID="STD-Atmaca-2003" TOTAL_1="13" TOTAL_2="13" WEIGHT="12.652903170252516"/>
<CONT_DATA CI_END="3.473662247960672" CI_START="-7.273662247960672" EFFECT_SIZE="-1.9" ESTIMABLE="YES" MEAN_1="1.5" MEAN_2="3.4" ORDER="167" SD_1="4.4" SD_2="5.4" SE="2.7417147918775213" STUDY_ID="STD-Conley-2003" TOTAL_1="5" TOTAL_2="8" WEIGHT="3.3493229853185253"/>
<CONT_DATA CI_END="4.231417341315552" CI_START="-3.8314173413155532" EFFECT_SIZE="0.19999999999999973" ESTIMABLE="YES" MEAN_1="3.8" MEAN_2="3.6" ORDER="168" SD_1="6.0" SD_2="4.0" SE="2.0568833780186058" STUDY_ID="STD-Shaw-2006" TOTAL_1="12" TOTAL_2="13" WEIGHT="5.693394326044593"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="3.3156379437627495" CI_END="1.3696235568868393" CI_START="-0.5570628322130249" DF="3" EFFECT_SIZE="0.40628036233690723" ESTIMABLE="YES" I2="9.519674618168592" ID="CMP-001.39.02" NO="2" P_CHI2="0.34547212833471597" P_Z="0.4084665366635869" STUDIES="4" TAU2="0.0948389021439697" TOTAL_1="257" TOTAL_2="260" WEIGHT="78.30437951838437" Z="0.8265952178945382">
<NAME>medium term</NAME>
<CONT_DATA CI_END="2.5640643717757365" CI_START="-0.9640643717757371" EFFECT_SIZE="0.7999999999999998" ESTIMABLE="YES" MEAN_1="4.1" MEAN_2="3.3" ORDER="172" SD_1="5.6" SD_2="5.3" SE="0.9000493813613166" STUDY_ID="STD-Bitter-2004" TOTAL_1="72" TOTAL_2="75" WEIGHT="20.969972955551757"/>
<CONT_DATA CI_END="3.837153154367393" CI_START="-0.8371531543673929" EFFECT_SIZE="1.5" ESTIMABLE="YES" MEAN_1="5.0" MEAN_2="3.5" ORDER="169" SD_1="6.8" SD_2="5.9" SE="1.1924469902521468" STUDY_ID="STD-Naber-2005" TOTAL_1="57" TOTAL_2="57" WEIGHT="14.169539340455643"/>
<CONT_DATA CI_END="1.9463359714281045" CI_START="-0.946335971428105" EFFECT_SIZE="0.4999999999999998" ESTIMABLE="YES" MEAN_1="2.3" MEAN_2="1.8" ORDER="170" SD_1="4.9" SD_2="5.0" SE="0.7379400758568108" STUDY_ID="STD-Tollefson-2001" TOTAL_1="90" TOTAL_2="90" WEIGHT="26.486824299791095"/>
<CONT_DATA CI_END="0.8909774470518563" CI_START="-3.2909774470518567" EFFECT_SIZE="-1.2000000000000002" ESTIMABLE="YES" MEAN_1="4.2" MEAN_2="5.4" ORDER="171" SD_1="4.7" SD_2="4.6" SE="1.066844831611815" STUDY_ID="STD-Volavka-2002" TOTAL_1="38" TOTAL_2="38" WEIGHT="16.678042922585867"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.8905642501344396" CI_END="13.001871488057724" CI_START="2.4784608875118153" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="5.676674197768101" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="6" I2="0.0" I2_Q="0.0" ID="CMP-001.40" LOG_CI_END="1.1140058691097672" LOG_CI_START="0.3941820697120909" LOG_EFFECT_SIZE="0.7540939694109291" METHOD="MH" MODIFIED="2009-09-20 23:33:20 +0100" MODIFIED_BY="[Empty name]" NO="40" P_CHI2="0.8277043668224866" P_Q="0.0" P_Z="4.0160865066201406E-5" Q="0.0" RANDOM="YES" SCALE="38.8217879300869" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="632" TOTAL_2="632" WEIGHT="99.99999999999999" Z="4.106552248594745">
<NAME>Adverse effects: 11. White blood cell count: number of participants with a decrease</NAME>
<GROUP_LABEL_1>clozapine</GROUP_LABEL_1>
<GROUP_LABEL_2>olanzapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours clozapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours olanzapine</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="20.942804971075702" CI_START="0.22415547730726543" DF="0" EFFECT_SIZE="2.1666666666666665" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" I2="0.0" ID="CMP-001.40.01" LOG_CI_END="1.3210348483971615" LOG_CI_START="-0.6494506445507751" LOG_EFFECT_SIZE="0.3357921019231931" NO="1" P_CHI2="1.0" P_Z="0.504134716733027" STUDIES="1" TAU2="0.0" TOTAL_1="12" TOTAL_2="13" WEIGHT="13.344611027659989" Z="0.6679982455266427">
<NAME>short term</NAME>
<DICH_DATA CI_END="20.942804971075702" CI_START="0.22415547730726543" EFFECT_SIZE="2.1666666666666665" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.3210348483971615" LOG_CI_START="-0.6494506445507751" LOG_EFFECT_SIZE="0.3357921019231931" ORDER="173" O_E="0.0" SE="1.1574729326181195" STUDY_ID="STD-Shaw-2006" TOTAL_1="12" TOTAL_2="13" VAR="1.3397435897435899" WEIGHT="13.344611027659989"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.028563612367470403" CI_END="31.14025431423971" CI_START="0.9954966491076316" DF="1" EFFECT_SIZE="5.567766053111885" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="1" I2="0.0" ID="CMP-001.40.02" LOG_CI_END="1.4933221550150166" LOG_CI_START="-0.0019601974914328357" LOG_EFFECT_SIZE="0.745680978761792" NO="2" P_CHI2="0.8657905918113353" P_Z="0.05060369773734327" STUDIES="2" TAU2="0.0" TOTAL_1="130" TOTAL_2="129" WEIGHT="23.17426600027294" Z="1.954825267455145">
<NAME>medium term</NAME>
<DICH_DATA CI_END="41.95082298864738" CI_START="0.5959358653527592" EFFECT_SIZE="5.0" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="1" LOG_CI_END="1.6227404852105425" LOG_CI_START="-0.22480047653850477" LOG_EFFECT_SIZE="0.6989700043360189" ORDER="174" O_E="0.0" SE="1.0852547064066471" STUDY_ID="STD-Tollefson-2001" TOTAL_1="90" TOTAL_2="90" VAR="1.1777777777777778" WEIGHT="15.17973714503413"/>
<DICH_DATA CI_END="128.0236611809205" CI_START="0.3642991067685153" EFFECT_SIZE="6.829268292682927" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="2.107290242856141" LOG_CI_START="-0.43854189361117346" LOG_EFFECT_SIZE="0.8343741746224838" ORDER="175" O_E="0.0" SE="1.4954343990332195" STUDY_ID="STD-Volavka-2002" TOTAL_1="40" TOTAL_2="39" VAR="2.2363240418118466" WEIGHT="7.994528855238809"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="19.807187378785642" CI_START="2.473849470040412" DF="0" EFFECT_SIZE="7.0" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="4" I2="0.0" ID="CMP-001.40.03" LOG_CI_END="1.2968228100869614" LOG_CI_START="0.39337326994155214" LOG_EFFECT_SIZE="0.8450980400142568" NO="3" P_CHI2="1.0" P_Z="2.456529146316874E-4" STUDIES="1" TAU2="0.0" TOTAL_1="490" TOTAL_2="490" WEIGHT="63.48112297206706" Z="3.666749825489408">
<NAME>long term</NAME>
<DICH_DATA CI_END="19.807187378785642" CI_START="2.473849470040412" EFFECT_SIZE="7.0" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="4" LOG_CI_END="1.2968228100869614" LOG_CI_START="0.39337326994155214" LOG_EFFECT_SIZE="0.8450980400142568" ORDER="176" O_E="0.0" SE="0.530690732028763" STUDY_ID="STD-Meltzer-2003" TOTAL_1="490" TOTAL_2="490" VAR="0.2816326530612244" WEIGHT="63.48112297206706"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2010-09-30 13:43:26 +0100" MODIFIED_BY="[Empty name]" NO="2">
<NAME>CLOZAPINE versus OLANZAPINE - Sensitivity Analysis</NAME>
<CONT_OUTCOME CHI2="0.5080695698341458" CI_END="5.544309099886522" CI_START="-1.2311984677808527" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="MD" EFFECT_SIZE="2.1565553160528346" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.01" MODIFIED="2009-09-20 23:27:11 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.9727106767436817" P_Q="0.8991809184964604" P_Z="0.21215498560727886" Q="0.01605190757325059" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="290" TOTAL_2="287" UNITS="" WEIGHT="100.0" Z="1.247661730997701">
<NAME>Mental state: 1a. PANSS total score, excluding possibly skewed data (high = poor)</NAME>
<GROUP_LABEL_1>clozapine</GROUP_LABEL_1>
<GROUP_LABEL_2>olanzapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours clozapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours olanzapine</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="7.981086382514089" CI_START="-3.101086382514089" DF="0" EFFECT_SIZE="2.44" ESTIMABLE="YES" I2="0.0" ID="CMP-002.01.01" MODIFIED="2009-04-18 23:25:28 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.38810229426591436" STUDIES="1" TAU2="0.0" TOTAL_1="37" TOTAL_2="37" WEIGHT="37.37953003584753" Z="0.8630639900091058">
<NAME>short term</NAME>
<CONT_DATA CI_END="7.981086382514089" CI_START="-3.101086382514089" EFFECT_SIZE="2.44" ESTIMABLE="YES" MEAN_1="-2.39" MEAN_2="-4.83" ORDER="188" SD_1="14.2" SD_2="9.7" SE="2.8271368383406386" STUDY_ID="STD-Krakowski-2006" TOTAL_1="37" TOTAL_2="37" WEIGHT="37.37953003584753"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.49201766226089516" CI_END="6.268444270386883" CI_START="-2.293722317994718" DF="3" EFFECT_SIZE="1.9873609761960824" ESTIMABLE="YES" I2="0.0" ID="CMP-002.01.02" NO="2" P_CHI2="0.9206416115750281" P_Z="0.3629001162255946" STUDIES="4" TAU2="0.0" TOTAL_1="253" TOTAL_2="250" WEIGHT="62.62046996415248" Z="0.9098528736663926">
<NAME>medium term</NAME>
<CONT_DATA CI_END="7.502754640080644" CI_START="-7.902754640080635" EFFECT_SIZE="-0.19999999999999574" ESTIMABLE="YES" MEAN_1="-37.9" MEAN_2="-37.7" ORDER="189" SD_1="23.4" SD_2="23.1" SE="3.9300490727579613" STUDY_ID="STD-Bitter-2004" TOTAL_1="70" TOTAL_2="70" WEIGHT="19.343343740604418"/>
<CONT_DATA CI_END="13.572644866337145" CI_START="-8.77264486633714" EFFECT_SIZE="2.400000000000002" ESTIMABLE="YES" MEAN_1="-30.2" MEAN_2="-32.6" ORDER="190" SD_1="29.6" SD_2="29.6" SE="5.700433760245361" STUDY_ID="STD-Naber-2005" TOTAL_1="56" TOTAL_2="52" WEIGHT="9.194152205461561"/>
<CONT_DATA CI_END="10.685247227751553" CI_START="-3.6852472277515522" EFFECT_SIZE="3.5" ESTIMABLE="YES" MEAN_1="-22.1" MEAN_2="-25.6" ORDER="191" SD_1="23.1" SD_2="25.5" SE="3.6660098269294052" STUDY_ID="STD-Tollefson-2001" TOTAL_1="87" TOTAL_2="89" WEIGHT="22.230040117655424"/>
<CONT_DATA CI_END="12.240086310274894" CI_START="-7.440086310274894" EFFECT_SIZE="2.3999999999999995" ESTIMABLE="YES" MEAN_1="-6.7" MEAN_2="-9.1" ORDER="192" SD_1="22.31" SD_2="22.31" SE="5.020544452802316" STUDY_ID="STD-Volavka-2002" TOTAL_1="40" TOTAL_2="39" WEIGHT="11.852933900431072"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="2.9081086765983213" CI_END="5.274021280519753" CI_START="-3.0335750423690313" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="1.1202231190753609" ESTIMABLE="YES" I2="31.226779243358813" I2_Q="0.0" ID="CMP-002.02" MODIFIED="2010-09-30 13:43:26 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.23362123507970334" P_Q="0.9467177810596622" P_Z="0.5970997902008044" Q="0.0044661245310551045" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="4.386333407120006" TOTALS="YES" TOTAL_1="98" TOTAL_2="106" UNITS="" WEIGHT="100.0" Z="0.528575747472853">
<NAME>Mental state: 1b. BPRS-18 (1-7) total score, excluding possibly skewed data (high = poor)</NAME>
<GROUP_LABEL_1>clozapine</GROUP_LABEL_1>
<GROUP_LABEL_2>olanzapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours clozapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours olanzapine</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="2.903642552067266" CI_END="9.382205447586353" CI_START="-8.74275393947953" DF="1" EFFECT_SIZE="0.31972575405341186" ESTIMABLE="YES" I2="65.56049919822108" ID="CMP-002.02.01" NO="1" P_CHI2="0.08837977242140882" P_Z="0.9448719354290896" STUDIES="2" TAU2="28.47371152777783" TOTAL_1="11" TOTAL_2="17" WEIGHT="50.36857519284608" Z="0.06914784739565064">
<NAME>short term</NAME>
<CONT_DATA CI_END="3.923876252308963" CI_START="-13.763876252308963" EFFECT_SIZE="-4.92" ESTIMABLE="YES" MEAN_1="-5.8" MEAN_2="-0.88" ORDER="193" SD_1="7.36" SD_2="8.73" SE="4.512264675304409" STUDY_ID="STD-Conley-2003" TOTAL_1="5" TOTAL_2="8" WEIGHT="18.149906513902526"/>
<CONT_DATA CI_END="10.458300495018648" CI_START="-1.6583004950186355" EFFECT_SIZE="4.400000000000006" ESTIMABLE="YES" MEAN_1="48.7" MEAN_2="44.3" ORDER="194" SD_1="5.4" SD_2="6.5" SE="3.0910264386518027" STUDY_ID="STD-Moresco-2004" TOTAL_1="6" TOTAL_2="9" WEIGHT="32.21866867894356"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="5.4325435224404455" CI_START="-3.032543522440447" DF="0" EFFECT_SIZE="1.1999999999999993" ESTIMABLE="YES" I2="0.0" ID="CMP-002.02.02" NO="2" P_CHI2="1.0" P_Z="0.5784268880651382" STUDIES="1" TAU2="0.0" TOTAL_1="87" TOTAL_2="89" WEIGHT="49.63142480715392" Z="0.5556840157645789">
<NAME>medium term</NAME>
<CONT_DATA CI_END="5.4325435224404455" CI_START="-3.032543522440447" EFFECT_SIZE="1.1999999999999993" ESTIMABLE="YES" MEAN_1="-14.0" MEAN_2="-15.2" ORDER="195" SD_1="13.3" SD_2="15.3" SE="2.1595006621683916" STUDY_ID="STD-Tollefson-2001" TOTAL_1="87" TOTAL_2="89" WEIGHT="49.63142480715392"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.940406757442491" CI_END="1.4404635202403455" CI_START="-0.7686961083348065" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="MD" EFFECT_SIZE="0.33588370595276945" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.03" MODIFIED="2009-09-20 23:31:41 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.9186936238700567" P_Q="0.5798853047079968" P_Z="0.55118103748203" Q="0.30642026935737554" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="290" TOTAL_2="287" UNITS="" WEIGHT="100.0" Z="0.595991306509497">
<NAME>Mental state: 2a. PANSS positive subscore, excluding possibly skewed data (high = poor)</NAME>
<GROUP_LABEL_1>clozapine</GROUP_LABEL_1>
<GROUP_LABEL_2>olanzapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours clozapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours olanzapine</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="1.8552277208444963" CI_START="-2.1152277208444965" DF="0" EFFECT_SIZE="-0.13000000000000012" ESTIMABLE="YES" I2="0.0" ID="CMP-002.03.01" NO="1" P_CHI2="1.0" P_Z="0.8978754500196496" STUDIES="1" TAU2="0.0" TOTAL_1="37" TOTAL_2="37" WEIGHT="30.958046134904986" Z="0.1283456377900163">
<NAME>short term</NAME>
<CONT_DATA CI_END="1.8552277208444963" CI_START="-2.1152277208444965" EFFECT_SIZE="-0.13000000000000012" ESTIMABLE="YES" MEAN_1="-1.54" MEAN_2="-1.41" ORDER="196" SD_1="5.0" SD_2="3.6" SE="1.0128898982347223" STUDY_ID="STD-Krakowski-2006" TOTAL_1="37" TOTAL_2="37" WEIGHT="30.958046134904986"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.6339864880851155" CI_END="1.8741372424911993" CI_START="-0.7845702622082072" DF="3" EFFECT_SIZE="0.544783490141496" ESTIMABLE="YES" I2="0.0" ID="CMP-002.03.02" NO="2" P_CHI2="0.8886097540629018" P_Z="0.4218508556935363" STUDIES="4" TAU2="0.0" TOTAL_1="253" TOTAL_2="250" WEIGHT="69.04195386509501" Z="0.8032143574741097">
<NAME>medium term</NAME>
<CONT_DATA CI_END="2.4197981369101487" CI_START="-2.6197981369101515" EFFECT_SIZE="-0.10000000000000142" ESTIMABLE="YES" MEAN_1="-11.8" MEAN_2="-11.7" ORDER="200" SD_1="7.9" SD_2="7.3" SE="1.28563491818523" STUDY_ID="STD-Bitter-2004" TOTAL_1="70" TOTAL_2="70" WEIGHT="19.21598733669778"/>
<CONT_DATA CI_END="4.5189181115803585" CI_START="-1.7189181115803573" EFFECT_SIZE="1.4000000000000004" ESTIMABLE="YES" MEAN_1="-7.6" MEAN_2="-9.0" ORDER="197" SD_1="8.0" SD_2="8.5" SE="1.5913139915743277" STUDY_ID="STD-Naber-2005" TOTAL_1="56" TOTAL_2="52" WEIGHT="12.542562106049202"/>
<CONT_DATA CI_END="2.5867883329020356" CI_START="-1.7867883329020366" EFFECT_SIZE="0.39999999999999947" ESTIMABLE="YES" MEAN_1="-6.4" MEAN_2="-6.8" ORDER="198" SD_1="7.2" SD_2="7.6" SE="1.1157288348924488" STUDY_ID="STD-Tollefson-2001" TOTAL_1="87" TOTAL_2="89" WEIGHT="25.51412674055416"/>
<CONT_DATA CI_END="4.219750339085913" CI_START="-2.219750339085913" EFFECT_SIZE="1.0" ESTIMABLE="YES" MEAN_1="-2.3" MEAN_2="-3.3" ORDER="199" SD_1="7.3" SD_2="7.3" SE="1.6427599509393502" STUDY_ID="STD-Volavka-2002" TOTAL_1="40" TOTAL_2="39" WEIGHT="11.769277681793861"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="2.0967984738765573" CI_START="-4.316798473876558" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.11" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.04" MODIFIED="2009-09-20 23:31:46 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Q="1.0" P_Z="0.4975046846602792" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="5" TOTAL_2="8" UNITS="" WEIGHT="100.0" Z="0.6784211856660645">
<NAME>Mental state: 2b. BPRS positive subscore, excluding possibly skewed data (high = poor)</NAME>
<GROUP_LABEL_1>clozapine</GROUP_LABEL_1>
<GROUP_LABEL_2>olanzapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours clozapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours olanzapine</GRAPH_LABEL_2>
<CONT_DATA CI_END="2.0967984738765573" CI_START="-4.316798473876558" EFFECT_SIZE="-1.11" ESTIMABLE="YES" MEAN_1="-0.8" MEAN_2="0.31" ORDER="201" SD_1="2.87" SD_2="2.87" SE="1.636151735017263" STUDY_ID="STD-Conley-2003" TOTAL_1="5" TOTAL_2="8" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="-1.0981771766624302" CI_START="-20.901822823337568" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-11.0" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.05" MODIFIED="2009-09-20 23:27:36 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="1.0" P_Q="1.0" P_Z="0.029455442788192808" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="12" TOTAL_2="13" UNITS="" WEIGHT="100.0" Z="2.1773368615652107">
<NAME>Mental state: 3. SANS, excluding possibly skewed data (high=poor)</NAME>
<GROUP_LABEL_1>clozapine</GROUP_LABEL_1>
<GROUP_LABEL_2>olanzapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours clozapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours olanzapine</GRAPH_LABEL_2>
<CONT_DATA CI_END="-1.0981771766624302" CI_START="-20.901822823337568" EFFECT_SIZE="-11.0" ESTIMABLE="YES" MEAN_1="-25.0" MEAN_2="-14.0" MODIFIED="2009-01-26 15:35:19 +0000" MODIFIED_BY="[Empty name]" ORDER="1279" SD_1="12.62" SD_2="12.62" SE="5.052043252550498" STUDY_ID="STD-Shaw-2006" TOTAL_1="12" TOTAL_2="13" WEIGHT="100.0"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" MODIFIED="2009-09-21 00:10:03 +0100" MODIFIED_BY="[Empty name]" NO="3">
<NAME>CLOZAPINE versus QUETIAPINE</NAME>
<DICH_OUTCOME CHI2="1.2056491743922801" CI_END="6.324383771883174" CI_START="0.5957415838774398" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="1.9410560026208568" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-003.01" LOG_CI_END="0.8010182156172544" LOG_CI_START="-0.22494208427551324" LOG_EFFECT_SIZE="0.2880380656708706" METHOD="MH" MODIFIED="2009-09-20 23:49:32 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.5472639105721276" P_Q="0.0" P_Z="0.2711062147817409" Q="0.0" RANDOM="YES" SCALE="82.23239625026929" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="119" TOTAL_2="119" WEIGHT="200.0" Z="1.1005186749438451">
<NAME>Leaving the study early - short term</NAME>
<GROUP_LABEL_1>clozapine</GROUP_LABEL_1>
<GROUP_LABEL_2>quetiapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours clozapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours quetiapine</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.27309082961831316" CI_END="5.500232694503605" CI_START="0.41603792074771323" DF="1" EFFECT_SIZE="1.5127145711765562" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" I2="0.0" ID="CMP-003.01.01" LOG_CI_END="0.7403810632762731" LOG_CI_START="-0.380867082784516" LOG_EFFECT_SIZE="0.17975699024587857" MODIFIED="2009-09-20 23:49:21 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.6012659675796092" P_Z="0.5297173393055504" STUDIES="2" TAU2="0.0" TOTAL_1="47" TOTAL_2="47" WEIGHT="100.0" Z="0.628437564136028">
<NAME>any reason</NAME>
<DICH_DATA CI_END="72.54727677061535" CI_START="0.1424124117811954" EFFECT_SIZE="3.2142857142857144" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8606211148345155" LOG_CI_START="-0.8464521586403041" LOG_EFFECT_SIZE="0.5070844780971057" MODIFIED="2009-01-18 14:53:11 +0000" MODIFIED_BY="[Empty name]" ORDER="334" O_E="0.0" SE="1.5901482410679288" STUDY_ID="STD-Atmaca-2003" TOTAL_1="13" TOTAL_2="14" VAR="2.528571428571428" WEIGHT="17.15550290131362"/>
<DICH_DATA CI_END="5.3446083732386045" CI_START="0.31335139405438683" EFFECT_SIZE="1.2941176470588236" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.7279158877351333" LOG_CI_START="-0.5039683688472687" LOG_EFFECT_SIZE="0.11197375944393231" ORDER="209" O_E="0.0" SE="0.723614910241919" STUDY_ID="STD-Li--2005" TOTAL_1="34" TOTAL_2="33" VAR="0.5236185383244206" WEIGHT="82.84449709868638"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="130.82359964630137" CI_START="0.3745501586294664" DF="0" EFFECT_SIZE="7.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" I2="0.0" ID="CMP-003.01.02" LOG_CI_END="2.116686094689066" LOG_CI_START="-0.42649001466055253" LOG_EFFECT_SIZE="0.8450980400142568" MODIFIED="2009-09-20 23:49:27 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.19271374269536654" STUDIES="1" TAU2="0.0" TOTAL_1="36" TOTAL_2="36" WEIGHT="100.0" Z="1.3025930180328125">
<NAME>adverse effects</NAME>
<DICH_DATA CI_END="130.82359964630137" CI_START="0.3745501586294664" EFFECT_SIZE="7.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="2.116686094689066" LOG_CI_START="-0.42649001466055253" LOG_EFFECT_SIZE="0.8450980400142568" ORDER="210" O_E="0.0" SE="1.493874235556739" STUDY_ID="STD-Liu--2004" TOTAL_1="36" TOTAL_2="36" VAR="2.231660231660231" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-003.01.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2009-09-20 23:49:32 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="36" TOTAL_2="36" WEIGHT="0.0" Z="0.0">
<NAME>inefficacy</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="211" O_E="0.0" SE="0.0" STUDY_ID="STD-Liu--2004" TOTAL_1="36" TOTAL_2="36" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.3491846972103387" CI_START="0.846946514746145" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0689655172413792" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="29" I2="0.0" I2_Q="0.0" ID="CMP-003.02" LOG_CI_END="0.13007140666866301" LOG_CI_START="-0.07214401479802994" LOG_EFFECT_SIZE="0.028963695935316558" METHOD="MH" MODIFIED="2009-09-21 00:09:04 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Q="0.0" P_Z="0.5744848997376291" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="38" TOTAL_2="38" WEIGHT="100.0" Z="0.5614586709623418">
<NAME>Global state: No clinically important change - less than "common criteria" - short term</NAME>
<GROUP_LABEL_1>clozapine</GROUP_LABEL_1>
<GROUP_LABEL_2>quetiapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours clozapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours quetiapine</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.3491846972103387" CI_START="0.846946514746145" EFFECT_SIZE="1.0689655172413792" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="29" LOG_CI_END="0.13007140666866301" LOG_CI_START="-0.07214401479802994" LOG_EFFECT_SIZE="0.028963695935316558" ORDER="212" O_E="0.0" SE="0.11878233955201534" STUDY_ID="STD-Li--2003" TOTAL_1="38" TOTAL_2="38" VAR="0.014109244189450268" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.8889364744555674" CI_START="0.46620169260720146" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9384164222873901" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="11" I2="0.0" I2_Q="0.0" ID="CMP-003.03" LOG_CI_END="0.2762173527035637" LOG_CI_START="-0.3314261540487471" LOG_EFFECT_SIZE="-0.027604400672591716" METHOD="MH" MODIFIED="2009-09-21 00:09:33 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Q="0.0" P_Z="0.8586625958383605" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="31" TOTAL_2="32" WEIGHT="100.0" Z="0.1780768840014837">
<NAME>Mental state: 1. No clinically important change - less than 50% reduction PANSS total - short term</NAME>
<GROUP_LABEL_1>clozapine</GROUP_LABEL_1>
<GROUP_LABEL_2>quetiapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours clozapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours quetiapine</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.8889364744555674" CI_START="0.46620169260720146" EFFECT_SIZE="0.9384164222873901" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="11" LOG_CI_END="0.2762173527035637" LOG_CI_START="-0.3314261540487471" LOG_EFFECT_SIZE="-0.027604400672591716" ORDER="213" O_E="0.0" SE="0.35693280375017633" STUDY_ID="STD-Li--2002" TOTAL_1="31" TOTAL_2="32" VAR="0.12740102639296189" WEIGHT="100.0"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="1.6053044630016642" CI_END="2.8502806984962215" CI_START="-1.8552113499212544" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="MD" EFFECT_SIZE="0.4975346742874836" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.04" MODIFIED="2009-09-20 22:56:02 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.6581877202751667" P_Q="1.0" P_Z="0.678527631988149" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="116" TOTAL_2="116" UNITS="" WEIGHT="100.0" Z="0.4144731444148509">
<NAME>Mental state: 2a. PANSS total score - short term (high = poor)</NAME>
<GROUP_LABEL_1>clozapine</GROUP_LABEL_1>
<GROUP_LABEL_2>quetiapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours clozapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours quetiapine</GRAPH_LABEL_2>
<CONT_DATA CI_END="4.107328570728953" CI_START="-4.467328570728938" EFFECT_SIZE="-0.1799999999999926" ESTIMABLE="YES" MEAN_1="77.06" MEAN_2="77.24" MODIFIED="2009-01-18 15:02:05 +0000" MODIFIED_BY="[Empty name]" ORDER="335" SD_1="5.28" SD_2="6.08" SE="2.1874527310434506" STUDY_ID="STD-Atmaca-2003" TOTAL_1="13" TOTAL_2="14" WEIGHT="30.11456264084489"/>
<CONT_DATA CI_END="6.592334547774861" CI_START="-7.992334547774867" EFFECT_SIZE="-0.7000000000000028" ESTIMABLE="YES" MEAN_1="48.4" MEAN_2="49.1" ORDER="216" SD_1="15.2" SD_2="14.3" SE="3.720647218671296" STUDY_ID="STD-Li--2002" TOTAL_1="31" TOTAL_2="32" WEIGHT="10.409189802137051"/>
<CONT_DATA CI_END="3.6522946091451027" CI_START="-5.4522946091451" EFFECT_SIZE="-0.8999999999999986" ESTIMABLE="YES" MEAN_1="43.7" MEAN_2="44.6" ORDER="215" SD_1="9.8" SD_2="10.3" SE="2.3226419694713885" STUDY_ID="STD-Li--2003" TOTAL_1="38" TOTAL_2="37" WEIGHT="26.710952538116253"/>
<CONT_DATA CI_END="6.750247812209512" CI_START="-1.4702478122095108" EFFECT_SIZE="2.6400000000000006" ESTIMABLE="YES" MEAN_1="46.76" MEAN_2="44.12" ORDER="217" SD_1="8.23" SD_2="8.91" SE="2.0971037450844103" STUDY_ID="STD-Li--2005" TOTAL_1="34" TOTAL_2="33" WEIGHT="32.7652950189018"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="9.582630780541207E-33" CI_END="3.1128796157296126" CI_START="-1.3328796157296114" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.8900000000000005" ESTIMABLE="YES" I2="100.00000000000001" I2_Q="0.0" ID="CMP-003.05" MODIFIED="2009-09-20 22:56:10 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.0" P_Q="1.0" P_Z="0.43260988462733396" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="36" TOTAL_2="36" UNITS="" WEIGHT="99.99999999999999" Z="0.7847334304103095">
<NAME>Mental state: 2b. BPRS-18 (1-7) total score - short term (high = poor)</NAME>
<GROUP_LABEL_1>clozapine</GROUP_LABEL_1>
<GROUP_LABEL_2>quetiapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours clozapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours quetiapine</GRAPH_LABEL_2>
<CONT_DATA CI_END="3.1128796157296126" CI_START="-1.3328796157296114" EFFECT_SIZE="0.8900000000000006" ESTIMABLE="YES" MEAN_1="31.42" MEAN_2="30.53" ORDER="218" SD_1="5.06" SD_2="4.55" SE="1.1341430930687517" STUDY_ID="STD-Liu--2004" TOTAL_1="36" TOTAL_2="36" WEIGHT="99.99999999999999"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.01640593408646232" CI_END="2.0700845440147653" CI_START="-0.6771378459997974" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="0.6964733490074839" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.06" MODIFIED="2009-09-20 22:56:19 +0100" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.8980811953327662" P_Q="1.0" P_Z="0.3203316478061565" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="72" TOTAL_2="70" UNITS="" WEIGHT="100.0" Z="0.9937766124856227">
<NAME>Mental state: 3. Positive symptoms: PANSS positive subscore - short term (high = poor)</NAME>
<GROUP_LABEL_1>clozapine</GROUP_LABEL_1>
<GROUP_LABEL_2>quetiapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours clozapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours quetiapine</GRAPH_LABEL_2>
<CONT_DATA CI_END="2.616450381716357" CI_START="-1.4164503817163578" EFFECT_SIZE="0.5999999999999996" ESTIMABLE="YES" MEAN_1="14.1" MEAN_2="13.5" ORDER="219" SD_1="4.3" SD_2="4.6" SE="1.0288201199725406" STUDY_ID="STD-Li--2003" TOTAL_1="38" TOTAL_2="37" WEIGHT="46.40369499584197"/>
<CONT_DATA CI_END="2.656274588628899" CI_START="-1.0962745886289003" EFFECT_SIZE="0.7799999999999994" ESTIMABLE="YES" MEAN_1="15.33" MEAN_2="14.55" ORDER="220" SD_1="3.53" SD_2="4.26" SE="0.9573005440042338" STUDY_ID="STD-Li--2005" TOTAL_1="34" TOTAL_2="33" WEIGHT="53.596305004158026"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.2850064681426578" CI_START="0.8854257204030391" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0666666666666667" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="30" I2="0.0" I2_Q="0.0" ID="CMP-003.07" LOG_CI_END="0.10890531371524691" LOG_CI_START="-0.05284786651475983" LOG_EFFECT_SIZE="0.028028723600243534" METHOD="MH" MODIFIED="2009-09-21 00:10:03 +0100" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="1.0" P_Q="0.0" P_Z="0.49698053368977635" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="36" TOTAL_2="36" WEIGHT="100.0" Z="0.6792483302150762">
<NAME>Mental state: 4 No clinically important change - less than 50% reduction SANS - short term</NAME>
<GROUP_LABEL_1>clozapine</GROUP_LABEL_1>
<GROUP_LABEL_2>quetiapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours clozapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours quetiapine</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.2850064681426578" CI_START="0.8854257204030391" EFFECT_SIZE="1.0666666666666667" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="30" LOG_CI_END="0.10890531371524691" LOG_CI_START="-0.05284786651475983" LOG_EFFECT_SIZE="0.028028723600243534" ORDER="221" O_E="0.0" SE="0.09501461875826148" STUDY_ID="STD-Liu--2004" TOTAL_1="36" TOTAL_2="36" VAR="0.009027777777777773" WEIGHT="100.0"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.11360539867081106" CI_END="3.4781486645428306" CI_START="0.9852662054396053" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="2.231707434991218" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.08" MODIFIED="2009-09-20 22:56:35 +0100" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="0.7360762386686961" P_Q="1.0" P_Z="4.493827188292388E-4" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="72" TOTAL_2="70" UNITS="" WEIGHT="100.0" Z="3.5092438318865247">
<NAME>Mental state: 5a. Negative symptoms: PANSS negative subscore - short term (high = poor)</NAME>
<GROUP_LABEL_1>clozapine</GROUP_LABEL_1>
<GROUP_LABEL_2>quetiapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours clozapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours quetiapine</GRAPH_LABEL_2>
<CONT_DATA CI_END="3.83549336339372" CI_START="0.16450663660628018" EFFECT_SIZE="2.0" ESTIMABLE="YES" MEAN_1="14.9" MEAN_2="12.9" ORDER="222" SD_1="3.9" SD_2="4.2" SE="0.9364934140993698" STUDY_ID="STD-Li--2003" TOTAL_1="38" TOTAL_2="37" WEIGHT="46.114550002042314"/>
<CONT_DATA CI_END="4.1279936003410995" CI_START="0.7320063996589001" EFFECT_SIZE="2.4299999999999997" ESTIMABLE="YES" MEAN_1="12.29" MEAN_2="9.86" ORDER="223" SD_1="3.25" SD_2="3.81" SE="0.8663391846659716" STUDY_ID="STD-Li--2005" TOTAL_1="34" TOTAL_2="33" WEIGHT="53.88544999795768"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="4.7669254328314416E-33" CI_END="7.943316832836454" CI_START="-4.663316832836453" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="1.6400000000000003" ESTIMABLE="YES" I2="100.0" I2_Q="0.0" ID="CMP-003.09" MODIFIED="2009-09-20 22:56:41 +0100" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="0.0" P_Q="1.0" P_Z="0.6100904374174008" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="36" TOTAL_2="36" UNITS="" WEIGHT="100.00000000000001" Z="0.5099443705417004">
<NAME>Mental state: 5b. Negative symptoms: SANS - short term (high = poor)</NAME>
<GROUP_LABEL_1>clozapine</GROUP_LABEL_1>
<GROUP_LABEL_2>quetiapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours clozapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours quetiapine</GRAPH_LABEL_2>
<CONT_DATA CI_END="7.943316832836454" CI_START="-4.663316832836453" EFFECT_SIZE="1.6400000000000006" ESTIMABLE="YES" MEAN_1="48.64" MEAN_2="47.0" ORDER="224" SD_1="13.29" SD_2="13.99" SE="3.2160370713728477" STUDY_ID="STD-Liu--2004" TOTAL_1="36" TOTAL_2="36" WEIGHT="100.00000000000001"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="3.822665551848552" CI_START="1.517622779416084" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="2.4086021505376345" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="12" I2="0.0" I2_Q="0.0" ID="CMP-003.10" LOG_CI_END="0.5823663028998944" LOG_CI_START="0.18116383666056093" LOG_EFFECT_SIZE="0.38176506978022773" METHOD="MH" MODIFIED="2009-09-20 23:53:14 +0100" MODIFIED_BY="[Empty name]" NO="10" P_CHI2="1.0" P_Q="0.0" P_Z="1.9146769420719709E-4" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="31" TOTAL_2="32" WEIGHT="100.0" Z="3.730015891170061">
<NAME>Adverse effects: 1. At least one adverse effect - short term</NAME>
<GROUP_LABEL_1>clozapine</GROUP_LABEL_1>
<GROUP_LABEL_2>quetiapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours clozapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours quetiapine</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.822665551848552" CI_START="1.517622779416084" EFFECT_SIZE="2.4086021505376345" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="12" LOG_CI_END="0.5823663028998944" LOG_CI_START="0.18116383666056093" LOG_EFFECT_SIZE="0.38176506978022773" ORDER="225" O_E="0.0" SE="0.2356683146532219" STUDY_ID="STD-Li--2002" TOTAL_1="31" TOTAL_2="32" VAR="0.05553955453149001" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.6446857236108774" CI_END="2.4672137123475673" CI_START="0.7917172322784645" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.3976178346670063" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="13" I2="72.5627920804849" I2_Q="0.0" ID="CMP-003.11" LOG_CI_END="0.3922067701112705" LOG_CI_START="-0.10142990223472115" LOG_EFFECT_SIZE="0.14538843393827464" METHOD="MH" MODIFIED="2009-01-18 15:13:39 +0000" MODIFIED_BY="[Empty name]" NO="11" P_CHI2="0.05624861626068278" P_Q="0.0" P_Z="0.2482880781404072" Q="0.0" RANDOM="YES" SCALE="24.269953307837905" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="1.5348410914699298" TOTALS="SUB" TOTAL_1="67" TOTAL_2="68" WEIGHT="200.0" Z="1.1545175237222753">
<NAME>Adverse effects: 2. Cardiac problems - short term</NAME>
<GROUP_LABEL_1>clozapine</GROUP_LABEL_1>
<GROUP_LABEL_2>quetiapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours clozapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours quetiapine</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="60.72270366447716" CI_START="1.0539715153928504" DF="0" EFFECT_SIZE="7.999999999999998" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="1" I2="0.0" ID="CMP-003.11.01" LOG_CI_END="1.783351100180289" LOG_CI_START="0.022828873803598042" LOG_EFFECT_SIZE="0.9030899869919435" NO="1" P_CHI2="1.0" P_Z="0.04434721001788308" STUDIES="1" TAU2="0.0" TOTAL_1="36" TOTAL_2="36" WEIGHT="100.0" Z="2.0107940959607418">
<NAME>ECG abnormalities</NAME>
<DICH_DATA CI_END="60.72270366447716" CI_START="1.0539715153928504" EFFECT_SIZE="8.0" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="1" LOG_CI_END="1.783351100180289" LOG_CI_START="0.022828873803598042" LOG_EFFECT_SIZE="0.9030899869919435" ORDER="226" O_E="0.0" SE="1.0341394704992382" STUDY_ID="STD-Liu--2004" TOTAL_1="36" TOTAL_2="36" VAR="1.0694444444444446" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.1770488250133533" CI_START="0.6661959360901029" DF="0" EFFECT_SIZE="1.2043010752688172" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="12" I2="0.0" ID="CMP-003.11.02" LOG_CI_END="0.33786816914035883" LOG_CI_START="-0.17639802090786583" LOG_EFFECT_SIZE="0.0807350741162465" NO="2" P_CHI2="1.0" P_Z="0.5382953941736359" STUDIES="1" TAU2="0.0" TOTAL_1="31" TOTAL_2="32" WEIGHT="100.00000000000001" Z="0.6153927309208352">
<NAME>palpitation</NAME>
<DICH_DATA CI_END="2.1770488250133533" CI_START="0.6661959360901029" EFFECT_SIZE="1.2043010752688172" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="12" LOG_CI_END="0.33786816914035883" LOG_CI_START="-0.17639802090786583" LOG_EFFECT_SIZE="0.0807350741162465" ORDER="227" O_E="0.0" SE="0.30208250569302375" STUDY_ID="STD-Li--2002" TOTAL_1="31" TOTAL_2="32" VAR="0.09125384024577574" WEIGHT="100.00000000000001"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-003.12" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2009-09-20 22:56:54 +0100" MODIFIED_BY="[Empty name]" NO="12" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="YES" TOTAL_1="13" TOTAL_2="14" WEIGHT="0.0" Z="0.0">
<NAME>Adverse effects: 3a. Extrapyramidal: antiparkinson medication use - short term</NAME>
<GROUP_LABEL_1>clozapine</GROUP_LABEL_1>
<GROUP_LABEL_2>quetiapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours clozapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours quetiapine</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-01-18 15:17:55 +0000" MODIFIED_BY="[Empty name]" ORDER="336" O_E="0.0" SE="0.0" STUDY_ID="STD-Atmaca-2003" TOTAL_1="13" TOTAL_2="14" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.8242168243150234" CI_END="2.991719641871149" CI_START="0.4961270537990004" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RR" EFFECT_SIZE="1.218307453688983" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="9" I2="0.0" I2_Q="0.0" ID="CMP-003.13" LOG_CI_END="0.4759208927709023" LOG_CI_START="-0.3044070902480926" LOG_EFFECT_SIZE="0.08575690126140484" METHOD="MH" MODIFIED="2009-09-20 22:57:01 +0100" MODIFIED_BY="[Empty name]" NO="13" P_CHI2="0.7680489309971363" P_Q="0.0" P_Z="0.6666179190603485" Q="0.0" RANDOM="YES" SCALE="34.08534206274342" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="165" TOTAL_2="168" WEIGHT="300.0" Z="0.4307943366270888">
<NAME>Adverse effects: 3b. Extrapyramidal: various symptoms - short term</NAME>
<GROUP_LABEL_1>clozapine</GROUP_LABEL_1>
<GROUP_LABEL_2>quetiapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours clozapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours quetiapine</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.05154791123739284" CI_END="12.609395414723236" CI_START="0.5020370537075268" DF="1" EFFECT_SIZE="2.5160253820343015" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="2" I2="0.0" ID="CMP-003.13.01" LOG_CI_END="1.1006942638653783" LOG_CI_START="-0.29926422782143214" LOG_EFFECT_SIZE="0.40071501802197307" MODIFIED="2009-09-20 22:54:01 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.8203913563327558" P_Z="0.26185620811248445" STUDIES="2" TAU2="0.0" TOTAL_1="67" TOTAL_2="68" WEIGHT="100.0" Z="1.1220146997945244">
<NAME>akathisia</NAME>
<DICH_DATA CI_END="21.627941066970436" CI_START="0.19707039305481966" EFFECT_SIZE="2.064516129032258" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.3350151775151826" LOG_CI_START="-0.7053786172159535" LOG_EFFECT_SIZE="0.3148182801496145" ORDER="229" O_E="0.0" SE="1.1985374151372459" STUDY_ID="STD-Li--2002" TOTAL_1="31" TOTAL_2="32" VAR="1.436491935483871" WEIGHT="47.07630091197954"/>
<DICH_DATA CI_END="27.49853429898478" CI_START="0.3272901712558647" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.4393095460910985" LOG_CI_START="-0.48506703665177375" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="230" O_E="0.0" SE="1.1303883305208782" STUDY_ID="STD-Liu--2004" TOTAL_1="36" TOTAL_2="36" VAR="1.277777777777778" WEIGHT="52.92369908802047"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.39231007030102066" CI_END="3.431441070245275" CI_START="0.2996214268113046" DF="1" EFFECT_SIZE="1.0139690673219768" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="5" I2="0.0" ID="CMP-003.13.02" LOG_CI_END="0.5354765449469131" LOG_CI_START="-0.5234271321836094" LOG_EFFECT_SIZE="0.0060247063816518875" NO="2" P_CHI2="0.5310880019720656" P_Z="0.9822064921072426" STUDIES="2" TAU2="0.0" TOTAL_1="67" TOTAL_2="68" WEIGHT="100.0" Z="0.022302703787874096">
<NAME>tremor</NAME>
<DICH_DATA CI_END="3.841834001121545" CI_START="0.12326944908169932" EFFECT_SIZE="0.6881720430107527" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.5845385958316651" LOG_CI_START="-0.9091445449717608" LOG_EFFECT_SIZE="-0.16230297457004791" ORDER="231" O_E="0.0" SE="0.8773968707587259" STUDY_ID="STD-Li--2002" TOTAL_1="31" TOTAL_2="32" VAR="0.7698252688172043" WEIGHT="50.25692986900196"/>
<DICH_DATA CI_END="8.448516541066857" CI_START="0.2663189435758477" EFFECT_SIZE="1.5" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.9267804587026505" LOG_CI_START="-0.574597940591288" LOG_EFFECT_SIZE="0.17609125905568124" ORDER="232" O_E="0.0" SE="0.8819171036881968" STUDY_ID="STD-Liu--2004" TOTAL_1="36" TOTAL_2="36" VAR="0.7777777777777777" WEIGHT="49.74307013099805"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="5.406985266742608" CI_START="0.04926759826370491" DF="0" EFFECT_SIZE="0.5161290322580645" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" I2="0.0" ID="CMP-003.13.03" LOG_CI_END="0.7329551861872201" LOG_CI_START="-1.307438608543916" LOG_EFFECT_SIZE="-0.2872417111783479" NO="3" P_CHI2="1.0" P_Z="0.5810593566322131" STUDIES="1" TAU2="0.0" TOTAL_1="31" TOTAL_2="32" WEIGHT="100.0" Z="0.551837993451066">
<NAME>rigor</NAME>
<DICH_DATA CI_END="5.406985266742608" CI_START="0.04926759826370491" EFFECT_SIZE="0.5161290322580645" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7329551861872201" LOG_CI_START="-1.307438608543916" LOG_EFFECT_SIZE="-0.2872417111783479" ORDER="233" O_E="0.0" SE="1.1985374151372459" STUDY_ID="STD-Li--2002" TOTAL_1="31" TOTAL_2="32" VAR="1.436491935483871" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0813839435278021" CI_END="165.23617327722542" CI_START="6.957593985804186" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="33.90643309802613" ESTIMABLE="YES" EVENTS_1="51" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-003.14" LOG_CI_END="2.2181051285471716" LOG_CI_START="0.8424590816593964" LOG_EFFECT_SIZE="1.530282105103284" METHOD="MH" MODIFIED="2009-09-20 22:57:21 +0100" MODIFIED_BY="[Empty name]" NO="14" P_CHI2="0.7754306310887129" P_Q="0.0" P_Z="1.2972633931634615E-5" Q="0.0" RANDOM="YES" SCALE="266.42139489720637" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="67" TOTAL_2="68" WEIGHT="100.0" Z="4.360566177577591">
<NAME>Adverse effects: 4. Hypersalivation - short term</NAME>
<GROUP_LABEL_1>clozapine</GROUP_LABEL_1>
<GROUP_LABEL_2>quetiapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours clozapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours quetiapine</GRAPH_LABEL_2>
<DICH_DATA CI_END="199.63443240385928" CI_START="4.1846311378226" EFFECT_SIZE="28.903225806451612" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="1" LOG_CI_END="2.30023544934276" LOG_CI_START="0.6216571823129451" LOG_EFFECT_SIZE="1.4609463158278526" ORDER="234" O_E="0.0" SE="0.9860051831497423" STUDY_ID="STD-Li--2002" TOTAL_1="31" TOTAL_2="32" VAR="0.9722062211981568" WEIGHT="67.16302017817517"/>
<DICH_DATA CI_END="745.4396775934097" CI_START="2.9633517860647993" EFFECT_SIZE="47.0" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="0" LOG_CI_END="2.8724125052695335" LOG_CI_START="0.4717832106019012" LOG_EFFECT_SIZE="1.6720978579357175" ORDER="235" O_E="0.0" SE="1.4101415309944274" STUDY_ID="STD-Liu--2004" TOTAL_1="36" TOTAL_2="36" VAR="1.9884991374353074" WEIGHT="32.83697982182482"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="28.520157018315178" CI_START="20.759842981684823" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="24.64" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.15" MODIFIED="2009-09-20 23:32:22 +0100" MODIFIED_BY="[Empty name]" NO="15" P_CHI2="1.0" P_Q="1.0" P_Z="1.465203346561565E-35" Q="0.0" RANDOM="YES" SCALE="32.718769911722994" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="13" TOTAL_2="14" UNITS="" WEIGHT="100.0" Z="12.446277908628739">
<NAME>Adverse effects: 5. Lipids: average triglyceride change - short term (high = poor)</NAME>
<GROUP_LABEL_1>clozapine</GROUP_LABEL_1>
<GROUP_LABEL_2>quetiapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours clozapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours quetiapine</GRAPH_LABEL_2>
<CONT_DATA CI_END="28.520157018315178" CI_START="20.759842981684823" EFFECT_SIZE="24.64" ESTIMABLE="YES" MEAN_1="36.28" MEAN_2="11.64" MODIFIED="2009-01-18 15:34:19 +0000" MODIFIED_BY="[Empty name]" ORDER="337" SD_1="5.61" SD_2="4.58" SE="1.9797083257250436" STUDY_ID="STD-Atmaca-2003" TOTAL_1="13" TOTAL_2="14" WEIGHT="100.0"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.8324068254313612" CI_END="9.491756277299135" CI_START="2.107864865975095" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="4.472956468971883" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="7" I2="0.0" I2_Q="0.0" ID="CMP-003.16" LOG_CI_END="0.9773465781775151" LOG_CI_START="0.3238427650592379" LOG_EFFECT_SIZE="0.6505946716183766" METHOD="MH" MODIFIED="2009-09-20 22:57:33 +0100" MODIFIED_BY="[Empty name]" NO="16" P_CHI2="0.36157756135467944" P_Q="0.0" P_Z="9.521289689914962E-5" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="67" TOTAL_2="68" WEIGHT="100.0" Z="3.902477994186987">
<NAME>Adverse effects: 6. Sedation - short term</NAME>
<GROUP_LABEL_1>clozapine</GROUP_LABEL_1>
<GROUP_LABEL_2>quetiapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours clozapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours quetiapine</GRAPH_LABEL_2>
<DICH_DATA CI_END="19.896553056871593" CI_START="2.148144130210415" EFFECT_SIZE="6.537634408602151" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="3" LOG_CI_END="1.2987778443471858" LOG_CI_START="0.33206341709041404" LOG_EFFECT_SIZE="0.8154206307187999" ORDER="237" O_E="0.0" SE="0.5678528398842192" STUDY_ID="STD-Li--2002" TOTAL_1="31" TOTAL_2="32" VAR="0.32245684776457273" WEIGHT="45.69827973953636"/>
<DICH_DATA CI_END="9.02192758357679" CI_START="1.1707586768073392" EFFECT_SIZE="3.25" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="4" LOG_CI_END="0.9552993368185284" LOG_CI_START="0.0684673851392203" LOG_EFFECT_SIZE="0.5118833609788743" ORDER="238" O_E="0.0" SE="0.5209294783053857" STUDY_ID="STD-Liu--2004" TOTAL_1="36" TOTAL_2="36" VAR="0.27136752136752135" WEIGHT="54.30172026046364"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.5253560101986009" CI_END="3.9634613251368678" CI_START="0.898503502383365" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.8871099284876038" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="9" I2="0.0" I2_Q="0.0" ID="CMP-003.17" LOG_CI_END="0.59807462476946" LOG_CI_START="-0.046480225663739334" LOG_EFFECT_SIZE="0.2757971995528604" METHOD="MH" MODIFIED="2009-09-20 23:32:27 +0100" MODIFIED_BY="[Empty name]" NO="17" P_CHI2="0.4685659315648464" P_Q="0.0" P_Z="0.09348586251182062" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="67" TOTAL_2="68" WEIGHT="100.00000000000001" Z="1.6772896140563127">
<NAME>Adverse effects: 7a. Weight: number of participant with weight gain - short term</NAME>
<GROUP_LABEL_1>clozapine</GROUP_LABEL_1>
<GROUP_LABEL_2>quetiapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours clozapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours quetiapine</GRAPH_LABEL_2>
<DICH_DATA CI_END="4.071983341378988" CI_START="0.5128928534220264" EFFECT_SIZE="1.4451612903225806" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="5" LOG_CI_END="0.6098059926189822" LOG_CI_START="-0.28997335229123944" LOG_EFFECT_SIZE="0.15991632016387128" ORDER="239" O_E="0.0" SE="0.5285348411798544" STUDY_ID="STD-Li--2002" TOTAL_1="31" TOTAL_2="32" VAR="0.27934907834101386" WEIGHT="51.315400532072125"/>
<DICH_DATA CI_END="7.241445210440331" CI_START="0.8630873835776708" EFFECT_SIZE="2.5" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="4" LOG_CI_END="0.8598252491092992" LOG_CI_START="-0.06394523176522404" LOG_EFFECT_SIZE="0.3979400086720376" ORDER="240" O_E="0.0" SE="0.5426273532033234" STUDY_ID="STD-Liu--2004" TOTAL_1="36" TOTAL_2="36" VAR="0.2944444444444444" WEIGHT="48.68459946792789"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="4.295455216644863" CI_START="-0.07545521664486454" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="2.1099999999999994" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.18" MODIFIED="2009-09-20 23:32:34 +0100" MODIFIED_BY="[Empty name]" NO="18" P_CHI2="1.0" P_Q="1.0" P_Z="0.05845180690887502" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="13" TOTAL_2="14" UNITS="" WEIGHT="100.0" Z="1.8922940977616634">
<NAME>Adverse effects: 7b. Weight: average weight change - short term (high = poor)</NAME>
<GROUP_LABEL_1>clozapine</GROUP_LABEL_1>
<GROUP_LABEL_2>quetiapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours clozapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours quetiapine</GRAPH_LABEL_2>
<CONT_DATA CI_END="4.295455216644863" CI_START="-0.07545521664486454" EFFECT_SIZE="2.1099999999999994" ESTIMABLE="YES" MEAN_1="6.52" MEAN_2="4.41" MODIFIED="2009-01-18 15:41:06 +0000" MODIFIED_BY="[Empty name]" ORDER="339" SD_1="3.41" SD_2="2.21" SE="1.1150486610383945" STUDY_ID="STD-Atmaca-2003" TOTAL_1="13" TOTAL_2="14" WEIGHT="100.0"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="103.27371208434164" CI_START="0.2574412551452299" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="5.156250000000001" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-003.19" LOG_CI_END="2.013989787641349" LOG_CI_START="-0.5893218558533484" LOG_EFFECT_SIZE="0.7123339658940004" METHOD="MH" MODIFIED="2009-09-20 22:57:55 +0100" MODIFIED_BY="[Empty name]" NO="19" P_CHI2="1.0" P_Q="0.0" P_Z="0.283453094971722" Q="0.0" RANDOM="YES" SCALE="144.16731028426037" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="31" TOTAL_2="32" WEIGHT="100.0" Z="1.0725945328947457">
<NAME>Adverse effects: 8. White blood cell count: number of participant with a decrease - short term</NAME>
<GROUP_LABEL_1>clozapine</GROUP_LABEL_1>
<GROUP_LABEL_2>quetiapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours clozapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours quetiapine</GRAPH_LABEL_2>
<DICH_DATA CI_END="103.27371208434164" CI_START="0.2574412551452299" EFFECT_SIZE="5.15625" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.013989787641349" LOG_CI_START="-0.5893218558533484" LOG_EFFECT_SIZE="0.7123339658940003" ORDER="242" O_E="0.0" SE="1.5291981459892532" STUDY_ID="STD-Li--2002" TOTAL_1="31" TOTAL_2="32" VAR="2.3384469696969696" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-004" MODIFIED="2009-01-18 15:47:22 +0000" MODIFIED_BY="[Empty name]" NO="4">
<NAME>CLOZAPINE versus QUETIAPINE - Sensitivity Analysis</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="4.107328570728953" CI_START="-4.467328570728938" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.1799999999999926" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-004.01" MODIFIED="2009-01-18 15:47:22 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.9344181003033182" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="13" TOTAL_2="14" UNITS="" WEIGHT="100.0" Z="0.0822874924086381">
<NAME>Mental state: 1. PANSS total score - excluding possibly skewed data - short term (high = poor)</NAME>
<GROUP_LABEL_1>clozapine</GROUP_LABEL_1>
<GROUP_LABEL_2>quetiapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours clozapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours quetiapine</GRAPH_LABEL_2>
<CONT_DATA CI_END="4.107328570728953" CI_START="-4.467328570728938" EFFECT_SIZE="-0.1799999999999926" ESTIMABLE="YES" MEAN_1="77.06" MEAN_2="77.24" MODIFIED="2009-01-18 15:47:22 +0000" MODIFIED_BY="[Empty name]" ORDER="340" SD_1="5.28" SD_2="6.08" SE="2.1874527310434506" STUDY_ID="STD-Atmaca-2003" TOTAL_1="13" TOTAL_2="14" WEIGHT="100.0"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-005" MODIFIED="2010-10-05 14:42:12 +0100" MODIFIED_BY="[Empty name]" NO="5">
<NAME>CLOZAPINE versus RISPERIDONE</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="15.481653934100752" CI_START="0.061814734588180265" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9782608695652174" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-005.01" LOG_CI_END="1.189817355318686" LOG_CI_START="-1.2089079911311469" LOG_EFFECT_SIZE="-0.009545317906230389" METHOD="MH" MODIFIED="2009-01-18 19:05:46 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="0.0" P_Z="0.9875545555862576" Q="0.0" RANDOM="YES" SCALE="51.222073040584554" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="160" TOTAL_2="153" WEIGHT="100.0" Z="0.01559868398012787">
<NAME>Death - short term</NAME>
<GROUP_LABEL_1>clozapine</GROUP_LABEL_1>
<GROUP_LABEL_2>risperidone</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours clozapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours risperidone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="15.481653934100752" CI_START="0.061814734588180265" DF="0" EFFECT_SIZE="0.9782608695652174" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" I2="0.0" ID="CMP-005.01.01" LOG_CI_END="1.189817355318686" LOG_CI_START="-1.2089079911311469" LOG_EFFECT_SIZE="-0.009545317906230389" MODIFIED="2009-01-16 13:56:50 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.9875545555862576" STUDIES="2" TAU2="0.0" TOTAL_1="149" TOTAL_2="144" WEIGHT="100.0" Z="0.01559868398012787">
<NAME>Natural causes</NAME>
<DICH_DATA CI_END="15.481653934100752" CI_START="0.061814734588180265" EFFECT_SIZE="0.9782608695652174" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.189817355318686" LOG_CI_START="-1.2089079911311469" LOG_EFFECT_SIZE="-0.009545317906230389" MODIFIED="2009-01-16 13:56:50 +0000" MODIFIED_BY="[Empty name]" ORDER="328" O_E="0.0" SE="1.4090231423865962" STUDY_ID="STD-Azorin-2001" TOTAL_1="138" TOTAL_2="135" VAR="1.9853462157809985" WEIGHT="100.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="245" O_E="0.0" SE="0.0" STUDY_ID="STD-Wahlbeck-2000" TOTAL_1="11" TOTAL_2="9" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-005.01.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="11" TOTAL_2="9" WEIGHT="0.0" Z="0.0">
<NAME>Suicide</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="246" O_E="0.0" SE="0.0" STUDY_ID="STD-Wahlbeck-2000" TOTAL_1="11" TOTAL_2="9" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="6.546527426139527" CI_END="1.1583725135021485" CI_START="0.7296239551699233" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9193347240595032" ESTIMABLE="YES" EVENTS_1="103" EVENTS_2="118" I2="8.348356167535579" I2_Q="0.0" ID="CMP-005.02" LOG_CI_END="0.06384824379784962" LOG_CI_START="-0.1369009155961393" LOG_EFFECT_SIZE="-0.03652633589914484" METHOD="MH" MODIFIED="2009-09-20 23:17:46 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.36482421507587715" P_Q="0.0" P_Z="0.4757025789931755" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.008602884821639453" TOTALS="YES" TOTAL_1="319" TOTAL_2="336" WEIGHT="100.0" Z="0.7132314084467346">
<NAME>Leaving the study early: 1. Any reason</NAME>
<GROUP_LABEL_1>clozapine</GROUP_LABEL_1>
<GROUP_LABEL_2>risperidone</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours clozapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours risperidone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="5.956229204805375" CI_END="1.5401717449651189" CI_START="0.5989193413846332" DF="4" EFFECT_SIZE="0.9604366960470275" ESTIMABLE="YES" EVENTS_1="60" EVENTS_2="68" I2="32.843417161097925" ID="CMP-005.02.01" LOG_CI_END="0.18756915183116005" LOG_CI_START="-0.22263166166786094" LOG_EFFECT_SIZE="-0.017531254918350437" MODIFIED="2009-01-18 19:12:31 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.2024411489878465" P_Z="0.8669524419164805" STUDIES="5" TAU2="0.09077812844470101" TOTAL_1="226" TOTAL_2="241" WEIGHT="47.38369019432662" Z="0.16753076597123615">
<NAME>short term</NAME>
<DICH_DATA CI_END="14.45413717356195" CI_START="0.06918434410800384" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1599921719703592" LOG_CI_START="-1.1599921719703592" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-01-18 19:10:42 +0000" MODIFIED_BY="[Empty name]" ORDER="674" O_E="0.0" SE="1.3627702877384937" STUDY_ID="STD-Atmaca-2003" TOTAL_1="14" TOTAL_2="14" VAR="1.8571428571428572" WEIGHT="0.7452984460376574"/>
<DICH_DATA CI_END="1.6265578901072004" CI_START="0.7349354539781119" EFFECT_SIZE="1.0933503836317136" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="34" LOG_CI_END="0.21126952467702467" LOG_CI_START="-0.1337508013403754" LOG_EFFECT_SIZE="0.03875936166832464" MODIFIED="2009-01-18 19:12:31 +0000" MODIFIED_BY="[Empty name]" ORDER="675" O_E="0.0" SE="0.20266664738077886" STUDY_ID="STD-Azorin-2001" TOTAL_1="138" TOTAL_2="135" VAR="0.04107376996056496" WEIGHT="27.991768131006392"/>
<DICH_DATA CI_END="2.274078044403178" CI_START="0.4397386459365979" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="9" LOG_CI_END="0.35680536522068085" LOG_CI_START="-0.35680536522068085" LOG_EFFECT_SIZE="0.0" ORDER="249" O_E="0.0" SE="0.41917847549134185" STUDY_ID="STD-Bondolfi-1998" TOTAL_1="43" TOTAL_2="43" VAR="0.1757105943152455" WEIGHT="7.54441513826994"/>
<DICH_DATA CI_END="1.072439144471375" CI_START="0.2538248642173736" EFFECT_SIZE="0.5217391304347826" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="23" LOG_CI_END="0.03037265752797525" LOG_CI_START="-0.5954658374679114" LOG_EFFECT_SIZE="-0.28254658996996806" ORDER="250" O_E="0.0" SE="0.3676206299110972" STUDY_ID="STD-Heinrich-1994" TOTAL_1="20" TOTAL_2="40" VAR="0.1351449275362319" WEIGHT="9.673450881643088"/>
<DICH_DATA CI_END="33.65276363918611" CI_START="0.7161127630438451" EFFECT_SIZE="4.909090909090909" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="1" LOG_CI_END="1.5270207352454117" LOG_CI_START="-0.14501858591592473" LOG_EFFECT_SIZE="0.6910010746647435" ORDER="251" O_E="0.0" SE="0.9821641739782941" STUDY_ID="STD-Wahlbeck-2000" TOTAL_1="11" TOTAL_2="9" VAR="0.9646464646464648" WEIGHT="1.4287575973695394"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.561862209235214" CI_START="0.6037300907345234" DF="0" EFFECT_SIZE="0.9710526315789474" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="19" I2="0.0" ID="CMP-005.02.02" LOG_CI_END="0.19364271685984139" LOG_CI_START="-0.21915717777534097" LOG_EFFECT_SIZE="-0.012757230457749777" NO="2" P_CHI2="1.0" P_Z="0.9035785252646902" STUDIES="1" TAU2="0.0" TOTAL_1="40" TOTAL_2="41" WEIGHT="20.631187470263633" Z="0.12114204758586178">
<NAME>medium term</NAME>
<DICH_DATA CI_END="1.561862209235214" CI_START="0.6037300907345234" EFFECT_SIZE="0.9710526315789474" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="19" LOG_CI_END="0.19364271685984139" LOG_CI_START="-0.21915717777534097" LOG_EFFECT_SIZE="-0.012757230457749777" ORDER="252" O_E="0.0" SE="0.24248070150113998" STUDY_ID="STD-Volavka-2002" TOTAL_1="40" TOTAL_2="41" VAR="0.05879689060048495" WEIGHT="20.631187470263633"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.184811092331855" CI_START="0.5698273610759221" DF="0" EFFECT_SIZE="0.8216676810712112" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="31" I2="0.0" ID="CMP-005.02.03" LOG_CI_END="0.07364911144492604" LOG_CI_START="-0.24425670132503718" LOG_EFFECT_SIZE="-0.08530379494005559" NO="3" P_CHI2="1.0" P_Z="0.2928748820939784" STUDIES="1" TAU2="0.0" TOTAL_1="53" TOTAL_2="54" WEIGHT="31.985122335409752" Z="1.0518358527032001">
<NAME>long term</NAME>
<DICH_DATA CI_END="1.184811092331855" CI_START="0.5698273610759221" EFFECT_SIZE="0.8216676810712112" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="31" LOG_CI_END="0.07364911144492604" LOG_CI_START="-0.24425670132503718" LOG_EFFECT_SIZE="-0.08530379494005559" ORDER="253" O_E="0.0" SE="0.18673944808022927" STUDY_ID="STD-McGurk-2005" TOTAL_1="53" TOTAL_2="54" VAR="0.03487162146930864" WEIGHT="31.985122335409752"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="4.225057712181095" CI_END="3.2115373665421476" CI_START="1.1056745096524332" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="RR" EFFECT_SIZE="1.8843871690769802" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="20" I2="0.0" I2_Q="0.0" ID="CMP-005.03" LOG_CI_END="0.506712979437043" LOG_CI_START="0.04362729743294564" LOG_EFFECT_SIZE="0.27517013843499427" METHOD="MH" MODIFIED="2009-09-20 22:58:38 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.5174891591311805" P_Q="0.0" P_Z="0.01984527704378841" Q="0.0" RANDOM="YES" SCALE="46.82519946560008" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="305" TOTAL_2="322" WEIGHT="100.0" Z="2.329260358987812">
<NAME>Leaving the study early: 2. Adverse effects</NAME>
<GROUP_LABEL_1>clozapine</GROUP_LABEL_1>
<GROUP_LABEL_2>risperidone</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours clozapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours risperidone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.8905756755723518" CI_END="2.6994620241035006" CI_START="0.8222178411080197" DF="3" EFFECT_SIZE="1.4898140278610164" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="17" I2="0.0" ID="CMP-005.03.01" LOG_CI_END="0.43127722221722464" LOG_CI_START="-0.08501310380147399" LOG_EFFECT_SIZE="0.17313205920787533" MODIFIED="2009-01-18 19:14:33 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.8277016111314198" P_Z="0.18867697694226745" STUDIES="4" TAU2="0.0" TOTAL_1="212" TOTAL_2="227" WEIGHT="80.45160853114768" Z="1.3145030364345902">
<NAME>short term</NAME>
<DICH_DATA CI_END="2.652697330027832" CI_START="0.6413559632903612" EFFECT_SIZE="1.3043478260869565" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="12" LOG_CI_END="0.42368770026597086" LOG_CI_START="-0.19290086286183178" LOG_EFFECT_SIZE="0.11539341870206955" MODIFIED="2009-01-18 19:14:33 +0000" MODIFIED_BY="[Empty name]" ORDER="676" O_E="0.0" SE="0.36218717414388335" STUDY_ID="STD-Azorin-2001" TOTAL_1="138" TOTAL_2="135" VAR="0.1311795491143317" WEIGHT="56.40684083646177"/>
<DICH_DATA CI_END="15.477505790203258" CI_START="0.06460989345149956" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1897009751564562" LOG_CI_START="-1.1897009751564562" LOG_EFFECT_SIZE="0.0" ORDER="255" O_E="0.0" SE="1.3976724838434158" STUDY_ID="STD-Bondolfi-1998" TOTAL_1="43" TOTAL_2="43" VAR="1.9534883720930232" WEIGHT="3.7878003542774987"/>
<DICH_DATA CI_END="10.785844188799869" CI_START="0.6593003743272465" EFFECT_SIZE="2.6666666666666665" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="1.0328541422238666" LOG_CI_START="-0.1809166776793044" LOG_EFFECT_SIZE="0.4259687322722811" ORDER="256" O_E="0.0" SE="0.7129749878735812" STUDY_ID="STD-Heinrich-1994" TOTAL_1="20" TOTAL_2="40" VAR="0.5083333333333332" WEIGHT="14.556243831916582"/>
<DICH_DATA CI_END="15.263162010358725" CI_START="0.17543454944630382" EFFECT_SIZE="1.6363636363636365" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.183644514051096" LOG_CI_START="-0.755884874160934" LOG_EFFECT_SIZE="0.21387981994508104" ORDER="257" O_E="0.0" SE="1.1392891634610582" STUDY_ID="STD-Wahlbeck-2000" TOTAL_1="11" TOTAL_2="9" VAR="1.297979797979798" WEIGHT="5.700723508491842"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="18.137671386637596" CI_START="0.9268003395620167" DF="0" EFFECT_SIZE="4.1" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="2" I2="0.0" ID="CMP-005.03.02" LOG_CI_END="1.258581529204266" LOG_CI_START="-0.033013815764795" LOG_EFFECT_SIZE="0.6127838567197355" NO="2" P_CHI2="1.0" P_Z="0.06291825933761101" STUDIES="1" TAU2="0.0" TOTAL_1="40" TOTAL_2="41" WEIGHT="12.854931434895255" Z="1.8597686870836534">
<NAME>medium term</NAME>
<DICH_DATA CI_END="18.137671386637596" CI_START="0.9268003395620167" EFFECT_SIZE="4.1" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="2" LOG_CI_END="1.258581529204266" LOG_CI_START="-0.033013815764795" LOG_EFFECT_SIZE="0.6127838567197355" ORDER="258" O_E="0.0" SE="0.758689499134897" STUDY_ID="STD-Volavka-2002" TOTAL_1="40" TOTAL_2="41" VAR="0.5756097560975609" WEIGHT="12.854931434895255"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="55.99907668615696" CI_START="0.9083453432469201" DF="0" EFFECT_SIZE="7.132075471698113" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="1" I2="0.0" ID="CMP-005.03.03" LOG_CI_END="1.7481808664095424" LOG_CI_START="-0.04174900593667006" LOG_EFFECT_SIZE="0.8532159302364363" NO="3" P_CHI2="1.0" P_Z="0.06168766276182143" STUDIES="1" TAU2="0.0" TOTAL_1="53" TOTAL_2="54" WEIGHT="6.693460033957053" Z="1.8685340919052496">
<NAME>long term</NAME>
<DICH_DATA CI_END="55.99907668615696" CI_START="0.9083453432469201" EFFECT_SIZE="7.132075471698113" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="1" LOG_CI_END="1.7481808664095424" LOG_CI_START="-0.04174900593667006" LOG_EFFECT_SIZE="0.8532159302364363" ORDER="259" O_E="0.0" SE="1.0514136673119303" STUDY_ID="STD-McGurk-2005" TOTAL_1="53" TOTAL_2="54" VAR="1.1054706998103223" WEIGHT="6.693460033957053"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="4.464840377113116" CI_END="0.699312844105439" CI_START="0.22721786654736442" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="RR" EFFECT_SIZE="0.39861807847463154" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="46" I2="0.0" I2_Q="0.0" ID="CMP-005.04" LOG_CI_END="-0.1553284951075503" LOG_CI_START="-0.6435575222662233" LOG_EFFECT_SIZE="-0.3994430086868868" METHOD="MH" MODIFIED="2009-09-20 23:18:03 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.48460169311270596" P_Q="0.0" P_Z="0.0013409134954203159" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="305" TOTAL_2="322" WEIGHT="100.0" Z="3.2070764635146527">
<NAME>Leaving the study early: 3. Inefficacy</NAME>
<GROUP_LABEL_1>clozapine</GROUP_LABEL_1>
<GROUP_LABEL_2>risperidone</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours clozapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours risperidone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="3.3351448250707114" CI_END="0.955408631051019" CI_START="0.10945200227080339" DF="3" EFFECT_SIZE="0.3233749954083359" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="23" I2="10.048883711177542" ID="CMP-005.04.01" LOG_CI_END="-0.01981083966884757" LOG_CI_START="-0.9607762892152153" LOG_EFFECT_SIZE="-0.4902935644420314" MODIFIED="2009-01-18 19:16:24 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.3427810923707565" P_Z="0.041102641249159105" STUDIES="4" TAU2="0.12679399272717162" TOTAL_1="212" TOTAL_2="227" WEIGHT="30.528688559853297" Z="2.042493119426266">
<NAME>short term</NAME>
<DICH_DATA CI_END="0.8462937361337923" CI_START="0.013960572195047502" EFFECT_SIZE="0.10869565217391304" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="9" LOG_CI_END="-0.07247887355554763" LOG_CI_START="-1.855096781135563" LOG_EFFECT_SIZE="-0.9637878273455552" MODIFIED="2009-01-18 19:16:24 +0000" MODIFIED_BY="[Empty name]" ORDER="677" O_E="0.0" SE="1.0471185830134568" STUDY_ID="STD-Azorin-2001" TOTAL_1="138" TOTAL_2="135" VAR="1.0964573268921096" WEIGHT="7.501198581035255"/>
<DICH_DATA CI_END="2.587668299966842" CI_START="0.09661207350385806" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" LOG_CI_END="0.4129086055644666" LOG_CI_START="-1.0149685968924291" LOG_EFFECT_SIZE="-0.3010299956639812" ORDER="261" O_E="0.0" SE="0.8387421368293256" STUDY_ID="STD-Bondolfi-1998" TOTAL_1="43" TOTAL_2="43" VAR="0.7034883720930232" WEIGHT="11.691371841980114"/>
<DICH_DATA CI_END="1.4548086564205178" CI_START="0.027495024739829333" EFFECT_SIZE="0.2" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="10" LOG_CI_END="0.1628058765347771" LOG_CI_START="-1.5607458852068146" LOG_EFFECT_SIZE="-0.6989700043360187" ORDER="262" O_E="0.0" SE="1.0124228365658294" STUDY_ID="STD-Heinrich-1994" TOTAL_1="20" TOTAL_2="40" VAR="1.0250000000000001" WEIGHT="8.024140628925657"/>
<DICH_DATA CI_END="54.867363612714385" CI_START="0.11391106822839378" EFFECT_SIZE="2.5" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.7393140927647355" LOG_CI_START="-0.9434340754206603" LOG_EFFECT_SIZE="0.3979400086720376" ORDER="263" O_E="0.0" SE="1.5758595538097082" STUDY_ID="STD-Wahlbeck-2000" TOTAL_1="11" TOTAL_2="9" VAR="2.483333333333333" WEIGHT="3.3119775079122693"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="6.928491935952064" CI_START="0.15163833770929122" DF="0" EFFECT_SIZE="1.025" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" I2="0.0" ID="CMP-005.04.02" LOG_CI_END="0.8406387158286682" LOG_CI_START="-0.819190985045122" LOG_EFFECT_SIZE="0.010723865391773066" NO="2" P_CHI2="1.0" P_Z="0.9797949678305171" STUDIES="1" TAU2="0.0" TOTAL_1="40" TOTAL_2="41" WEIGHT="8.65207209571779" Z="0.02532595956303944">
<NAME>medium term</NAME>
<DICH_DATA CI_END="6.928491935952064" CI_START="0.15163833770929122" EFFECT_SIZE="1.025" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8406387158286682" LOG_CI_START="-0.819190985045122" LOG_EFFECT_SIZE="0.010723865391773066" ORDER="264" O_E="0.0" SE="0.9749921825827943" STUDY_ID="STD-Volavka-2002" TOTAL_1="40" TOTAL_2="41" VAR="0.9506097560975609" WEIGHT="8.65207209571779"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="3.6458520289742894E-31" CI_END="0.7980118101835338" CI_START="0.18878515733910384" DF="0" EFFECT_SIZE="0.3881401617250674" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="21" I2="100.0" ID="CMP-005.04.03" LOG_CI_END="-0.09799068125630722" LOG_CI_START="-0.7240321537832851" LOG_EFFECT_SIZE="-0.4110114175197962" NO="3" P_CHI2="0.0" P_Z="0.010066755098934165" STUDIES="1" TAU2="0.0" TOTAL_1="53" TOTAL_2="54" WEIGHT="60.81923934442892" Z="2.5735278281866267">
<NAME>long term</NAME>
<DICH_DATA CI_END="0.7980118101835338" CI_START="0.18878515733910384" EFFECT_SIZE="0.3881401617250674" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="21" LOG_CI_END="-0.09799068125630722" LOG_CI_START="-0.7240321537832851" LOG_EFFECT_SIZE="-0.4110114175197962" ORDER="265" O_E="0.0" SE="0.36773985991761515" STUDY_ID="STD-McGurk-2005" TOTAL_1="53" TOTAL_2="54" VAR="0.13523260457222722" WEIGHT="60.81923934442892"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.4868376485562935" CI_START="0.4304437681016717" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="20" I2="0.0" I2_Q="0.0" ID="CMP-005.05" LOG_CI_END="0.17226354943286235" LOG_CI_START="-0.3660835754489752" LOG_EFFECT_SIZE="-0.09691001300805639" METHOD="MH" MODIFIED="2009-09-21 00:10:17 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="1.0" P_Q="0.0" P_Z="0.4804108859241235" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="20" TOTAL_2="40" WEIGHT="100.0" Z="0.7056418673315619">
<NAME>Global state: No clinically important change - less than much improved on CGI - short term</NAME>
<GROUP_LABEL_1>clozapine</GROUP_LABEL_1>
<GROUP_LABEL_2>risperidone</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours clozapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours risperidone</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.4868376485562935" CI_START="0.4304437681016717" EFFECT_SIZE="0.8" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="20" LOG_CI_END="0.17226354943286235" LOG_CI_START="-0.3660835754489752" LOG_EFFECT_SIZE="-0.09691001300805639" ORDER="266" O_E="0.0" SE="0.3162277660168379" STUDY_ID="STD-Heinrich-1994" TOTAL_1="20" TOTAL_2="40" VAR="0.09999999999999998" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.6861590384342606" CI_END="1.088801333863702" CI_START="0.8448811928743051" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9591182251202919" ESTIMABLE="YES" EVENTS_1="176" EVENTS_2="181" I2="0.0" I2_Q="0.0" ID="CMP-005.06" LOG_CI_END="0.036948644239079266" LOG_CI_START="-0.07320435721212148" LOG_EFFECT_SIZE="-0.01812785648652113" METHOD="MH" MODIFIED="2009-09-21 00:10:42 +0100" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.8906389318531747" P_Q="0.0" P_Z="0.5188612675522013" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="312" TOTAL_2="310" WEIGHT="500.0" Z="0.6451017287301504">
<NAME>Mental state: 1. No clinically important change - various criteria</NAME>
<GROUP_LABEL_1>clozapine</GROUP_LABEL_1>
<GROUP_LABEL_2>risperidone</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours clozapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours risperidone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="3.4178475069407298E-31" CI_END="1.2796246721279172" CI_START="0.5046222184373269" DF="0" EFFECT_SIZE="0.8035714285714286" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="12" I2="100.0" ID="CMP-005.06.01" LOG_CI_END="0.10708260501766044" LOG_CI_START="-0.29703363147937384" LOG_EFFECT_SIZE="-0.09497551323085672" MODIFIED="2009-09-20 23:57:42 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.35691335822344017" STUDIES="1" TAU2="0.0" TOTAL_1="14" TOTAL_2="15" WEIGHT="100.0" Z="0.9212625899877827">
<NAME>less than 20% reduction on BPRS-18 (1-7) total score -short term</NAME>
<DICH_DATA CI_END="1.2796246721279172" CI_START="0.5046222184373269" EFFECT_SIZE="0.8035714285714286" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="12" LOG_CI_END="0.10708260501766044" LOG_CI_START="-0.29703363147937384" LOG_EFFECT_SIZE="-0.09497551323085672" ORDER="267" O_E="0.0" SE="0.23737987772599078" STUDY_ID="STD-Breier-1999" TOTAL_1="14" TOTAL_2="15" VAR="0.05634920634920633" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.1710040892696636" CI_START="0.7763869381860984" DF="0" EFFECT_SIZE="0.953494771601541" ESTIMABLE="YES" EVENTS_1="77" EVENTS_2="79" I2="0.0" ID="CMP-005.06.02" LOG_CI_END="0.06855841167710182" LOG_CI_START="-0.10992177972548177" LOG_EFFECT_SIZE="-0.020681684024189975" MODIFIED="2009-09-20 23:58:01 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.6496646879123122" STUDIES="1" TAU2="0.0" TOTAL_1="138" TOTAL_2="135" WEIGHT="99.99999999999999" Z="0.4542280631649187">
<NAME>less than 20% reduction on BPRS and mildly ill or better - short term</NAME>
<DICH_DATA CI_END="1.1710040892696636" CI_START="0.7763869381860984" EFFECT_SIZE="0.953494771601541" ESTIMABLE="YES" EVENTS_1="77" EVENTS_2="79" LOG_CI_END="0.06855841167710182" LOG_CI_START="-0.10992177972548177" LOG_EFFECT_SIZE="-0.020681684024189975" MODIFIED="2009-01-18 19:22:04 +0000" MODIFIED_BY="[Empty name]" ORDER="678" O_E="0.0" SE="0.10484014792107384" STUDY_ID="STD-Azorin-2001" TOTAL_1="138" TOTAL_2="135" VAR="0.010991456616112644" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.1004377048503243E-30" CI_END="1.2081353387852307" CI_START="0.7774665146889486" DF="0" EFFECT_SIZE="0.9691670501610676" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="41" I2="100.0" ID="CMP-005.06.03" LOG_CI_END="0.08211558792361674" LOG_CI_START="-0.10931830686573041" LOG_EFFECT_SIZE="-0.013601359471056835" NO="3" P_CHI2="0.0" P_Z="0.7806205076618262" STUDIES="1" TAU2="0.0" TOTAL_1="53" TOTAL_2="54" WEIGHT="100.0" Z="0.278510498189348">
<NAME>less than 20% reduction on 4-item BPRS psychosis and no psychotic symptoms rated less than mild - long term</NAME>
<DICH_DATA CI_END="1.2081353387852307" CI_START="0.7774665146889486" EFFECT_SIZE="0.9691670501610676" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="41" LOG_CI_END="0.08211558792361674" LOG_CI_START="-0.10931830686573041" LOG_EFFECT_SIZE="-0.013601359471056835" ORDER="269" O_E="0.0" SE="0.11244921741232466" STUDY_ID="STD-McGurk-2005" TOTAL_1="53" TOTAL_2="54" VAR="0.012644826496644262" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.319668639777292" CI_START="0.6913746265216417" DF="0" EFFECT_SIZE="0.9551886792452831" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="32" I2="0.0" ID="CMP-005.06.04" LOG_CI_END="0.12046489637107431" LOG_CI_START="-0.1602865631272024" LOG_EFFECT_SIZE="-0.01991083337806406" NO="4" P_CHI2="1.0" P_Z="0.7810120120890466" STUDIES="1" TAU2="0.0" TOTAL_1="53" TOTAL_2="54" WEIGHT="100.0" Z="0.27800045202203544">
<NAME>less than 40% improvement on the 4-item BPRS psychosis cluster - long term</NAME>
<DICH_DATA CI_END="1.319668639777292" CI_START="0.6913746265216417" EFFECT_SIZE="0.9551886792452831" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="32" LOG_CI_END="0.12046489637107431" LOG_CI_START="-0.1602865631272024" LOG_EFFECT_SIZE="-0.01991083337806406" ORDER="270" O_E="0.0" SE="0.1649147970514257" STUDY_ID="STD-McGurk-2005" TOTAL_1="53" TOTAL_2="54" VAR="0.027196890286512926" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.4605551372504004" CI_END="1.9883491012025714" CI_START="0.7045451008286615" DF="1" EFFECT_SIZE="1.1835884495842903" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="17" I2="0.0" ID="CMP-005.06.05" LOG_CI_END="0.2984926373125737" LOG_CI_START="-0.15209120068935852" LOG_EFFECT_SIZE="0.07320071831160758" MODIFIED="2009-09-20 23:58:10 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.49736467463072476" P_Z="0.5242410261424035" STUDIES="2" TAU2="0.0" TOTAL_1="54" TOTAL_2="52" WEIGHT="100.00000000000001" Z="0.6368216497485525">
<NAME>less than 20% reduction on PANSS total - short term</NAME>
<DICH_DATA CI_END="1.9389227603776968" CI_START="0.5920602961253857" EFFECT_SIZE="1.0714285714285714" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="14" LOG_CI_END="0.287560508712593" LOG_CI_START="-0.22763406195770658" LOG_EFFECT_SIZE="0.029963223377443202" ORDER="271" O_E="0.0" SE="0.3026278410659888" STUDY_ID="STD-Bondolfi-1998" TOTAL_1="43" TOTAL_2="43" VAR="0.09158361018826136" WEIGHT="76.49070516685906"/>
<DICH_DATA CI_END="4.770124151147974" CI_START="0.5613451276249934" EFFECT_SIZE="1.6363636363636365" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="3" LOG_CI_END="0.6785296824901814" LOG_CI_START="-0.2507700426000194" LOG_EFFECT_SIZE="0.21387981994508104" ORDER="272" O_E="0.0" SE="0.5458752586258128" STUDY_ID="STD-Wahlbeck-2000" TOTAL_1="11" TOTAL_2="9" VAR="0.29797979797979796" WEIGHT="23.509294833140952"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="8.406945784465133" CI_END="3.4367699178116258" CI_START="-6.424713485439984" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.493971783814179" ESTIMABLE="YES" I2="52.42029504470644" I2_Q="0.0" ID="CMP-005.07" MODIFIED="2009-09-20 23:18:48 +0100" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="0.07775867031577544" P_Q="0.7597730921227926" P_Z="0.5526110994333547" Q="0.09350067280252539" RANDOM="YES" SCALE="25.228589263692168" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="14.9195289824375" TOTALS="YES" TOTAL_1="232" TOTAL_2="236" UNITS="" WEIGHT="100.00000000000001" Z="0.5938520140345951">
<NAME>Mental state: 2a. PANSS total score (high = poor)</NAME>
<GROUP_LABEL_1>clozapine</GROUP_LABEL_1>
<GROUP_LABEL_2>risperidone</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours clozapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours risperidone</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="8.313445111662608" CI_END="5.346233867450626" CI_START="-6.850822336186014" DF="3" EFFECT_SIZE="-0.7522942343676942" ESTIMABLE="YES" I2="63.91387734320376" ID="CMP-005.07.01" MODIFIED="2009-01-18 19:30:05 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.03995905902382335" P_Z="0.8089547691275621" STUDIES="4" TAU2="22.003392943116022" TOTAL_1="192" TOTAL_2="195" WEIGHT="83.97861550174002" Z="0.24177466767730257">
<NAME>short term</NAME>
<CONT_DATA CI_END="2.613814557623807" CI_START="-5.013814557623813" EFFECT_SIZE="-1.2000000000000028" ESTIMABLE="YES" MEAN_1="77.06" MEAN_2="78.26" MODIFIED="2009-01-18 19:29:11 +0000" MODIFIED_BY="[Empty name]" ORDER="679" SD_1="5.28" SD_2="4.62" SE="1.9458595095148137" STUDY_ID="STD-Atmaca-2003" TOTAL_1="13" TOTAL_2="13" WEIGHT="33.83372040677325"/>
<CONT_DATA CI_END="-1.9155028962084009" CI_START="-13.284497103791601" EFFECT_SIZE="-7.600000000000001" ESTIMABLE="YES" MEAN_1="-37.5" MEAN_2="-29.9" MODIFIED="2009-01-18 19:30:05 +0000" MODIFIED_BY="[Empty name]" ORDER="680" SD_1="22.5" SD_2="23.9" SE="2.900306918203696" STUDY_ID="STD-Azorin-2001" TOTAL_1="126" TOTAL_2="130" WEIGHT="27.126215876605738"/>
<CONT_DATA CI_END="13.742138179576505" CI_START="-5.342138179576507" EFFECT_SIZE="4.199999999999999" ESTIMABLE="YES" MEAN_1="-23.2" MEAN_2="-27.4" ORDER="274" SD_1="21.5" SD_2="23.6" SE="4.868527307054453" STUDY_ID="STD-Bondolfi-1998" TOTAL_1="43" TOTAL_2="43" WEIGHT="16.386740781368598"/>
<CONT_DATA CI_END="30.58636170279864" CI_START="-4.586361702798641" EFFECT_SIZE="13.0" ESTIMABLE="YES" MEAN_1="76.0" MEAN_2="63.0" ORDER="275" SD_1="22.0" SD_2="17.0" SE="8.972798399112238" STUDY_ID="STD-Wahlbeck-2000" TOTAL_1="10" TOTAL_2="9" WEIGHT="6.631938436992428"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="8.022322760417206E-33" CI_END="6.117806489596328" CI_START="-13.317806489596327" DF="0" EFFECT_SIZE="-3.5999999999999996" ESTIMABLE="YES" I2="100.0" ID="CMP-005.07.02" NO="2" P_CHI2="0.0" P_Z="0.4677919165143951" STUDIES="1" TAU2="0.0" TOTAL_1="40" TOTAL_2="41" WEIGHT="16.021384498259987" Z="0.726076440387865">
<NAME>medium term</NAME>
<CONT_DATA CI_END="6.117806489596328" CI_START="-13.317806489596327" EFFECT_SIZE="-3.6" ESTIMABLE="YES" MEAN_1="-6.7" MEAN_2="-3.1" ORDER="277" SD_1="22.31" SD_2="22.31" SE="4.958155642781778" STUDY_ID="STD-Volavka-2002" TOTAL_1="40" TOTAL_2="41" WEIGHT="16.021384498259987"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="5.162704110102964" CI_END="0.9717132027301463" CI_START="-6.925783897036494" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="-2.977035347153174" ESTIMABLE="YES" I2="61.26061154490388" I2_Q="79.70078591665359" ID="CMP-005.08" MODIFIED="2009-09-20 23:18:57 +0100" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="0.07567172629540875" P_Q="0.026451051177357132" P_Z="0.13950055026760158" Q="4.926299096576382" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="7.342224647006733" TOTALS="YES" TOTAL_1="170" TOTAL_2="167" UNITS="" WEIGHT="100.0" Z="1.4776534862660047">
<NAME>Mental state: 2b. BPRS-18 (1-7) total score - short term (high = poor)</NAME>
<GROUP_LABEL_1>clozapine</GROUP_LABEL_1>
<GROUP_LABEL_2>risperidone</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours clozapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours risperidone</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.23640501352658225" CI_END="-2.2281467972536357" CI_START="-7.991542448854979" DF="1" EFFECT_SIZE="-5.1098446230543075" ESTIMABLE="YES" I2="0.0" ID="CMP-005.08.01" MODIFIED="2009-01-21 21:10:10 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.6268147715159793" P_Z="5.100533268590757E-4" STUDIES="2" TAU2="0.0" TOTAL_1="140" TOTAL_2="145" WEIGHT="64.21554847007489" Z="3.4754204060238068">
<NAME>short term</NAME>
<CONT_DATA CI_END="-2.217059522236337" CI_START="-8.782940477763663" EFFECT_SIZE="-5.5" ESTIMABLE="YES" MEAN_1="-23.2" MEAN_2="-17.7" MODIFIED="2009-01-18 19:36:18 +0000" MODIFIED_BY="[Empty name]" ORDER="681" SD_1="13.2" SD_2="13.6" SE="1.6750004100376732" STUDY_ID="STD-Azorin-2001" TOTAL_1="126" TOTAL_2="130" WEIGHT="39.99895949470759"/>
<CONT_DATA CI_END="2.2152558100771227" CI_START="-9.815255810077117" EFFECT_SIZE="-3.799999999999997" ESTIMABLE="YES" MEAN_1="32.0" MEAN_2="35.8" MODIFIED="2009-01-21 21:10:10 +0000" MODIFIED_BY="[Empty name]" ORDER="1251" SD_1="6.37" SD_2="9.89" SE="3.069064461145557" STUDY_ID="STD-Breier-1999" TOTAL_1="14" TOTAL_2="15" WEIGHT="24.2165889753673"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="4.320314003583874" CI_START="-3.5203140035838776" DF="0" EFFECT_SIZE="0.3999999999999986" ESTIMABLE="YES" I2="0.0" ID="CMP-005.08.02" NO="2" P_CHI2="1.0" P_Z="0.8414959837052813" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="22" WEIGHT="35.78445152992511" Z="0.1999803059396044">
<NAME>long term</NAME>
<CONT_DATA CI_END="4.320314003583874" CI_START="-3.5203140035838776" EFFECT_SIZE="0.3999999999999986" ESTIMABLE="YES" MEAN_1="31.7" MEAN_2="31.3" ORDER="279" SD_1="7.9" SD_2="6.5" SE="2.0001969599986595" STUDY_ID="STD-McGurk-2005" TOTAL_1="30" TOTAL_2="22" WEIGHT="35.78445152992511"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="4.453515941124782" CI_END="0.31795632909867133" CI_START="-2.2945683712922715" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.9883060210968002" ESTIMABLE="YES" I2="10.18332362834749" I2_Q="0.0" ID="CMP-005.09" MODIFIED="2009-09-20 23:19:20 +0100" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="0.3480950324957993" P_Q="0.643266442825535" P_Z="0.13810346977441276" Q="0.21449554766450696" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.24622643862490398" TOTALS="YES" TOTAL_1="279" TOTAL_2="283" UNITS="" WEIGHT="100.0" Z="1.482890635838925">
<NAME>Mental state: 3a. Positive symptoms: PANSS positive subscore (high = poor)</NAME>
<GROUP_LABEL_1>clozapine</GROUP_LABEL_1>
<GROUP_LABEL_2>risperidone</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours clozapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours risperidone</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="4.239020393460275" CI_END="0.8142472470775453" CI_START="-2.5899372899935162" DF="3" EFFECT_SIZE="-0.8878450214579856" ESTIMABLE="YES" I2="29.228932122425427" ID="CMP-005.09.01" MODIFIED="2009-01-18 19:40:35 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.236784279019724" P_Z="0.3066124454672817" STUDIES="4" TAU2="0.8963642871233625" TOTAL_1="239" TOTAL_2="242" WEIGHT="84.56741211559664" Z="1.0223560132894867">
<NAME>short term</NAME>
<CONT_DATA CI_END="-0.38355371586920217" CI_START="-3.816446284130797" EFFECT_SIZE="-2.0999999999999996" ESTIMABLE="YES" MEAN_1="-10.4" MEAN_2="-8.3" MODIFIED="2009-01-18 19:40:35 +0000" MODIFIED_BY="[Empty name]" ORDER="682" SD_1="6.6" SD_2="7.4" SE="0.8757539922518509" STUDY_ID="STD-Azorin-2001" TOTAL_1="126" TOTAL_2="130" WEIGHT="43.841123490285675"/>
<CONT_DATA CI_END="5.438169862851794" CI_START="-2.2381698628517928" EFFECT_SIZE="1.6000000000000005" ESTIMABLE="YES" MEAN_1="-6.7" MEAN_2="-8.3" ORDER="281" SD_1="7.1" SD_2="10.7" SE="1.9582859139896382" STUDY_ID="STD-Bondolfi-1998" TOTAL_1="43" TOTAL_2="43" WEIGHT="10.883944522408978"/>
<CONT_DATA CI_END="1.3213026253477715" CI_START="-3.5213026253477744" EFFECT_SIZE="-1.1000000000000014" ESTIMABLE="YES" MEAN_1="19.7" MEAN_2="20.8" ORDER="283" SD_1="5.4" SD_2="7.9" SE="1.2353811827394274" STUDY_ID="STD-Ren-2002" TOTAL_1="60" TOTAL_2="60" WEIGHT="25.06135711870228"/>
<CONT_DATA CI_END="7.894392325710013" CI_START="-3.8943923257100126" EFFECT_SIZE="2.0" ESTIMABLE="YES" MEAN_1="17.0" MEAN_2="15.0" ORDER="282" SD_1="6.0" SD_2="7.0" SE="3.007398284970656" STUDY_ID="STD-Wahlbeck-2000" TOTAL_1="10" TOTAL_2="9" WEIGHT="4.780986984199707"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="2.779739460961595" CI_START="-3.5797394609615947" DF="0" EFFECT_SIZE="-0.3999999999999999" ESTIMABLE="YES" I2="0.0" ID="CMP-005.09.02" NO="2" P_CHI2="1.0" P_Z="0.8052514342014075" STUDIES="1" TAU2="0.0" TOTAL_1="40" TOTAL_2="41" WEIGHT="15.432587884403356" Z="0.24655655076184577">
<NAME>medium term</NAME>
<CONT_DATA CI_END="2.779739460961595" CI_START="-3.5797394609615947" EFFECT_SIZE="-0.3999999999999999" ESTIMABLE="YES" MEAN_1="-2.3" MEAN_2="-1.9" ORDER="284" SD_1="7.3" SD_2="7.3" SE="1.622345862496951" STUDY_ID="STD-Volavka-2002" TOTAL_1="40" TOTAL_2="41" WEIGHT="15.432587884403356"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.5589069290874917" CI_START="-4.758906929087491" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-2.0999999999999996" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-005.10" MODIFIED="2009-09-20 23:59:13 +0100" MODIFIED_BY="[Empty name]" NO="10" P_CHI2="1.0" P_Q="1.0" P_Z="0.12162805182197306" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="14" TOTAL_2="15" UNITS="" WEIGHT="100.0" Z="1.5479760959315167">
<NAME>Mental state: 3b. Positive symptoms: BPRS-18 (1-7) positive subscore - short term (high = poor)</NAME>
<GROUP_LABEL_1>clozapine</GROUP_LABEL_1>
<GROUP_LABEL_2>risperidone</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours clozapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours risperidone</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.5589069290874913" CI_START="-4.758906929087491" EFFECT_SIZE="-2.0999999999999996" ESTIMABLE="YES" MEAN_1="7.43" MEAN_2="9.53" ORDER="285" SD_1="2.21" SD_2="4.73" SE="1.3566100959306444" STUDY_ID="STD-Breier-1999" TOTAL_1="14" TOTAL_2="15" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="10.140405753104815" CI_END="1.9596597681834311" CI_START="-1.7088351683023213" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="MD" EFFECT_SIZE="0.12541229994055492" ESTIMABLE="YES" I2="60.55384668630966" I2_Q="0.0" ID="CMP-005.11" MODIFIED="2009-09-20 23:19:55 +0100" MODIFIED_BY="[Empty name]" NO="11" P_CHI2="0.038127930500802876" P_Q="0.41249519971782356" P_Z="0.8933963534688237" Q="0.671598454568807" RANDOM="YES" SCALE="7.1" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="2.5766236672979015" TOTALS="YES" TOTAL_1="279" TOTAL_2="283" UNITS="" WEIGHT="100.00000000000001" Z="0.1340078671812429">
<NAME>Mental state: 4a. Negative symptoms: PANSS negative subscore (high = poor)</NAME>
<GROUP_LABEL_1>clozapine</GROUP_LABEL_1>
<GROUP_LABEL_2>risperidone</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours clozapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours risperidone</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="9.468807298536008" CI_END="2.7999844113756165" CI_START="-1.7066720332585588" DF="3" EFFECT_SIZE="0.5466561890585288" ESTIMABLE="YES" I2="68.31702340733203" ID="CMP-005.11.01" MODIFIED="2009-01-18 19:45:01 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.02366559482388908" P_Z="0.6344404785964517" STUDIES="4" TAU2="3.516250165792604" TOTAL_1="239" TOTAL_2="242" WEIGHT="81.16713850761607" Z="0.4754861861086939">
<NAME>short term</NAME>
<CONT_DATA CI_END="0.015112238489882968" CI_START="-3.4151122384898853" EFFECT_SIZE="-1.700000000000001" ESTIMABLE="YES" MEAN_1="-8.8" MEAN_2="-7.1" MODIFIED="2009-01-18 19:45:01 +0000" MODIFIED_BY="[Empty name]" ORDER="683" SD_1="6.8" SD_2="7.2" SE="0.8750733442137052" STUDY_ID="STD-Azorin-2001" TOTAL_1="126" TOTAL_2="130" WEIGHT="26.203797656569826"/>
<CONT_DATA CI_END="2.5643307894546745" CI_START="-2.764330789454674" EFFECT_SIZE="-0.09999999999999964" ESTIMABLE="YES" MEAN_1="-6.1" MEAN_2="-6.0" ORDER="287" SD_1="6.1" SD_2="6.5" SE="1.3593774224784616" STUDY_ID="STD-Bondolfi-1998" TOTAL_1="43" TOTAL_2="43" WEIGHT="19.79486148985024"/>
<CONT_DATA CI_END="3.8586101839865248" CI_START="-1.2586101839865305" EFFECT_SIZE="1.2999999999999972" ESTIMABLE="YES" MEAN_1="19.9" MEAN_2="18.6" ORDER="288" SD_1="7.1" SD_2="7.2" SE="1.305437346894391" STUDY_ID="STD-Ren-2002" TOTAL_1="60" TOTAL_2="60" WEIGHT="20.4595330356434"/>
<CONT_DATA CI_END="7.602165215365481" CI_START="0.39783478463451827" EFFECT_SIZE="4.0" ESTIMABLE="YES" MEAN_1="21.0" MEAN_2="17.0" ORDER="289" SD_1="4.0" SD_2="4.0" SE="1.837873166945363" STUDY_ID="STD-Wahlbeck-2000" TOTAL_1="10" TOTAL_2="9" WEIGHT="14.708946325552601"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="1.422563247538512" CI_START="-4.222563247538512" DF="0" EFFECT_SIZE="-1.4000000000000001" ESTIMABLE="YES" I2="0.0" ID="CMP-005.11.02" NO="2" P_CHI2="1.0" P_Z="0.3309768741358846" STUDIES="1" TAU2="0.0" TOTAL_1="40" TOTAL_2="41" WEIGHT="18.83286149238394" Z="0.9721481283896852">
<NAME>medium term</NAME>
<CONT_DATA CI_END="1.422563247538512" CI_START="-4.222563247538512" EFFECT_SIZE="-1.4000000000000001" ESTIMABLE="YES" MEAN_1="-1.6" MEAN_2="-0.2" ORDER="290" SD_1="6.48" SD_2="6.48" SE="1.4401097519151018" STUDY_ID="STD-Volavka-2002" TOTAL_1="40" TOTAL_2="41" WEIGHT="18.83286149238394"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.060489605824938286" CI_END="3.739880911986222" CI_START="-2.509754284760078" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="0.6150633136130722" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-005.12" MODIFIED="2009-09-20 23:20:07 +0100" MODIFIED_BY="[Empty name]" NO="12" P_CHI2="0.8057237681273618" P_Q="1.0" P_Z="0.6996572842650508" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="34" TOTAL_2="35" UNITS="" WEIGHT="99.99999999999999" Z="0.3857831393170268">
<NAME>Mental state: 4b. Negative symptoms: SANS - short term (high = poor)</NAME>
<GROUP_LABEL_1>clozapine</GROUP_LABEL_1>
<GROUP_LABEL_2>risperidone</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours clozapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours risperidone</GRAPH_LABEL_2>
<CONT_DATA CI_END="7.828048965487798" CI_START="-5.1680489654878015" EFFECT_SIZE="1.3299999999999983" ESTIMABLE="YES" MEAN_1="48.93" MEAN_2="47.6" ORDER="291" SD_1="8.43" SD_2="9.42" SE="3.3153920259472014" STUDY_ID="STD-Breier-1999" TOTAL_1="14" TOTAL_2="15" WEIGHT="23.12508748527674"/>
<CONT_DATA CI_END="3.963956171254792" CI_START="-3.163956171254795" EFFECT_SIZE="0.3999999999999986" ESTIMABLE="YES" MEAN_1="34.9" MEAN_2="34.5" ORDER="292" SD_1="5.8" SD_2="5.7" SE="1.818378398463862" STUDY_ID="STD-Zhou-2000" TOTAL_1="20" TOTAL_2="20" WEIGHT="76.87491251472325"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.44269704670700705" CI_START="-18.442697046707007" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-9.0" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-005.13" MODIFIED="2010-10-05 14:42:05 +0100" MODIFIED_BY="[Empty name]" NO="13" P_CHI2="1.0" P_Q="1.0" P_Z="0.06175147633737428" Q="0.0" RANDOM="YES" SCALE="19.741266410506075" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="10" TOTAL_2="9" UNITS="" WEIGHT="100.0" Z="1.8680760140464372">
<NAME>General functioning: GAF score - short term (high = good)</NAME>
<GROUP_LABEL_1>clozapine</GROUP_LABEL_1>
<GROUP_LABEL_2>risperidone</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours risperidone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours clozapine</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.44269704670700705" CI_START="-18.442697046707007" EFFECT_SIZE="-9.0" ESTIMABLE="YES" MEAN_1="35.0" MEAN_2="44.0" ORDER="293" SD_1="11.0" SD_2="10.0" SE="4.817791102892602" STUDY_ID="STD-Wahlbeck-2000" TOTAL_1="10" TOTAL_2="9" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="-0.449308052902623" CI_START="-93.55069194709738" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-47.0" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-005.14" MODIFIED="2010-10-05 14:42:12 +0100" MODIFIED_BY="[Empty name]" NO="14" P_CHI2="1.0" P_Q="1.0" P_Z="0.04782933953806504" Q="0.0" RANDOM="YES" SCALE="115.9143222237063" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="10" TOTAL_2="9" UNITS="" WEIGHT="100.0" Z="1.9788815895168772">
<NAME>Social functioning: SFS score - short term (high = good)</NAME>
<GROUP_LABEL_1>clozapine</GROUP_LABEL_1>
<GROUP_LABEL_2>risperidone</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours risperidone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours clozapine</GRAPH_LABEL_2>
<CONT_DATA CI_END="-0.449308052902623" CI_START="-93.55069194709738" EFFECT_SIZE="-47.0" ESTIMABLE="YES" MEAN_1="687.0" MEAN_2="734.0" ORDER="294" SD_1="49.0" SD_2="54.0" SE="23.7507894605632" STUDY_ID="STD-Wahlbeck-2000" TOTAL_1="10" TOTAL_2="9" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="2.7671198095342135" CI_START="-2.5671198095342107" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.10000000000000142" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-005.15" MODIFIED="2009-09-21 00:00:08 +0100" MODIFIED_BY="[Empty name]" NO="15" P_CHI2="1.0" P_Q="1.0" P_Z="0.9414192554087906" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="10" TOTAL_2="9" UNITS="" WEIGHT="100.0" Z="0.07348616202143433">
<NAME>Treatment satisfaction: DAI score - short term (high = good)</NAME>
<GROUP_LABEL_1>clozapine</GROUP_LABEL_1>
<GROUP_LABEL_2>risperidone</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours risperidone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours clozapine</GRAPH_LABEL_2>
<CONT_DATA CI_END="2.7671198095342135" CI_START="-2.5671198095342107" EFFECT_SIZE="0.10000000000000142" ESTIMABLE="YES" MEAN_1="16.1" MEAN_2="16.0" ORDER="295" SD_1="2.8" SD_2="3.1" SE="1.3608004180546749" STUDY_ID="STD-Wahlbeck-2000" TOTAL_1="10" TOTAL_2="9" WEIGHT="100.0"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.668175123351471" CI_START="0.954024111535391" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.2615384615384615" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="26" I2="0.0" I2_Q="0.0" ID="CMP-005.16" LOG_CI_END="0.22224164049414327" LOG_CI_START="-0.02044064901242106" LOG_EFFECT_SIZE="0.1009004957408611" METHOD="MH" MODIFIED="2009-09-21 00:11:35 +0100" MODIFIED_BY="[Empty name]" NO="16" P_CHI2="1.0" P_Q="0.0" P_Z="0.10314457536004235" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="40" TOTAL_2="41" WEIGHT="100.0" Z="1.6297962086679227">
<NAME>Cognitive functioning: No clinically important change - less than 0.5 SD improved - medium term</NAME>
<GROUP_LABEL_1>clozapine</GROUP_LABEL_1>
<GROUP_LABEL_2>risperidone</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours clozapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours risperidone</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.668175123351471" CI_START="0.954024111535391" EFFECT_SIZE="1.2615384615384615" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="26" LOG_CI_END="0.22224164049414327" LOG_CI_START="-0.02044064901242106" LOG_EFFECT_SIZE="0.1009004957408611" ORDER="296" O_E="0.0" SE="0.1425527781528632" STUDY_ID="STD-Volavka-2002" TOTAL_1="40" TOTAL_2="41" VAR="0.020321294559099437" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="5.739343963124063" CI_END="1.9538527411203517" CI_START="0.706322331816142" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.174755218815174" ESTIMABLE="YES" EVENTS_1="122" EVENTS_2="130" I2="82.57640583270295" I2_Q="0.0" ID="CMP-005.17" LOG_CI_END="0.2908918285082257" LOG_CI_START="-0.1509970624289976" LOG_EFFECT_SIZE="0.06994738303961401" METHOD="MH" MODIFIED="2009-09-21 00:01:39 +0100" MODIFIED_BY="[Empty name]" NO="17" P_CHI2="0.016589015845545507" P_Q="0.0" P_Z="0.5349336525964157" Q="0.0" RANDOM="YES" SCALE="5.51827870343619" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.11374251292399883" TOTALS="YES" TOTAL_1="158" TOTAL_2="175" WEIGHT="100.0" Z="0.6204924105681923">
<NAME>Adverse effects: 1. At least one adverse effect - short term</NAME>
<GROUP_LABEL_1>clozapine</GROUP_LABEL_1>
<GROUP_LABEL_2>risperidone</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours clozapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours risperidone</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.0624271980748248" CI_START="0.8370121879339774" EFFECT_SIZE="0.9430082256169212" ESTIMABLE="YES" EVENTS_1="107" EVENTS_2="111" LOG_CI_END="0.026299180079872784" LOG_CI_START="-0.07726821809522919" LOG_EFFECT_SIZE="-0.025484519007678213" MODIFIED="2009-01-18 19:56:34 +0000" MODIFIED_BY="[Empty name]" ORDER="684" O_E="0.0" SE="0.060836002354944074" STUDY_ID="STD-Azorin-2001" TOTAL_1="138" TOTAL_2="135" VAR="0.003701019182530761" WEIGHT="57.3683378345308"/>
<DICH_DATA CI_END="2.385180805927474" CI_START="1.0452351394276538" EFFECT_SIZE="1.5789473684210527" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="19" LOG_CI_END="0.377521305824916" LOG_CI_START="0.019214001708750917" LOG_EFFECT_SIZE="0.19836765376683346" ORDER="298" O_E="0.0" SE="0.21047148408759578" STUDY_ID="STD-Heinrich-1994" TOTAL_1="20" TOTAL_2="40" VAR="0.04429824561403508" WEIGHT="42.6316621654692"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="15.295147270011068" CI_START="0.027690637326764495" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6507936507936508" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-005.18" LOG_CI_END="1.1845536629647146" LOG_CI_START="-1.5576670484324067" LOG_EFFECT_SIZE="-0.1865566927338462" METHOD="MH" MODIFIED="2009-01-18 20:02:50 +0000" MODIFIED_BY="[Empty name]" NO="18" P_CHI2="1.0" P_Q="0.0" P_Z="0.789717413732514" Q="0.0" RANDOM="YES" SCALE="238.0176020898689" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="73" TOTAL_2="94" WEIGHT="100.0" Z="0.2666775852968839">
<NAME>Adverse effects: 2. Cardiac problems</NAME>
<GROUP_LABEL_1>clozapine</GROUP_LABEL_1>
<GROUP_LABEL_2>risperidone</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours clozapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours risperidone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="15.295147270011068" CI_START="0.027690637326764495" DF="0" EFFECT_SIZE="0.6507936507936508" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" ID="CMP-005.18.01" LOG_CI_END="1.1845536629647146" LOG_CI_START="-1.5576670484324067" LOG_EFFECT_SIZE="-0.1865566927338462" NO="1" P_CHI2="1.0" P_Z="0.789717413732514" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="40" WEIGHT="100.0" Z="0.2666775852968839">
<NAME>short term</NAME>
<DICH_DATA CI_END="15.295147270011068" CI_START="0.027690637326764495" EFFECT_SIZE="0.6507936507936508" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="1.1845536629647146" LOG_CI_START="-1.5576670484324067" LOG_EFFECT_SIZE="-0.1865566927338462" ORDER="299" O_E="0.0" SE="1.6107940200861126" STUDY_ID="STD-Heinrich-1994" TOTAL_1="20" TOTAL_2="40" VAR="2.59465737514518" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-005.18.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="53" TOTAL_2="54" WEIGHT="0.0" Z="0.0">
<NAME>long term</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="300" O_E="0.0" SE="0.0" STUDY_ID="STD-McGurk-2005" TOTAL_1="53" TOTAL_2="54" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.6985184156459976" CI_END="0.6781076901932654" CI_START="0.22299074773091768" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="RR" EFFECT_SIZE="0.38885953875182455" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="37" I2="0.0" I2_Q="0.0" ID="CMP-005.19" LOG_CI_END="-0.1687013304061167" LOG_CI_START="-0.6517131562019182" LOG_EFFECT_SIZE="-0.4102072433040174" METHOD="MH" MODIFIED="2009-09-20 23:22:04 +0100" MODIFIED_BY="[Empty name]" NO="19" P_CHI2="0.7463450964263516" P_Q="0.0" P_Z="8.713477341346715E-4" Q="0.0" RANDOM="YES" SCALE="18.793394899921513" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="142" TOTAL_2="162" WEIGHT="99.99999999999999" Z="3.3290755221104242">
<NAME>Adverse effects: 3a. Extrapyramidal: antiparkinson medication use</NAME>
<GROUP_LABEL_1>clozapine</GROUP_LABEL_1>
<GROUP_LABEL_2>risperidone</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours clozapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours risperidone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="2.7058037866910176" CI_END="0.7708316419177093" CI_START="0.19324238544989936" DF="4" EFFECT_SIZE="0.3859499258510627" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="24" I2="0.0" ID="CMP-005.19.01" LOG_CI_END="-0.11304046626852052" LOG_CI_START="-0.7138976100732543" LOG_EFFECT_SIZE="-0.4134690381708873" MODIFIED="2009-01-18 20:11:25 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.6081996095984852" P_Z="0.0069877406742086395" STUDIES="5" TAU2="0.0" TOTAL_1="102" TOTAL_2="121" WEIGHT="64.62091003870086" Z="2.697427939046738">
<NAME>short term</NAME>
<DICH_DATA CI_END="2.5333740706490695" CI_START="0.00805572438028364" EFFECT_SIZE="0.14285714285714285" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.4036993211858072" LOG_CI_START="-2.093895401214321" LOG_EFFECT_SIZE="-0.8450980400142569" MODIFIED="2009-01-18 20:11:25 +0000" MODIFIED_BY="[Empty name]" ORDER="685" O_E="0.0" SE="1.4670995032311038" STUDY_ID="STD-Atmaca-2003" TOTAL_1="14" TOTAL_2="14" VAR="2.152380952380952" WEIGHT="3.7399999101839483"/>
<DICH_DATA CI_END="4.680805125661779" CI_START="0.21363846029770756" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.6703205606720961" LOG_CI_START="-0.6703205606720961" LOG_EFFECT_SIZE="0.0" ORDER="302" O_E="0.0" SE="0.7874992309581577" STUDY_ID="STD-Bondolfi-1998" TOTAL_1="43" TOTAL_2="43" VAR="0.6201550387596898" WEIGHT="12.980471116845573"/>
<DICH_DATA CI_END="0.811895667775382" CI_START="0.05655698037255998" EFFECT_SIZE="0.21428571428571427" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="10" LOG_CI_END="-0.09049977595665577" LOG_CI_START="-1.2475137859604954" LOG_EFFECT_SIZE="-0.6690067809585756" ORDER="303" O_E="0.0" SE="0.6796357567879738" STUDY_ID="STD-Breier-1999" TOTAL_1="14" TOTAL_2="15" VAR="0.46190476190476193" WEIGHT="17.427628447455092"/>
<DICH_DATA CI_END="7.768496439207262" CI_START="0.019626919639079757" EFFECT_SIZE="0.3904761904761905" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.8903369710090208" LOG_CI_START="-1.707147855709426" LOG_EFFECT_SIZE="-0.4084054423502026" ORDER="305" O_E="0.0" SE="1.5257754449716752" STUDY_ID="STD-Heinrich-1994" TOTAL_1="20" TOTAL_2="40" VAR="2.3279907084785134" WEIGHT="3.4578765882822244"/>
<DICH_DATA CI_END="1.1925310377869938" CI_START="0.1403362819062484" EFFECT_SIZE="0.4090909090909091" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="6" LOG_CI_END="0.07646969116221912" LOG_CI_START="-0.8528300339279817" LOG_EFFECT_SIZE="-0.38818017138288136" ORDER="304" O_E="0.0" SE="0.5458752586258128" STUDY_ID="STD-Wahlbeck-2000" TOTAL_1="11" TOTAL_2="9" VAR="0.29797979797979796" WEIGHT="27.014933975934024"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="5.417218904385685E-32" CI_END="1.0041002460812867" CI_START="0.15478324999404705" DF="0" EFFECT_SIZE="0.39423076923076916" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="13" I2="100.0" ID="CMP-005.19.02" LOG_CI_END="0.0017770735127864603" LOG_CI_START="-0.8102760386708764" LOG_EFFECT_SIZE="-0.4042494825790449" NO="2" P_CHI2="0.0" P_Z="0.05101117797804585" STUDIES="1" TAU2="0.0" TOTAL_1="40" TOTAL_2="41" WEIGHT="35.37908996129913" Z="1.9513857276977755">
<NAME>medium term</NAME>
<DICH_DATA CI_END="1.004100246081287" CI_START="0.15478324999404708" EFFECT_SIZE="0.3942307692307692" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="13" LOG_CI_END="0.0017770735127865564" LOG_CI_START="-0.8102760386708763" LOG_EFFECT_SIZE="-0.40424948257904486" ORDER="306" O_E="0.0" SE="0.4770040178244182" STUDY_ID="STD-Volavka-2002" TOTAL_1="40" TOTAL_2="41" VAR="0.2275328330206379" WEIGHT="35.37908996129913"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="18.245012922205373" CI_END="2.015452418993855" CI_START="1.0132641640952682" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="RR" EFFECT_SIZE="1.4290506326248886" ESTIMABLE="YES" EVENTS_1="72" EVENTS_2="78" I2="67.11430117597993" I2_Q="0.0" ID="CMP-005.20" LOG_CI_END="0.30437254974169653" LOG_CI_START="0.005722683319649008" LOG_EFFECT_SIZE="0.15504761653067273" METHOD="MH" MODIFIED="2009-09-20 23:22:17 +0100" MODIFIED_BY="[Empty name]" NO="20" P_CHI2="0.005648207579084796" P_Q="0.0" P_Z="0.041843121005448784" Q="0.0" RANDOM="YES" SCALE="186.8236882574533" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.33903547396695216" TOTALS="SUB" TOTAL_1="327" TOTAL_2="344" WEIGHT="600.0" Z="2.0350770481139016">
<NAME>Adverse effects: 3b. Extrapyramidal: various symptoms - short term</NAME>
<GROUP_LABEL_1>clozapine</GROUP_LABEL_1>
<GROUP_LABEL_2>risperidone</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours clozapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours risperidone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="5.262685996981282" CI_END="2.2819943012321193" CI_START="0.25983296786776355" DF="1" EFFECT_SIZE="0.7700242541287026" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="48" I2="80.99829629634738" ID="CMP-005.20.01" LOG_CI_END="0.3583145555306908" LOG_CI_START="-0.585305746047112" LOG_EFFECT_SIZE="-0.11349559525821067" MODIFIED="2009-01-18 20:15:19 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.021787422720599303" P_Z="0.6373006798236327" STUDIES="2" TAU2="0.5010248237837346" TOTAL_1="158" TOTAL_2="175" WEIGHT="100.0" Z="0.4714762468295343">
<NAME>at least one EPS</NAME>
<DICH_DATA CI_END="0.7702453394864348" CI_START="0.27877774572617703" EFFECT_SIZE="0.4633867276887872" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="38" LOG_CI_END="-0.1133709207831056" LOG_CI_START="-0.5547418980563633" LOG_EFFECT_SIZE="-0.33405640941973447" MODIFIED="2009-01-18 20:15:19 +0000" MODIFIED_BY="[Empty name]" ORDER="686" O_E="0.0" SE="0.25926349687188543" STUDY_ID="STD-Azorin-2001" TOTAL_1="138" TOTAL_2="135" VAR="0.06721756081023815" WEIGHT="54.067480441495235"/>
<DICH_DATA CI_END="3.1251328157845895" CI_START="0.6271733444736576" EFFECT_SIZE="1.4" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="10" LOG_CI_END="0.4948684792598177" LOG_CI_START="-0.20261240790334173" LOG_EFFECT_SIZE="0.14612803567823798" ORDER="308" O_E="0.0" SE="0.4097037257057139" STUDY_ID="STD-Heinrich-1994" TOTAL_1="20" TOTAL_2="40" VAR="0.16785714285714284" WEIGHT="45.932519558504765"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="156.90994575594544" CI_START="0.5162196673369944" DF="0" EFFECT_SIZE="9.000000000000002" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" I2="0.0" ID="CMP-005.20.02" LOG_CI_END="2.195650472267817" LOG_CI_START="-0.2871654533891673" LOG_EFFECT_SIZE="0.954242509439325" NO="2" P_CHI2="1.0" P_Z="0.13191823498596858" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0" Z="1.5065804369071778">
<NAME>akathisia</NAME>
<DICH_DATA CI_END="156.90994575594544" CI_START="0.5162196673369944" EFFECT_SIZE="9.0" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="2.195650472267817" LOG_CI_START="-0.2871654533891673" LOG_EFFECT_SIZE="0.9542425094393249" ORDER="309" O_E="0.0" SE="1.4584183648679576" STUDY_ID="STD-Zhou-2000" TOTAL_1="20" TOTAL_2="20" VAR="2.1269841269841274" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.6080061992060575" CI_START="0.38343467139933374" DF="0" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="7" I2="0.0" ID="CMP-005.20.03" LOG_CI_END="0.41630861937498354" LOG_CI_START="-0.41630861937498354" LOG_EFFECT_SIZE="0.0" NO="3" P_CHI2="1.0" P_Z="1.0" STUDIES="1" TAU2="0.0" TOTAL_1="43" TOTAL_2="43" WEIGHT="100.0" Z="0.0">
<NAME>dyskinesia</NAME>
<DICH_DATA CI_END="2.6080061992060575" CI_START="0.38343467139933374" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="7" LOG_CI_END="0.41630861937498354" LOG_CI_START="-0.41630861937498354" LOG_EFFECT_SIZE="0.0" ORDER="310" O_E="0.0" SE="0.4890834875635335" STUDY_ID="STD-Bondolfi-1998" TOTAL_1="43" TOTAL_2="43" VAR="0.23920265780730898" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="5.311101367468561" CI_START="0.047071216062885626" DF="0" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" I2="0.0" ID="CMP-005.20.04" LOG_CI_END="0.7251845904253741" LOG_CI_START="-1.3272445817533365" LOG_EFFECT_SIZE="-0.3010299956639812" NO="4" P_CHI2="1.0" P_Z="0.5653344259186854" STUDIES="1" TAU2="0.0" TOTAL_1="43" TOTAL_2="43" WEIGHT="99.99999999999999" Z="0.5749362343562306">
<NAME>dystonia</NAME>
<DICH_DATA CI_END="5.311101367468561" CI_START="0.047071216062885626" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7251845904253741" LOG_CI_START="-1.3272445817533365" LOG_EFFECT_SIZE="-0.3010299956639812" ORDER="311" O_E="0.0" SE="1.2056070554260303" STUDY_ID="STD-Bondolfi-1998" TOTAL_1="43" TOTAL_2="43" VAR="1.4534883720930232" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.454743051716452" CI_START="1.0275989365637044" DF="0" EFFECT_SIZE="1.588235294117647" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="17" I2="0.0" ID="CMP-005.20.05" LOG_CI_END="0.39000603940732254" LOG_CI_START="0.011823646154104181" LOG_EFFECT_SIZE="0.20091484278071337" NO="5" P_CHI2="1.0" P_Z="0.03729516350761737" STUDIES="1" TAU2="0.0" TOTAL_1="43" TOTAL_2="43" WEIGHT="100.0" Z="2.0825181861179853">
<NAME>parkinsonism</NAME>
<DICH_DATA CI_END="2.454743051716452" CI_START="1.0275989365637044" EFFECT_SIZE="1.588235294117647" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="17" LOG_CI_END="0.39000603940732254" LOG_CI_START="0.011823646154104181" LOG_EFFECT_SIZE="0.20091484278071337" ORDER="312" O_E="0.0" SE="0.22214620982997885" STUDY_ID="STD-Bondolfi-1998" TOTAL_1="43" TOTAL_2="43" VAR="0.049348938541824997" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="5.589897580584607" CI_START="0.7155766169836816" DF="0" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="4" I2="0.0" ID="CMP-005.20.06" LOG_CI_END="0.7474038507138955" LOG_CI_START="-0.14534385938593308" LOG_EFFECT_SIZE="0.3010299956639812" NO="6" P_CHI2="1.0" P_Z="0.1862414830200649" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0" Z="1.321779811009935">
<NAME>tremor</NAME>
<DICH_DATA CI_END="5.589897580584607" CI_START="0.7155766169836816" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="4" LOG_CI_END="0.7474038507138955" LOG_CI_START="-0.14534385938593308" LOG_EFFECT_SIZE="0.3010299956639812" ORDER="313" O_E="0.0" SE="0.5244044240850758" STUDY_ID="STD-Zhou-2000" TOTAL_1="20" TOTAL_2="20" VAR="0.275" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="2.612944653327551" CI_END="-0.014630725260119659" CI_START="-0.43330522071140193" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.2239679729857608" ESTIMABLE="YES" I2="0.0" I2_Q="3.104339880689691" ID="CMP-005.21" MODIFIED="2009-09-21 00:02:38 +0100" MODIFIED_BY="[Empty name]" NO="21" P_CHI2="0.455224747790671" P_Q="0.3562802817252281" P_Z="0.03599824737424193" Q="2.064075932335199" RANDOM="YES" SCALE="3.365383185362445" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="127" TOTAL_2="129" UNITS="" WEIGHT="300.0" Z="2.096947225167721">
<NAME>Adverse effects: 3c. Extrapyramidal: symptom scales (high = poor)</NAME>
<GROUP_LABEL_1>clozapine</GROUP_LABEL_1>
<GROUP_LABEL_2>risperidone</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours clozapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours risperidone</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="1.9127747511913231" CI_START="-1.3127747511913235" DF="0" EFFECT_SIZE="0.2999999999999998" ESTIMABLE="YES" I2="0.0" ID="CMP-005.21.01" MODIFIED="2009-01-18 20:38:18 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.7154231989123513" STUDIES="1" TAU2="0.0" TOTAL_1="40" TOTAL_2="41" WEIGHT="100.00000000000001" Z="0.36458234166158693">
<NAME>ESRS score</NAME>
<CONT_DATA CI_END="1.9127747511913231" CI_START="-1.3127747511913235" EFFECT_SIZE="0.2999999999999998" ESTIMABLE="YES" MEAN_1="5.1" MEAN_2="4.8" MODIFIED="2009-01-18 20:38:18 +0000" MODIFIED_BY="[Empty name]" ORDER="688" SD_1="3.8" SD_2="3.6" SE="0.8228593810461237" STUDY_ID="STD-Volavka-2002" TOTAL_1="40" TOTAL_2="41" WEIGHT="100.00000000000001"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.548868720992352" CI_END="0.09724654976517166" CI_START="-1.7264902618796008" DF="1" EFFECT_SIZE="-0.8146218560572145" ESTIMABLE="YES" I2="0.0" ID="CMP-005.21.02" MODIFIED="2009-09-20 23:22:52 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.45878039718324937" P_Z="0.07995574841565393" STUDIES="2" TAU2="0.0" TOTAL_1="34" TOTAL_2="35" WEIGHT="100.0" Z="1.7509428868207813">
<NAME>SAS score</NAME>
<CONT_DATA CI_END="0.03023656891446791" CI_START="-1.9702365689144692" EFFECT_SIZE="-0.9700000000000006" ESTIMABLE="YES" MEAN_1="11.36" MEAN_2="12.33" MODIFIED="2009-01-18 20:39:38 +0000" MODIFIED_BY="[Empty name]" ORDER="689" SD_1="1.08" SD_2="1.63" SE="0.5103341575683058" STUDY_ID="STD-Breier-1999" TOTAL_1="14" TOTAL_2="15" WEIGHT="83.11107131056673"/>
<CONT_DATA CI_END="2.168866215650331" CI_START="-2.2688662156503305" EFFECT_SIZE="-0.04999999999999999" ESTIMABLE="YES" MEAN_1="0.1" MEAN_2="0.15" MODIFIED="2009-01-18 20:39:11 +0000" MODIFIED_BY="[Empty name]" ORDER="690" SD_1="3.58" SD_2="3.58" SE="1.1320954023402798" STUDY_ID="STD-Heinrich-1994" TOTAL_1="20" TOTAL_2="20" WEIGHT="16.888928689433264"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="6.283427950293845E-32" CI_END="0.01702012521610094" CI_START="-0.4170201252161009" DF="0" EFFECT_SIZE="-0.19999999999999998" ESTIMABLE="YES" I2="100.0" ID="CMP-005.21.03" MODIFIED="2009-01-18 20:40:12 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Z="0.0708791572252047" STUDIES="1" TAU2="0.0" TOTAL_1="53" TOTAL_2="53" WEIGHT="100.0" Z="1.8062509019275441">
<NAME>BARS score</NAME>
<CONT_DATA CI_END="0.01702012521610094" CI_START="-0.417020125216101" EFFECT_SIZE="-0.2" ESTIMABLE="YES" MEAN_1="0.3" MEAN_2="0.5" MODIFIED="2009-01-18 20:40:12 +0000" MODIFIED_BY="[Empty name]" ORDER="691" SD_1="0.57" SD_2="0.57" SE="0.11072658830872811" STUDY_ID="STD-McGurk-2005" TOTAL_1="53" TOTAL_2="53" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="12.039997411019602" CI_START="-8.6399974110196" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="1.7000000000000002" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-005.22" MODIFIED="2009-09-20 23:23:21 +0100" MODIFIED_BY="[Empty name]" NO="22" P_CHI2="1.0" P_Q="1.0" P_Z="0.7472724953160583" Q="0.0" RANDOM="YES" SCALE="22.718733944303175" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="17" TOTAL_2="14" UNITS="" WEIGHT="100.0" Z="0.32223787311273017">
<NAME>Adverse effects: 4. Glucose: average change - medium term (high = poor)</NAME>
<GROUP_LABEL_1>clozapine</GROUP_LABEL_1>
<GROUP_LABEL_2>risperidone</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours clozapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours risperidone</GRAPH_LABEL_2>
<CONT_DATA CI_END="12.039997411019602" CI_START="-8.6399974110196" EFFECT_SIZE="1.7000000000000002" ESTIMABLE="YES" MEAN_1="4.4" MEAN_2="2.7" ORDER="318" SD_1="17.1" SD_2="12.2" SE="5.275605823668282" STUDY_ID="STD-Volavka-2002" TOTAL_1="17" TOTAL_2="14" WEIGHT="100.0"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="3.3160287066515246" CI_END="10.296769609176456" CI_START="1.8597717365829387" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="4.376030289800623" ESTIMABLE="YES" EVENTS_1="66" EVENTS_2="19" I2="39.686891250722326" I2_Q="0.0" ID="CMP-005.23" LOG_CI_END="1.0127009954860102" LOG_CI_START="0.2694596433437796" LOG_EFFECT_SIZE="0.6410803194148949" METHOD="MH" MODIFIED="2009-09-20 23:23:26 +0100" MODIFIED_BY="[Empty name]" NO="23" P_CHI2="0.19051710048233728" P_Q="0.0" P_Z="7.219084068175998E-4" Q="0.0" RANDOM="YES" SCALE="11.782234384894473" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.2507084587803696" TOTALS="YES" TOTAL_1="178" TOTAL_2="195" WEIGHT="100.0" Z="3.3811206376745804">
<NAME>Adverse effects: 5. Hypersalivation -short term</NAME>
<GROUP_LABEL_1>clozapine</GROUP_LABEL_1>
<GROUP_LABEL_2>risperidone</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours clozapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours risperidone</GRAPH_LABEL_2>
<DICH_DATA CI_END="4.622362880335631" CI_START="1.6376850688951476" EFFECT_SIZE="2.751358695652174" ESTIMABLE="YES" EVENTS_1="45" EVENTS_2="16" LOG_CI_END="0.664864036933028" LOG_CI_START="0.214230389493349" LOG_EFFECT_SIZE="0.4395472132131885" MODIFIED="2009-01-18 21:21:06 +0000" MODIFIED_BY="[Empty name]" ORDER="1038" O_E="0.0" SE="0.26470443517859804" STUDY_ID="STD-Azorin-2001" TOTAL_1="138" TOTAL_2="135" VAR="0.07006843800322061" WEIGHT="59.4198911433538"/>
<DICH_DATA CI_END="79.95314931160169" CI_START="1.2507324709658363" EFFECT_SIZE="10.0" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="1" LOG_CI_END="1.9028355750455181" LOG_CI_START="0.09716442495448202" LOG_EFFECT_SIZE="1.0" ORDER="320" O_E="0.0" SE="1.0606601717798212" STUDY_ID="STD-Heinrich-1994" TOTAL_1="20" TOTAL_2="40" VAR="1.125" WEIGHT="13.855063670308333"/>
<DICH_DATA CI_END="30.336789726207257" CI_START="2.109649721595685" EFFECT_SIZE="8.0" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="2" LOG_CI_END="1.4819696213432916" LOG_CI_START="0.32421035264059545" LOG_EFFECT_SIZE="0.9030899869919435" ORDER="321" O_E="0.0" SE="0.6800735254367721" STUDY_ID="STD-Zhou-2000" TOTAL_1="20" TOTAL_2="20" VAR="0.46249999999999997" WEIGHT="26.725045186337873"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="3.353312939591126" CI_END="35.19625172396118" CI_START="28.93939645023815" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="32.067824087099666" ESTIMABLE="YES" I2="70.17874507942788" I2_Q="70.17874507942788" ID="CMP-005.24" MODIFIED="2009-09-20 23:23:47 +0100" MODIFIED_BY="[Empty name]" NO="24" P_CHI2="0.06706998199868064" P_Q="0.06706998199868064" P_Z="0.0" Q="3.353312939591126" RANDOM="YES" SCALE="41.60459186610944" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="224.78115200387887" TOTALS="SUB" TOTAL_1="30" TOTAL_2="27" UNITS="" WEIGHT="200.0" Z="20.090533510417146">
<NAME>Adverse effects: 6. Lipids: average change (high = poor)</NAME>
<GROUP_LABEL_1>clozapine</GROUP_LABEL_1>
<GROUP_LABEL_2>risperidone</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours clozapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours risperidone</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="34.00589661611919" CI_START="-19.805896616119185" DF="0" EFFECT_SIZE="7.100000000000001" ESTIMABLE="YES" I2="0.0" ID="CMP-005.24.01" MODIFIED="2009-01-18 21:29:35 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.6050161763660028" STUDIES="1" TAU2="0.0" TOTAL_1="17" TOTAL_2="14" WEIGHT="100.0" Z="0.5172005411593508">
<NAME>average cholesterol change</NAME>
<CONT_DATA CI_END="34.00589661611919" CI_START="-19.805896616119185" EFFECT_SIZE="7.100000000000001" ESTIMABLE="YES" MEAN_1="16.3" MEAN_2="9.2" MODIFIED="2009-01-18 21:26:30 +0000" MODIFIED_BY="[Empty name]" ORDER="1039" SD_1="39.6" SD_2="36.7" SE="13.727750524167517" STUDY_ID="STD-Volavka-2002" TOTAL_1="17" TOTAL_2="14" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="35.55979173085945" CI_START="29.26020826914056" DF="0" EFFECT_SIZE="32.410000000000004" ESTIMABLE="YES" I2="0.0" ID="CMP-005.24.02" MODIFIED="2009-01-18 21:29:35 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="13" TOTAL_2="13" WEIGHT="100.0" Z="20.167185060712118">
<NAME>average triglyceride change</NAME>
<CONT_DATA CI_END="35.55979173085945" CI_START="29.26020826914056" EFFECT_SIZE="32.410000000000004" ESTIMABLE="YES" MEAN_1="36.28" MEAN_2="3.87" MODIFIED="2009-01-18 21:27:14 +0000" MODIFIED_BY="[Empty name]" ORDER="1040" SD_1="5.61" SD_2="1.45" SE="1.6070661275944866" STUDY_ID="STD-Atmaca-2003" TOTAL_1="13" TOTAL_2="13" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.587668299966842" CI_START="0.09661207350385806" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" I2="0.0" I2_Q="0.0" ID="CMP-005.25" LOG_CI_END="0.4129086055644666" LOG_CI_START="-1.0149685968924291" LOG_EFFECT_SIZE="-0.3010299956639812" METHOD="MH" MODIFIED="2009-09-21 00:02:43 +0100" MODIFIED_BY="[Empty name]" NO="25" P_CHI2="1.0" P_Q="0.0" P_Z="0.40857001147857763" Q="0.0" RANDOM="YES" SCALE="13.31648448412169" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="43" TOTAL_2="43" WEIGHT="100.0" Z="0.8264127317845636">
<NAME>Adverse effects: 7a. Prolactin: associated side effects - short term</NAME>
<GROUP_LABEL_1>clozapine</GROUP_LABEL_1>
<GROUP_LABEL_2>risperidone</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours clozapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours risperidone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.587668299966842" CI_START="0.09661207350385806" DF="0" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" I2="0.0" ID="CMP-005.25.01" LOG_CI_END="0.4129086055644666" LOG_CI_START="-1.0149685968924291" LOG_EFFECT_SIZE="-0.3010299956639812" NO="1" P_CHI2="1.0" P_Z="0.40857001147857763" STUDIES="1" TAU2="0.0" TOTAL_1="43" TOTAL_2="43" WEIGHT="100.0" Z="0.8264127317845636">
<NAME>disminished sexual drive</NAME>
<DICH_DATA CI_END="2.587668299966842" CI_START="0.09661207350385806" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" LOG_CI_END="0.4129086055644666" LOG_CI_START="-1.0149685968924291" LOG_EFFECT_SIZE="-0.3010299956639812" ORDER="324" O_E="0.0" SE="0.8387421368293256" STUDY_ID="STD-Bondolfi-1998" TOTAL_1="43" TOTAL_2="43" VAR="0.7034883720930232" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="3.5479563203142783" CI_END="-10.519602535120914" CI_START="-46.6907226802043" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="-28.605162607662606" ESTIMABLE="YES" I2="71.81476011205741" I2_Q="71.81476011205741" ID="CMP-005.26" MODIFIED="2009-09-21 00:02:51 +0100" MODIFIED_BY="[Empty name]" NO="26" P_CHI2="0.05961898489604256" P_Q="0.05961898489604256" P_Z="0.0019352598007844725" Q="3.5479563203142783" RANDOM="YES" SCALE="54.61175852178953" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="122.89300824175825" TOTALS="YES" TOTAL_1="25" TOTAL_2="30" UNITS="" WEIGHT="100.0" Z="3.0999918309442402">
<NAME>Adverse effects: 7b. Prolactin: average at endpoint (high = poor)</NAME>
<GROUP_LABEL_1>clozapine</GROUP_LABEL_1>
<GROUP_LABEL_2>risperidone</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours clozapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours risperidone</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="-23.297767877037273" CI_START="-53.70223212296273" DF="0" EFFECT_SIZE="-38.5" ESTIMABLE="YES" I2="0.0" ID="CMP-005.26.01" NO="1" P_CHI2="1.0" P_Z="6.917930125635593E-7" STUDIES="1" TAU2="0.0" TOTAL_1="13" TOTAL_2="14" WEIGHT="46.514392473851935" Z="4.963653547350659">
<NAME>short term</NAME>
<CONT_DATA CI_END="-23.297767877037273" CI_START="-53.70223212296273" EFFECT_SIZE="-38.5" ESTIMABLE="YES" MEAN_1="12.2" MEAN_2="50.7" ORDER="325" SD_1="7.7" SD_2="27.9" SE="7.756383404427834" STUDY_ID="STD-Breier-1999" TOTAL_1="13" TOTAL_2="14" WEIGHT="46.514392473851935"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-8.19091202343515" CI_START="-31.80908797656485" DF="0" EFFECT_SIZE="-20.0" ESTIMABLE="YES" I2="0.0" ID="CMP-005.26.02" NO="2" P_CHI2="1.0" P_Z="9.020582634625157E-4" STUDIES="1" TAU2="0.0" TOTAL_1="12" TOTAL_2="16" WEIGHT="53.485607526148065" Z="3.3194163485437747">
<NAME>medium term</NAME>
<CONT_DATA CI_END="-8.19091202343515" CI_START="-31.80908797656485" EFFECT_SIZE="-20.0" ESTIMABLE="YES" MEAN_1="12.0" MEAN_2="32.0" ORDER="326" SD_1="18.0" SD_2="12.2" SE="6.025155599650518" STUDY_ID="STD-Volavka-2002" TOTAL_1="12" TOTAL_2="16" WEIGHT="53.485607526148065"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="1.8244699457057003" CI_END="2.4207607607084953" CI_START="1.235333922891345" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RR" EFFECT_SIZE="1.72929115157265" ESTIMABLE="YES" EVENTS_1="69" EVENTS_2="41" I2="0.0" I2_Q="0.0" ID="CMP-005.27" LOG_CI_END="0.3839518710451517" LOG_CI_START="0.09178436752851321" LOG_EFFECT_SIZE="0.23786811928683244" METHOD="MH" MODIFIED="2009-09-21 00:02:58 +0100" MODIFIED_BY="[Empty name]" NO="27" P_CHI2="0.7680025624235343" P_Q="0.0" P_Z="0.0014158088131799842" Q="0.0" RANDOM="YES" SCALE="15.43314119213444" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="232" TOTAL_2="247" WEIGHT="99.99999999999997" Z="3.1914086355323836">
<NAME>Adverse effects: 8. Sedation - short term</NAME>
<GROUP_LABEL_1>clozapine</GROUP_LABEL_1>
<GROUP_LABEL_2>risperidone</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours clozapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours risperidone</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.8355616268201365" CI_START="1.0181012052004978" EFFECT_SIZE="1.6990846681922196" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="19" LOG_CI_END="0.4526390904853855" LOG_CI_START="0.007790951552270742" LOG_EFFECT_SIZE="0.2302150210188281" MODIFIED="2009-01-18 21:37:31 +0000" MODIFIED_BY="[Empty name]" ORDER="1041" O_E="0.0" SE="0.2613059988431133" STUDY_ID="STD-Azorin-2001" TOTAL_1="138" TOTAL_2="135" VAR="0.06828082503139711" WEIGHT="43.1360390147043"/>
<DICH_DATA CI_END="2.68201449521504" CI_START="0.8824948222868094" EFFECT_SIZE="1.5384615384615385" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="13" LOG_CI_END="0.4284611207097988" LOG_CI_START="-0.05428783399550991" LOG_EFFECT_SIZE="0.18708664335714445" ORDER="328" O_E="0.0" SE="0.28356912563976383" STUDY_ID="STD-Bondolfi-1998" TOTAL_1="43" TOTAL_2="43" VAR="0.08041144901610017" WEIGHT="36.628668784725114"/>
<DICH_DATA CI_END="4.52321691233217" CI_START="0.3183574937726204" EFFECT_SIZE="1.2" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="5" LOG_CI_END="0.6554474149778653" LOG_CI_START="-0.4970849228826155" LOG_EFFECT_SIZE="0.07918124604762482" ORDER="331" O_E="0.0" SE="0.67700320038633" STUDY_ID="STD-Heinrich-1994" TOTAL_1="20" TOTAL_2="40" VAR="0.4583333333333333" WEIGHT="6.426249452750278"/>
<DICH_DATA CI_END="54.867363612714385" CI_START="0.11391106822839378" EFFECT_SIZE="2.5" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.7393140927647355" LOG_CI_START="-0.9434340754206603" LOG_EFFECT_SIZE="0.3979400086720376" ORDER="329" O_E="0.0" SE="1.5758595538097082" STUDY_ID="STD-Wahlbeck-2000" TOTAL_1="11" TOTAL_2="9" VAR="2.483333333333333" WEIGHT="1.186052751346528"/>
<DICH_DATA CI_END="7.7319789505847645" CI_START="1.163996960871102" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="4" LOG_CI_END="0.8882906630418067" LOG_CI_START="0.0659518463975181" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="330" O_E="0.0" SE="0.48304589153964794" STUDY_ID="STD-Zhou-2000" TOTAL_1="20" TOTAL_2="20" VAR="0.23333333333333334" WEIGHT="12.622989996473757"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.28986475495723596" CI_END="14.0088002383845" CI_START="1.4282243900239358" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="4.472997895755582" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-005.28" LOG_CI_END="1.1464009424120545" LOG_CI_START="0.15479644532071588" LOG_EFFECT_SIZE="0.650598693866385" METHOD="MH" MODIFIED="2009-09-21 00:03:27 +0100" MODIFIED_BY="[Empty name]" NO="28" P_CHI2="0.5903072863203875" P_Q="0.0" P_Z="0.010114433733367949" Q="0.0" RANDOM="YES" SCALE="58.3682850396414" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="178" TOTAL_2="176" WEIGHT="100.0" Z="2.5718923464088705">
<NAME>Adverse effects: 9. Seizures</NAME>
<GROUP_LABEL_1>clozapine</GROUP_LABEL_1>
<GROUP_LABEL_2>risperidone</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours clozapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours risperidone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.2264235483232735E-31" CI_END="13.558593343801517" CI_START="1.1293139984731493" DF="0" EFFECT_SIZE="3.9130434782608696" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="3" I2="100.0" ID="CMP-005.28.01" LOG_CI_END="1.1322146353486437" LOG_CI_START="0.05281471149482019" LOG_EFFECT_SIZE="0.5925146734217319" MODIFIED="2009-01-18 21:39:31 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0314158777498036" STUDIES="1" TAU2="0.0" TOTAL_1="138" TOTAL_2="135" WEIGHT="84.39412392058226" Z="2.1517648733415613">
<NAME>short term</NAME>
<DICH_DATA CI_END="13.558593343801517" CI_START="1.1293139984731493" EFFECT_SIZE="3.9130434782608696" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="3" LOG_CI_END="1.1322146353486437" LOG_CI_START="0.05281471149482019" LOG_EFFECT_SIZE="0.5925146734217319" MODIFIED="2009-01-18 21:39:31 +0000" MODIFIED_BY="[Empty name]" ORDER="1042" O_E="0.0" SE="0.6340448583875317" STUDY_ID="STD-Azorin-2001" TOTAL_1="138" TOTAL_2="135" VAR="0.40201288244766503" WEIGHT="84.39412392058226"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="165.86995661376008" CI_START="0.5124460562435036" DF="0" EFFECT_SIZE="9.219512195121952" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" I2="0.0" ID="CMP-005.28.02" LOG_CI_END="2.2197677310609607" LOG_CI_START="-0.2903518448259808" LOG_EFFECT_SIZE="0.9647079431174899" NO="2" P_CHI2="1.0" P_Z="0.1319296181873947" STUDIES="1" TAU2="0.0" TOTAL_1="40" TOTAL_2="41" WEIGHT="15.605876079417746" Z="1.5065360569062858">
<NAME>medium term</NAME>
<DICH_DATA CI_END="165.86995661376008" CI_START="0.5124460562435036" EFFECT_SIZE="9.21951219512195" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="2.2197677310609607" LOG_CI_START="-0.2903518448259808" LOG_EFFECT_SIZE="0.9647079431174899" ORDER="333" O_E="0.0" SE="1.4744566641682826" STUDY_ID="STD-Volavka-2002" TOTAL_1="40" TOTAL_2="41" VAR="2.1740224545102595" WEIGHT="15.605876079417746"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="4.211172630896235" CI_END="6.46128705508952" CI_START="0.8029414572712907" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="2.277725893048087" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="14" I2="52.50729012326541" I2_Q="0.0" ID="CMP-005.29" LOG_CI_END="0.8103190358354122" LOG_CI_START="-0.09531611812216115" LOG_EFFECT_SIZE="0.35750145885662543" METHOD="MH" MODIFIED="2009-09-21 00:03:33 +0100" MODIFIED_BY="[Empty name]" NO="29" P_CHI2="0.12177430982866289" P_Q="0.0" P_Z="0.12176678656396914" Q="0.0" RANDOM="YES" SCALE="58.3682850396414" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.4307212839917196" TOTALS="YES" TOTAL_1="103" TOTAL_2="104" WEIGHT="100.0" Z="1.5474001439046159">
<NAME>Adverse effects: 10a. Weight: number of participants with weight gain</NAME>
<GROUP_LABEL_1>clozapine</GROUP_LABEL_1>
<GROUP_LABEL_2>risperidone</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours clozapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours risperidone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="4.463911479171697" CI_END="88.46891652459826" CI_START="0.24449666081443655" DF="1" EFFECT_SIZE="4.65084451214351" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="10" I2="77.59812208046843" ID="CMP-005.29.01" LOG_CI_END="1.9467907085162934" LOG_CI_START="-0.611727067827752" LOG_EFFECT_SIZE="0.6675318203442707" NO="1" P_CHI2="0.03461818268542227" P_Z="0.3064348407212051" STUDIES="2" TAU2="3.650454887189096" TOTAL_1="63" TOTAL_2="63" WEIGHT="63.44597451692161" Z="1.0227314725002712">
<NAME>short term</NAME>
<DICH_DATA CI_END="3.1189919299747624" CI_START="0.8207780133694396" EFFECT_SIZE="1.6" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="10" LOG_CI_END="0.4940142510726412" LOG_CI_START="-0.08577428576079167" LOG_EFFECT_SIZE="0.2041199826559248" ORDER="334" O_E="0.0" SE="0.34057065653550256" STUDY_ID="STD-Bondolfi-1998" TOTAL_1="43" TOTAL_2="43" VAR="0.11598837209302325" WEIGHT="51.763663314070165"/>
<DICH_DATA CI_END="365.6063394889459" CI_START="1.4469114532845637" EFFECT_SIZE="23.0" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="0" LOG_CI_END="2.5630137176449375" LOG_CI_START="0.1604419543902485" LOG_EFFECT_SIZE="1.3617278360175928" ORDER="335" O_E="0.0" SE="1.411282546657839" STUDY_ID="STD-Zhou-2000" TOTAL_1="20" TOTAL_2="20" VAR="1.9917184265010353" WEIGHT="11.682311202851444"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="5.657408105184492" CI_START="0.5687302387733743" DF="0" EFFECT_SIZE="1.79375" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="4" I2="0.0" ID="CMP-005.29.02" LOG_CI_END="0.7526175083209035" LOG_CI_START="-0.24509368016476846" LOG_EFFECT_SIZE="0.25376191407806753" NO="2" P_CHI2="1.0" P_Z="0.31875947839677654" STUDIES="1" TAU2="0.0" TOTAL_1="40" TOTAL_2="41" WEIGHT="36.5540254830784" Z="0.9970103933501249">
<NAME>medium term</NAME>
<DICH_DATA CI_END="5.657408105184492" CI_START="0.5687302387733743" EFFECT_SIZE="1.79375" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="4" LOG_CI_END="0.7526175083209035" LOG_CI_START="-0.24509368016476846" LOG_EFFECT_SIZE="0.25376191407806753" ORDER="336" O_E="0.0" SE="0.5860604908665178" STUDY_ID="STD-Volavka-2002" TOTAL_1="40" TOTAL_2="41" VAR="0.3434668989547038" WEIGHT="36.5540254830784"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="15.002571752975665" CI_END="4.504155119694612" CI_START="1.1691235333803882" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="MD" EFFECT_SIZE="2.8366393265375005" ESTIMABLE="YES" I2="80.00342841616492" I2_Q="0.0" ID="CMP-005.30" MODIFIED="2009-09-21 00:03:59 +0100" MODIFIED_BY="[Empty name]" NO="30" P_CHI2="0.0018144564891723336" P_Q="0.4370849401227843" P_Z="8.556730455907791E-4" Q="0.6039239426181862" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="2.266160917464076" TOTALS="YES" TOTAL_1="230" TOTAL_2="229" UNITS="" WEIGHT="100.00000000000001" Z="3.334127892496442">
<NAME>Adverse effects: 10b. Weight: average weight change (high=poor)</NAME>
<GROUP_LABEL_1>clozapine</GROUP_LABEL_1>
<GROUP_LABEL_2>risperidone</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours clozapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours risperidone</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="14.39864781035748" CI_END="5.4122793925124695" CI_START="0.9154730557543713" DF="2" EFFECT_SIZE="3.1638762241334204" ESTIMABLE="YES" I2="86.10980679337592" ID="CMP-005.30.01" MODIFIED="2009-01-18 21:49:39 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="7.470940214755473E-4" P_Z="0.005815718601202996" STUDIES="3" TAU2="3.357381431246118" TOTAL_1="192" TOTAL_2="190" WEIGHT="76.25581891332094" Z="2.7579944460381873">
<NAME>short term</NAME>
<CONT_DATA CI_END="7.8745322046019535" CI_START="4.085467795398046" EFFECT_SIZE="5.9799999999999995" ESTIMABLE="YES" MEAN_1="6.52" MEAN_2="0.54" MODIFIED="2009-01-18 21:48:54 +0000" MODIFIED_BY="[Empty name]" ORDER="1043" SD_1="3.41" SD_2="0.72" SE="0.9666158253650485" STUDY_ID="STD-Atmaca-2003" TOTAL_1="13" TOTAL_2="13" WEIGHT="22.616476133444866"/>
<CONT_DATA CI_END="3.115849518900396" CI_START="1.2841504810996036" EFFECT_SIZE="2.1999999999999997" ESTIMABLE="YES" MEAN_1="2.4" MEAN_2="0.2" MODIFIED="2009-01-18 21:49:39 +0000" MODIFIED_BY="[Empty name]" ORDER="1044" SD_1="4.6" SD_2="2.9" SE="0.46727874906095224" STUDY_ID="STD-Azorin-2001" TOTAL_1="136" TOTAL_2="134" WEIGHT="29.134188105429732"/>
<CONT_DATA CI_END="3.225322417588136" CI_START="-0.02532241758813547" EFFECT_SIZE="1.6" ESTIMABLE="YES" MEAN_1="2.7" MEAN_2="1.1" ORDER="339" SD_1="4.6" SD_2="2.9" SE="0.8292613692947786" STUDY_ID="STD-Bondolfi-1998" TOTAL_1="43" TOTAL_2="43" WEIGHT="24.505154674446338"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="3.6335894522597023" CI_START="0.16641054774029818" DF="0" EFFECT_SIZE="1.9000000000000004" ESTIMABLE="YES" I2="0.0" ID="CMP-005.30.02" NO="2" P_CHI2="1.0" P_Z="0.03170544259530582" STUDIES="1" TAU2="0.0" TOTAL_1="38" TOTAL_2="39" WEIGHT="23.744181086679074" Z="2.1481046540586797">
<NAME>medium term</NAME>
<CONT_DATA CI_END="3.6335894522597023" CI_START="0.16641054774029818" EFFECT_SIZE="1.9000000000000004" ESTIMABLE="YES" MEAN_1="4.2" MEAN_2="2.3" ORDER="340" SD_1="4.7" SD_2="2.8" SE="0.8845006673255399" STUDY_ID="STD-Volavka-2002" TOTAL_1="38" TOTAL_2="39" WEIGHT="23.744181086679074"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.9179151064062976" CI_END="4.9912508212167825" CI_START="0.3251086851365279" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="1.2738520289548563" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-005.31" LOG_CI_END="0.6982093946574178" LOG_CI_START="-0.4879714283614993" LOG_EFFECT_SIZE="0.10511898314795932" METHOD="MH" MODIFIED="2009-09-21 00:05:30 +0100" MODIFIED_BY="[Empty name]" NO="31" P_CHI2="0.6319421007514596" P_Q="0.0" P_Z="0.7283037372032328" Q="0.0" RANDOM="YES" SCALE="29.218667281692987" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="147" TOTAL_2="147" WEIGHT="99.99999999999997" Z="0.3473828223543745">
<NAME>Adverse effects: 11. White blood cell count: number of participants with a decrease</NAME>
<GROUP_LABEL_1>clozapine</GROUP_LABEL_1>
<GROUP_LABEL_2>risperidone</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours clozapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours risperidone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.7960030329633865" CI_END="8.579199246825182" CI_START="0.10256714436805375" DF="1" EFFECT_SIZE="0.9380532861791042" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" I2="0.0" ID="CMP-005.31.01" LOG_CI_END="0.9334467541757245" LOG_CI_START="-0.9889917357624872" LOG_EFFECT_SIZE="-0.027772490793381358" NO="1" P_CHI2="0.37229114027797927" P_Z="0.9548405696052593" STUDIES="2" TAU2="0.0" TOTAL_1="54" TOTAL_2="52" WEIGHT="38.07122848530001" Z="0.05662920504441957">
<NAME>short term</NAME>
<DICH_DATA CI_END="7.961364031061661" CI_START="0.013956290740833538" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9009874823623856" LOG_CI_START="-1.8552299918017108" LOG_EFFECT_SIZE="-0.4771212547196625" ORDER="341" O_E="0.0" SE="1.6190157878205267" STUDY_ID="STD-Bondolfi-1998" TOTAL_1="43" TOTAL_2="43" VAR="2.6212121212121207" WEIGHT="18.521443599705172"/>
<DICH_DATA CI_END="54.867363612714385" CI_START="0.11391106822839378" EFFECT_SIZE="2.5" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.7393140927647355" LOG_CI_START="-0.9434340754206603" LOG_EFFECT_SIZE="0.3979400086720376" ORDER="342" O_E="0.0" SE="1.5758595538097082" STUDY_ID="STD-Wahlbeck-2000" TOTAL_1="11" TOTAL_2="9" VAR="2.483333333333333" WEIGHT="19.549784885594843"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="8.719141861572762" CI_START="0.2711168469936557" DF="0" EFFECT_SIZE="1.5375" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" I2="0.0" ID="CMP-005.31.02" LOG_CI_END="0.94047374374875" LOG_CI_START="-0.5668434948538412" LOG_EFFECT_SIZE="0.18681512444745435" NO="2" P_CHI2="1.0" P_Z="0.6270868113512207" STUDIES="1" TAU2="0.0" TOTAL_1="40" TOTAL_2="41" WEIGHT="61.92877151469997" Z="0.48583125875191496">
<NAME>medium term</NAME>
<DICH_DATA CI_END="8.719141861572762" CI_START="0.2711168469936557" EFFECT_SIZE="1.5375" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.94047374374875" LOG_CI_START="-0.5668434948538412" LOG_EFFECT_SIZE="0.18681512444745435" ORDER="343" O_E="0.0" SE="0.8854056072958281" STUDY_ID="STD-Volavka-2002" TOTAL_1="40" TOTAL_2="41" VAR="0.7839430894308942" WEIGHT="61.92877151469997"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-005.31.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="53" TOTAL_2="54" WEIGHT="0.0" Z="0.0">
<NAME>long term</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="344" O_E="0.0" SE="0.0" STUDY_ID="STD-McGurk-2005" TOTAL_1="53" TOTAL_2="54" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-006" MODIFIED="2009-09-20 23:37:35 +0100" MODIFIED_BY="[Empty name]" NO="6">
<NAME>CLOZAPINE vs. RISPERIDONE - Sensitivity Analysis</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="-2.217059522236337" CI_START="-8.782940477763663" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-5.5" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-006.01" MODIFIED="2009-04-18 23:28:19 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.0010249708155409167" Q="0.0" RANDOM="YES" SCALE="13.47" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="126" TOTAL_2="130" UNITS="" WEIGHT="100.0" Z="3.2835812857361013">
<NAME>Mental state: 1. BPRS-18 (1-7) total score, excluding possibly skewed data (high = poor)</NAME>
<GROUP_LABEL_1>clozapine</GROUP_LABEL_1>
<GROUP_LABEL_2>risperidone</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours clozapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours risperidone</GRAPH_LABEL_2>
<CONT_DATA CI_END="-2.217059522236337" CI_START="-8.782940477763663" EFFECT_SIZE="-5.5" ESTIMABLE="YES" MEAN_1="-23.2" MEAN_2="-17.7" MODIFIED="2009-01-18 21:58:03 +0000" MODIFIED_BY="[Empty name]" ORDER="1045" SD_1="13.2" SD_2="13.6" SE="1.6750004100376732" STUDY_ID="STD-Azorin-2001" TOTAL_1="126" TOTAL_2="130" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="3.333696665170308" CI_END="1.211998664601364" CI_START="-2.909966780978468" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.8489840581885518" ESTIMABLE="YES" I2="40.00653926028911" I2_Q="0.0" ID="CMP-006.02" MODIFIED="2009-09-20 23:37:31 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.1888415014061633" P_Q="0.5491779002044052" P_Z="0.41945263851604164" Q="0.3587924115030021" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="1.3876723060418323" TOTALS="YES" TOTAL_1="209" TOTAL_2="214" UNITS="" WEIGHT="100.0" Z="0.8073712404758646">
<NAME>Mental state: 2. PANSS positive subscore, excluding possibly skewed data (high = poor)</NAME>
<GROUP_LABEL_1>clozapine</GROUP_LABEL_1>
<GROUP_LABEL_2>risperidone</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours clozapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours risperidone</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="2.974904253667306" CI_END="2.8691250482596926" CI_START="-4.198297660688119" DF="1" EFFECT_SIZE="-0.6645863062142128" ESTIMABLE="YES" I2="66.38547278396432" ID="CMP-006.02.01" MODIFIED="2009-01-18 22:09:21 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0845653107118921" P_Z="0.7124176224830846" STUDIES="2" TAU2="4.544085612062357" TOTAL_1="169" TOTAL_2="173" WEIGHT="72.49186090763752" Z="0.36861109868219255">
<NAME>short term</NAME>
<CONT_DATA CI_END="-0.38355371586920217" CI_START="-3.816446284130797" EFFECT_SIZE="-2.0999999999999996" ESTIMABLE="YES" MEAN_1="-10.4" MEAN_2="-8.3" MODIFIED="2009-01-18 22:09:21 +0000" MODIFIED_BY="[Empty name]" ORDER="1048" SD_1="6.6" SD_2="7.4" SE="0.8757539922518509" STUDY_ID="STD-Azorin-2001" TOTAL_1="126" TOTAL_2="130" WEIGHT="51.31949395517033"/>
<CONT_DATA CI_END="5.438169862851794" CI_START="-2.2381698628517928" EFFECT_SIZE="1.6000000000000005" ESTIMABLE="YES" MEAN_1="-6.7" MEAN_2="-8.3" ORDER="351" SD_1="7.1" SD_2="10.7" SE="1.9582859139896382" STUDY_ID="STD-Bondolfi-1998" TOTAL_1="43" TOTAL_2="43" WEIGHT="21.17236695246718"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="2.779739460961595" CI_START="-3.5797394609615947" DF="0" EFFECT_SIZE="-0.3999999999999999" ESTIMABLE="YES" I2="0.0" ID="CMP-006.02.02" NO="2" P_CHI2="1.0" P_Z="0.8052514342014075" STUDIES="1" TAU2="0.0" TOTAL_1="40" TOTAL_2="41" WEIGHT="27.508139092362484" Z="0.24655655076184577">
<NAME>medium term</NAME>
<CONT_DATA CI_END="2.779739460961595" CI_START="-3.5797394609615947" EFFECT_SIZE="-0.3999999999999999" ESTIMABLE="YES" MEAN_1="-2.3" MEAN_2="-1.9" ORDER="352" SD_1="7.3" SD_2="7.3" SE="1.622345862496951" STUDY_ID="STD-Volavka-2002" TOTAL_1="40" TOTAL_2="41" WEIGHT="27.508139092362484"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="8.27477537552824" CI_END="2.0187942551631375" CI_START="-2.3077887505926133" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.14449724771473807" ESTIMABLE="YES" I2="63.74523943124573" I2_Q="0.0" ID="CMP-006.03" MODIFIED="2009-09-20 23:37:35 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.04066152651131705" P_Q="0.575978256263538" P_Z="0.8958417827095086" Q="0.3127818225725676" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="3.027660318302094" TOTALS="YES" TOTAL_1="219" TOTAL_2="223" UNITS="" WEIGHT="99.99999999999999" Z="0.1309159681019823">
<NAME>Mental state: 3. PANSS negative subscore, excluding possibly skewed data (high = poor)</NAME>
<GROUP_LABEL_1>clozapine</GROUP_LABEL_1>
<GROUP_LABEL_2>risperidone</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours clozapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours risperidone</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="7.961993552955672" CI_END="3.367467284875221" CI_START="-2.5924739646170925" DF="2" EFFECT_SIZE="0.3874966601290642" ESTIMABLE="YES" I2="74.88066290561672" ID="CMP-006.03.01" MODIFIED="2009-01-18 22:10:55 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.018667071185337947" P_Z="0.7988301472737536" STUDIES="3" TAU2="5.0965320885711085" TOTAL_1="179" TOTAL_2="182" WEIGHT="76.12026458497289" Z="0.2548614042285127">
<NAME>short term</NAME>
<CONT_DATA CI_END="0.015112238489882968" CI_START="-3.4151122384898853" EFFECT_SIZE="-1.700000000000001" ESTIMABLE="YES" MEAN_1="-8.8" MEAN_2="-7.1" MODIFIED="2009-01-18 22:10:55 +0000" MODIFIED_BY="[Empty name]" ORDER="1049" SD_1="6.8" SD_2="7.2" SE="0.8750733442137052" STUDY_ID="STD-Azorin-2001" TOTAL_1="126" TOTAL_2="130" WEIGHT="32.11468756474519"/>
<CONT_DATA CI_END="2.5643307894546745" CI_START="-2.764330789454674" EFFECT_SIZE="-0.09999999999999964" ESTIMABLE="YES" MEAN_1="-6.1" MEAN_2="-6.0" ORDER="354" SD_1="6.1" SD_2="6.5" SE="1.3593774224784616" STUDY_ID="STD-Bondolfi-1998" TOTAL_1="43" TOTAL_2="43" WEIGHT="24.98669131982435"/>
<CONT_DATA CI_END="7.602165215365481" CI_START="0.39783478463451827" EFFECT_SIZE="4.0" ESTIMABLE="YES" MEAN_1="21.0" MEAN_2="17.0" ORDER="355" SD_1="4.0" SD_2="4.0" SE="1.837873166945363" STUDY_ID="STD-Wahlbeck-2000" TOTAL_1="10" TOTAL_2="9" WEIGHT="19.018885700403356"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="1.422563247538512" CI_START="-4.222563247538512" DF="0" EFFECT_SIZE="-1.4000000000000001" ESTIMABLE="YES" I2="0.0" ID="CMP-006.03.02" NO="2" P_CHI2="1.0" P_Z="0.3309768741358846" STUDIES="1" TAU2="0.0" TOTAL_1="40" TOTAL_2="41" WEIGHT="23.8797354150271" Z="0.9721481283896852">
<NAME>medium term</NAME>
<CONT_DATA CI_END="1.422563247538512" CI_START="-4.222563247538512" EFFECT_SIZE="-1.4000000000000001" ESTIMABLE="YES" MEAN_1="-1.6" MEAN_2="-0.2" ORDER="356" SD_1="6.48" SD_2="6.48" SE="1.4401097519151018" STUDY_ID="STD-Volavka-2002" TOTAL_1="40" TOTAL_2="41" WEIGHT="23.8797354150271"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-007" MODIFIED="2009-09-20 23:37:43 +0100" MODIFIED_BY="[Empty name]" NO="7">
<NAME>CLOZAPINE versus ZIPRASIDONE</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.5087353295215662" CI_START="0.6628067762667884" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="28" I2="0.0" I2_Q="0.0" ID="CMP-007.01" LOG_CI_END="0.17861306017993295" LOG_CI_START="-0.17861306017993295" LOG_EFFECT_SIZE="0.0" METHOD="MH" MODIFIED="2009-09-20 23:28:31 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="0.0" P_Z="1.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="73" TOTAL_2="73" WEIGHT="100.0" Z="0.0">
<NAME>Leaving the study early: any reason - medium term</NAME>
<GROUP_LABEL_1>clozapine</GROUP_LABEL_1>
<GROUP_LABEL_2>ziprasidone</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours clozapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours ziprasidone</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.5087353295215662" CI_START="0.6628067762667884" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="28" LOG_CI_END="0.17861306017993295" LOG_CI_START="-0.17861306017993295" LOG_EFFECT_SIZE="0.0" ORDER="358" O_E="0.0" SE="0.20983639139719978" STUDY_ID="STD-Sacchetti-2006" TOTAL_1="73" TOTAL_2="73" VAR="0.04403131115459882" WEIGHT="100.0"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="7.718701546423268" CI_START="-6.718701546423268" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.5" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-007.02" MODIFIED="2009-09-20 23:37:43 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.8920141818991236" Q="0.0" RANDOM="YES" SCALE="14.21415749316967" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="73" TOTAL_2="73" UNITS="" WEIGHT="100.0" Z="0.13575599239943506">
<NAME>Mental state: PANSS total score - medium term (high = poor)</NAME>
<GROUP_LABEL_1>clozapine</GROUP_LABEL_1>
<GROUP_LABEL_2>ziprasidone</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours clozapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours ziprasidone</GRAPH_LABEL_2>
<CONT_DATA CI_END="7.718701546423268" CI_START="-6.718701546423268" EFFECT_SIZE="0.5" ESTIMABLE="YES" MEAN_1="-24.5" MEAN_2="-25.0" ORDER="359" SD_1="22.5" SD_2="22.0" SE="3.6830786705079603" STUDY_ID="STD-Sacchetti-2006" TOTAL_1="73" TOTAL_2="73" WEIGHT="100.0"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-007.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="YES" TOTAL_1="73" TOTAL_2="73" WEIGHT="0.0" Z="0.0">
<NAME>Adverse effects: 1. Cardiac problems</NAME>
<GROUP_LABEL_1>clozapine</GROUP_LABEL_1>
<GROUP_LABEL_2>ziprasidone</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours clozapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours olanzapine</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="360" O_E="0.0" SE="0.0" STUDY_ID="STD-Sacchetti-2006" TOTAL_1="73" TOTAL_2="73" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-008" MODIFIED="2010-10-05 15:11:48 +0100" MODIFIED_BY="[Empty name]" NO="8">
<NAME>CLOZAPINE versus ZOTEPINE</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.5438503877193064" CI_START="0.31738826760529903" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="10" I2="0.0" I2_Q="0.0" ID="CMP-008.01" LOG_CI_END="0.18860521119649018" LOG_CI_START="-0.4984091311679766" LOG_EFFECT_SIZE="-0.1549019599857432" METHOD="MH" MODIFIED="2009-09-21 00:05:55 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="0.0" P_Z="0.3767874963600075" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="25" TOTAL_2="25" WEIGHT="100.0" Z="0.8838309304048205">
<NAME>Leaving the study early: any reason</NAME>
<GROUP_LABEL_1>clozapine</GROUP_LABEL_1>
<GROUP_LABEL_2>zotepine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours clozapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours zotepine</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.5438503877193064" CI_START="0.31738826760529903" EFFECT_SIZE="0.7" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="10" LOG_CI_END="0.18860521119649018" LOG_CI_START="-0.4984091311679766" LOG_EFFECT_SIZE="-0.1549019599857432" ORDER="361" O_E="0.0" SE="0.40355562548072954" STUDY_ID="STD-Lindenberg-1997" TOTAL_1="25" TOTAL_2="25" VAR="0.16285714285714284" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.8738407948418998" CI_START="0.016901248898864955" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.12152777777777779" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="12" I2="0.0" I2_Q="0.0" ID="CMP-008.02" LOG_CI_END="-0.058567684321842305" LOG_CI_START="-1.7720812024960682" LOG_EFFECT_SIZE="-0.9153244434089551" METHOD="MH" MODIFIED="2009-09-21 00:06:54 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Q="0.0" P_Z="0.03626473322691314" Q="0.0" RANDOM="YES" SCALE="121.56333741221304" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="24" TOTAL_2="35" WEIGHT="100.0" Z="2.0939466473100956">
<NAME>Global state: no clinically important change - less than successfully and no increase on CGI-S - short term</NAME>
<GROUP_LABEL_1>clozapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Zotepine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours clozapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours zotepine</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.8738407948418998" CI_START="0.016901248898864955" EFFECT_SIZE="0.12152777777777778" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="12" LOG_CI_END="-0.058567684321842305" LOG_CI_START="-1.7720812024960682" LOG_EFFECT_SIZE="-0.9153244434089552" ORDER="362" O_E="0.0" SE="1.0065263226042516" STUDY_ID="STD-Lin-2003" TOTAL_1="24" TOTAL_2="35" VAR="1.013095238095238" WEIGHT="100.0"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="-2.171130504393011" CI_START="-9.82886949560699" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-6.0" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-008.03" MODIFIED="2009-09-20 23:29:15 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="0.002130958903581936" Q="0.0" RANDOM="YES" SCALE="10.650462358313733" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="24" TOTAL_2="35" UNITS="" WEIGHT="100.0" Z="3.0713462343735625">
<NAME>Mental state: BPRS-18 total score - short term (high=poor)</NAME>
<GROUP_LABEL_1>clozapine</GROUP_LABEL_1>
<GROUP_LABEL_2>zotepine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours clozapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours zotepine</GRAPH_LABEL_2>
<CONT_DATA CI_END="-2.1711305043930107" CI_START="-9.82886949560699" EFFECT_SIZE="-6.0" ESTIMABLE="YES" MEAN_1="-1.3" MEAN_2="4.7" ORDER="363" SD_1="6.3" SD_2="8.7" SE="1.9535407414669979" STUDY_ID="STD-Lin-2003" TOTAL_1="24" TOTAL_2="35" WEIGHT="100.0"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.8563924813853225" CI_START="0.003321426222522643" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.05333333333333334" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="13" I2="0.0" I2_Q="0.0" ID="CMP-008.04" LOG_CI_END="-0.06732715420711773" LOG_CI_START="-2.4786753899203577" LOG_EFFECT_SIZE="-1.2730012720637376" METHOD="MH" MODIFIED="2010-10-05 15:11:41 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Q="0.0" P_Z="0.038507429114259834" Q="0.0" RANDOM="YES" SCALE="746.3150978612576" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="24" TOTAL_2="35" WEIGHT="100.0" Z="2.069412130994516">
<NAME>Adverse effects: 1. Extrapyramidal: antiparkinson medication use - short term</NAME>
<GROUP_LABEL_1>clozapine</GROUP_LABEL_1>
<GROUP_LABEL_2>zotepine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours clozapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours zotepine</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.8563924813853225" CI_START="0.003321426222522643" EFFECT_SIZE="0.05333333333333334" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="13" LOG_CI_END="-0.06732715420711773" LOG_CI_START="-2.4786753899203577" LOG_EFFECT_SIZE="-1.2730012720637376" ORDER="364" O_E="0.0" SE="1.4164378900242311" STUDY_ID="STD-Lin-2003" TOTAL_1="24" TOTAL_2="35" VAR="2.0062962962962962" WEIGHT="100.0"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="-18.13369130419729" CI_START="-48.66630869580271" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-33.4" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-008.05" MODIFIED="2010-10-05 15:11:48 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="1.0" P_Q="1.0" P_Z="1.8024310019401625E-5" Q="0.0" RANDOM="YES" SCALE="66.86309084220213" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="24" TOTAL_2="35" UNITS="" WEIGHT="100.0" Z="4.288056686659036">
<NAME>Adverse effects: 2. Prolactin: average change - short term (high=poor)</NAME>
<GROUP_LABEL_1>clozapine</GROUP_LABEL_1>
<GROUP_LABEL_2>zotepine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours clozapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours zotepine</GRAPH_LABEL_2>
<CONT_DATA CI_END="-18.13369130419729" CI_START="-48.66630869580271" EFFECT_SIZE="-33.4" ESTIMABLE="YES" MEAN_1="1.0" MEAN_2="34.4" MODIFIED="2009-01-18 22:33:55 +0000" MODIFIED_BY="[Empty name]" ORDER="365" SD_1="29.39" SD_2="29.39" SE="7.7890761341644055" STUDY_ID="STD-Lin-2003" TOTAL_1="24" TOTAL_2="35" WEIGHT="100.0"/>
</CONT_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2010-10-05 14:46:47 +0100" MODIFIED_BY="[Empty name]">
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2010-10-05 14:46:47 +0100" MODIFIED_BY="[Empty name]" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>Methodological quality summary: review authors' judgements about each methodological quality item for each included study.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAASsAAAQUCAIAAACu0qg8AAAy6klEQVR42u3du24lxRbG8S2REDiY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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES/>
<EXTENSIONS/>
</COCHRANE_REVIEW>